SCIENTIFIC

REPORT
2017

“I am among those
who think that science
has great beauty.”
Marie Curie
(1867-1934)
 Index
1 INTRODUCTION 2

2 EXECUTIVE SUMMARY 4
2.1 Global Analysis 6
2.2 Research Structure 10
2.3 Training Report and Teaching 18
2.4 Innovation and Transfer Activities 24
2.5 Quality Committe 36
2.6 Clinical Trials 38
2.7 Platforms 58
2.8 Scientific Production 82
2.9 CIBERs and RETICs 92
2.10 Institutional Projects 94
2.11 Internationalization 96

3
“One sometimes finds what one
is not looking for.”
INFORMATION GROUPS BY AREA 98 Alexander Fleming
(1881-1955)
3.1 Neuroscience Area 100
3.2 Cardiovascular Area 116
3.3 Infectious Diseases and Immunity Area 140
3.4 Large System Pathologies Area 184
3.5 Cancer and Human Molecular Genetics Area 240
3.6 Surgery, Transplant and Health Technologies Area 284

4 ASSOCIATED CLINICIANS 304

1
 The Hospital La Paz Institute for Health Research (Ins-
tituto de Investigación Sanitaria del Hospital Universi-
tario La Paz, IdiPAZ) was created in 2009, as a result
of the relationship that has been forged over the years
between La Paz University Hospital (HULP), the Autono-
mous University of Madrid (UAM), and the Foundation
for Biomedical Research of La Paz University Hospital
(FIBHULP). Recently, we have incorporated Fuenlabrada
University Hospital to our structure, which reinforces
several lines of existing research and creates new ones.
Since its establishment, IdiPAZ has promoted the con-
figuration of multidisciplinary teams capable of addres-
sing several facets of translational research, bearing in
mind the need to generate innovation and transfer the
results to the healthcare system. Over the years, we have
maintained a progressive growth of our scientific activi-
ty, which is structured into six research areas: neuros-
ciences, cardiovascular, infectious diseases and immunity,
large system pathologies, cancer and human molecular
genetics and surgery, transplants and health technologies.
The increasing scientific contributions performed by our
research groups over the previous years have placed Idi-
PAZ among the top three health research institutes with
the best scientific evaluation of Spain.
An evidence of our excellent position in clinical research
is the fact that in 2017, IdiPAZ researchers have been
improving in terms of scientific production; in particular,
we published 1,119 articles, 870 of which were original.
In addition, the overall impact factor reached 4,930.997
points, exceeding the 4,000 point threshold for the fifth
consecutive year. There has also been a consolidation in
the quality of the source journals, with a mean impact
factor of 4.41 and with more than 476 of the manus-
cripts published in journals in the first quartile of their
subject area.
The 2017 Scientific Report also shows data reflecting
the commitment of IdiPAZ to biomedical research trai-
ning. The university involvement in most of the research
groups has resulted in a high participation in graduate
programmes, generating 100 Doctoral Theses this year;
it is worth mentioning four of them with European
mention and three international theses. In parallel, our
institution is making a great effort to open its activities,
therefore we have organized several activities and work-
shops with the collaboration of our researchers and
other institutions to increase our visibility and current
potential while improving our plans for the future taking
into account the internationalization aspects.
In addition, during the period 2013-2017, the UAI filed
24 priority patents (19 Spanish patents and 5 European
patents) and 16 PCT; 5 national or regional phase entry
applications were filed (2 at the EPO, 2 at the USPTO
and 1 at the CIPO (Canadian Intellectual Property Offi-
ce) and 26 patents were granted (1 at the EPO and 1
at the USPTO).Finally, we have done an effort to conti-
nue and improve our translational research with a direct
application to the care of our patients, and in this stra-
tegic process 353 new contracts for clinical trials were
signed in 2017
The excellence of our research institute is based on our
human capital, our people; therefore we wish to express
our admiration for them, who enable IPAZ to continue
advancing to a promising future. There have been many
achievements and we are confident that we will achieve
many more. Our human potential and desire to continue
progressing represent the best guarantee of continued
success.
Hospital Universitario La Paz
Fundación para la Investigación Biomédica

Dr. Rafael Pérez-Santamarina Feijóo Dr. Eduardo López-Collazo Dr. Carlos Mur de Viu Bernady
Managing Director of HULP Scientific Director of IdiPAZ Managing Director of HUF
Chairman of the Board of FIBHULP

1
Introduction
The Scientific Report of IdiPAZ provides an opportunity
to recognize the achievements and improvements of our
researchers. This report reflects the effort of the fifty-
five research groups that constitute IdiPAZ, as well as
the associated clinical groups. We congratulate all our
members for the magnificent performed work and the
achieved results.

2 3
 2
“Any man could, if he were so inclined,
be the sculptor of his own brain.”
Santiago Ramón y Cajal
(1852-1934)

Executive Summary
2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.3.1 Training Committee
2.3.2 Training Courses
2.3.3 Doctoral Theses

2.4 Innovation and Transfer Activities

2.4.1 Innovation and Transfer Activities
2.4.2 Patents and Trademarks

2.5 Quality Committe

2.6 Clinical Trials

2.7 Platforms
2.7.1 Biobank
2.7.2 UCICEC
2.7.3 Experimental Surgery
2.7.4 Simulation Platform (CEASEC)
2.7.5 Cell Culture Unit
2.7.6 Sanger Sequencing Facility
2.7.7 Image Laboratory
2.7.8 Flow Cytometry Laboratory
2.7.9 Radioisotope Laboratory
2.7.10 Biostatistics Section
2.7.11 Documentalist
2.7.12 PAIN Platform
2.7.13 Internationalization Platform
2.7.14 Tissue Engineering and 3D Printing Platform
2.7.15 Food, Nutrition and Health Platform

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

4 5
 2
Executive Summary

2.1
Global Analysis Is necessary to highlight the quality of the journals in which the articles were published in 2017, with a 17.43% of
them published in journals of the first decile of their subject area, and a 42.5% in journals in the first quartile.

Distribution of publications by quartile between 2009-2017

100

90
80
70 Quartile 1 (%)
60 Quartile 2 (%)
50 Quartile 3 (%)
40 Quartile 4 (%)
In 2017, the scientific production of IdiPAZ included 1,119 publications that reached almost
30
5,000 points (4,930.997) of total impact factor. Of the total of publications, 46.82% are docu- Not Indexed (%)
20
ments belong to IdiPAZ, so the author the first, the last or the corresponding author of the
10
publication is a researcher of the institute.
0
2009
2009 2010
2010 2011
2011 2012
2012 2013
2013 2014
2014 2015
2015 2016
2016 2017
2017
Total Impact factor Mean impact factor
Publications 1,119 4,930.997 4.41
Owned Publications 524 1,628.77 3.11
595 3,032.23 5.1
Distribution of originals by quartile between 2009-2017
Un-owned Publications
Originals 870 4,031.56 4.63 100
Owned Originals 354 1,049.58 2.96 90

Un-owned Originals 516 2,981.98 5.78 80

70 Quartile 1 (%)
60 Quartile 2 (%)
Total impact factor between 2009-2017 50 Quartile 3 (%)
40 Quartile 4 (%)
5000
30
Not Indexed (%)
4500
20
4000
10
3500
0
3000 2009
2009 2010
2010 2011
2011 2012
2012 2013
2013 2014
2014 2015
2015 2016
2016 2017
2017
2500
2000
1500
1000
500
0
2009 2010 2011 2012 2013 2014 2015 2016 2017

Mean impact factor between 2009-2017

5

0
2009 2010 2011 2012 2013 2014 2015 2016 2017

!
6 7
 2
Executive Summary
2.1 Global Analysis

Considering originals published by IdiPAZ researchers, 870 articles, we keep the trend of the last years, exceeding the
4,000-point threshold (4,031.56 points). Moreover, about 18% of the originals published in this year were in first-decile jour-
nals of their subject area, and 44% were in first quartile journals.
Total impact factor for original papers
between 2009-2017
IdiPAZ researchers evidenced their participation in national and international scientific networks, with near 80% of the total
documents published in collaboration, which 84.83% of the originals publications. In addition, collaboration among IdiPAZ
research groups is also reflected by the percentage of intramural collaboration, which reached 10.55% in 2017 for all manus-
cripts and 9.43% for originals.
Papers with interntational collaboration
between 2009-2017

4500 60

4000
50
3500

3000 40
2500
30
2000
%
1500 20
1000

500 10

0
0
2009 2010 2011 2012 2013 2014 2015 2016 2017
2009 2010 2011 2012 2013 2014 2015 2016 2017
Total
Original papers

Mean impact factor for original papers

between 2009-2017
5
The upward trend in scientific activity conducted by our groups is also reinforced by the analysis of originals belong to IdiPAZ
researchers. In 2017, 354 original IdiPAZ articles were published, with a mean impact factor of 2.96.The growth rates achieved
4 in previous years have been increased in both indexes.

3 Owned originals between 2009-2017

2 450 1.200

400
1 1.000
350

0 300 800
2009 2010 2011 2012 2013 2014 2015 2016 2017

Number of articles

Impact factor
250
600
200

150 400

100
200
50

0 0
2009 2010 2011 2012 2013 2014 2015 2016 2017

8 9
 2
Executive Summary

2.2
Research Structure
External Scientific Members
Committee Eduardo López-Collazo.
José Luis López-Sendón
Juan Tamargo Menéndez.
Enrique Gómez Barrena
Professor. Institute of Pharmacology and Toxicology, Spanish National
Francisco García Río
Research Council (CSIC) - Complutense University of Madrid.
Jesús Frías Iniesta
Reiner Albert Veitia Jaime Feliú Battle
Professor. Génomique Fonctionnelle. Université Denis Diderot, Paris Jesús Mingorance Cruz
VII. Group leader of the Molecular Oncology and Ovarian Pathologies,
l’Institut Jacques Monod. Paris Rafael Selgas Gutiérrez
Nuria Vilaboa Díaz
Joaquín Arribas López
Inmaculada Ibáñez de Cáceres
Principal investigator. Vall d´Hebron Hospital. Barcelona
Eduardo López Granados
Chairman of the Technical Committee on Cancer Screening Health
Research Fund (FIS). Institute of Health Carlos III Blanca Fuentes Gimeno
Javier de Castro Carpeño
Jacinta Cecilia Bustamante
Amparo Cano García
Associate Professor. Paris Descartes University, Laboratory of Human
Genetics of Infectious diseases (INSERM U980), Imagine Institut. Center Francisco Arnalich Fernández
Scientific Director Governing Council for the Study of Primary Immunodeficiencies, Necker Enfants-Malades Guillermo Reglero Rada
Eduardo López-Collazo Hospital. Paris Fernando Rodríguez Artalejo
Chairman
Carlos Belmonte Martínez Mercedes Salaices Sánchez
Fernando Prados Roa. Health Care Vice Councillor CAM
Scientific Assistant Professor. Miguel Hernández University. Institute of Neuroscienciences. Nora Butta Coll
Alicante. President of the International Brain Research Organization
Director Deputy Chairman
(IBRO)
Rosario Perona Abellón
Ignacio Zapardiel Gutiérrez Rafael Garesse Alarcón. Chancelor of UAM Antonio Pérez Martínez
Juan Pedro Bolaños Hernández Ignacio Zapardiel Gutierrez
Members Professor. Department of Biochemistry and Molecular Biology. University
Technical Assistant Rafael Pérez-Santamarina Feijóo. Chairman of the of Salamanca. Institute of Functional Biology and Genomics
Alfonso Gil Martínez

Director Board of FIBHULP

Paloma Gómez Campelo
Executive Committee
Chairman
Rafael Pérez-Santamarina Feijóo. Chairman of the
Board of FIBHULP; permanent delegation to Rodolfo
Álvarez-Walther Sala
Members
Juan Antonio Vargas Núñez. Dean of UAM Medical School
Eduardo López-Collazo. Scientific Director of IdiPAZ
Ana Coloma Zapatero. Director of FIBHULP
Francisco García Río. HULP Representative
Francisco Arnalich Fernández. UAM Representative
Carlos Mur de Viu Bernadi. Managing Director of HUF
Ángel Pueyo Cañero. HUF Representative
Secretary
Ana Coloma Zapatero. Director of FIBHULP
Isabel Fabregat Romero.
Rodolfo Álvarez-Sala Walther. FIBHULP Patron Research Ethics Committee
Centre d´Oncologia Molecular. L´Hospitalet, Barcelona IDIBELL- Bellvitge
Teresa Chavarría Giménez. FIBHULP Patron Biomedical Research. Institute Barcelona President
José María Muñoz y Ramón. FIBHULP Patron
Carmen Maroto Vela
Almudena Castro Conde
Juan Antonio Vargas Núñez. FIBHULP Patron
Professor. Chief of Microbiology. Clinical Hospital University of Granada Vicepresident
Eduardo López-Collazo. Scientific Director of IdiPAZ Jesús Frías Iniesta
Santiago Rodríguez de Córdoba
Almudena Castro Conde. FIBHULP Patron
Professor. Cellular and Molecular Medicine Department. Centro de Technical Secretary
Exuperio Díez Tejedor. FIBHULP Patron
Investigaciones Biológicas Emma Fernández de Uzquiano
Francisco Arnalich Fernández. FIBHULP Patron
Santiago Moreno Guillén Members
Fernando Rodríguez Artalejo. UAM Representative
Chief of Infectious diseases Service. Ramón y Cajal Hospital. Madrid José Manuel Añón Elizalde
Amparo Cano García. UAM Representative
Professor. Alcalá University. Madrid José Ignacio Bernardino de la Serna
Pablo Lapunzina Badía. FIBHULP Patron
Antonio Buño Soto
Juan José Pérez Blanco. FIBHULP Patron
Nora Butta Coll
Francisco Javier García-Samaniego Rey. FIBHULP Research Committee
Fernando Cabañas González
Patron
Chairman Filiberto Chuliá Fernández
Carlos Mur de Viu Bernadi. HUF Representative Francisco Arnalich Fernández Jaime Fernández-Bujarrabal Villoslada
Secretary Secretary Elena García Higuera
Ana Coloma Zapatero. Director of FIBHULP Inmaculada Ibáñez de Cáceres María Justa García-Matres Cortés

10 11
 2
Executive Summary
2.2 Research Structure

Pedro Herranz Pinto Members FIBHULP Public Projects Manager

Carlos Lahoz Rallo
Verónica Pérez Blanco
Nuria Rodríguez Salas
Míriam Romero Portales
Filomena Trocoli González
Ramón Usandizaga Elío
Elena Villamañán Bueno
Rosa Villanueva Peña
Member from outside the
institution
Evaristo Moliné Jorques
Eva Prieto Utiel
Technical Secretary
Emma Fernández Uzquiano
Paz Lavilla Uriol
Sol de Gracia García
María Isabel Arribas Álvarez
Ana María Briones Alonso
Alfonso Gil Martínez
María Fernández Velasco
Julián Nevado Blanco
Alejandro Martín Quirós
Alberto Borobia Pérez
Paloma Gómez Campelo
Inmaculada Ibáñez de Cáceres
María Ángeles Martínez Huedo
María Isabel Sánchez Pérez
Rocío Rosas Alonso
Víctor Manuel Toledano Real
Technical Secretary
Mercedes Ruiz Balibrea
Lucía Medina Royo
Director
Ana Coloma Zapatero
Human Resources Manager
Head: Ana Gloria Herrera Puerta
María Quintanar Jaime
Private Projects Manager
Francisco Gil Gadea
Nathalia García Quero
Clinical Trial Manager
Head: Sara Moral Álamo
Desirée Hernández López
Head: Silvia Arce Santamaría
Raquel Carmona del Mazo
Institutional Project Manager
José Luis Narro Villanueva
Marisa Tejedor Botello
International Project Manager
Adriana Varela Fernández
Santiago Rello Varona
Contracting Manager and Head of
Legal Department
Sara Fernández Morata
Accountants
Head: Laura López Revuelta
Mónica García López
Researcher Reception and Attention
Carmen García Artiaga

Documentation Service
Animal Welfare Ethics Raúl Román Cañizares
Committee
Carmen Fernández Criado
Fernando Carceller Benito
Nuria Vilaboa Díaz
Carlota Largo Aramburu

Quality Assurance Committee

Coordinator
José Jonay Ojeda Feo

Members
Blanca Fuentes Gimeno
Alberto Martín Vega
María Luisa Díaz Martínez
Margarita Rodrigo Angulo
Gema Vallés Pérez
Paloma Gómez Campelo
María Dolores Pérez Garre

Training Committee
Coordinator
Bárbara Martínez de Miguel

12 13
 2
Executive Summary
2.2 Research Structure

Research Areas
Large System Pathologies Area
Neuroscience Area Coordinator: Francisco García Río

Coordinator: Exuperio Díez Tejedor GROUP DIRECTOR

Internal Medicine and Systemic Diseases Francisco Arnalich Férnandez
GROUP DIRECTOR Organic Dysfunction and Failure in the Aggression Abelardo García de Lorenzo y Mateos
Psychiatry and Mental Health Consuelo de Dios Perrino Respiratory Diseases Francisco García Río
Neurology and Cerebrovascular Diseases Exuperio Díez Tejedor Regulation of Gene Expression and by Hypoxia Luis del Peso Ovalle
Neuroprotective Strategies in Neurodegenerative Nephrology Rafael Selgas Gutiérrez
Antonio Cuadrado Pastor
Diseases Neonatology Adelina Pellicer Martínez
Involvement of Glycinergic and Glutamatergic Aging and Fragility in the Elderly Juan Ignacio González Montalvo
Francisco Zafra Gómez
Systems in Central Nervous System Pathologies Molecular Hepatology Paloma Jara Vega
Diagnosis and Treatment of Allergic Diseases Santiago Quirce Gancedo
Gynecologic Oncology Ignacio Zapardiel Gutiérrez
Patient Blood Management Manuel Quintana Díaz
Endocrine Diseases Lucrecia Herranz de la Morena
Urology Luis Martínez-Piñeiro Lorenzo
Health Care Nurses Research Jesús Castro Toro
Cardiovascular Area Maternal and Fetal Medicine José Luis Bartha Rasero
Coordinator: José Luis López-Sendón Hentschel Emergency and Critical Pathology Cesar Carballo Carmona

GROUP DIRECTOR
Research on Invasive Clinical Cardiology – ICCI-Paz José Luis López-Sendón Hentschel Cancer and Human Molecular
Cardiovascular Epidemiology and Nutrition Fernando Rodríguez Artalejo Genetics Area
Coagulopathies and Alterations of Haemostasis Víctor Jiménez Yuste Coordinator: Amparo Cano García
Vascular Physiology and Pharmacology Mercedes Salaices Sánchez GROUP DIRECTOR
Vascular Pharmacology and Metabolism (FARMAVSM) Carlos F. Sánchez Ferrer INGEMM- Institute of Medical and Molecular Genetics Pablo Lapunzina Badía
Cardiology Research Group (HUF) Alejandro Curcio Ruigómez Translational Oncology Jaime Feliú Battle
Inmaculada Ibáñez de Cáceres
Experimental Therapies and Biomarkers in Cancer
Javier de Castro Carpeño
Oto-Neurosurgery Research Luis Lassaletta Atienza
Cancer Molecular Pathology and Therapeutic Targets David Hardisson Hernáez
Mechanisms of Tumour Progression Amparo Cano García

Infectious Diseases and Immunity Area Animal and Cell Models for Detection and
Characterization of Leukemic Stem Cells
Carmela Calés Bourguet

Coordinator: Eduardo López-Collazo Research and Diagnosis of Inherited Metabolic Diseases María Belén Pérez González
Regulation of Ciliary Structure and Function by
Francesc García Gonzalo
GROUP DIRECTOR Phosphoinositides
AIDS and Infectious Diseases José Ramón Arribas López Onco-Hematology Research Group (HUF) Manuel Hidalgo
Molecular Microbiology Jesús Mingorance Cruz
Immuno-Rheumatology
Innate Immune Response
María Eugenia Miranda Carús
Eduardo López-Collazo
Surgery, Transplant and Health
Diagnosis and Treatment of Diseases associated with Margarita López Trascasa
Technologies Area
Abnormalities of the Complement System Pilar Sánchez-Corral Gómez Coordinator: Leopoldo Martínez Martínez
Lymphocyte Pathophysiology in Immunodeficiencies Eduardo López Granados GROUP DIRECTOR
Drug Hypersensibility and Innate Immune Response Teresa Bellón Heredia Congenital Malformation Surgery Leopoldo Martínez Martínez
Pediatric Respiratory, Systemic and Neurological Bone Pathophysiology and Biomaterials Nuria Vilaboa Díaz
Cristina Calvo Rey
Infections & Host Immune Response Cellular Engineering María Paz de Miguel González
Pediatric Systemic Infections; HIV, Tuberculosis, Clinical Pharmacology Jesús Frías Iniesta
María José Mellado Peña
Imported and Emergent Diseases Osteoarticular Surgery Research – GICOA Enrique Gómez Barrena
Translational Research in Pediatric Oncology, Reconstructive and Regenerative Research Luis Landín Jarillo
Antonio Pérez Martínez
Hematopoietic Transplantation and Cell Therapy
Transplant Francisco Hernández Oliveros
Intestinal Diseases Research Group (HUF) Fernando Bermejo San José
Rehabilitation- LAMBECOM (HUF) Juan Carlos Miangolarra Page

14 15
 2
Executive Summary
2.2 Research Structure

Public Research Contracts Data: Human Resources

Ramón y Cajal Stabilisation Predoctoral Fellowship - ISCIII Programme Organisation Total
Contracts (I3) - CAM • Clara Escudero Duch (FI14/00447). Bone Pathophysiology
• Karen Elise Heath. INGEMM - Institute of Medical and Mole- and Biomaterials Group Ramón y Cajal Stabilisation Contracts (I3) CAM 3
cular Genetics Group • Natalia Stella Ascariz (FI14/00391). Molecular Microbiology
Miguel Servet Stabilisation Contracts (I2) ISCIII/ CAM 14
• Jesús Mingorance Cruz. Molecular Microbiology Group Group
• Rebeca Pérez de Diego. Innate Immune Response Group • Andrés Esteban Cantos (FI17/00192). AIDS and Infectious Technical Support Stabilisation Contracts CAM 3
Diseases Group TOTAL ESTABLISHED 20
Miguel Servet Stabilisation • María del Carmen Gómez de Frutos (FI17/00188). Neuro- Miguel Servet Contracts CP Type 1 ISCIII 1
Contracts (I2) - ISCIII/ CAM logy and Cerebrovascular Diseases
Miguel Servet Contracts CP Type 1I ISCIII 2
• Teresa Bellón Heredia. Drug Hypersensibility and Innate Immune
Response Group Predoctoral Contract - MECD Intensification Contracts ISCIII 2
• Irene Francisco Recuero (FPU13/00945). Associated Clinician
• Juan Ángel Fresno Vara. Translational Oncology Group Río Hortega Contracts ISCIII 1
• Daniel Ruiz Pérez (FPU13/01638). Respiratory Diseases Group
• Ángel Campos Barros. INGEMM - Institute of Medical and Juan Rodés Contracts ISCIII 1
Molecular Genetics Group Technical Support Stabilisation Sara Borrell Postdoctoral Contracts ISCIII 1
• María Paz de Miguel González. Cellular Engineering Group Contracts - CAM Predoctoral Fellowship ISCIII 4
• Eduardo López-Collazo. Innate Immune Response Group • Francisco Gayá Moreno. AIDS and Infectious Diseases Group
• Juan Antonio Rey Herranz. Oto-Neurosurgery Research Group Predoctoral Contract MECD 2
• María Teresa Vallejo Cremades. Congenital Malformation Sur-
• Berta Rodés Soldevila. AIDS and Infectious Diseases Group gery Group Technical Support in Management Contracts ISCIII 1
• Pilar Sánchez-Corral Gómez. Diagnosis and Treatment of Di- • Beatriz Sanz Minguela. Cell Culture Unit Youth Guarantee Contracts CAM 7
seases Associated with Abnormalities of the Complement System Group TOTAL PROGRAMMES 22
• María Rosa Torres Jiménez. Metabolic-Vascular Unit Technical Support in Management
• David Vicent López. Molecular Hepatology Group Contracts - ISCIII TOTAL ESTABLISHED + PROGRAMMES 42
• Nuria Vilaboa Díaz. Bone Pathophysiology and Biomaterials Group • Adriana Varela Fernández (GIS17/00029). Associated Clinician
• Nora Viviana Butta Coll. Coagulopathies and Alterations of Hae- UCICEC CAIBER 4
Youth Guarantee Contracts - CAM
mostasis Group FIS Projects ISCIII 13
• María Inmaculada Ibáñez de Cáceres. Experimental Therapies Graduate
• Roberto Mediavilla Torres (PEJ-2017-AI/SAL-5716). Psy- European Projects EU 8
and Biomarkers in Cancer Group
chiatry and Mental Health Research Network ISCIII 8
• Rosa María Rodríguez Pérez. Diagnosis and Treatment of Aller-
gic Diseases Group Research Network CAM 4
Predoctoral
• Emilio Llanos González (PEJD-2017-PR/BIO-4674). Inna- SAF/MAT MINECO 2
Miguel Servet Contracts Type I - te Immune Response Group Biobank ISCIII 2
ISCIII
• María Dolores Gutiérrez Fernández (MS15/00069). Neu- Technical Support Commercial clinical trials EECC Promoters 43
rology and Cerebrovascular Diseases • Beatriz Mora Rojas (PEJ-2017-TL/BMD-5831). AIDS and Private projects Pharmaceutical Industry 58
Infectious Diseases Group In-house Projects FIBHULP 7
Miguel Servet Contracts Type II • Verónica Valdés Blanco (PEJ-2017-TL/BMD-5661). Mole- ITEMAS Network ISCIII 2
- ISCIII cular Hepatology
• María Fernández Velasco (CPII16/00047). Innate Immune RETOS MINECO 4
• Virginia Rufo Rabadán (PEJ-2017-TL/BMD-6201). INGEMM
Response Group - Institute of Medical and Molecular Genetics TOTAL EMPLOYEES DEPENDET ON P.I. 155
• Laura Saldaña Quero (CPII16/00038). Bone Pathophysiology • Sonia Jiménez Rodríguez (PEJ-2017-TL/BMD-6939). Mo- Private projects Pharmaceutical Industry 7
and Biomaterials Group lecular Microbiology Group TOTAL FELLOWS DEPENDET ON P.I. 7
• César Vélez Casanova (PEJ-2017-TL/BMD-6873). Diagno-
Intensification Contracts - TOTAL STAFF DEPENDENT ON P.I. 162
sis and Treatment of Diseases Associated with Abnormalities of the
ISCIII Complement System
• José Ramón Arribas López. AIDS and Infectious Diseases Group Technical Unit Staff FIBHULP 14
• Francisco José García Río. Respiratory Diseases Group
TOTAL TECHNICAL UNIT 14
Río Hortega Contracts - ISCIII
• Rosa de Miguel Buckley (CM17/00064). AIDS and Infectious TOTAL 218
Diseases Group

Juan Rodés Contracts - ISCIII

• Talía Sainz Acosta (JR16/00021). Pediatric Systemic Infections;
HIV, Tuberculosis, Imported and Emergent Diseases

Sara Borrell Postdoctoral

Contracts - ISCIII
• Raquel Rodrigues Díez (CD15/00003). Vascular Physiology
and Pharmacology

16 17
 2
Executive Summary

2.3
Training Report
IdiPAZ Demand
• Researh Areas
Area Coordinators

and Teaching • Research Groups

Groups Director

Research Research Area

IdiPAZ
Training Training
TRAINING
Adapting to PLAN Aimed at basic
the Institute’s and clinical
strategic objectives researches

IdiPAZ Opportunities
• HULP Continuing Education
• UAM Training Opportunities
• Institute Opportunities

2.3.1.
Training Committee
One of the main priorities of IdiPAZ Research Institute is to encourage and develop trai-
ning programs for researchers, with special attention to the scientific training in research 2.3.2.
methodology. Training courses conducted
IdiPAZ’s Training Committee is responsible for designing, planning and evaluating the trai-
ning activities given by the Institute, as well as ensuring the development of a global Training by IdiPAZ in 2017
Plan that meets the proposed objectives. The main objective of IdiPAZ’s Training Commit-
tee is to draw up, promote and evaluate the training plan, aimed at maintaining or improving TITLE HEAD DATES ASSISTANTS HOURS ASSESSMENT
the skills or actions of idiPAZ’s basic or clinical researchers. Introducción a las Normas de buena
The committee is composed of competent training professionals from the different struc- práctica clínica para investigadores Emma Fernández Septiember
23 6 8.4
tures of IdiPAZ and guarantees the representation of all the different types of IdiPAZ y aspectos éticos de la investigación. de Uzquiano 26th-28th
members, as well as the correct coordination between all the training activities that make Edición 03
up the plan.
Investigación clínica y lectura crítica:
IdiPAZ’s Training Plan includes the HULP training offer, the UAM offer and the implemen- Juan José Ríos Octuber
búsqueda y recuperación de la 18 12 -
tation of the Institute’s own training offer in line with its strategic objectives and linked to Blanco 16th-19th
literatura científica
the detection of new training needs not covered by the existing training offers from each
of those entities. The objective of the Institute’s own training offer is to complement the Análisis de datos biomédicos con Octuber
Rosario Madero 19 12 8.4
training provided by both HULP and UAM. SPSS. Nivel básico 23rd-26th

The design of the plan includes, as origin and addressees, healthcare professionals with Técnicas de escritura científica en Noviember
Simón Bartlett 23 12 8.7
research activity as well as research professionals. inglés 13rd-16th
The detection of training needs arises as a result of communication with area coordinators
and group directors, analysis of the Needs Assessment Surveys submitted by members of
the Institute, reception and analysis of new proposals or suggestions from IdiPAZ members,
selection of activities with successive editions planned, reception and analysis of proposals
made within the Continuing Medical Training Committee that meet the requirements of
interest in research, analysis of new training proposals by IdiPAZ’S Training Committee itself
and other study techniques.

18 19
 2
Executive Summary
2.3 Training Report and Teaching
2.3.3.
IdiPAZ Doctoral Theses
Álvarez García J. Tratamiento mediante implante de células
troncales mesenquimales de la isquemia crítica de las extre-
midades en un modelo murino experimental[dissertation].
Madrid: UAM: 2017(24/01/2017).
Directors: Riera del Moral L, García Arranz M.
Andrés Moreno AM. Trasplante intestinal y rechazo:
estudio experimental con células troncales mesen-
quimales derivadas de tejido adiposo para su preven-
ción y perspectivas clínicas futuras en la búsqueda de la
tolerancia inmunológica[dissertation]. Madrid: UAM:
2017(22/06/2017).
Director: Tovar Larrucea JA.
Anta Redondo D. Anestesia intradural con mepivacaina hi-
perbárica a dosis bajas en la cirugía ambulatoria de la hernia
inguinal[dissertation]. Madrid: UAM: 2017(05/07/2017).
Directors: Gilsanz Rodríguez F, Gredilla Díaz E.
Ballesteros Ortega D. Características de los pacientes con
infarto de miocardio con enfermedad coronaria no obs-
tructiva (IMECNO). Registro ARIAM-SEMICYUC. Elabora-
ción de Score predictivo de IMECNO.[dissertation]. Ma-
drid: UAX: 2017(22/06/2017).
Directors: Blancas Gómez-Casero R, Quintana Díaz M.
Ben Abdelhanin M. Evaluación del eje entero-insular en
relación a la forma de la curva durante la sobrecarga
oral de glucosa en gestantes[dissertation]. Madrid: UAM:
2017(18/09/2017).
Directors: Gómez Rioja R; Herranz de la Morena L.
Bobolea I. Fenotipos y endotipos de asma grave: Meca-
nismos moleculares implicados en la patogénesis y en la
desensibilización a aspirina [dissertation]. Madrid: UAM:
2017(19/09/2017).
Directors: Quirce Gancedo S; Álvarez Sala R.
Burgos Frías N. Estudio predictivo de las necesidades trans-
fusionales del paciente quemado quirúrgico y validación del
método[dissertation]. Madrid: UAM: 2017(20/09/2017).
Directors: Gilsanz Rodríguez F, Domínguez Ruiz Huerta A.
Cachafeiro Fuciños L. La influencia del síndrome de inhala-
ción en la evolución y el pronóstico del paciente quemado
crítico[dissertation]. Madrid: UAM: 2017(13/07/2017).
Directors: García de Lorenzo y Mateos A, Sánchez
Sánchez M.
Cara Fuentes G. Rol of CD80 in the pathegenesis of protei-
nuria in minimal change disease[dissertation]. Madrid: UAX:
(01/06/2017).
Director: Espinosa Román L.
Casado Abad MG. Evaluación de la implantación de un
sistema de trazabilidad mediante lectura de código de
barras en el proceso farmacoterapéutico del paciente
oncológico[dissertation]. Madrid: UAM: 2017(01/05/2018).
Directors: Zamora Auñon P, Romero JA, Benedi J.
Castillo Gallego MC. Diagnostic imaging techniques and
predictive factors in spondyloarthritis and psoriatic arthri-
tis [dissertation]. Madrid: UAM: 2017(12/06/2017).
Directors: de Miguel E, McGonnagle D,
Marzo-Ortega H.
Cebolla Lorenzo S. Hacia una valoración integral del pacien-
te con infección por VIH. Evaluación de una herramienta
20
de detección de depresión en contextos médicos no es-
pecializados en salud mental[dissertation]. Madrid: UAM:
2017(15/09/2017).
Directors: Rodríguez-Vega B, Bayón Pérez C, Hernando
Jerez MA.
Cedillo Mireles JL. Implicación fisiopatológica del recep-
tor nicotínico α7 y de su duplicado parcial dupα7 en
sepsis y cáncer de pulmón[dissertation]. Madrid: UAM:
2017(05/09/2017).
Directors: Montiel López C; Arnalich Fernández F.
Climent Alcalá FJ. Utilidad de una unidad especiali-
zada en la atención de niños con patología crónica
compleja[dissertation]. Madrid: UAM: 2017(18/09/2017).
Directors: Calvo Rey C, Albajara Velasco L, Mellado Peña MJ
Concepción Rodríguez NA. Estudio de validación diagnós-
tica: relación entre espectroscopía óptica e índice tobillo
brazo en la enfermedad arterial periférica[dissertation].
Madrid: UAM: 2017(22/09/2017).
Directors: Riera del Moral L, Rodríguez Montes JA.
Conejo Pérez MN. Eficacia de la formación y mentoría sobre
las competencias, práctica y barreras percibidas por las en-
fermeras, en la Práctica Basada en Evidencias[dissertation].
Madrid: UAH: 2017(27/06/2017).
Directors: Casas Martínez MF; Molina Arias M.
Cuesta López E. Resonancia magnética cardiaca en ataxia
de Friedreich: seguimiento cardiaco de las terapias antioxi-
dantes [dissertation]. Madrid: UAM: 2017(06/06/2017).
Directors: López-Sendón JL, Arpa Gutiérrez FJ, Bret
Zurita M.
Dayse da Silva IL. Expressäo de Qa-2 e sua relaçäo com o
infiltrado linfocítico e a diferenciaçäo celular em dois mo-
delos murinos de adenocarcinoma mamário[dissertation].
Minas Gerais: Universidade Federal de Minas Gerais:
2017(26/06/2017).
Directors: Ferreira E; Quintanilla M.
de Arriba Sánchez A. Ensayo piloto sobre una nueva fórmula
inmunomoduladora preoperatoria en cáncer de cabeza y
cuello[dissertation]. Madrid: 2017(23/06/2017).
Directors: Gómez Candela C, López Plaza B
Díaz Almirón M. Desarrollo del Algoritmo CAPRI para la
estimación de la abundancia de complejos enzimáticos y su
aplicación en la modelización del metabolismo en cáncer de
mama[dissertation]. Madrid: UAM: 2017(15/09/2017).
Directors: Gámez-Pozo A, Fresno Vara JA.
Díaz Tascón A. Valoración de escalas pronósticas basadas
en hallazgos la tomografía computarizada en pacientes con
trauma cráneo encefálico grave[dissertation]. Madrid: UAM:
2017(21/09/2017).
Directors: Quintana Díaz M, Martí de Gracia M.
Encinas Hernández JL. El tratamiento quirúrgico prenatal del
mielingocele[dissertation]. Madrid: UAM: 2017(16/06/2017).
Directors: López Santamaría M, Tovar Larrucea JA.
Escosa García L. Cribado de la infección congénita por cito-
megalovirus en prematuros de peso adecuado y neonatos
de bajo peso para la edad gestacional[dissertation]. Madrid:
UAM: 2017(06/07/2017).
Directors: del Rosal Rabes T; Mellado MJ.
Fernández Heredero A. Incidencia y factores asociados
a nefropatía inducida por contrastes en pacientes some-
tidos a reparación endovascular de aneurismas de aorta
abdominal[dissertation]. Madrid: UAM: 2017(10/05/2017).
Directors: Riera del Moral L, Rodríguez Montes JA.
Fernández Mulero S. Relación entre los niveles de creatinqui-
nasa plasmática postoperatoria y el deterioro de la función re-
nal tras cirugía de la fractura de cadera[dissertation]. Madrid:
UAM: 2017(27/07/2017).
Directors: Gilsanz Rodríguez F, Aguilar Sánchez JL.
Fernández Rincón A. Infecciones por virus respiratorios en
una cohorte de recién nacidos y desarrollo de sibilancias
recurrentes[dissertation]. Madrid: UAM: 2017(21/09/2017).
Directors: Calvo Rey C; García García ML.
Fernández Rodríguez L. Análisis de la utilidad de la tomogra-
fía computarizada volumétrica de tórax en la evaluación de
operabilidad de pacientes con cáncer de pulmón[dissertation].
Madrid: UAM: 2017(23/10/2017).
Directors: García Río FJ; Torres Sánchez I.
García Díaz EF. El violín: un instrumento para el desarrollo mu-
sical y cognitivo desde la infancia[dissertation]. Madrid: UAM:
2017(22/09/2017).
Directors: del Olmo Barros MJ; Gutiérrez Rivas E.
García Fernández-Villalta M. Adherencia al calendario va-
cunal infantil y cumplimiento de las recomendaciones de
inmunización adicional en niños con patología crónica
compleja[dissertation]. Madrid: UAM: 2017(22/09/2017).
Directors: Méndez Echevarría A; Mellado MJ.
García López Hortelano M. Experiencia epidemiológica, clínica
y preventiva en una unidad de referencia de vacunación inter-
nacional pediátrica y niño viajero[dissertation]. Madrid: UAM:
2017(21/12/2017).
Directors: Mellado Peña MJ; Díaz J.
Gómez Rivas J. Pérdida de función androgénica y vulnera-
bilidad vascular. Potencial efecto protector de extractos de
espirulina[dissertation]. Madrid: UAM: 2017(19/09/2017).
Directors: Rodríguez Bethancourt F; Ferrer Parra M.
Gómez Santos C. Análisis comparativo de los resultados del
trasplante de sangre de cordón umbilical y haploidéntico en
pacientes pediátricos con hemopatías malignas[dissertation].
Madrid: UAM: 2017(07/09/2017).
Director: Pérez Martínez A.
González Carrasco E. Infecciones respiratorias virales en el niño
prematuro: morbilidad a corto y medio plazo[dissertation].
Madrid: UAX: 2017(06/06/2017).
Directors: Calvo Rey C; García García ML.
González García E. Papel del estrés oxidativo y del FGF21
en la progresión de la arteriosclerosis y el síndrome meta-
bólico en pacientes en diálisis[dissertation]. Madrid: UAM:
2017(03/04/2017).
Directors: Bajo Rubio MA, Díez JJ
Hernández Martín A. Interacciones entre los virus de la he-
patitis B y Delta en diferentes situaciones clínicas. Identifica-
ción de marcadores de replicación de virus delta en pacientes
con evidencia de infección pasada por el virus de la hepatitis
B[dissertation]. Madrid: Universidad Europea: (28/09/2017).
Directors: García-Samaniego Rey J, Madejón Seiz A.
Herrero de Lucas E. Lactato y parámetros hemodinámicos
en el paciente quemado crítico[dissertation]. Madrid: UAM:
2017(19/01/2017).
Directors: García de Lorenzo y Mateos A, Sánchez Sánchez SM.
Herrero Ruiz B. Crecimiento longitudinal fetal en el tercer
trimestre como predictor de la aparicion de eventos perinata-
les y hallazgos placentarios significativos[dissertation]. Madrid:
UAM: 2017(26/09/2017).
Directors: Bartha Rasero Jl; de la Calle Fernández Miranda M.
Iglesias Rosado C. Efecto del consumo de productos cárnicos
con antioxidantes naturales y omega-3 sobre factores de riesgo
cardiovascular en una población con dislipemia[dissertation].
Madrid: UAX: 2017(14/07/2017).
Directors: Gómez Candela C, Bermejo López LM
Jaquotot Herranz M. Utilidad de la monitorización de los niveles
de infliximab y anticuerpos anti-infliximab en el manejo de los
pacientes con enfermedad inflamatoria intestinal[dissertation].
Madrid: UAM: 2017(28/09/2017).
Director: Martín Arranz MD.
Jiménez Diéz V. Estudio anatómico de la región lateral del
codo. Descripción de las estructuras implicadas en la epicon-
dilitis lateral[dissertation]. Madrid: UCM: 2017(01/06/2017).
Directors: Sañudo Tejero JR, Cecilia López D, Barco Laakso, R.
Jurado Palomo J. Eficacia y seguridad de la profilaxis a cor-
to plazo con Andrógenos Atenuados y/o Concentrado Plas-
mático de C1 Inhibidor en la realización de procedimientos
odontoestomatológicos, maxilofaciales y otorrinolaringoló-
gicos en pacientes con angioedema hereditario por déficit
de la proteína inhibidor de la C1 Esterasa funcionalmente
activa[dissertation]. Madrid: UAM: 2017(17/10/2017).
Directors: Caballero MT; Álvarez-Sala Walther R.
Laiglesia Lorenzo MA. Generación de células mesenquima-
les de placenta para uso clínico[dissertation]. Madrid: UAM:
2017(11/09/2017).
Directors: Gómez Barrena E; Gonzalo RM.
Lekue Madanabeitia AL. Calidad de vida en pacientes implanta-
dos con BAHA[dissertation]. Madrid: UAM: 2017(22/09/2017).
Director: Lassaletta Atienza L.
López Oliva MO. Manejo de la infección y enfermedad por
citomegalovirus en el trasplante renal. Importancia de la
monitorización inmunológica: respeusta específica T CD8
y expresión de CD94/NKG2C[dissertation]. Madrid: UAM:
2017(04/04/2017).
Directors: Selgas Gutiérrez R, Jiménez Martín C,
Bellon Heredia T
López-Tofiño Alcázar A. Supervivencia y calidad de
vida al año tras un episodio de shock séptico en pa-
cientes postquirúrgicos[dissertation]. Madrid: UAM:
2017(05/05/2017).
Director: Gilsanz Rodríguez F
Luna Castaño P. La valoración del dolor en los pacientes pre-
verbales: indicadores fisiológicos y conductuales utilizados por
las enfermeras en las UCI pediátricas[dissertation]. Madrid:
UAH: 2017(29/06/2017).
Directors: Casa Martínez MF; Gómez González JL.
Martín del Valle F. Infecciones neurológicas y sistémicas por pa-
rechovirus humano en niños menores de 3 años[dissertation].
Madrid: UAM: 2017(22/06/2017).
Directors: Calvo Rey C; Cabrerizo M.
Martín Sánchez C. Identificación de un nuevo receptor nico-
tínico α7dup/α7 mixto y su papel fisiopatológico en la neu-
rotransmisión y neuroinflamación[dissertation]. Madrid: UAM:
2017(20/09/2017).
Directors: Montiel López C; Arnalich Fernández F.
Martínez Jáñez N. Estudio de concordancia entre el 8-Gene
Score y otros test moleculares comerciales (Mammaprint,
21
 2
Executive Summary
2.3 Training Report and Teaching
Oncotype DX) para decidir la necesidad de quimiotera-
pia adyuvante en pacientes con cáncer de mama positivo
para receptores hormonales[dissertation]. Madrid: UAM:
2017(22/06/2017).
Directors: Espinosa Arranz E, Carrato Mena A.
Martínez Sánchez N. Implicaciones clínicas, resultados obs-
tétrico-perinatales y complicaciones fetales en gestantes
portadoras de anticuerpos anti-RO/SS-A y ANTI-LA/SS-
B[dissertation]. Madrid: UAM: 2017(27/09/2017).
Directors: Bartha Rasero JL.
Martínez Silveira C. Feito do consumo de hidrolisado de clara
de ovo sobre as alterações neurológicas, reprodutivas e car-
diovasculares promovidas pela exposição ao clorato de alu-
minio em ratos[dissertation]. Uruguaiana, Brasi: Universidade
Federal do Pampa (l): 2017(13/12/2017).
Directors: Wiggers G; Miguel M.
Martínez Virto AM. Servicios de urgencias hospitalarias: in-
fluencia de la caracterización de los pacientes y su proceso
asistencial durante su tiempo de permanencia[dissertation].
Madrid: UAM: 2017(27/09/2017).
Directors: Quintana Díaz M; Sarriá Santamera A.
Medrano Rodríguez C. Bases Moleculáres de los defec-
tos congénitos de glicosilación[dissertation]. Madrid: UAM:
2017(01/03/2017).
Directors: Pérez González B, Pérez Cerdá C.
Mena de la Cruz R. Splicing alternativo en SERPING1: Expre-
sión del ARNm total y de dos variantes alternativas del mensa-
jero del gen del inhibidor de C1 en pacientes con angioedema
hereditario[dissertation]. Madrid: UAM: 2017(27/03/2017).
Director: López Trascasa M.
Miranda Maldonado IC. Perfil inmunohistoquímico de la res-
puesta inmune celular en la endometritis crónica por Chla-
mydia trachomatis y gérmenes asociados[dissertation]. Ma-
drid: UAM: 2017(20/11/2017).
Directors: Hardisson Hernáez D; Gallegos Ávila MG.
Mirón Rodríguez MF. Anestesia general en cirugía mayor am-
bulatoria odontológica con discapacitados intelectuales. Es-
tudio prospectivo observacional[dissertation]. Madrid: UAM:
2017(29/06/2017).
Directors: Gilsanz Rodríguez F, García Miguel MF.
Molina Angulo B. Patrón de recaída postrasplante hemato-
poyético en pacientes pediátricos con hemopatías malignas.
Evaluación del efecto aloinmune[dissertation]. Madrid: UAM:
2017(01/09/2017).
Director: Pérez Martínez A.
Molina Crespo A. Análisis de gasdermina b como marcador de
respuesta a tratamiento y nueva diana terapéutica en tumores
her2+[dissertation]. Madrid: UAM: 2017(25/09/2017).
Directors: Moreno Bueno G; Sarrio López D.
Moro Agud M. Análisis de la mejora continua de la calidad de un
Servicio de Farmacia certificado por la Norma ISO 9001. Eco-
lución de 8 años[dissertation]. Madrid: UCM: 2017(26/06/2017).
Directors: Romero Garrido JA, Herrero Ambrosio A; Benedí
Gonzalez J.
Mota Jiménez A. Deciphering intratumor molecular heteroge-
neity in gynecological cancer progression[dissertation].
Madrid: UAM: 2017(12/05/2017).
Directors: Moreno Bueno G.
Muñoz San José A. Eficacia de una intervención basada en min-
dfulness sobre la calidad de vida, depresión, ansiedad, fatiga y
22
cognición social en pacientes con esclerosis múltiple [disser-
tation]. Madrid: UAM: 2017(15/09/2017).
Directors: Rodríguez-Vega B, Bayón Pérez C.
Nieto Moral C. Encefalía hepática aguda sobre crónica en la
colestasis experimental microquirúrgica experimental: altera-
ciones metabólicas y vasculares[dissertation]. Madrid: UCM:
2017(26/06/2017).
Directors: Blanco Rivero J; Aller MA; Higuera Matas A.
Novo Torres JR. Tratamiento percutáneo de las estenosis bi-
liares en el trasplante hepático infantil[dissertation]. Madrid:
UAM: (25/09/2017).
Directors: Garzón Moll G, López Santamaría M.
Olabarrieta Arnal I. Infecciones respiratorias de origen vírico
en recién nacidos prematuros moderados y tardíos durante
sus dos primeros años de vida[dissertation]. Madrid: UAM:
2017(24/04/2017).
Directors: Calvo Rey C; García García ML.
Oviedo Céspedes DC. Análisis de perfiles neuropsicológicos
y de biomarcadores proteómicos y vasculares en deterioro
cognitivo leve y la enfermedad de Alzheimer en panameños
adultos[dissertation]. Madrid: UCM: 2017(03/07/2017).
Directors: Fernández Guinea S; Frank García A; Briton G.
Panal Cusatí M. Relación de los biomarcadores del cán-
cer de mama con la carga tumoral OSNA del ganglio
centinela[dissertation]. Madrid: UAM: 2017(04/09/2017).
Directors: Hardisson Hernáez D; Herrera de la Muela M.
Pedrero Escalas MF. Ensayo clínico hospitalario: homeopatía
en las otitis secretoras infantiles[dissertation]. Madrid: UAM:
2017(17/02/2017).
Directors: Lassaletta Atienza L; Jiménez Antolín JA.
Pérez Robles T. Evaluación de la adherencia al tratamiento pro-
filáctico en pacientes con hemofilia y su relación con los epi-
sodios de sangrado.[dissertation]. Madrid: UCM: (16/06/207).
Directors: Romero Garrido JA, Benedí González B, Iglesias
Peinado I.
Pérez Torres A. Efectos a corto plazo de un programa de edu-
cación nutricional sobre el estado nutricional de pacientes
con enfermedad renal crónica avanzada[dissertation]. Madrid:
UCM: 2017(20/06/2017).
Directors: Selgas Gutiérrez R, López Sobaler AM
Pintado Berninches L. Uso de los peptidos GSE24.2 y GSE4
como posible tratamiento de celulas de pacientes con ataxia
telangiectasia. [dissertation]. Madrid: UAM: 2017(11/05/2017).
Director: Perona Abellón R.
Plasencia Rodríguez C. Immunogenicity of biological drugs in
inflammatory rheumatic disease: Clinical relevance and thera-
peutic drug monitoring[dissertation].
Madrid: UAM: 2017(14/06/2017).
Directors: Balsa A, Wolbink G.
Pozuelo Echegaray I. Coagulopatía temprana del paciente que-
mado crítico[dissertation]. Madrid: UAM: 2017(19/09/2017).
Directors: Sánchez Sánchez SM, Quintana Díaz M.
Prieto Muñoz I. Cáncer y diabetes: influencia del estado pro-
inflamatorio diabético en las características del cáncer de
colon[dissertation].
Madrid: UAM: 2017(26/06/2017).
Directors: Rodríguez Salas N, Cassinello Plaza F.
Prieto Pozuelo M. Aplicabilidad de la RT-PCR a tiempo real
a partir de tejido fijado en formol e incluido en parafina a
la búsqueda de perfiles de expresión génica con valor pro-
nóstico en cáncer de endometrio[dissertation]. Madrid: UAM:
2017(12/09/2017).
Directors: Hardisson Hernáez D; Mendiola Sabio M.
Quevedo Teruel S. Papel de las interleucinas en el desarrollo
de sibilancias recurrentes tras un episodio de bronquiolitis
grave[dissertation]. Madrid: UAX: 2017(05/05/2017).
Directors: Calvo Rey C; García García ML.
Quirós Fernández R. Estudio de intervención nutricional para
evaluar el efecto de la suplementación oral con hidroxitiro-
sol y punicalagina sobre diferentes marcadores tempranos de
la aterosclerosis en sujetos de mediana edad, aparentemente
sanos sin enfermedad cardiovascular establecida[dissertation].
Madrid: UAM: 2017(13/07/2017).
Directors: Gómez Candela C, López Plaza B
Ramón Vázquez A. Estudio del perfil transcripcional de los
receptores nucleares LXR en un modelo celular de ma-
crófago murino inmortalizado[dissertation]. Madrid: UCM:
2017(01/07/2017).
Directors: Castrillo A; Boscá Gomar L.
Refoyo Salicio E. Valor de la resonancia magnética en
el diagnóstico de la cardiopatía chagásica en área no
endémica[dissertation]. Madrid: UCM: 2017(12/07/2017).
Directors: Tamargo Menéndez J, López-Sendón JL.
Revello Álvarez R. Redicción multivariante del síndrome
de respuesta inflamatoria fetal a partir del uso combina-
do de marcadores bioquímicos [dissertation]. Madrid: UAM:
2017(08/09/2017).
Director: Bartha Rasero JL
Riera Banal J. Nuevos métodos no invasivos para el estudio
del flujo sanguíneo cerebral en recién nacidos[dissertation].
Madrid: UPM: 2017(19/07/2017).
Directors: Pellicer Martínez A; Serrano JJ.
Rivas Pollmar MI. Estudio del efecto sobre la hemostasia de
los distintos agentes terapéuticos utilizados en el tratamien-
to de la trombocitopenia inmune [dissertation]. Madrid: UAM:
(20/09/2017).
Directors: Álvarez Román MT; Jiménez-Yuste V; Butta Col N.
Rivera Núñez MA. Escalas de valoración de riesgo
tromboembólico y tromboprofilaxis en el paciente de
urgencias[dissertation]. Madrid: UAM: 2017(19/05/2017).
Directors: Quintana Díaz M, Huerta Álvarez C.
Rodríguez Centeno J. Estudio de los telómeros en dictyoste-
lium discoideum. Desarrollo de un modelo celular de disquera-
tosis congénita[dissertation]. Madrid: UAM: 2017(08/06/2017).
Director: Sastre Garzón L.
Rojas Inastrillas M. Niveles de anticuerpos frente a enferme-
dades infecciosas prevenibles mediante vacunación y con im-
pacto en la salud infantil en mujeres embarazadas en la Comu-
nidad Autónoma de Madrid[dissertation]. Malaga: Universidad
de Málaga: 2017(15/09/2017).
Directors: Méndez Echevarría A; Moreno Pérez D.
Romanillos Arroyo JO. ¿Mejora la PTH (Teriparatida)
los resultados en fracturas pertrocantéreas inestables
osteoporóticas?[dissertation]. Madrid: UAM: 2017(07/09/2017).
Directors: Gil Garay E; Herruzo Cabrera R.
Rosado Caracena R. Síntomas neurológicos postoperatorios
tras dos abordajes de plexo braquial en cirugía de miembro
superior[dissertation]. Madrid: UAM: 2017(20/09/2017).
Directors: García de Lorenzo y Mateos A, Olarra Nuel J.
Rosales Mendoza CE. Papel de la pro-proteína convertasa
subtilisina kexina de tipo 9 (PCSK9) en el macrófago. Implica-
ciones en el desarrollo de aterosclerosis[dissertation]. Madrid:
UAM: 2017(01/09/2017).
Directors: Boscá Gomar L, Martínez Valverde A.
Sainz de la Maza Redondo D. Identificación bioquímica, genéti-
ca y funcional de genes implicados en la potencialidad de célu-
las germinales[dissertation]. Madrid: UAM: 2017(13/01/2017).
Directors: de Miguel MP; Arnalich-Montiel F.
Salas Aizpurúa C. El papel de la comunicación médico-pa-
ciente en la satisfacción del usuario y del profesional de la
medicina[dissertation]. Madrid: UAX: 2017(19/01/2017).
Directors: Calvo Rey C; García García ML.
Salgado Aranda P. Factores de riesgo de colonización intestinal
por enterobacterias productoras de carbapenemasas al ingre-
so en una unidad de cuidados críticos[dissertation]. Madrid:
UAM: 2017(16/09/2017).
Directors: Gilsanz Rodríguez F, Maseda Garrido E.
Sánchez Recalde A. Pevalencia y factores predictivos de mor-
talidad y complicaciones a largo plazo en un serie de 481 pa-
cientes con coartación de aorta[dissertation]. Madrid: UAM:
2017(25/09/2017).
Directors: López-Sendón JL, Oliver JM.
Santurino Fontecha C. Desarrollo de un queso de cabra en-
riquecido de manera natural en omega-3 y ácido linoleico
conjugado. Ensayo clínico en voluntarios con sobrepeso y
obesidad[dissertation]. Madrid: UAM: 2017(28/07/2017).
Directors: Fontecha Alonso FJ, Gómez Candela C
Silva Zaragueta P. Abordaje del hidrosalpinx mediante dis-
positivo essure previo al tratamiento de fecundación in
vitro[dissertation]. Madrid: UAM: 2017(22/06/2017).
Directors: Bartha Rasero JL; Hernández Gutiérrez A.
Sotillo Torquemada A. Estructura fina de la población de Kle-
bsiella pneumoniae ST11 productora de OXA-48 del Hos-
pital Universitario La Paz determinada por secuenciación
genómica[dissertation]. Madrid: UAM: 2017(15/12/2017).
Director: Mingorance Cruz J.
Soto J. Identificación de marcadores epigenéticos con significa-
do clínico asociado a la respuesta a derivados de platino en cán-
cer de ovario[dissertation]. Madrid: UAM: 2017(21/04/2017).
Director: Ibáñez de Cáceres I.
Torres Santos-Olmo RM. Evaluación de una intervención
docente en la formación de residentes rotantes en un ser-
vicio de urgencias de un hospital universitario de tercer
nivel[dissertation]. Madrid: UAM: 2017(13/09/2017).
Directors: Quintana Díaz M, Huerta Álvarez C.
Valentí Soler M. Robots sociales y animales en la terapia de
personas con demencia avanzada[dissertation]. Madrid: UAM:
2017(20/04/2017).
Directors: Frank García A; Martínez Martín P.
Valero González N. Valor de los biomarcadores en el diag-
nóstico diferencial entre síndrome de respuesta inflamatoria
sistémica y sepsis en el paciente gran quemado[dissertation].
Madrid: UAM: 2017(27/06/2017).
Directors: Lorente Balanza JA, García de Lorenzo y Mateos A.
Vallecillo Hernández N. Nuevas estrategias para la prevención
de la pérdida auditiva neurosensorial en el ratón: Ácidos gra-
sos omega-3 y Dendrogenina B[dissertation]. Madrid: UAM:
2017(01/09/2017).
Directors: Murillo Cuesta S.
Vilches Aguirre Y. Desarrollo de un modelo predictivo de su-
pervivencia en pacientes con cáncer avanzado[dissertation].
Madrid: UAM: 2017(01/06/2017).
Directors: Alonso A, Feliú Batlle J.
23
 2
Executive Summary
2.4
Innovation and
Transfer Activities
2.4.1.
Innovation and
Transfer Activities
The Innovation Support Unit (or Innovation Unit) of FIBHULP was created in June 2010 within
the framework of the ITEMAS Network –currently called ITEMAS Platform- of the Carlos III
Institute of Health. Since its creation, the Innovation Support Unit has contributed to promoting
and protecting innovative/ground breaking research conducted by IdiPAZ. The Innovation Unit
also intends to harness our institute’s considerable innovative potential generated, as a step
prior to its subsequent transfer to society.
Therefore, one of the main commitments of the Innovation Unit is that researchers and health
personnel perceive it as a resource at their service, to provide support and advice in all that
relates to the identification, management, protection, transfer, marketing and dissemination of
their research results.
ACTIVITIES
The main aim of the Innovation Support Unit is to identify
the potential transferable research results generated within
our institute and to accompany and support the researcher
throughout the whole innovation process: from the birth of
the idea to its placement on the market.
Since the Innovation Unit has been in operation, several pro-
jects sponsored by the institute itself have been managed and
different collaboration agreements have been signed with
important private institutions and organisations to promote
innovation.
Our main objectives are:
• Promoting a culture of innovation and entrepreneurship
within the institute by fostering the generation of inno-
vative ideas and solutions that meet the needs of patients
and society, in general, and supporting their development
through various initiatives.
• Actively searching and identifying knowledge and re-
search results emerged within the institute and
transferable to the market.
• Fostering and managing the protection and
transfer of knowledge and research results to
society and promoting the current technolo-
gy portfolio of the institute while getting an
economic return which allows its reinvestment
in research and development.
• Promoting the participation of industry in the innovation
process acting as a stakeholder actively involved in it.
• Formalising business alliances, including technology com-
panies as well as industrial and financial partners, to de-
24
velop collaborative projects and to transfer the results to
the market.
• Generating resources that achieve the greatest impact on
society, enabling a better quality health care and at the
same time contributing to the sustainability of the Natio-
nal Health System.
• Boosting a fruitful collaboration among all entities that
make up the ITEMAS Platform.
In the last years the UAI has definitely consolidated its presen-
ce and visibility in the whole environment Hospital-Institute.
Its impact in the Hospital has been strengthened by the crea-
tion of both the Innovation Platform and the Innovation Com-
mittee as two linked structures within the organisation.The In-
novation Platform is an initiative launched from the Hospital’s
Management Board in order to promote, extend, enhance and
stimulate innovation throughout the Hospital. The main mis-
sion of the Innovation Platform is to build a culture of innova-
tion among all Hospital and Institute staff. The Innovation Unit
is integrated into this platform as its main driver and, as such,
it establishes its objectives and marks its lines of action and
will be responsible for channelling the entire workload. It also
forms part of the Innovation Committee, a decision-making
body on the ideas to be supported by FIBHULP.
Among the greatest achievements of the Innovation Support
Unit are the following:
1. The UAI has become one of IdiPAZ’s most in-demand and
requested platforms as it is responsible for promoting, sup-
porting and managing all innovation projects.
At December 31 2017, the UAI had 192 innovation pro-
jects or ideas in active state, 41 of which were in the captu-
re phase, 57 in the evaluation phase, 14 in development, 53
in transfer and 27 in the market. According to these data,
it follows that 14% of the projects have been successfully
exploited and positioned in the market, very positive per-
centage (although far lower than the aspired figure) given
the precariousness of the times we go through and the
resources (both human and financial) with which the UAI
counts. Among the various types of projects handled by the
UAI it is particularly noteworthy the volume of medical
device-type projects, followed by projects such as “Bio”,
“Health ICT” and “eHealth”. Although the UAI has more
than eight years of experience, most of the activity (151
projects) and its achievements have taken place in the last
five years, period 2013-2017.
2. The UAI has built a wide and diverse technology portfolio.
Each year the number of innovation projects managed by
the UAI increases with respect to the previous year, also in-
creasing the number of Hospital services, research groups
and professionals in general who join IdiPAZ’s innovation
community.
During the period 2013-2017, the UAI filed 24 priority pa-
tents (19 Spanish patents and 5 European patents) and 16
PCT; 5 national or regional phase entry applications were
filed (2 at the EPO, 2 at the USPTO and 1 at the CIPO (Ca-
nadian Intellectual Property Office) and 26 patents were
granted (1 at the EPO and 1 at the USPTO).
UAI’s portfolio of patents in active state during period
2013-2017 reached the figure of 44 patent families and 1
utility model.
As for the software, during the period 2013-2017 the UAI
registered 13 new computer applications.
Special mention should also be made to the UAI trademark
portfolio. During the period 2013-2017, 16 trademark
applications were filed and 12 were granted.
It is important to note that these trademarks, besides
allowing IdiPAZ to distinguish its products or services from
competitors’ products or services, are associated with the
know-how of the institution, know-how that has been
transferred along with the distinctive sign in the case of the
license agreements signed by the institution in respect of
trademarks.
3. The UAI has prepared a catalogue of technology offers -ba-
sed on specification sheets- which includes the complete
portfolio of exploitable IdiPAZ results. This catalogue aims
to promote the transfer of IdiPAZ’s technology portfolio
to the industrial sector, generate collaborative projects for
technological development and foster the exploitation of
research results. Those validated specification sheets are
published on IdiPAZ’s website. The catalogue is updated as
the Institute’s technology portfolio grows.
4. The UAI has been, is, and will continue to be the principal
architect for the transfer and exploitation of IdiPAZ’s te-
chnology portfolio. During the period 2013-2017 the UAI
succeeded in signing 20 license agreements of intellectual
property rights (copyright) and bringing 10 patents, 10
software, and 16 trademarks into commercial exploitation,
which has meant a significant achievement in terms of eco-
nomic return.
5. Thanks to UAI’s support and management it has been pos-
sible to create and consolidate the first technology-based
company of the Hospital (and also of the region of Ma-
drid) according to the regulations established by the De-
partment of Health of the Community of Madrid. The spin-
off concerned, Biomedica Molecular Medicine, exploits the
research results in oncology –specifically, a genomic test
to determine whether breast cancer patients should have
chemotherapy – designed by some members of IdiPAZ.
6. Through the promotion of a culture of innovation, the UAI
has managed to create a large community of innovative
professionals. Over the last year its promotional activity
has consisted in the celebration of several working days,
workshops, seminars, etc.:
• “La Paz 3.0: innovando para crecer” Workshop, June 14
2017
• “El know-how, su protección y transferencia a debate”
Workshop, September 12 2017
• “¿Quieres emprender con tecnologías de la salud?
Oportunidades para la imaginación y el negocio. Taller
de experiencias organizado por la Fundación para el
conocimiento Madri+d” Workshop, November 15
2017
25
 2
Executive Summary
2.4 Innovation and Transfer Activities

In addition, the UAI has collaborated with important insti-
tutions and private entities to promote innovation, in parti-
cular it has participated in various forums and round tables
organised by various stakeholders of the biomedical sector.
7. The UAI has succeeded in creating a wide-ranging network
of contacts. By virtue of its membership in the ITEMAS
Platform, the Unit has continued to strengthen ties and
creating synergies with the members of this Platform in
order to achieve its established objectives.
Apart from the above results it is important to emphasize
that several innovation projects managed by the Innovation
Unit have been awarded with prestigious awards and aids
over the last year:
• Award obtained in the second edition of the Healths-
tart Program by one of our innovation projects, in
particular ENDOSEAL project, led by Drs Pedro de
María Pallarés and Consuelo Froilán Torres. Healthstart
is the program of the Madrimasd Knowledge Founda-
tion (Madri+d Foundation) and the Medical Technology
Innovation Platform (ITEMAS Platform), promoted by
the Institute of Health Carlos III (ISCIII) for the accele-
ration of technological start-ups of the Community of
Madrid in the healthcare sector,
• Aid intended to carry out Feasibility Studies granted by
the Foundation for Health Innovation and Prospective
in Spain (FIPSE) to one of our innovation projects. The
innovation project is FACE MIRROR, and is led by Dr.
Alfonso Gil Martínez.
ORGANISATION Valdivieso Ámate F, Montoliú JL, Pozueta Larios J, inventors; UAM, CSIC, assignees. Alzheimer’s disease animal
Since its implementation, the Innovation Support Unit has model, method for obtaining same and uses thereof. P200503002, PCT/ES2006/000673, EP1956091, EP20060841725,
been integrated into the organisational structure of FIBHULP, US20090222932, CA2638983, JP2009517066; 2005 December 02.
as one of the Support Platforms for IdiPAZ research. Ballesteros García P, López Larrubia P, Domínguez Mateo L, Marco Contelles JL, Cerdán García-Esteller S, inventors;
The Innovation Unit is directed by Dr. Javier de Castro Car- Universidad Nacional de Educación a Distancia, CSIC, assignees. Set of magnetic resonance imaging and spectroscopy cell
peño, M.D. and Ph.D. in Medicine and a member of the Medi- acidity extrinsic indicators comprise polyol derivatives based on alditols. P200300936; 2003 April 23.
cal Oncology Department of the La Paz University Hospital/
Autonomous University of Madrid and of the Translational
Neuroprotective Strategies in Neurodegenerative Diseases
Oncology Unit of IdiPAZ. Group
The Innovation Unit also consists of a team of two experts Cuadrado Pastor A, Innamorato NG, inventors: CSIC, UAM. Use of sulforaphane as supplementary therapy for early-
in fostering innovation and protecting research results and stage neurodegenerative disease. P201231693; 2012 November 06.
technology transfer: León Martínez R, Egea Maíquez J, Buendía Abaitua I, Parada Pérez E, Navarro González de Mesa E, inventors;
Estela Sánchez Simón, Law Graduate; and Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, CSIC, DNS NEUROSCIENCE
María Dolores Pérez Garre, Bachelor of Chemical Sciences. S.A., assignees. Use of 3-(2-isothiocyanatoethyl)-5-methoxy-1H-indole for the treatment of neurodegenerative diseases.
P201300667; 2013 July 17.
CONTACT León Martínez R, Buendía Abaitua I, Navarro González de Mesa E, Michalska P, Gameiro Ros I, López Vivo A, Egea
Coordinator Maíquez J, García López M, García García A, inventors; Fundación para la Investigación Biomédica del Hospital Univer-
Javier de Castro Carpeño sitario de La Princesa, UAM, DNS NEUROSCIENCE S.A., assignees. Compounds derived from 3-alkylamine-1H-indolyl
acrylate and its use for the treatment of neurodegenerative diseases. P201400810, PCT/ES2015/000139, CA2964309; 2014
javier.decastro@salud.madrid.org
October15.
Phone: (+34) 91 207 12 34
Members
Estela Sánchez Simón
e_sanchez.innovacion@idipaz.es
Phone: (+34) 91 207 12 34 Cardiovascular Area
María Dolores Pérez Garre
maria.dolores.perez@idipaz.es Research on Invasive Clinical Cardiology- ICCI-PAZ Group
Phone: (+34) 91 207 12 34
Riera del Moral LF, inventor; FIBHULP, assignee.Aortic endoprosthesis for the treatment of aneurysm. P201231638,
PCT/ES2013/070712; 2012 October 24.
Filgueiras Rama D, López de Sá y Areses E, Millet Roig J, Calvo Saiz CJ, inventors; Centro Nacional de Investigaciones
Cardiovasculares Carlos III (CNIC), FIBHULP, Universidad Politécnica de Valencia, assignees. Method of predicting or prog-
nosticating neurological performance in patients who have suffered a cardiac arrest and optionally comatose status due to
ventricular fibrillation. PCT/EP2015/076893, EP3020333; 2014 November 17.

2.4.2. Vascular Physiology and Pharmacology Group

Patents and trademarks

Neuroscience Area
Psychiatry and mental health
Rodríguez Vega B, authors; FIBHULP, assignee. Trademark name: En calma; ESM
3.695.071; 2017 December 12.
Neurology and Cerebrovascular Diseases Group
Valdivieso Amate F, Bullido Gómez-Heras MJ, Martínez García A, inventors; UAM, assignee. Method of identifying
compounds that induce or inhibit endoplasmic reticulum stress or oxidative stress. P200702997, PCT/ES2008/000705,
EP2221379, US20100304384; 2007 November 13.
Vergés Milano J, García García A, Ruhí Roura R, Montell Bonaventura E, García López M, Aláez Versón CR, Es-
caich Ferrer J, Egea Máiquez J, Lorrio González S, Negredo Madrigal P, inventors; BIOIBÉRICA S.A., UAM, assig-
nees. Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases. P200902399, PCT/
EP2010/070613, US20120309707, CA20102785237; 2010 December 22.
Pérez Girón JV, Ruiz-Castellanos MJ, de Luis Jiménez O, Pérez Boto V, Sanz González R, Hernández Vélez MC, Mas
Gutiérrez JA, Alonso Gordo MJ, Salaíces Sánchez M, Ros Pérez M, Coloma Jerez A, Asenjo Barahona A, Sanz Mon-
taña JL, Puente Prieto J, Jensen J, inventors; NANOATE, S.L., assignee. Method for producing biosensors. P201031224,
PCT/ES2011/070536; 2010 August 05.
Miguel Castro M, López-Alonso Fandiño R, Recio Sánchez MI, Ramos González MM, Aleixandre de Artiñano A,
inventors; CSIC, assignee. Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis.
P200301829, PCT/ES2004/070059, EP1661913, US8227207, AT388166, DE602004012289, DK1661913, JP2007523045;
2003 July 31.
Miguel Castro M, López-Alonso Fandiño R, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, as-
signee. Production of and antihypertensive properties of peptides derived from egg white proteins. P200501246 PCT/
ES2006/070067; 2005 May 23.
Recio Sánchez MI; Quirós del Bosque A, Hernández Ledesma B, Gómez Ruiz JA, Miguel Castro M, Amigo Garrido
L, López Expósito I, Ramos González MM, Aleixandre de Artiñano A, (Contreras Gómez M), inventors; CSIC, assig-
nee. Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same. P200501373,
PCT/ES2006/070079, EP1905779, EP2495250, US8354502, AU2006256720, BRPI0611729, CA2611416, CN101305017,
CN103254278, JP2008545774, KR20080045108, MX2007015528, NO20080103; 2005 June 08.
Garcés Rimón M, Miguel Castro M, López-Alonso Fandiño R, López-Miranda González V, Uranga Ocio J, inventors;
CSIC, Universidad Rey Juan Carlos, assignees; Use of multifunctional bioactive products derived from the enzymatic hy-
drolysis of egg white proteins for treating metabolic syndrome. P201331767, PCT/ES2014/070880; 2013 December 04.
Miguel Castro M, Garcés Rimón M, López-Alonso Fandiño R, Sandoval Huertas M, inventors; CSIC, Mario Sando-
val Huertas, assignees. Healthy food compositions having gel or foam textures and comprising hydrolyzed egg products.
P201331886, PCT/ES2014/070902, EP3106042, US9648897, AR098685, JP2015130856, MX2014015135; 2013 December 20.

Valdivieso Ámate F, Burgos Muñoz JS, Ramírez Moreno C, Sastre Merlín I, inventors; UAM, CSIC, assignees. Method of González-Muñiz R, Pérez de Vega MJ, Miguel M, Balsera-Paredes B, Moreno S, inventors; CSIC, assignee. Triazolyl
identifying therapeutic compounds which can be used for the treatment and/or prevention of infections and diseases cau- polyphenols with antioxidant activity and uses thereof; P201531450; 2015 November 08.
sed by human herpes viruses. P200400965, PCT/ES2005/000209, EP1769677, US20070218004, AT447321, AU2005235319, González-Muñiz R, Miguel Castro M, Pérez de Vega MJ, Balsera-Paredes B, S Moreno, inventors; CSIC, assignee.
CA2562787, JP2007533315; 2004 April 21. Compounds with antioxidant activity and uses thereof. P201630362; 2016 March 29.

26 27
 2
Executive Summary
2.4 Innovation and Transfer Activities
Infectious Diseases and Immunity Area
AIDS and Infectious Diseases Group
Romero Gómez M, Solá Lamoglia R, González García JJ, inventors; Servicio Andaluz de Salud, Universidad de
Sevilla, Fundació Institut Mar D’Investigacions Mèdiques, FIBHULP, assignees. Kit for decision making in patients with
Hepatitis C genotypes 1 and 4. P201330731; 2013 May 21.
Molecular Microbiology Group
Vicente Muñoz M, Mingorance Cruz J, Rueda González MS, inventors; CSIC, assignee. Method for determining state of
growth and viability of bacterial FTsZ population, whether natural or cultivated, is based on determining existence of FTsZ
rings in actively growing individual cells. P200200370; 2002 February 15.
Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; BIOTOOLS BIOTECHNOLOGICAL
& MEDICAL LABORATORIES S.A., assignee. Composition, method and kit for detecting bacteria by means of sequencing.
PCT/ES2009/000507, EP2492352, US2013157265, CA2775273, MX2012004627; 2009 October 22.
Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; 2B BLACKBIO S.L., assignee. Composi-
tion, method and kit for detecting fungi and yeasts by means of sequencing. PCT/ES2010/000248; 2010 June 02.
Immuno-Rheumatology Group
Pascual-Salcedo Pascual MD, Balsa Criado A, Plasencia Rodríguez C, authors;
FIBHULP, assignee. Trademark name: BioDrug Analysis BIDA. CM 13.808.531, 2015
March 10.
Fernández Luna JL, Martínez Taboada VM, López Hoyos M, Torices del Val S, Muñoz Cacho P, Varela Egocheaga I,
Juliá Cano A, Marsal Barril S, Balsa Criado A, inventors; FIBHULP, Fundación Instituto de Investigación Marqués de Val-
decilla, Servicio Cántabro de Salud, Universidad de Cantabria, FUNDACIÓ HOSPITAL UNIVERSITARI VALL D´HEBRON
- INSTITUT DE RECERCA (VHIR), assignees. Method for predicting the clinical response to anti-inflammatory agent
therapies. P201600636, PCT/ES2017/000089; 2016 July 26.
Innate Immune Response Group
Llamas Matías MA, López-Collazo E, inventors; FIBHULP, Llamas Matías MA, Empireo S.L., assignees. Method for deter-
mine the risk of developing an infectious disease. P201330768, PCT/ES2014/070434, EP3006570; 2013 May 27.
Diagnosis and Treatment of Diseases Associated with
Abnormalities of the Complement System Group
López Trascasa M, authors; FIBHULP, assignee. Trademark name: COMPLEMENTest;
CM 009.658.791; 2011, January 14.
Lumphocyte Pathophysiology in Immunodeficiencies Group
Van Dongen JJM, Orfao de Matos Correia E Vale JA, Van Der Burg M, Pérez Andrés M, Van Zelm MC, Kalina T, Vlkova
M, López Granados E, Blanco Álvarez E, Kienzler AK, inventors; Erasmus University Medical Center Rotterdam, assig-
nee. Reagents, methods, and kits for diagnosing primary immunodeficiencies. PCT/NL2015/050762, US62/072,498; 2014
Oct 30.
Drug Hypersensibility and Innate Immune Response Group
Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso
P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts
of pyridazine[1’,6’:1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013
July 25.
Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P,
Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of
piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.
Sánchez Niño MD, Ortiz Arduán A; FIBHULP, Instituto de Investigación Sanitaria Fundación Jiménez Díaz. Pharmaceutical
composition and its use in the manufacture of a medicament for treating chronic kidney disease and method for screening
compounds. P201430081, PCT/ES2015/070039; 2014 January 27.
28
Large System Pathologies Area
Organic Dysfunction and Failure in the Agression Group
Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asen-
sio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López
Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Trademark name: SINOIRES; CM
13.080.056; 2014 July 14.
Nephrology Group
Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P,
Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of
pyridazine[1’,6’:1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.
Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P,
Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of
piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.
Aguilera Peralta AI, López-Cabrera M, Selgas Gutiérrez R, Steppan S, Passlickdeetjen J, inventors; Fresenius Medical
Care Deutschland GMBH, assignee. Pharmaceutical compositions containing steviosides. PCT/EP2015/074955, EP3212199,
US2017304335, CN107073022; 2014 October 31.
López-Cabrera M, Aguilera Peralta AI, Selgas Gutiérrez R, Passlickdeetjen J. Buechel J, Steppan S, inventors; Fre-
senius Medical Care AG & Co. KGaA, assignee. Method and kit for diagnosing epitelial to mesenchymal transition of the
peritoneum (EMT-Chip). WO2017042253, DE102015115158; 2015 September 09.
Sánchez Niño MD, Ortiz Arduán A; FIBHULP, Instituto de Investigación Sanitaria Fundación Jiménez Díaz. Pharmaceutical
composition and its use in the manufacture of a medicament for treating chronic kidney disease and method for selecting
compounds. P201430081, PCT/ES2015/070039; 2014 January 27.
Neonatology Group
Segovia Iñigo C, Montes Bueno MT, inventors; Segovia Iñigo C, assignee. Positioning device for neonates (Utility model).
U201330102; 2013 January 31.
Diagnosis and Treatment of Allergic Diseases Group
Valenta R, Constantin C, Quirce Gancedo, SE, inventors; Phadia AB, assignee. Novel wheat allergens. PCT/SE2008/051377,
EP2225266, US2010305049, AU2008330230, CA2707190, CN101932597, JP2011505134, RU2010126590; 2007 Novem-
ber 30.
Caballero Molina MT, Prior Gómez N, Remor Bitencourt EA, authors, FI-
BHULP, assignee. Trademark name: HAE-QoL HEREDITARY ANGIOEDEMA
QUALITY OF LIFE. CM 13.083.068; 2014 July 15.
Sánchez Herreros R, Martínez Fernández J, Castro Morera A, Gasset Vega M, Rodríguez Pérez RM, Pedrosa Delgado
M, Quirce Gancedo S, inventors; FIBHULP, CSIC, assignees. Food allergen extracts and methods of producing and using
the same. EP16382413.9 (Publication Number pending); 2016 September 06.
del Pozo Abejón V, Sastre Dominguez J, Rodrigo-Muñoz JM, Sastre Turrión B, Quirce Gancedo S, Cañas Mañas JA,
inventors; FIISFJD, Centro de Investigación Biomédica en Red (CIBER), FIBHULP, Fundación Conchita Rábago de Jiménez
Díaz, assignees. In vitro method for identifying severity levels in bronchial asthma patients. P201730739; 2017 May 29.
Gynecologic Oncology Group
Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Laparoscopic surgical instrument. P201230950,
PCT/ES2013/000139; 2012 June 18.
Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Surgical device. P201330532, PCT/
ES2014/070277; 2013 April, 15.
Emergency and Critical Pathology
Carballo Cardona C; author; FIBHULP, assignee. Trademark name: Diagether.
CM15869911, 2016 September 29.
Associated Clinician
de la Oliva Senovilla P, inventor; FIBHULP, Instituto de Salud Carlos III, assignees. Shut-off valve for the interruption te-
chnique used in the analysis of respiratory mechanics. PCT/ES2005/000271, EP1897578; 2005 May 16.
29
 2
Executive Summary
2.4 Innovation and Transfer Activities
Cancer and Human Molecular Genetics Area
INGEMM- Institute of Medical and Molecular Genetics Group
Friedman S, Li D, Narla G, Martignetti J, Heath K, inventors; Mount Sinai School of Medicine, assignee; Kruppel-
like factor 6 (klf6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein. PCT/
US2001/025046, EP1332362, CA2419064, AU8479001, US2005181374, US2011059899; 2000 August 09.
INGEMM, author; FIBHULP, assignee.Trademark name: INGEMM INSTITUTO DE GENÉTI-
CA MÉDICA Y MOLECULAR DEL HOSPITAL UNIVERSITARIO LA PAZ; ESM 2.884.849,
USM 77.891.143, CM 8.746.869; 2009 July 16, 2009 December 11, 2009 December 10.
INGEMM, author; FIBHULP, assignee. Trademark name: KaryoArray; USM 79.078.751, CM
8.512.907; 2010 January 07, 2009 August 27.
INGEMM, author; FIBHULP, assignee. Trademark name: OverGrowthArray; ESM 2.958.709-
3, USM 85.334.932, CM 10.009.256; 2010 December 02, 2011 June 01, 2011 May 31.
Experimental Therapies and Biomarkers in Cancer Group
INGEMM, author; FIBHULP, assignee. Trademark name: MetabolArray; ESM 2.958.711-5,
USM 85.334.903, CM 10.009.348; 2010 December 02, 2011 June 01, 2011 May 31.
Palomares M, Lapunzina P, Nevado J, Vallespin E, Vallcorba I, Melero J, authors; FI-
BHULP, Hospital Infanta Cristina (Badajoz) Fundesalud, assignees. Trademark name: On-
coHematoArray; ESM 2.958.703-4, USM 85.334.842, CM 10.009.181; 2010 December 02,
2011 June 01, 2011 May 31.
Lapunzina P, Nevado J, Solera J, Vallespin E, Martínez P, Martínez-González V, authors;
FIBHULP, assignee.Trademark name: ONCOSeq; USM 85.457.843, CM 9.969.064; 2011 Oc-
tober 27, 2011 May 16.
INGEMM, author; FIBHULP, assignee. Trademark name: OncoArray; ESM 2.962.910, USM
85.363.107, CM 10.091.882; 2011 January 05, 2011 July 05, 2011 July 01.
Moreno JC, Moya CM, Vallespin E, Lapunzina P, Nevado J, authors; FIBHULP, assignee.
Trademark name: ThyroArray; USM 85.686.688, CM 10.904.951; 2012 July 25, 2012 May 23.
Lapunzina Badía P, Borobia Pérez AM, Carcas Sanjuán AJ, Tenorio Castaño JA, Arias
Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Trademark name:
PharmArray; USM 86.004.412, CM 11.608.403; 2013 July 08, 2013 February 27.
Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias
Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees.
Trademark name: ClinPharmarray., CM15489511; 2016 May 31, 2016 September 07.
Translational Oncology Group
Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez
Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal
adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.
Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP,
30
UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer.
P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.
Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, Sánchez Navarro I, inventors; FIBHULP, assignee. Method for tumor
subclassification. P200803509, PCT/ES2009/070533; 2008 December 11.
Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method
to obtain useful data for the prediction of a patient’s clinical response to an anticancer treatment. P200930400; 2009 July 01.
Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method
to obtain useful data for the prediction of a patient’s pathological response to an anticancer treatment. P200930438; 2009
July 10.
Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado
Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fin-
gerprint for predicting the clinical response to an antitumor therapy in colorectal cancer. P201130863, PCT/ES2012/070379;
2011 May 26.
Moreno Rubio J, Cejas Guerrero P, Feliú Batlle J, Ramírez de Molina AI, Reglero Rada G, Vargas Alonso T, Molina
Arranz S, González-Vallinas Garrachón M, inventors; FIBHULP, Fundación Imdea Alimentacion, assignees. Methods and kits
for the prognosis of colorectal cancer. P201231918, PCT/ES2013/070864; 2012 December 10.
Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, López Vacas R, Berges Soria J, inventors; FIBHULP, assignee. Method
for tumor subclassification. P201430887, 2014 June 09.
Miranda Utrera N, Castellano D, Villacampa Aubá F, Fresno Vara JA, Gámez Pozo A, inventors; FIBH12O, FIBHULP, assig-
nees. Prognostic method for determining the risk of relapse in renal cancer patients with a clear cell type of renal carcinoma,
stages I and II, and kit for same. P201531360, PCT/EP2016/072723; 2015 September 23.
Perona Abellón R, Sánchez Pérez I, Machado Pinilla R, Sastre Garzón L, Murguía Ibáñez JR, inventors; CSIC, UAM,
Universidad Politécnica de Valencia, assignees. Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can in-
duce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof. P200502511,
PCT/ES2006/070152, EP1947175, US20090202503, US2015337022, AT469212, CA2625981, DK1947175, JP2009511036,
JP5560398, PT1947175; 2005 October 14.
Perona Abellón R, Sastre Garzón L, Machado Pinilla R, Sánchez Pérez I, inventors; CSIC, UAM, assignees. Use of
inductor agents GSE24.2 for producing pharmaceutical compositions for treating illnesses relating to cellular senescence.
P200703106, PCT/ES2008/070212, EP2216043, US2011300115, JP2011504483, CA2706467; 2007 November 23.
Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez
Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal
adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.
Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP,
UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer.
P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.
Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado
Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fin-
gerprint for predicting the clinical response to an antitumor therapy in colorectal cáncer. P201130863, PCT/ES2012/070379;
2011 May 26.
Martínez Máñez R, Murguía Ibáñez JR, Perona Abellón R, Agostini A, Mondragón Martínez L, Moreno Torres M, Man-
guán García C, Marcos Martínez MD, Soto Camino J, Sancenón Galarza F, inventors; Universidad Politécnica de Valencia,
CSIC, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Centro de
Investigación Biomédica en Red de Enfermedades Raras (CIBERER), assignees. Release of substances into senescent cells.
P201231370, PCT/ES2013/070581, EP2893923, JP2015529216, US2015306037; 2012 September 04.
Ibáñez de Cáceres I, Belda Iniesta C, Pernía Arias O, Perona Abellón R, Cortés Sempere M; inventors. FIBHULP, CSIC,
UAM, Fundación Hospital de Madrid, assignees. Method for predicting the response to a treatment consisting of radiotherapy
combined with cisplatin-based chemotherapy. P201330783, PCT/ES2014/070433, EP3006572, US20160122828; 2013 May 29.
Perona Abellón R, Sastre Garzón L, Pintado Berninches L, Carrillo García J, Molina Pachón A, Irradiccio Silva L,
Manguán García C, inventors; CSIC, UAM, Advanced Medical Projects, Centro de Investigación Biomédica en Red (CIBER),
assignees. Peptides derived from GSE 24.2 for treating diseases caused by oxidative stress and damage to DNA. P201331573,
AU2014338820, CA2931429, EP3061815 PCT/ES2014/070803; 2013 October 25.
Ibáñez de Cáceres I, Pernía Arias O, de Castro Carpeño J, Vera Puente O, Jiménez Hernández J, Perona Abellón
R, Rojo Todo F, inventors; FIBHULP, CSIC, UAM, Instituto de Investigación Sanitaria FJD, assignees. Determination of
methylation and miRNA levels in response to a platinum-based antitumor compound. P201530997, PCT/ES2016/070516;
2015 July 09.
Ibáñez de Cáceres I, de Castro Carpeño J, Vera Puente O, Pernía Arias O, Rodríguez Antolín C, González Muñoz
VM, Martín Palma ME, Salgado Figueroa AM, inventors; FIBHULP, FIBIOHRC, assignees. MAFG as a potential therapeutic
target to restore chemosensitivity in platinum-resistant cancer cells. EP17382610.8 (Publication Number pending); 2017
September 15.
31
 2
Executive Summary
2.4 Innovation and Transfer Activities
Oto-Neurosurgery Research Group
Polak M, Roca-Ribas Serdá F, Gavilán Bouzas J, Lassaletta Atienza L, Miró Castillo N, Rodrigo Dacosta J, inventors;
MED-EL Elektromedizinische Geraete GmbH, assignee. Hearing treatment in patients with questionable cochlear nerve
functionality. US2011275953, PCT/US2011/035312; 2010 May 05.
Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Navares Zaera R, Martínez Vega R, Cediel Algovia R, inventors; CSIC,
UCM, assignees. Anechoic acoustic chamber for evaluating the auditory function in laboratory animals. P201031720; 2010
November 23.
Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Cediel Algovia R, inventors; CSIC, UCM, assignees. Method for designing a
reverberating acoustic chamber for hearing test with animals. Procedimiento para diseñar una cámara acústica reverberante
para ensayos auditivos con animales. P200802895, PCT/ES2009/070433; 2008 October 14.
Cancer Molecular Pathology and Therapeutics Targets Group
Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee.
Method to obtain useful data for the prediction of a patient’s clinical response to an anticancer treatment. P200930400;
2009 July 01.
Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method
to obtain useful data for the prediction of a patient’s pathological response to an anticancer treatment. P200930438; 2009
July 10.
Mechanisms of Tumour Progression Group
Matías-Guiu Guía FJ, Dolcet Roca FJ, Reventós Puigjaner J, Colás Ortega E, Prat Díaz de Losada J, Palacios Calvo
J, Abal Posada M, López López R, Moreno Bueno G, Gil Moreno A, inventors; Institut de Recerca Biomèdica de Lleida
Fundació Doctor Pifarré, Universitat deLleida, Fundació Hospital Universitari Vall d’Hebron-Institut de Recerca, Fundació
Institut de Recerca de L’Hospital de la Santa Creu i Sant Pau, Servicio Andaluz de Salud, Servizo Galego de Saúde, Fun-
dación MD Anderson International España, assignees. Method to predict risk of recurrence in endometrial carcinoma.
Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. EP14155510.2, PCT/EP2015/053387;
2014 February 18.
García García JF, Martín Moreno AM, Roncador G, Martínez Torrecuadra JL, Moreno Bueno G, inventors; Fundación
MD Anderson International España, Fundación Centro Nacional de Investigaciones Oncológicas (CNIO), assignees; Method
for the diagnosis and/or prognosis of lymphomas. P201231304; 2012 August 14.
Olmeda Casadomé D, Peinado Selgas H, Portillo Pérez F, Nieto Toledano MA, Cano García A, inventors; UAM, assignee.
Materials and methods for the derepression of the E-cadherin promoter. US20060003956; 2004 March 03.
Olmeda Casadomé D, Moreno Bueno G, Portillo Pérez F, Cano García A, inventors; UAM, CSIC, assignees. Method for
the diagnosis and/or prognosis of breast cancer. P200702342, PCT/ES2008/000563; 2007 August 28.
Hergueta Redondo M, Sanz PG, Rojo A, García JF, Moreno-Bueno G, inventors; UAM, CSIC, Fundación MD Anderson
International España, assignees; Gasdermin B2 as a new biomarker of malignance and resistance of Trastuzumab inhibitor in
Her2+ tumors. P201231560; 2012 October 10.
Animal and Cell Models for Detection and Characterisation of
Leukemic Stem Cells Group
Campanero García MR, Molina Privado I, inventors; CSIC, UAM, assignees. Method for identifying patients with spora-
dic Burkitt’s lymphoma, identification method and use of compounds for the treatment of sporadic Burkitt’s lymphoma.
P200702595, PCT/ES2008/070182; 2007 October 03.
Molina Privado I, Campanero García MR, Rodríguez Martínez M, inventors; CSIC, UAM, assignees; Method for the diffe-
rential diagnosis between Burkitt lymphoma and diffuse large B-cell lymphoma. P200900651; 2009 March 09.
Zapata Hernández JM, Pérez Chacón G, inventors; CSIC, UAM, assignees; Use of an indolic compound with nucleophilic
substituents at C3 and the dimeric variants thereof in the production of a pharmaceutical composition that can be used in
the treatment of B-lymphoid neoplasms. P201331397, PCT/ES2014/070726; 2013 September 25.
Research and Diagnosis of Inherited Metabolic Diseases Group
Pérez González B, Ruiz Desviat L, Jorge Finnigan A, Ugarte Pérez M, Martínez Ruiz A, Underhaug J, Barnejee R,
inventors; UAM, Universidad de Bergen, Universidad de Michigan, assignees; Compounds useful for the treatment of methyl-
malonic aciduria. P201330171; 2013 February 11.
Pérez González B, Gámez Abascal A, Yuste Checa P, Arduim Brasil S, Ugarte Pérez M, Martínez Ruiz A, Under-
haug J, inventors; UAM, Universidad de Bergen, assignees; Compounds for treating congenital disorders of glycosylation.
EP16382373.5; 2016.
Associated Clinician
Glaría Enríquez A, Mañas Rueda A, Velázquez Soto R, inventors; FIBHULP, assignee. Isolation and immobilization device
for test animals. P201031519, PCT/ES2011/070709; 2010 October 14.
32
Surgery, Transplant and Health
Technologies Area
Bone Pathophysiology and Biomaterials Group
Vilaboa Díaz NE, González Carrasco JL, Saldaña Quero L, Frutos Torres E. inventors; FIBHULP, CSIC, CIBER-BBN,
assignees. Method to obtain a metallic-coated biomaterial; P201030949, PCT/ES2011/070400; 2010 June 21.
Vilaboa Díaz NE, Gónzalez Carrasco JL, Multigner Domínguez M, Lieblich Rodríguez M, Muñoz Hernández M,
Frutos Torres E, Saldaña Quero L, inventors; FIBHULP, CSIC, CIBER-BBN, Universidad Alfonso X El Sabio, assignees.
Magnesium/polymer composite biomaterial for biomedical applications; P201030950, PCT/ES2011/070440; 2010 June 21.
Fabiilli M, Wilson C, Padilla F, Martín Saavedra FM, inventors; The regents of the University of Michigan, assignee.
Ultrasound-triggerable agents for tissue engineering; PCT/US2013/044817, US2013/0330389; 2012 June 08.
Vilaboa Díaz NE, Calzado Martín A, Crespo García L, Saldaña Quero L, Moreo Calvo P, Alastrué Vera V, inven-
tors; FIBHULP, CIBER-BBN, assignees. Chamber device for dynamic cell culture on biomaterials; P201330040, PCT/
ES2013/070819; 2013 January 16.
Martín Saavedra FM, Vilaboa Díaz NE, Cebrián Hernando V, Arruebo Gordo M, Santamaría Ramiro J, Gómez Navas-
cués L, inventors; FIBHULP, CIBER-BBN, Universidad de Zaragoza, assignees. Fibrin hydrogel with plasmonic nanoparticles;
P201330894, PCT/ES2014/070484; 2013 June 14.
González Carrasco JL, Benavente Castro R, Cifuentes Cuellar SC, Lieblich Rodríguez M, Olalde Graells B, Atorrasa-
gasti Goyalde G, Argarate Madariaga N, Pacha Olivenza MA, Fernández Calderón MC, Saldaña Quero L, González
Martín ML, Pérez Giraldo C, Gallardo Moreno AM, inventors; CSIC, Fundación Tecnalia Research & Innovation, FIBHULP,
Universidad de Extremadura, Centro de Investigación Biomédica en Red (CIBER). Moldable, biodegradable, biocompatible
and bioresorbable implant material, method for its preparation and uses thereof. P201530683; 2015 May 18.
Voellmy R, Vilaboa Díaz NE, inventors; HSF Pharmaceuticals S.A., assignee. Inhibitors of heat shock factor I and uses
thereof. US 62/495,501; 2016 September 16.
Cellular Engineering Group
de Miguel González MP, Arnalich Montiel F, Royuela MM, inventors; FIBHULP, Fundación para la Investigación Biomédi-
ca del Hospital Universitario Ramón y Cajal, Universidad de Alcalá, assignees. Corneal endothelium injector; P201131222,
PCT/ES2012/070543; 2011 July 18.
Clinical Pharmacology Group
Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio
Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M,
Gómez Rioja R, authors; FIBHULP, assignee.Trademark name: SINOIRES; CM 13.080.056;
2014 July 14.
Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Trademark name: IBJ IberoAme-
rican Journals; ESM 3.063.048; 2013 February 12.
Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Trademark name: IberoAmerican
Journals Plus; ESM 3.063.052; 2013 February 12.
Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Trademark name: IberoAmerican
Journals Clinical Pharmacology; ESM 3.063.053; 2013 February 12.
Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Trademark name: IberoAmerican
Journals Medicine; ESM 3.063.049; 2013 February 12.
Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias
Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Trademark name:
PharmArray; USM 86.004.412, CM 11.608.403; 2013 July 08, 2013 February 27.
33
 2
Executive Summary
2.4 Innovation and Transfer Activities

Carcas Sansuán AJ, Borobia Pérez AM, authors; FIBHULP, assignee. Trademark name:
CRDataX; CM 13.681.614; 2015 May 28.
Other Trademarks of IdiPAZ
Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias FIBHULP, author; FIBHULP, assignee.Trademark name: IdiPAZ Instituto de Inves-
Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees. tigación Hospital Universitario La Paz; USM 85.078.878, CM 8.871.873; 2010 July
Trademark name: ClinPharmarray., CM15489511; 2016 May 31, 2016 September 07. 06, 2010 February 10.

Osteoarticular Surgery Research- GICOA Group FIBHULP, author; FIBHULP, assignee. Trademark name: CEASEC Centro Avanzado de Si-
Arenas Vara MA, Conde del Campo A, De Damborenea González JJ, Matykina E, Esteban Moreno J, Gómez Barrena mulación y Entrenamiento Clínico; ESM 3.567.901-8; 2015 June 22.
E, Pérez-Jorge Peremarch C, Pérez Tanoira R, inventors; CSIC, Instituto de Investigación Sanitaria Fundación Jiménez Díaz,
assignees. Titanium materials anodised with fluorine. P201030720, PCT/ES2011/070342; 2010 May 14.

Emergency and critical pathology

Carballo Cardona C; author; FIBHULP, assignee. Trademark name: Diagether. CM15869911, 2016 September 29. FIBHULP, author; FIBHULP, assignee. Trademark name: InnoPAZ Plataforma de Innovación
Hospital Universitario La Paz; ESM 3.572.575-3; 2015 July 27.
Associated Clinician
Castell Gómez JT, inventor; FIBHULP, assignee. System of “partial” or “total” openings and buttonholes for patient pyjama
or nightgown. P200401758; 2004 July 16.
García Fernández J, inventor; FIBHULP, assignee. Anaesthesia machine simulator. P200702128, PCT/ES2008/070109,
US20090044803; 2007 July 30. Associated Clinician
de Miguel del Campo E, Posadas Mañanes SJ, Reglero Rada GJ, Largo Aramburu C, García Grande A, Merino Martín Gómez Candela C, López Plaza B, Bermejo López L, authors; FIBHULP, assignee. Tra-
JJ, Caz Bonillo V, Fornari Reale T, Rodríguez García-Risco M, Señorans Rodríguez FJ, inventors; FIBHULP, UAM, assig- demark name: NUTRinvest Grupo de investigación en Nutrición y Alimentos Funcionales;
nees. Composition for the protection of tissues from the digestive tract and the nervous system of radiotherapy patients; ESM 3.649.812-2; 2017 February 02.
P200931189; 2009 December 17.
Goldman Tarlovky L, inventor; FIBHULP, assignee. System and method to obtain data on a patient’s breathing cycle.
P201030927, PCT/ES2011/070242; 2010 June 16.
De la Quintana Jiménez P, authors; FIBHULP, assignee. Trademark name: #OdeOstomía;
de Miguel del Campo E, Reglero Rada GJ, Largo Aramburu C, Fornari Reale T, Rodríguez García-Risco M, Jaime CM 016922734; 2017 September 21.
de Pablo L, Santoyo Díez S, Señorans Rodríguez FJ, García Grande A, Merino Martín J, Caz Bonillo JV, Posadas
Mañanes SJ, inventors; FIBHULP, UAM, assignees. Composition for the reduction of symptoms associated with menopause;
P201031225, PCT/ES2011/070586; 2010 August 05.
Castell Gómez JT, inventor; FIBHULP, assignee. Surgical device for interrupted suture. P201031491, PCT/ES2011/002352, De la Quintana Jiménez P, authors; FIBHULP, assignee.Trademark name: CM 016922858;
EP2626014, US13/878035; 2010 October 07. 2017 September 21.
Álvarez Gallego M, inventor; FIBHULP, assignee. Device for the extraction of surgical specimens by insufflation and suction.
P201031490, PCT/ES2011/002357; 2010 October 07.
de Miguel del Campo E, Largo Aramburu C, Tabernero Urbieta M, Reglero Rada GJ, Marín Martín F, Fornari Reale
T, Prodanov Prodanov M, Ruiz Rodríguez A, Ibáñez Ezequiel E, Jaime de Pablo L, Soler Rivas C, Rodríguez García- De la Quintana Jiménez P, authors; FIBHULP, assignee. Trademark name: Ostomía; CM
Risco M, Santoyo Díez S, González Lorente M, Arranz Gutiérrez E, Gil Ramírez A, inventors; FIBHULP, UAM, CSIC, 017131822; 2017 August 22.
assignees. Functional heart-healthy beverage containing wine and extracts of hops; P201131014, PCT/ES2012/070443;
2011 June 16.
Reglero Rada GJ, de Miguel del Campo E, Marín Martín F, Fornari Reale T, Prodanov Prodanov M, Ruiz Rodríguez A,
Largo Aramburu C, Tabernero Urbieta M, Ibáñez Ezequiel E, Jaime de Pablo L, Soler Rivas C, Rodríguez García-Risco
M, Santoyo Díez S, González Lorente M, Arranz Gutiérrez E, Gil Ramírez A, inventors; FIBHULP, UAM, CSIC, assignees.
Method to obtain extract of hop and the extract obtained. P201230584, PCT/ES2012/070443; 2011 June 16.
Brian Gahan P, Stroun M, García del Olmo D, García Arranz M, Vega Clemente ML, inventors; Peter Brian Gahan, Mau-
rice Stroun, FIBHULP, assignees. Method for blocking tumour growth. EP2808027; 2013 May 29.
Castell Gómez JT, Carrascal Morillo T, inventors; FIBHULP, UNED, assignees. Synthetic surgical mesh. P201331453, PCT/
ES2014/000161; 2013 October 03.
Álvarez Gallego M, Castejón Sisamón C, García Prada JC, Meneses Alonso J, inventors; FIBHULP, UC3M, assignees.
Rectoscope. P201630551, PCT/ES2017/070249; 2016 April 29.
Froilán Torres C, de María Pallarés P, Díaz Lantada A, Ortego García P, inventors; FIBHULP, UPM, assignees. Endoscopic
accessory. P201730569; 2017 March 31.

34 35
 2
Executive Summary

2.5
Quality Committe Protocol/ Clinical pathway
Guía clínica manejo insuficiencia cardiaca
Status
Review
Protocol/ Clinical pathway
Protocolo de valoración de orificio del cateter
Status

Review
Guía clínica manejo neumonía Review peritoneal
Guía de práctica clínica sobre tratamiento de la Protocolo de vuelta a diálisis tras fallo de
Review Review
insuficiencia cardiaca crónica trasplante renal
Hemorrragia digestiva alta con hipertensión Protocolo para la preparación para colonoscopia
The vision of IdiPAZ is to be a reference centre for multidisciplinary translational biomedical Review New
portal en los pacientes en diálisis
research at the national and european level. To achieve this objective, the institution combines its
efforts to ensure the quality of all its processes, thus ensuring the provision of the best service, Hemorrragia digestiva alta sin hipertensión portal Review Protocolo PROA diarrea del viajero New
research and teaching. Hiperrtensión Pulmonar Review Protocolo PROA endocarditis New
IdiPAZ is committed to a comprehensive quality model backed by the maturity of the quality mana- Hipertensión Arterial Review Protocolo PROA fiebre en niño inmigrante New
gement team of the IdiPAZ institutions. To support and facilitate quality, the institution maintains a Infección en paciente inmunodeprimido Review Protocolo PROA gastroenteritis New
Quality Committee.
Infección nosocomial Review Protocolo PROA infección de cateter New
During 2017, the Quality Committee fostered these principles but also achieved specific quality goals.
Insuficiencia cardiaca Review Protocolo PROA infeccion del SNC y niño grave New
The quality and innovation management system has been adapted to the requirements of the ISO
9001:2015 and the UNE 166002:2014, including currently in its scope the Innovation Support Unit, Lupus y síndrome Antifosfolípido Review Protocolo PROA infecciones osteoarticulares New
the Central Research and Clinical Trials Unit, the Technical Secretariat and the Quality Committee. Manejo de fluorouracilo en las consultas de Protocolo PROA infecciones piel y partes blandas New
Review
By the end of the current year a new working quality plan for IdiPAZ has been developed to further Oftalmología
Protocolo PROA Infecciones respiratorias New
expand the scope to new platforms and units until the reaccreditation process will take place in 2020. Manejo del paciente asmático en Urgencias.
Nueva Protocolo PROA infecciones urinarias New
Moreover, considering that IdiPAZ is a continuously evolving organisation, the Quality activities of our Consenso multidisciplinar
institution has been enriched by the different achievements made by the Hospital Universitario La Paz Protocolo PROA transmisión vertical VIH New
Manejo enfermedad infalmatoria intestinal en
Nueva Salud bucodental para pacientes oncológicos Nueva
and Universidad Autónoma de Madrid. urgencias
The hospital, with its accumulative experience about quality of care improvement, has continued working Manejo enfermedad perianal enfermedad Score de evalución del donante del trasplante
Nueva New
intensively during this year. Protocols, clinical pathways and participation in clinical practice guidelines has inflamatoria con cirugía renal
been developed and reviewed. The attached tables show the clinical pathways reviewed in 2017 as well Nutrición en Hemodiálisis Review Sedación Paliativa New
as the protocols developed or updated in the same period. In addition, the staff members continuously Patología infección VIH Review Seguimiento de pólipos Nueva
collaborate in the improvement of the institution by participating in clinical committees and creating
Preparación para la colonoscopia en paciente Síndrome metabólico Review
improvement groups, as well as implementing satisfaction surveys for patients and professionals. Review
ERCA Solicitud de pruebas de diagnóstico cardiológico:
Also during 2017 hospital departments quality management systems are being integrated in an overall
Prevención de Endocarditis Infecciosa en ECG, Holter, Rx tórax, Ecocardiografía
management system according to the standards ISO 9001:2015, ISO 14001:2015, ISO 22000:2005 Review
Pacientes Portadores de Pótesis Valvulares Review transtorácica, ecocardiografía transesofágica y 3D,
and IQNetSR10. The hospital has also 25 accredited units within the Spanish National Accreditation
Cardiacas y Dispositivos Intravasculares Test de isquemia, TC y RM, cateterismo
System.
Prevención de lesiones de piel y tejidos blandos TC cardiaco y RM cardiaca Review
Review
en pacientes sometidos a cirugía cardiaca Trasplante hepático Review
Protocol/ Clinical pathway Status Protocol/ Clinical pathway Status Protocolo anestésico para la cirugía de Tratamiento con anakinra Review
New
Abordaje multidisciplinar de las esofagitis CMA lesiones lumbares y cervicales Review estrabismos
Review Uso de megadosis vit C en el paciente quemado Nueva
eosinofílica Consulta de alta resolución de Nódulo Tiroideo New Protocolo antiestrés de la enfermedad renal Review
Vasculitis necrotizantes sistémicxas Review
Abordaje multidisciplinar de las intolerancias Derivación de pacientes con VPH entre Protocolo asistencial en Unidad de aislamiento de
Review Review Review Vía clínica agitación psicomotriz Review
alimentarias ginecología, dermatología y cirugía general alto nivel
Actuación del Fracaso Renal en la enfermedad de Protocolo de actuación en el ictus en edad infantil Review Vía clínica cirugía bariátrica Review
Review Diabetes-II Review
Ebola Protocolo de alergia al dializador New Vía clínica de cáncer de pulmon Review
Dislipemia Review
Actuación en VATS New Protocolo de carta de duelo y seguimiento Via clínica de hemorragias cerebrales Review
Dispensación de Mepolizumab para el Review
AngioOCT en lesiones melanóticas Review Nueva telefónico Vía clinica de ictus en el apartado de nutrición Review
tratamiento del asma eosinofílica refractaria grave
Asepsia/antisepsia en los quirófanos de Cirugía Protocolo de derivación de pacientes a ERCA Review Vía clinica de primera crisis epiléptica Nueva
Review Enfermedad de Fabry Review
Cardiaca de Adultos Protocolo de inclusión en lista de espera de Vía clínica para implante de bomba de infusión
Enfermedad del viajero menos prevalentes Review Review
Atención a Pacientes con ELA que ingresan trasplante continua de levodopa intraduodenal en la Review
para realización de Gastrostomía Radiológica o Review Enfermedad ósea en la fibrosis quística New
Protocolo de inclusión en lista de espera de enfermedad de Parkinson avanzada
Endoscópica Percutánea Enfermedad Tromboembólica Review Review
trasplante Vía clínica para implante de bomba subcutánea de
Atención a pacientes con ITS Review Enfermedades tropicales más prevalentes Review Protocolo de la administración del hidroferol en apomorfina en infusión continua en la enfermedad Review
New
Atención a pacientes neurológicos (educación Esclerosis sistémica Review ERCA de Parkinson avanzada
New
alimentaria) Fatiga crónica Review Protocolo de osteodistrofia en diálisis peritoneal Review Vía clínica Sd. Abstinencia alcohólica Review
Atención del paciente con agonía Review Gastrostomía endoscópica percutánea Review Protocolo de tratamiento de las peritonitis en Vía clínica de Trombosis venosas cerebrales Nueva
Review
Bronquiolitis y terapia de alto flujo Review Guía clínica manejo enfermedad tromboembólica CAPD Vía de recuperación acelerada tras cirugía
Review New
Cierre percutáneo de orejuela Nueva venosa Protocolo de vacunación del VHB Review torácica

36 37
 2
Executive Summary
2.6
Clinical Trials
Balsa Criado A. Ensayo de fase IV, aleatorizado, doble ciego, controlado con placebo
y de grupos paralelos para evaluar la eficacia y la seguridad de golimumab (MK-8259
[SCH 900259]) tras la retirada del tratamiento, en comparación con su continuación
(pauta completa o reducida), en sujetos con espondiloartritis axial no radiológica. Type:
Clinical Trial, phase IV.
HULP code: 4859. Sponsored´s protocol code: 8259-038. Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 14/06/2017
Redondo Sánchez A. A randomized, double blinded, phase III study of atezolizumab
versus placebo in patients with late relapse of epithelial ovarian, fallopian tube or peri-
toneal cancer treated by platinum-based chemotherapy and bevacizumab atalante.Type:
Clinical Trial, phase III.
HULP code: 4876. Sponsored´s protocol code: GINECO-OV236b. Sponsored by: Grupo Español de
Investigación Cáncer de Ovario (GEICO). Signed date: 27/11/2017
Hierro Llanillo L. Estudio abierto y multicéntrico para evaluar la farmacocinética, la segu-
ridad y la eficacia de glecaprevir/pibrentasvir en pacientes pediátricos con infección crónica
por el virus de la hepatitis c (VHC) de genotipo 16. Type: Clinical Trial, phase III.
HULP code: 4847. Sponsored´s protocol code: M16-123. Sponsored by: Abbvie Deutschland GMBH. Signed date:
28/08/2017
Martín Arranz MD. Estudio fase III, multicéntrico, internacional, aleatorizado, doble ciego, de gru-
pos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de células madre. Type:
Clinical Trial, phase III.
HULP code: 4848. Sponsored´s protocol code: Cx601-0303. Sponsored by: Tigenix S.A.U. Signed date: 02/06/2017
Sáenz de Pipaón Marcos M. Estudio aleatorizado, en doble ciego, controlado, con grupos paralelos y multina-
cional, para investigar el efecto sobre la composición de la microbiota intestinal de una leche infantil parcialmente
hidrolizada, suplementada con simbióticos, y su efectividad clínica en lactantes con gran riesgo de desarrollar alergia. Type:
Healthcare product.
HULP code: 4850. Sponsored´s protocol code: EBB15BL89859. Sponsored by: Nutricia Reseach B.V. (Danone). Signed date: 24/07/2017
Humala Barbier KK. Estudio de fase III, aleatorizado, doble ciego, multicéntrico y controlado con placebo, de pracinostat en
combinación con azacitidina en pacientes ≥ 18 años con leucemia mieloide aguda (LMA) de diagnóstico reciente no aptos
para la quimioterapia de inducción habitual. Type: Clinical Trial, phase III.
HULP code: 4853. Sponsored´s protocol code: FRAN-16-52. Sponsored by: Helsinn Healthcare S.A. Signed date: 13/11/2017
Redondo Sánchez A. Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone
sarcomas. Type: Clinical Trial, phase I.
HULP code: 4854. Sponsored´s protocol code: GEIS-52. Sponsored by: Grupo Español de Investigación en Sarcomas. Signed date: 13/06/2017
Abad Gurumeta A. Ensayo de fase III, abierto, aleatorizado, multicéntrico y controlado para evaluar la farmacocinética y
farmacodinámica de edoxabán y comparar la eficacia y seguridad de edoxabán con un tratamiento estándar anticoagulante
en sujetos pediátricos desde el nacimiento hasta antes de los 18 años con tromboembolismo venoso (TEV) confirmado.
Type: Clinical Trial, phase III.
HULP code: 4855. Sponsored´s protocol code: DU176b-D-U312. Sponsored by: Daiichi Sankyo Inc. Signed date: 15/09/2017
de Lucas Laguna R. Estudio multicéntrico, doble ciego, aleatorizado, comparado con placebo, en el que se evalúan la segu-
ridad, la tolerabilidad y la eficacia de ixekizumab en pacientes con psoriasis en placas de moderada a grave y entre 6 y < 18
años. Type: Clinical Trial, phase III.
HULP code: 4856. Sponsored´s protocol code: MC-RHCD. Sponsored by: Lilly S.A. Signed date: 18/07/2017
Rodríguez Salas N. Estudio multicéntrico, fase II de nivolumab en combinación con ipilimumab para pacientes con tumores
pediátricos sólidos avanzados del adulto. Type: Clinical Trial, phase II.
HULP code: 4845. Sponsored´s protocol code: GETHI021. Sponsored by: Grupo Español de Tumores Huérfanos e Infrecuentes. Signed date:
18/07/2017
Pascual Pascual SI. Estudio de fase III, doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia, la segu-
ridad y la tolerabilidad de idebenona en pacientes con distrofia muscular de Duchenne que reciben glucocorticoesteroides.
Type: Clinical Trial, phase III.
38
HULP code: 4858. Sponsored´s protocol code: SNT-III-012. Sponsored by: Santhera Pharmaceuticals Ltd. Signed date: 20/09/2017
Redondo Sánchez A. Estudio de fase IIIB, aleatorizado, en doble ciego, controlado con placebo y multicéntrico, del retratamiento con
olaparib en pacientes con cáncer epitelial de ovario tratado previamente con un Parpi y con respuesta a la repetición de la quimiotera-
pia con platino (OREO). Type: Clinical Trial, phase IIIb.
HULP code: 4844. Sponsored´s protocol code: D0816C00014. Sponsored by: Astrazeneca AB. Signed date: 00/01/1900
Canales Albendea MA. Estudio fase II de seguridad y eficacia de atezolizumab administrado en combinación con terapia anti-CD20
obinutuzumab o rituximab en pacientes con linfoma de células del manto o de la zona marginal y macroglobulinemia de Waldenström
refractarios o en recaída. Type: Clinical Trial, phase II.
HULP code: 4860. Sponsored´s protocol code: MO39107. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 29/06/2017
Espinosa Arranz E. Estudio de fase III multicéntrico, abierto, randomizado, con dos grupos de tratamiento para evaluar la eficacia y la
seguridad de cobimetinib en combinación con atezolizumab frente a pembrolizumab en pacientes con melanoma BRAFV600 tipo salvaje
avanzado, no tratados previamente. Type: Clinical Trial, phase III.
HULP code: 4862. Sponsored´s protocol code: CO39722. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 06/10/2017
Feliú Batlle J. Estudio fase I-II, en estudio preliminar de eficacia, en abierto, de determinación de la dosis, en fase I-II y llevado a cabo
en humanos por primera vez para evaluar la seguridad, la tolerabilidad, la farmacocinética y la farmacodinámica de CX-2009 en adultos
con tumores sólidos irresecables metastásicos o localmente avanzados (Proclaim-CX-2009). Type: Clinical Trial, phase I.
HULP code: 4867. Sponsored´s protocol code: CTMX-M-2009-001. Sponsored by: Cytomx Thereapeutics Inc. Signed date: 19/07/2017
Balsa Criado A. Estudio de fase III, aleatorizado, con comparador activo, doble ciego para comparar ABT-494 con abatacept en sujetos
con artritis reumatoide de actividad moderada a grave con respuesta insuficiente o intolerancia a los farme biológicos (Farmeb) en
tratamiento estable con fármacos antirreumáticos modificadores de la enfermedad sintéticos convencionales (Farmesc). Type: Clinical
Trial, phase III.
HULP code: 4868. Sponsored´s protocol code: M15-925. Sponsored by: Abbvie Deutschland GMBH. Signed date: 21/11/2017
Aracil Santos F. Ensayo clínico aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad, la tolerabilidad, la farma-
cocinética y la eficacia de una única infusión de bezlotoxumab (MK-6072, anticuerpo monoclonal humano frente a la toxina b de c.
difficile) en niños y adolescentes de 1 a menos de 18 años que reciben tratamiento antibacteriano para la infección por c. difficile. Type:
Clinical Trial, phase III.
HULP code: 4869. Sponsored´s protocol code: 6072-001. Sponsored by: Merck Sharp & Dhome Corp. Signed date: 08/06/2017
Canales Albendea MA. Estudio de fase III randomizado, doble ciego y controlado con placebo, de itacitinib o placebo en combinación
con corticosteroides para el tratamiento de primera línea de la enfermedad de injerto contra huésped en fase aguda.Type: Clinical Trial,
phase III.
HULP code: 4872. Sponsored´s protocol code: INCB 39110-301. Sponsored by: Incyte Corporation. Signed date: 13/06/2017
Ruiz de Valbuena Maiz M. Ensayo aleatorizado y doble ciego de fase IIIB para evaluar la seguridad y la eficacia de 2 regímenes de tra-
tamiento con aztreonam 75 mg polvo y disolvente para solución para inhalación por nebulizador / aztreonam solución para inhalación
(AZLI) en pacientes pediátricos con fibrosis quística (FQ) e infección/colonización de las vías respiratorias por pseudomonas aerugino-
sa (PA) de nueva aparición. Type: Clinical Trial, phase IIIb.
HULP code: 4873. Sponsored´s protocol code: GS-US-205-1850. Sponsored by: Gilead Sciences Inc. Signed date: 30/06/2017
Arribas López JR. Tratamiento antirretroviral guiado por genotipo proviral: ensayo clínico piloto de prueba de concepto. Type: Clinical
Trial, phase II.
HULP code: 4874. Sponsored´s protocol code: TAR-PRO. Sponsored by: Fundación para la Investigacion Biomedica Hospital Universitario La Paz. Signed
date: 13/09/2017
Martín Arranz MD. Estudio de fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia y
la seguridad de mongersen (GED-0301) en el tratamiento de sujetos adultos y adolescentes con enfermedad de Crohn activa. Type:
Clinical Trial, phase III.
HULP code: 4816. Sponsored´s protocol code: GED-0301-CD-003. Sponsored by: Celgene International Sarl. Signed date: 06/04/2017
Pinto Marín A. Estudio de fase Ib/II, randomizado, doble ciego, controlado con placebo, multicéntrico, de grupos paralelos de B-701 más
docetaxel en comparación con placebo más docetaxel en el tratamiento del carcinoma urotelial localmente avanzado o metastásico en
pacientes con recidiva tras el tratamiento de referencia o que no hayan respondido a este. Type: Clinical Trial, phase Ib.
HULP code: 4857. Sponsored´s protocol code: B-701-U21. Sponsored by: Bioclin Therapeutics Inc. Signed date: 25/09/2017
Redondo Sánchez A. Phase I dose escalation and cohort expansion study of TSR-042, an anti-PD-1 monoclonal antibody, in patients
with advanced solid tumors. Type: Clinical Trial, phase I.
HULP code: 4831. Sponsored´s protocol code: TSR-042. Sponsored by: Tesaro Inc. Signed date: 16/03/2017
Martín Arranz MD. Estudio de fase III multicentrico, doble ciego y controlado con placebo de la eficacia y seguridad de etrolizumab
durante la inducción y el mantenimiento en pacientes con colitis ulcerosa activa de moderada a grave resistentes o intolerantes a los
inhibidores del FNT. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4188. Sponsored´s protocol code: GA28950. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 09/01/2017
Balsa Criado A. Ensayo de fase II, exploratorio, aleatorizado, en doble ciego y con doble simulación, controlado con placebo y con
producto activo, para evaluar la eficacia y la seguridad de la aplicación tópica de GRT7019 en sujetos con dolor crónico por gonartrosis.
Type: Clinical Trial, phase II.
39
 2
Executive Summary
2.6 Clinical Trials
HULP code: 4819. Sponsored´s protocol code: KF7019-01. Sponsored by: Grünenthal GMBH. Signed date: 06/07/2017
Jiménez Yuste VM. Explorer ™5- ensayo multicéntrico para evaluar la eficacia y seguridad de la administración de concizumab en
profilaxis en pacientes con hemofilia A grave sin inhibidores. Type: Clinical Trial, phase II.
HULP code: 4821. Sponsored´s protocol code: NN7415-4255. Sponsored by: Novo Nordisk A/S. Signed date: 25/07/2017
Jiménez Yuste VM. Explorer ™4- ensayo multicéntrico, aleatorizado, abierto y controlado para evaluar la eficacia y seguridad de la
administración de concizumab en profilaxis en pacientes con hemofilia A y B e inhibidores. Type: Clinical Trial, phase II.
HULP code: 4822. Sponsored´s protocol code: NN7415-4310. Sponsored by: Novo Nordisk A/S. Signed date: 25/07/2017
Custodio Carretero AB. Ensayo clínico ensayo clínico de fase III, aleatorizado, doble ciego y controlado con placebo, de pembrolizumab
(MK-3475) en combinación con cisplatino y 5-fluorouracilo frente a un placebo en combinación con cisplatino y 5-fluorouracilo como
tratamiento de primera línea en sujetos con carcinoma esofágico avanzado/metastásico (Keynote-590). Type: Clinical Trial, phase III.
HULP code: 4823. Sponsored´s protocol code: MK3475-590. Sponsored by: Merck Sharp & Dhome Corp. Signed date: 04/05/2017
Canales Albendea MA. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y multicéntrico entre bendamustina con
rituximab (BR) en monoterapia y en combinación con acalabrutinib (ACP-196) en pacientes con linfoma de células del manto no trata-
do previamente. Type: Clinical Trial, phase III.
HULP code: 4824. Sponsored´s protocol code: ACE-LY-308. Sponsored by: Acerta Pharma B.V. Signed date: 31/07/2017
Balsa Criado A. Estudio en fase I/III, aleatorizado y de grupos paralelos para evaluar la eficacia, la farmacocinética y la seguridad de CT-
P13 subcutáneo y CT-P13 intravenoso en pacientes con artritis reumatoide activa. Type: Clinical Trial, phase I.
HULP code: 4825. Sponsored´s protocol code: CT-P13 3.5. Sponsored by: Celltrion Inc. Signed date: 30/05/2017
Pinto Marín A. Triton 3: un estudio multicéntrico, aleatorizado, abierto de fase III de rucaparib versus elección del médico para pacien-
tes con cáncer de próstata metastásico resistente a la castración asociado con deficiencia de recombinación homóloga. Type: Clinical
Trial, phase III.
HULP code: 4828. Sponsored´s protocol code: CO-338-063. Sponsored by: Clovis Oncology Inc. Signed date: 19/09/2017
Redondo Sánchez A. A randomized, double-blind, placebo-controlled phase II trial of palbociclib in combination with letrozole versus
letrozole in combination with placebo for patients with estrogen receptor positive advanced or recurrent endometrial cancer. Type:
Clinical Trial, phase II.
HULP code: 4846. Sponsored´s protocol code: ENGOT-EN3-NSGO. Sponsored by: Grupo Español de Investigación Cáncer de Ovario (GEICO). Signed
date: 08/08/2017
Feliú Batlle J. Estudio de fase III de BBI-608 más nab-paclitaxel con gemcitabina en pacientes adultos con adenocarcinoma pancreático
metastásico. Type: Clinical Trial, phase III.
HULP code: 4830. Sponsored´s protocol code: CanStem111P. Sponsored by: Boston Biomedical Inc. Signed date: 30/06/2017
Pinto Marín A. Estudio fase II, internacional, multicéntrico, prospectivo para evaluar la eficacia, la seguridad y la calidad de vida de
pazopanib administrado diariamente por vía oral, en pacientes con carcinoma de células renales avanzado y/o metastásico después de
terapia previa con tratamiento con agentes inhibidores del control de la inmunidad (checkpoint inhibitors). Type: Clinical Trial, phase II.
HULP code: 4877. Sponsored´s protocol code: CPZP034A2410. Sponsored by: Novartis Farmaceutica S.A. Signed date: 04/10/2017
de Castro Carpeño J. Estudio de fase II/III, aleatorizado, abierto y de dos partes, de dinutuximab e irinotecán versus irinotecán como
tratamiento de segunda línea en sujetos con cáncer de pulmón microcítico en recidiva o resistente. Type: Clinical Trial, phase II/III.
HULP code: 4832. Sponsored´s protocol code: DIV-SCLC-301. Sponsored by: United Therapeutics Corporation. Signed date: 12/06/2017
Zamora Auñón P. Estudio fase II, aleatorizado, abierto y multicéntrico, para evaluar el efecto de vinorelbina oral metronómica frente
al mejor tratamiento de soporte como terapia de mantenimiento después de quimioterapia de primera línea basada en taxanos en
pacientes con cáncer de MAAM HER-2 negativo resistente al tratamiento endocrino. Type: Clinical Trial, phase II.
HULP code: 4833. Sponsored´s protocol code: ATRIO-01/16 MAVERICK. Sponsored by: Fundación para el Fomento de la Investigación Sanitaria y
Biomédica de la Comunidad Valenciana Fisabio. Signed date: 03/05/2017
Gómez Candela C. A phase 3, randomized, open-label, assessor-blind, non-inferiority, active-comparator study evaluating the efficacy
and safety of liprotamase in subjects with cystic fibrosis-related exocrine pancreatic insufficiency. Type: Clinical Trial, phase III.
HULP code: 4834. Sponsored´s protocol code: AN-EPI3333. Sponsored by: Linical France Sarl. Signed date: 12/04/2017
Rodríguez Salas N. Tratamiento preoperatorio de inducción con 12 semanas de panitumumab combinado con folfox 6m en una po-
blación enriquecida (quádruple wild-type) de pacientes con cáncer de recto de tercio medio MRT3 y fascia mesorrectal no invadida.
Type: Clinical Trial, phase II.
HULP code: 4835. Sponsored´s protocol code: GEMCAD-1601. Sponsored by: Grupo GEMCAD. Signed date: 22/05/2017
Redondo Sánchez A. Ensayo fase II de nab-paclitaxel para el tratamiento de tumores desmoides y tumores desmoplásicos de células
pequeñas y redondas y sarcoma de Ewing en recaída múltiple o refractarios. Type: Clinical Trial, phase II.
HULP code: 4836. Sponsored´s protocol code: GEIS-39. Sponsored by: Grupo Español de Investigación en Sarcomas. Signed date: 11/10/2017
de Castro Carpeño J. Estudio de fase III, abierto y aleatorizado para comparar atezolizumab (anticuerpo anti-PD-l1) con un derivado del
platino (cisplatino o carboplatino) en combinación con pemetrexed o gemcitabina en pacientes con cáncer de pulmón no microcítico y no
epidermoide o epidermoide en estadio IV seleccionados por PD-l1 que no han recibido quimioterapia previa. Type: Clinical Trial, phase III.
HULP code: 4837. Sponsored´s protocol code: GO29431. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 24/07/2017
Bartha Rasero JL. Ensayo clínico controlado, aleatorizado, doble ciego con prevastatina versus placebo para la prevención de preclamp-
sia. STATIN. Type: Clinical Trial, phase III.
HULP code: 4838. Sponsored´s protocol code: FFIS/2016/02/ST STATIN. Sponsored by: Fundación para la Formación e Investigación Sanitarias de la
Región de Murcia. Signed date: 12/05/2017
Herranz Pinto P. Ensayo fase III, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y seguridad de tralokinumab
en monoterapia en pacientes con dermatitis atópica moderada a grave que sean candidatos para un tratamiento sistémico.Type: Clinical
Trial, phase III.
HULP code: 4842. Sponsored´s protocol code: LP0162-1325. Sponsored by: Leo Pharma A/S. Signed date: 10/11/2017
40
Moreno Gómez JR. Edoxabán frente al tratamiento estándar y sus efectos en los resultados clínicos de los pacientes que se han some-
tido a una implantación de válvula aórtica transcatéter (en fibrilación auricular). Type: Clinical Trial, phase III.
HULP code: 4843. Sponsored´s protocol code: DU176B-C-U4001. Sponsored by: Daiichi Sankyo Inc. Signed date: 23/10/2017
Pérez Valero I. Ensayo clinico fase IV abierto, aleatorizado y piloto diseñado para evalurar la potencial neurotoicidad de dolutegravir/
lamivudina/abacavir en paciente VIH neuro sintomáticos y su revesibilidad tras el cambio a elvitegravir/cobicistat/emtricitabina/tenofovir
alafenamida. Estudio Dream. Type: Clinical Trial, phase IV.
HULP code: 4829. Sponsored´s protocol code: GESIDA 9016. Sponsored by: Fundación SEIMC-GESIDA. Signed date: 31/05/2017
Martín Arranz MD. Estudio multicéntrico aleatorizado, doble ciego y controlado con placebo, con tratamiento de mantenimiento du-
rante 52 semanas y una extensión abierta para evaluar la eficacia y la seguridad de risankizumab en sujetos con enfermedad de Crohn
que respondan al tratamiento de inducción en los estudios M16-006 o M15-991. Type: Clinical Trial, phase III.
HULP code: 4936. Sponsored´s protocol code: M16-000. Sponsored by: Abbvie Deutschland GMBH. Signed date: 21/12/2017
Feliú Batlle J. Ensayo de fase II para evaluar la eficacia y seguridad de Folfiri + panitumumab como tratamiento de primera línea en
pacientes ancianos con cáncer colorrectal metastásico no resecable, RAS/BRAF no mutado y buen estado funcional. Type: Clinical Trial,
phase II.
HULP code: 4875. Sponsored´s protocol code: GEMCAD-16-03. Sponsored by: Grupo GEMCAD. Signed date: 26/07/2017
Zamora Auñón P. Ensayo en fase II doble ciego y controlado con placebo de seribantumab más fulvestrant en mujeres posmenopáusicas
con cáncer de mama metastásico positivo para receptores hormonales, positivo para herregulina (HRG+) y negativo para HER2 cuya
enfermedad ha progresado después de un tratamiento sistémico previo. Type: Clinical Trial, phase II.
HULP code: 4916. Sponsored´s protocol code: MM-121-02-02-10. Sponsored by: Merrimack Pharmaceuticals. Signed date: 12/09/2017
Aguilar-Amat Prior MJ. Estudio de extensión abierto y multicéntrico para evaluar la seguridad y eficacia a largo plazo de lacosamida
como tratamiento complementario para las crisis tónico-clónicas generalizadas primarias no controladas en pacientes con epilepsia
idiopática generalizada. Type: Clinical Trial, phase III.
HULP code: 4920. Sponsored´s protocol code: EP0012. Sponsored by: UCB Biosciencies GMBH. Signed date: 20/11/2017
Aguilar-Amat Prior MJ. Estudio doble ciego, aleatorizado, controlado con placebo, de grupos paralelos, multicéntrico para evaluar
la seguridad y la eficacia de lacosamida como tratamiento complementario para las crisis tónico-clónicas generalizadas primarias no
controladas en pacientes con epilepsia idiopática generalizada. Type: Clinical Trial, phase III.
HULP code: 4921. Sponsored´s protocol code: SP0982. Sponsored by: UCB Biosciencies GMBH. Signed date: 17/11/2017
Montes Ramírez ML. eEtudio fase IIIB, aleatorizado, multicéntrico, abierto, de grupos paralelos, de no inferioridad que evalúa la eficacia,
seguridad y tolerabilidad de cabotegravir de acción prolongada más rilpivirina de acción prolongada administrados cada 8 semanas o
cada 4 semanas en adultos infectados por VIH-1 que presentan supresión virológica. Type: Clinical Trial, phase IIIb.
HULP code: 4925. Sponsored´s protocol code: 207966. Sponsored by: Laboratorios Viiv Healthcare S.L. Signed date: 14/09/2017
Canales Albendea MA. Estudio en fase II de TAK-659 en pacientes con linfoma difuso de células B grandes recidivante o resistente
después de dos o más líneas previas de quimioterapia. Type: Clinical Trial, phase II.
HULP code: 4928. Sponsored´s protocol code: C34004. Sponsored by: Millennium Pharmaceuticals Inc. Signed date: 22/09/2017
Remesal Camba A. Estudio abierto de seguimiento a largo plazo de tofacitinib para el tratamiento de la artritis idiopática juvenil (AIJ).
Type: Clinical Trial, phase II/III.
HULP code: 4931. Sponsored´s protocol code: A3921145. Sponsored by: Pfizer S.L.U. Signed date: 12/12/2017
Remesal Camba A. Eficacia, seguridad y tolerabilidad de tofacitinib para el tratamiento de la artritis idiopática juvenil (AIJ) de curso
poliarticular en sujetos niños y adolescentes. Type: Clinical Trial, phase III.
HULP code: 4932. Sponsored´s protocol code: A3921104. Sponsored by: Pfizer S.L.U. Signed date: 12/12/2017
Canales Albendea MA. Un estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo de fase III del inhibidor de tirosina
kinasa de bruton (BTK) ibrutinib, en combinación con rituximab en comparación con placebo en combinación con rituximab en sujetos
sin tratamiento previo con linfoma folicular. Type: Clinical Trial, phase III.
HULP code: 4909. Sponsored´s protocol code: PCYC-1141-CA. Sponsored by: Pharmacyclics Llc. Signed date: 09/10/2017
Martín Arranz MD. Estudio de inducción multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la
seguridad de risankizumab en sujetos con enfermedad de Crohn activa moderada o grave sin respuesta al tratamiento biológico previo.
Type: Clinical Trial, phase III.
HULP code: 4935. Sponsored´s protocol code: M15-991. Sponsored by: Abbvie Deutschland GMBH. Signed date: 18/12/2017
Sánchez Sánchez M. Estudio comparativo de fase III de grupos paralelos, aleatorizado y doble ciego sobre la eficacia y seguridad de FB-
1201-LYO (interferón beta-1A recombinante humano) y placebo en el tratamiento de pacientes con síndrome de dificultad respiratoria
aguda grave o moderado. Type: Clinical Trial, phase III.
HULP code: 4906. Sponsored´s protocol code: FPCLI002. Sponsored by: Faron Pharmaceuticals Ltd. Signed date: 13/09/2017
Martín Arranz MD. Estudio de inducción multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la
seguridad de risankizumab en sujetos con enfermedad de Crohn activa moderada o grave. Type: Clinical Trial, phase III.
HULP code: 4937. Sponsored´s protocol code: M16-006. Sponsored by: Abbvie Deutschland GMBH. Signed date: 18/12/2017
de Castro Carpeño J. Estudio de fase III, aleatorizado y abierto de lorlatinib (PF-06463922) en monoterapia en comparación con crizo-
tinib en monoterapia en el tratamiento de primera línea de pacientes con carcinoma pulmonar no microcítico avanzado ALK-positivo.
Type: Clinical Trial, phase III.
HULP code: 4938. Sponsored´s protocol code: B7461006. Sponsored by: Pfizer Inc. Signed date: 18/10/2017
López-Sendón Hentschel JL. Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, multicéntrico, para de-
mostrar los efectos de sotagliflozina sobre los eventos cardiovasculares y renales en pacientes con diabetes tipo 2, factores de riesgo
cardiovascular y función renal moderadamente reducida (SCORED). Type: Clinical Trial, phase III.
HULP code: 4943. Sponsored´s protocol code: EFC14875. Sponsored by: Sanofi-Aventis Recherche & Developpement. Signed date: 27/11/2017
Lisbona Catalán A. Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, multicéntrico, para demostrar los
41
 2
Executive Summary
2.6 Clinical Trials
efectos de sotagliflozina sobre los eventos cardiovasculares y renales en pacientes con diabetes tipo 2, factores de riesgo cardiovascular
y función renal moderadamente reducida (SCORED). Type: Clinical Trial, phase III.
HULP code: 4943. Sponsored´s protocol code: EFC14875. Sponsored by: Sanofi-Aventis Recherche & Developpement. Signed date: 27/11/2017
Cansino Alcaide JR. Ensayo multicéntrico, controlado y aleatorizado para evaluar el uso combinado de un dispositivo médico y un
complemento alimenticio en el control del PH urinario de pacientes con un catéter doble J implantado. Type: Healthcare Product.
HULP code: 4944. Sponsored´s protocol code: DEV-LCD-02-17. Sponsored by: Devicare S.L. Signed date: 17/11/2017
Zamora Auñón P. Ensayo de fase III, aleatorizado y abierto para evaluar la eficacia y la seguridad de palbociclib + tratamiento anti-HER2
+ tratamiento endocrino frente a tratamiento anti-HER2 + tratamiento endocrino tras el tratamiento de inducción para el cáncer de
mama metastásico positivo para receptores hormonales (HR+)/positivo para HER2. Type: Clinical Trial, phase III.
HULP code: 4945. Sponsored´s protocol code: AFT-38. Sponsored by: Alliance Foundation Trials Llc. Signed date: 11/10/2017
Herranz Pinto P. Estudio de fase III, multicéntrico, aleatorizado, doble ciego y comparado con placebo, para evaluar la eficacia y la
seguridad de baricitinib en pacientes con dermatitis atópica de moderada a grave. Type: Clinical Trial, phase III.
HULP code: 4951. Sponsored´s protocol code: I4V-MC-JAHM. Sponsored by: Lilly S.A. Signed date: 20/12/2017
de Castro Carpeño J. Estudio de fase III aleatorizado de la combinación de pembrolizumab (MK 3475) más epacadostat (INCB024360)
solos o con quimioterapia a base de platino en comparación con pembrolizumab más quimioterapia a base de platino más placebo
como tratamiento de primera línea en pacientes con cáncer de pulmón no microcítico metastásico. Type: Clinical Trial, phase III.
HULP code: 4952. Sponsored´s protocol code: MK-3475-715. Sponsored by: Merck Sharp and Dohme de España S.A. Signed date: 26/10/2017
Castelo Fernández B. Estudio de fase III, aleatorizado y abierto para evaluar pembrolizumab como tratamiento neoadyuvante y en
combinación con la asistencia habitual como tratamiento adyuvante en el carcinoma epidermoide de cabeza y cuello locorregionalmen-
te avanzado (CECC LA), extirpable, en estadio III-VA. Type: Clinical Trial, phase III.
HULP code: 4953. Sponsored´s protocol code: MK-3475-689. Sponsored by: Merck Sharp & Dhome Corp. Signed date: 22/11/2017
Humala Barbier KK. Estudio de fase IIIB, abierto y multicéntrico, para evaluar la seguridad y eficacia de midostaurina (PKC412) en
pacientes adultos con leucemia mieloide aguda (LMA) con mutación en FLT3 de nuevo diagnóstico, que son candidatos a quimioterapia
7+3 ó 5+2. Type: Clinical Trial, phase IIIb.
HULP code: 4933. Sponsored´s protocol code: CPKC412A2408. Sponsored by: Novartis Farmaceutica S.A. Signed date: 28/11/2017
López Oliva MO. Suspensión de la profilaxis con valganciclovir en trasplantados renales CMV-seropositivo que mantienen la inmunidad
celular CD8+ CMV-específica tras recibir timoglobulina. Type: Clinical Trial, phase III.
HULP code: 4892. Sponsored´s protocol code: FCO-TIM-2015-01. Sponsored by: Fundación para la Investigacion Biomedica de Córdoba (FIBICO-
IMIBIC). Signed date: 19/06/2017
Zamora Auñón P. Ensayo de fase III aleatorizado de palbociclib con tratamiento endocrino adyuvante estándar frente a monoterapia
con tratamiento endocrino adyuvante estándar en cáncer de mama precoz con receptores hormonales positivos (RH+) y HER2-
negativo. Type: Clinical Trial, phase III.
HULP code: 4879. Sponsored´s protocol code: AFT-05-ABCSG 42-BIG 14-03. Sponsored by: Austrian Breast & Colorectal Cancer Group (ABCSG).
Signed date: 23/06/2017
Frank García A. A 6-months prospective, multi-center, double-blind, placebo-controlled, randomized, adaptive-trial-design study to
evaluate safery, tolerability and exploratory endpoints of either placebo or two different oral doses of LM11A-31-BHS in patients with
mild to moderate probable Alzheimer´s disease. Type: Clinical Trial, phase II.
HULP code: 4880. Sponsored´s protocol code: NSC15001. Sponsored by: Pharmatrophix Inc. Signed date: 20/09/2017
Canales Albendea MA. Estudio de fase I, abierto, de determinación de dosis y ampliación de cohortes, para evaluar la seguridad y la
eficacia del tratamiento combinado de INCB050465 con bendamustina y obinutuzumab en sujetos con linfoma folicular recidivante o
resistente al tratamiento (Citadel 102). Type: Clinical Trial, phase I.
HULP code: 4881. Sponsored´s protocol code: INCB 50465-102. Sponsored by: Incyte Corporation. Signed date: 28/06/2017
Asencio Durán M. Estudio intervencionista en fase IV, multicéntrico y de un solo grupo para evaluar una pauta de tratar y extender
con aflibercept intravítreo para el tratamiento del edema macular secundario a la oclusión de la vena central de la retina. Type: Clinical
Trial, phase IV.
HULP code: 4882. Sponsored´s protocol code: BAY 86-5321/17514. Sponsored by: Bayer AG. Signed date: 12/09/2017
de Castro Carpeño J. Estudio de fase III/IV multicéntrico, con un solo grupo de tratamiento, para investigar la seguridad a largo plazo y
la eficacia de atezolizumab (Tecentriq) en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico, tratados
previamente (Tail). Type: Clinical Trial, phase III.
HULP code: 4883. Sponsored´s protocol code: MO39171. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 05/09/2017
Martín Salces M. Estudio en fase III prospectivo, abierto, internacional y multicéntrico sobre la eficacia y la seguridad de la profilaxis
con RVWF en la enfermedad grave de Von Willebrand. Type: Clinical Trial, phase III.
HULP code: 4884. Sponsored´s protocol code: 071102. Sponsored by: Baxalta Innovations GMHB. Signed date: 20/10/2017
Arribas López JR. Estudio de fase III, aleatorizado, multicéntrico, con grupos paralelos y de ausencia de inferioridad para evaluar la
eficacia, la seguridad y la tolerabilidad del cambio a dolutegravir más lamivudina en adultos infectados por el VIH 1 con supresión viro-
lógica. Type: Clinical Trial, phase III.
HULP code: 4885. Sponsored´s protocol code: 204862. Sponsored by: Viiv Healthcare Uk Limited. Signed date: 23/06/2017
Cartón Sánchez AJ. Estudio prospectivo, aleatorizado, abierto y multicéntrico de la seguridad y farmacocinética de apixaban comparado
con un antagonista de la vitamina K o HBPM en sujetos pediátricos con cardiopatías congénitas o adquiridas que requieren anticoagu-
lación crónica para la prevención del tromboembolismo. Type: Clinical Trial, phase II.
HULP code: 4887. Sponsored´s protocol code: CV185-362. Sponsored by: Bristol Myers Squibb International Corporation. Signed date: 08/09/2017
Feliú Batlle J. Estudio aleatorizado, multicéntrico, doble ciego, controlado con placebo, de fase II/III del inhibidor de la tirosina quinasa
de Bruton, ibrutinib, en combinación con nab-paclitaxel y gemcitabina frente a placebo en combinación con nab-paclitaxel y gemcitabina,
en el tratamiento de primera línea de pacientes con adenocarcinoma de páncreas metastásico. Type: Clinical Trial, phase II.
HULP code: 4913. Sponsored´s protocol code: PH1603. Sponsored by: Ph Research S.L. Signed date: 11/11/2017
42
Gómez Barrena E. Estudio aleatorizado, doble ciego, doble simulación, multicéntrico, de diseño adaptativo de escalada de dosis (parte
1) y dosis-respuesta (parte 2) para evaluar la seguridad y la eficacia de JNJ-64179375 intravenoso frente a apixaban oral en sujetos
sometidos a un reemplazo total de rodilla. Type: Clinical Trial, phase II.
HULP code: 4890. Sponsored´s protocol code: 64179375THR2001. Sponsored by: Janssen Cilag International NV. Signed date: 18/10/2017
de Castro Carpeño J. Estudio de fase III, aleatorizado, doble ciego y controlado con placebo de rovalpituzumab tesirina como trata-
miento de mantenimiento después de una primera línea de tratamiento quimioterápico basado en platino en pacientes con cáncer de
pulmón microcítico en estadio avanzado (MERU). Type: Clinical Trial, phase III.
HULP code: 4814. Sponsored´s protocol code: M16-298. Sponsored by: Abbvie Deutschland GMBH. Signed date: 20/06/2017
García-Samaniego Rey J. Ensayo fase II, multicéntrico, doble ciego, aleatorizado, de grupos paralelos y controlado con placebo para
investigar la seguridad, tolerabilidad, farmacodinámica y farmacocinética de distintas dosis orales de BI 1467335 durante 12 semanas de
tratamiento, en comparación con placebo en pacientes con evidencia clínica de EHNA. Type: Clinical Trial, phase II.
HULP code: 4893. Sponsored´s protocol code: 1386.4. Sponsored by: Boehringer Ingelheim España S.A. Signed date: 05/07/2017
Sánchez Sánchez M. Prospective, randomized, controlled, double-blind, multi-centric, international study on the efficacy and safety of an
early target controlled plasma volume replacement therapy with a balanced gelatin solution vs a balanced electrolyte solution in patients
with severe sepsis/septic shock. Type: Clinical Trial, phase IV.
HULP code: 4894. Sponsored´s protocol code: GENIUS. Sponsored by: Braun Melsungen AG. Signed date: 23/11/2017
Herranz Pinto P. Estudio clínico abierto para evaluar la eficacia y la seguridad a largo plazo de dimetilfumarato en adultos con psoriasis
crónica en placas moderada-grave en la práctica clínica (Estudio Dimeskin 1). Type: Clinical Trial, phase IV.
HULP code: 4895. Sponsored´s protocol code: M-41-008-41. Sponsored by: Almirall S.A. Signed date: 03/10/2017
de Castro Carpeño J. Estudio de extensión de fase IV, multicéntrico, abierto en pacientes con tumores malignos ALK positivo que hayan
finalizado un estudio previo de ceritinib (LDK378) patrocinado por Novartis y que vayan a beneficiarse del tratamiento continuado con
ceritinib según el criterio del investigador. Type: Clinical Trial, phase IV.
HULP code: 4896. Sponsored´s protocol code: CLDK378A2X01B. Sponsored by: Novartis Farmaceutica S.A. Signed date: 18/08/2017
Rubio Aparicio PM. Ensayo clínico en fase III multicéntrico, aleatorizado, doble ciego, controlado por placebo, con grupos paralelos
para investigar la eficacia, seguridad y tolerabilidad de naloxona HCL LP comprimidos en pacientes con estreñimiento inducido por
opioides. Type: Clinical Trial, phase I.
HULP code: 4898. Sponsored´s protocol code: BAY 73-4506/15906. Sponsored by: Bayer AG. Signed date: 29/11/2017
Jiménez Yuste VM. Estudio abierto, multicéntrico y no controlado de la eficacia de RFVIIIFC para la inducción de tolerancia inmune (ITI)
en sujetos con hemofilia A grave con inhibidores que se someten al primer tratamiento de ITI. Type: Clinical Trial, phase IV.
HULP code: 4899. Sponsored´s protocol code: 997HA402. Sponsored by: Bioverativ Therapeutics Inc. Signed date: 25/09/2017
Martín Arranz MD. Estudio en fase I abierto, aleatorizado, de grupos paralelos para evaluar la farmacocinética, la eficacia y la seguridad
de CT-P13 subcutáneo y CT-P13 intravenoso en pacientes con enfermedad activa de Crohn y pacientes con colitis ulcerosa activa.Type:
Clinical Trial, phase I.
HULP code: 4901. Sponsored´s protocol code: CT-P13 1.6. Sponsored by: Celltrion Inc. Signed date: 06/09/2017
Montejano Sánchez R. Estudio de fase IIB, comparativo, multicéntrico, aleatorizado, doble ciego, para evaluar la eficacia y seguridad de
VIS410 por vía intravenosa administrado junto con oseltamivir (Tamiflu®) en comparación con oseltamivir en monoterapia en adultos
hospitalizados con infección por el virus de la gripe A que requieren soporte con oxígeno. Type: Clinical Trial, phase II.
HULP code: 4903. Sponsored´s protocol code: VIS410-203. Sponsored by: Visterra Inc. Signed date: 23/10/2017
López Carrasco A. Estudio aleatorizado, controlado con placebo, doble ciego, de grupos paralelos, multicéntrico, de dosis-respuesta
para evaluar la eficacia y seguridad de diferentes dosis orales de BAY1128688 en mujeres con endometriosis sintomática durante un
tratamiento de 12 semanas. Type: Clinical Trial, phase II.
HULP code: 4904. Sponsored´s protocol code: BAY 1128688/17472. Sponsored by: Bayer AG. Signed date: 20/10/2017
de Castro Carpeño J. Ensayo de fase III, abierto, multicéntrico de avelumab (MSB0010718C) frente al doblete con base de platino como
tratamiento de primera línea del cáncer de pulmón no microcítico PD-l1+ recurrente o en estadio IV. Type: Clinical Trial, phase III.
HULP code: 4889. Sponsored´s protocol code: EMR100070-005. Sponsored by: Merck KGAA. Signed date: 00/01/1900
de Castro Carpeño J. Ensayo clinico fase II, exploratorio y multicentrico, de quimioinmunoterapia neo-adyuvante para el tratamiento
del cáncer de pulmón no microcitico estadio III operable. Type: Clinical Trial, phase II.
HULP code: 4738. Sponsored´s protocol code: 4738 NADIM (GECP 16/03) JAVIER DE CASTRO. Sponsored by: Grupo Español Cáncer Pulmón. Signed
date: 18/01/2017
Mostaza Prieto JM. Estudio de fase III, internacional, multicéntrico, aleatorizado y abierto, para evaluar la eficacia en la reducción de
CLDL y presión arterial, y la seguridad de Trinomia® versus tratamiento habitual en pacientes de muy alto riesgo cardiovascular sin
evento previo estudio vulcano_FMD-TRI-2016-01. Type: Clinical Trial, phase III.
HULP code: 4756. Sponsored´s protocol code: FMD-TRI-2016-01. Sponsored by: Ferrer Internacional S.A. Signed date: 31/10/2017
Bravo Ortiz MF. Ensayo clinico fase III, aleatorizado, multicentrico, doble ciego para evaluar dos pautas de administración del ibuprofeno
en el tratamiento del ductus arterioso persistente eco-guiado: impacto en el pronóstico intestinal. Type: Clinical Trial, phase III.
HULP code: 4711. Sponsored´s protocol code: IBU24h-EchoG. Sponsored by: Fundación para la Investigacion Biomédica Hospital Universitario La Paz.
Signed date: 03/04/2017
Moral Pumarega MT. Ensayo clínico fase III, aleatorizado, multicéntrico, doble ciego para evaluar dos pautas de administración del ibu-
profeno en el tratamiento del ductus arterioso persistente eco-guiado: impacto en el pronóstico intestinal. Type: Clinical Trial, phase III.
HULP code: 4711B. Sponsored´s protocol code: IBU24h-EchoG. Sponsored by: Fundación para la Investigacion Biomédica Hospital Universitario La
Paz. Signed date: 18/04/2017
Cabañas González F. Ensayo clínico fase III, aleatorizado, multicéntrico, doble ciego para evaluar dos pautas de administración del ibu-
profeno en el tratamiento del ductus arterioso persistente eco-guiado: impacto en el pronóstico intestinal. Type: Clinical Trial, phase III.
HULP code: 4711C. Sponsored´s protocol code: IBU24h-EchoG. Sponsored by: Fundación para la Investigacion Biomédica Hospital Universitario La
Paz. Signed date: 03/04/2017
43
 2
Executive Summary
2.6 Clinical Trials
Hernández Gutiérrez A. Seguridad y beneficios del dispositivo de captura de células tumorales metastásicas en pacientes con cáncer
de ovario avanzado. Type: Healthcare product
HULP code: 4723. Sponsored´s protocol code: MTRAP-2016-01. Sponsored by: Mtrap Inc. Signed date: 10/01/2017
Rodríguez Salas N. Estudio de fase III de BBI-608 en combinación con 5-fluorouracilo, ácido folínico e irinotecán (Folfiri) en pacientes
adultos con cáncer colorrectal (CCR) metastático previamente tratado. Type: Clinical Trial, phase III.
HULP code: 4725. Sponsored´s protocol code: CANSTEM303C. Sponsored by: Boston Biomedical Inc. Signed date: 22/01/2017
Jiménez Yuste VM. ECHO: expanding communications on hemophilia A outcomes - estudio observacional, internacional, longitudinal,
prospectivo en pacientes en tratamiento de hemofilia A de moderada a grave para la evaluacion de los resultados comunicados por los
pacientes y la asociacion con su enfermedad. Type: EPA-SP.
HULP code: 4727. Sponsored´s protocol code: BAY-FAC-2016-01. Sponsored by: Bayer Hispania S.L. Signed date: 08/02/2017
Sánchez García L. Estudio multicéntrico aleatorizado y abierto en fase IIB para comparar la eficacia, seguridad y farmacocinetica (PK)
de la dosis óptima y la dosis estándar de vancomicina en neonatos y niños menores o iguales a 90 días de vida con sospecha de sepsis
o sepsis confirmada por germenes gram-positivos. Type: Clinical Trial, phase II.
HULP code: 4729. Sponsored´s protocol code: NEOVANC. Sponsored by: Fondazione Penta Onlus. Signed date: 17/02/2017
Pérez Martínez A. LCH-IV international collaborative treatment protocol for children and adolescents with langerhans cell histiocyto-
sis. Type: Clinical Trial, phase IV.
HULP code: 4709. Sponsored´s protocol code: LCH-IV 042011. Sponsored by: Sociedad Española de Oncología y Hematología Pediátricas. Signed date:
17/02/2017
González Martínez B. Research study for treatment of children and adolescents with acute myeloid leukaemia 0-18 years.Type: Clinical
Trial, phase III.
HULP code: 4733. Sponsored´s protocol code: NOPHO-DBH AML 2012. Sponsored by: Västra Götaland Regionen. Signed date: 15/09/2017
Quesadas Simón A. Estudio fase IV para evaluar la eficacia y la seguridad de la nueva insulina glargina 300 u/ml (GLA-300) durante la
hospitalización y la intensificación al alta en pacientes con diabetes tipo 2. Type: Clinical Trial, phase IV.
HULP code: 4697. Sponsored´s protocol code: GLARGL07710. Sponsored by: Sanofi Aventis S.A. Signed date: 15/05/2017
Alonso Melgar A. Estudio de grupo unico de ALXN1210 en pacientes adultos y adolescentes con síndrome hemolítico urémico atípico
(SHUA) sin tratamiento previo con inhibidores del complemento. Type: Clinical Trial, phase III.
HULP code: 4739. Sponsored´s protocol code: ALXN1210-aHUS-311. Sponsored by: Alexion Pharmaceutical Inc. Signed date: 31/01/2017
Gómez Carrera L. Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad del tratamiento
con nintedanib durante 52 semanas en pacientes con enfermedad pulmonar intersticial fibrosante progresiva (EPI-FP). Type: Clinical
Trial, phase III.
HULP code: 4740. Sponsored´s protocol code: 1199.247. Sponsored by: Boehringer Ingelheim España S.A. Signed date: 25/01/2017
Labrandero de Lera C. Estudio multicéntrico, abierto, aleatorizado, basado en acontecimientos, para evaluar la eficacia, la seguridad
y la farmacocinética de macitentán frente al tratamiento de referencia en niños con hipertensión arterial pulmonar. Type: Clinical Trial,
phase III.
HULP code: 4744. Sponsored´s protocol code: AC-055-312. Sponsored by: Actelion Pharmaceuticals Ltd. Signed date: 19/09/2017
Rodríguez Salas N. Estudio de fase III, multicéntrico, aleatorizado y abierto, de 3 grupos: encorafenib + cetuximab, con o sin binimetinib,
frente a irinotecan / cetuximab o 5-fluorouracilo (5-fu)/ácido folínico (fa)/irinotecan (folfiri)/cetuximab en infusión, con una evaluacion
previa de la seguridad de encorafenib + binimetinib + cetuximab, en pacientes con cáncer colorrectal metastásico con la mutante V600E
del gen BRAF. Type: Clinical Trial, phase III.
HULP code: 4748. Sponsored´s protocol code: ARRAY818-302. Sponsored by: Array Biopharma Inc. Signed date: 16/02/2017
López de Sa Areces E. Estudio clínico unicéntrico de una serie de casos para evaluar la viabilidad de integrar la hipotermia terapéutica
con el sistema IVTM de zoll como adjuvante de la angioplastia coronaria percutánea en pacientes con infarto agudo de miocardio.Type:
Healthcare Product.
HULP code: 4749. Sponsored´s protocol code: COOL-AMI. Sponsored by: Zoll Circulation Inc. Signed date: 24/07/2017
Moreno Gómez JR. Estudio clínico unicéntrico de una serie de casos para evaluar la viabilidad de integrar la hipotermia terapéutica
con el sistema IVTM de zoll como adjuvante de la angioplastia coronaria percutánea en pacientes con infarto agudo de miocardio.Type:
Healthcare Product.
HULP code: 4749. Sponsored´s protocol code: COOL-AMI. Sponsored by: Zoll Circulation Inc. Signed date: 24/07/2017
Díez Tejedor E. Estudio de fase IB/II, multicéntrico, aleatorizado, con doble enmascaramiento (con sujetos del estudio, sin enmascara-
miento, para el promotor), controlado con placebo, de dosis unica ascendente, para evaluar la seguridad, la farmacocinética y la farma-
codinámica de DS-1040B en sujetos con ictus isquémico agudo. Type: Clinical Trial, phase II.
HULP code: 4753. Sponsored´s protocol code: DS1040-A-U103. Sponsored by: Daiichi-Sankyo Development Limited. Signed date: 14/03/2017
Añón Elizalde JM. Estudio de fase IB/IIA, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo y multicéntrico para
evaluar la seguridad y eficacia de las células madre alogénicas expandidas derivadas del tejido adiposo (EASC) CX611 para el tratamien-
to intravenoso de pacientes adultos con neumonía bacteriana grave adquirida en la comunidad e ingresados en unidades de cuidados
intensivos (Estudio Sepcell). Type: Clinical Trial, phase Ib.
HULP code: 4754. Sponsored´s protocol code: Cx611-0204. Sponsored by: Tigenix S.A.U. Signed date: 18/09/2017
Zamora Auñón P. Estudio de fase IIIB, abierto, multicéntrico, para evaluar la seguridad y la eficacia de ribociclib (IEE011) en combinación
con letrozol en el tratamiento de hombres y mujeres postmenopáusicas con cáncer de mama avanzado (CMA) con receptor hormonal
positivo (HR+) y HER2 negativo (HER2-) que no hayan recibido tratamiento hormonal para la enfermedad avanzada. Type: Clinical Trial,
phase IIIb.
HULP code: 4817. Sponsored´s protocol code: CLEE011A2404. Sponsored by: Novartis Farmaceutica S.A. Signed date: 06/04/2017
Feliú Batlle J. Estudio preliminar de eficacia, en abierto y de determinación de la dosis de Probody™ (Probody TX) therapeutics en
pacientes con tumores sólidos irresecables localmente o linfomas metastásicos o en estaío avanzado. Type: Clinical Trial, phase II.
HULP code: 4731. Sponsored´s protocol code: CTMX-M-072-001. Sponsored by: Cytomx Thereapeutics Inc. Signed date: 24/01/2017
44
de Andrés Ares J. Estudio aleatorizado, doble ciego, controlado con un placebo y en grupos paralelos para evaluar la eficacia y la segu-
ridad del BIB074 en sujetos con dolor neuropático por radiculopatía lumbosacra. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4712. Sponsored´s protocol code: 1014802-203. Sponsored by: Biogen Idec Ltd. Signed date: 28/12/2017
Pinto Marín A. Estudio de fase III, multicéntrico, multinacional, aleatorizado, abierto, con grupos paralelos sobre avelumab (MSB0010718c)
más los mejores cuidados paliativos frente a los mejores cuidados paliativos solos como tratamiento de mantenimiento en pacientes
con cáncer urotelial localmente avanzado o mestastásico sin progresión de la enfermedad tras completar la quimioterapia de primera
línea basada en platino. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4659. Sponsored´s protocol code: B9991001. Sponsored by: Pfizer S.L.U. Signed date: 19/04/2017
Ares Segura S. Estudio de fase IIB aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad y la eficacia de MEDI8897,
un anticuerpo monoclonal con una semivida prolongada frente al virus respiratorio sincitial, en prematuros sanos. Type: Clinical Trial,
phase II.
HULP code: ANEXO-I 4660. Sponsored´s protocol code: D5290C00003. Sponsored by: Medimmune. Signed date: 09/01/2017
de la Calle Fernández-Miranda M. Estudio en fase III, aleatorizado, enmascarado para el observador, controlado con placebo y con
grupos secuenciales para determinar la inmunogenicidad y la seguridad de una vacuna. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4663. Sponsored´s protocol code: RSV-M-301. Sponsored by: Novavax Inc. Signed date: 13/07/2017
Omeñaca Terés F. Estudio para evaluar la seguridad, la reactogenicidad y la inmunogenicidad de la vacuna experimental frente al virus
respiratorio sincitial (VRS) de GSK biologicals basada en proteínas virales codificadas por un adenovector derivado del chimpancé
(CHAD155RSV) (GSK3389245A) en niños seropositivos frente al VRS. Type: Clinical Trial, phase II.
HULP code: 4668. Sponsored´s protocol code: 204838 (RSV PED-002). Sponsored by: Glaxosmithkline S.A. Signed date: 16/05/2017
González García JJ. Estudio fase III, aleatorizado, multicéntrico, abierto, de grupos paralelos, para evaluar la eficacia, seguridad y tolerabi-
lidad de una pauta de tratamiento intramuscular de acción prolongada con cabotegravir y rilpivirina en el mantenimiento de la supresión
virológica, tras una inducción con un tratamiento de comprimido único con un inhibidor de la integrasa en pacientes adultos infectados
por el VIH-1 que no han recibido un tratamiento antirretroviral previo. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4679. Sponsored´s protocol code: 201584. Sponsored by: Laboratorios Viiv Healthcare S.L. Signed date: 12/12/2017
Pérez Martínez A. Estudio adaptativo y aleatorizado de fase III para comparar la eficacia y la seguridad de defibrotide frente al mejor
tratamiento de soporte en la prevención de la enfermedad venooclusiva hepática en pacientes adultos y pediátricos sometidos a un
trasplante hematopoyético de células madre. Type: Clinical Trial, phase IIIa.
HULP code: ANEXO-I 4696. Sponsored´s protocol code: 15-007. Sponsored by: Jazz Pharmaceuticals Ireland Ltd. Signed date: 26/04/2017
de Castro Carpeño J. Estudio en fase III abierto, multicéntrico de brigatinib (AP26113) frente a crizotinib en pacientes con cáncer de
pulmón avanzado positivo para ALK. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4698. Sponsored´s protocol code: AP26113-13-301. Sponsored by: Ariad Pharmaceutical Inc. Signed date: 30/10/2017
Díez Tejedor E. Estudio en fase II, aleatorizado, controlado con placebo y doble ciego, para evaluar la seguridad, eficacia y farmacociné-
tica del ARGX-113 en pacientes con miastenia gravis que presentan debilidad muscular generalizada. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4701. Sponsored´s protocol code: ARGX 113 1602. Sponsored by: Argenx BVBA. Signed date: 20/07/2017
de Andrés Ares J. Estudio de ampliación abierto y no controlado para evaluar la seguridad, la tolerabilidad y el mantenimiento del efecto
del BIIB074 a largo plazo en sujetos con dolor neuropático por raiculopatía lumbosacra. Type: Clinical Trial, phase II.
HULP code: 4710. Sponsored´s protocol code: 1014802-204. Sponsored by: Convergence Pharmaceuticals Ltd. Signed date: 28/03/2017
de Andrés Ares J. Estudio de ampliación abierto y no controlado para evaluar la seguridad, la tolerabilidad y el mantenimiento del efecto
del BIIB074 a largo plazo en sujetos con dolor neuropático por raiculopatía lumbosacra. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4710. Sponsored´s protocol code: 1014802-204. Sponsored by: Biogen Idec Ltd. Signed date: 28/12/2017
Olveira Martín A. Estudio multicéntrico de fase III, doble ciego, aleatorizado, a largo plazo y controlado con placebo para evaluar la
seguridad y la eficacia del ácido obeticólico en sujetos con esteatohepatitis no alcohólica. Type: Clinical Trial, phase III.
HULP code: 4759. Sponsored´s protocol code: 747-303. Sponsored by: Intercept Pharmaceuticals Inc. Signed date: 07/02/2017
Ramos Ramos JC. Estudio en fase II, multicéntrico, aleatorizado, doble ciego, para evaluar la seguridad, tolerabilidad y eficacia de CD101
inyectable frente a caspofungina intravenosa seguido de desescalado a fluconazol oral, en el tratamiento de pacientes con candidemia.
Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4715. Sponsored´s protocol code: CD101.IV.2.03. Sponsored by: Cidara Therapeutics Inc. Signed date: 06/11/2017
Pérez Martínez A. Estudio abierto, multicéntrico, de grupos paralelos para comparar la farmacocinética (FC), la farmacodinámica (FD)
y la seguridad de febuxostat entre pacientes pediátricos (de 6 y <18 años de edad) y adultos. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4717. Sponsored´s protocol code: FLO-02. Sponsored by: Menarini Ricerche S.P.A. Signed date: 07/06/2017
Murias Loza SM. Estudio aleatorizado, doble ciego, controlado con placebo de canakinumab en pacientes con fiebres periódicas here-
ditarias (Traps, Hids o FMFRC) con retirada aleatorizada/reducción de la frecuencia de la dosis y posterior fase de tratamiento abierto
a largo plazo. Type: Clinical Trial, phase III.
HULP code: ANEXO-IV 4138. Sponsored´s protocol code: CACZ885N2301. Sponsored by: Novartis Farmaceutica S.A. Signed date: 20/09/2017
de Castro Carpeño J. Estudio de fase II, de grupos paralelos, sobre MGCD265 en pacientes con cáncer de pulmón no microcítico lo-
calmente avanzado o metastásico con alteraciones genéticas en el factor de transición epitelio-mesenquimal.Type: Clinical Trial, phase II.
HULP code: 4531. Sponsored´s protocol code: 265-109. Sponsored by: Mirati Therapeutics Inc. Signed date: 17/10/2017
García-Samaniego Rey J. Estudio en fase IIB, abierto, multicéntrico y aleatorizado para investigar la eficacia, seguridad y farmacocinética
de pautas de tratamiento diferentes con al-335, odalasvir y simeprevir en sujetos con hepatitis C crónica sin cirrosis, infectados por los
genotipos 1, 2, 4, 5 y 6 del virus, que hayan, o no, recibido tratamiento previamente. Type: Clinical Trial, phase II.
HULP code: 4617. Sponsored´s protocol code: 64294178HPC2001. Sponsored by: Janssen Cilag International NV. Signed date: 10/01/2017
Ramos Ramos JC. Estudio clínico multicéntrico, aleatorizado y abierto de S-649266 o mejor tratamiento disponible para infecciones
graves provocadas por patógenos gram negativos resistentes a carbapenemos. Type: Clinical Trial, phase IV.
HULP code: 4640. Sponsored´s protocol code: 1424R2131. Sponsored by: Shinogi Ltd. Signed date: 22/03/2017
45
 2
Executive Summary
2.6 Clinical Trials
Redondo Sánchez A. Estudio de fase III de ADXS11-001 administrado tras la quimiorradioterapia como tratamiento adyuvante en
cáncer de cuello uterino localmente avanzado de riesgo alto: AIM2CERV. Type: Clinical Trial, phase III.
HULP code: 4649. Sponsored´s protocol code: ADXS001-02. Sponsored by: Advaxis Inc. Signed date: 00/01/1900
Martín Arranz MD. Estudio en fase II, multicéntrico, de extension en ensayo abierto para observar la eficacia a largo plazo, seguridad y
tolerabilidad a repetidas administraciones de ABT 494 en sujetos con enfermedad de Crohn. Type: Clinical Trial, phase II.
HULP code: 4671. Sponsored´s protocol code: M14-327. Sponsored by: Abbvie Spain S.L.U. Signed date: 28/02/2017
Pérez Martínez A. Estudio adaptativo y aleatorizado de fase III para comparar la eficacia y la seguridad de defibrotide frente al mejor
tratamiento de soporte en la prevención de la enfermedad venooclusiva hepática en pacientes adultos y pediátricos sometidos a un
trasplante hematopoyético de células madre. Type: Clinical Trial, phase IIIa.
HULP code: 4696. Sponsored´s protocol code: 15-007. Sponsored by: Jazz Pharmaceuticals Ireland Ltd. Signed date: 10/01/2017
Custodio Carretero AB. Ensayo en fase III, abierto y multicéntrico del avelumab (MSB0010718C) como tratamiento de tercera línea del
adenocarcinoma de la unión gastroesofágica o gástrico, metastásico, recurrente o irresecable. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4704. Sponsored´s protocol code: EMR100070-008. Sponsored by: Merck KGAA. Signed date: 24/01/2017
Martín Arranz MD. Estudio aleatorizado de optimización de dosis para evaluar la eficacia y la seguridad de cobitolimod en pacientes
con colitis ulcerosa activa de carácter moderado o severo. Type: Clinical Trial, phase II.
HULP code: 4797. Sponsored´s protocol code: CSUC-01/16. Sponsored by: Index Pharmaceuticals AB. Signed date: 20/04/2017
Lara Lara M. Ensayo de fase III de grupos paralelos, doble ciego, aleatorizado y controlado con placebo, para evaluar la eficacia y la
seguridad de ALD403 administrado por vía intravenosa en pacientes con migraña crónica. Type: Clinical Trial, phase III.
HULP code: 4755. Sponsored´s protocol code: ALD403-CLIN-011. Sponsored by: Alder Biopharmaceuticals Inc. Signed date: 05/01/2017
Pinto Marín A. Estudio en fase II, multicéntrico y abierto de rucaparib en pacientes con cáncer de próstata metastásico resistente a la
castración asociado con deficiencia de recombinación homólogica. Type: Clinical Trial, phase II.
HULP code: 4787. Sponsored´s protocol code: CO-338-052. Sponsored by: Clovis Oncology Inc. Signed date: 08/09/2017
Balsa Criado A. Estudio de fase IIB multicéntrico, aleatorizado, doble ciego, controlado con placebo, de intervalos de dosis y grupos para-
lelos, para evaluar la eficacia y la seguridad de bimekizumab en pacientes con espondilitis anquilosante activa. Type: Clinical Trial, phase II.
HULP code: 4788. Sponsored´s protocol code: AS0008. Sponsored by: UCB Biosciencies GMBH. Signed date: 13/03/2017
de Lucas Laguna R. Estudio de fase III, doble ciego, aleatorizado, controlado con vehiculo y con un seguimiento abierto de 24 meses
sobre la eficacia y la seguridad de oleogel-S10 en pacientes con epidermólisis ampollosa hereditaria. Type: Clinical Trial, phase III.
HULP code: 4789. Sponsored´s protocol code: BEB-13. Sponsored by: Amryt Research Limited. Signed date: 24/04/2017
García-Samaniego Rey J. Estudio prospectivo de seguimiento de 3 años de duración en pacientes tratados en un estudio anterior en
fase II o III con una pauta posológica que contenga odalasvir y AL-335 con o sin simeprevir para el tratamiento de la infección por el
virus de la hepatitis c (VHC). Type: Clinical Trial, phase II.
HULP code: 4790. Sponsored´s protocol code: 64294178HPC3001. Sponsored by: Janssen Cilag International NV. Signed date: 21/03/2017
Gandía González M. Rescue-ASDH – Randomised evaluation of surgery with craniectomy for patients undergoing evacuation of acute
subdural haematoma. Type: NO-EPA.
HULP code: 4791. Sponsored´s protocol code: RESCUE-ASDH. Sponsored by: Cambridge University Hospitals NHS Foundation Trust and University.
Signed date: 11/08/2017
Frank García A. Estudio de 24 meses, de grupos paralelos, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad
de E2609 en pacientes con enfermedad de Alzheimer temprana. Type: Clinical Trial, phase III.
HULP code: 4792. Sponsored´s protocol code: E2609-G000-302. Sponsored by: EISAI Europe Limited. Signed date: 14/09/2017
López Arrieta JM. Estudio de 24 meses, de grupos paralelos, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad
de E2609 en pacientes con enfermedad de Alzheimer temprana. Type: Clinical Trial, phase III.
HULP code: 4793. Sponsored´s protocol code: E2609-G000-301. Sponsored by: EISAI Europe Limited. Signed date: 14/09/2017
García-Samaniego Rey J. Clínico estudio de fase III, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad y
eficacia de selonsertib en pacientes con esteatohepatitis no alcohólica (EHNA) y fibrosis en puentes (F3). Type: Clinical Trial, phase III.
HULP code: 4785. Sponsored´s protocol code: GS-US-384-1943. Sponsored by: Gilead Sciences Inc. Signed date: 30/03/2017
Alonso Melgar A. Estudio en fase III multicéntrico y abierto de ALXN1210 en niños y adolescentes con síndrome hemolítico urinémico
atípico (SHUA). Type: Clinical Trial, phase III.
HULP code: 4796. Sponsored´s protocol code: ALXN1210-Ahus-312. Sponsored by: Alexion Pharmaceutical Inc. Signed date: 10/07/2017
Moreno Gómez JR. Stent liberador de sirolimus de filamento delgado en una poblacion abierta a todos los candidatos interesados
frente a stent liberador de everolimus. Type: Healthcare Product.
HULP code: 4784. Sponsored´s protocol code: ECRI-007. Sponsored by: European Cardiovascular Research Institute. Signed date: 20/02/2017
Lavín Dapena C. Estudio prospectivo, con doble enmascaramiento, aleatorizado, multicéntrico, con comparador activo y grupos parale-
los de 6 meses de duración para evaluar la seguridad y la eficacia hipotensora ocular de PG324 solución oftálmica en comparación con
ganfort® (bimatoprost 0,03 %/timolol 0,5 %) solución oftálmica en sujetos con presión intraocular elevada (Mercury 3). Type: Clinical
Trial, phase III.
HULP code: 4798. Sponsored´s protocol code: PG324-CS303. Sponsored by: Aerie Pharmaceuticals Ireland Ltd. Signed date: 26/06/2017
de Castro Carpeño J. Estudio de extensión multicéntrico, internacional de alectinib en pacientes con tumores positivos para quinasa
del linfoma anaplásico (alk) o reordenación durante la transfección (RET). Type: Clinical Trial, phase IIIb.
HULP code: 4799. Sponsored´s protocol code: BO39694. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 17/04/2017
Carballo Cardona C. ensayo clínico fase iiib, aleatorizado, abierto, para evaluar el alivio del dolor con metoxiflurano inhalado, en com-
paración con el protocolo actual para el tratamiento del dolor de origen traumático, en adultos atendidos en unidades de urgencias
españolas. Type: Clinical Trial, phase IIIb.
HULP code: 4803. Sponsored´s protocol code: InMEDIATE. Sponsored by: Mundipharma Pharmaceuticals S.L. Signed date: 31/05/2017
Bernardino de la Serna JI. Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad, tole-
46
rabilidad y eficacia de evolocumab (AMG 145) en el C-LDL de sujetos con VIH e hiperlipidemia y/ó dislipidemia mixta. Type: Clinical
Trial, phase III.
HULP code: 4804. Sponsored´s protocol code: 20130286. Sponsored by: Amgen S.A. Signed date: 21/04/2017
Quirce Gancedo SE. Estudio piloto de reslizumab en pacientes con asma grave que no han respondido a omalizuma. Type: Clinical Trial,
phase II.
HULP code: 4805. Sponsored´s protocol code: SEP-RES-20196-01. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 10/03/2017
de Castro Carpeño J. A randomised phase II trial of osimertinib and bevacizumab versus osimertinib alone as second-line treatment in
stage IIIB-IVB NSLC with confirmed EGFRM and T790M. Type: Clinical Trial, phase II.
HULP code: 4806. Sponsored´s protocol code: BOOSTER (ETOP 10/16. Sponsored by: Grupo Español Cáncer Pulmón. Signed date: 21/04/2017
Redondo Sánchez A. Ensayo clínico ensayo fase II multicéntrico de palbociclib en segunda línea de sarcomas avanzados con sobreex-
presión de CDK4. Type: Clinical Trial, phase II.
HULP code: 4807. Sponsored´s protocol code: GEIS-51. Sponsored by: Grupo Español de Investigación en Sarcomas. Signed date: 29/09/2017
Zamora Auñón P. Trastuzumab y pertuzumab sin quimioterapia en cáncer de mama HER2 positivo: estrategia adaptada en función de
la respuesta evaluada por FDG-PET. Estudio Phergain. Type: Clinical Trial, phase II.
HULP code: 4810. Sponsored´s protocol code: PHERGAIN. Sponsored by: Medica Scientia Innovation Research. Signed date: 05/04/2017
Jiménez Yuste VM. Ensayo clínico en fase IIIB multicéntrico, con un solo grupo de tratamiento, para evaluar la seguridad y tolerancia del
tratamiento profiláctico con emicizumab en pacientes con hemofilia A que presentan inhibidores. Type: Clinical Trial, phase IIIb.
HULP code: 4811. Sponsored´s protocol code: MO39129. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 10/05/2017
Baltasar Tello P. Estudio multicéntrico, no aleatorizado y abierto, para evaluar la eficacia y seguridad de ibrutinib seguido por con-
solidación con ofatumumab, en pacientes con leucemia linfocítica crónica (LLC) o linfoma linfocítico de células pequeñas (LLCP) sin
tratamiento previo. Type: Clinical Trial, phase II.
HULP code: 4794. Sponsored´s protocol code: GELLC-7. Sponsored by: Fundación Pethema. Signed date: 02/10/2017
Pinto Marín A. Estudio de fase III multicéntrico, randomizado, controlado con placebo de atezolizumab (anticuerpo anti-DP-L1) en
monterapia y en combinación con quimioterapia basada en platino en placientes con carcinoma urotelial localmente avanzado o metas-
tásico no tratado previamente. Type: Clinical Trial, phase III.
HULP code: 4771. Sponsored´s protocol code: WO30070. Sponsored by: Daiichi-Sankyo Development Limited. Signed date: 23/03/2017
Moreno Gómez JR. Evaluación de la seguridad y eficacia del tratamiento antitrombótico con edoxabán en comparación con un anta-
gonista de la vitamina K (AVK), tras una intervención coronaria percutánea (ICP) con colocación de stent satisfactoria (tratamiento
con edoxabán comparado con AVK en pacientes que padecen fibrilación auricular sometidos a ICP. Entrust - FA ICP). Type: Clinical
Trial, phase III.
HULP code: 4761. Sponsored´s protocol code: DSE-EDO-01-15-EU. Sponsored by: Daiichi-Sankyo Europe GMBH. Signed date: 15/02/2017
de Castro Carpeño J. A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors. Type:
Clinical Trial, phase II.
HULP code: 4762. Sponsored´s protocol code: GECP16/04. Sponsored by: Grupo Español Cáncer Pulmón. Signed date: 03/02/2017
Merino Llorens JL. Anticoagulantes orales no antagonistas de la vitamina K en pacientes con episodios de frecuencia auricular rapida.
Type: Clinical Trial, phase III.
HULP code: 4763. Sponsored´s protocol code: NOAH-AFNET 6. Sponsored by: Kompetenznetz Vorhofflimmern E.V. Signed date: 09/01/2017
Castro Conde A. Pemafibrato para reducir los episodios cardiovasculares mediante la reducción de los triglicéridos en pacientes con
diabetes (Prominent). Type: Clinical Trial, phase I.
HULP code: 4764. Sponsored´s protocol code: K-877-302. Sponsored by: Kowa Research Institute Inc. Signed date: 28/06/2017
Martín Arranz MD. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, prueba de concepto de ustekinumab en
pacientes con lupus eritematoso sistémico activo. Type: Clinical Trial, phase III.
HULP code: 4765. Sponsored´s protocol code: CNTO1275CRD3005. Sponsored by: Janssen Cilag International NV. Signed date: 25/01/2017
Iniesta Pérez S. Estudio doble ciego, aleatorizado, de fase III, controlado con placebo para evaluar la seguridad y eficacia de una única
administración por vía oral de nolasiban para mejorar las tasas de embarazo después de un tratamiento FIV o ICSI en los días 3 y 5 de
ciclos de transferencia de embriones frescos. Type: Clinical Trial, phase III.
HULP code: 4766. Sponsored´s protocol code: 16-OBE001-005. Sponsored by: Obseva S.A. Signed date: 08/04/2017
Redondo Sánchez A. Forward1: un sello abierto, aleatorizado fase 3 estudio para evaluar la seguridad y eficacia de mirvetuximab so-
ravtansine (IMGN853) versus elección del investigador de la quimioterapia en mujeres con folato del receptor alfa positivo avanzado
cancer epitelial de ovario, primaria peritoneal cáncer o cáncer primario de trompa de falopio. Type: Clinical Trial, phase III.
HULP code: 4767. Sponsored´s protocol code: IMGN-0403. Sponsored by: Immunogen Inc. Signed date: 27/01/2017
Pascual Pascual SI. Estudio de extensión del seguimiento internacional, multicéntrico, doble ciego de 9 meses de duración para evaluar
la seguridad y tolerabilidad a largo plazo de PXT3003 en pacientes con enfermedad de charcot-marie-tooth de tipo 1A. Type: Clinical
Trial, phase III.
HULP code: 4768. Sponsored´s protocol code: PXT3003-03. Sponsored by: Pharnext. Signed date: 29/06/2017
García-Samaniego Rey J. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia
de selonsertib en pacientes con cirrosis compensada debida a esteatohepatitis no alcohólica (EHNA). Type: Clinical Trial, phase III.
HULP code: 4786. Sponsored´s protocol code: GS-US-384-1944. Sponsored by: Gilead Sciences Inc. Signed date: 30/03/2017
Herranz Pinto P. Estudio multicéntrico de fase III, aleatorizado, doble ciego para evaluar la eficacia comparativa de guselkumab
(CNTO1959) y secukinumab en el tratamiento de la psoriasis en placa de moderada a grave. Type: Clinical Trial, phase III.
HULP code: 4770. Sponsored´s protocol code: CNTO1959PSO3009. Sponsored by: Janssen Cilag International NV. Signed date: 03/02/2017
Martín Arranz MD. Estudio de fase III, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos sobre la eficacia y la
seguridad de SHP647 como tratamiento de mantenimiento en sujetos con colitis ulcerosa de moderada a grave (Fígaro UC 303). Type:
Clinical Trial, phase III.
47
 2
Executive Summary
2.6 Clinical Trials
HULP code: 4972. Sponsored´s protocol code: SHP647-303. Sponsored by: Shire Human Genetic Therapies Inc. Signed date: 28/12/2017
Gómez Senent S. Phase II, multicentre, randomised, double-blind, placebo controlled, proof of concept study of efficacy and safety of
rifamycin SV-MMX® 600 mg tablets administered three or two times daily to patients with diarrhoea-predominant irritable bowel
syndrome (IBS -D). Type: Clinical Trial, phase II.
HULP code: 4772. Sponsored´s protocol code: CB-01-11/28. Sponsored by: Cosmo Technologies Ltd. Signed date: 20/07/2017
Gómez Barrena E. A multi-centre, open-label, randomized, comparative clinical trial of two different doses of bone marrow autolo-
gous human mesenchymal stem cells plus biomaterial versus iliac crest autologous graft, for bone healing in non-union after long bone
fractures. Type: Clinical Trial, phase III.
HULP code: 4773. Sponsored´s protocol code: ORTHOUNION. Sponsored by: Universidad Autónoma de Madrid. Signed date: 12/05/2017
de Castro Carpeño J. Estudio en fase I, abierto, no aleatorizado y multicéntrico para evaluar la farmacocinética, la seguridad y la tole-
rabilidad de osimertinib tras la administración de una dosis oral única de 80 mg a pacientes con tumores sólidos avanzados y función
renal normal o disfunción renal grave. Type: Clinical Trial, phase I.
HULP code: 4774. Sponsored´s protocol code: 4774. Sponsored by: Astrazeneca AB. Signed date: 30/01/2017
de Castro Carpeño J. Estudio en fase I, abierto, no aleatorizado y multicéntrico para evaluar la farmacocinética, la seguridad y la tole-
rabilidad de osimertinib tras la administración de una dosis oral única de 80 mg a pacientes con tumores sólidos avanzados y función
renal normal o disfunción renal grave. Type: Clinical Trial, phase I.
HULP code: 4775. Sponsored´s protocol code: 4775. Sponsored by: Astrazeneca AB. Signed date: 30/01/2017
Custodio Carretero AB. Estudio clínico de fase II de durvalumab (MEDI4736) mas tremelumumab para el tratamiento de pacientes con
tumores neuroendocrinos avanzados de origen gastroenteropaticos o pulmonares (DUNE). Type: Clinical Trial, phase II.
HULP code: 4777. Sponsored´s protocol code: ESR 15-11561-61 DUNElo. Sponsored by: Icapem. Signed date: 06/03/2017
Espinosa Arranz E. Ensayo de fase II, multicéntrico, internacional, no controlado para identificar los mecanismos moleculares de re-
sistencia y sensibilidad a la reexposición a palbociclib tras la progresión a una combinación de palbociclib en pacientes con cáncer de
mama metastásico HER positivo (Bioper). Código: Medopp089. Type: Clinical Trial, phase II.
HULP code: 4778. Sponsored´s protocol code: MEDOPP089. Sponsored by: Medica Scientia Innovation Research. Signed date: 25/04/2017
Prados Sánchez C. Ensayo clínico con enmascaramiento doble, multicéntrico y controlado con placebo para investigar la eficacia y
seguridad de 12 meses de terapia con Promixin® inhalado (colistimetato de sodio) para el tratamiento de pacientes con bronquiectasia
no debida a fibrosis quística con infección crónica por pseudomonas aeruginosa (p. aeruginosa). Type: Clinical Trial, phase III.
HULP code: 4779. Sponsored´s protocol code: Z7224L01. Sponsored by: Zambon S.A. Signed date: 08/06/2017
Prados Sánchez C. Estudio en fase IIA, aleatorizado, doble ciego, controlado con placebo para evaluar varias dosis de GLPG2222 en
sujetos con fibrosis quística que son homocigotos para la mutación F508DEL. Type: Clinical Trial, phase II.
HULP code: 4780. Sponsored´s protocol code: GLPG2222-CL-202. Sponsored by: Galapagos NV. Signed date: 01/06/2017
Redondo Sánchez A. Estudio de fase IB/II para evaluar la eficacia y tolerabilidad de PM01183 en combinación con olaparib en pacientes
con tumores sólidos avanzados. Type: Clinical Trial, phase Ib.
HULP code: 4782. Sponsored´s protocol code: POLA/ACOG1401. Sponsored by: Poveda Velasco, Andrés. Signed date: 13/03/2017
del Hierro Zarzuelo A. Estudio con doble enmascaramiento de SYL1001 en pacientes con xeroftalmía de moderada a grave. Type:
Clinical Trial, phase III.
HULP code: 4769. Sponsored´s protocol code: SYL1001_IV. Sponsored by: Sylentis S.A.U. Signed date: 29/03/2017
Roldán Rabadán I. Estudio no intervencionista sobre el tratamiento con edoxaban en la práctica clinica habitual para pacientes con
fibrilación auricular no valvular. Etna-AF-Europe. Type: EPA-SP.
HULP code: PI-2559B. Sponsored´s protocol code: DSE-EDO-2016-01. Sponsored by: Daiichi-Sankyo Development Limited. Signed date: 30/03/2017
Romero Ribate D. Estudio retrospectivo para valorar los criterios que motivan los cambios en la terapia de mantenimiento de los
pacientes con asma persistente moderada-grave. Type: EPA-OD.
HULP code: PI-2623B. Sponsored´s protocol code: STEP (MUN-ASM-2016-01). Sponsored by: Mundipharma Pharmaceuticals S.L. Signed date: 27/01/2017
Jiménez Martín C. Estudio piloto de evaluación de una nueva prueba diagnóstica en sangre basada en el análisis del perfil de respuesta
inmunitaria, para la identificación de biomarcadores asociados con la tolerancia o el rechazo crónico al trasplante de riñón. Type: NO-
EPA.
HULP code: PI-2446. Sponsored´s protocol code: PI-2446. Sponsored by: Biohope Scientific Solutions For Human Health S.L. Signed date: 09/02/2017
Carcas Sansuán AJ. Riesgo de acidosis láctica asociado al uso de metformina en pacientes diabéticos tipo 2 con enfermedad renal
crónica moderada-severa: estudio de casos y control. Type: EPA-OD.
HULP code: PI-2449. Sponsored´s protocol code: CPC-MET-2016. Sponsored by: Fundación Idibell. Signed date: 20/02/2017
Camarena Grande C. Registro observacional de enfermedad y resultados clínicos de pacientes con deficiencia de lipasa ácida lisosomal
(LAL) (enfermedad de Wolman y enfermedad por almacenamiento de ésteres de colesterol) y portadores del trastorno.Type: NO-EPA.
HULP code: PI-2497. Sponsored´s protocol code: LAL DEFICIENCY. Sponsored by: Pharmaceuticals Inc. Signed date: 28/11/2017
Montes Ramírez ML. Evidencia en vida real de la efectividad de paritaprevir/r/ombitasvir ± dasabuvir (régimen abbvie) ± ribavirina en
pacientes con hepatitis c crónica – estudio observacional retrospectivo en España. Estudio VIE-REAL. Type: EPA-OD.
HULP code: PI-2508. Sponsored´s protocol code: ABB-OMB-2016-01. Sponsored by: Abbvie Spain S.L.U. Signed date: 03/02/2017
García-Samaniego Rey J. Evidencia en vida real de la efectividad de paritaprevir/r/ombitasvir ± dasabuvir (régimen Abbvie) ± ribavirina
en pacientes con hepatitis c crónica – estudio observacional retrospectivo en España. (Estudio VIE-REAL). Type: EPA-OD.
HULP code: PI-2508B. Sponsored´s protocol code: ABB-OMB-2016-01. Sponsored by: Abbvie Spain S.L.U. Signed date: 03/02/2017
Burgueño García M. International, multicenter, prospective registry to colect data of treatment patterns in patients with bilateral con-
dylar fracture (BCFX) of the mandible. Type: NO-EPA.
HULP code: PI-2526. Sponsored´s protocol code: RP-BCFx-1.0. Sponsored by: Ao Investigation And Publishing Foundation (AOCID). Signed date:
19/01/2017
48
Bartha Rasero JL. Estudio observacional, multicéntrico, prospectivo, abierto, para evaluar la seguridad de Nife-Par® en el tratamiento
de la amenaza de parto pretérmino. Type: EPA-OD.
HULP code: PI-2536. Sponsored´s protocol code: REI-NIF-2016-01. Sponsored by: Laboratorio Reig Jofre S.A. Signed date: 18/01/2017
de Castro Carpeño J. Un estudio multicéntrico, en fase I, abierto y no aleatorizado para evaluar el efecto de AZD9291 sobre la farma-
cocinética de la simvastatina (un sustrato sensible de CYP3a4) en pacientes con cáncer de pulmón no microcítico (CPNM) positivos
para EGFrm cuya enfermedad ha progresado con el tratamiento con TKI del EGFR. Type: Clinical Trial, phase I.
HULP code: ANEXO-I 4262. Sponsored´s protocol code: D5160C00014. Sponsored by: Astrazeneca AB. Signed date: 02/02/2017
Antorrena Miranda MI. Estudio no intervencionista sobre el tratamiento con edoxaban en la práctica clinica habitual para pacientes
con fibrilación auricular no valvular. ETNA-AF-EUROPE. Type: EPA-SP.
HULP code: PI-2559. Sponsored´s protocol code: DSE-EDO-2016-01. Sponsored by: Daiichi-Sankyo Development Limited. Signed date: 30/03/2017
Redondo Sánchez A. Estudio de fase III para evaluar la eficacia y la seguridad de pazopanib en monoterapia frente a placebo entre mu-
jeres con cáncer epitelial de ovario, de trompa de falopio o peritoneal primario que no hayan progresado después de la quimioterapia
en primera línea. Type: Clinical Trial, phase III.
HULP code: ANEXO-V 2880. Sponsored´s protocol code: VEG110655. Sponsored by: Novartis Farmaceutica S.A. Signed date: 22/09/2017
Baltasar Tello P. Registro regional para evaluar la práctica médica con observación longitudinal para el diagnóstico, seguimiento y tra-
tamiento de la leucemia linfática crónica. Type: NO-EPA.
HULP code: PI-2576. Sponsored´s protocol code: LL-RLLC-ONC001. Sponsored by: Life Length S.L. Signed date: 25/05/2017
Moreno Gómez JR. Registro posterior a la comercialización de Biomatrix Alpha™ (Stent Farmacoactivo A9™ (BA9™) de biolimús,
cobalto y cromo). Type: NO-EPA.
HULP code: PI-2579. Sponsored´s protocol code: BMXAlphaRegistry16EU01. Sponsored by: Biosensors Europe S.A. Signed date: 01/07/2017
Esteban Rodríguez I. Estudio no intervencional multinacional para evaluar la expresión de PD L1 en muestras citológicas frente a
histológicas de pacientes con cáncer de pulmón no microcítico o microcítico. Type: NO-EPA.
HULP code: PI-2583. Sponsored´s protocol code: MO29978. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 10/01/2017
Pérez Martínez A. Incidence and outcomes associated with the management of adenovirus infections in allogeneic hematopoietic cell
transplant recipients: advance. Type: EPA-OD.
HULP code: PI-2592. Sponsored´s protocol code: CHI-ADE-2016-01. Sponsored by: Chimerix Inc. Signed date: 11/01/2017
Bajo Rubio MA. VEIFIE. Evaluacion de la seguridad, efectividad y adherencia de velphoro en la vida real. Estudio no intervencionista para
investiga la seguridad, la efectividad y la adherencia de velphoro a corto y a largo plazo en la vida real en pacientes con hiperfosfatenia
sometidos a hemodiálisis o al adialisis peritoneal. Type: EPA-LA.
HULP code: PI-2593. Sponsored´s protocol code: VFMCRP-MEAF-PA21-EU. Sponsored by: Kantar Health. Signed date: 17/02/2017
Hardisson Hernández D. Evaluation of molecular subtype in the prediction of non-sentinel lymph node affectation, based on the osna
predictive value, total tumor load. Type: NO-EPA.
HULP code: PI-2594. Sponsored´s protocol code: SYS-PAM-2016-01. Sponsored by: Sysmex Europe GMBH. Signed date: 04/05/2017
Magdaleno del Rey G. Estudio retrospectivo multicéntrico de la efectividad y seguridad de los regímenes que contienen darunavir/
cobicistat (DRV/C) en la práctica clínica habitual. Estudio CODAR. Type: EPA-OD.
HULP code: PI-2595. Sponsored´s protocol code: GESIDA 9316. Sponsored by: Fundación SEIMC-GESIDA. Signed date: 05/01/2017
Morera López RM. Caracterización y epidemiología en España del dolor irruptivo oncológico. Type: NO-EPA.
HULP code: PI-2596. Sponsored´s protocol code: CARPE-DIO. Sponsored by: Takeda Farmacéutica España S.A.U. Signed date: 16/01/2017
Martín Arranz MD. Estudio de fase III, de extensión de seguridad a largo plazo de SHP647 en sujetos con colitis ulcerosa de moderada
a grave (AIDA). Type: Clinical Trial, phase III.
HULP code: 4965. Sponsored´s protocol code: SHP647-304. Sponsored by: Shire Human Genetic Therapies Inc. Signed date: 28/12/2017
Magallanes García L. Un registro no intervencionista a largo plazo para evaluar la seguridad y efectividad de Humira® (adalimumab)
en pacientes pediátricos con enfermedad de Crohn (EDC) activa entre moderada y grave (CAPE). Type: EPA-LA.
HULP code: PI-2558. Sponsored´s protocol code: P11-292. Sponsored by: Abbvie Deutschland GMBH. Signed date: 09/05/2017
López Arrieta JM. Estudio multicéntrico de fase IIA/IIB, aleatorizado, doble ciego, controlado con placebo, de 56 semanas de seguimien-
to, para evaluar la seguridad y la eficacia de bimagrumab i.v. sobre la masa corporal magra total y la actividad fisica en pacientes después
de tratamiento quirúrgico de fractura de cadera. Type: Clinical Trial, phase II.
HULP code: ANEXO-III 4206. Sponsored´s protocol code: CBYM338D2201. Sponsored by: Novartis Farmaceutica S.A. Signed date: 21/12/2017
Balsa Criado A. Ensayo fase IIIb, aleatorizado, doble ciego para evaluar la eficacia y seguridad de abatacept SC en compbinación con me-
totrexato comparado con metotrexato en monoterapia para conseguir la remisión clínica en adultos con artritis reumatoide temprana
sin tratamiento previo con metotrexato. Type: Clinical Trial, phase IIIb.
HULP code: ANEXO-II 4470. Sponsored´s protocol code: IM101-550. Sponsored by: Bristol Myers Squibb International Corporation. Signed date:
03/05/2017
Martín Arranz MD. Estudio multicéntrico de fase II, aleatorizado, doble ciego y controlado con placebo de grupos paralelos para in-
vestigar la seguridad y la eficacia de APD334 en pacientes con colitis ulcerativa activa de moderada a grave. Type: Clinical Trial, phase II.
HULP code: ANEXO-II 4498. Sponsored´s protocol code: APD334-003. Sponsored by: Arena Pharmaceuticals Inc. Signed date: 30/03/2017
Martín Arranz MD. Estudio de extensión del estudio APD334-003 en pacientes con colitis ulcerosa activa moderada o grave. Type:
Clinical Trial, phase II.
HULP code: ANEXO-II 4541. Sponsored´s protocol code: APD334-005. Sponsored by: Arena Pharmaceuticals Inc. Signed date: 13/06/2017
Redondo Sánchez A. Estudio de fase Ib (abierto) / fase II (aleatorizado, doble ciego) en el que se evalúan gemcitabina y docetaxel, con
o sin olaratumab, en el tratamiento del sarcoma de tejidos blandos en estadio avanzado. Type: Clinical Trial, phase II.
HULP code: ANEXO-II 4543. Sponsored´s protocol code: I5B-MC-JGDL. Sponsored by: Lilly S.A. Signed date: 07/06/2017
Balsa Criado A. Estudio fase IIA, aleatorizado, doble-ciego, paralelo, controlado con placebo y naproxeno para evaluar la eficacia anal-
gésica de ASP7962 en pacientes con dolor secundario a osteoartritis en rodilla. Type: Clinical Trial, phase II.
49
 2
Executive Summary
2.6 Clinical Trials
HULP code: ANEXO-II 4561. Sponsored´s protocol code: 7962-CL-0022. Sponsored by: Astellas Pharma Europe B.V. Signed date: 30/07/2017
Feliú Batlle J. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de GS-5745 en
combinación con MFOLFOX6 como tratamiento de primera línea en pacientes con adenocarcinoma gástrico avanzado o de la unión
gastroesofágica. Type: Clinical Trial, phase III.
HULP code: ANEXO-II 4569. Sponsored´s protocol code: GS-US-296-1080. Sponsored by: Gilead Sciences Inc. Signed date: 04/08/2017
Chaverri Rada D. Estudio prospectivo, fase II, multicéntrico, randomizado, doble ciego, controlado con placebo, de grupos paralelos para
comparar la eficacia y seguridad de masitinib versus placebo en el tratamiento de pacientes con esclerosis lateral amiotrofica (ELA).
Type: Clinical Trial, phase II.
HULP code: ANEXO-II EC12/25. Sponsored´s protocol code: AB10015. Sponsored by: Abscience. Signed date: 03/02/2017
Álvarez Román MT. Estudio de extension de fase IIIB, abierto, multicéntrico, sobre la seguridad y eficacia de una proteína de fusión del
factor IX recombinante de la coagulación con la albumina (RIXFB) en pacientes con hemofilia B. Type: Clinical Trial, phase IIIb.
HULP code: ANEXO-III 4011. Sponsored´s protocol code: CSL654_3003. Sponsored by: CSL Behring GMBH Clinical. Signed date: 09/11/2017
de Castro Carpeño J. Estudio de biomarcadores no intervencionista en pacientes con cáncer de pulmón no microcítico (NSCLC) del
tipo histológico adenocarcinoma elegibles para el tratamiento con Vargatef® según la ficha técnica autorizada. Type: EPA-SP.
HULP code: PI-2388. Sponsored´s protocol code: 1199.223. Sponsored by: Boehringer Ingelheim España S.A. Signed date: 24/01/2017
Díaz Fernández MC. Estudio abierto y a largo plazo con un periodo de retirada farmacológica aleatorizado, controlado con placebo y
doble ciego de LUM001, un inhibidor del trasportador apical de ácidos biliares depenciente de sodio (ASBTI), en pacientes con síndro-
me de Alagille. Type: Clinical Trial, phase III.
HULP code: ANEXO-III 4187. Sponsored´s protocol code: LUM001-304. Sponsored by: Lumena Paharmaceuticals Inc. Signed date: 11/10/2017
Fernández-Lahera Martínez J. Estudio retrospectivo para valorar los criterios que motivan los cambios en la terapia de mantenimien-
to de los pacientes con asma persistente moderada-grave. Type: EPA-OD.
HULP code: PI-2623C. Sponsored´s protocol code: STEP (MUN-ASM-2016-01). Sponsored by: Mundipharma Pharmaceuticals S.L. Signed date: 27/01/2017
Arribas López JR. Estudio de fase III, aleatorizado, controlado con tratamiento activo y abierto para evaluar el cambio de tratamiento
a un régimen en un solo comprimido administrado una vez al día de darunavir/cobicistat/emtricitabina/tenofovir alafenamida (D/C/F/
TAF) frente a la continuación del régimen actual formado por un inhibidor de la proteasa potenciado (IPP) combinado con emtricitabi-
na/tenofovir disoproxil fumarato (FTC/TDF) en sujetos infectados por el virus de la inmunodeficiencia humana de tipo 1 (VIH-1) con
supresión virológica. Type: Clinical Trial, phase III.
HULP code: ANEXO-III 4300. Sponsored´s protocol code: TMC114IFD3013. Sponsored by: Janssen-Cilag España S.A. Signed date: 15/06/2017
González García JJ. Estudio fase III aleatorizado, multicéntrico, de grupos paralelos, de no inferioridad, para evaluar la eficacia, seguridad
y tolerabilidad del cambio de una terapia antirretroviral basada en INI, ITINN o IP a dolutegravir más rilpivirina en pacientes adultos
infectados por el VIH-1 con supresión de la carga viral. Type: Clinical Trial, phase III.
HULP code: ANEXO-III 4372. Sponsored´s protocol code: 201637. Sponsored by: Laboratorios VIIV Healthcare S.L. Signed date: 13/07/2017
Martín Arranz MD. Estudio multicéntrico de fase II, aleatorizado, doble ciego y controlado con placebo de grupos paralelos para in-
vestigar la seguridad y la eficacia de APD334 en pacientes con colitis ulcerativa activa de moderada a grave. Type: Clinical Trial, phase II.
HULP code: ANEXO-III 4498. Sponsored´s protocol code: APD334-003. Sponsored by: Arena Pharmaceuticals Inc. Signed date: 13/06/2017
Torres Jiménez R. Pioneer 6 - Resultados cardiovasculares. Ensayo para investigar la seguridad cardiovascular de semaglutida oral en
sujetos con diabetes tipo 2. Type: Clinical Trial, phase III.
HULP code: ANEXO-III 4626. Sponsored´s protocol code: NN9924-4221. Sponsored by: Novo Nordisk A/S. Signed date: 04/04/2017
Balsa Criado A. Estudio abierto de seguimiento a largo plazo de CP-690, 550, un inhibidor de la janus quinasa 3 moderadamente selec-
tivo, para el tratamiento de la artritis reumatoide. Type: Clinical Trial, phase II.
HULP code: ANEXO-IV 2372. Sponsored´s protocol code: A3921024. Sponsored by: Pfizer S.L.U. Signed date: 28/02/2017
Jara Vega P. Estudio abierto, no comparativo, a largo plazo, para evaluar la eficacia y la seguridad de un régimen de inmunosupresor
basado en modigraf en pacientes pediátricos receptores de un aloinjerto de organo sólido. Type: Clinical Trial, phase IV.
HULP code: ANEXO-IV 3252. Sponsored´s protocol code: F506-CL-0404. Sponsored by: Astellas Pharma Europe B.V. Signed date: 02/08/2017
Baltasar Tello P. Estudio de fase II de LY2784544 en pacientes con neoplasias mieloproliferativas. Type: Clinical Trial, phase II.
HULP code: ANEXO-IV 3558. Sponsored´s protocol code: I3X-MC-JHTB. Sponsored by: Lilly S.A. Signed date: 22/02/2017
García Puig J. Estudio aleatorizado, multicéntrico, doble ciego, paralelo, controlado con placebo de los efectos de JNJ-28431754 en
efectos cardiovasculares en sujetos adultos con diabetes mellitus tipo II. Ensayo CANVAS: estudio de evaluación cardiovascular con
canaglifocina. Type: Clinical Trial, phase III.
HULP code: ANEXO-V 3019. Sponsored´s protocol code: 28431754DIA3008. Sponsored by: Janssen Cilag International NV. Signed date: 16/02/2017
de Castro Carpeño J. Estudio en fase III, abierto y aleatorizado para investigar la eficacia y seguridad de atezolizumab (anticuerpo anti-
PD-L1) en comparación con el tratamiento de soporte óptimo. Type: Clinical Trial, phase III.
HULP code: ANEXO-II 4480. Sponsored´s protocol code: GO29527. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 20/02/2017
Quesadas Simón A. Ensayo clinico aleatorizado, controlado con placebo, para evaluar los resultados clínicos cardiovasculares tras el
tratamiento con exenatida una vez a la semana en pacientes con diabetes mellitus de tipo II. Type: Clinical Trial, phase III.
HULP code: ANEXO-III 4103. Sponsored´s protocol code: BCB109. Sponsored by: Bristol Myers Squibb International Corporation. Signed date: 10/04/2017
Castelo Fernández B. Estudio epidemiológico, retrospectivo, longitudinal para caracterizar la historia natural de los pacientes con
carcinoma diferenciado de tiroides avanzado en España y Portugal. Estudio Erudit. Type: EPA-OD.
HULP code: PI-2895. Sponsored´s protocol code: EIS-CDT-2017-01. Sponsored by: Eisai Farmaceutica S.A. Signed date: 11/09/2017
Castelo Fernández B. Caracterización y epidemiología en España del dolor irruptivo oncológico. Type: NO-EPA.
HULP code: PI-2596B. Sponsored´s protocol code: CARPE-DIO. Sponsored by: Takeda Farmacéutica España S.A.U. Signed date: 16/01/2017
López de la Guía A. Estudio observacional para valorar la carga de la enfermedad, en términos de calidad de vida relacionada con la
salud y costes sanitarios directos, en pacientes con mieloma múltiple de nuevo diagnóstico no candidatos a trasplante autólogo de
progenitores hematopoyéticos en España. Type: EPA-SP.
50
HULP code: PI-2839. Sponsored´s protocol code: CEL-MIE-2016-01. Sponsored by: Celgene S.L. Signed date: 21/11/2017
Antorrena Miranda MI. Estudio observacional retrospectivo del uso de evolocumab en unidades españolas de cardiología (Retrospec-
tive observational study of evolocumab use in spanish cardiology units). Type: EPA-OD.
HULP code: PI-2844. Sponsored´s protocol code: 20160139. Sponsored by: Amgen S.A. Signed date: 04/08/2017
Diestro Tejeda MD. Estudio observacional, prospectivo y multicéntrico para evaluar el uso clínico de la prueba molecular Gynec®-DX
para el descarte de cáncer de endometrio y posterior seguimiento en mujeres asintomáticas con formaciones polipoideas endometria-
les. Type: Healthcare Product.
HULP code: PI-2847. Sponsored´s protocol code: RJ-GYN-01. Sponsored by: Laboratorio Reig Jofre S.A. Signed date: 28/08/2017
Martínez Marín V. Caracterización del riesgo de trombosis en pacientes con cáncer (Estudio Cartago). Type: EPA-SP.
HULP code: PI-2849. Sponsored´s protocol code: AJT-ACO-2016-01. Sponsored by: Trujillo Santos, Antonio Javier. Signed date: 18/09/2017
Martínez Piñeiro L. Estudio prospectivo no intervencional poscomercialización para evaluar los criterios sobre qué renovación del
tratamiento con análogos de la LHRH se realiza en pacientes con cáncer de próstata localmente avanzado o metastásico (Estudio
Anaren). Type: EPA-SP.
HULP code: PI-2853. Sponsored´s protocol code: IPS-TRI-2016-02. Sponsored by: Ipsen Pharma S.A. Signed date: 13/09/2017
Manso de Lema A. Optimizing irradiation through molecular assessment of lymph node after primary sistemic treatment (Optimal
IIA). Type: NO-EPA.
HULP code: PI-2856. Sponsored´s protocol code: GIC-RAD-2016-01. Sponsored by: Grupo de Investigación Clínica en Oncología Radioterápica. Signed
date: 25/07/2017
Álvarez Román MT. Estudio prospectivo, multicéntrico, no intervencional de 24 meses para evaluar la efectividad de elocta en compa-
ración con productos del factor convencional en el tratamiento profiláctico de pacientes con hemofilia a (A-Sure). Type: EPA-SP.
HULP code: PI-2868. Sponsored´s protocol code: SOB-EFM-2016-01. Sponsored by: Swedish Orphan Biovitrum AB. Signed date: 20/10/2017
Gómez Carrera L. Estudio retrospectivo, de revisión de historias clínicas, multicéntrico para describir el perfil clínico de los pacientes
diagnosticados con FPI tratados con nintedanib (OFWV®) en la práctica clínica habitual en España. Type: EPA-OD.
HULP code: PI-2832. Sponsored´s protocol code: 1199-0295. Sponsored by: Boehringer Ingelheim España S.A. Signed date: 19/07/2017
Asencio Durán M. Estudio transversal de la carga de la atrofia geográfica. Type: EPA-OD.
HULP code: PI-2879. Sponsored´s protocol code: MX30135. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 07/08/2017
Peinado Peinado R. Estudio observacional smart registry – Estrategias de optimización de la respuesta a la terapia de resincronización
cardiaca. Type: NO-EPA.
HULP code: PI-2831. Sponsored´s protocol code: C1949. Sponsored by: Guidant Europe NV; Boston Scientific Company. Signed date: 05/09/2017
García Río FJ. Carga de la enfermedad en pacientes con EPOC eosinofílica en España: estudio observacional multicéntrico.Type: EPA-OD.
HULP code: PI-2903. Sponsored´s protocol code: HO-16-16447. Sponsored by: Glaxosmithkline S.A. Signed date: 20/12/2017
Álvarez Román MT. Estudio epidemiológico internacional para determinar la prevalencia de los anticuerpos neutralizantes y las res-
puestas inmunitarias adaptativas a los virus adenoasociados (VAA) en adultos con hemofilia. Type: NO-EPA.
HULP code: PI-2904. Sponsored´s protocol code: 201601. Sponsored by: Baxalta Innovations GMHB. Signed date: 13/09/2017
Fernández-Lahera Martínez J. Estudio descriptivo observacional transversal sobre el uso de laba y corticoide inhalado en un disposi-
tivo presurizado en pacientes con EPOC. Estudio Aries. Type: EPA-OD.
HULP code: PI-2927. Sponsored´s protocol code: PI-2927 D589BR00041. Sponsored by: Astrazeneca Farmaceutica Spain S.A. Signed date: 29/11/2017
Fernández-Lahera Martínez J. Estudio descriptivo observacional transversal sobre el uso de laba y corticoide inhalado en un disposi-
tivo presurizado en pacientes con EPOC. Estudio Aries. Type: EPA-OD.
HULP code: PI-2927. Sponsored´s protocol code: PI-2927 EPA-OD. Sponsored by: Astrazeneca Farmaceutica Spain S.A. Signed date: 29/11/2017
Bernad Pineda M. Estudio observacional transversal para evaluar la adherencia al tratamiento en pacientes con artritis reumatoide en
España. Type: EPA-OD.
HULP code: PI-2936. Sponsored´s protocol code: FRD-ART-2017-01. Sponsored by: Fundación Ramón Domínguez. Signed date: 16/10/2017
Lara Lara M. La carga de la migraña en centros de cefalea especializados que tratan pacientes que han fallado a tratamientos preven-
tivos (Become). Type: EPA-SP.
HULP code: PI-2937. Sponsored´s protocol code: CAMG334A3301/NOV-MIG-2017-01. Sponsored by: Novartis Farmaceutica S.A. Signed date: 27/11/2017
Martín Carbonero L. Estudio observacional para evaluar la tasa de reinfección en personas que se inyectan drogas (PID) infectadas con
el virus de la hepatitis C (VHC) que se han sometido con éxito a un tratamiento para el VHC en España. Estudio Liverate. Type: EPA-SP.
HULP code: PI-2950. Sponsored´s protocol code: MER-MET-2017-01. Sponsored by: Merck Sharp and Dohme de España S.A. Signed date: 27/11/2017
Vivancos Matellano F. Estudio de evaluación de la monoterapia y de la terapia combinada con el gel intestinal de levodopa-carbidopa.
Type: EPA-OD.
HULP code: PI-2953. Sponsored´s protocol code: ABB-LEV-2017-01. Sponsored by: Abbvie Spain S.L.U. Signed date: 05/12/2017
Burgos García A. Evaluacion de la colonoscopia con dispositivo especifico para la deteccion de adenomas: estudio multicéntrico pros-
pectivo y aleatorizado. Type: Healthcare Product.
HULP code: PI-3016. Sponsored´s protocol code: ENDOCOLES. Sponsored by: Herreros de Tejada Echanojauregui, Alberto. Signed date: 15/12/2017
Sánchez Méndez JI. Estudio para la validación del valor pronóstico de la carga tumoral total, determinado por Osna, de la metástasis
en el ganglio centinela del cáncer de mama. Type: NO-EPA.
HULP code: PI-2872. Sponsored´s protocol code: GES-2017-01. Sponsored by: Fundación Española de Senología Y Patología Mamaria (SESPM). Signed
date: 11/09/2017
Álvarez Román MT. Estudio de mercado sobre los diferentes tratamientos para la hemofília A en la práctica clínica habitual.Type: EPA-OD.
HULP code: PI-2766. Sponsored´s protocol code: PHA-HEM-2017-01. Sponsored by: Phamax AG. Signed date: 01/06/2017
Álvarez Román MT. Caracterización farmacocinética de la población con hemofilia A en España, utilizando una aplicación médica online
basada en un modelo poblacional publicado y un algoritmo bayesiano. Type: EPA-SP.
HULP code: PI-2627. Sponsored´s protocol code: STH-OCT-2016-01. Sponsored by: Fundación Seth. Signed date: 20/11/2017
51
 2
Executive Summary
2.6 Clinical Trials
Martín Arranz MD. Estudio de seguridad posautorización de golimumab para la colitis ulcerosa (CU) usando el registro español Eneida.
Type: EPA-SP.
HULP code: PI-2631. Sponsored´s protocol code: MK825-042-00. Sponsored by: Merck Sharp & Dhome Corp. Signed date: 28/06/2017
Morera López RM. Estudio multicéntrico para el tratamiento de metástasis pulmonares con radioterapia estereotaxica corporal (SBRT)
en pacientes Oligomert. Type: NO-EPA.
HULP code: PI-2634. Sponsored´s protocol code: GICOR-SEOR 2-16. Sponsored by: Grupo de Investigación Clínica en Oncología Radioterápica. Signed
date: 09/05/2017
Antorrena Miranda MI. Manejo de edoxabán en procedimientos diagnósticos y terapéuticos. Estudio EMIT-AF/VTE. Type: EPA-SP.
HULP code: PI-2679. Sponsored´s protocol code: DSE-EDO-2016-02. Sponsored by: Daiichi-Sankyo Development Limited. Signed date: 08/05/2017
Balsa Criado A. Estudio retrospectivo sobre la eficacia en práctica clínica de golimumab tras el fracaso de un primer anti-TNF-α en
pacientes con espondiloartritis. Go-Beyond Spain. Type: EPA-OD.
HULP code: PI-2706. Sponsored´s protocol code: MSD-GOL-2016-01. Sponsored by: Merck Sharp & Dhome Corp. Signed date: 08/05/2017
Jiménez Yuste VM. Valoración del estatus articular de los pacientes con hemofilia A en España mediante técnica ecográfica. Estudio
Artiha. Type: EPA-OD.
HULP code: PI-2723. Sponsored´s protocol code: PFI-MOR-2017-01. Sponsored by: Pfizer Inc. Signed date: 18/10/2017
Gómez Candela C. Estudio retrospectivo de costes en pacientes con nutrición parenteral domiciliaria y síndrome de intestino corto,
en la práctica clínica real en España. Estudio Cosincor. Type: EPA-OD.
HULP code: PI-2726. Sponsored´s protocol code: CHI-NPD-2016-01. Sponsored by: Shire Pharmaceuticals Ibérica S.L. Signed date: 23/06/2017
Feliú Batlle J. S-Avant seguimiento del estudio Avant hasta 8 y 10 años (mediana de seguimiento) en pacientes con carcinoma de colón.
Type: Clinical Trial, phase EPA-OD.
HULP code: PI-2730. Sponsored´s protocol code: C13-01. Sponsored by: Grupo Tratamiento Tumores Digestivos (GERCOR). Signed date: 26/04/2017
Arribas López JR. Determinación de frecuencias de mutaciones mediante genotipo provira. Type: EPA-OD.
HULP code: PI-2836. Sponsored´s protocol code: GEN-PRO. Sponsored by: Fundación para la Investigacion Biomédica Hospital Universitario La Paz.
Signed date: 13/09/2017
Magallanes García L. Factores farmacogenómicos y monitorización terapéutica como predictores de respuesta a anti-TNFS en enfer-
medad inflamatoria intestinal en niños. Type: EPA-AS.
HULP code: PI-2748. Sponsored´s protocol code: LLF-TNF-2016-01. Sponsored by: López Fernández, Luis Andrés. Signed date: 08/05/2017
Arribas López JR. Ensayo clínico fase IIB, aleatorizado, controlado con principio activo, doble ciego, para investigar la seguridad, eficacia
y dosis-respuesta de BMS-955176, administrado con tenofovir/emtricitabina en adultos infectados por VIH 1 naive a tratamiento. Type:
Clinical Trial, phase II.
HULP code: ANEXO-II 4424. Sponsored´s protocol code: AI468-038. Sponsored by: VIIV Healthcare UK Limited. Signed date: 17/02/2017
Barrientos Ruiz I. Estudio observacional de la epidemiología e historia natural de tumores mesenquimales de baja incidencia. Type:
NO-EPA.
HULP code: PI-2792. Sponsored´s protocol code: TMBI-2013. Sponsored by: Grupo Español de Investigación en Sarcomas. Signed date: 31/05/2017
Custodio Carretero AB. Estudio para evaluar el uso de recursos y los costes asociados al síndrome carcinoide controlado y no contro-
lado en pacientes con tumores neuroendocrinos (NETS) en España. Estudio Recosy. Type: Clinical Trial, phase EPA-OD.
HULP code: PI-2793. Sponsored´s protocol code: IPS-SOM-2017-01. Sponsored by: Ipsen Pharma S.A. Signed date: 12/06/2017
Mellado Peña MJ. Estudio de la infección por virus influenza en niños hospitalizados en España en dos estaciones gripales consecutivas.
Análisis de costos médicos directos. Type: NO-EPA.
HULP code: PI-2794. Sponsored´s protocol code: HOSPIGRIP-2016. Sponsored by: Fundación Vasca de Innovación e Investigación Sanitarias. Signed date:
08/06/2017
Redondo Sánchez A. Identificación de biomarcadores pronósticos en el osteosarcoma de alto grado. Type: EPA-OD.
HULP code: PI-2797. Sponsored´s protocol code: GEIS 44. Sponsored by: Grupo Español de Investigación en Sarcomas. Signed date: 13/07/2017
Martínez Marín V. Retrospective observational study of patients with metastatic, unresectable or locally advanced gastrointestinal stro-
mal tumours (GIST) treated with sunitinib. exploratory analysis of prognostic and predictive factors in long-term responder patients.
Type: EPA-OD.
HULP code: PI-2798. Sponsored´s protocol code: GEIS 43. Sponsored by: Grupo Español de Investigación en Sarcomas. Signed date: 17/07/2017
Gómez Carrera L. Estudio retrospectivo para evaluar el perfil clínico de pacientes con fibrosis pulmonar idiopática tratados y no tra-
tados, con pirfenidona en España. Estudio Aeras. Type: EPA-OD.
HULP code: PI-2807. Sponsored´s protocol code: SEP-PIR-2016-01. Sponsored by: Fundación Española del Pulmón (SEPAR). Signed date: 22/06/2017
Baltasar Tello P. Registro regional para evaluar la práctica médica con observación longitudinal para el diagnóstico, seguimiento y tra-
tamiento de la leucemia linfática crónica. Type: NO-EPA.
HULP code: PI-2809. Sponsored´s protocol code: REG-GMLLC. Sponsored by: Asociacion Madrileña de Hematologia y Memoterapia (AMHH). Signed
date: 15/05/2017
Martín Carbonero L. Estudio observacional del uso concomitante de los fármacos ledipasvir/sofosbuvir y tenofovir disoproxil fumara-
to + potenciadores farmacocinéticos en adultos coinfectados por hepatitis C crónica y VIH 1. Type: EPA-LA.
HULP code: PI-2820. Sponsored´s protocol code: GS-EU-3371820. Sponsored by: Gilead Sciences International Ltd. Signed date: 26/07/2017
Quesadas Simón A. Revisión observacional en serie de historias clínicas del uso de Repatha® en sujetos europeos con hiperlipidemia.
Type: EPA-SP.
HULP code: PI-2828. Sponsored´s protocol code: AMG-EVO-2016-01. Sponsored by: Amgen S.A. Signed date: 17/07/2017
Burgueño García M. Registro prospectivo, multicéntrico, internacional para recopilar datos sobre los patrones de tratamiento de los
pacientes con osteonecrosis mandibular asociada a fármacos (MRONJ/ONMF) y su resultado. Type: NO-EPA.
HULP code: PI-2737. Sponsored´s protocol code: RP-MRONJ. Sponsored by: AO Investigation and Publishing Foundation (AOCID). Signed date: 01/06/2017
Quesadas Simón A. Ensayo clínico exploratorio fase II/ III, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para
evaluar la eficacia, seguridad y farmacodinamia de dapagliflozina y combinación de dapagliflozina con saxagliptina en pacientes con
52
diabetes mellitus tipo 2, insuficiencia renal crónica 3 y albuminuria tratados con inhibidores de la enzima convertidora de angiotensina
(IECA) o bloqueantes del receptor de angiotensina II . Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4493. Sponsored´s protocol code: D1690C00023. Sponsored by: Astrazeneca AB. Signed date: 26/04/2017
de Castro Carpeño J. Estudio de fase II, de un solo grupo y abierto, de evaluación de la eficacia, la seguridad y la farmacocinética de
hm61713 (bi1482694)) en pacientes con cáncer de pulmón no microcítico (cpnm) con la mutación t790m tras el tratamiento con un
inhibidor de la tirosina cinasa del receptor del factor de crecimiento epidérmico (egfr-tki). Type: Clinical Trial, phase II.
HULP code: ANEXO-II 4461. Sponsored´s protocol code: HM-EMSI-202. Sponsored by: Hanmi Pharmaceutical Ltd. Signed date: 20/10/2017
de Castro Carpeño J. Un estudio multicéntrico, en fase I, abierto y no aleatorizado para evaluar el efecto de la rifampicina (un inductor
de CYP3A4) sobre la farmacocinética de AZD9291 en pacientes con cáncer de pulmón no microcítico (CPNM) positivos para EGFM
cuya enfermedad ha progresado con el tratamiento con TKI del EGFR. Type: Clinical Trial, phase I.
HULP code: ANEXO-I 4360. Sponsored´s protocol code: D5160C00013. Sponsored by: Astrazeneca AB. Signed date: 02/02/2017
Pinto Marín A. Estudio fase II de dos grupos, multicéntrico y abierto para determinar la eficacia y la seguridad de dos pautas posológicas
diferentes de JNJ-42756493, un pan-inhibidor tirosina quinasa del FGFR, en sujetos con cáncer urotelial metastásico o no resecable
quirurgicamente con alteraciones genómicas del FGFR. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4378. Sponsored´s protocol code: 42756493BLC2001. Sponsored by: Janssen Cilag International NV. Signed date: 31/05/2017
Quesadas Simón A. Estudio a largo plazo, aleatorizado, doble ciego, controlado con placebo para determinar el efecto de albiglutida,
cuando se añade al tratamiento hipoglucemiante estándar, sobre eventos cardiovasculares mayores en pacientes con diabetes mellitus
tipo 2. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4396. Sponsored´s protocol code: GLP116174. Sponsored by: Lilly Research Laboratories. Signed date: 28/03/2017
de Castro Carpeño J. Estudio fase III, abierto, multicéntrico, aleatorizado que evalúa la eficacia y seguridad de MPDL3280A (anticuerpo
anti-PD-L1) en combinación con carboplatino + paclitaxel o MPDL3280A en combinación con carboplatino  + NAB-paclitaxel compa-
rado con carboplatino + NAB-paclitaxel en pacientes con cáncer de pulmón no microcítico  escamoso estadio IV que no han recibido
quimioterapia previa. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4404. Sponsored´s protocol code: GO29437. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 05/04/2017
de Castro Carpeño J. Estudio fase III, abierto, aleatorizado de MPDL3280A (anticuerpo anti-PD-L1) en combinación con carboplatino
+ paclitaxel con o sin bevacizumab comparado con carboplatino  + paclitaxel + bevacizumab en pacientes con cáncer de pulmón no
epidermoide no microcítico  en estadio IV que no han recibido quimioterapia previa. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4405. Sponsored´s protocol code: GO29436. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 05/04/2017
Sastre Urgüelles A. Ensayo adaptativo de fase 3 aleatorizado, abierto y controlado para investigar la eficacia, seguridad y tolerabilidad
del anticuerpo Bite® blinatumomab como tratamiento de consolidación frente a la quimioterapia de consolidación convencional en su-
jetos pediátricos con leucemia linfoblástica aguda (LLA) de precursores B en primera recaída de alto riesgo.Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4416. Sponsored´s protocol code: 20120215. Sponsored by: Amgen S.A. Signed date: 20/09/2017
de Castro Carpeño J. Estudio de fase III multicéntrico, abierto, randomizado de alectinib frente a pemetrexed o docetaxel en pacientes
con cáncer de pulmón no microcítico avanzado quinasa del linfoma anaplásico positivo, tratados previamente con quimioterapia basada
en platino y crizotinib. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4455. Sponsored´s protocol code: MO29750. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 16/10/2017
Díez Tejedor E. Estudio de superioridad, fase III, multicéntrico, aleatorizado, doble-ciego, doble simulación, con comparador activo y
dirigido por eventos , que compara rivaroxaban 15 mg en una toma diaria con aspirina 100 mg, en la prevención secundaria de accidente
cerebrovascular y embolia sistémica en pacientes que han sufrido un accidente cerebrovascular embólico de etiología indeterminada
(ACEI). (Navigate Esus). Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4328. Sponsored´s protocol code: BAY 59-7939/1657. Sponsored by: Bayer Heathcare AG. Signed date: 14/12/2017
de Castro Carpeño J. Estudio de fase III, multicéntrico, aleatorizado, en doble ciego y controlado con placebo, para evaluar la eficacia y
la seguridad de AZD9291 frente a placebo en pacientes con carcinoma de pulmón no microcítico con mutación del receptor del factor
de crecimiento epidérmico, en estadio IB-IIIA, tras la resección completa del tumor, con o sin quimioterapia adyuvante. Type: Clinical
Trial, phase III.
HULP code: ANEXO-I 4474. Sponsored´s protocol code: D5164C00001. Sponsored by: Astrazeneca AB. Signed date: 10/10/2017
García Río FJ. Ensayo clínico, aleatorizado, doble ciego, con control activo y de grupos paralelos para evaluar el efecto sobre las exacer-
baciones del tratamiento una vez al día oral inhalado de la combinación a dosis fijas de tiotropio+olodaterol comparado con tiotropio
durante 52 semanas en pacientes con enfermedad pulmonar obstructiva crónica grave a muy grave. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4327. Sponsored´s protocol code: 1237.19. Sponsored by: Boehringer Ingelheim España S.A. Signed date: 09/01/2017
Martín Arranz MD. Estudio multicéntrico de fase II, aleatorizado, doble ciego y controlado con placebo de grupos paralelos para in-
vestigar la seguridad y la eficacia de APD334 en pacientes con colitis ulcerativa activa de moderada a grave. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4498. Sponsored´s protocol code: APD334-003. Sponsored by: Arena Pharmaceuticals Inc. Signed date: 16/01/2017
Herranz Pinto P. Estudio abierto de dupilumab en pacientes con dermatitis atópica que han participado en ensayos clínicos previos
con dupilumab. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4514. Sponsored´s protocol code: R668-AD-1225 04. Sponsored by: Regeneron Pharmaceuticals Inc. Signed date: 12/02/2017
López de Sa Areces E. Estudio prospectivo abierto del andexanet alfa en pacientes tratados con un inhibidor de factor XA que pre-
sentan una hemorragia mayor aguda. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4523. Sponsored´s protocol code: 14-505. Sponsored by: Portola Pharmaceuticals Inc. Signed date: 03/10/2017
Pascual Pascual SI. Estudio en fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico e internacional que evalúa en
grupos paralelos la eficacia y seguridad de 2 dosis de PXT3003 en pacientes con síndrome de Charcot-Marie-Tooth de tipo 1A tratados
durante 15 meses. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4534. Sponsored´s protocol code: CLN-PXT3003-02. Sponsored by: Pharnext. Signed date: 12/06/2017
Martín Arranz MD. Estudio de extensión del estudio APD334-003 en pacientes con colitis ulcerosa activa moderada o grave. Type:
Clinical Trial, phase II.
53
 2
Executive Summary
2.6 Clinical Trials
HULP code: ANEXO-I 4541. Sponsored´s protocol code: APD334-005. Sponsored by: Arena Pharmaceuticals Inc. Signed date: 16/01/2017
Álvarez Román MT. Estudio clínico de fase III, prospectivo, aleatorizado y multicéntrico para comparar la seguridad y la eficacia de
BAX 855 tras la profilaxis guiada por FC dirigida a dos concentraciones mínimas de FVIII distintas en sujetos con hemofilia A grave.
Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4547. Sponsored´s protocol code: 261303. Sponsored by: Baxter Innovations GMBH. Signed date: 18/07/2017
de Castro Carpeño J. Estudio de fase II, multicéntrico, de tres cohortes con el inhibidor oral de CMET, INC280, en pacientes adultos
con cáncer de pulmón de células no pequeñas (NSCLC) avanzado y EGFR wild type (WT), que han recibido una o dos líneas previas
de terapia sistémica para enfermedad avanzada/metastásica. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4554. Sponsored´s protocol code: CINC280A2201. Sponsored by: Novartis Farmaceutica S.A. Signed date: 16/10/2017
de Castro Carpeño J. Ensayo en fase III, aleatorizado, con el anticuerpo monoclonal anti-PD-1 pembrolizumab (MK-3475), en compa-
ración con placebo para pacientes con CPNM en fase temprana después de resección y finalización del tratamiento complementario
de referencia. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4558. Sponsored´s protocol code: EORTC 1416-LCG. Sponsored by: Merck & Co. Inc. Signed date: 07/04/2017
Balsa Criado A. Estudio fase IIA, aleatorizado, doble-ciego, paralelo, controlado con placebo y naproxeno para evaluar la eficacia anal-
gésica de ASP7962 en pacientes con dolor secundario a osteoartritis en rodilla. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4561. Sponsored´s protocol code: 7962-CL-0022. Sponsored by: Astellas Pharma Europe B.V. Signed date: 16/01/2017
Pinto Marín A. Estudio en fase III multinacional, aleatorizado, con doble enmascaramiento y controlado con placebo sobre la eficacia y
seguridad de ODM-201 en varones con cáncer de próstata no metastásico de alto riesgo resistente a la castración. Type: Clinical Trial,
phase III.
HULP code: ANEXO-I 4463. Sponsored´s protocol code: 17712. Sponsored by: Bayer AG. Signed date: 22/11/2017
de Castro Carpeño J. Estudio en fase III, aleatorizado, abierto, sobre la eficacia y seguridad de dacomitinib (PF-00299804) frente a
gefitinib, en el tratamiento de primera línea del cáncer de pulmón no microcitico localmente avanzado o metastásico en pacientes con
mutación(es) ectivadora(s) del receptor del factor de crecimiento epidemico (EGFR). Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4001. Sponsored´s protocol code: DP312804. Sponsored by: Sfj Lungcancer Ltd. Signed date: 30/03/2017
Morado Arias M. Subregistro prospectivo, multicéntrico y observacional de seguridad postautorización para caracterizar el perfil de
seguridad a largo plazo del uso comercial de eliglustat. Type: Clinical Trial, phase EPA-LA.
HULP code: PI-3019. Sponsored´s protocol code: PI-3019 OBS14099. Sponsored by: Sanofi Aventis S.A. Signed date: 18/12/2017
Jiménez Yuste VM. Estudio post-autorizacion de tipo observacional de factor IX grifols (concentrado de factor IX humano de alta
pureza doblementeinactivado) en profilaxis o tratamiento de pacientes con hemofilia B. Type: EPA-LA.
HULP code: 2007. Sponsored´s protocol code: INS-FAC-2004-01. Sponsored by: Instituto Grifols S.A. Signed date: 01/11/2017
Zamora Auñón P. Estudio fase III aleatorizado, multicéntrico, abierto de lapatinib, trastuzumab, la administración secuencial de ambos
y la adminsitración combinada de ambos como tratamiento adyuvante en pacientes con cáncer de mama HER2/ERBB2 positivo. Type:
Clinical Trial, phase III.
HULP code: ANEXO-I 2436. Sponsored´s protocol code: EGF 106708. Sponsored by: Novartis Farmaceutica S.A. Signed date: 21/07/2017
Canales Albendea MA. Estudio fase III, abierto, de ofatumumab añadido a fludarabina-ciclofosfamida frente a la combinación fludarabina-
ciclofosfamida en sujetos con leucemia linfocitica crónica en recaída. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 2824. Sponsored´s protocol code: OMB110913. Sponsored by: Glaxosmithkline S.A. Signed date: 24/04/2017
Gil Garay E. Estudio prospectivo, multicéntrico, no aleatorizado. Estudio de resultados clínicos del sistema acetabular R3 en pacientes
con enfermedades degenerativas de cadera. Type: EPA-SP.
HULP code: ANEXO-I 2929. Sponsored´s protocol code: R3H01/01/05/200. Sponsored by: Smith Nephew. Signed date: 18/12/2017
Álvarez Román MT. Evaluacion en abierto y multicéntrico de la seguridad y la eficacia a largo plazo de la proteína recombinante de
fusión del factor VIII de coagulación humano en la prevención y el tratamiento de episodios de sangrado en sujetos con hemofilia tra-
tados previamente. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 3543. Sponsored´s protocol code: 8HA01EXT. Sponsored by: Bioverativ Therapeutics Inc. Signed date: 24/08/2017
Quesadas Simón A. Ensayo multicéntrico, randomizado, doble ciego, controlado con placebo para evaluar el efecto de dapagliflozina
10mg una vez al día en la incidencia de muerte cardiovascular, infarto de miocardio o ictus isquémico en pacientes con diabetes tipo 2.
Type: Clinical Trial, phase IV.
HULP code: ANEXO-I 3919. Sponsored´s protocol code: D1693C0001. Sponsored by: Astrazeneca AB. Signed date: 28/03/2017
Castillo Grau P. Estudio de seguimiento a largo plazo de los sujetos que participaron en un ensayo clinico en el que se administro
asunaprevir (BMS-650032) y/o daclatasvir (BMS-790052) para el tratamiento de la hepatitis C crónica. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 3956. Sponsored´s protocol code: AI444-046. Sponsored by: Bristol Myers Squibb International Corporation. Signed date:
03/05/2017
Canales Albendea MA. Estudio de fase IB/II, abierto para evaluar la seguridad y la farmacocinética de GDC‑0199 (ABT-199) en com-
binación con rituximab (R) o obinutuzumab (G) más ciclofosfamida, doxorrubicina, vincristina y prednisona (CHOP) en pacientes con
linfoma no Hodgkin (LNH) de células B y LDCGB (linfoma difuso de células grandes B). Type: Clinical Trial, phase Ib.
HULP code: ANEXO-I 4354. Sponsored´s protocol code: GO27878. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 06/11/2017
Quesadas Simón A. Estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos, con control activo, para evaluar la eficacia y
seguridad de LCZ696 comparado con valsartan, sobre la morbilidad y mortalidad en pacientes con insuficiencia cardiaca (clase II-IV
NYHA) con fracción de eyección preservada. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 3990. Sponsored´s protocol code: CLCZ696D2301. Sponsored by: Novartis Farmaceutica S.A. Signed date: 31/05/2017
Méndez Echevarría AM. Estudio multicéntrico, abierto, aleatorizado, de fase II/III para determinar la seguridad y eficacia de la solitro-
micina en adolescentes (de 12 a 17 años de edad, ambos inclusive) y niños (2 meses a < 12 años de edad) con neumonía bacteriana
adquirida en la comunidad sospechada o confirmada. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4599. Sponsored´s protocol code: CE01-203. Sponsored by: Chiltern International Spain S.A. Signed date: 16/08/2017”
54
García Puig J. Estudio aleatorizado, multicéntrico, doble ciego, de grupos paralelos y controlado con placebo de los efectos de canagli-
fozina en los criterios de valoración renales en sujetos adultos con diabetes mellitus de tipo 2. Type: Clinical Trial, phase IV.
HULP code: ANEXO-I 4069. Sponsored´s protocol code: 28431754DIA4003. Sponsored by: Janssen-Cilag España S.A. Signed date: 16/02/2017
Silvestre García J. Estudio observacional Leadless. Type: EPA-OD.
HULP code: ANEXO-I 4078. Sponsored´s protocol code: LCP005. Sponsored by: Sjm International Inc. Signed date: 17/05/2017
Pinto Marín A. Estudio de fase III, aleatorizado, doble ciego y controlado con placebo, de dicloruro de radio 223 en combinacion con
acetato de abiraterona y prednisona/preednisolona en el tratamiento de pacientes con metastasis predominantemente óseas en pacien-
tes asintomáticos o con síntomas leves, que nunca han recibido quimioterapia. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4086. Sponsored´s protocol code: BAY 88-8223/153. Sponsored by: Bayer AG. Signed date: 17/10/2017
Sáenz de Pipaón Marcos M. Estudio multicéntrico, aleatorizado, doble ciego controlado con placebo para evaluar la eficacia y seguri-
dad del uso de NTRA-2112 para tratar la mala absorción intestinal causada por inmadurez gastrointestinal en niños prematuros. Type:
Clinical Trial, phase III.
HULP code: ANEXO-I 4231. Sponsored´s protocol code: FIT-EU-04. Sponsored by: Nutrinia Ltd. Signed date: 26/07/2017
Redondo Sánchez A. Ensayo de fase II aleatorizado, doble ciego, controlado con placebo, de dicloruro de radio-223 en combinación
con exemestano y everolimus frente a placebo en combinación con exemestano y everolimus, administrado a pacientes con cáncer de
mama metastásico negativo para HER2 y positivo para los receptores hormonales, con metastasis óseas. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4263. Sponsored´s protocol code: BAY 88-8223/17096. Sponsored by: Bayer Pharma AG. Signed date: 07/11/2017
Martín Arranz MD. Estudio de fase III, aleatorizado, multicéntrico, doble ciego, con doble simulación, para evaluar la eficacia y seguridad
de etrolizumab comparado con infliximab en pacientes con colitis ulcerosa activa entre moderada e intensa que no han recibido trata-
miento previo con inhibidores del FNT. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4273. Sponsored´s protocol code: GA29103. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 09/01/2017
Martín Arranz MD. Estudio abierto de extensión y supervisión de la seguridad de pacientes con colitis ulcerosa de moderada a grave
previamente inscritos en estudios de fase III con etrolizumab. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4274. Sponsored´s protocol code: GA28951. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 16/02/2017
González García JJ. Estudio de seguimiento a largo plazo para evaluar la durabilidad de la respuesta virológica y/o los patrones de
resistencia viral de sujetos con hepatitis C crónica que han sido tratados previamente con MK-5172 en un ensayo clínico previo. Type:
Clinical Trial, phase II.
HULP code: ANEXO-I 4310. Sponsored´s protocol code: 5172-017. Sponsored by: Merck Sharp and Dohme de España S.A. Signed date: 06/04/2017
Arribas López JR. Ensayo clínico de fase III, multicéntrico, doble ciego, aleatorizado, controlado con un comparador activo para evaluar
la seguridad y la eficacia de 100 mg de doravirina (MK-1439) una vez al día frente a 800 mg de darunavir una vez al día más 100 mg de
ritonavir una vez al día, cada uno de ellos en combinación con Truvada™ o Epzicom™/Kivexa™, en sujetos infectados por el VIH 1 no
tratados previamente. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4326. Sponsored´s protocol code: MK-1439-018. Sponsored by: Merck & Co. Inc. Signed date: 14/03/2017
Díaz Fernández MC. Estudio postautorización de seguridad (EPAS) no intervencional para evaluar la seguridad a largo plazo del trata-
miento con orfadin en la tirosinemia hereditaria tipo 1 (TH-1) en la práctica clínica estándar. Type: EPA-SP.
HULP code: ANEXO-I 3986. Sponsored´s protocol code: SOBI.NTBC-005. Sponsored by: Swedish Orphan Biovitrum AB. Signed date: 05/09/2017
García Puig J. Ensayo clínico aleatorizado, controlado con placebo, para evaluar los resultados clínicos cardiovasculares tras el trata-
miento con exenatida una vez a la semana en pacientes con diabetes mellitus de tipo 2. Type: Clinical Trial, phase III.
HULP code: ANEXO-II 4103. Sponsored´s protocol code: BCB109. Sponsored by: Bristol Myers Squibb International Corporation. Signed date: 18/01/2017
de Paz Arias R. Estudio fase III, multicéntrico, abierto, aleatorizado de imatinib frente a nilotinib, en pacientes adultos con leucemia
mieloide crónica cromosoma filadelfia positivo (PH+) en fase cronica (LMC-FC) de nuevo diagnóstico. Type: Clinical Trial, phase III.
HULP code: ANEXO-II 2412. Sponsored´s protocol code: CAMN107A2303. Sponsored by: Novartis Farmaceutica S.A. Signed date: 30/05/2017
Martín Arranz MD. Estudio fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo para evaluar
la eficacia y seguridad de células madre alogénicas expandidas derivadas del tejido adiposo (EASC) para el tratamiento de la enfermedad
de Crohn fistulizante perianal tras un periodo de 24 semanas. Estudio Admire-CD. Type: Clinical Trial, phase III.
HULP code: ANEXO-II 3581. Sponsored´s protocol code: CX601-0302. Sponsored by: Tigenix S.A.U. Signed date: 23/01/2017
Espinosa Arranz E. Estudio en fase III, aleatorizado, doble ciego que compara la combinacion del inhibidor de BRAF (dabrafenib) y el
inhibidor de MEK (trametinib) frente a dabrafenib y placebo como terapia de primera línea en pacientes con melanoma cutaneo no-
resecable (estadío IIIC) o metastásico (estadio IV) con la mutación BRAF V600E/K. Type: Clinical Trial, phase III.
HULP code: ANEXO-II 3606. Sponsored´s protocol code: MEK 115306. Sponsored by: Glaxosmithkline S.A. Signed date: 07/09/2017
López-Sendón Hentschel JL. Registro global del tratamiento antitrombótico oral a largo plazo en pacientes con fibrilación auricular
(fase II/III-estados mienbros de la UE/AEE). Type: EPA-LA.
HULP code: ANEXO-II 3661. Sponsored´s protocol code: BOE-DAB-2012-01. Sponsored by: Boehringer Ingelheim España S.A. Signed date: 30/10/2017
Baltasar Tello P. Ensayo clínico de fase III, aleatorizado, doble ciego, controlado, paralelo, de volasertib intravenoso en combinación
con dosis bajas de citarabina subcutánea vs. placebo + dosis bajas de citarabina en pacientes > 65 años con leucemia mieloide aguda
previamente no tratada, que no puedan recibir tratamiento intensivo de inducción de remisión. Type: Clinical Trial, phase III.
HULP code: ANEXO-II 3789. Sponsored´s protocol code: 1230.14. Sponsored by: Boehringer Ingelheim España S.A. Signed date: 06/04/2017
Espinosa Arranz E. Estudio de fase III, multicéntrico, aleatorizado, controlado, de dos grupos, para evaluar la seguridad y eficacia de
MK-3475 en comparación con ipilimumab en pacientes con melanoma avanzado. Type: Clinical Trial, phase III.
HULP code: ANEXO-II 3830. Sponsored´s protocol code: 3475-006. Sponsored by: Merck Sharp and Dohme de España S.A. Signed date: 02/06/2017
Espinosa Arranz E. Combi-AD: estudio de fase III, aleatorizado y doble ciego de dabrafenib (GSK2118436) en combinacion con tra-
metinib (GSK1120212) frente a dos placebos en el tratamiento adyuvante de melanoma de alto riesgo con la mutacion BRAF V600 tras
resección quirúrgica. Type: Clinical Trial, phase III.
HULP code: ANEXO-II 3855. Sponsored´s protocol code: BRF115532. Sponsored by: Novartis Farmaceutica S.A. Signed date: 20/07/2017
55
 2
Executive Summary
2.6 Clinical Trials
González García JJ. Estudio de seguimiento a largo plazo de los sujetos que participaron en un ensayo clínico en el que se administro
asunaprevir (BMS-650032) y/o daclatasvir (BMS-790052) para el tratamiento de la hepatitis C crónica. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 3956. Sponsored´s protocol code: AI444-046. Sponsored by: Bristol Myers Squibb S.A.U. Signed date: 25/05/2017
Álvarez Román MT. Estudio multicéntrico, abierto y de administración repetida, para evaluar la seguridad y la eficacia de UCB7665 en
sujetos con trombocitopenia inmune primaria. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4562. Sponsored´s protocol code: TP0001. Sponsored by: UCB Biosciencies GMBH. Signed date: 18/09/2017
Canales Albendea MA. Estudio de fase II de brazo único, abierto, de nivolumab (BMS-936558) en sujetos con linfoma folicular (LF)
recidivante o refractario. Type: Clinical Trial, phase II.
HULP code: ANEXO-II 4085. Sponsored´s protocol code: CA209-140. Sponsored by: Bristol Myers Squibb International Corporation. Signed date:
03/05/2017
Martín Arranz MD. Groupe d´etude thérapeutique des affections inflammatoires digestives; (co-sponsor) GETECCU (Grupo Español
de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa) para la realizacion del estudio observacional titulado: IBD cancer and serious
infections in europe: I-CARE. Type: EPA-SP.
HULP code: ANEXO-I PI-2115. Sponsored´s protocol code: GET-EII-2015-01. Sponsored by: Grupo Español de Trabajo en Enfermedad de Crhon Y
Colitis Ulcerosa (GETECCU). Signed date: 30/06/2017
Quesadas Simón A. Estudio aleatorizado, doble ciego, motivado por los acontecimientos, controlado con placebo y multicéntrico, de
los efectos de la canagliflozina en los resultados renales y cardiovasculares en sujetos con diabetes mellitus tipo 2 y nefropatía diabética.
Type: Clinical Trial, phase III.
HULP code: ANEXO-II 4160. Sponsored´s protocol code: 28431754DNE3001. Sponsored by: Janssen Cilag International NV. Signed date: 03/07/2017
Remesal Camba A. Estudio de extension a largo plazo para evaluar la seguridad y la eficaia de tocilizumab administrado por vía subcu-
tánea en pacientes con artritis idiopática juvenil de curso poliarticular y artritis idiopática juvenil sistémica. Type: Clinical Trial, phase I.
HULP code: ANEXO-II 4166. Sponsored´s protocol code: WA29231. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 25/09/2017
Herranz Pinto P. Estudio aleatorizado, doble ciego y controlado con placebo, para demostrar la eficacia y la seguridad a largo plazo de
dupilumab en pacientes adultos con dermatitis atópica de grado moderado a severo. Type: Clinical Trial, phase III.
HULP code: ANEXO-II 4170. Sponsored´s protocol code: R668-AD-1224. Sponsored by: Regeneron Pharmaceuticals Inc. Signed date: 24/08/2015
Álvarez Román MT. Estudio de extensión de fase III, abierto, multicéntrico para evaluar la seguridad y eficacia del factor de la coagula-
ción VIII recombinante (RVIII-cadena sencilla, CSL627) en pacientes con hemofilia A severa. Type: Clinical Trial, phase III.
HULP code: ANEXO-II 4179. Sponsored´s protocol code: CSL-3001. Sponsored by: CSL Behring GMBH Clinical. Signed date: 22/09/2017
Gómez Prieto P. Ensayo aleatorizado y doble ciego para evaluar la eficacia, la seguridad y la inmunogenicidad de ABP 798 en compara-
ción con rituximab en sujetos con linfoma no Hodgkin (LNH) de células B CD20+. Type: Clinical Trial, phase III.
HULP code: ANEXO-II 4216. Sponsored´s protocol code: 20130109. Sponsored by: Amgen S.A. Signed date: 31/10/2017
Gasior Kabat M. Estudio fase IIIB, multicéntrico, abierto, aleatorizado que evalúa la eficacia y la seguridad de ruxolitinib frente a la mejor
terapia disponible en pacientes con policitemia severa. Type: Clinical Trial, phase IIIb.
HULP code: ANEXO-II 4220. Sponsored´s protocol code: CINC424B2401. Sponsored by: Novartis Farmaceutica S.A. Signed date: 03/01/2017
Sáenz de Pipaón Marcos M. Estudio multicéntrico, aleatorizado, doble ciego controlado con placebo para evaluar la eficacia y seguri-
dad del uso de NTRA-2112 para tratar la mala absorción intestinal causada por inmadurez gastrointestinal en niños prematuros. Type:
Clinical Trial, phase III.
HULP code: ANEXO-II 4231. Sponsored´s protocol code: FIT-EU-04. Sponsored by: Nutrinia Ltd. Signed date: 19/10/2017
Arribas López JR. Estudio de fase III, aleatorizado, controlado con tratamiento activo y abierto para evaluar el cambio de tratamiento
a un régimen en un solo comprimido administrado una vez al día de darunavir/cobicistat/emtricitabina/tenofovir alafenamida (C/C/F/
TAF) frente a la continuación del régimen actual formado por un inhibidor de la proteasa potenciado (IPP) combinado con emtricitabi-
na/tenofovir disoproxil fumarato (FTC/TDF) en sujetos infectados por el virus de la inmunodeficiencia humana de tipo 1 (VIH-1) con
supresión virológica. Type: Clinical Trial, phase III.
HULP code: ANEXO-II 4300. Sponsored´s protocol code: TMC114IFD3013. Sponsored by: Janssen-Cilag España S.A. Signed date: 27/05/2017
Martín Arranz MD. Estudio de fase III, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia
y la seguridad de SHP647 como tratamiento de inducción en sujetos con colitis ulcerosa de moderada a grave (Fígaro UC 302). Type:
Clinical Trial, phase III.
HULP code: 4971. Sponsored´s protocol code: SHP647-302. Sponsored by: Shire Human Genetic Therapies Inc. Signed date: 28/12/2017
Redondo Sánchez A. Estudio de fase III, aleatorizado y en doble ciego, del tratamiento de mantenimiento con niraparib frente a placebo
en pacientes con cáncer de ovario sensible al plantino. Type: Clinical Trial, phase III.
HULP code: ANEXO-II 3996. Sponsored´s protocol code: PR-30-5011-C. Sponsored by: Tesaro Inc. Signed date: 20/01/2017
Bernardino de la Serna JI. Estudio de fase IIIB, abierto y aleatorizado para evaluar el cambio de una pauta con tenofovir disoproxil
fumarato (TDF) por una combinación en dosis fijas (CDF) de elvitegravir/cobicistat/emtricitabina/tenofovir alafenamida (E/C/F/TAF) en
sujetos 60 años infectados por el VIH 1 con supresión virológica. Type: Clinical Trial, phase IIIb.
HULP code: ANEXO-I 4745. Sponsored´s protocol code: GS-US-292-1826. Sponsored by: Gilead Sciences Inc. Signed date: 10/04/2017
Frank García A. Estudio de extensión, multicéntrico, aleatorizado, con dos periodos, doble ciego controlado con placebo y abierto, para
determinar la seguridad y tolerabilidad a largo plazo de JNJ-54861911 en sujetos en el espectro de enfermedad de Alzheimer temprana.
Type: Clinical Trial, phase II.
HULP code: ANEXO-II 4437. Sponsored´s protocol code: 54861911ALZ2004. Sponsored by: Janssen Cilag International NV. Signed date: 01/06/2017
Feliú Batlle J. Elección de terapias personalizadas en pacientes con carcinoma de páncreas metastásico de acuerdo al análisis genético
del tumor y al modelo avatar. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4607. Sponsored´s protocol code: ERCAVATAR2015. Sponsored by: Hospital Universitario de Fuenlabrada. Signed date: 24/10/2017
Escribano Palomino E. Inmunogenicidad y seguridad de una dosis de recuerdo de Infanrix Hexa® (217744) de GSK biologicals en
niños sanos nacidos de madres vacunadas con Boostrix® en el embarazo o en el posparto inmediato. Type: Clinical Trial, phase IV.
HULP code: ANEXO-I 4613. Sponsored´s protocol code: 201334 BOOSTRIX-049. Sponsored by: Glaxosmithkline S.A. Signed date: 05/04/2017
56
Redondo Sánchez A. Estudio de fase II aleatorizado de MLN0128 (inhibidor doble de TORC1/2), MLN0128 + MLN1117 (inhibidor de
PI3K), paclitaxel semanal, o la combinación de paclitaxel semanal y MLN0128 en mujeres con cáncer de endometrio avanzado, recu-
rrente o persistente. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4614. Sponsored´s protocol code: C31004. Sponsored by: Millennium Pharmaceuticals Inc. Signed date: 06/07/2017
Pinto Marín A. Estudio exploratorio de fase II, abierto y con un solo grupo de tratamiento con afatinib oral en monoterapia tras el
fracaso a platino en pacientes con carcinoma urotelial avanzado/metastásico con alteraciones genéticas en los receptores ERBB. Type:
Clinical Trial, phase II.
HULP code: ANEXO-I 4632. Sponsored´s protocol code: 1200.261. Sponsored by: Boehringer Ingelheim España S.A. Signed date: 26/04/2017
Borobia Pérez A. Ensayo clínico estudio en fase I, en abierto, de dosis única y no randomizado para evaluar la farmacocinética (FC) y
la farmacodinámica (FD) de edoxabán en pacientes pediátricos. Type: Clinical Trial, phase I.
HULP code: ANEXO-I 4634. Sponsored´s protocol code: DU176B-A-U157. Sponsored by: Daiichi-Sankyo Development Limited. Signed date: 28/02/2017
Feliú Batlle J. Ensayo de fase III, multicéntrico y no enmascarado sobre el tratamiento de mantenimiento con avelumab (MSB0010718C)
frente a la continuación de la quimioterapia de primera línea en sujetos con un adenocarcinoma gástrico, o de la zona de unión gas-
troesofágica, irresecable, localmente avanzado o metastásico. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4643. Sponsored´s protocol code: EMR100070-007. Sponsored by: Merck KGAA. Signed date: 15/09/2017
de Castro Carpeño J. Estudio cesto, abierto, multicéntrico, global, en fase II con entrectinib para el tratamiento de pacientes con tu-
mores sólidos localmente avanzados o metastásicos que albergan reordenaciones en los genes NTRK1/2/3, ROS1 o ALK. Type: Clinical
Trial, phase II.
HULP code: ANEXO-I 4648. Sponsored´s protocol code: RXDX-101-02. Sponsored by: Ignyta Inc. Signed date: 21/07/2017
Redondo Sánchez A. Estudio de fase III, multicéntrico, aleatorizado, abierto de avelumab (MSB0010718C) en monoterapia o en combi-
nación con doxorubicina liposomal pegilada frente a doxorubicina liposomal pegilada en monoterapia en pacientes con cáncer de ovario
refractario/resistente a platino. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4652. Sponsored´s protocol code: B9991009. Sponsored by: Pfizer Inc. Signed date: 21/07/2017
Martínez Marín V. Caracterización del riesgo de trombosis en pacientes con cáncer. Estudio Cartago. Type: EPA-SP.
HULP code: ANEXO-I PI-2849. Sponsored´s protocol code: AJT-ACO-2016-01. Sponsored by: Trujillo Santos, Antonio Javier. Signed date: 15/12/2017
Alonso Melgar A. Estudio de grupo único de ALXN1210 en pacientes adultos y adolescentes con síndrome hemolítico urémico atípico
(SHUA) sin tratamiento previo con inhibidores del complemento. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4739. Sponsored´s protocol code: ALXN1210-aHUS-311. Sponsored by: Alexion Pharmaceutical Inc. Signed date: 05/05/2017
Antorrena Miranda MI. Manejo de edoxaban en procedimientos diagnósticos y terapéuticos. Estudio Emit-AF/VTE. Type: EPA-SP.
HULP code: ANEXO-I PI-2679. Sponsored´s protocol code: DSE-EDO-2016-02. Sponsored by: Daiichi-Sankyo Development Limited. Signed date:
08/05/2017
Lara Lara M. ensayo de fase 3 de grupos paralelos, doble ciego, aleatorizado y controlado con placebo, para evaluar la eficacia y la
seguridad de ald403 administrado por vía intravenosa en pacientes con migraña crónica. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4755. Sponsored´s protocol code: ALD403-CLIN-011. Sponsored by: Alder Biopharmaceuticals Inc. Signed date: 02/06/2017
Martín Arranz MD. Etudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, prueba de concepto de ustekinumab en
pacientes con lupus eritematoso sistémico activo. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4765. Sponsored´s protocol code: CNTO1275CRD3005. Sponsored by: Janssen Cilag International NV. Signed date: 19/10/2017
García-Samaniego Rey J. Clínico estudio de fase III, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad y
eficacia de selonsertib en pacientes con esteatohepatitis no alcohólica (EHNA) y fibrosis en puentes (F3). Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4785. Sponsored´s protocol code: GS-US-384-1943. Sponsored by: Gilead Sciences Inc. Signed date: 30/03/2017
García-Samaniego Rey J. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia
de selonsertib en pacientes con cirrosis compensada debida a esteatohepatitis no alcohólica (EHNA). Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4786. Sponsored´s protocol code: GS-US-384-1944. Sponsored by: Gilead Sciences Inc. Signed date: 21/08/2017
Rodríguez Salas N. Tratamiento preoperatorio de inducción con 12 semanas de panitumumab combinado con folfox 6m en una po-
blación enriquecida (Quádruple Wild-Type) de pacientes con cáncer de recto de tercio medio MRT3 y fascia mesorrectal no invadida.
Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4835. Sponsored´s protocol code: GEMCAD-1601. Sponsored by: Grupo GEMCAD. Signed date: 23/06/2017
Dalmau González-Gallerza R. Estudio multicéntrico tipo probe (prospective, randomized, open, blinded for the end-point evaluators):
prospectivo, aleatorizado, abierto, ciego para el evaluador, para comparar la adherencia a largo plazo de las medidas de prevención
secundaria tras un síndrome coronario agudo después de un programa de rehabilitación cardiaca intensivo de menor duración frente
a un programa estándar. Type: NO-EPA.
HULP code: ANEXO-I FIB-022. Sponsored´s protocol code: FIB-022. Sponsored by: Fundación Casa del Corazón. Signed date: 25/04/2017
Martín Arranz MD. Registro no intervencionista de larga duración para evaluar la seguridad y la efectividad de humira (Adalimumab)
en pacientes con colitis ulcerosa (CU) de actividad moderada a grave (Legacy). Type: EPA-LA.
HULP code: ANEXO-I PI-1629. Sponsored´s protocol code: ABB-ADA-2013-01. Sponsored by: Abbvie Spain S.L.U. Signed date: 04/10/2017
Bajo Rubio MA. Estudio de la enfermedad de Fabry en pacientes en diálisis peritoneal. Type: NO-EPA.
HULP code: ANEXO-I PI-1920. Sponsored´s protocol code: GSS-FBZ-2014-04. Sponsored by: Sanofi Aventis S.A. Signed date: 30/05/2017
Pascual Pascual SI. Ensayo multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar los efectos del fosfato sódico
de dexametasona intra-eritrocito en los síntomas neurológicos de pacientes con ataxia telangiectasia. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4598. Sponsored´s protocol code: IEDAT-02-2015. Sponsored by: Erydel S.P.A. Signed date: 13/03/2017
Álvarez Román MT. Estudio multicéntrico de fase II, abierto, de un solo brazo, prospectivo, intervencional, del factor derivado del
plasma VIII/VWF (Alphanate®) en la terapia de inducción de tolerancia inmune en sujetos con hemofilia congénita A. Type: Clinical Trial,
phase II.
HULP code: ANEXO-I 4655. Sponsored´s protocol code: GBI1406. Sponsored by: Grifols S.A. Signed date: 06/04/2017
57
 2
Executive Summary

2.7 • W-2D tube system with a data matrix codification for availability and transfer of samples associated with the

Platforms liquids, with a scanner to read col boxes and reader for
the identification and the traceability of the tubes
• Combined refrigerator of 4º C y – 20º C
biobank.
• Training of trainees (FCTs) of training cycles.
Sample/collection management:
• Cryostat to cut frozen samples
• Coordinating a collection of samples in multiple study/
• Microtome y bath/coating to cut paraffin samples research centers
• Laser Microdissector • Storage of pre-existing collections under LIB 14/2007.
• Biological safety cabins IIA • Storage of preexisting samples in accordance with Spain’s
• Centrifuge with capacity to process samples in tubes and Biobank laws LIB 14/2007 and 1716/2011 Royal Decree

2.7.1.
Eppendorfs
• Management and control of Informed Consent (CI) and/
• Automatic platform to manipulate and trace liquids or clinic’s regarding samples
• Automatic nucleoids acid extractors. DNA and ARN
Biobank from blood and frozen tissue or in paraffin
• Aliquot of blood/salines/plasma/other liquids
• Sample reception and codification
• One mini coolers to freeze inclined biological samples
IdiPAZ’s Biobank main objective is to promote biomedical research, which will increase below 1ºC Histology techniques:
and enhance the quality of scientific production in Spain. • Two containers to freeze and transport Isopentane • Making paraffin block
Biobank’s work is specialized in the management of human biological samples for bio- • One container for the transport of isopentame samples • Making frozen tissue blocks
medical research (register, processing, storage and final assignment) in compliance with • Two pairs of gloves to work in low temperatures • Paraffin/frozen cuts
Spain’s present legislation Law14/2007 on Biomedical Research and the Royal Decree • Two pairs of cryogenic work gloves • Hematoxylin and eosin stain (H&E)
of Biobanks 1716/2011.Thus the confidentiality of the samples and associated data will • Other kinds of stains
• Vortex Mixer /agitator
be guaranteed.
• Spectrophotometer (Nanodrop®) • Laser microdissection
The Biobank participates through the central node and peripheral nodes in various • One set of automatic micropipettes
cooperative network structures (IDINET Platform). It is also part of the Hospitals
Cell techniques:
• One automatic electronic pipette • Purifying and freezing of mononuclear cells of peripheral
Network (RetBioH), created in January 2010, through which we participate in the
• Fungibility: basically kits and the necessary products to blood (PMBCs)
European platform called Biobanking and Biomolecular Resources Research Infras-
process and preserve tissues, blood, cells, DNA and ARN Molecular Techniques:
tructure (BBMRI).
• Printer/photocopier/scanner • DNA and RNA blood extraction
IdiPAZ’s Biobank also offers the scientific community the use of its equipment and the • 3 computers and a management computer system
support of its professionals through an extensive offer of samples and services. • DNA and RNA extraction from frozen tissue and paraffin
• Label printing system and a bar code reader connected • DNA and RNA quantification via spectrophotometer
to the management software
COMPOSITION (NANODROP)
Researchers who wish to deposit their collections in IdiPAZ’
Science Coordinator:
Biobank will have to sign an agreement of sample deposit (in
Paloma Gómez Campelo
which the terms and conditions under which the Biobank will
Coordinator of Professionals/Experts: deposit the samples) and in agreement with the existing legis-
Marina Arranz Álvarez lation on the subject.
Senior Experts in Pathology and Cytology: On the other hand researchers who wish to use our sam-
Cristina Salinas Sánchez ples will have to sign a Transfer Agreement (Material Transfer
Fabiola Guillén Cardeñosa Agreement) in which the terms and conditions under which
Contact: the Biobank will grant the samples.
Email: biobanco.hulp@salud.madrid.org
Email: biobanco@idipaz.es BIOBANK’S SCIENTIFIC
Phone: Biobank Laboratory (+34) 91 207 11 91 INDICATORS
Scientific Committee In the year 2017, Biobank IdiPAZ has worked on 35 research
• David Hardisson Hernáez projects funded by Spanish State aid, private foundations, in-
• Francisco Arnalich Fernández dustrial companies or cooperatives such as the National Net-
• Inmaculada Ibáñez de Cáceres
PORTFOLIO OF SERVICES work of Hospital Biobanks (RetBioH). The principal resear-
chers of these projects belonged to IdiPAZ research groups
• Enrique Espinosa Arranz Technical and scientific assessment: and to external, national and international groups. Of these
• Eduardo López Granados • Collection and management of new collection projects and together with the central node of the biobank, a
• Work Methodology/ Methods total of 3,647 new samples have been stored, generating more
EQUIPMENT • Quality control of DNA/ARN sample treatment than 11,500 aliquots.
• Eight -80ºC deep freezers equipped with remote alarm temperature control and a • Expert training to use Biobank management system During the same period 22 requests for samples were pro-
CO2 backup system. Seven of these are equipped with an open door control software • Training and advice on the use of Biobank management cessed and a total of 1,984 samples were assigned, maintaining
• One tank of liquid nitrogen at its gas phase with an alarm temperature control and software (Bio-e-Bank). the demand for samples and increasing the opening of new
a lack of CO2 detector • Information to the investigator on the custody, deposit, projects.

58 59
 2
Executive Summary
2.7 Platforms

2.7.2.
UCICEC
La Paz Central Research and Clinical Trials Unit (Unidad Project Manager Paediatrics Oncology Trials
Central de Investigación Clínica y Ensayos Clinicos de La Mario Muñoz
Paz, HULP-UCICEC), is one of the IdiPAZ supported plat- Email: mmunoz.amm@gmail.com
forms of investigation. Its purpose is to promote and sup-
port clinical research at La Paz University Hospital and to Senior Clinical Research Associate
establish collaboration links with other investigation cen- Guiomar Rodríguez Beloso
tres. Presently HULP-UCICEC is integrated in the Spanish Email: guiomar.rodriguez@idipaz.es
Clinical Research Network (SCReN). Vega Mauleón Martínez
Its wide portfolio of services provides support to resear- Email: vega.mauleon@idipaz.es
chers in design, set-up (including IRBs and Competent
Authority approvals), management, data analysis and re- Junior Clinical Research Associate
port writing of clinical trials and research projects. As Trials Elena Arconada Luque
Managers, assists the Principal Investigators in the prepara- Email: e.arconadaluque@gmail.com
tion of feasibility and financial reports, administrative tasks
(i.e., investigators coordination, schedule of visits), as well
as projects development and research, particularly in the
recruitment and follow-up of patients and data collection,
assistance in audit, inspections and adverse drug reactions
management according to regulatory procedures, among
other tasks. We also perform nursing activities and labo-
ratory management, obtaining, processing and shipping the
samples to central laboratories. All operations are GCP
compliant as needed.
HULP-UCICEC also runs a Phase I-II Trial Unit; the faci-
lities and equipment allows harbour early phase clinical
• Phase I/II Clinical Trial Unit: PORTFOLIO OF SERVICES
- A hospital ward with eight beds and four chairs The portfolio of services includes more than 80 tasks grouped
trials both in healthy volunteers and patients (children and
(children and adults) into:
adults).
- 1 Doctor’s office • Methodologic support
COMPOSITION - 1 Central point for sample collection • Clinical trial pre-study activities
- 1 Sitting room • Study development
Head Bioinformatic • Carlos III Satellite Unit
Jesús Frías Iniesta • Finalization and closure tasks
Jose Carlos Martínez Ávila - 1 Work office and doctor´s office
Email: jesus.frias@salud.madrid.org • Pharmacovigilance
Email: josecarlos.martinez.avila@idipaz.es - 1 Laboratory • Statistics and data management
UCICEC Manager Clinical Trials Nurses • Medical and nursing tasks
Alberto M. Borobia Vega Mauleón Martínez EQUIPMENT
Email: alberto.borobia@salud.madrid.org Email: vega.mauleon@idipaz.es • 1 ECG RESEARCH ACTIVITY
Phone: (+34) 91 207 14 66 • 1 Centrifuge (Carlos III Satellite Unit)
Raquel de Madariaga Castell During 2017, the platform has provided assistance and sup-
Scientific Coordinator E-mail: raquel.madariaga@idipaz.es • 2 Refrigerated centrifuge port in start-up, coordination, data-management, laboratory
Antonio J. Carcas • 1 Refrigerator management or nursing tasks in more than 140 commercial
Laura Vitón Vara (MSc)
Email: antonio.carcas@salud.madrid.org • 1 Room temperature chamber (Carlos III Satellite Unit) clinical trials of 46 Research Groups and more than 50 in-
E-mail: laura.viton@idipaz.es
• 3 -20ºC freezers (1 in Carlos III Satellite Unit) dependent clinical research projects. In this period, 11 audits
Safety and Pharmacovigilance Coordinators
Nursing supervisor • 2 -80ºC deep freezer have been conducted and have been successfully overcome.
Antonio J. Carcas
Elena Martín de Castro During 2017 UCICEC has been also certified to the ISO
Email: antonio.carcas@salud.madrid.org • 4 Vital signs monitors
Email: elena.martin@salud.madrid.org 9001:2008 standard.
Elena Ramírez • Defibrillator
HULP-UCICEC has also provided methodological support
Email: elena.ramirez@salud.madrid.org Receptionist /Clinical Trials Assistant • Temperature recording system
in almost 150 clinical independent projects, including advice
Cristina Miragall Roig • Digital clocks synchronised by GPS
Responsible for Pharmacovigilance on study requirements and documentation, protocol develo-
Email: cristina.miragall@salud.madrid.org • 2 medical scales (1 in Carlos III Satellite Unit)
Hoi Y. Tong pment and design and preparation of application reports for
Tel: (+34) 91 207 14 66 • Digital blood pressure monitors and pulse oximeters competitive projects.
Email: hoi.tong@idipaz.es
• Digital timers Finally, more than 10 early phase trials have been conducted
Project Manager / Senior Monitor FACILITIES • Crash trolley in our Phase I Unit.
Maria Posada Novoa • 3 Work offices (9 work stations) • 2 Cure trolleys
Email: maria.posada@idipaz.es • 1 Meeting room (with audiovisual and teleconference • Video surveillance system
Guiomar Rodríguez Beloso systems)
• 11 patient calling devices
Email: guiomar.rodriguez@idipaz.es • 1 Archive room
• 4 patient surveillance cameras

60 61
 2
Executive Summary
2.7 Platforms
2.7.3.
Experimental Surgery
The Experimental Surgery Section is a support unit for
research and teaching. In the research field, the Section de-
velops biomedical research projects and fine-tunes proce-
dures for new diagnostic and therapeutic techniques that
use laboratory animals. In the teaching field, the Section
organises and supports training courses in surgical, micro-
surgical, laparoscopic and anaesthetic techniques.
COMPOSITION
Section Head:
Juan José Vázquez Estévez
Email: jjose.vazquez@salud.madrid.org
Phone: (+34) 91 727 71 54
Veterinarian:
Carlota Largo Aramburu
Email: carlota.largo@salud.madrid.org
Phone: (+34) 91 727 15 81
Secretary:
Irene Cuevas Gordo
Email: Irene.cuevas@salud.madrid.org
Phone: (+34) 91 727 71 54
Technicians and assistants:
Javier Rubio Bolívar
Sonsoles Jiménez
Isabel Rodríguez
Mª Teresa Arranz
Pablo Llorente
Pedro Gallego
Domingo Ortega
Daniel Ruiz
EQUIPMENT
The Section consists of two microsurgery rooms, an ope-
rating room and an animal facility. The microsurgery room
has surgical loupes and microscopes, as well as inhalers
anaesthesia systems for rodents. All experimental proce-
dures with rodents are performed in this room. Its layout,
with fixed and mobile posts, allows for the implementation
of microsurgical and laparoscopic courses with simulators.
The operating room is equipped with double team surgical
tables and anaesthesia stations with monitoring equipment,
which allow for two surgeries to be performed simulta-
neously. It is also equipped with laparoscopic, ultrasound
and C-Arm X-ray equipment. All procedures performed
on large animals are carried out here, along with training
courses on surgical, laparoscopic and anaesthetic techni-
ques. The animal facility has a total of five rooms for con-
ventional accommodation of animals, in both the breeding
phase and for experimentation. Two of these rooms have
modular enclosures for housing large species such as pigs,
sheep and rabbits. The remaining three accommodate ro-
dents (rat, mouse and gerbil). The housing of rodents has
controlled ventilation systems (a ventilated rack for mice
and another for rats) and conventional systems in shelves.
It also has a sealed positive and negative pressure room.
62
ANIMAL FACILITY steel cages with plastic grids. They also have a box structu- ce of procedures with a table and surgical lamp, sur-
re inside that allows the animal to hide or go up to a higher gical cart, monitoring equipment and a C-arm X-Ray.
The research and teaching at IdiPAZ involving the use of
position. The stainless steel feeders and drinking water are • Store room (clean material).
laboratory animals is managed via the animal platform of
located in the cage door. Faeces and urine are collected in • Control room with computers for environmental
IdiPAZ, and is overseen by Dr. Carlota Largo Aramburu. In
an extractible stainless steel tray. This room has a central
this department we develop biomedical research projects, control.
drain with similar characteristics as those in the large ani-
training courses specific to the various specialties as well The animal facility complies with all current legislation and
mal room.
as procedures for putting in place new diagnostic techni- is registered with number ES-280790001941.
ques or therapies that involve the use of experimental ani- The rodent area is separated from the rest of the facility
mals. In addition, the animal facility works with the Ethics via a gate system (without locking doors) where staff can Contact:
Committee for Animal Wellbeing, whose authorisations is dress appropriately before entering (boots, robe, gloves, Carlota Largo Aramburu
hat and mask). In this area, 5 rooms are located for the
required for all procedures. Email: carlota.largo@salud.madrid.org
housing of rats and mice in both breeding and experimen-
The animal facility is located in basement 2 of the IdiPAZ Phone: (+34) 91 727 71 54
tal phases and a room for fish. There is a storeroom for
building within the hospital complex. The facility provides
feed and shavings and a room for handling and the perfor-
a total of 10 rooms for animal housing, in both breeding
mance of procedures.
PORTAFOLIO OF SERVICE
and experimental phases, two rooms for animal handling
In addition to two large areas of animals, the animal facility • Animals for experimentation (own breeding)
and experimental procedures, a room for washing material,
which includes a cage washer, an autoclave and a pressure- includes: • Housing and maintenance of animals
based washing system, and several storage rooms for clean • A washroom equipped with a cage washer (Hobart), • Leasing of spaces for conducting courses (microsur-
materials, feed and wood shavings for cages. In addition, a stainless steel pool and an autoclave. It also has a gery laboratories and operating room)
for its proper functioning, the animal facility is connected pressure wash system for cleaning the cages and/or • Performance of surgical procedures on large animals
with the rest of the departments of Experimental Surgery visits that require it. (leasing space and anaesthesia, does not include sur-
where there is a double operating theatre, a microsurgery • A room for handling large animals for the performan- gery)
room and various additional rooms (dressing areas, offices,
and store rooms).
The species typically used include: rodents (rats, mice and
gerbils), rabbits, pigs, sheep and goats, and occasionally
dogs, cats or guinea pigs. Recently, a fish housing unit has
been established (zebra fish). To avoid contamination and
permit a good workflow, the rooms for housing of large
animals are physically separated from those for the rodents
and the rest of the facilities (washing area, store rooms,
or the handling room). In addition, all the rooms include
an external video camera system to monitor the interior
while avoiding the unnecessary entrance of unauthorised
personnel.
The cages provide the minimum dimensions required for
housing pigs and/or small ruminants. The structure of each
cage is includes stainless steel anchored to the wall, with
sliding separators that allow the expansion of the space by
uniting two cages.The rooms have the slope needed to en-
courage the elimination of solid residue via a drain located
in the rear of the cage. All of the drains are equipped with
protection systems to prevent the entrance of rodents or
insects. For the cleanliness of the room and the animals,
there are hot and cold water connections via a hose.
The rabbit room includes modular mobile crate racks of
3, 6 or 9 cages. The rabbits are kept in individual stainless
63
 2
Executive Summary
2.7 Platforms

2.7.4.
Simulation Platform (CEASEC)
OBJECTIVES Secretary Governing Council: School Courses Simulation (Summary)
The IdiPAZ/FIBHULP Simulation Centre offers professio- Ana Coloma Zapatero
nals from various fields the following possibilities: Estela Sánchez Simón Course Director length
• Learning and training on the approach for patients Contact: Curso RCP Básico Dr. Manuel Quintana 16 de enero
in critical clinical conditions: cardiopulmonary resus- Irene Cuevas Gordo Dr. Juan Pedro Pérez Robledo
citation, shock of various origins, acute respiratory Suturas y Cirugía Menor 24 y 25 de enero
Email: irene.cuevas@salud.madrid.org Dr. Joaquín Díaz Domínguez
failure of various aetiologies, multiple trauma, arr- Phone: (+34) 91 727 71 54 SIMUVAD 2017 Dr. Pedro Garrido 10 y 11 de febrero
hythmias, complicated births, difficult airways, safety, Dr. Javier Arias Gallo
and leadership. Clinical Simulation Technician: Curso de Microcirugía Experimental y Colgajos
Dra. María José Morán Soto 13 al 17 de febrero
• Ongoing training of teams who treat patients in Javier Rubio Bolívar Microvasculares en la Rata
Dr. Javier González Martín-Moro
critical conditions: ICU, anaesthesia, emergency de- Dr. Javier Murcia
partment, surgery. Activity of CEASEC II Curso de Cirugía Control de Daños
Dr. Juan Vázquez Estévez
23 de febrero
• Learning and training on managing patients with tech- CEASEC is the Advanced Clinical Training and Simulation Dr. Francisco Reinoso
nology-dependent conditions: mechanical ventilation, Center. During 2017, the CEASEC activity has highly in- Curso de CRM en Anestesia y REA 27 de febrero
Dr. Juan Vázquez Estévez
extracorporeal membrane oxygenation, dialysis, hae- creased by 31 % compared to 2016. The platform has pro- Curso de Asistencia Inicial al Trauma Pediátrico (AITP) Dr. José Antonio Ruiz Domínguez 16 y 17 de marzo
modialysis and haemofiltration and external ventri- vided assistance and support for research and teaching in RCP Básico + DESA Dr. Manuel Quintana 20 de marzo
cular assistance. more than 50 courses.
Reanimación cardiopulmonar pediátrica y neonatal Dr. Miguel del Río García 21,22 y 23 de marzo
• Learning and training on managing technology for
diagnostic and therapeutic use: echocardiography, ab- RCP Básico + DESA Dr. Manuel Quintana 28 de marzo
dominal ultrasonography, catheterisation, laparosco- Atención al paciente pediátrico grave en el servicio de urgencias
Dr. José Antonio Ruiz Domínguez 29 de marzo
pic surgery, bronchoscopy, laryngoscopy, endoscopy (CRM - Crisis resources)
and colonoscopy. SIMUMED 2017 Dr. Pedro Garrido 30 y 31 de marzo
• Learning the use of invasive techniques: arterial and IX Curso de Ecografía en el Paciente Pediátrico Crítico Dr. Juan José Menéndez Suso 4, 5 y 6 de abril
central venous cannulation, nasogastric and vesical RCP Básico + DESA Dr. Manuel Quintana 7 de abril
catheterisation, suturing, thoracentesis, paracentesis,
Shock 2017 - Madrid Dr. Emilio Maseda Garrido 21 de abril
tracheostomy, nerve blocks.
RCP Básico Instrumentalizado Pediátrico Dr. José Antonio Ruiz Domínguez 26 de abril
• Learning to perform a correct medical history re-
view and physical examination and communicating XXXI Curso Nacional Práctico Multidisciplinario de Microcirugía
Dr. César Casado Sánchez 24, 25, 26, 27 y 28 de abril
and contacting patients, using actors and advanced Vasculo Nervioso y sus Aplicaciones Clínicas.
simulators. Dr. Javier Arias Gallo
Curso de Microcirugía Experimental y Colgajos Microvasculares
Dra. María José Morán Soto 22,23,24,25 y 26 de mayo
en la Rata
Dr. Javier González Martín-Moro
COMPOSITION
CRM Cuidado Críticos Adultos Dr. Manuel Quintana 29 de mayo
Governing Council Atención al paciente pediátrico grave en el servicio de urgencias
Javier Cobas Gamallo Dr. José Antonio Ruiz Domínguez 7 de Junio
(CRM - Crisis resources)
Ana Coloma Zapatero II Curso endoscopia endonasal de base de cráneo: Cirugía en
Carlota Largo Aramburu Dr. Carlos Pérez López 22 de junio
directo y desección endoscópica en rata Wistar
Elena Martín de Castro Atención al paciente pediátrico grave en el servicio de urgencias
Dr. José Antonio Ruiz Domínguez 4 de octubre
Juan Vázquez Estévez (CRM - Crisis resources)
Juan José Pérez Blanco Soporte Vital Avanzado Dr. Manolo Quintana 17 de octubre
Manuel Quintana Díaz REA Pulmonar Dr. Miguel del Río García 18,19 y 20 de octubre
Pedro de la Oliva Senovilla Curso MACTAC Dr. Juan José Vázquez Estévez 20 de octubre
Ramón Cantero Cid Curso de Asistencia Inicial al Trauma Pediátrico (AITP) Dr. José Antonio Ruiz Domínguez 2 y 3 de noviembre
Ana Mª Sánchez Torres X Curso de Ecografia en el Paciente Pediátrico Crítico Dr. Juan José Menéndez Suso 6, 7 y 8 de noviembre
Emilia Guash Arévalo RCP Pediátrico Dr. Miguel del Río 22,23 y 24 de noviembre
Esteban López de Sá y Areses Dr. Juan Vázquez
Ignacio Zapadiel Gutierrez III Curso Cirugía Control de Daños 23 de noviembre
Dr. Javier Murcia
Esther Rey Cuevas RCP Pediátrico Miguel del Río 22,23 y 24 de noviembre
Juan José Ríos Blanco Soporte Vital Inmediato Dr. César Carballo 27 y 28 de noviembre
Dolores Elorza CRM Anestesiología Pediátrica Dr. Francisco Reinoso 30 de noviembre
Chairman Governing Council Dr. Juan Vázquez
Formación Continua en Transplante Pediátrico 12 de diciembre
Juan Vázquez Estévez Dr. Francisco Hernández
Manuel Quintana Díaz Curso de microciurgía vascular cerebral y By-Pass Extra 13,14, 15, 16 y 17 de
Dr. González Llanos
Miguel del Río García Intracraneal diciembre

64 65
 2
Executive Summary
2.7 Platforms
2.7.5.
Cell Culture Unit
PRESENTATION
The Cell Culture Unit is established as a core support
division integrated into the Health Research Institute of
the University Hospital La Paz (IdiPAZ). This platform is a
fundamental basis for the development of research initia-
tives that use cell culture-related technologies as experi-
mental tools for the prevention, diagnosis and treatment
of various pathologies in disciplines such as Biomedical and
Pharmacological Research or Health Sciences. This unit
facilitates the employment and development of in vitro
model systems and experimental techniques, helping to
elucidate the molecular and cellular mechanisms involved
in a biological process, as well as to predict cellular and
tissue responses to a specific microenvironment and/or to
identify and develop novel drugs and therapeutic targets.
The Cell Culture Unit accomplishes its mission by pro-
viding users with assistance at scientific and instrumental
level through access to knowledge, equipment, material
and human resources. According to IdiPAZ strategic plan
and other institutional guidelines, this division contribu-
tes to the translation of biomedical research by fostering
the synergies and cooperation between clinic- and basic-
oriented research groups belonging to IdiPAZ as well as to
external institutions. It also provides a dynamic and shared
operational environment offering a convenient basis for
empowering scientific knowledge, dissemination, innova-
tion and creativity as well as the creation of synergies and
alliances between researchers of various categories and
disciplines. Moreover, the close collaboration and physical
proximity with other facilities such as the Imaging and Flow
Cytometry Unit, enables us to address innovative insights
and to apply inventive methods to obtain a detailed study
and characterization at cellular and molecular level.
COMPOSITION
Head:
Gema Vallés Pérez
Email: gema.valles@salud.madrid.org
Phone: (+34) 91 727 70 00 (ext. 1576)
Technical Support:
Beatriz Sanz Minguela
Phone: (+34) 91 727 70 00 (ext. 2142)
Secretary:
Susana García Pérez
Email: investigacion.hulp@salud.madrid.org
Phone: (+34) 91 207 15 12
EQUIPMENT AND FACILITIES
The Cell Culture Unit consists of an experimentation la-
boratory, a cryopreservation room and a warehouse. All
facilities are located in the IdiPAZ building.
The experimentation laboratory is fitted with the fo-
llowing equipment:
Cabinets:
3 Telstar Bio-II-A biological safety cabinets
66
2 Nuaire NU-437-400E biological safety cabinets
1 Heraeus HS-12 biological safety cabinets
1 Faster BH-EN 2004 biological safety cabinet
1 Gelaire BSB 4A biological safety cabinet
1 Esco Class II BSC biological safety cabinet
3 Faster BIO 48 vertical laminar flow cabinets
1 Faster TWO 30 vertical laminar flow cabinet
Incubators:
3 Thermo Forma Scientific incubators
2 HERAcell incubators
2 Biotech Galaxy S incubators
2 Nuaire Autoflow incubators
1 Sanyo O2/CO2 incubator
This equipment is complemented with a centralized
and alarmed gas system, which guarantees a constant
and controlled supply of CO2 and N2.
Microscopes:
1 Nikon DIAPHOT TMD inverted light microscope
connected to a Nikon D80 digital camera.
1 Leica DMIL inverted light microscope connected to
a Canon Powershot S70 digital camera.
1 Optika inverted light microscope
1 Motic AE2000 inverted light microscope connected
to an automatic counter Celeromics
1 Lan Optics inverted light microscope
Centrifuges:
2 Eppendorf 5810R refrigerated centrifuges
2 Eppendorf 5804 centrifuge
1 Hettich Universal 32R refrigerated centrifuge
1 Kubota 2010 centrifuge
Cell Separation System:
1 Milteny Biotec autoMACS cell separation system
Freezing systems:
1 Liebherr refrigerator (4 ° C and -20 ° C)
1 Balay refrigerator (4 ° C and -20 ° C)
1 Whirlpool refrigerator (4 ° C and -20 ° C)
1 Beko refrigerator (4 ° C and -20 ° C)
Other equipment:
1 Presoclave 75 P-Selecta autoclave
1 Millipore water purification system
1 Heidolph Reax 2000 vortex
1 Raypa thermostatic waterbath
1 Memmert thermostatic waterbath
2 Precisterm thermostatic waterbath
1 Grant JB Aqua 12 Plus thermostatic waterbath
Vacuum pumps, pipettes, counters, automatic pipettors,
freezing containers, cell counting cameras, etc ....
The cryopreservation room is equipped with:
2 Statebourne Biorack 3000 liquid nitrogen tank
1 Thermo Locator 6 Plus liquid nitrogen tank
1 10 K Taylor Wharton liquid nitrogen tank
1 MVE cryosystem 4000 liquid nitrogen tank
1 Cryo Diffusion B2016 liquid nitrogen tank
1 Cryo Diffusion B2048 liquid nitrogen tank
1 Cryo Diffusion B2011 liquid nitrogen tank
1 SEO GT40 liquid nitrogen tank
1 MVE XLC 511 liquid nitrogen tank
The infrastructure for cryopreservation is com-
pleted with a liquid nitrogen transfer device and
an alarmed Oxygen O2 detector coupled to a
mechanical ventilation system.
PLATFORM OPERATING
STANDARDS
The Cell Culture Unit works as a support structure for
biomedical research, and therefore provides technical as-
sistance and scientific consultation to researchers who
request their services. With regard to facilities and equi-
pment available, associated staff will be responsible for
their proper maintenance and operation and will provide
support and supervision to users in order to obtain op-
timal utilization and exploitation. This Unit is oriented to
specialized training, exchange and dissemination of scien-
tific knowledge and an active collaboration with users to
develop cell culture-related procedures and technology.
This service aims not only to meet the needs of IdiPAZ
researchers but also provide adequate support to non-
IdiPAZ scientists that do not have specific facilities to
perform their cell culture experimentation. Users (from
the IdiPAZ or other facility or institution) who request
services for the first time or who demand additional infor-
mation, please contact to the Head of the Platform.
All users must respect the internal rules of the Service, the
established principles of prevention, health and safety, gui-
delines on handling and management of reagents, materials
and waste disposal in addition to operating instructions
and procedures for instruments and equipment.
PORTFOLIO OF SERVICES
The Cell Culture Platform activities focused on providing
users with flexible and results-oriented services in a colla-
borative and translational research framework. In general,
this Division offers support for experimental approaches
developed by IdiPAZ and non-IdiPAZ scientists on an ex-
tensive range of matters including cell experimentation,
consumables and reagents, equipment and laboratory area,
technical assistance, training and research.
The specific support provided by this Unit includes:
- Scientific and technical advice, personalized support
and consultation: guidance in experimental setup and
design, study planning, optimization of techniques and
protocols, reagents and material acquisition, cells supply,
troubleshooting, analysis and interpretation of results…
- Basic training and hands-on experiments (implementa-
tion of the self-service mode) according to biosafety,
waste disposal and good laboratory practice guidelines.
- Access to specific facilities including instrumentation,
equipment, materials and reagents.
- Preparation and supply of certain materials, reagents
and sterile solutions.
- Management and general supervision including good
laboratory practices and work habits, maintenance,
cleaning and waste disposal and operation and mainte-
nance of the equipment.
- Performance of experimental procedures: cell separa-
tion, cell isolation for cultivation, maintenance and pro-
pagation of cell lines and primary cultures, cryopreser-
vation and resuscitation, viability and proliferation, etc.
- Control and maintenance of cryopreserved stock cells.
- Elaboration and management of protocols and guideli-
nes, operating procedures, reports and other required
mandatory documentation.
- Detection, identification and treatment of contamina-
tions in cell cultures.
Besides to these standard services, this platform offers
collaboration with individual researchers as an effective
way to improve and to expand the portfolio of techno-
logy and services offered. Furthermore, and as part of its
commitment to warrant users the optimal development of
their research projects, the contact to other centralised
equipment and affiliated facilities, infrastructures and com-
mon equipment is also provided.
Pricing services available on the web: http://www.idipaz.es/
PaginaDinamica.aspx?IdPag=191&Lang=EN
67
 2
Executive Summary
2.7 Platforms
2.7.6.
Sanger Sequencing Facility
Presentation
The main role of the Sanger sequencing laboratory is to
provide support for medical research.The goal is to increa-
se the volume and quality of scientific results in a number
of research groups both inside our Institute and elsewhere.
Our laboratory is located inside INGEMM. This allows for
frequent interactions with the hospital’s various research
groups, and thus allows for the laboratory members to
stay up to date on state-of-the-art techniques in genetics.
Therefore, the laboratory is an translational-
research model.
Nowadays, the Sanger sequencing method is
regarded it as the gold standard for validation
of Next-Generation Sequencing single nucleo-
tide variants.
In order to achieve the goals stated above, our
laboratory owns the necessary equipment and
infrastructure for performing tasks such as con-
ventional sequencing (Sanger method), marker
DNA genotyping, and other molecular biology
techniques based on capillary electrophoresis.
The equipment can use up to 5 simultaneous
colours on the same sample when it migra-
tes into the genetic analysers. Therefore, we
are able to detect more than 30 polymorphic
markers per sample. In addition, the laboratory
equipment allows us to carry out extractions
of DNA and RNA.
The laboratory is regularly involved in quality
control audits on the Sanger sequencing and
genotyping, as well as result homologation. Such audits are
performed at both national and international levels (e.g.,
EMQN).
COMPOSITION:
Lab Manager:
María del Rocío Mena de la Cruz
Email: mariarocio.mena@salud.madrid.org
Technician:
María Victoria Gómez del Pozo
Email: mgdelpozo@salud.madrid.org
EQUIPMENT:
Devices:
• Eppendrof 5415D Centrifuge.
• Veriti Termocycler(Applied Biosystems).
• Gerentics Analyzers 3130xl y 3730xl, (Applied
Biosystems-Life Technologies).
Software:
• Sequencing Analysis v5.3.1
• Sequence Scanner v1.0
• GeneMapper v4.0
• Peak Scanner v1.0
• Variant report v1.0
68
2.7.7.
Portfolio of services
• Nucleic Acid quantitation (Tecan).
• PCR purification for Sanger sequencing (Exosap).
• Sanger Sequencing.
• Fragments Analysis:
- QF-PCR
- MLPAs
- MSI
- Fragil-X Syndrome testing
Research Activities:
During 2017 our laboratory has supported eleven IdiPAZ´s
research groups, and one external research group.The clo-
se interaction with these users has enabled us to contribu-
ted with them at different levels: from initial brainstorming
as research staff, to sample processing in fields such as
rare disease, microbiology, genotyping cellular, immunology,
oncology, etc. The collaboration of our laboratory´s staff
with two of these groups has led to the authorship of one
original article, besides other thirty articles thanks to our
sequencing services, as well as the development of a the-
sis. Moreover, our participation in several international and
national congresses during the last year, has allowed us to
be updated in new techniques.
Image Laboratory
Presentation
Image Unit is a shared cen-
tralized research unit inte-
grated by the Microscopy
laboratory and the Immu-
nohistochemistry labora-
tory and located in the Idi-
Paz building at the La Paz
University Hospital. The
Image Unit supports many
of the research projects
using animal or patient tis-
sue or cellular samples. It
provides researchers with
access to the equipment
and expertise in histology,
imaging and analysis that Technician
enable high quality data interpretation to support grant Paula Sánchez Gismera
applications and national and international scientific pu-
Phone: (+34) 91 727 75 26
blications. The laboratory mission is encompassed in the
continuation and improvement of designing integrated his- Secretary:
tology, immunohistochemistry and imaging protocols for Susana García Pérez
animal and pre-clinical studies. The objectives are based Email: investigacion.hulp@salud.madrid.org
on technical quality and innovation criteria to improve the Phone: (+34) 91 207 15 12
laboratory’s facilities and the promotion of the Bioimaging
techniques applied to clinical and basic health science re-
RESEARCH HIGHLIGHTS
search. The platform offers complete flexibility and adap-
tability to the specific requirements of each by providing In 2017, the laboratory supported and collaborated with
high-end instruments, scientific and technical assistance in the groups belonging to the 6 research areas of IdiPAZ;
the histology and image analysis fields for Biomedical and Neurosciences, Infectious disease and immunity, Cancer
Health Sciences. and human molecular genetics, Cardiovascular, Organ sys-
The Unit aims to provide an extensive variety of techniques tem pathologies and Surgery, transplant and health tech-
ranging from routine histological to immunohistochemical nologies. In fact, the Operation Time in 2017 (calculated as
the total time of use per year of some equipment from
and immunofluorescence techniques in cells, whole or-
Microscopy lab and from immunohistochemistry) doubled
gans and frozen, fresh or embedded in paraffin tissues. The
the same one in 2016.
Microscopy section offers facilities to perform a range of
real time and end-point assays, including cell number, pro-
liferation, apoptosis, cell size, shape and viability measures,
cell migration and invasion. The platform, that allows to do
conventional, fluorescence, confocal and high-content mi-
croscopy, includes a Leica TCS SPE inverted confocal, Leica
DM6000 inverted fluorescence microscope, a microscope
inverted Nikon Eclipse Ti with in vivo incubation system,
an Olympus mycroscope connected to image analysis pro-
gramme, and two Zeiss microscopes connected to a digital
camera. In addition, the lab offers image analysis program-
mes (NIS Elements AR, Nanosight 3.1, LASAF, Image Pro-
Plus, ImageJ, and Huygens deconvolution confocality simu- The cooperation with other facilities provided by IdiPAZ
lator. The histology laboratory offers advice, protocols and and the rest of groups belonging Institute enables us to
automated high-throughput equipment allowing citospines, develop and implement new techniques and protocols. In
fixation techniques (paraffined or freezed), sectioning of addition, as observed in 2016, we have extended the num-
tissues (microtomes and cryostats), and classical or advan- ber of users inside Hospital La Paz (HULP, clinical and basic
ced immuno-staining (Dako Autostainer). researchers), associated IdiPaz groups (UAM), as well as
other research groups (UCM, CSIC etc).
COMPOSITION Our platform belongs to the Spanish Network of Advan-
ced Optical Microscopy. This allows us to implement the
Head
María Teresa Vallejo Cremades collaboration with other image core platforms and the
knowledge of recent advances in the field and supporting
Email: tvallejo.hulp@salud.madrid.org
Bioimaging techniques. During 2017, the platform has colla-
Phone: (+34) 91 727 75 26
69
 2
Executive Summary
2.7 Platforms

2.7.7.
Image Laboratory
borated in the achievement of the different scientific goals • Automated Immunohistochemistry autostainer (Au-
of the groups belonging to IdiPAZ, reflecting an increase tostainer Plus DAKO)
of publications of high impact required to obtain public • 2 Cryostat for frozen sectioning (Leica CM 3050S
funding (MICYNN, FIS, networks), private (clinical trials) and Leica CM1950)
and international (Horizon 2020, European networks) of • PTLink DAKO
researchers. The platform maintains the training activities • Crison pH meter
and scientific dissemination collaborating in achieving more
• Liebher upright freezer (-20ºC and 4ºC)
than three theses from those presented in the 2017. Fur-
thermore, it has the achievement to be considered as tutor • Liebher economy freezer (-20ºC)
centre trainees of the Community of Madrid, has maintai- • Shandon Cytospin 2
ned a collaboration agreement with two institutes for their • Memmert BE 500 oven
students perform regulated practices in workplaces. • Memmert UN 30 oven
• Selecta Agimatic-E magnetic stirrer with heating
• Pippetors
• Olympus CH microscope, for practical laboratory
applications
• Gilson pipette sets
• NUAIRE laboratory fume hood.
Dissection equipped and staining area with manual options
for Do-It-Yourself staining and cover slipping.
The laboratory is equipped with shared facilities from
Translational Oncology and Anatomopathology Breast and
Gynecological Cancer groups that use them for diagnostic
and clinical research purpose (ESCO fume hood and Cri-
son Microtome). Permission to use must be asked to the
head of these laboratories.
RESOURCES, EQUIPMENT AND
The Microscopy laboratory equipment includes:
MANAGEMENT OF THE LABORATORY • Leica TCS SPE inverted confocal. Leica DMI4000B in-
verted microscope; Ilumination source, Lasers diode
The Image Unit’s staff introduces the lab with some safety
regulations and the basic training for the use of the requi- 405, Lasers diode 488, Lasers diode 532 and Lasers
red instrument on at any time of the year. Basic safety regu- diode 635; Dishes, Standard microscope slides.
lations for the proper work in the lab will also be explained NIKON microscope ECIPSE IT to conventional and
to new users. Users must schedule the time of work in fluorescence microscopy, in vivo imaging and High
any equipment and booking reserve it is mandatory in all Content (equipped with incubation chamber)
the facilities. Access to the Immunohistochemistry Lab is - Camera IMAGING SOURCE
free, but the magnetic individual card is required for entry - Camera Camera ANDOR Neo SCHOS refrige-
into the Microscopy lab. The services of the image core rated.
facility are available to all scientists in collaboration, Do-It- - Lauda Ecoline Star incubator edition 003
Yourself model or in a fee model (in this case, it must be
consulted the head of the laboratory, the lab will support
the service depending on staff availability).
The equipment is housed in two different laboratories be-
longing to the Image platform; the Immunohistochemistry
and the Microscopy laboratories:
- Hotplate (OKO LAB)
- Doser gases (Okolab)
- Adapter culture plates microscope
• Leica DMI6000B inverted microscope. Filter cubes:
A4(UV), L5 (green), N3 (red) and Y5 (far red)
• Olympus BX41 (Bright feld) upright microscope with
an attached Digital camera
• Zeiss Axioplan 2 upright microscope with fve objec-
tives from 5x to 100x, phase contrast and fuorescent
capabilities
• Zeiss Axio Lab.Al microscope fve objectives from 5x
to100x. ERC5S Axocan camera.
• Nanosight LM10 viewing unit measures nanoparti-
cles, exosomes, vesicles’s size based on the scattering
of light, includes a microscope, a LM10 viewing unit, a
Marlin camera, an objective x20 and is connected
to a image analysis software.
• Digital microscopy (photography with a Leica DFC
350 FXR2 digital camera attached)
• Image ProPlus 5.0 image analysis software
• Leica LAS AF image analysis software
• Analysis station with Huygens deconvolution soft-
ware, Image J, LASAF Lite programme and related
image analysis software.
• Nanosight NTA 3.1 analytical software.
The laboratory is equipped with shared facility from Neu-
roscience group (Leica TCS SPE inverted confocal).
Service Portfolio
• Collection and processing for fixing and decalcifica-
tion of samples.
• Sample processing in paraffin by hand or automatic.
- Complete paraffin embedding processing.
- Serial cut in microtome and tissue assembly.
• Antibodies’ validation.
• Buffer preparation and distribution of consumables.
• Sample processing frozen.
- Preparation of freeze blocks.
- Serial sections of blocks freeze and cuts collected
on slides or floating.
• Staining.
- Hematoxylin - eosin.
- Masson trichrome.
- Nissl.
- PAS.
- Acetylcholinesterase.
• Cytochemical and immunohistochemical techniques.
- Decalcification of samples required.
- Dewaxing cuts, performing staining.
- Immunohistochemical staining automated system
Autostainer.
- Immunofluorescence in frozen tissue and paraffin.
Protocols.
- Dehydration and slide assembly.
• Image acquisition. Viewing and digital format acquisi-
tion.
- Light microscopy.
- Light microscopy with phase contrast.
- Epifluorescence.
- Confocal microscopy.
- Advanced Microscopy in living cell.
• Fluorescence localization by confocal microscopy.
• 3D reconstruction.
• In vivo image acquisition of biological samples (incu-
bation system for the temperature and CO2).
• Morphometry in biological samples.
• Large images acquisitions (scanning the entire slide)
for bright field and fluorescence.
• Collaboration for sample processing protocols for
microscopy (fastening, staining, marking, etc.) and ad-
vice for planning projects that could require the use
of microscopy.

Immunohistochemistry Laboratory:
• Tissue processor providing efficient, reliable and ti-
mely processing of paraffin wax (Leica TP1020)
• Embedding unit for high quality paraffin blocking (Lei-
ca EG1160)
• Selecta Wax dispenser, paraffin wax dispenser with
adjustable temperature from ambient to 100 ºC
• 2 microtomes for specimen sectioning Leica RM2255
• 1 microtome for specimen sectioning Shandon AS325
• Leica EG 1150C Cold plate
• 2 thermostatic water Leica HI 1210 baths
• 1 thermostatic water Selecta Thermofn bath

70 71
 2
Executive Summary
2.7 Platforms
2.7.8.
Flow Cytometry Laboratory
Flow Cytometry has undergone significant advances within
the research activity of IdiPAZ, and currently almost all
- Each analyser has two lasers, a 488nm argon laser and a
groups involved in research at the Institute use these te-
chniques. The equipment allows for phenotypic analysis of
subpopulations, quantification of soluble factors in biolo-
gical samples and culture supernatants, cell cycle experi-
ments.
COMPOSITION
Head
Víctor M. Toledano Real
Email: victor.toledano@idipaz.es
• One cytometer analyser Becton Dickinson FACSCeles-
Phone: (+34) 91 727 00 00 (ext. 2484)
Secretary
Susana García Pérez
Email: investigacion.hulp@salud.madrid.org
Phone: (+34) 91 207 15 12
EQUIPMENT
The Flow Cytometry Laboratory of IdiPAZ has the fo-
llowing facilities:
• One Beckman Coulter Navios cytometer analyser is
a clinical system that delivers analytical excellence by
coupling extraordinary sensitivity, resolution and dyna-
mic range with high-speed data collection. With supe-
rior detection capabilities, the Navios provides accura-
te measurements, especially for rare events, which is
critical to clinical diagnosis and monitoring. The fully-
featured, easy-to-use Navios software provides tools
to improve the quality of results as well as optimize
workflow efficiencies in a clinical lab.
- This analyser has three lasers; Blue solid state Dio-
de: 488nm, 22mwlaser output, Red solid state Dio-
de: 638nm, 25mwlaser output and Violet solid state
Diode: 405nm, 40mw laser output. The Navios can
analyse ten colours simultaneously in samples mar-
• The laboratory also has an additional Mac G5 OSX
ked with the following fluorochromes:• FL1: FITC,
GFP, Cy2, Alexa 488 • FL2: PE, Cy3 • FL3: PI, ECD,
PE-TEXAS RED, RED RFD • FL4: PE-Cy5, PerCP,
Activity of the flow cytometry platform distributed by usa-
Per-CP5.5, TC 7AAD, SPRD • FL5:PE-Cy7 • FL6:
ge hours (%) of each group
APC, Alexa 647 • FL7: APC-Alexa700, Alexa 700
• FL8: APC-Cy7, APC-Alexa750, APC-
Alexa780 • FL9: Pacific Blue, eFluor 450
Cyan, Cyan, Violet RFD • FL10: Pacific
Orange, AmCyan
- The Navios is connected to computer
using the Navios acquisition and analysis
programme.
• Two Becton Dickinson FACSCalibur™ cyto-
meter analysers is a platform allows users to
perform both cell analysis and cell sorting in a
single benchtop system. The system supports
a wide variety of research and clinical applica-
tions and is complemented by a broad suite
of intuitive software solutions to streamline
analysis for a wide range of applications in-
cluding enumeration of lymphocyte subsets,
72
2.7.9.
stem cells, residual white blood cells, and reticulocytes.
635nm solid-state red diode laser. The FACSCalibur™
can analyse four colours simultaneously in samples mar-
ked with the following fluorochromes: • FL1: FITC, Alexa
488 • FL2: PE, PI • FL3: PE-Cy5, PerCP, Per-CP5.5 • FL4:
APC, APCCy7, Alexa 647
- The two cytometers are connected to Macintosh
G4 OS.9.2.2 computers using the CellQuest™
acquisition and analysis programme, and Macin-
tosh G5 OSX with CellQuestPro™ acquisition
and analysis software
ta. It is designed to make multicolored flow cytometry
more accessible and allow researchers to benefit from
technological innovations in equipment and reagents.
These parallel advances in optical and reagent techno-
logy allow multi-laser equipment to complement the
new bright fluorochromes, allowing for a deeper and
more powerful insight into cell analysis.
- This analyser has three lasers; BUV12: 4 Blue(488nm)
/ 2 ultra violet (355nm) / 6 violet (405nm) . Can
analyse twelve colours simultaneously in samples
marked with the following fluorochromes: FITC;
PE; Brilliant Blue 515 (BB515); Brilliant Blue 700
(BB700); PERCP; PERCP CY5.5; PE CY5; PE CY7;
Brilliant Ultra Violet 395 (BUV 395); Brilliant Ultra
Violet 496 496); Brilliant Ultra Violet 563 (BUV
563); Brilliant Ultra Violet 661 (BUV 661); Brilliant
Ultra Violet 737 (BUV 737); Brilliant Violet 421 (BV
4219; Brilliant Violet 480 (BV 480); Brilliant Violet
2.7.10.
510 (BV 510); Brilliant Violet 605 (BV 605); Brilliant
Violet 650 (BV 650); Brilliant Violet 711 (BV 711);
Brilliant Violet 786 (BV 786); V450; V500; PACIFIC
BLUE; PACIFIC ORANGE.
- The FACSCelesta is connected to computer using
the DIVA acquisition and analysis programme.
analysis station with CellQuestPro™ acquisition and
analysis software
Radioisotope Laboratory
The radioactive facility of IdiPAZ laboratories is authori- Composition
sed by the Nuclear Safety Council (Consejo de Seguridad
Person Responsible
Nuclear, CSN) to operate with non-encapsulated sources
Nuria Vilaboa Díaz
radioisotopes: 14C, 3H, 33P, 32P, 125I, 51Cr.
Email: nuria.vilaboa@salud.madrid.org
Personnel of the Radiological Protection Department of
HULP conduct radiological protection and periodically Phone: (+34) 91 207 10 34
monitor laboratory contamination levels. They are also David Vicent López
responsible for the removal and management of waste Email: david.vicent@salud.madrid.org
products and the management of users’ personal dosi-
Phone: (+34) 91 207 10 30
meters.
Secretary
EQUIPMENT Susana García Pérez
Email: investigacion.hulp@salud.madrid.org
Contains exclusive areas for the use of ß and γ isotopes;
aliquot withdrawal and storage of radiolabeled com- Phone: (+34) 91 207 15 12
pounds; and equipment for exclusive use with radioactive
material.
The laboratory has the following equipment:
• CO2 incubator
• Cell harvester
• Beta counter
• Hybridisation oven
• Gel dryer
• SpeedVac® concentrator
• Screens and containers specifically for γ and β radia-
tion emitters
• High-energy γ and β contamination detectors (Gei-
ger counter)
Biostatistic Section
Presentation Analysis with competitive risks...), Generalized Li-
near Models including Models with Mixed Effects and
The Biostatistics Section has the mission of giving methodo-
Generalized Equation Models, development of Risk
logical support to the professionals of the “La Paz” Univer-
Models for classification and prediction, construction
sitary Hospital and, in general, to the IdiPaz professionals,
of scoring systems for risk assessment, Analysis of
and to provide technical solutions for the optimization of
growth curves, clinical trial methodology, methods of
clinical processes by incorporating the necessary techno-
sequential data analysis, analysis of high-dimensional
logies for this.
ACTIVITY ARRIED OUT DURING 2017
PORTFOLIO OF SERVICES Distribuiton by Center:
• Study design
• Creation of data collection systems (such as ms Access)
• Technical support in the development of studies.
• Support for the design and analysis of observational
epidemiological studies.
• Assistance in the design, analysis and interpretation
of validation studies of diagnostic tests in the clinical
hospital context.
• Development of information processing systems
(clinical image, readings of measuring devices, imple-
mentation of statistical methods...) Analysis of results:
Multivariate Analysis (Discriminant Analysis, Corres-
pondence Analysis, Factor Analysis, Survival Analysis,
73
 2
Executive Summary
2.7 Platforms
2.7.10.
Biostatistic Section
data (Analysis of microarrays). Biclúster analysis. Re-
sampling methods (Bootstrap, Jackknife, ...).
• Presentation and dissemination of results
• Realization of training activities
Distribution by ‘Research Dissemination Objectives’
By Researched Statement
Distribution by ‘Researched Statement’
Distribution by ‘Required Support’
Pertaining to a Research Line
74
2.7.11.
COMPOSICIÓN
Clinical Biostatistics
Rosario Madero Jarabo
Email: rosario.madero@salud.madrid.org
Phone: (+34) 91 207 71 12
Mariana Díaz Almirón
Email: mariana.diaz@idipaz.es
Phone: (+34) 91 207 17 91
Bioengineer
Francisco Gayá Moreno
Email: francisco.gaya@salud.madrid.org
Phone: (+34) 91 207 17 91
Clinical Epidemiologist
Jesús Díez Sebastían
Email: jdiezs@salud.madrid.org
Phone: (+34) 91 727 75 70
Computer tools
Main programs used for data analysis:
• SAS 9.3 (Copyright © 2012, SAS Institute Inc.,
Cary, NC, USA)
• SAS Enterprise Guide 5.1 (Copyright © 2012, SAS
Institute Inc., Cary, NC, USA)
• R version 3.5.0 R Core Team (2018). R: A language
and environment for statistical computing. R Foun-
2.7.12.
dation for Statistical Computing, Vienna, Austria.
URL https://www.R-project.org/.
• SPSS 9 (Copyright 1999 by SPSS Inc. )
• SYSTAT 11 (Copyright (c) 2004 by SYSTAT Soft-
ware Inc., Richmon, CA, USA.)
• nQuery Advisor 5.0 (Copyright (c) 1995-2002)
• PEST 4.0 Planning and Evaluation of Sequential
Trials (Medical and pharmaceutical Statistics Re-
search Unit. The University of Readyng, UK)
• Review Manager (RevMan) Version 5.0. (Meta-aná-
lisis) Copenhagen: The Nordic Cochrane Centre,
The Cochrane Collaboration, 2008.
• Joinpoint Regression Program, Version 4.5.0.1.
June, 2017; Statistical Research and Applications
Branch, National Cancer Institute.
Jobs Pertaining to a Research Line: With Financial Support
Documentalist
IdiPAZ’s Documentalist Platform aims to control and COMPOSITION
analyze the scientific production generated through the ac-
Head
tivity of the researchers from the Institute. This control is
carried out thanks to the use of different tools specifically Raúl Román Cañizares
created for this purpose and whose results are published Email: documentalista@idipaz.es
in the bibliometric reports that appear on our website. In Phone: (+34) 91 207 15 12
these reports you can observe the scientific production
of each one of the research groups that form part of Idi- SERVICE PORTFOLIO
PAZ. However, the information contained in the reports • Draw up of IdiPAZ’s Annual Research Report
has not yet been validated by the groups, hence its provi-
• Support to researchers in their access and use of da-
sional nature. The information supervised and validated by
tabases, literature searches, etc.
the directors of each group will be officially published in
the Annual Research Report together with the rest of the • Design and creation of tools to control the scientific
information from the different committees and platforms production
that make up our Institute. • Development of Bibliometric Reports
The Documentation Platform also provides assistance • Evaluation of researchers
to all IdiPAZ members who need help regarding access • Bibliometric assessment of Research Groups
and use of databases, bibliographic searches, bibliometric • Advice on literature search tools
indicators or any other related subject. As an additional • Advice on the use of bibliometric techniques
service, for some time now, we have also been in char- • Poster printing for congress
ge of printing the posters that our researchers present at
congresses around the world.
PAIN Platform
The PAIN Platform-Early-Stage Researches Support Plat-
form (Plataforma de Apoyo al Investigador Novel) from
IdiPAZ that aims to promote the design and develop-
ment of research projects in several health areas, with
high methodological quality, to enable our professionals in
early-stage research. Additionally, the mission of the PAIN
Platform is to promote the training and development of
early career researchers of IdiPAZ.
COMPOSITION
Head
Paloma Gómez Campelo
Email: pgomezc@salud.madrid.org
Phone: (+34) 91 207 15 12
SERVICE PORTFOLIO
• Methodological and epidemiological support to the
study design of the professionals in early-stage re-
search.
• Technical and methodological support in developing a
research protocol for a study.
• Analysis of the grounds for refusal of rejected projects.
• Methodological support to write grant proposals to
access all available funding programs.
• Technical support in writing other scientific documents.
75
 2
Executive Summary
2.7 Platforms

2.7.13.
Internationalization Platform Projects
The IdiPAZ Internationalization Platform is a tool to sup- • Identifying and actively participate in international
Acronym Title Web Logo Program
port IdiPAZ researchers to continue being a reference in networks interesting for the center
Quantification of the intestinal load of a targeted
the international area. • Introducing and disseminating the capabilities of the
qMAR set of resistance genes to Monitor Antibiotic H2020-MSCA
The main objective is to promote at international level the center and its research groups Resistance in paediatric transplant patients
different research groups of IdiPAZ, identifying possible • Identifying, defining, validating and developing project
synergies between groups and centers, new partners and ideas that emerged in the center European Paediatric Translational Research
• Supporting and encouraging participation in informa- EPTRI https://eptri.eu/ SAPHeIN
funding sources, as well as to forge strategic alliances. Infrastructure
tion events
• Organising information and training sessions on spe-
Specific objectives cific required areas
Effect of early and adult-life stress on the brain
EpiAD epigenome: relevance for the occurrence of JPND
• Conduct an active monitoring international funding • Advising on the proposal preparation and the nego- Alzheimer’s Disease.
programs for R & D + i tiation phase with the European Commission and Implementing SAPHetydoc for the wide adoption
• Identifying and disseminate interesting opportunities with any other international funding agency SAPHeIN CEF TELECOM
of eINvoicing
and calls for research groups • Managing the international approved projects.

Clinical validation of miniature wearable dialysis

Programmes WEAKID H2020
machine
H2020
H2020 is the leading European program for funding research and innovation projects in various subject areas. For the period
ORTHOpedic randomized clinical trial with
2014-2020 it accounts with a budget of nearly € 80,000m. ORTHOUNION expanded bone marrow MSC and bioceramics https://orthounion.eu/ H2020
Most activities are implemented through competitive calls managed by the European Commission with preset priorities in versus autograft in long bone nonUNIONs
work programs.
The program structure can be seen reflected in the following figure: ERN TransplantChild European Reference Network on transplantation EU Health
http://www.transplantchild.com/
(Coordinated by the HULP) in children Programme
Excellent Science Industrial Leadership Societal Challenges
European Reference Network on hepatological
Health, Demographic Change and Wellbeing ERN RARE-LIVER http://www.rare-liver.eu/ H2020
European Research Council- ERC Leadership in enabling and industrial diseases
technologies
Food Security, Sustainable, Agriculture and
Marie Sklowdoska-Curie Actions Forestry, Marine, Maritime and Inland Water
Research and the Bioeconomy VIRUSCAN Optomechanics for Virology https://viruscanproject.eu/ H2020
Access to Risk Finance
Future and Emerging Secure, Clean and Efficient Energy
Technologies-FET Nicotinamide for the treatment of Friedreich
Smart, Green and Integrated Transport NICOFA E-Rare
Innovation in SMEs ataxia
Climate Action, Enviorement, Resource
Research Infrastructures Efficiency and Raw Material REgenerative Stem cell therapy for STroke in
RESSTORE http://www.resstore.eu/ H2020
Europe
Inclusive, innovative and reflective societies
Secure societies- Protecting freedom and
security of Europe and its citizens ENABLE European Gram-negative Antibacterial Engine https://enable-project.eu/ IMI

Spreading Excellence and Widening Participation NEO-CIRC

Dobutamine for NEOnatal CIRCulatory
http://neocirculation.eu/ FP7
failure defined by novel biomarkers
Science with and for Society
MINECO –
Impulso a la participación en H2020 de
H2020PAZ Europa Redes
IdiPAZ
EU Health Programme Its aim is to enable break-through scientific developments y Gestores
The Health Program of the EU is the main instrument avai- leading to new concepts and products and thereby contri-
lable to the European Commission to carry out the Health butes to strengthen Europe’s research and innovation capa-
Strategy of the EU. It is implemented through annual work cities. These networks, COST Actions, represent the main
plans, in which the criteria and funding priorities are esta- instrument available to the program for its implementation. Composition
blished. The calls are continuously open with two court dates per
Team
The total budget of the third program is 449.4 million eu- year.
José Luis Narro Villanueva Adriana Varela Fernández
ros for the period 2014-2020. Email: jose.luis.narro@idipaz.es Email: adriana.varela@idipaz.es
Other programmes:
COST • IMI Phone: (+34) 91 727 75 76 Phone: (+34) 91 207 17 90
COST is the first and widest European intergovernmental • INTERREG-SUDOE Marisa Tejedor Botello Santiago Rello Varona
framework for transnational Cooperation in Science and • AAL Email: marisa.tejedor@idipaz.es Email: santiago.rello@idipaz.es
Technology. • ERA-NETs Phone: (+34) 91 727 75 76 Phone: Phone: (+34) 91 727 75 76

76 77
 2
Executive Summary
2.7 Platforms

2.7.13.
Internationalization Plattform
2.7.14.
Documentation
Webs:
Participant portal: it is the entry point for electronic
administration of EU-funded research and innovation
projects.
CORDIS: it is the European Commission’s primary pu-
blic repository and portal to disseminate information
on all EU-funded research projects and their results in
the broadest sense.
Eshorizonte2020: it is the H2020 Spanish portal.
European IPR Helpdesk: it offers free of charge, first-
line support on IP and IPR matters to beneficiaries of
EU funded research projects and EU SMEs involved in
transnational partnership agreements, especially within
the Enterprise Europe Network (EEN).
EURAXESS – Researchers in Motion: it is a unique pan-
European initiative providing access to a complete ran-
ge of information and support services to researchers
wishing to pursue their research careers in Europe or
stay connected to it.
Documents and Forms:
Project Abstract
Research Group Profile
Participant Guidelines H2020
Annotated Model Grant Agreement - AMGA October
2017 version
Events organized by the Internationalization
Platform:
26/04/2017 - Basic Training Workshop on the HORI-
ZON 2020 Program
01/03/2017 - FET Infoday 2017
20/10/2017 - Conference of presentation of the Euro-
pean Program H2020 for the sanitary field of the Com-
munity of Madrid
Tissue Engineering and
3D Printing Platform
The Tissue Engineering and 3D Printing Platform purpose
is to promote the development of research and solutions
based on tissue engineering and bioprinting and offer diffe-
rent services as computer imaging, virtual planning, com-
puter aided design, and 3D printing technologies to the
professionals of HULP and IdiPAZ.
The main areas of activities of the platform are:
• Bioprinting of tissues and organs
• Lab on a Chip (LOC) and Organ on a Chip (OOC)
devices
• Tissue engineering approaches to develop tissue mo-
dels and organs
• Development of new medical devices (biomodels,
surgical guides, prosthesis and implants) based on
emerging technologies as 3D printing
• Computer imaging, virtual planning and 3D printing
to plan surgeries
Composition
Director
Ramón Cantero Cid
Scientific advisor
Maria Paz de Miguel
Scientific coordinator
José Manuel Baena
Email: PITI3D@idipaz.com
Phone: (+34) 91 207 15 12 (ext 2484)
Technicians and assistants
Daniel Cermeño Pampliega
Email: PITI3D@idipaz.com
Phone: (+34) 91 207 15 12 (ext 2484)
Equipment
• A Bioprinter Unit (V1 REGEMAT 3D) for thermo-
plastics, microextrusion, UV curing and injection of
cell laden biomaterials
• Fused deposition modelling (FDM) 3D printer for
prototyping
• A Bioreactor to mature tissues based on mechanical
excitation
Service Portfolio
• Computer imaging and tissue segmentation from
TAC and MRI
• 3D virtual planning
• Computer Aided Design (CAD)
• 3D printing of biomodels, surgical guides, prosthesis
and implants in polymers and metals
• Biomaterials processing and manufacturing
• Bioprinting of mesh structures with or without cells
• 3D cell cultures
• Development of biofabrication processes
• Development of Lab on a Chip (LOC) and Organ on
a Chip (OOC) devices
• Education and training in the areas of activities

Portfolio of services
• Participation in international networks of interest to
the centre
• Targeted dissemination of funding and project invol-
vement opportunities
• Organization of information sessions and training
courses
• Preparation and dissemination of scientific and tech-
nological profiles of the research groups
• Identification of project proposals under preparation
in which the centre can be involved
• Advice on the definition of the project idea and the
preparation of proposals
• Identification of partners for projects coordinated or
participated by researchers at the center
• Support in the negotiation phase with the European
Commission - EC before the signing of the grant
agreement- GA
• Management of funded projects

78 79
 2
Executive Summary
2.7 Platforms

2.7.15.
Food, Nutrition and Health Platform
DESCRIPTION
The IdiPAZ Food, Nutrition and Health Platform (NU-
TRinvest) is a structure created to provide scientific-tech-
nical service and support in Human Research and Specia-
lized Advice in Nutrition and Food issues.
The Platform provide service of Specialized Advice in Nu-
trition and Food at 3 levels: 1. Industries (agro-food or
pharmaceutical sector) interesting in the new products
development with an improved nutritional profile; 2. Com-
panies interested in creating new technological tools to
facilitate the acquisition of guidelines and healthy habits
(web, app, etc.); and 3. Individual interested in knowing
their nutritional status through a precision and individuali-
zed nutritional assessment.
TEAM COMPOSITION
Head
Carmen Gómez Candela
Email: cgcandela@salud.madrid.org
Phone: (+34) 91 727 12 09
Project manager
Bricia López Plaza
Email: bricia.plaza@idipaz.es
Laura Mª Bermejo López
Email: lauram.bermejo@idipaz.es
Phone: (+34) 91727 70 00 Ext 42199
Clinical Research Associate
Samara Palma Milla (Endocrinologist)
Email: samara.palma@salud.madrid.org
Marina Morato Martínez (Nutritionist)
Email: marina.morato@idipaz.es
Marlhyn Valero Pérez (Nutritionist)
Email: marlhyn.valero@idipaz.es
OBJECTIVE
To implement clinical trials or epidemiological studies well
designed in the area of human nutrition, in order to vali-
date the activity and efficacy of bioactive compounds,
nutrients, foods, dietary patterns or artificial nutri-
tion, on different parameters related to the health
promotion, the disease prevention or its thera-
peutic activity.
MAIN SECTORS
• Agri-food/pharmaceutical industries inter-
ested in designing or validating the effecti-
veness of new products.
• Institutions/government agencies with an in-
terest in expanding knowledge in the area of
nutrition for the generation/implementation
of political measures in Public Health.
• Public or private institutions that want to
develop computer applications, or informa-
tion or communication programs in the field
of Nutrition of interest to health professio-
nals, consumers or patients.
• Researchers with interest in the inclusion of
nutritional variables in their research pro-
jects.
• Individuals interested in obtain information about their
nutritional health and who wish to receive precision
and individualized nutrition through detailed analysis.
SERVICE PORTFOLIO
• Scientific advice to improve nutritional profiles of foods
or nutritional formulas.
• Scientific-technical support in the area of Human Nu-
trition research:
- Create well designed Project Plan for Clinical Trials
and other human studies.
- Management and Submission of applications to the
Ethics Committee: The platform prepares and ma-
nagement all the documents required by obtain the
approval of the Ethics Committee (Informed con-
sent form, Letters from ethics committees. Study
questionnaire (copies of any questionnaires or draft
questionnaires), Case Record Forms (CRFs), Budget
details, etc.)
- Field work execution (all activities are carried out
by members of the platform team with consolidated
qualifications in the area):
• Dietary studies: through the use of validated
tools (Food records (24h, 3-7 days), Food Fre-
quency Questionnaires, Weighted food records,
DIAL software, calorimetry ...)
• Diagnostic and screening nutritional studies: using
validated methodology (Subjective Global As-
sessment (SGA), Nutritional Status Assessment
(NSA), Malnutrition Universal Screening Tool
(MUST), Mini Nutrition Assessment (MNA))
• Anthropometric studies: Weight, Height, Cir-
cumferences, Folds, Bioelectrical Impedance,
DXA…
• Biochemical studies (blood, urine, feces): measure-
ments of health markers related to the area of nu-
trition (glucose metabolism parameters, curves for
calculating the glycemic index, lipid metabolism, in-
flammation, oxidationa and hormonal biomarkers...)
• Physical activity studies: through the use of valida-
ted questionnaires (IPAQ, MINNESOTA...)
• Functional capacity studies: through dynamometry
and validated questionnaires.
• Sensory perception studies: through the use of va-
lidated questionnaires
• Satiety control studies: using biochemical markers
and handling of validated questionnaires
• Quality of life studies: through the use of validated
questionnaires
• Gastrointestinal Tolerance Studies: through the use
of validated questionnaires.
• Nutrigenetics and Metabolic Studies with our co-
llaborating centers.
- Production of scientific and technical report
• Development of computer applications for websites or
mobile apps in the nutrition / food area.
• Individual nutritional status evaluations and proposals
for individualized nutrition intervention programs.
• To contribute and design components for nutrition
education strategies and programs
EQUIPMENT
• Dual-energy x-ray absorptiometry (DXA)
• Bioelectric Impedance System (BIA)
• Holtain Skinfold Calipers
• Tanita digital healthcare scales
• Executive Diameter Tape

80 81
 2
Executive Summary

2.8
Scientific Production
ANALES DE PSICOLOGÍA 0212-9728 1 0.756 Q4
ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND
1932-8486 1 1.373 Q3
EVOLUTIONARY BIOLOGY
ANDROLOGY 2047-2919 1 2.734 Q2
ANGIOLOGÍA 0003-3170 2 Not Indexed
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY 1081-1206 1 3.263 Q2
ANNALS OF INDIAN ACADEMY OF NEUROLOGY 0972-2327 1 1.131 Q4
ANNALS OF NEUROLOGY 0364-5134 1 10.244 Q1
ANNALS OF ONCOLOGY 0923-7534 2 13.926 Q1
ANNALS OF PLASTIC SURGERY 0148-7043 1 1.536 Q3
ANNALS OF SURGICAL ONCOLOGY 1068-9265 1 3.857 Q1
Total of Impact
Journal ISSN Quartile ANNALS OF THE RHEUMATIC DISEASES 0003-4967 5 12.35 Q1
documents factor
A & A CASE REPORTS 2325-7237 2 Not Indexed ANNALS OF THORACIC MEDICINE 1817-1737 1 1.395 Q4
ACTA BIOMATERIALIA 1742-7061 2 6.383 Q1 ANNALS OF THORACIC SURGERY 0003-4975 1 3.779 Q1
ACTA NEUROLOGICA SCANDINAVICA 0001-6314 1 3.126 Q2 ANNALS OF TRANSLATIONAL MEDICINE 2305-5839 4 Not Indexed
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA 0001-6349 1 2.649 Q2 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 0066-4804 3 4.255 Q1
ACTA ORTHOPAEDICA ET TRAUMATOLOGICA TURCICA 1017-995X 1 0.637 Q4 ANTIOXIDANTS & REDOX SIGNALING 1523-0864 2 6.53 Q1
ACTAS DERMO-SIFILIOGRÁFICAS 0001-7310 8 Not Indexed ANTIVIRAL THERAPY 1359-6535 1 2.146 Q3
ACTAS ESPAÑOLAS DE PSIQUIATRÍA 1139-9287 2 0.878 Q4 APHASIOLOGY 0268-7038 1 1.702 Q4
ACTAS UROLÓGICAS ESPAÑOLAS 0210-4806 2 1.26 Q4 APPLIED HEALTH ECONOMICS AND HEALTH POLICY 1175-5652 1 1.885 Q2
ADVANCES IN NEUROBIOLOGY 2190-5215 2 Not Indexed ARCHIVES OF BONE AND JOINT SURGERY 2345-4644 1 Not Indexed
AGE AND AGEING 0002-0729 1 4.013 Q1 ARCHIVES OF CARDIOVASCULAR DISEASES 1875-2136 1 2.37 Q2
AGING AND DISEASE 2152-5250 1 5.058 Q1 ARCHIVOS ARGENTINOS DE PEDIATRÍA 0325-0075 1 0.405 Q4
AIDS 0269-9370 4 4.914 Q1 ARCHIVOS DE BRONCONEUMOLOGÍA 0300-2896 2 2.633 Q2
AIDS RESEARCH AND HUMAN RETROVIRUSES 0889-2229 1 1.935 Q3 ARCHIVOS DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA 1989-7286 1 Not Indexed
AIMS BIOENGINEERING 2375-1495 1 Not Indexed ARCHIVOS ESPAÑOLES DE UROLOGÍA 0004-0614 8 0.465 Q4
ALLERGOLOGIA ET IMMUNOPATHOLOGIA 1578-1267 3 1.644 Q4 ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 1079-5642 1 6.086 Q1
ALLERGOLOGIE 0344-5062 1 0.22 Q4 ARTHRITIS & RHEUMATOLOGY 2326-5191 1 7.871 Q1
ALLERGY 0105-4538 5 6.048 Q1 ARTHRITIS CARE & RESEARCH 2151-464X 2 4.149 Q2
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY 1710-1484 2 2.051 Q3 ARTHRITIS RESEARCH & THERAPY 1478-6354 1 4.269 Q2
AMERICAN HEART JOURNAL 0002-8703 1 4.171 Q2 ARTIFICIAL ORGANS 0160-564X 1 2.111 Q2
AMERICAN JOURNAL OF CARDIOLOGY 0002-9149 1 3.171 Q2 ATENCIÓN PRIMARIA 0212-6567 2 1.148 Q3
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS 1175-3277 1 2.643 Q2 ATHEROSCLEROSIS SUPPLEMENTS 1567-5688 1 3.078 Q2
AMERICAN JOURNAL OF CASE REPORTS 1941-5923 1 Not Indexed AUTOIMMUNITY REVIEWS 1568-9972 2 8.745 Q1
AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL BEST PRACTICE & RESEARCH-CLINICAL ANAESTHESIOLOGY 1521-6896 1 Not Indexed
2164-7712 1 Not Indexed
IMMUNOLOGY BIOCHEMIA MEDICA 1330-0962 1 3.653 Q1
AMERICAN JOURNAL OF GASTROENTEROLOGY 0002-9270 2 10.231 Q1 BIOCHEMICAL JOURNAL 0264-6021 2 3.857 Q2
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 1079-2082 1 1.872 Q3 BIOCHEMICAL PHARMACOLOGY 0006-2952 1 4.235 Q1
AMERICAN JOURNAL OF HEMATOLOGY 0361-8609 2 5.303 Q1 BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE 0006-3002 1 5.108 Q1
AMERICAN JOURNAL OF HUMAN GENETICS 0002-9297 1 8.855 Q1 BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH 0167-4889 2 4.651 Q1
AMERICAN JOURNAL OF INFECTION CONTROL 0196-6553 1 1.929 Q2 BIODRUGS 1173-8804 2 3.825 Q1
AMERICAN JOURNAL OF KIDNEY DISEASES 0272-6386 1 7.129 Q1 BIOMEDICAL MATERIALS 1748-6041 1 2.897 Q2
AMERICAN JOURNAL OF MEDICAL GENETICS PART A 1552-4825 2 2.264 Q3 BIOMEDICINE & PHARMACOTHERAPY 0753-3322 2 3.457 Q2
AMERICAN JOURNAL OF MEDICINE 0002-9343 3 5.117 Q1 BJU INTERNATIONAL 1464-4096 1 4.688 Q1
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 0002-9378 1 5.732 Q1 BLOOD 0006-4971 2 15.132 Q1
AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION 0894-9115 2 1.843 Q2 BLOOD PRESSURE 0803-7051 1 2.107 Q3
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY 1931-857X 1 3.164 Q2 BLOOD PRESSURE MONITORING 1359-5237 1 1.194 Q4
AMERICAN JOURNAL OF PREVENTIVE MEDICINE 0749-3797 1 4.127 Q1 BLOOD TRANSFUSION 1723-2007 2 2.138 Q3
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE BMC CANCER 1471-2407 1 3.288 Q2
1073-449X 2 15.239 Q1
MEDICINE BMC CARDIOVASCULAR DISORDERS 1471-2261 1 1.812 Q3
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE 0002-9637 1 2.564 Q2 BMC MEDICAL GENETICS 1471-2350 1 1.913 Q3
ANAEROBE 1075-9964 1 2.742 Q2 BMC MEDICAL RESEARCH METHODOLOGY 1471-2288 1 2.524 Q2
ANAESTHESIA 0003-2409 1 5.431 Q1 BMC MUSCULOSKELETAL DISORDERS 1471-2474 1 1.998 Q2
ANAIS BRASILEIROS DE DERMATOLOGIA 0365-0596 1 0.884 Q4 BMC PULMONARY MEDICINE 1471-2466 1 2.721 Q2
ANALES DE PEDIATRÍA 1695-4033 21 1.318 Q3 BMJ OPEN 2044-6055 5 2.413 Q2

82 83
 2
Executive Summary
2.8 Scientific Production

BONE & JOINT JOURNAL 2049-4394 1 3.581 Q1 COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY 1943-0264 1 9.247 Q1
BONE & JOINT RESEARCH 2046-3758 1 2.362 Q2 COLORECTAL DISEASE 1462-8910 1 2.778 Q1
BONE MARROW TRANSPLANTATION 0268-3369 1 4.497 Q1 COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE 1541-2555 1 2.604 Q3
BRAIN 0006-8950 1 10.84 Q1 CORNEA 0277-3740 1 2.464 Q2
BRAIN STRUCTURE & FUNCTION 1863-2653 1 4.231 Q1 CRITICAL CARE 1466-609X 1 6.425 Q1
BRITISH JOURNAL OF ANAESTHESIA 0007-0912 1 6.499 Q1 CRITICAL CARE MEDICINE 0090-3493 2 6.63 Q1
BRITISH JOURNAL OF CANCER 0007-0920 3 5.922 Q1 CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES 1040-8363 1 6.481 Q1
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 0306-5251 2 3.838 Q1 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 1040-8428 2 4.495 Q1
BRITISH JOURNAL OF DERMATOLOGY 0007-0963 1 6.129 Q1 CURRENT ALLERGY & CLINICAL IMMUNOLOGY 1609-3607 1 Not Indexed
BRITISH JOURNAL OF HAEMATOLOGY 0007-1048 1 5.128 Q1 CURRENT ALLERGY AND ASTHMA REPORTS 1529-7322 1 3.449 Q2
BURNS 0305-4179 2 2.134 Q2 CURRENT ENVIRONMENTAL HEALTH REPORTS 2196-5412 1 Not Indexed
CANCER CHEMOTHERAPY AND PHARMACOLOGY 0344-5704 1 2.808 Q2 CURRENT MEDICAL RESEARCH AND OPINION 0300-7995 2 2.665 Q1
CANCER LETTERS 0304-3835 1 6.491 Q1 CURRENT ONCOLOGY REPORTS 1523-3790 1 3.122 Q3
CANCER RESEARCH 0008-5472 2 9.13 Q1 CURRENT OPINION IN INFECTIOUS DISEASES 0951-7375 1 3.782 Q2
CANCER TREATMENT REVIEWS 0305-7372 1 8.122 Q1 CURRENT OPINION IN OBSTETRICS & GYNECOLOGY 1040-872X 1 2.821 Q1
CARDIOVASCULAR & HEMATOLOGICAL DISORDERS DRUG TARGETS 2212-4063 2 Not Indexed CURRENT PHARMACEUTICAL DESIGN 1381-6128 1 2.757 Q2
CARDIOVASCULAR REVASCULARIZATION MEDICINE 1553-8389 1 Not Indexed CYTOMETRY PART B-CLINICAL CYTOMETRY 1552-4949 1 2.757 Q2
CASE REPORTS IN DERMATOLOGICAL MEDICINE 2090-6463 1 Not Indexed DERMATOLOGIC SURGERY 1076-0512 1 2.471 Q2
CASE REPORTS IN GENETICS 2090-6544 1 Not Indexed DERMATOLOGIC THERAPY 1396-0296 1 1.55 Q3
CELL REPORTS 2211-1247 2 8.032 Q1 DIABETES 0012-1797 1 7.273 Q1
CELLULAR SIGNALLING 0898-6568 1 3.487 Q2 DIAGNOSTIC CYTOPATHOLOGY 8755-1039 1 1.014 Q4
CENTRAL EUROPEAN JOURNAL OF UROLOGY 2080-4806 3 Not Indexed DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE 0732-8893 2 2.341 Q3
CEREBRAL CORTEX 1047-3211 2 6.308 Q1 DIGESTIVE DISEASES AND SCIENCES 0163-2116 1 2.819 Q3
CHEST 0012-3692 3 7.652 Q1 DISABILITY AND REHABILITATION 1464-5165 1 2.042 Q2
CHILDS NERVOUS SYSTEM 0256-7040 1 1.235 Q3 EARLY HUMAN DEVELOPMENT 0378-3782 3 2.025 Q2
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY 1941-3149 1 4.712 Q1 EFORT OPEN REVIEWS 1988-8856 3 Not Indexed
CIRUGÍA CARDIOVASCULAR 1134-0096 6 Not Indexed ELIFE 2050-084X 1 7.616 Q1
CIRUGÍA ESPAÑOLA 0009-739X 1 0.841 Q4 EMBO MOLECULAR MEDICINE 1757-4676 1 10.293 Q1
CIRUGÍA PEDIÁTRICA 0214-1221 5 Not Indexed EMERGENCIAS 1137-6821 4 3.608 Q1
CLINICA CHIMICA ACTA 0009-8981 1 2.926 Q2 EMERGING INFECTIOUS DISEASES 1080-6040 2 7.422 Q1
CLÍNICA E INVESTIGACIÓN EN ARTERIOSCLEROSIS 1578-1879 3 Not Indexed ENDOCRINOLOGÍA DIABETES Y NUTRICIÓN 2530-0180 2 Not Indexed
CLÍNICA Y SALUD 1130-5274 1 0.324 Q4 ENFERMEDADES INFECCIOSAS Y MICROBIOLOGÍA CLÍNICA 0213-005X 15 1.707 Q3
CLINICAL & TRANSLATIONAL ONCOLOGY 1699-048X 13 2.392 Q3 ENFERMERIA CLÍNICA 1130-8621 1 Not Indexed
CLINICAL AND EXPERIMENTAL DERMATOLOGY 0307-6938 1 1.484 Q3 ENVIRONMENTAL RESEARCH 0013-9351 1 4.732 Q1
CLINICAL AND EXPERIMENTAL IMMUNOLOGY 0009-9104 1 3.542 Q2 ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH 0944-1344 1 2.8 Q2
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 0392-856X 7 3.201 Q2 EPILEPSY & BEHAVIOR 1525-5050 1 2.6 Q2
CLINICAL AND TRANSLATIONAL ALLERGY 2045-7022 1 3.539 Q2 ESMO OPEN 2059-7029 1 Not Indexed
CLINICAL CANCER RESEARCH 1078-0432 3 10.199 Q1 EUROINTERVENTION 1774-024X 2 4.417 Q2
CLINICAL CARDIOLOGY 0160-9289 1 2.733 Q2 EUROPEAN ADDICTION RESEARCH 1022-6877 1 2.653 Q2
CLINICAL CASE REPORTS 2050-0904 1 Not Indexed EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY 1764-1489 2 Not Indexed
EUROPEAN CLINICAL RESPIRATORY JOURNAL 2001-8525 1 Not Indexed
CLINICAL CHEMISTRY 0009-9147 4 8.636 Q1
CLINICAL CHEMISTRY AND LABORATORY MEDICINE 1434-6621 2 3.556 Q1 EUROPEAN HEART JOURNAL 0195-668X 4 23.425 Q1
EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING 2047-2404 3 8.336 Q1
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 1542-3565 1 7.683 Q1
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY 2055-6837 1 Not Indexed
CLINICAL GENETICS 0009-9163 6 3.512 Q2
EUROPEAN JOURNAL OF CANCER 0959-8049 2 7.191 Q1
CLINICAL IMMUNOLOGY 1521-6616 2 3.557 Q2
EUROPEAN JOURNAL OF CANCER CARE 0961-5423 2 2.409 Q1
CLINICAL INFECTIOUS DISEASES 1058-4838 5 9.117 Q1
EUROPEAN JOURNAL OF CANCER PREVENTION 0959-8278 1 2.886 Q3
CLINICAL KIDNEY JOURNAL 1753-0784 3 Not Indexed
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS
CLINICAL LUNG CANCER 1525-7304 1 4.204 Q2 0934-9723 5 2.537 Q2
DISEASES
CLINICAL MICROBIOLOGY AND INFECTION 1198-743X 4 5.394 Q1 EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 0031-6970 1 2.679 Q2
CLINICAL NUCLEAR MEDICINE 0363-9762 1 6.281 Q1 EUROPEAN JOURNAL OF ENDOCRINOLOGY 0804-4643 1 4.333 Q1
CLINICAL NUTRITION 0261-5614 2 5.496 Q1 EUROPEAN JOURNAL OF HAEMATOLOGY 0902-4441 2 2.595 Q3
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH 0009-921X 3 4.091 Q1 EUROPEAN JOURNAL OF HEART FAILURE 1388-9842 1 10.683 Q1
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS 1179-1438 1 Not Indexed EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY 1080-0549 1 6.442 Q1 2047-9956 1 0.538 Q4
PRACTICE
CLINICAL RHEUMATOLOGY 0770-3198 1 2.141 Q3 EUROPEAN JOURNAL OF HUMAN GENETICS 1018-4813 1 3.636 Q2
CLINICAL SCIENCE 0143-5221 1 5.22 Q1 EUROPEAN JOURNAL OF INTERNAL MEDICINE 0953-6205 4 3.282 Q1
CLINICAL THERAPEUTICS 0149-2918 1 3.185 Q2 EUROPEAN JOURNAL OF MEDICAL GENETICS 1769-7212 1 2.004 Q3
CLINICOECONOMICS AND OUTCOMES RESEARCH 1178-6981 1 Not Indexed EUROPEAN JOURNAL OF NEUROLOGY 1351-5101 3 4.621 Q1
CLINICS IN PLASTIC SURGERY 0094-1298 1 2.016 Q2 EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY 1090-3798 2 2.362 Q2
COCHRANE DATABASE OF SYSTEMATIC REVIEWS 1469-493X 1 6.754 Q1 EUROPEAN JOURNAL OF PEDIATRIC SURGERY 0939-7248 7 1.494 Q3

84 85
 2
Executive Summary
2.8 Scientific Production

EUROPEAN JOURNAL OF PEDIATRIC SURGERY REPORTS 2194-7619 2 Not Indexed IMMUNOBIOLOGY 0171-2985 1 2.873 Q3
EUROPEAN JOURNAL OF PEDIATRICS 0340-6199 3 2.242 Q2 IMMUNOLOGIC RESEARCH 0257-277X 2 2.487 Q3
EUROPEAN JOURNAL OF PHARMACOLOGY 0014-2999 1 3.04 Q2 IMMUNOLOGY 0019-2805 1 3.358 Q2
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY 2047-4873 2 4.542 Q1 IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA 0889-8561 1 3.694 Q2
EUROPEAN RESPIRATORY JOURNAL 0903-1936 6 12.242 Q1 IMMUNOLOGY LETTERS 0165-2478 1 2.436 Q3
EUROPEAN SPINE JOURNAL 0940-6719 2 2.634 Q2 INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY 2363-8397 1 Not Indexed
EUROPEAN UROLOGY 0302-2838 1 17.581 Q1 INFECTION 0300-8126 1 2.773 Q2
EUROPEAN UROLOGY FOCUS 2405-4569 1 Not Indexed INFLAMMATORY BOWEL DISEASES 1078-0998 1 4.347 Q1
EUROSURVEILLANCE 1560-7917 3 7.127 Q1 INTEGRATIVE CANCER THERAPIES 1534-7354 1 2.657 Q1
EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY 1064-1297 1 2.354 Q2 INTENSIVE CARE MEDICINE 0342-4642 2 15.008 Q1
EXPERIMENTAL AND MOLECULAR MEDICINE 1226-3613 1 5.584 Q1 INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY 2042-6976 1 2.454 Q1
EXPERT OPINION ON ORPHAN DRUGS 2167-8707 1 0.684 Q4 INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS 0924-8579 3 4.253 Q1
EXPERT REVIEW OF CLINICAL IMMUNOLOGY 1744-666X 1 3.436 Q2 INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS 0391-3988 1 1.133 Q4
EXPERT REVIEW OF HEMATOLOGY 1747-4086 4 1.937 Q3 INTERNATIONAL JOURNAL OF BEHAVIORAL NUTRITION AND
1479-5868 1 5.548 Q1
FAMILIAL CANCER 1389-9600 1 1.943 Q3 PHYSICAL ACTIVITY
FAMILY PRACTICE 0263-2136 1 1.675 Q2 INTERNATIONAL JOURNAL OF CANCER 0020-7136 1 7.36 Q1
FARMACIA HOSPITALARIA 0214-753X 2 Not Indexed INTERNATIONAL JOURNAL OF CARDIOLOGY 0167-5273 5 4.034 Q2
FEBS LETTERS 1873-3468 1 2.999 Q2 INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY
1178-2005 1 2.917 Q2
DISEASE
FERTILITY AND STERILITY 0015-0282 3 4.803 Q1
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE 1368-5031 1 2 Q2
FOOD & FUNCTION 2042-6496 1 3.289 Q1
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY 0300-5771 1 8.36 Q1
FOOD AND CHEMICAL TOXICOLOGY 0278-6915 1 3.977 Q1
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY 0885-6230 1 2.94 Q2
FREE RADICAL BIOLOGY AND MEDICINE 0891-5849 3 6.02 Q1
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 1048-891X 4 2.192 Q2
FRONTIERS IN AGING NEUROSCIENCE 1663-4365 1 3.582 Q2
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS 0020-7292 1 2.072 Q2
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY 2296-634X 1 Not Indexed
INTERNATIONAL JOURNAL OF HEMATOLOGY 0925-5710 1 1.942 Q3
FRONTIERS IN IMMUNOLOGY 1664-3224 1 5.511 Q1
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES 1201-9712 1 3.202 Q2
FRONTIERS IN MEDICINE 2296-858X 1 Not Indexed
INTERNATIONAL JOURNAL OF INTERACTIVE MULTIMEDIA AND
FRONTIERS IN MICROBIOLOGY 1664-302X 4 4.019 Q1 1989-1660 2 Not Indexed
ARTIFICIAL INTELLIGENCE
FRONTIERS IN MOLECULAR NEUROSCIENCE 1662-5099 1 3.902 Q2
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1422-0067 2 3.687 Q2
FRONTIERS IN NEURAL CIRCUITS 1662-5110 1 3.131 Q2
INTERNATIONAL JOURNAL OF NEPHROLOGY 2090-214X 1 Not Indexed
FRONTIERS IN NEUROANATOMY 1662-5129 2 3.152 Q1
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY 2222-3959 1 1.166 Q4
FRONTIERS IN PHARMACOLOGY 1663-9812 3 3.831 Q1
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY
FRONTIERS IN PHYSIOLOGY 1664-042X 1 3.394 Q1 0360-3016 1 5.554 Q1
PHYSICS
FRONTIERS IN PSYCHOLOGY 1664-1078 1 2.089 Q2 INTERNATIONAL JOURNAL OF STROKE 1747-4930 1 3.859 Q1
FUTURE CARDIOLOGY 1479-6678 1 Not Indexed INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY 1066-8969 1 1.188 Q3
FUTURE ONCOLOGY 1479-6694 2 2.369 Q3 INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY 1937-6448 1 3.622 Q2
GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL 2033-6403 1 Not Indexed INVESTIGATIONAL NEW DRUGS 0167-6997 1 3.502 Q1
GACETA MÉDICA DE MÉXICO 0016-3813 1 0.342 Q4 JACC-CARDIOVASCULAR INTERVENTIONS 1936-8798 2 9.881 Q1
GACETA SANITARIA 0213-9111 3 1.581 Q3 JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 1525-4135 3 4.116 Q1
GASTRIC CANCER 1436-3291 1 5.045 Q1 JAMA FACIAL PLASTIC SURGERY 2168-6076 1 2.388 Q2
GENETICS IN MEDICINE 1098-3600 2 9.937 Q1 JAMA NEUROLOGY 2168-6149 1 11.46 Q1
GLIAL AMINO ACID TRANSPORTERS 2190-5215 2 Not Indexed JBJS REVIEWS 2329-9185 1 Not Indexed
GUT 0017-5749 1 17.016 Q1 JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN
GYNECOLOGIC AND OBSTETRIC INVESTIGATION 0378-7346 3 1.183 Q4 2213-2198 3 6.966 Q1
PRACTICE
GYNECOLOGIC ONCOLOGY 0090-8258 1 4.54 Q1 JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 0305-7453 2 5.217 Q1
HAEMATOLOGICA 0390-6078 4 9.09 Q1 JOURNAL OF ARTHROPLASTY 0883-5403 1 3.338 Q1
HAEMOPHILIA 1351-8216 6 2.768 Q2 JOURNAL OF BIOLOGICAL CHEMISTRY 0021-9258 1 4.01 Q2
HEADACHE 0017-8748 1 3.091 Q2 JOURNAL OF BODYWORK AND MOVEMENT THERAPIES 1532-9283 1 Not Indexed
HEARING RESEARCH 1878-5891 1 2.824 Q1 JOURNAL OF BONE AND JOINT SURGERY-AMERICAN
HEART RHYTHM 1547-5271 1 4.743 Q1 0021-9355 3 4.583 Q1
VOLUME
HELIYON 2405-8440 2 Not Indexed JOURNAL OF BURN CARE & RESEARCH 1559-047X 1 1.923 Q2
HEPATOLOGY 0270-9139 2 14.079 Q1 JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 0171-5216 1 3.282 Q2
HIP INTERNATIONAL 1120-7000 1 1.276 Q3 JOURNAL OF CELL SCIENCE 0021-9533 1 4.401 Q2
HIV CLINICAL TRIALS 1528-4336 1 1.379 Q4 JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 1582-4934 1 4.302 Q1
HIV MEDICINE 1464-2662 2 2.932 Q2 JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM 1559-7016 1 Not Indexed
HOSPITAL PRACTICE 2154-8331 2 Not Indexed JOURNAL OF CLINICAL ANESTHESIA 0952-8180 1 1.818 Q3
HUMAN MOLECULAR GENETICS 0964-6906 2 4.902 Q1 JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM 0021-972X 2 5.789 Q1
HUMAN MUTATION 1059-7794 3 5.359 Q1 JOURNAL OF CLINICAL EPIDEMIOLOGY 0895-4356 1 4.245 Q1
HYPERTENSION 0194-911X 1 6.823 Q1 JOURNAL OF CLINICAL MICROBIOLOGY 0095-1137 1 4.054 Q1
HYPERTENSION RESEARCH 0916-9636 1 3.439 Q1 JOURNAL OF CLINICAL ONCOLOGY 0732-183X 2 26.303 Q1
HYPERTENSION: METHODS AND PROTOCOLS 1064-3745 1 Not Indexed JOURNAL OF CLINICAL ORTHOPAEDICS AND TRAUMA 0976-5662 2 Not Indexed

86 87
 2
Executive Summary
2.8 Scientific Production

JOURNAL OF CLINICAL PATHOLOGY 0021-9746 1 2.894 Q2 JOURNAL OF VOICE 0892-1997 1 Not Indexed
JOURNAL OF CLINICAL VIROLOGY 1386-6532 1 3.101 Q2 JOVE-JOURNAL OF VISUALIZED EXPERIMENTS 1940-087X 1 1.184 Q2
JOURNAL OF CRITICAL CARE 0883-9441 2 2.872 Q2 KIDNEY INTERNATIONAL 0085-2538 1 8.429 Q1
JOURNAL OF CROHNS & COLITIS 1873-9946 2 6.637 Q1 LABORATORY INVESTIGATION 0023-6837 1 4.254 Q1
JOURNAL OF DERMATOLOGICAL TREATMENT 0954-6634 2 2.144 Q2 LANCET 0140-6736 10 53.254 Q1
JOURNAL OF DIABETES AND ITS COMPLICATIONS 1056-8727 1 2.792 Q3 LANCET DIABETES & ENDOCRINOLOGY 2213-8587 1 19.313 Q1
JOURNAL OF ELECTROCARDIOLOGY 0022-0736 1 1.421 Q4 LANCET GASTROENTEROLOGY & HEPATOLOGY 2468-1253 2 Not Indexed
JOURNAL OF ENDOMETRIOSIS AND PELVIC PAIN DISORDERS 2284-0265 1 Not Indexed LANCET HIV 2352-3018 4 11.355 Q1
JOURNAL OF ENDOUROLOGY 2152-4920 1 2.038 Q2 LANCET INFECTIOUS DISEASES 1473-3099 1 25.148 Q1
JOURNAL OF EVALUATION IN CLINICAL PRACTICE 1356-1294 1 1.483 Q3 LANCET NEUROLOGY 1474-4422 2 27.138 Q1
JOURNAL OF EXPERIMENTAL MEDICINE 0022-1007 1 10.79 Q1 LANCET ONCOLOGY 1470-2045 1 36.418 Q1
JOURNAL OF FUNCTIONAL FOODS 1756-4646 1 3.47 Q1 LANCET RESPIRATORY MEDICINE 2213-2600 1 21.466 Q1
JOURNAL OF GERIATRIC CARDIOLOGY 1671-5411 1 1.581 Q3 LEUKEMIA 0887-6924 1 10.023 Q1
JOURNAL OF HEPATOLOGY 0168-8278 1 14.911 Q1 LEUKEMIA & LYMPHOMA 1042-8194 1 2.644 Q2
JOURNAL OF HUMAN EVOLUTION 0047-2484 1 3.992 Q1 LEUKEMIA RESEARCH 0145-2126 1 2.319 Q3
JOURNAL OF HUMAN GENETICS 1434-5161 4 2.942 Q2 LIFE SCIENCES 0024-3205 1 3.234 Q2
JOURNAL OF HYPERTENSION 0263-6352 7 4.092 Q1 LIVER INTERNATIONAL 1478-3223 1 4.5 Q1
JOURNAL OF IMMUNOLOGY 0022-1767 2 4.539 Q2 MALARIA JOURNAL 1475-2875 1 2.845 Q1
JOURNAL OF INFECTIOUS DISEASES 0022-1899 3 5.186 Q1 MAYO CLINIC PROCEEDINGS 0025-6196 1 7.199 Q1
JOURNAL OF INHERITED METABOLIC DISEASE 0141-8955 3 4.092 Q1 MEDICINA CLÍNICA 0025-7753 16 1.168 Q3
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH 1079-9907 1 2.419 Q3 MEDICINA INTENSIVA 0210-5691 6 1.755 Q4
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL MEDICINE 0025-7974 7 2.028 Q2
1018-9068 5 3.457 Q2
IMMUNOLOGY
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE 0195-9131 1 4.291 Q1
JOURNAL OF INVESTIGATIVE DERMATOLOGY 0022-202X 2 6.448 Q1
METABOLIC SYNDROME AND RELATED DISORDERS 1540-4196 1 1.744 Q3
JOURNAL OF LEUKOCYTE BIOLOGY 0741-5400 1 4.224 Q2
METHODS IN MOLECULAR BIOLOGY 1940-6029 2 Not Indexed
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE 1476-4954 3 1.493 Q4
MINERVA ANESTESIOLOGICA 0375-9393 2 2.693 Q2
JOURNAL OF MEDICAL GENETICS 0022-2593 1 5.751 Q1
MINERVA UROLOGICA E NEFROLOGICA 1827-1758 1 1.449 Q3
JOURNAL OF MEDICAL VIROLOGY 0146-6615 2 1.988 Q3
MODERN PATHOLOGY 0893-3952 1 6.655 Q1
JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY 1553-4650 1 3.061 Q1
MOLECULAR AND CELLULAR ENDOCRINOLOGY 0303-7207 1 3.563 Q2
JOURNAL OF MOLECULAR DIAGNOSTICS 1525-1578 1 4.88 Q1
MOLECULAR DIAGNOSIS & THERAPY 1177-1062 1 2.716 Q2
JOURNAL OF MOLECULAR MEDICINE-JMM 0946-2716 1 4.938 Q1
MOLECULAR GENETICS & GENOMIC MEDICINE 2324-9269 1 2.695 Q2
JOURNAL OF NEUROCHEMISTRY 0022-3042 1 4.609 Q1
MOLECULAR GENETICS AND METABOLISM 1096-7192 1 3.774 Q2
JOURNAL OF NEUROINTERVENTIONAL SURGERY 1759-8486 2 3.524 Q1
MOLECULAR GENETICS AND METABOLISM REPORTS 2214-4269 1 Not Indexed
JOURNAL OF NEURO-ONCOLOGY 0167-594X 1 3.06 Q2
MOLECULAR NEUROBIOLOGY 0893-7648 1 5.076 Q1
JOURNAL OF NEUROVIROLOGY 1355-0284 1 3.228 Q2
MOLECULAR ONCOLOGY 1878-0261 2 5.264 Q1
JOURNAL OF OBSTETRICS AND GYNAECOLOGY 0144-3615 1 0.545 Q4
MOLECULAR PATHOGENESIS AND SIGNAL TRANSDUCTION BY
JOURNAL OF OPHTHALMOLOGY 2090-004X 1 1.68 Q3 0070-217X 1 5.829 Q1
HELICOBACTER PYLORI
JOURNAL OF PATHOLOGY 0022-3417 1 6.253 Q1
MOLECULAR SYNDROMOLOGY 1661-8769 1 Not Indexed
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM 0334-018X 1 1.086 Q4
MUCOSAL IMMUNOLOGY 1933-0219 1 7.36 Q1
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 0277-2116 5 2.752 Q1
MUSCULOSKELETAL SCIENCE AND PRACTICE 2468-7812 1 0 Q4
JOURNAL OF PEDIATRICS 0022-3476 2 3.667 Q1
MYCOSES 0933-7407 1 2.793 Q1
JOURNAL OF PHYSIOLOGY-LONDON 0022-3751 1 4.54 Q1
NATURE COMMUNICATIONS 2041-1723 1 12.353 Q1
JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY 1748-6815 1 2.158 Q2
NATURE GENETICS 1061-4036 2 27.125 Q1
JOURNAL OF PREVENTIVE MEDICINE AND HYGIENE 1121-2233 2 Not Indexed
NATURE MEDICINE 1078-8956 1 32.621 Q1
JOURNAL OF RENAL NUTRITION 1051-2276 1 2.651 Q2
JOURNAL OF RHEUMATOLOGY 0315-162X 1 3.47 Q2 NATURE REVIEWS CARDIOLOGY 1759-5002 1 15.162 Q1
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY 0960-0760 1 4.095 Q1 NEFROLOGÍA 0211-6995 4 1.167 Q4
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES 1052-3057 1 1.598 Q4 NEONATOLOGY 1661-7800 1 2.688 Q1
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 0190-9622 1 6.898 Q1 NEPHRON 1660-8151 2 2.203 Q2
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 0735-1097 2 16.834 Q1 NEUROCHEMICAL RESEARCH 0364-3190 2 2.772 Q3
JOURNAL OF THE AMERICAN HEART ASSOCIATION 2047-9980 5 4.45 Q2 NEUROCIRUGÍA 1130-1473 1 0.31 Q4
NEUROLOGÍA 0213-4853 2 1.938 Q3
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS
1525-8610 3 5.325 Q1 NEUROLOGY 0028-3878 4 7.609 Q1
ASSOCIATION
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 1046-6673 4 8.655 Q1 NEUROMUSCULAR DISORDERS 0960-8966 1 2.487 Q3
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND NEUROPEDIATRICS 0174-304X 1 1.605 Q3
0926-9959 1 4.287 Q1 NEUROPHARMACOLOGY 0028-3908 1 4.249 Q1
VENEREOLOGY
JOURNAL OF THROMBOSIS AND THROMBOLYSIS 0929-5305 1 2.62 Q2 NEUROSURGICAL FOCUS 1092-0684 1 2.647 Q2
JOURNAL OF TRAVEL MEDICINE 1195-1982 1 1.8 Q2 NEUROTOXICITY RESEARCH 1029-8428 1 3.186 Q2
JOURNAL OF VASCULAR SURGERY-VENOUS AND LYMPHATIC NEW ENGLAND JOURNAL OF MEDICINE 0028-4793 4 79.258 Q1
2213-333X 1 1.619 Q3
DISORDERS NEW MICROBIOLOGICA 1121-7138 1 1.412 Q4
JOURNAL OF VIRAL HEPATITIS 1352-0504 3 4.237 Q1 NICOTINE & TOBACCO RESEARCH 1462-2203 1 4.291 Q1

88 89
 2
Executive Summary
2.8 Scientific Production

NUCLEIC ACIDS RESEARCH 0305-1048 2 11.561 Q1 REVISTA ALERGIA MÉXICO 0002-5151 1 Not Indexed
NUTRICIÓN HOSPITALARIA 0212-1611 9 Not Indexed REVISTA BRASILEIRA DE ANESTESIOLOGIA 0034-7094 1 0.85 Q4
NUTRIENTS 2072-6643 1 4.196 Q1 REVISTA BRASILEIRA DE TERAPIA INTENSIVA 1982-4335 1 Not Indexed
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL 0163-5581 1 2.261 Q3 REVISTA CLÍNICA ESPAÑOLA 0014-2565 5 1.184 Q3
OBSTETRICAL & GYNECOLOGICAL SURVEY 0029-7828 1 2.014 Q3 REVISTA DE GASTROENTEROLOGÍA DE MÉXICO 0375-0906 1 Not Indexed
ONCOGENE 0950-9232 3 6.854 Q1 REVISTA DE NEUROLOGÍA 0210-0010 5 0.601 Q4
ONCOGENESIS 2157-9024 1 4.722 Q1 REVISTA DE PSIQUIATRÍA Y SALUD MENTAL 1888-9891 1 2.233 Q2
ONCOIMMUNOLOGY 2162-402X 1 5.503 Q1 REVISTA ESPAÑOLA DE CARDIOLOGÍA 0300-8932 26 5.166 Q1
ONCOLOGIST 1083-7159 1 5.306 Q1 REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS 1130-0108 7 1.632 Q4
ONCOLOGY 0030-2414 1 Not Indexed REVISTA ESPAÑOLA DE QUIMIOTERAPIA 0214-3429 5 0.605 Q4
ONCOTARGET 1949-2553 5 Not Indexed REVISTA ESPAÑOLA DE ANESTESIOLOGÍA Y REANIMACIÓN 2340-3284 14 Not Indexed
OPHTHALMIC SURGERY LASERS & IMAGING RETINA 2325-8160 1 1.511 Q3 REVISTA ESPAÑOLA DE CIRUGÍA ORTOPÉDICA Y
0976-5662 3 Not Indexed
ORAL ONCOLOGY 1368-8375 1 4.636 Q1 TRAUMATOLOGÍA
ORBIT-AN INTERNATIONAL JOURNAL ON ORBITAL DISORDERS AND REVISTA ESPAÑOLA DE GERIATRÍA Y GERONTOLOGÍA 1578-1747 5 Not Indexed
0167-6830 1 Not Indexed REVISTA ESPAÑOLA DE PATOLOGÍA 1699-8855 1 Not Indexed
FACIAL RECONSTRUCTIVE SURGERY
ORPHANET JOURNAL OF RARE DISEASES 1750-1172 2 3.607 Q2 REVISTA IBEROAMERICANA DE MICOLOGÍA 1130-1406 2 0.989 Q4
ORTHOPEDICS 0147-7447 1 1.463 Q3 REVISTA PORTUGUESA DE CARDIOLOGÍA 0870-2551 2 0.827 Q4
OSTEOPOROSIS INTERNATIONAL 0937-941X 3 3.856 Q2 RHEUMATOLOGY INTERNATIONAL 0172-8172 4 1.952 Q4
OTOLOGY & NEUROTOLOGY 1537-4505 1 2.182 Q2 RMD OPEN 2056-5933 1 Not Indexed
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 1942-0900 1 4.936 Q2 SCANDINAVIAN JOURNAL OF RHEUMATOLOGY 0300-9742 1 3.021 Q3
PAIN MEDICINE 1526-2375 2 2.782 Q1 SCIENCE OF THE TOTAL ENVIRONMENT 0048-9697 1 4.61 Q1
PALLIATIVE & SUPPORTIVE CARE 1478-9515 1 1.494 Q3 SCIENTIFIC REPORTS 2045-2322 25 4.122 Q1
PARASITES & VECTORS 1756-3305 1 3.163 Q1 SEMERGEN 1578-8865 6 Not Indexed
PEDIATRIC ALLERGY AND IMMUNOLOGY 0905-6157 1 4.137 Q1 SEMINARS IN NEPHROLOGY 0270-9295 1 3.35 Q1
PEDIATRIC CRITICAL CARE MEDICINE 1529-7535 1 3.092 Q1 SLEEP 1550-9109 1 5.135 Q1
PEDIATRIC DERMATOLOGY 0736-8046 2 1.041 Q4 SLEEP MEDICINE 1389-9457 1 3.395 Q2
PEDIATRIC INFECTIOUS DISEASE JOURNAL 0891-3668 6 2.305 Q2 SPINE 0362-2436 4 2.792 Q1
PEDIATRIC RESEARCH 0031-3998 1 3.123 Q1 SPINE JOURNAL 1529-9430 2 3.119 Q1
PEDIATRICS 0031-4005 2 5.515 Q1 STEM CELL RESEARCH 1873-5061 1 1.829 Q3
PEDIATRICS AND NEONATOLOGY 1875-9572 1 1.232 Q3 STEM CELLS INTERNATIONAL 1687-966X 1 3.989 Q2
PEERJ 2167-8359 3 2.118 Q2 STROKE 0039-2499 2 6.239 Q1
PHARMACOGENETICS AND GENOMICS 1744-6880 1 2.25 Q2 SURGICAL INFECTIONS 1096-2964 1 1.689 Q3
PHARMACOGENOMICS 1462-2416 2 2.302 Q3 TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY 1028-4559 1 1.029 Q4
PHARMACOLOGICAL RESEARCH 1043-6618 2 4.897 Q1 THERANOSTICS 1838-7640 1 8.537 Q1
PHYSICS IN MEDICINE AND BIOLOGY 0031-9155 1 2.665 Q2 THERAPEUTIC DRUG MONITORING 0163-4356 6 2.092 Q2
PLASTIC AND RECONSTRUCTIVE SURGERY 0032-1052 1 3.475 Q1 THERAPEUTICS AND CLINICAL RISK MANAGEMENT 1178-203X 1 1.995 Q3
PLATELETS 0953-7104 1 2.356 Q3 THROMBOSIS AND HAEMOSTASIS 0340-6245 1 4.952 Q1
PLOS ONE 1932-6203 31 2.766 Q1 THROMBOSIS RESEARCH 0049-3848 3 2.779 Q2
PLOS PATHOGENS 1553-7374 3 6.158 Q1 TORTURE 1018-8185 4 Not Indexed
PM&R 1934-1482 1 1.85 Q2 TOXICOLOGY 0300-483X 2 3.265 Q2
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF TOXICOLOGY AND APPLIED PHARMACOLOGY 0041-008X 1 3.616 Q1
0027-8424 1 9.504 Q1
THE UNITED STATES OF AMERICA TOXICOLOGY LETTERS 0378-4274 1 3.166 Q2
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS 0952-3278 1 2.437 Q3 TOXINS 2072-6651 1 3.273 Q1
PROTEOMICS 1615-9853 1 3.532 Q2 TRANSFUSION CLINIQUE ET BIOLOGIQUE 1246-7820 1 0.936 Q4
PSYCHIATRIC GENETICS 0955-8829 1 1.586 Q4 TRENDS IN BIOTECHNOLOGY 0167-7799 1 13.578 Q1
PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND TRIALS 1745-6215 1 2.067 Q3
1942-9681 1 2.673 Q2
POLICY TUMOR BIOLOGY 1010-4283 1 Not Indexed
PSYCHOLOGY HEALTH & MEDICINE 1354-8506 1 1.589 Q3 TURKISH NEUROSURGERY 1019-5149 1 0.775 Q4
PULMONARY CIRCULATION 2045-8932 1 2.283 Q2 ULTRASOUND IN OBSTETRICS & GYNECOLOGY 0960-7692 1 5.654 Q1
RADIOLOGÍA 0033-8338 1 Not Indexed UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL
RECOMBINANT VIRUS VACCINES: METHODS AND PROTOCOLS 1064-3745 1 Not Indexed 1078-1439 1 3.397 Q1
INVESTIGATIONS
REDOX BIOLOGY 2213-2317 6 7.126 Q1 UROLOGICAL SCIENCE 1879-5226 1 Not Indexed
REPRODUCTION FERTILITY AND DEVELOPMENT 1031-3613 1 2.105 Q1 VACCINE 0264-410X 3 3.285 Q2
REPRODUCTIVE TOXICOLOGY 0890-6238 1 2.58 Q2 VOX SANGUINIS 0042-9007 1 2.107 Q3
RESPIRATORY CARE 0020-1324 1 2.073 Q3 WORK-A JOURNAL OF PREVENTION ASSESSMENT & REHABILITATION 1051-9815 1 0.902 Q4
RESPIRATORY MEDICINE CASE REPORTS 2213-0071 1 Not Indexed WORLD ALLERGY ORGANIZATION JOURNAL 1939-4551 1 5.676 Q1
RESPIRATORY RESEARCH 1465-993X 1 3.751 Q2 WORLD JOURNAL OF CRITICAL CARE MEDICINE 2220-3141 1 Not Indexed
RESUSCITATION 0300-9572 1 5.863 Q1 WORLD JOURNAL OF EMERGENCY SURGERY 1749-7922 2 3.198 Q1
REUMATOLOGÍA CLÍNICA 1699-258X 3 Not Indexed WORLD JOURNAL OF GASTROENTEROLOGY 1007-9327 1 3.3 Q2
REVIEWS IN ANALYTICAL CHEMISTRY 0793-0135 1 2.111 Q2 WORLD JOURNAL OF PEDIATRICS 1708-8569 1 1.228 Q3
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS 1389-9155 1 4.963 Q1 WORLD JOURNAL OF UROLOGY 0724-4983 3 2.981 Q2

90 91
 2
Executive Summary

2.9
CIBERs and RETICs 2.9.2.
RECTICs- Networks for Cooperative
Research in Health
Funding Principal
Project Acronym Network IdiPAZ Group End Date
Organisation Researcher
Tropical Disease Cooperative Instituto de Salud AIDS and Infectious
RD12/0018/0023 RICET Research Network Carlos III
Mora Rillo, Marta
Diseases
31/12/2017
Research Network for
Instituto de Salud Cabañas González, Congenital Malformation
RD12/0026/0004 SAMID Maternal and Child Health and
Carlos III Fernando Surgery
31/12/2017
Development
Cooperative Cancer Research Instituto de Salud Mechanisms of Tumour
RD12/0036/007 RTICC Network Carlos III
Cano García, Amparo
Progression
30/06/2017
Medical Technology Innovation Instituto de Salud de Castro Carpeño, Experimental Therapies and
PT13/0006/0012 ITEMAS Platform Carlos III Javier Biomarkers in Cancer
31/12/2017
Instituto de Salud Gómez Campelo,
PT13/0010/0003 ReTBioH Biobanks Platform
Carlos III Paloma
Innate Immune Response 31/12/2017
INVICTUS Vascular and Cerebral Instituto de Salud Díez Tejedor, Neurology and
RD16/0019/0005 31/12/2021
PLUS Diseases Network Carlos III Exuperio Cerebrovascular Diseases
Research and Clinical Trials Instituto de Salud
PT13/0002/0015 UCICEC Units Platform Carlos III
Frías Iniesta, Jesús Clinical Pharmacology 31/12/2017
Instituto de Salud González García, AIDS and Infectious
RD12/0017/0016 RIS Research Network for AIDS
Carlos III Juan Diseases
31/12/2017
Research on Invasive
Cardiovascular Research Instituto de Salud López-Sendón
RD12/0042/0063 RIC Network Carlos III Hentschel, José Luis
Clinical Cardiology - 31/12/2017
ICCI-Paz
Research Network for
Instituto de Salud Martínez Martínez, Congenital Malformation
RD12/0026/0011 SAMID Maternal and Child Health and
Carlos III Leopoldo Surgery
31/12/2017

2.9.1.
Development
Investigational Network in
Instituto de Salud Miranda Carús, María
RD12/0009/0012 RIER Inflammation and Rheumatic
Carlos III Eugenia
Immuno-Rheumatology 31/12/2017

CIBER- Network Biomedical RD12/0036/0021 RTICC

Diseases
Cooperative Cancer Research Instituto de Salud
Muñoz Terol, Alberto
Mechanisms of Tumour
30/06/2017
Research Center RD12/0043/0019 RETICEF
Network
Cooperative Research
Carlos III
Instituto de Salud
Otero Puime, Ángel
Progression
Aging and Fragility in the
31/12/2017
Funding Principal Network in Aging and Fragility Carlos III Elderly
Acronym CIBER IdiPAZ Group End Date
Organisation Researcher Cardiovascular Research Instituto de Salud Salaices Sánchez, Vascular Physiology and
RD12/0042/0024 RIC Network Carlos III Mercedes Pharmacology
30/06/2017
Networked Biomedical Research
Instituto de Salud Vilaboa Díaz, Bone Pathophysiology and
CIBER-bbn Center for Bio-engineering,
Carlos III Nuria Elda biomaterials
31/12/2017 RD12/0021/0004 REDINREN
Research Network for Renal Instituto de Salud Selgas Gutiérrez,
Nephrology 31/12/2017
Biomaterials and Nanomedicine Diseases Carlos III Rafael
Networked Biomedical Research Research Network for the Ministerio de
Instituto de Salud García-Samaniego Vilaboa Díaz, Nuria Bone Pathophysiology and
CIBERehd Center for Hepatic and Digestive Associated Clinician 31/12/2017 MAT2014-52905-REDT BIOIMPLANT Development of Titanium Economía y 31/05/2017
Carlos III Rey, Javier Elda Biomaterials
Diseases Implants Functionalized Competitividad
Diagnosis and Treatment of Instituto de Salud González García, AIDS and Infectious
RD16/0025/0018 RIS Research Network for AIDS
Carlos III Juan Diseases
31/12/2021
Sánchez Corral Diseases Associated with
31/12/2017 Asthma, Adverse and Allergic Instituto de Salud Laguna Martínez,
Networked Biomedical Research Instituto de Salud Gómez, Pilar Abnormalities of the Complement RD16/0006/0033 ARADYAL Associated Clinician 31/12/2021
CIBERer Center for Rare Diseases Carlos III System
Reactions Carlos III José Julio
Research Network for
Lapunzina Badía, Instituto de Salud Martínez Martínez, Congenital Malformation
Pablo
Cell Therapy and Gene Metastasis 31/12/2017 RD16/0022/0006 SAMID Maternal and Child Health and
Carlos III Leopoldo Surgery
31/12/2021
Development
Networked Biomedical Research Rodríguez Tropical Disease Cooperative Instituto de Salud AIDS and Infectious
Instituto de Salud Cardiovascular Epidemiology and RD16/0027/0002 RICET Mora Rillo, Marta 31/12/2021
CIBEResp Center for Public Health and
Carlos III
Artalejo,
Nutrition
31/12/2017 Research Network Carlos III Diseases
Epidemiology Fernando
Research Network for Renal Instituto de Salud Selgas Gutiérrez,
Networked Biomedical Research RD16/0009/0008 REDINREN Diseases Carlos III Rafael
Nephrology 31/12/2021
Instituto de Salud Cuadrado Pastor, Neuroprotective Strategies in
CIBERned Center for Neurodegenerative
Carlos III Antonio Neurodegenerative Diseases
31/12/2017 Research Network for
Diseases Instituto de Salud Cabañas González, Congenital Malformation
RD16/0022/0004 SAMID Maternal and Child Health and
Carlos III Fernando Surgery
31/12/2021
Networked Biomedical Research Instituto de Salud Salaices Sánchez, Vascular Physiology and Development
CIBERcv Center for Cardiovascular Diseases Carlos III Mercedes Pharmacology
31/12/2022
Investigational Network in
Instituto de Salud Miranda Carús, María
Networked Biomedical Research Instituto de Salud Cano García, RD16/0012/0012 RIER Inflammation and Rheumatic
Carlos III Eugenia
Immuno-Rheumatology 31/12/2021
CIBERonc Center for Cancer Carlos III Amparo
Mechanisms of Tumour Progression 31/12/2022 Diseases
Networked Biomedical Research Instituto de Salud Muñoz Terol, Ministerio de Neuroprotective Strategies
Research Network NRF2 as a Cuadrado Pastor,
CIBERonc Center for Cancer Carlos III Alberto
Mechanisms of Tumour Progression 31/12/2022 SAF2015-71304-REDT
Node of the Pathogenesome
Economía y
Antonio
in Neurodegenerative 31/12/2017
Competitividad Diseases

92 93
 2
Executive Summary

2.10
Institutional
Projects Main lines of Action
Mission
TransplantChild aims to improve life expectancy and quality of life for EU paediatric patients requiring transplantation, by:
• Ensuring their access through the network to the best possible advice on diagnostic, care practices and support pro-
cedures, considering a cross-cutting approach.
• Developing and joining efforts within the Network & stakeholders for integrative, innovative and better procedures,
information, training, knowledge and expertise.
Vision
To become a network of excellence for patients / families based on their health outcomes achieved throughout the life of
the transplanted patient.
• Is based on innovative monitoring techniques and evidence-based treatments.
• Has highly specialized multidisciplinary teams committed to improving the quality of life of patients and their families,
research, and dissemination of knowledge.

TransplantChild (http://www.transplantchild.com) is an Strategic areas

ERN for Paediatric transplantation (PT), both Solid Organ
Transplantation (SOT) and Hematopoietic Stem Cell Trans- • To improve patient healthcare by facilitating the patient/family
plantation (HSCT) which are low-prevalence and complex Network
empowerment, access to information, experience and neces-
conditions that require highly specialized expertise and resou- organization sary knowledge to facilitate their decision-making and self-care.
rces. It’s the only ERN coordinated by Spanish Center (Hospital Quality-safety • To harmonise clinical best practices by the development of cli-
Universitario La Paz-FIBHULP), and the only focused in a therapeutic nical practice guidelines.
process. Improvement Research • Identifying, aligning and prioritising research and innovation fo-
in and
The network scope is a cross-cutting approach to supports common areas in Innovation
cused on facilitating continuous improvement transplanted pa-
healthcare
different types of transplants as immunosuppression, rejection, tolerance, risk of in- Paediatric tient care.
fection and psychosocial wellbeing. patient/families • To harmonise and spread knowledge exchanging and disse-
minating knowledge and best practices within and outside the
network.
Members of the network Harmonise • To Identify and fulfill education and training in PT, promoting
evidence-based Spread the use of standardized continuous education training program-
TransplantChild is integrated by 18 Healthcare Providers (HCP) institutions from 11 Members States. Together, ERN members and safe clinical Knowledge
practise mes.
advice on the patient’s diagnosis, treatment and support during the transplant process (pre-transplant, transplant surgery and
post-transplant phases). Professional • TO facilitate the development of effective organisational struc-
education tures and to define the mechanisms needed for planning-moni-
Whilhelmina Children Hospital Karolinska Lund Hospital (Skane Univ Hospital) and training
toring and organization, quality and safety.
Saint Luc

Children's Memorial Health Institute

KCH (King's College Hospital NHS foundation Trust)

Vilnius UH Santariskiu Klinikos

Added value of the Network

Paris Necker Bicetre

Hannover Medical School

Hospital Universitario la Paz • The scarcity and fragmentation of specialist knowledge are the main reasons why patients may not find a satisfactory
treatment and follow-up program.
H Sta María Hospital de Coimbra • TransplantChild aims to consolidate knowledge and expertise scattered across countries. This will result in:
Papa Giovanni XXIII Bambino Gesu - Better chances for patients to receive an accurate diagnosis and advice on the best treatment and support for their
Centro Hospitalario do Porto EPE (CHP) specific condition.
Ospiedaliera di Podova ISMETT - Giving healthcare providers access to a much larger pool of expertise.
- Facilitating the patients’ access to care, improving their health care outcomes and the sustainability of this complex
procedure for national healthcare systems.

94 95
 2
Executive Summary

2.11
Internationalization

1 5
America ASIA
Brazil India
Canada
Chile
Colombia
2 Israel
Japan
South Korea
El Salvador Taiwan
Mexico
Nicaragua
USA
5 United Arab Emirates

Venezuela

2 3
EUROPE
Austria
1
Belgium
Bulgaria
Czech Republic
Denmark
England
Finland
France 4
Germany
Greece
Ireland
Italy
Latvia 3
Lithuania
AFRICA
Netherlands
Egypt
Norway
South Africa
Poland
Portugal
Romania
Russia 4
Scotland
Sweden OCEANIA
Switzerland Australia
Turkey New Zealand
Wales

96 97
 3
Information
Groups by Area
3.1 Neuroscience Area
99 383.757
“Science knows no country,
because knowledge belongs 82 336.208
to humanity, and is the torch 17,17% 43,43%
which illuminates the world.”
Louis Pasteur
(1822-1895)

3.2 Cardiovascular Area

176 925.517
124 689.377
21.02% 52.84%

3.3 Infectious Diseases and

Immunity Area
243 1,123.881
194 988.524
19.75% 46.09%

3.4 Large System

Pathologies Area
354 1,664.556
271 1,329.417
11.86% 31.92%

3.5 Cancer and Human

Molecular Genetics Area
183 904.712
153 794.333
18.03% 48.09%

3.6 Surgery, Transplant and

Health Technologies Area
167 407.477
136 333.042
13.77% 30.54%
98 99
 3
Information Groups by Area

Psychiatry and
Mental Health Group

8 10.62 0

3.1 Consuelo de Dios Perrino. Facultativo Especialista

de Área en Psiquiatría. HULP
Strategic Objective
Neuroscience
The group is devoted to assess the efficacy of psy-
Blanca Amador Sastre. Facultativo Especialista de Área en
chotherapeutic techniques as adjunctive to other
Psicología Clínica. HULP
therapeutic measures in mental disorders and other

Area
Elena Barbero Val. Licenciada. HULP medical diseases.
Carmen Bayón Pérez. Facultativo Especialista de Área en Their main areas of investigation are: research in bipo-
Psiquiatría. HULP. Profesora Asociada. Facultad de Medicina. UAM lar disorder, severe mental disorder, and other medical
María Fe Bravo Ortiz. Jefe de Servicio de Psiquiatría. HULP disorder such as multiple slerosis, cancer and chronic
Profesora Asociada. Facultad de Medicina. UAM pain. We participate in clinical trials on new tratments
Exuperio Díez Tejedor Rosa Calvo Sagardoy. Psicóloga Clínica. Servicio de Psiquiatría.
and specific therapies in order to improve and the
prognosis of these disorder.
HULP Moreover, the group is involved in the evaluation of
Susana Cebolla Lorenzo. Facultativo Especialista de Área en new treatments or new indications in mental disorders
Psiquiatría. HULP through the participation in clinical trials.
99 383.757 María Teresa González Salvador. Facultativo Especialista We are specially focused in the assessment of the effi-
cacy and effectiveness of techniques such as Mindful-
82 336.208 de Área en Psiquiatría. HULP
ness and we evaluate hypothetical mediators of res-
Nieves González Suárez. Facultativo Especialista de Área en
17,17% 43,43% ponse, such as neurotrophic factors or factors related
Psiquiatría. HULP
to inflammatory response.
Ana Hospital Moreno. Facultativo Especialista de Área en
Psicología Clínica. HULP
Psychiatry and Mental Health Group Eduardo Jiménez Sola. Facultativo Especialista de Área en Research Lines
Psiquiatría. HULP Psychotherapeutic interventions in mental disorders.
Neurology and Cerebrovascular Diseases Group Ainoa Muñoz San José. Facultativo Especialista de Área en
Psiquiatría. HULP
Neuroprotective Strategies in Neurodegenerative Óscar Pajares González-Gallego. Enfermero Especialista Research Activity
en Salud Mental CSM Fuencarral. HULP
Diseases Group Doctoral TheseS
Ángela Palao Tarrero. Facultativo Especialista de Área en
Muñoz San José A. Eficacia de una intervención basada en
Psiquiatría. HULP
Involvement of Glycinergic and Glutamatergic Systems Pau Pérez Sales. Facultativo Especialista de Área en Psiquiatría.
mindfulness sobre la calidad de vida, depresión, ansiedad,
fatiga y cognición social en pacientes con esclerosis múlti-
in Central Nervous System Pathologies Group HULP ple [dissertation]. Madrid: UAM: 2017(15/09/2017).
Beatriz Rodríguez Vega. Facultativo Especialista de Área en Directors: Rodríguez-Vega B, Bayón Pérez C .
Psiquiatría. HULP. Profesora Asociada. Facultad de Medicina. UAM
Cebolla Lorenzo S. Hacia una valoración integral del pa-
Rosa Villanueva Peña. Facultativo Especialista de Área en ciente con infección por VIH. Evaluación de una herramien-
Psiquiatría. HULP ta de detección de depresión en contextos médicos no
100 101
 3
Information Groups by Area
3.1 Neuroscience Area
especializados en salud mental[dissertation]. Madrid: UAM:
2017(15/09/2017).
Directors: Rodríguez-Vega B, Bayón Pérez C, Hernando
Jerez MA.
PUBLICATIONS
• Crespo-Facorro B, Bernardo M, Argimón J, Arrojo M, Bravo-Ortiz
MF, Cabrera-Cifuentes A, Carretero-Román J, Franco-Martín MA,
García-Portilla P, Haro J, Olivares J, Penades R, del Pino-Montes J,
Sanjuan J, Arang C. Effectiveness, efficiency and efficacy in the mul-
tidimensional treatment of schizophrenia: Rethinking project. Rev
Psiquiatr Salud Ment. 2017; 10(1): 4-20. Article. IF: 2.233; Q2
• Fortí-Buratti MA, Palanca-Maresca I, Fajardo-Simón L, Olza-Fernán-
dez I, Bravo-Ortiz MF, Marín-Gabriel MA. Differences in mother-
to-infant bonding according to type of C-section: Elective versus
unplanned. Early Hum Dev. 2017; 115: 93-8. Article. IF: 2.025; Q2
• García-López A, Ezquiaga E, de Dios C, Agud JL. Depressive symptoms
in early- and late-onset older bipolar patients compared with younger
ones. Int J Geriatr Psych. 2017; 32(2): 201-7. Article. IF: 2.94; Q1
• González-Baeza A, Arribas JR, Pérez-Valero I, Monge S, Bayón C,
Martín P, Rubio S, Carvajal F. Vocal emotion processing deficits in
HIV-infected individuals. J Neurovirol. 2017; 23(2): 304-12. Article.
IF: 3.228; Q2
• Pérez-Sales P.   Ill-treatment and torture in demonstrations and
other non-custodial settings . How can academic research help in
the discussion? Torture. 2017; 3: 3-16. Article. IF: Not Indexed
• Pérez-Sales P. Psychotherapy for torture survivors. Suggested
pathways for research. Torture. 2017; 1: 1-12. Article. Not Indexed
• Pérez-Sales P. Drawing the fine line between interrogation and tor-
ture: towards a Universal Protocol on Investigative Interviewing.
Torture. 2017; 1: 1-11. Article. Not Indexed
• Pérez-Sales P,Witcombe N, Otero Oyague D.  Rehabilitation of tortu-
re survivors and prevention of torture: Priorities for research through
a modified Delphi Study. Torture. 2017; 3: 3-48. Article. Not Indexed
Public Projects
Bravo Ortiz MF, Arango López C. AGES: ambiente y genes
en esquizofrenia-grupos de investigación de la Comunidad
de Madrid (AGES-S2010/BMD-2422). CAM. 2016-2017.
Managment centre: FIBHGM
Bravo Ortiz MF, Rodríguez Vega B. Desarrollo de habilida-
des y actitudes para el establecimiento de la relación médico
paciente a través de un programa on-line de entrenamiento
en mindfulness. UAM. 2016-2017.
Managment centre: UAM
de Dios Perrino C. Terapia congnitiva basada en mindful-
ness frente a intervención psicoeducativa en pacientes con
trastorno bipolar con síntomas subsindrómicos depresivos:
ensayo piloto randomizado (PI13/00352). ISCIII. 2014-2017.
Managment centre: FIBHULP
Private Projects
Alcobendas Rueda RM. Registro de enfermedades autoin-
flamatorias en la Comunidad de Madrid. Swedish Orphan
Biovitrum S.L. 2014-Ongoing.
Managment centre: FIBHULP
Bayón Pérez C. Curso de investigación mindfulness en
la práctica clínica. Astrazeneca Farmaceutica Spain S.A.
2012-Ongoing.
102
Managment centre: FIBHULP
Bravo Ortiz MF. Jornadas de investigación en el ámbito de
intervenciones grupales en salud mental. Astrazeneca Far-
maceutica Spain S.A. 2011-Ongoing.
Managment centre: FIBHULP
Bravo Ortiz MF. Programa de ayuda a la formación en in-
vestigación en centros de investigación. Fundacion Alicia Ko-
plowitz. 2015-Ongoing.
Managment centre: FIBHULP
Bravo Ortiz MF. XIV Jornadas de investigación en psiquiatría
y salud mental: “cognición, emoción y salud mental”. Janssen-
Cilag España S.A. 2014-Ongoing.
Managment centre: FIBHULP
Bravo Ortiz MF. XVII Jornadas de investigación. “Constru-
yendo puentes entre la salud mental infarto-juvenil y de
adultos”. Janssen-Cilag España S.A. 2016-Ongoing.
Managment centre: FIBHULP
Calvo Sagardoy R. Cambios biomagnéticos y cognitivo-
emocionales en el tratamiento de las alteraciones de la
imagen corporal en pacientes con transtornos en la con-
ducta alimentaria. Colegio Oficial de Psicólogos de Madrid.
2005-Ongoing.
Managment centre: FIBHULP
de Dios Perrino C. Regulación epigenética del sistema
oxitocina-vasopresina y prosociabilidad en la mania bipolar.
Fundacion para la Investigación Biomedica Hospital Univer-
sitario La Paz. 2015-Ongoing.
Managment centre: FIBHULP
Rodríguez Vega B. Comparación de dos estrategias de in-
tervención para el tratamiento de los trastornos depresivos
en pacientes oncológicos. Asociación Escuela Española de
Psicoterapia. 2007-Ongoing.
Managment centre: FIBHULP
Rodríguez Vega B. Evaluación cualitativa de dos estrategias
de tratamiento para la depresión en un muestra de pacien-
tes oncológicos PI-924. Asociación Escuela Española de Psi-
coterapia. 2007-Ongoing.
Managment centre: FIBHULP
CLINICAL TRIALS
Bravo Ortiz MF. Ensayo clínico fase III, aleatorizado, multi-
céntrico, doble ciego para evaluar dos pautas de administra-
ción del ibuprofeno en el tratamiento del ductus arterioso
persistente eco-guiado: impacto en el pronóstico intestinal.
Type: Clinical Trial, phase III.
HULP code: 4711. Sponsored´s protocol code: IBU24h-EchoG.
Sponsored by: Fundación para la Investigación Biomédica
Hospital Universitario La Paz.
Signed date: 03/04/2017
Patents and Trademarks
Rodríguez Vega B, authors; FIBHULP, as-
signee. Trademark name: En calma; ESM
3.695.071; 2017 December 12.
Neurology and Cerebrovascular
Diseases Group
55 217.086 20
Exuperio Díez Tejedor. Jefe de Servicio de Neurología.
HULP. Catedrático del Departamento de Neurología. Facultad de
Medicina. UAM
María José Aguilar-Amat Prior. Facultativo Especialista de Área
en Neurología. HULP
María Alonso de Leciñana Cases. Facultativo Especialista de
Área en Neurología. HULP
Joaquín Arcas Martínez. Facultativo Especialista de Área en
Neurología Pediátrica. HULP
Juan José Arévalo Manso. Enfermero. HULP
Francisco Javier Arpa Gutiérrez. Profesor Asociado Facultad de
Medicina. UAM
María Jesus Bullido Gómez-Heras. Profesor Titular.
Departamento de Biología Molecular. Facultad de Ciencias.
UAM - CSICS - CBM Severo Ochoa
Fernando Carceller Benito. Facultativo Especialista de Área en
Neurología . HULP
Sebastián Cerdán García-Esteller. Investigador Postdoctoral.
Laboratorio de Imagen y Espectroscopia por Resonancia Magnética. IIB
Alberto Sols
María Delia Chaverri Rada. Facultativo Especialista de Área en
Neurología. HULP
Jorge Eduardo Collazos Castro. Jefe de Laboratorio de
Reparación Neural y Biomateriales. Hospital Nacional de Parapléjicos
de Toledo
Josué Fernández Carnero. Profesor e Investigador Postdoctoral.
Centro Superior de Estudios La Salle
Andrés Francisco Fernández Prieto. Facultativo Especialista
de Área en Radiología. HULP
Mireya Fernández-Fournier Fernández. Facultativo
Especialista de Área en Neurología. HULP
Ana Frank García. Jefa de Sección en Servicio de Neurología. HULP.
Profesora Asociada Facultad de Medicina. UAM
Remedios Frutos Martínez. Facultativo Especialista de Área en
Radiología. HULP
Blanca Fuentes Gimeno. Facultativo Especialista de Área en
Neurología. HULP
Alfonso Gil Martínez. Fisioterapeuta. HULP
Maria del Carmen Gómez de Frutos. Investigadora
Predoctoral. HULP
David Gómez Andrés. Investigador Predoctoral. Departamento de
Anatomía, Histología y Neuriociencia. UAM
Ana Cristina Guadaño Ferraz. Científico Titular. Departamento
de Fisiopatología Endocrina y del Sistema Nervioso. IIB Alberto Sols
María Dolores Gutiérrez Fernández. Investigadora
Postdoctoral. Contrato Miguel Serve Tipo I (CT15/000 69). Laboratorio
de Neurociencias y Enfermedades Cerebrovasculares. HULP
María Hernández Barral. Facultativo Especialista de Área en
Neurología. HULP
Rafael Herruzo Cabrera. Jefe de Sección de Medicina Preventiva
y Salud Pública. HULP. Catedrático Facultad de Medicina. UAM
Vicente Iváñez Mora. Facultativo Especialista de Área en
Neurología. HULP
Roy La Touche Arbizu. Profesor Titular. Centro Superior de Estudio
La Salle
Manuel Lara Lara. Facultativo Especialista de Área en Neurología.
HULP
Fernando Laso García. Investigador Predoctoral. HULP
Jesús María López Arrieta. Jefe de Sección de Geriatría. Profesor
Asociado de Prácticas. Facultad de Psicología. HULP - Hospital de
Cantoblanco - UAM
María Pilar López Larrubia. Científica Titutlar. CSIC. IIB Alberto
Sols
Ibai López de Uralde Villanueva. Investigador Predoctoral.
Centro Superior de Estudio La Salle
Begoña Marín Aguilera. Facultativo Especialista de Área en
Radiología. HULP
Juan Andrés Martín Gonzalo. Profesor Titular. Escuela
Universitaria de Fisioterapia de la ONCE
Ángel Martín Montes. Facultativo Especialista de Área en
Neurología. HULP
Mercedes Martínez Moreno. Facultativo Especialista de Área en
Medicina Física y Rehabilitación. HULP
103
 3
Information Groups by Area
3.1 Neuroscience Area
Antonio Martínez Bermejo. Jefe de Servicio de Neurología Pediátrica.
HULP. Profesor Asociado. Facultad de Medicina. UAM
Arturo Martínez Arroyo. Técnico de Laboratorio. HULP
Susana Moraleda Perez. Jefe de Sección de Medicina Física y
Rehabilitación. HULP
Pilar Negredo Madrigal. Profesor Interino. Departamento de Anatomía,
Histología y Neurociencia. UAM
Susana Noval Martín. Facultativo Especialista de Área en Oftalmología.
HULP
Jesús Oliván Palacios. Facultativo Especialista de Área en Neurofisiología
Clínica. HULP - Hospital Carlos III
Laura Otero Ortega. Investigadora Postdoctoral. HULP
Joaquín Pardo Montero. Profesor Titular. Centro Superior de Estudio La
Salle
Alba París Alemany. Profesora. Investigadora Predoctoral. Centro Superior
de Estudio La Salle
Samuel Ignacio Pascual Pascual. Jefe de Sección de Área en
Neurología Pediátrica. HULP. Profesor Asociado Facultad de Medicina. UAM
José Francisco Paz Solís. Facultativo Especialista de Área en
Neurocirugía. HULP
Inmaculada Puertas Muñoz. Facultativo Especialista de Área en
Neurología. HULP
Irene Pulido Valdeolivas. Investigadora Predoctoral. Departamento de
Anatomía, Histología y Neuriociencia. HULP
Estrella Rausell Tamayo. Catedrática del Departamento de Anatomía,
Histología y Neurociencias. Facultad de Medicina. UAM
José María Roda Frade. Jefe de Servicio de Neurocirugía. HULP
Irene Rodríguez Andonaegui. Profesor Ayudante. Escuela Universitaria
de Fisioterapia de la ONCE
Francisco Javier Rodríguez de Rivera Garrido. Facultativo
Especialista de Área en Neurología. HULP
Aranzazu Royo Orejas. Jefe de Sección de Área en Radiología. HULP
Gerardo Ruiz Ares. Facultativo Especialista de Área en Neurología. HULP
María Teresa Salas Campos. Técnico Superior Psicología. Servicio de
Neurología. HULP
Susana Santiago Pérez. Facultativo Especialista de Área en
Neurofisiología. HULP
Borja Enrique Sanz Cuesta. Facultativo Especialista de Área en
Neurología (Contrato Río Hortega). HULP
Antonio Tallón Barranco. Facultativo Especialista de Área en Neurología.
HULP
Gema Torrijos Barbero. Especialista en Neuropsicología. Unidad de
Memoria y Demencias. HULP - Hospital de Cantoblanco
Arturo Ugalde Canitrot. Facultativo Especialista de Área en
Neurofisiología Clínica. HULP
Francisco Vivancos Matellano. Facultativo Especialista de Área en
Neurología. HULP
Strategic Objective
CEREBROVASCULAR
• Development of translational research studies (both
animal and clinical studies) in cerebrovascular disea-
ses, with the objectives of increasing the understan-
ding of the pathogenesis of both cerebral infarction
(with cortical and subcortical affectation) and cerebral
hemorrhage. To identify prognostic biomarkers and
therapeutic targets mainly aimed at the promotion of
brain protection and repair, with a special interest on
104
the development of cell therapy as well as in trophic
factors, extracellular vesicles and remyelinizating drugs.
Clinical trials of cell therapy in acute cerebral infarc-
tion (clinical trial AMASCIS and European Consortium
RESSTORE-H2020).
• Development of innovative strategies in the diagnosis
and treatment of ischemic stroke, through the develop-
ment of an independent operator-ultrasound device for
brain visualization and for enhancement by ultrasound
of drug therapies (BDNF, exosomes) in the ischemic
area.
• Evaluation of the benefit of the implementation of
prehospital clinical scales able to identify of patients
of cerebral artery occlusion susceptible to mechanical
thrombectomy in order to shorten treatment delay and
improve the prognosis of patients. Comparative analysis
of benefit and risk of primary mechanical thrombec-
tomy versus intravenous throm-bolysis in patients with
acute ischemic stroke within the first 4.5 hours from
onset.
• Study of the clinical (neurological and neuropsy-cholo-
gical) and anthropological factors influencing functional
recovery and reintegration of stroke pa tients as well as
the compliance with the recommendations for secon-
dary stroke prevention.
HEADACHES AND NEUROPATHIC PAIN
• Analysis of the expression of the phenomenon central
painful awareness in different primary and secondary
headaches.
NEURODEGENERATION  • COMPASS-31 Study (collaboration with the Mayo Cli-
Amyotrophic Lateral Sclerosis
• ECAS scale (Edinburgh Cognitive Assessment Scale)
validation and adaptation to Spanish language. Analysis
of the different profiles of cognitive impairment in ALS
patients by means of the ECAS scale (Edimburgh Cog-
nitive Assesment Scale).
• SOPHIA Project: European Project on harmonization
and optimization of the production and procesing of
samples for the study of biomarkers in ALS and other
motor neuron diseases.
• Functional study of Autonomic Nervous System in Am-
yotrophic Lateral Sclerosis. Identification of differential
patterns of the disease presentation and their impact
on clinical outcome . Alzheimer´s disease.
• Study of the lysosomal pathway involvement in a model
of neurodegeneration and cholesterol dysregulation in
Alzheimer’s disease. Parkinson´s disease.
• Tremor as a negative predictive factor in developing de-
mentia associated with Parkinson’s disease.
• Evaluation of the benefits and risks of continuous infu-
sion of intraduodenal levodopa in idiopathic Parkinson’s
disease. Hereditary ataxias
• Assessment of therapeutic response to Frenkel training
exercises enhanced by Wii game console in patients
with cerebellar ataxia.
• Participation in the Registry of the European Consor-
tium EFACTS (European Friedreich’s Ataxia Consor-
tium for Translational Studies) aimed at improve the
knowledge of the epigenetic mechanisms related to si-
lencing the expression of frataxin and the pathogenesis
of the disease, identification of biomarkers and genes
modifying the clinical expression of the disease, develo-
pment of new therapies as well as cellular and animal
models for the study of Friedrich’s Ataxia.
COGNITION, BEHAVIOR AND
NEUROLOGICAL ANTHROPOLOGY
• Analysis of the medium and long term results of work-
shops on post-stroke care attended by family and
patients during the hospitalization time for an acute
stroke on the degree of knowledge and ack - nowledge
of stroke and its risk factors.
• Evaluation of the perceived quality of physicianpatient-
family communication in cerebrovascular diseases and
dementias.
NEUROIMMUNOLOGY
Multiple sclerosis
• Study of remyelinizators substances as a biomarker
white matter lesion in multiple sclerosis patients.
• Analysis of white matter biomarkers in Theiler’s Mou-
rine Encephalomyelitis Virus (TMEV) animal model.
Development of new reparative therapies based on
the enhancement of remyelinization in experimental
animal model.
• Analysis of molecular and neuroimaging biomarkers of
brain damage and repair in Multiple Sclerosis.
AUTONOMIC NERVOUS SYSTEM
• Evaluation of the Autonomic Nervous System in mo-
vement disorders.
• Evaluation of the Autonomic Nervous System in focal
autonomic neuropathies and in Fabry disease.
nic): Registry of patients and controls with central and
peripheral dysautonomia.
NEUROMUSCULAR DISEASES
• Observational study of the clinical course of patients
with Charcot-Marie-Tooth disease. Identification of
prognostic factors.
• Efficacy of evaluation of Eslicarbazepine acetate in neu-
ropathic pain in patients with peripheral neuropathies.
SLEEP
• Development and evaluation of intervention protocols
in childhood insomnia treatment.
• Analysis of sleep microstructure in newborns with
Prader Willi Syndrome.
• Study on the efficacy of child insomnia treatment with
oral iron supplements against placeb.
EPILEPSY
• Evaluation of the benefit of the implementation of an
outpatient clinic for first seizures.
• Analysis of factors influencing the recurrence of seizu-
res, tolerance and adherences to drugs, during the first
monotherapy in patients with epilepsia.
• Analysis of neuropsychological disorders in the pri-
mary generalized epilepsy.
• Evaluation of cognitive impact of antiepileptic
treatment after the first seizure and at the start of the
first monotherapy as well as in elderly patients with
focal epilepsy.
• Influence of stress as a trigger of seizures in epilepsy.
• Depression and anxiety: impact on the therapeutic
compliance of patients with epilepsy.
• Registry of patients treated with i.v. antiepileptic drugs.
Analysis of indications, response and adverse events.
BRAIN DEVELOPMENT DISORDERS
• Study and functional classification of the gait of pedia-
tric patients with cerebral palsy.
• Study and functional classification of the gait of pa-
tients with familial spastic paraparesis.
• Gait analysis as a tool for the differential diagnosis bet
- ween child cerebral palsy and PEF in paediatric pa-
tients.
Research Lines
• Cerebrovascular diseases.
• Neurodegenerative diseases.
• Neuroimmunology. Multiple sclerosis.
• Neuromuscular diseases and spinocerebellar ataxias.
Motor neuron diseases Amyotrophic lateral sclerosis.
• Developmental disorders and neurological maturation
(TRADESMA).
• Headache and neuropathic pain.
Research Activity
Doctoral TheseS
Valentí Soler M. Robots sociales y animales en la terapia de
personas con demencia avanzada[dissertation]. Madrid: UAM:
2017(20/04/2017).
Directors: Frank García A; Martínez Martín P.
Oviedo Céspedes DC. Análisis de perfiles neuropsicológicos
y de biomarcadores proteómicos y vasculares en deterioro
cognitivo leve y la enfermedad de Alzheimer en panameños
adultos.[dissertation]. Madrid: UCM: 2017(03/07/2017).
Directors: Fernández Guinea S; Frank García A; Briton G.
BOOKS AND BOOK CHAPTERS
Rodríguez de Rivera FJ. Esclerosis lateral amiotrofica. In:
Gutiérrez-Rivas E. Manual de enfermedades neuromuscula-
res. Madrid: Ergón Creación, 2017. p.147-158
Noval S. Oftalmología pediátrica y estrabismo. In: Asencio
Durán M. Examen OPE, Madrid 2017. Preguntas razonadas y
respuestas. Madrid: Editorial Glosa S.L., 2017
Noval S, Álvarez A, Carceller F, SacedaF. Tumores de nervio
óptico en la infancia: gliomas. In: Arbizu Duralde A, Sánchez
Orgaz M. Diagnóstico por la imagen en patología ocular y
orbitaria. Madrid: Prodiko (Proyectos de difusión de conte-
nido S.L.), 2017
Noval S, Buitrago M, Fraile J, de Manuel S, Jiménez A. Neu-
ropatías ópticas. In:Arbizu Duralde A, Sánchez Orgaz M. Diag-
nóstico por la imagen en patología ocular y orbitaria. Madrid:
Prodiko (Proyectos de difusión de contenido S.L.), 2017.
Noval Martín S, Cabrejas Martínez L, Jarrín Hernández
E, Pérez Flores I. Guía práctico-clínica sobre la indicación
y administración de la inyección de toxina botulínica en el
tratamiento de los estrabismos. Madrid: Sociedad Española
de Estrabología y Oftalmología Pediátrica, 2017.
105
 3
Information Groups by Area
3.1 Neuroscience Area
Pascual Pascual SI, García Romero M. Síndromes miasténi-
cos congénitos. In: Gutiérrez-Rivas E. Manual de enfermeda-
des neuromusculares. Madrid: Ergón Creación, 2017. p.359-
365
PUBLICATIONS
• Alonso de Lecinana M, Kawiorski Michal M, Ximénez-Carrillo A,
Cruz-Culebras A, García-Pastor A, Martínez-Sánchez P, Fernández-
Prieto A, Caniego JL, Méndez JC, Zapata-Wainberg G, de Felipe-
Mimbrera A, Díaz-Otero F, Ruiz-Ares G, Frutos R, Barcena-Ruiz E,
Fandino E, Marín B,Vivancos J, Masjuan J, Gil-Núñez A, Díez-Tejedor
E, Fuentes B. Mechanical thrombectomy for basilar artery thrombo-
sis: a comparison of outcomes with anterior circulation occlusions.
J Neurointerv Surg. 2017; 9(12): 1173-8. Article. IF: 3.524; Q1
• Alonso-Pérez JL, López-López A, La Touche R, Lerma-Lara S, Suá-
rez E, Rojas J, Bishop MD, Villafane Jorge H, Fernández-Carnero J.
Hypoalgesic effects of three different manual therapy techniques on
cervical spine and psychological interaction: A randomized clinical
trial. J Bodyw Mov Ther. 2017; 21(4): 798-803. Article. Not Indexed
• Berge E, Salman RAS, van der Worp HB, Stapf C, Sandercock P, Spri-
gg N, Macleod MR, Kelly PJ, Nederkoorn PJ, Ford GA. (Diéz Tejedor
E) Increasing value and reducing waste in stroke research. Lancet
Neurol. 2017; 16(5): 399-408. Article. IF: 27.138; D1
• Cacheiro P, Ordóñez-Ugalde A, Quintans B, Pineiro-Hermida S, Ami-
go J, García-Murias M, Pascual-Pascual SI, Grandas F, Arpa J, Carra-
cedo A, Sobrido MJ. Evaluating the calling performance of a rare
disease NGS panel for single nucleotide and copy number variants.
Mol Diagn Ther. 2017; 21(3): 303-13. Article. IF: 2.716; Q2
• Calle D,Yilmaz D, Cerdán S, Kocer A. Drug delivery from engineered
organisms and nanocarriers as monitored by multimodal imaging
technologies. Aims Bioeng. 2017; 4(2): 198-222. Review. IF: Not In-
dexed
• Cerdán S. Twenty-seven years of cerebral pyruvate recycling. Neu-
rochem Res. 2017; 42(6): 1621-8. Article. IF: 2.772; Q3
• Contreras L, Rial E, Cerdán S, Satrustegui J. Uncoupling protein 2
(UCP2) function in the brain as revealed by the cerebral metabo-
lism of (1-C-13) glucose. Neurochem Res. 2017; 42(1): 108-14. Arti-
cle. IF: 2.772; Q3
• de Leciñana MA, Martínez-Sánchez P, García-Pastor A, Kawiorski
MM, Calleja P, Sanz-Cuesta BE, Díaz-Otero F, Frutos R, Sierra-Hidal-
go F, Ruiz-Ares G, Fandino E, Díez-Tejedor E, Gil-Núñez A, Fuentes
B. Mechanical thrombectomy in patients with medical contraindi-
cations for intravenous thrombolysis: a prospective observational
study. J Neurointerv Surg. 2017; 9(11): 1041-6. Article. IF: 3.524; Q1
• de Pipaón MS, Dorronsoro I, Álvarez-Cuervo L, Butte NF, Madero R,
Barrios V, Coya J, Martínez-Biarge M, Martos-Moreno GA, Fewtrell
MS, Argente J, Quero J. The impact of intrauterine and extrauterine
weight gain in premature infants on later body composition. Pediatr
Res. 2017; 82(4): 658-64. Article. IF: 3.123; Q1
• de Sousa DA, Canhao P, Crassard I, Coutinho J, Arauz A, Conforto A,
Bejot Y, Giroud M, Ferro JM. (Diéz Tejedor E) Safety of pregnancy af-
ter cerebral venous thrombosis results of the ISCVT (International
Study on Cerebral Vein and Dural Sinus Thrombosis)-2 PREGNAN-
CY Study. Stroke. 2017; 48(11): 3130. Article. IF: 6.239; D1
• del Castillo LH, Bermejo AM, Pérez JAP, Requeroa PT, Luis AG, Fra-
gua RV. Neuropsychological performance in neurofibromatosis type
1. An Pediatr. 2017; 87(2): 73-7. Article. IF: 1.318; Q3
• Delgado-García G, Estanol-Vidal B, Góngora-Rivera F, Díez-Tejedor
E. Effectiveness of dexamethasone as an adjuvant in preemptive
analgesia for postoperative pain in patients undergoing abdominal
surgery. Gac Med Mex. 2017; 153(2): 283-6. Article. IF: 0.342; Q4
• Fernández-Carnero J, Gilarranz-de-Frutos L, León-Hernández JV,
Pecos-Martín D, Alguacil-Diego I, Gallego-Izquierdo T, Martín-Pinta-
do-Zugasti A. Effectiveness of different deep dry needling dosages in
106
the treatment of patients with cervical myofascial pain: A pilot RCT.
Am J Phys Med Rehab. 2017; 96(10): 733-40. Article. IF: 1.843; Q2
• Fernández-Fournier M, Perry DC, Tartaglia MC, de May M, Boxer A,
Coppola G, Christine CW, Huang EJ, Seeley WW, Miller BL, De Ar-
mond SJ, Grinberg LT, Geschwind MD. Precipitous deterioration of
motor function, cognition, and behavior. JAMA Neurol. 2017; 74(5):
591-6. Review. IF: 11.46; D1.
• Fuentes B, Sanz-Cuesta BE, Gutiérrez-Fernández M, Martínez-Sán-
chez P, Lisbona A, Madero-Jarabo R, Delgado-Mederos R, Gallego-
Cullere J, Rodríguez-Yáñez M, Martínez-Zabaleta M, Freijo M, de
Lecinana MA, Portilla JC, Gil-Núñez A, Díez-Tejedor E. Glycemia in
Acute Stroke II study: a call to improve post-stroke hyperglycemia
management in clinical practice. Eur J Neurol. 2017; 24(9): 1091-8.
Article. IF: 4.621; Q1
• García-Pastor A, Gil-Núñez A, Ramírez-Moreno JM, González-
Nafria N, Tejada J, Moniche F, Portilla-Cuenca JC, Martínez-Sánchez
P, Fuentes B, Gamero-García MA, de Lecinana MA, Canovas-Verge
D, Aladro Y, Parkhutik V, Lago-Martín A, de Arce-Borda AM, Usero-
Ruiz M, Delgado-Mederos R, Pampliega A, Ximénez-Carrillo A,
Bartulos-Iglesias M, Castro-Reyes E. Early risk
of recurrent stroke in patients
with symptomatic carotid
near-occlusion: Results from
CAOS, a multicenter registry
study. Int J Stroke. 2017; 12(7):
713-9. Article. IF: 3.859; Q1
• Gil-Martínez A, Navarro-Fer-
nández G, Mangas-Guijarro MA,
Lara-Lara M, López-López A,
Fernández-Carnero J, La Touche R.
Comparison between chronic mi-
graine and temporomandibular di-
sorders in pain-related disability and
fear-avoidance behaviors. Pain Med.
2017; 18(11): 2214-23. Article. IF: 2.782;
Q1
• Giner J, Esteban I, Carceller F, Saceda J,
Regojo RM. Spinal adrenal cortical adeno-
ma associated with Beckwith-Wiedemann
syndrome: case report and review of the
literature. Child Nerv Syst. 2017; 33(6):
1009-13. Review. IF: 1.235
• Gómez-González C, Esteban-Rodríguez MI,
Ruano Y, Vallespín E, Lapunzina P, Martínez P,
Pascual SI, Molano J, Prior C. Molecular diagno-
sis of limb-girdle muscular dystrophy Type 2A by Next-genera-
tion Sequencing. Ann Indian Acad Neur. 2017; 20(2): 164-5. Letter. IF:
1.131; Q4
• González-Suárez I, Ríos-Blanco JJ, Arpa J. Accelerated atherosclero-
sis in ANCA-associated vasculitis. Acta Neurol Scand. 2017; 136(6):
688-93. Article. IF: 3.126; Q2
• Haro-Martínez AM, García-Concejero VE, López-Ramos A, Mate-
Arribas E, López-Tappero J, Lubrini G, Díez-Tejedor E, Fuentes B.
Adaptation of melodic intonation therapy to Spanish: a feasibility
pilot study. Aphasiology. 2017; 31(11): 1333-43. Article. IF: 1.702; Q4
• Hernández-Jiménez E, Gutiérrez-Fernández M, Cubillos-Zapata C,
Otero-Ortega L, Rodríguez-Frutos B, Toledano V, Martínez-Sánchez
P, Fuentes B, Varela-Serrano A, Avendano-Ortiz J, Blazquez A, Man-
gas-Guijarro MA, Díez-Tejedor E, López-Collazo E. Circulating mo-
nocytes exhibit an endotoxin tolerance status after acute ischemic
stroke: Mitochondrial DNA as a putative explanation for poststroke
infections. J Immunol. 2017; 198(5): 2038-46. Article. IF: 4.539; Q2
• Herruzo R, Ruiz G, Pérez-Blanco V, Gallego S, Mora E, Vizcaino MJ,
Omeñaca F. Bla-OXA48 gene microorganisms outbreak, in a ter-
tiary Children’s Hospital, Over 3 years (2012-2014) Case Report.
Medicine. 2017; 96(40): e7665. Article. IF: 2.028; Q2
• Herruzo R, Ruiz G, Vizcaino M J, Rivas L, Pérez-Blanco V, Sánchez
M. Microbial competition in environmental nosocomial reservoirs
and diffusion capacity of OXA48-Klebsiella pneumoniae: potential
impact on patients and possible control methods. J Prev Med Hyg.
2017; 58(1): E34-41. Review. Not Indexed
• Herruzo R,Vizcaino M J, Herruzo I. An exception to the rule “no as-
sociation between antibiotic resistance and decreased disinfectant
microbicidal efficacy”: Orthophthalaldehyde (OPA) and Pseudomo-
nas aeruginosa isolated from ICU and paraplegic patients. J Prev
Med Hyg. 2017; 58(1): E42-E47. Review. Not Indexed
• Herruzo R,Vizcaino MJ, Herruzo I, Sánchez M. Surface disinfectants
for burn units evaluated by a new double method, using mi-
croorganisms recently isolated from patients,
on a surface germ-carrier mo-
del. J Burn Care
R e s .
2017; 38(3): E663-9. Ar-
ticle. IF: 1.923; Q2
• Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn
RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ,
O’Brien F, Wang JJ, Mantegazza R. Safety and efficacy of eculizumab
in anti-acetylcholine receptor antibody-positive refractory genera-
lised myasthenia gravis (REGAIN): a phase 3, randomised, double-
blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;
16(12): 976-86. Article. IF: 27.138; D1
• Illán-Gala I, Pérez-Lucas J, Martin-Montes A, Manez-Miro J, Arpa J,
Ruiz-Ares G. Long-term outcomes of adult chronic idiopathic hy-
drocephalus treated with a ventriculo-peritoneal shunt. Neurología.
2017; 32(4): 205-12. Article. IF: 1.938; Q3
• Lobo CC, Morales CR, Sanz DR, Corbalan IS, Romero EAS, Carnero
JF, López DL. Comparison of hand grip strength and upper limb
pressure pain threshold between older adults with or without non-
specific shoulder pain. PERRRJ. 2017; 5: e2995. Article. IF: 2.118; Q2
• López MV, de Castro PD, Valderrama EB, Herrero MCM, Villanueva
NG, Romero AJA, Pascual SIP. Outcome of arterial ischemic stroke
in children with heart disease. Eur J Paediatr Neuro. 2017; 21(5):
730-7. Article. IF: 2.362; Q2
• López-de-Uralde-Villanueva I, Acuyo-Osorio M, Prieto-Aldana M, La
Touche R. Reliability and minimal detectable change of a modified
passive neck flexion test in patients with chronic nonspecific neck
pain and asymptomatic subjects. Musculoskelet Sci Pract. 2017; 28:
10-7. Article. Not Indexed
• López-de-Uralde-Villanueva I, Notario-Pérez R, del Corral T, Ra-
mos-Díaz B, Acuyo-Osorio M, La Touche R. Functional limitations
and associated psychological factors in military personnel with
chronic nonspecific neck pain with higher levels of kinesiophobia.
WORK. 2017; 58(3): 287-97. Article. IF: 0.902; Q4
• López-de-Uralde-Villanueva I, Sollano-Vallez E, del Corral T. Re-
duction of cervical and respiratory muscle strength in patients
with chronic nonspecific neck pain and having moderate to severe
disability. Disabil Rehabil. 2017: 43374. Article. IF: .,042; Q2
• Martín-Pintado-Zugasti A, López-López A, Gutiérrez JLG, Pecos-
Martin D, Rodríguez-Fernández AL, Alguacil-Diego IM, Gallego-Iz-
quierdo T, Fernández-Carnero J. the role of psychological factors in
the perception of postneedling soreness and the influence of post-
needling intervention. PM&R. 2017; 9(4): 348-55. Article. IF: 1.85;
Q2
• Mediero S, Mardero OD, de los Bueis AB, Martín SN, García-
Miñaur S. Keratoconus associated with Williams-Beuren syn-
drome: a new case report. Int J Ophthalmol-Chi. 2017; 10(4):
658-60. Letter. IF: 1.166; Q4
• Muñoz-García D, López-de-Uralde-Villanueva I, Beltrán-
Alacreu H, La Touche R, Fernández-Carnero J. Patients with
concomitant chronic neck pain and myofascial pain in mas-
ticatory muscles have more widespread pain and distal hy-
peralgesia than patients with only chronic neck pain. Pain
Med. 2017; 18(3): 526-37. Article. IF: 2.782; Q1
• Ntaios G, Lip GYH, Vemmos K, Koroboki E, Manios E,
Vemmou A, Rodríguez-Campello A, Cuadrado-Godia E,
Roquer J, Arnao V, Caso V, Paciaroni M, Díez-Tejedor
E, Fuentes B, Lucas JP, Arauz A, Ameriso SF, Pertierra
L, Gómez-Schneider M, Hawkes MA, Bandini F, Cano
BC, Mohedano AMI, Pastor AG, Gil-Núñez A, Putaala
J, Tatlisumak T, Barboza MA, Athanasakis G, Gioule-
kas F, Makaritsis K, Papavasileiou V. Age- and sex-
specific analysis of patients with embolic stroke
of undetermined source. Neurology. 2017; 89(6):
53239. Article. IF: 7.609; D1
• Otero-Ortega L, Gómez de Frutos MC, Laso-García F,
Rodríguez-Frutos B, Medina-Gutiérrez E, López JA,Vázquez J, Díez-
Tejedor E, Gutiérrez-Fernández M. Exosomes promote restoration
after an experimental animal model of intracerebral hemorrhage.
J Cere Blood Flow Metab. 2017 :271678X17708917. Article. Not
Indexed
• Otero-Ortega L, Gómez-de Frutos MC, Laso-García F, Sánchez-
Gonzalo A, Martínez-Arroyo A, Díez-Tejedor E, Gutiérrez-Fernán-
dez M. Nogo A. Neutralization promotes axonal restoration after
white matter injury in subcortical stroke. Sci Rep-Uk. 2017; 7: 9431.
Article. IF: 4.122; Q1
• Otero-Ortega L, Laso-García F, Gómez-de Frutos MD, Rodríguez-
Frutos B, Pascual-Guerra J, Fuentes B, Díez-Tejedor E, Gutiérrez-
Fernández M. White Matter repair after extracellular vesicles admi-
nistration in an experimental animal model of subcortical stroke. sci
rep-uk. 2017; 7: 44433. Article. IF: 4.122; Q1
• Ozes B, Karagoz N, Schule R, Rebelo A, Sobrido MJ, Harmuth F,
Synofzik M, Pascual SIP, Colak M, Ciftci-Kavaklioglu B, Kara B, Or-
dóñez-Ugalde A, Quintans B, González MA, Soysal A, Zuchner S,
Battaloglu E. PLA2G6 mutations associated with a continuous cli-
nical spectrum from neuroaxonal dystrophy to hereditary spastic
paraplegia. Clin Genet. 2017; 92(5): 534-9. Article. IF: 3.512; Q2
• Pascual-Pascual SI, García-Romero M. Possible treatments for in-
fantile spinal atrophy. Rev Neurología. 2017; 64: S19-24. Article. IF:
0.601; Q4
• Pérez-Laso C, Cerdan S, Junque C, Gómez A, Ortega E, Mora M,
Avendano C, Gómez-Gil E, del Cerro M, Cruz Rodríguez, Guilla-
mon A. Effects of adult female rat androgenization on brain mor-
phology and metabolomic profile. Cereb Cortex. 2017: 43313. Ar-
ticle. IF: 6.308; D1
107
 3
Information Groups by Area
3.1 Neuroscience Area
• Pesantez-Ríos G, Armijos-Acurio L, Jimbo-Sotomayor R, Pascual-
Pascual SI, Pesantez-Cuesta G. Cannabidiol: its use in refractory
epilepsies. Rev Neurología. 2017; 65(4): 157-60. Article. IF: 0.601; Q4
• Rodríguez-Blanco L, Lubrini G, Vidal-Marino C, Ríos-Lago M. Effica-
cy of cognitive rehabilitation of attention, executive functions, and
working memory in psychotic disorders: A systematic review. Actas
Esp Psiquiatri. 2017; 45(4): 167-78. Review. IF: 0.878; Q4
• Rodríguez-Pardo J, Fuentes B, de Lecinana MA, Ximénez-Carrillo A,
Zapata-Wainberg G, Álvarez-Fraga J, Barriga FJ, Castillo L, Carnea-
do-Ruiz J, Díaz-Guzmán J, Egido-Herrero J, Felipe A, Fernández-Fe-
rro J, Frade-Pardo L, García-Gallardo A, García-Pastor A, Gil-Núñez
A, Gómez-Escalonilla C, Guillán M, Herrero-Infante Y, Masjuan-Valle-
jo J, Ortega-Casarrubios MA, Vivancos-Mora J, Díez-Tejedor E. The
Direct Referral to Endovascular Center criteria: a proposal for pre-
hospital evaluation of acute stroke in the Madrid Stroke Network.
Eur J Neurol. 2017; 24(3): 509-15. Article. IF: 4.621; Q1
• Rodríguez-Pardo J, Lara-Lara M, Sanz-Cuesta BE, Fuentes B, Díez-
Tejedor E. Occipital Condyle Syndrome: A red flag for malignancy.
comprehensive literature review and new case report. Headache.
2017; 57(5): 699-708. Review. IF: 3.091; Q2
• Romero-Moraleda B, La Touche R, Lerma-Lara S, Ferrer-Peña R,
Paredes V, Peinado AB, Muñoz-García D. Neurodynamic mobiliza-
tion and foam rolling improved delayed-onset muscle soreness in
a healthy adult population: a randomized controlled clinical trial.
PEERJ. 2017 ;5: e3908. Article. IF: 2.118; Q2
• Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jak-
obsdottir J, Kunkle BW, Boland A, Raybould R, Bis JC, Martin ER,
Grenier-Boley B, Heilmann-Heimbach S, Chouraki V, Kuzma AB,
Sleegers K, Vronskaya M, Ruiz A, Graham RR, Olaso R, Hoffmann
P, Grove ML, Vardarajan BN, Hiltunen M, Nothen MM, White CC,
Hamilton-Nelson KL, Epelbaum J, Maier W, Choi SH, Beecham GW,
Dulary C, Herms S, Smith AV, Funk CC, Derbois C, Forstner AJ, Ah-
mad S, Li HD, Bacq D, Harold D, Satizabal CL,Valladares O, Squassina
A,Thomas R, Brody JA, Qu LM, Sánchez-Juan P, Morgan T,Wolters FJ,
Zhao Y, García FS, Denning N, Fornage M, Malamon J, Naranjo MCD,
Majounie E, Mosley TH, Dombroski B,Wallon D, Lupton MK, Dupuis
J,Whitehead P, Fratiglioni L, Medway C, Jian XQ, Mukherjee S, Keller
L, Brown K, Lin HH, Cantwell LB, Panza F, McGuinness B, Moreno-
Grau S, Burgess JD, Solfrizzi V, Proitsi P, Adams HH, Allen M, Seripa
D, Pastor P, Cupples LA, Price ND, Hannequin D, Frank-García A,
Levy D, Chakrabarty P, Caffarra P, Giegling I, Beiser AS, Giedraitis V,
Hampel H, García ME, Wang X, Lannfelt L, Mecocci P, Eiriksdottir G,
Crane PK, Pasquier F, Boccardi V, Henandez I, Barber RC, Scherer M,
Tarraga L, Adams PM, Leber M, Chen Y, Albert MS, Riedel-Heller S,
Emilsson V, Beekly D, Braae A, Schmidt R, Blacker D, Masullo C, Sch-
midt H, Doody RS, Spalletta G, Longstreth WT, Fairchild TJ, Bossu
P, López OL, Frosch MP, Sacchinelli E, Ghetti B, Yang Q, Huebinger
RM, Jessen F, Li S, Kamboh MI, Morris J, Sotolongo-Grau O, Katz MJ,
Corcoran C, Dunstan M, Braddel A, Thomas C, Meggy A, Marshall R,
Gerrish A, Chapman J, Aguilar M,Taylor S, Hill M, Fairen MD, Hodges
A, Vellas B, Soininen H, Kloszewska I, Daniilidou M, Uphill J, Patel Y,
Hughes JT, Lord J, Turton J, Hartmann AM, Cecchetti R, Fenoglio C,
Serpente M, Arcaro M, Caltagirone C, Orfei MD, Ciaramella A, Pi-
chler S, Mayhaus M, Gu W, Lleo A, Forte J, Blesa R, Barber IS, Brookes
K, Cupidi C, Maletta RG, Carrell D, Sorbi S, Moebus S, Urbano M,
Pilotto A, Kornhuber J, Bosco P, Todd S, Craig D, Johnston J, Gill
M, Lawlor B, Lynch A, Fox NC, Hardy J, Albin RL, Apostolova LG,
Arnold SE, Asthana S, Atwood CS, Baldwin CT, Barnes LL, Barral S,
Beach TG, Becker JT, Bigio EH, Bird TD, Boeve BF, Bowen JD, Boxer
A, Burke JR, Burns JM, Buxbaum JD, Cairns NJ, Cao CH, Carlson
CS, Carlsson CM, Carney RM, Carrasquillo MM, Carroll S.L., Díaz
CC, Chui HC, Clark DG, Cribbs DH, Crocco EA, DeCarli C, Dick
M, Duara R, Evans DA, Faber KM, Fallon KB, Fardo DW, Farlow
MR, Ferris S, Foroud TM, Galasko DR, Gearing M, Geschwind DH,
Gilbert JR, Graff-Radford NR, Green RC, Growdon JH, Hamilton RL,
Harrell LE, Honig LS, Huentelman MJ, Hulette CM, Hyman BT, Jarvik
108
GP, Abner E, Jin LW, Jun G, Karydas A, Kaye JA, Kim R, Kowall NW,
Kramer JH, LaFerla FM, Lah JJ, Leverenz JB, Levey AI, Li G, Lieberman
AP, Lunetta KL, Lyketsos CG, Marson DC, Martiniuk F, Mash DC,
Masliah E, McCormick WC, McCurry SM, McDavid AN, Mckee AC,
Mesulam M, Miller BL, Miller CA, Miller JW, Morris JC, Murrell JR,
Myers AJ, O’Bryant S, Pankratz VS, Pankratz VS, Parisi JE, Paulson
HL, Perry W, Peskind E, Pierce A, Poon WW, Potter H, Quinn JF,
Raj A, Raskind M, Reisberg B, Reitz C, Ringman JM, Roberson ED,
Rogaeva E, Rosen HJ, Rosenberg RN, Sager MA, Saykin AJ, Schnei-
der JA, Schneider LS, Seeley WW, Smith AG, Sonnen JA, Spina S,
Stern RA, Swerdlow RH, Tanzi RE, Thornton-Wells TA, Trojanowski
JQ, Troncoso JC, Van Deerlin VM, Van Eldik LJ, Vinters HV, Vonsattel
JP, Weintraub S, Welsh-Bohmer KA, Wilhelmsen KC, Williamson J,
Woltjer RL, Wright CB, Yu CE, Yu L, Garzia F, Golamaully F, Septier
G, Engelborghs S, Vandenberghe R, De Deyn PP, Fernadez CM, Be-
nito YA, Thonberg H, Forsell C, Lilius L, Kinhult-Stahlbom A, Kilan-
der L, Brundin R, Concari L, Helisalmi S, Koivisto AM, Haapasalo A,
Dermecourt V, Fievet N, Hanon O, Dufouil C, Brice A, Ritchie K,
Dubois B, Himali JJ, Keene CD, Tschanz J, Fitzpatrick AL, Kukull WA,
Norton M, Aspelund T, Larson EB, Munger R, Rotter JI, Lipton RB,
Bullido MJ, Hofman A, Montine TJ, Coto E, Boerwinkle E, Petersen
RC, Álvarez V, Rivadeneira F, Reiman EM, Gallo M, O’Donnell CJ,
Reisch JS, Bruni AC, Royall DR, Dichgans M, Sano M, Galimberti D,
St George-Hyslop P, Scarpini E, Tsuang DW, Mancuso M, Bonuccelli
U, Winslow AR, Daniele A, Wu CK, Peters O, Nacmias B, Riemens-
chneider M, Heun R, Brayne C, Rubinsztein DC, Bras J, Guerreiro
R, Al-Chalabi A, Shaw CE, Collinge J, Mann D, Tsolaki M, Clarimon
J, Sussams R, Lovestone S, O’Donovan MC, Owen MJ, Behrens TW,
Mead S, Goate AM, Uitterlinden AG, Holmes C, Cruchaga C, In-
gelsson M, Bennett DA, Powell J, Golde TE, Graff C, De Jager PL,
Morgan K, Ertekin-Taner N, Combarros O, Psaty BM, Passmore P,
Younkin SG, Berr C, Gudnason V, Rujescu D, Dickson DW, Darti-
gues JF, DeStefano AL, Ortega-Cubero S, Hakonarson H, Campion
D, Boada M, Kauwe JK, Farrer LA, Van Broeckhoven C, Ikram MA,
Jones L, Haines JL, Tzourio C, Launer LJ, Escott-Price V, Mayeux- R,
Deleuze JF, Amin N, Holmans PA, Pericak-Vance MA, Amouyel P, van
Duijn CM, Ramírez A, Wang LS, Lambert JC, Seshadri S, Williams J,
Schellenberg GD. Rare coding variants in PLCG2, ABI3, and TREM2
implicate microglial-mediated innate immunity in Alzheimer’s disea-
se. Nat Genet. 2017; 49(9): 1373. Article. IF: 27.125; D
• Sivera R, Frasquet M, Lupo V, García-Sobrino T, Blanco-Arias P, Pardo
J, Fernández-Torrón R, de Munain AL, Márquez-Infante C,Villarreal L,
Carbonell P, Rojas-García R, Segovia S, Illa I, Frongia AL, Nascimento
A, Ortez C, García-Romero MD, Pascual SI, Pelayo-Negro AL, Ber-
ciano J, Guerrero A, Casasnovas C, Camacho A, Esteban J, Chumillas
MJ, Barreiro M, Díaz C, Palau F,Vilchez JJ, Espinos C, Sevilla T. Distri-
bution and genotype-phenotype correlation of GDAP1 mutations in
Spain. Sci Rep-Uk. 2017; 7: 6677. Article. IF: 4.122; Q1
• Soldevilla B, Cuevas-Martín C, Ibáñez C, Santacatterina F, Alberti
MA, Simo C, Casasnovas C, Márquez-Infante C, Sevilla T, Pascual SI,
Sánchez-Arago M, Espinos C, Palau F, Cuezva JM. Plasma metabo-
lome and skin proteins in Charcot-Marie-Tooth 1A patients. Plos
One. 2017; 12(6): e0178376. Article. IF: 2.766; Q1
• Tirado AG, Jiménez-Rolando B, Noval S, Bermejo AM. Cortical
blindness in a child secondary to mycoplasma pneumoniae infection.
J Stroke Cerebrovasc. 2017; 26(1) :E12-3. Article. IF: 1,598; Q4
• Vacas B, Rosal T, Méndez-Echevarría A, Royo A. Asymmetry of the
tongue. An Pediatr. 2017; 86(5): 290-1. Editorial Material. IF: 1.318
• van der Ploeg AT, Kruijshaar ME, Toscano A, Laforet P, Angelini C,
Lachmann RH, Pascual SIP, Roberts M, Rosler K, Stulnig T, van Doorn
PA,Van den Bergh PYK,Vissing J, Schoser B. European consensus for
starting and stopping enzyme replacement therapy in adult patients
with Pompe disease: a 10-year experience. Eur J Neurol. 2017; 24(6):
768-E31. Article. IF: 4.621; Q1
• Vázquez-López M, Castro PCD, Barredo-Valderrama E, Miranda-
Herrero MC, Gil-Villanueva N, Alcaraz-Romero AJ, Domingo AJD,
Pascual-Pascual SI. Ischaennic stroke in children with cardiopathy:
An epidemiological study. Neurología. 2017; 32(9): 602-9. Article. IF:
1.938; Q3
Public Projects
Bullido Gómez-Heras MJ. Identificación de alteraciones fun-
cionales en modelos patogénicos de la enfermedad de Al-
zheimer: implicación de la vía lisosomal (SAF2014-53954-R).
MINECO. 2015-2017.
Managment centre: UAM
Cerdán García-Esteller S, López Larrubia P. Cerebral regu-
lation of global energy balance in health and disease as detec-
ted by functional diffusion weighted MRI (SAF2014-53739-R).
MINECO. 2015-2017.
Managment centre: CSIC
Díez Tejedor E. Identificación de marcadores de daño de
fibras (axonal y mielina) en sustancia blanca cerebral y nue-
vas dianas terapéuticas para potenciar la reparación y re-
cuperación en el infarto subcortical. Estudio trasnacional
(PI12/01754). ISCIII. 2013-2017
Managment centre: FIBHULP
Díez Tejedor E. Red de enfermedades vasculares cerebrales.
INVICTUS PLUS (RD16/0019/0005). ISCIII. 2017-2020.
Managment centre: FIBHULP
Díez Tejedor E. Terapia reparadora con células madre mesen-
quimales alogénicas de tejido adiposo en el infarto cerebral
agudo comparado con tratamiento convencional. Evaluación
de seguridad. Estudio piloto (EC10-171). MSSSI. 2011-2017.
Managment centre: FIBHULP
Fuentes Gimeno B. Terapia reparadora con exosomas de cé-
lulas troncales mesenquimales en el infarto cerebral con daño
subcortical en un modelo animal experimental (PI15/01318).
ISCIII. 2016-2018.
Managment centre: FIBHULP
Gil Martínez A. Sistema de interacción natural para análisis
y rehabilitación de los trastornos de la marcha en la enfer-
medad de Parkinson (MOBEEZE) (RTC-2015-3870-1). MINE-
CO. 2015-2017.
Managment centre: FIBHULP
Gutiérrez Fernández MD. Exosomes as predictive biomar-
kers in acute ischemic stroke patients: a translational re-
search approach (CP15/00069). ISCIII. 2016-2018.
Managment centre: FIBHULP
Gutiérrez Fernández MD. Contrato Miguel Servet Tipo I
(CP15/00069). ISCIII. 2016-2021.
Managment centre: FIBHULP
Rodríguez de Rivera Garrido,Fj. Estudio doble ciego, con-
trolado con placebo, de grupos paralelos, aleatorizado, multi-
céntrico de la eficacia y seguridad de nicotinamida en pacien-
tes con ataxia de Friedreich (AC16/00082). ISCIII. 2017-2019.
Managment centre: FIBHULP
Ruiz Ares, G. Influencia de factores clínicos, bioquímicos y ul-
trasográficos asociados al pronóstico de la hemorragia intra-
cerebral parenquimatosa. Estudio traslacional (PI16/01052).
ISCIII. 2017-2019.
Managment centre: FIBHULP
Private Projects
Díez Tejedor E. Desarrollo de una base de datos para opti-
mizar terapéutica e investigación clínica en esclerosis múlti-
ple. Schering. 2004-Ongoing.
Managment centre: FIBHULP
Díez Tejedor E. Investigación en el campo de la esclerosis
múltiple. Donación Biomed Exuperio. 2007-Ongoing.
Managment centre: FIBHULP
Díez Tejedor E. Actualización y renovación de la actividad
en neurología crónica hospitalaria. Varios Financiadores.
2007-Ongoing.
Managment centre: FIBHULP
Díez Tejedor E. Evaluación computacional de la motrici-
dad y marcha en distintos trastornos neurológicos. Ebewe.
2008-Ongoing.
Managment centre: FIBHULP
Díez Tejedor E. Se formará en proyectos de inmunología
para la unidad de esclerosis múltiple, implantación del mode-
lo EAE, desarrolló técnicas para determinar las células regu-
ladoras y análisis de marcadores biológicos en pacientes con
EM que estén en tratamiento con NAT. Biogen. 2008-On-
going.
Managment centre: FIBHULP
Pascual Pascual SI. PI-713 Estudio de la eficacia de la toxi-
na botulínica en el pie equino espástico de la parálisis cere-
bral y de los factores que influyen en la misma. Allergan S.A.
2008-Ongoing.
Managment centre: FIBHULP
Vivancos Matellano F. Análisis de la diferente evolución clí-
nica de pacientes con enfermedad de Parkinson con trata-
miento adyuvante asociado de un inhibidor de la dopa de-
carboxilasa y un inhibidor de la COMT. Abbvie Spain S.L.U.
2008-Ongoing.
Managment centre: FIBHULP
Iváñez Mora V. Proyecto de creación de base de datos para
la investigación clínica y epidemiológica en epilepsia. EISAI
Farmaceutica SA. 2009-Ongoing.
Managment centre: FIBHULP
Díez Tejedor E. Sesiones clínicas de investigación del progra-
ma avance. Frank Merck. 2010-Ongoing.
Managment centre: FIBHULP
Díez Tejedor E. Registro clínico para el seguimiento de trata-
miento anticoagulante en prevención secundaria tras un ictus
cardioembólico. Boehringer Ingelheim España S.A. 2011-On-
going.
Managment centre: FIBHULP
Díez Tejedor E. Pacientes con esclerosis múltiple: análisis
de la respuesta a tratamientos biológicos. Fundación Biogen
Idec. 2013-Ongoing.
Managment centre: FIBHULP
Díez Tejedor E. Informatización de la gestión de pacientes.
Unidad de neuroinmunología y esclerosis múltiple en el
Hospital Universitario La Paz. Novartis Farmaceutica S.A.
2014-Ongoing.
Managment centre: FIBHULP
Rodríguez de Rivera Garrido FJ. Consorcio europeo de
109
 3
Information Groups by Area
3.1 Neuroscience Area
ataxia de Friedreich para la realización de estudios traslacio-
nales.Varios Financiadores. 2015-Ongoing.
Managment centre: FIBHULP
Alonso de Leciñana Cases M. Identificación de proteínas
implicadas en la neuroreparación tras la isquemia cerebral.
Estudio clínico-experimental. Fundación Hospital Ramón y
Cajal. 2016-Ongoing.
Managment centre: FIBHULP
Díez Tejedor E. Brain repair therapy with exosomes derived
mesenchymal stem cells in experimental intreacerebral he-
morrhage model. Roche Farma S.A. 2016-Ongoing.
Managment centre: FIBHULP
Gil Martínez A. Sistema de interacción natural para análisis y
rehabilitación de los trastornos de la marcha en la enferme-
dad de Parkinson (MOBEEZE). Fundación I+D del Software
Libre. 2016-Ongoing.
Managment centre: FIBHULP
Royo Orejas A. Actualización y renovación de la actividad
investigadora en la sección de neurorradiología del Hospital
Universitario La Paz.Varios Financiadores. 2016-Ongoing.
Managment centre: FIBHULP
Bullido Gómez-Heras MJ. Papel de la proteína lisosomal
LAMP2 en la neurodegeneración de tipo Alzheimer induci-
da por el virus HSV-1: estudio del interactoma de LAMP2
en neuronas infectadas. Fundación Ramón Areces. 2017-On-
going.
Managment centre: FIBHULP
Pascual Pascual SI. Safety evaluation on the use of botuli-
num toxin type a for the treatment of spasticity in children
after 20 years of experience 1996-2015. A retrospective mo-
nocenter observacional study based on a data base contai-
ning over 1000 children. Ipsen Innovation. 2017-Ongoing.
Managment centre: FIBHULP
Roda Frade JM. Programa de formación de un becario para
el estudio del paciente diagnosticado con dolor crónico y/o
trastornos del movimiento candidato a tratamiento con neu-
romodulacion medular y cerebral. Boston Scientific Ibérica
SA. 2017-Ongoing.
Managment centre: FIBHULP
INTERNATIONAL Projects
Díez Tejedor E. RESSTORE Regenerative stem cell therapy
for stroke in europe- resstore. Therapeutic efficacy of allo-
genic adipose tissue derived mesenchymal stem cells for en-
hancing functional outcome in stroke patients. (Topic PHC-
15-2015). H2020: UE. 2016-2020.
Managment centre: FIBHULP
CLINICAL TRIALS
Díez Tejedor E. Estudio de fase IB/II, multicéntrico, aleatori-
zado, con doble enmascaramiento (con sujetos del estudio,
sin enmascaramiento, para el promotor), controlado con pla-
cebo, de dosis única ascendente, para evaluar la seguridad, la
farmacocinética y la farmacodinámica de DS-1040B en su-
jetos con ictus isquémico agudo. Type: Clinical Trial, phase II.
HULP code: 4753. Sponsored´s protocol code: DS1040-A-U103.
110
Sponsored by: Daiichi-Sankyo Development Limited.
Signed date: 14/03/2017
Díez Tejedor E. Estudio de superioridad, fase III, multicéntrico,
aleatorizado, doble-ciego, doble simulación, con comparador
activo y dirigido por eventos, que compara rivaroxaban 15
mg en una toma diaria con aspirina 100 mg, en la prevención
secundaria de accidente cerebrovascular y embolia sistémica
en pacientes que han sufrido un accidente cerebrovascular
embólico de etiología indeterminada (ACEI). (Navigate Esus).
Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4328. Sponsored´s protocol code: BAY 59-
7939/1657.
Sponsored by: Bayer Heathcare AG.
Signed date: 14/12/2017
Díez Tejedor E. Estudio en fase II, aleatorizado, controlado
con placebo y doble ciego, para evaluar la seguridad, eficacia
y farmacocinética del ARGX-113 en pacientes con miastenia
gravis que presentan debilidad muscular generalizada. Type:
Clinical Trial, phase II.
HULP code: ANEXO-I 4701. Sponsored´s protocol code: ARGX 113
1602.
Sponsored by: Argenx BVBA.
Signed date: 20/07/2017
Frank García A. A 6-months prospective, multi-center,
double-blind, placebo-controlled, randomized, adaptive-trial-
design study to evaluate safery, tolerability and exploratory
endpoints of either placebo or two different oral doses of
LM11A-31-BHS in patients with mild to moderate probable
Alzheimer´s disease. Type: Clinical Trial, phase II.
HULP code: 4880. Sponsored´s protocol code: NSC15001.
Sponsored by: Pharmatrophix Inc.
Signed date: 20/09/2017
Frank García A. Estudio de 24 meses, de grupos paralelos,
doble ciego y controlado con placebo para evaluar la eficacia
y la seguridad de E2609 en pacientes con enfermedad de
Alzheimer temprana. Type: Clinical Trial, phase III.
HULP code: 4792. Sponsored´s protocol code: E2609-G000-302.
Sponsored by: EISAI Europe Limited.
Signed date: 14/09/2017
Frank García A. Estudio de extensión, multicéntrico, aleato-
rizado, con dos periodos, doble ciego controlado con place-
bo y abierto, para determinar la seguridad y tolerabilidad a
largo plazo de JNJ-54861911 en sujetos en el espectro de en-
fermedad de Alzheimer temprana. Type: Clinical Trial, phase II.
HULP code: ANEXO-II 4437.
Sponsored´s protocol code: 54861911ALZ2004.
Sponsored by: Janssen Cilag International NV.
Signed date: 01/06/2017
Lara Lara M. Ensayo de fase 3 de grupos paralelos, doble
ciego, aleatorizado y controlado con placebo, para evaluar
la eficacia y la seguridad de ALD403 administrado por vía
intravenosa en pacientes con migraña crónica. Type: Clinical
Trial, phase III.
HULP code: ANEXO-I 4755. Sponsored´s protocol code: ALD403-
CLIN-011.
Sponsored by: Alder Biopharmaceuticals Inc.
Signed date: 02/06/2017
Lara Lara M. Ensayo de fase III de grupos paralelos, doble
ciego, aleatorizado y controlado con placebo, para evaluar
la eficacia y la seguridad de ALD403 administrado por vía
intravenosa en pacientes con migraña crónica. Type: Clinical
Trial, phase III.
HULP code: 4755. Sponsored´s protocol code: ALD403-CLIN-011.
Sponsored by: Alder Biopharmaceuticals Inc.
Signed date: 05/01/2017
Lara Lara M. La carga de la migraña en centros de cefalea
especializados que tratan pacientes que han fallado a trata-
mientos preventivos (Become). Type: EPA-SP.
HULP code: PI-2937. Sponsored´s protocol code: CAMG334A3301/
NOV-MIG-2017-01.
Sponsored by: Novartis Farmaceutica S.A.
Signed date: 27/11/2017
López Arrieta JM. Estudio de 24 meses, de grupos paralelos,
doble ciego y controlado con placebo para evaluar la eficacia
y la seguridad de E2609 en pacientes con enfermedad de
Alzheimer temprana. Type: Clinical Trial, phase III.
HULP code: 4793. Sponsored´s protocol code: E2609-G000-301.
Sponsored by: EISAI Europe Limited.
Signed date: 14/09/2017
López Arrieta JM. Estudio multicéntrico de fase IIA/IIB, alea-
torizado, doble ciego, controlado con placebo, de 56 semanas
de seguimiento, para evaluar la seguridad y la eficacia de bi-
magrumab i.v. sobre la masa corporal magra total y la activi-
dad fisica en pacientes después de tratamiento quirúrgico de
fractura de cadera. Type: Clinical Trial, phase II.
HULP code: ANEXO-III 4206. Sponsored´s protocol code: CB-
YM338D2201.
Sponsored by: Novartis Farmaceutica S.A.
Signed date: 21/12/2017
Pascual Pascual SI. Ensayo multicéntrico, aleatorizado, doble
ciego, controlado con placebo para evaluar los efectos del
fosfato sódico de dexametasona intra-eritrocito en los sínto-
mas neurológicos de pacientes con ataxia telangiectasia.Type:
Clinical Trial, phase III.
HULP code: ANEXO-I 4598. Sponsored´s protocol code: IE-
DAT-02-2015.
Sponsored by: Erydel S.P.A.
Signed date: 13/03/2017
Pascual Pascual SI. Estudio de extensión del seguimiento
internacional, multicéntrico, doble ciego de 9 meses de du-
ración para evaluar la seguridad y tolerabilidad a largo plazo
de PXT3003 en pacientes con enfermedad de charcot-marie-
tooth de tipo 1A. Type: Clinical Trial, phase III.
HULP code: 4768. Sponsored´s protocol code: PXT3003-03.
Sponsored by: Pharnext.
Signed date: 29/06/2017
Pascual Pascual SI. Estudio de fase III, doble ciego, aleato-
rizado y controlado con placebo para evaluar la eficacia, la
seguridad y la tolerabilidad de idebenona en pacientes con
distrofia muscular de Duchenne que reciben glucocorticoes-
teroides. Type: Clinical Trial, phase III.
HULP code: 4858. Sponsored´s protocol code: SNT-III-012.
Sponsored by: Santhera Pharmaceuticals Ltd.
Signed date: 20/09/2017
Pascual Pascual SI. Estudio en fase III, aleatorizado, doble
ciego, controlado con placebo, multicéntrico e internacional
que evalúa en grupos paralelos la eficacia y seguridad de 2
dosis de PXT3003 en pacientes con síndrome de Charcot-
Marie-Tooth de tipo 1A tratados durante 15 meses.Type: Cli-
nical Trial, phase III.
HULP code: ANEXO-I 4534. Sponsored´s protocol code: CLN-
PXT3003-02.
Sponsored by: Pharnext.
Signed date: 12/06/2017
Vivancos Matellano F. Estudio de evaluación de la mono-
terapia y de la terapia combinada con el gel intestinal de
levodopa-carbidopa. Type: EPA-OD.
HULP code: PI-2953. Sponsored´s protocol code: ABB-LEV-2017-01.
Sponsored by: Abbvie Spain S.L.U.
Signed date: 05/12/2017
Patents and Trademarks
Valdivieso Amate F, Bullido Gómez-Heras MJ, Martínez
García A, inventors; UAM, assignee. Method of identifying
compounds that induce or inhibit endoplasmic reticulum
stress or oxidative stress. P200702997, PCT/ES2008/000705,
EP2221379, US20100304384; 2007 November 13.
Vergés Milano J, García García A, Ruhí Roura R, Montell
Bonaventura E, García López M, Aláez Versón CR, Escaich
Ferrer J, Egea Máiquez J, Lorrio González S, Negredo
Madrigal P, inventors; BIOIBÉRICA S.A., UAM, assignees.
Sulphated disaccharides for the treatment of neurodege-
nerative and/or neurovascular diseases. P200902399, PCT/
EP2010/070613, US20120309707, CA20102785237; 2010
December 22.
Valdivieso Ámate F, Burgos Muñoz JS, Ramírez Moreno C,
Sastre Merlín I, inventors; UAM, CSIC, assignees. Method
of identifying therapeutic compounds which can be used
for the treatment and/or prevention of infections and di-
seases caused by human herpes viruses. P200400965, PCT/
ES2005/000209, EP1769677, US20070218004, AT447321,
AU2005235319, CA2562787, JP2007533315; 2004 April 21.
Valdivieso Ámate F, Montoliú JL, Pozueta Larios J, inven-
tors; UAM, CSIC, assignees. Alzheimer’s disease animal model,
method for obtaining same and uses thereof. P200503002,
PCT/ES2006/000673, EP1956091, EP20060841725,
US20090222932, CA2638983, JP2009517066; 2005 Decem-
ber 02.
Ballesteros García P, López Larrubia P, Domínguez Mateo
L, Marco Contelles JL, Cerdán García-Esteller S, inventors;
Universidad Nacional de Educación a Distancia, CSIC, assig-
nees. Set of magnetic resonance imaging and spectroscopy
cell acidity extrinsic indicators comprise polyol derivatives
based on alditols. P200300936; 2003 April 23.
111
 3
Information Groups by Area
3.1 Neuroscience Area
Neuroprotective Strategies
in Neurodegenerative
Diseases Group
10 62.421 9
Antonio Cuadrado Pastor. Catedrático. Facultad de
Medicina. UAM
Ángel Juan García Yagüe. Investigador Postdoctoral. CIBERNED
Nadia Giselle Innamorato. Investigadora Predoctoral. UAM
Isabel Lastres Becker. Investigadora Senior (Contrato Ramón y Cajal).
UAM
Ángela Martínez Valverde. Investigadora Postdoctoral. IIB Alberto Sols
Patricia Rada Llano. Investigadora Postdoctoral. UAM
Strategic Objective
Oxidative stress is a key element in the aetiopatho-
genesis of neurodegenerative diseases and their co-
morbidities. Our laboratory studies the antioxidant
protection mechanisms activated by extracellular sig-
nals and how this response ould be regulated pharma-
cologically to provide a therapeutic benefit in these
diseases.
To meet these two objectives, we are studying signa-
lling pathways that regulate antioxidant metabolism
and provide a general protective response. An impor-
tant finding of this group was the observation that
the PI3K/AKT/GSK-3 survival pathway regulates the
transcription factor Nrf2, guardian of cellular redox
homeostasis, that provides protection against oxi-
dative, inflammatory and proteotoxic stress. For the
past year we have been working on the validation this
transcription factor as a new therapeutic target to mo-
dify progression of Parkinson’s and Alzheimer’s disease
as well as co-morbid retinopathy and type II diabetes.
112
Research Lines
• Role of oxidative stress in neuronal death and neu-
roinflammation in neurodegenerative diseases.
• The transcription factor Nrf2 as a new therapeutic
target in Parkinson’s and Alzheimer’s disease.
• Molecular basis of type 2 diabetes and its complica-
tions (diabetic retinopathy and nephropathy).
Research Activity
PUBLICATIONS
• Egea J, Fabregat I, Frapart YM, Ghezzi P, Gorlach A, Kietzmann T,
Kubaichuk K, Knaus UG, López MG, Olaso-González G, Petry
A, Schulz R, Vinal J, Winyard P, Abbas K, Ademowo OS, Afonso
CB, Andreadou I, Antelmann H, Antunes F, Aslan M, Bachschmid
MM, Barbosa RM, Belousov V, Berndt C, Bernlohr D, Bertran E,
Bindoli A, Bottari SP, Brito PM, Carrara G, Casas AI, Chatzi A,
Chondrogianni N, Conrad M, Cooke MS, Costa JG, Cuadrado A,
Dang PMC, De Smet B, Butuner BD, Dias IHK, Dunn JD, Edson
AJ, El Assar M, El-Benna J, Ferdinandy P, Fernandes AS, Fladmark
KE, Forstermann U, Giniatullin R, Giricz Z, Gorbe A, Griffiths
H, Hampl V, Hanf A, Herget J, Hernansanz-Agustin P, Hillion M,
Huang JJ, Ilikay S, Jansen-Durr P, Jaquet V, Joles JA, Kalyanaraman
B, Kaminskyy D, Karbaschi M, Kleanthous M, Klotz LO, Korac
B, Korkmaz KS, Koziel R, Kracun D, Krause KH, Kren V, Krieg T,
Laranjinha J, Lazou A, Li HG, Martínez-Ruiz A, Matsui R, McBean
GJ, Meredith SP, Messens J, Miguel V, Mikhed Y, Milisav I, Milkovic
L, Miranda-Vizuete A, Mojovic M, Monsalve M, Mouthuy PA, Mul-
vey J, Munzel T, Muzykantov V, Nguyen ITN, Oelze M, Oliveira
NG, Palmeira CM, Papaevgeniou N, Pavicevic A, Pedre B, Peyrot
F, Phylactides M, Pircala-
bioru GG, Pitt AR, Poul-
sen HE, Prieto I, Rigobello
MP, Robledinos-Antón N,
Rodríguez-Mañas L, Rolo
AP, Rousset F, Ruskovska T,
Saraiva N, Sasson S, Schro-
der K, Semen K, Seredenina
T, Shakirzyanova A, Smith GL,
Soldati T, Sousa BC, Spickett
CM, Stancic A, Stasia MJ, Stein-
brenner H, Stepanic V, Steven S,
Tokatlidis K, Tuncay E, Turan B,
Ursini F, Vacek J, Vajnerova O, Va-
lentova K, Van Breusegem F, Varisli L,
Veal EA, Yalcin AS, Yelisyeyeva O, Zarkovic N,
Zatloukalova M, Zielonka J, Touyz RM, Papapetro-
poulos A, Grune T, Lamas S, Schmidt HHHW, Di Lisa F, Daiber
A. European contribution to the study of ROS: A summary of the
findings and prospects for the future from the COST action BM1203
(EU-ROS). Redox Biol. 2017; 13: 94-162. Review. IF: 7.126; Q1
• Escoll M, Gargini R, Cuadrado A, Antón IM, Wandosell F. Mutant
p53 oncogenic functions in cancer stem cells are regulated by WIP
through YAP/TAZ. Oncogene. 2017; 36(25): 3515-27. Article. IF:
6.854; Q1
• Gameiro I, Michalska P, Tenti G, Cores A, Buendía I, Rojo AI, Geor-
gakopoulos ND, Hernández-Guijo JM, Ramos MT, Wells G, López
MG, Cuadrado A, Menéndez JC, León R. Discovery of the first dual
GSK3 beta inhibitor/Nrf2 inducer. A new multitarget therapeutic
strategy for Alzheimer’s disease. Sci Rep-Uk. 2017; 7: 45701. Article.
IF: 4.122; Q1
• Navarro E, González-Lafuente L, Pérez-Liebana I, Buendía I, López-
Bernardo E, Sánchez-Ramos C, Prieto I, Cuadrado A, Satrustegui J,
Cadenas S, Monsalve M, López MG. Heme-oxygenase I and PCG-1
alpha regulate mitochondrial biogenesis via microglial activation of
alpha7 nicotinic acetylcholine receptors using PNU282987. Antio-
xid Redox Sign. 2017; 27(2): 93-105. Article. IF: 6.53; D1
• Nayernia Z, Colaianna M, Robledinos-Antón N, Gutzwiller E, Sloan-
Bena F, Stathaki E, Hibaoui Y, Cuadrado A, Hescheler J, Stasia MJ,
Saric T, Jaquet V, Krause KH. Decreased neural precursor cell pool in
NADPH oxidase 2-deficiency: From mouse brain to neural differen-
tiation of patient derived iPSC. Redox Biol. 2017; 13: 82-93. Article.
IF: 7.126; Q1
• Pajares M, Cuadrado A, Rojo AI. Modulation of proteostasis by
transcription factor NRF2 and impact in neurodegenerative disea-
ses. Redox Biol. 2017; 11: 543-53. Review. IF: 7.126; Q1
• Robledinos-Antón N, Rojo AI, Ferreiro E, Núñez A, Krause KH,
Jaquet V, Cuadrado A. Transcription factor NRF2 controls the fate
of neural stem cells in the subgranular zone of the hippocampus.
Redox Biol. 2017; 13: 393-401. Article. IF: 7.126; Q1
• Rojo AI, Pajares M, Rada P, Núñez A, Nevado-Holgado AJ, Killik R,
Van Leuven F, Ribe E, Lovestone S,Yamamoto M, Cuadrado A. NRF2
deficiency replicates transcriptomic changes in Alzheimer’s patients
and worsens APP and TAU pathology. Redox Biol. 2017; 13: 444-51.
Article. IF: 7.126; Q1
• Tobón-Velasco JC, Limón-Pacheco JH, Orozco-Ibarra M, Macías-
Silva M, Vázquez-Victorio G, Cuevas E, Ali SF, Cuadrado A, Pe-
draza-Chaverri J, Santamaría A. 6-OHDA-induced apoptosis and
mitochondrial dysfunction are mediated by early modulation of
intracellular signals and interaction of Nrf2 and NF-kappa B factors.
Toxicology. 2017; 390: 167. Article. IF: 3.265; Q2
• Tobón-Velasco JC, Vázquez-Victorio G, Macías-Silva M, Cuevas E,
Ali SF, Maldonado PD, González-Trujano ME, Cuadrado A, Pedraza-
Chaverri J, Santamaría A. S-Allyl cysteine protects against 6-hydro-
xydopamineinduced neurotoxicity in the rat striatum: involvement
of Nrf2 transcription factor activation and modulation of signaling
kinase cascades. Free Radical Bio Med. 2017; 104: 382. Article. IF:
6.02; Q1
Public Projects
Cuadrado Pastor A. Red de investigación en NRF2 como
nodo del patogenosoma (SAF2015-71304-REDT). MINECO.
2015-2017.
Managment centre: UAM
Martínez Valderde A. Inflammation associated with cronic
metabolic damage in diabetes mellitus and its complications
(SAF2015-65267-R). MINECO. 2016-2018.
Managment centre: CSIC
Private Projects
Cuadrado Pastor A. Targeting NRF2 with SFX-01 to modi-
fy Parkinson’s disease progression in the AAV6-A-synuclein
mouse model. Evgen. 2016-Ongoing.
Managment centre: UAM
Martínez Valverde A. Desarrollo de mecanismo de acción
del glicinato de metformina en un modelo de hepatocitos.
Laboratorios Silanes. 2015-2017.
Managment centre: CSIC
Martínez Valverde A. Colaboración para el fomento de la
investigación desarrollada en el grupo IdiPAZ Estrategias
Neuroprotectoras en Enfermedades Neurodegenerativas.
FIBHULP. 2013-Ongoing.
Managment centre: FIBHULP
INTERNATIONAL Projects
Cuadrado Pastor A. Aproximación teranóstica avanzada en
cáncer combinando terapia fotodinámica y nanopartículas
(PCIN-2016-071). MINECO-EU. 2016-2018.
Managment centre: UAM
Cuadrado Pastor A. Anowledge transfer in redox biology
for developing advanced molecular tools in neurodegenera-
tive diseases - focus on the signature of NRF2 transcription
factor in diagnosis and therapy (P_37_732). EU. 2016-2020.
Managment centre: Víctor Babes National Institute of Patholo-
gy (Bucharest)
Patents and Trademarks
Cuadrado Pastor A, Innamorato NG, inventors: CSIC, UAM.
Use of sulforaphane as supplementary therapy for early-stage
neurodegenerative disease. P201231693; 2012 November 06.
León Martínez R, Egea Maíquez J, Buendía Abaitua I, Para-
da Pérez E, Navarro González de Mesa E, inventors; Funda-
ción para la Investigación Biomédica del Hospital Universita-
rio de La Princesa, UAM, CSIC, DNS NEUROSCIENCE S.A.,
assignees. Use of 3-(2-isothiocyanatoethyl)-5-methoxy-1H-
indole for the treatment of neurodegenerative diseases.
P201300667; 2013 July 17.
León Martínez R, Buendía Abaitua I, Navarro González de
Mesa E, Michalska P, Gameiro Ros I, López Vivo A, Egea
Maíquez J, García López M, García García A, inventors;
Fundación para la Investigación Biomédica del Hospital Uni-
versitario de La Princesa, UAM, DNS NEUROSCIENCE S.A.,
assignees. Compounds derived from 3-alkylamine-1H-indolyl
acrylate and its use for the treatment of neurodegenerati-
ve diseases. P201400810, PCT/ES2015/000139, CA2964309;
2014 October15.
113
 3
Information Groups by Area

3.1 Neuroscience Area

Research Activity Public Projects

Involvement of Glycinergic López Corcuera B, Rueda Aragón C. Estructura, función y
PUBLICATIONS
and Glutamatergic Systems
regulación del transportador neuronal de glicina GLYT2 en
• López-Corcuera B, Benito-Muñoz C, Aragón C. Glycine tansporters
mutaciones asociadas a hiperplexia humana: desarrollo de
nuevos modelos de estudio. (SAF2014-58045-R). MINECO.

in Central Nervous System

in glia cells: structural studies. Adv Neurobiol. 2017; 16: 13-32-. Arti-
cle. Not Indexed 2015-2017.
• Villarejo-López L, Jiménez E, Bartolomé-Martín D, Zafra F, Lapunzi- Managment centre: UAM

Pathologies Group na P, Aragón C, López-Corcuera B. P2X receptors up-regulate the

cell-surface expression of the neuronal glycine transporter GlyT2.
Neuropharmacology. 2017; 125: 99-116. Article. IF: 4.249. Q1
• Zafra F, Ibáñez I, Giménez C. Glutamate transporters: The arrestin
connection. Oncotarget. 2017; 8(4): 5664-5. Editorial Material. Not
Indexed
• Zafra F, Ibáñez I, Bartolomé-Martín D, Piniella D, Arribas-Blázquez
M, Giménez C. Glycine transporters and its coupling with NMDA
receptors. Adv Neurobiol. 2017;16:55-83. Article. Not Indexed
Porlán Alonso EM. Control de la división celular asimétrica
por reguladores mitóticos: implicaciones para procesos pa-
tológicos y regenerativos del sistema nervioso (SAF2015-
67756-R). MINECO. 2016-2018.
Managment centre: UAM
Zafra Gómez F. Regulación por microRNAs de las sinapsis
glutamatérgicas en isquemia. Desarrollo de técnicas no in-
vasivas para el estudio de la neurotransmisión mediada por
glutamato (SAF2014-55686-R). MINECO. 2015-2017.
Managment centre: UAM

Private Projects
Zafra Gómez F. Mecanismos moleculares del síndrome de
Dravet. Fundación Ramón Areces. 2015-2017.
Managment centre: UAM

4 4.249 -

Francisco Zafra Gómez. Catedrático. Facultad de Ciencias.
UAM
María del Carmen Aragón Rueda. Catedrática. Facultad de
Ciencias. UAM
Cecilio Giménez Martín. Catedrático. Facultad de Ciencias. UAM
Beatriz Fuensanta López Corcuera. Profesora Titular. Facultad
de Ciencias. UAM
• Regulation of GlyTs by receptors involved in pain
Enrique Núñez Balbuena. Investigador Posdoctoral. UAM
Eva María Porlan Alonso. Investigador Postdoctoral. UAM
already known or new mutants of human hype-
rekplexia.
D) Development of alternative cellular models for
the study of hyperekplexia mutants such as in-
fection of primary neurons with lentiviral par-
ticles or the generation of induced pluripotent
stem cells (iPSC) from patient samples.
signal processing in nociceptive pathways of the spi-
nal cord.

Strategic Objective Research Lines

The group studies the physiological and pathologi-
cal aspects of the glycine transporters (GlyTs) in the
central nervous system as emerging drug targets in
transmission mediated glycine dysfunctions as hype-
rekplexia or pain.
A) Identification, analysis and classification of muta-
tions in the gene of GlyT2 (SLC6A5) in human
patients with hyperekplexia.
B) Effects of mutations of hyperekplexia on the
molecular structure, biogenesis and intracellular
trafficking of GlyT2. Study of the interaction of
inhibitors with GlyT2 (dockings on 3D models)
for selecting regions that facilitate folding or acti-
vity of hyperekplexia mutants.
C) Study of the interactome of GlyT2 with proteins
114
The group studies the physiological and pathological
aspects of glutamate fuxes in brain as potential tar-
gets to prevent excitotoxicity, associated with brain
disfunctions like ischemia, o traumatic brain injury:
A) Identification of novel regulatory mechanisms
by characterization of the glutamate transporter
interactome.
B) Identification of novel regulatory mechanisms by
microRNAs and othe non-coding RNAs.
The group studies the physiological and pathological
aspects Neuronal reparation by adult neurogenesis:
A) Identification of novel regulatory mechanisms of
adult neurogenesis by kinases.
B) Identification of novel regulatory mechanisms
of adult neurogenesis by microRNAs and other
non-coding RNAs.
115
 3
Information Groups by Area

Research on Invasive
Clinical Cardiology –
ICCI-Paz GROUP

3.2 65 310.483 34

Cardiovascular José Luis López-Sendon Hentschel. Jefe de Servicio

de Cardiología. HULP
María Isabel Antorrena Miranda. Facultativo Especialista de
Esteban López de Sá y Areses. Jefe de Sección de Cuidados
Intensivos Cardiológicos. HULP
José Luis Merino Llorens. Facultativo Especialista de Área en

Area Área en Cardiología. HULP

Eduardo Armada Romero. Facultativo Especialista de Área en
Cardiología. HULP
Cardiología. Director Unidad Investigación en Arritmias/Electrofisiología
Robótica. HULP
Madría del Carmen Monedero Martín. Facultativo Especialista
de Área en Cardiología. HULP
Almudena Castro Conde. Facultativo Especialista de Área en
José Luis López-Sendón Hentschel Cardiología. HULP José Raúl Moreno Gómez. Jefe de Sección de Hemodinámica. HULP
Regina Dalmáu González-Gallarza. Facultativo Especialista de María del Mar Moreno Yangüela. Jefe de Sección de Imagen
Área en Cardiología. HULP Cardiaca. HULP
Francisco Javier Domínguez Melcón. Facultativo Especialista Rafael Peinado Peinado. Facultativo Especialista de Área en
Cardiología. HULP
176 925.517 de Área en Cardiología. HULP
Carlos Escobar Cervantes. Facultativo Especialista de Área en Elena María Refoyo Salicio. Facultativo Especialista de Área en
124 689.377 Cardiología. HULP
Cardiología. HULP
21.02% 52.84% Jaime Fernández de Bobadilla Osorio. Facultativo Juan Ramón Rey Blas. Facultativo Especialista de Área en Cardiología.
Especialista de Área en Cardiología. HULP HULP
Javier Fuertes Beneítez. Facultativo Especialista de Área en Luis Felipe Riera del Moral. Facultativo Especialista de Área en
Cardiología. HULP Angiología y Cirugía Vascular. HULP. Profesor Asociado Departamento de
Research on Invasive Clinical Cardiology – Guillermo Galeote García. Facultativo Especialista de Área en
Cirugía. UAM

ICCI-Paz Group
Cardiovascular Epidemiology and Nutrition Group
Coagulopathies and Alterations of Haemostasis Group
Vascular Physiology and Pharmacology Group
Vascular Pharmacology and Metabolism Group (FARMAVSM)
Cardiology Research Group (HUF)
116
Cardiología. HULP Inmaculada Roldán Rabadán. Facultativo Especialista de Área en
Cardiología. HULP
Elvira Ana González García. Facultativo Especialista de Área en
José Ruiz Cantador. Facultativo Especialista de Área en Cardiología.
Cardiología. HULP
HULP
Teresa González Gallego. Investigadora Senior (Contrato Ramón
Ángel Sánchez Recalde. Facultativo Especialista de Área en
y Cajal). IIB Alberto Sols
Cardiología. HULP
Gabriela Guzmán Martínez. Facultativo Especialista de Área en
Silvia Cayetana Valbuena López. Médico Interno Residente en
Cardiología. HULP
Cardiología. HULP
Ángel Manuel Iniesta Manjavacas. Facultativo Especialista de
Área en Cardiología. HULP
Santiago Jiménez Valero. Facultativo Especialista de Área en Strategic Objective
Cardiología. HULP The group consists of various healthcare units of the
Teresa López Fernández. Facultativo Especialista de Área en Department of Cardiology at Hospital La Paz: Cli-
Cardiología. HULP nic/Coronary Unit, interventional cardiology, cardiac
117
 3
Information Groups by Area
3.2 Cardiovascular Area
imaging, electrophysiology, rehabilitation and adult conge-
nital heart disease.
The main research lines focus on providing clinical respon-
ses, with local research protocols and direct participation
in clinical trials and international multicentre registries.
Moreover, clinical translational potential is reinforced
through an institutional relationship with the CNIC.
Research Lines
• Myocardial ischaemia. Acute and chronic. Diagnosis,
prognosis and treatment.
• Cardiac arrhythmias. Catheter navigation systems.
• Diagnosis and treatment. Post cardiac arrest hypother-
mia.
• Heart Failure. Diagnosis and treatment. Cardiotoxicity
of antineoplastic agents.
• Cardiac diagnostic imaging.
• Aortic stenosis. Diagnosis and treatment.
• Adult congenital heart diseases.
Research Activity
Doctoral TheseS
Cuesta López E. Resonancia magnética cardiaca en ata-
xia de Friedreich: seguimiento cardiaco de las terapias
antioxidantes[dissertation]. Madrid: UAM: 2017(06/06/2017).
Directors: López-Sendón JL, Arpa Gutiérrez FJ, Bret Zurita M.
Refoyo Salicio E. Valor de la resonancia magnética en
el diagnóstico de la cardiopatía chagásica en área no
endémica[dissertation]. Madrid: UCM: 2017(12/07/2017).
Directors: Tamargo Menéndez J, López-Sendón JL.
Sánchez Recalde A. Pevalencia y factores predictivos de mor-
talidad y complicaciones a largo plazo en un serie de 481 pa-
cientes con coartación de aorta[dissertation]. Madrid: UAM:
2017(25/09/2017).
Directors: López-Sendón JL, Oliver JM.
Fernández Heredero A. Incidencia y factores asociados
a nefropatía inducida por contrastes en pacientes some-
tidos a reparación endovascular de aneurismas de aorta
abdominal[dissertation]. Madrid: UAM: 2017(10/05/2017).
Directors: Riera del Moral L, Rodríguez Montes JA.
Concepción Rodríguez NA. Estudio de validación diagnósti-
ca: relación entre espectroscopía óptica e índice tobillo bra-
zo en la enfermedad arterial periférica[dissertation]. Madrid:
UAM: 2017(22/09/2017).
Directors: Riera del Moral L, Rodríguez Montes JA.
Álvarez García J. Tratamiento mediante implante de células
troncales mesenquimales de la isquemia crítica de las extre-
midades en un modelo murino experimental[dissertation].
Madrid: UAM: 2017(24/01/2017).
Directors: Riera del Moral L, García Arranz M.
PUBLICATIONS
• Alfonso F, Cuesta J, Pérez-Vizcayno MJ, del Blanco BG, Rumoroso
JR, Bosa F, de Prado AP, Masotti M, Moreno R, Cequier A, Gutiérrez
H, Touchard AG, López-Mínguez JR, Zueco J, Martí V, Velázquez M,
Moris C, Bastante T, García-Guimaraes M, Rivero F, Fernández C.
118
Bioresorbable vascular scaffolds for patients with in-stent resteno-
sis the RIBS VI Study. JACC-Cardiovasc Inte. 2017; 10(18): 1841-51.
Article. IF: 9.881; D1
• Alfonso F, Pérez-Vizcayno MJ, del Blanco BG, García-Touchard A,
López-Mínguez JR, Sabate M, Zueco J, Melgares R, Hernández R,
Moreno R, Domínguez A, Sanchís J, Moris C, Moreu J, Cequier A,
Romaguera R, Rivero F, Cuesta J, Gonzalo N, Jiménez-Quevedo P,
Cárdenas A, Fernández C. Usefulness of drug eluting balloons for
bare metal and drug eluting in stent restenosis (from the RIBS IV
and V Randomized Trials). Am J Cardiol. 2017; 119(7): 983-90. Arti-
cle. IF: 3.171; Q2
• Amat-Santos IJ, Cortés C, Franco LN, Muñoz-García AJ, de Lezo JS,
Gutiérrez-Ibanés E, Serra V, Larman M, Moreno R, Hernández JMD,
Puri R, Jiménez-Quevedo P, García JMH, Alonso-Briales JH, García
B, Lee DH, Rojas P, Sevilla T, Goncalves R, Vera S, Gómez I, Rodes-
Cabau J, San Román JA. Prosthetic mitral surgical valve in trans-
catheter aortic valve replacement recipients: A multicenter analysis.
JACC-Cardiovasc Inte. 2017; 10(19): 1973-81. Article. IF: 9.881; D1
• Aroca A, Polo L, Pérez-Farinos N, González-Rocafort A, Sánchez R,
Bret M, Rey J, Ruiz J, González A, Arreo V, Pérez N, Peña N, Jofre C,
Leyra F, Sánchez-Recalde A. Do porcine pulmonary bioprosthesis
perform the same job in children as in adults? A word of caution.
Cir Cardiov. 2017; 24(3): 135-41. Article. Not Indexed
• Ávila P, Oliver JM, Gallego P, González-García A, Rodríguez-Puras
MJ, Cambronero E, Ruiz-Cantador J, Campos A, Peinado R, Prieto
R, Sarnago F, Yotti R, Fernández-Avilés F. Natural history and clinical
predictors of atrial tachycardia in adults with congenital heart disea-
se. Circ-Arrhythmia Elec. 2017; 10(9): e005396. Article. IF: 4.712; Q1
• Bagai A, Alexander KP, Berger JS, Senior R, Sajeev C, Pracon R, Ma-
vromatis K, López-Sendón JL, Gosselin G, Díaz A, Perna G, Drozdz
J, Humen D, Petrauskiene B, Cheema AN, Phaneuf D, Banerjee S,
Miller TD, Kedev S, Schuchlenz H, Stone GW, Goodman SG, Maha-
ffey KW, Jaffe AS, Rosenberg YD, Bangalore S, Newby LK, Maron DJ,
Hochman JS, Chaitman BR. Use of troponin assay 99th percentile
as the decision level for myocardial infarction diagnosis. Am Heart J.
2017; 190: 135-9. Article. IF: 4.171; Q2
• Barrios V, Escobar C, Cicero AFG, Burke D, Fasching P, Banach M,
Bruckert E. A nutraceutical approach (Armolipid Plus) to reduce
total and LDL cholesterol in individuals with mild to moderate dys-
lipidemia: Review of the clinical evidence. Atheros-
clerosis Supp. 2017; 24: 1-15. Review. IF: 3.078; Q2
• Barrios V, Escobar C, Cosín-Sales J, Marzal D. Se-
lection of the best of 2016 in clinical cardiology:
Therapeutic novelties. Rev Esp Cardiol. 2017;
70(2): 123-4. Letter. IF: 5.166; Q1
• Barrios V, Escobar C, Valiente LP, Lobos JM,
Vargas-Ortega D, Polo J, Montañés NM.
Blood pressure control in anticoagulated
patients with hypertension and atrial fibri-
llation. Blood Pressure. 2017; 26(5): 279-
83. Article. IF: 2.107; Q3
• Bermejo ZB, Conde LP, Peinado R. ECG,
January 2017. Rev Esp Cardiol. 2017;
70(1): 54. Editorial Material. IF: 5.166;
Q1
• Bermejo ZB, Conde LP, Peinado R.
Response to ECG, January 2017.
Rev Esp Cardiol. 2017; 70(2): 120.
Editorial Material. IF: 5.166; Q1
• Bermejo ZB, Fernández TL, Val-
diris UR, Codón JC, de Antonio
IP, Rodríguez SR, García JMM,
Yanguela MM. Left-sided en-
docarditis extending to the
right chambers: Usefulness
of three-dimensional echo-
cardiography in preoperative assessment. Rev Port Cardiol. 2017;
36(4): 319-20. Editorial Material. IF: 0.827; Q4
• Caballero R, Utrilla RG, Amoros I, Matamoros M, Pérez-Hernández
M, Tinaquero D, Alfayate S, Nieto-Marín P, Guerrero-Serna G, Liu
QH, Ramos-Mondragón R, Ponce-Balbuena D, Herrón T, Campbell
KF, Filgueiras-Rama D, Peinado R, López-Sendón JL, Jalife J, Delpon
E, Tamargo J. TBX20 controls the expression of the KCNH2 gene
and of hERG channels. P Natl Acad Sci Usa. 2017; 114(3): E416-25.
Article. IF: 9.504; D1
• Caro-Codón J, Ruiz-Cantador J, Sánchez-Recalde A, Refoyo-Salicio
E, García AEG, López-Sendón JL. ST-elevation myocardial infarction
in anomalous origin of right coronary artery from the left sinus of
valsalva and interarterial course. Rev Esp Cardiol. 2017; 70(7): 596-
8. Letter. IF: 5.166; Q1
• Cedillo S, Sicras-Mainar A, Jiménez-Ruiz CA, de Bobadilla JF, Rejas-
Gutiérrez J. Budgetary impact analysis of reimbursement varenicline
for the smoking-cessation treatment in patients with cardiovascular
diseases, chronic obstructive pulmonary disease or type-2 diabetes
mellitus: A national health system
perspective. Eur Addict Res.
2017; 23(1): 7-18. Article. IF:
2.653; Q2
• Conde AC, Godoy RC,
Bueno MM, Esteban VA,
Senen AB, Abeytua M.
Selection of the best
of 2016 in vascular risk
and cardiac rehabilita-
tion. Rev Esp Cardiol.
2017; 70(2): 128-9.
Letter. IF: 5.166; Q1
• Cosín-Sales J, Escobar C, Marzal D, Barrios V. Selection of the best
of 2016 in diabetes and heart. Rev Esp Cardiol. 2017; 70(2): 124-5.
Letter. IF: 5.166; Q1
• Cowie MR, Filippatos GS, García MDAA, Anker SD, Baczynska A,
Bloomfield DM, Borentain M, Slot KB, Cronin M, Doevendans PA, El-
Gazayerly A, Gimpelewicz C, Honarpour N, Janmohamed S, Janssen
H, Kim AM, Lautsch D, Laws I, Lefkowitz M, López-Sendón J, Lyon
AR, Malik FI, McMurray JJV, Metra M, Pérez SF, Pfeffer MA, Pocock
SJ, Ponikowski P, Prasad K, Richard-Lordereau I, Roessig L, Rosano
GMC, Sherman W, Stough WG, Swedberg K,Tyl B, Zannad F, Boulton
C, de Graeff P. New medicinal products for chronic heart failure:
advances in clinical trial design and efficacy assessment. Eur J Heart
Fail. 2017; 19(6): 718-27. Review. IF: 10.683; D1
• Cuesta DM, Rodríguez-Sánchez I, de Bobadilla JF. Annular abscess
in HACEK infective endocarditis. Med Clin-Barcelona. 2017; 149(2):
91-2. Letter. IF: 1.168; Q3
• de Antonio IP, Cantador JR, García AEG, Ruiz JMO, Sánchez-Recalde
A, López-Sendón JL. Prevalence of neuroendocrine tumors in pa-
tients with cyanotic congenital heart disease. Rev Esp Cardiol. 2017;
70(8): 673-5. Letter. IF: 5.166; Q1
• de Isla LP, Fernández PLS, Walther LAS, Alonso VB, Conde AC, Ba-
silio EG, Ortiz LG, López PM, Ezquerra EA, Fort AC, Sales JC, Cer-
vantes CE, Marimón XGM, Doblas JJG, Martin DM, Eizagaechevarría
NM, Zarzosa CD, Rincón LM, Fores JS, Calvar JAS, Manterola FA,
Ynsaurriaga FA, Masip AE, González IF, Navarro MJ, Ortuno FM, de
Isla LP, Padial LR, Fernández PLS, Green AS, García RV. Comments on
the 2016 ESC/EAS guidelines for the management of dyslipidemias.
Rev Esp Cardiol. 2017; 70(2): 72-7. Editorial Material. IF: 5.166; Q1
• Divisón-Garrote JA, Ruilope LM, de la Sierra A, de la Cruz JJ, Vinyo-
les E, Gorostidi M, Escobar-Cervantes C,Velilla-Zancada SM, Segura
J, Banegas JR. Magnitude of hypotension based on office and ambu-
latory blood pressure monitoring: Results from a cohort of 5066
treated hypertensive patients aged 80 years and older. J Am Med Dir
Assoc. 2017; 18(5): 452.e1. Article. IF: 5.325; D1
• Escaned J, Collet C, Ryan N, de Maria GL, Walsh S, Sabate M, Davies
J, Lesiak M, Moreno R, Cruz-González I, Hoole SP, West NE, Piek JJ,
Zaman A, Fath-Ordoubadi F, Stables RH, Appleby C, van Mieghem
N, van Geuns RJ, Uren N, Zueco J, Buszman P, Íñiguez A, Goicolea
J, Hildick-Smith D, Ochala A, Dudek D, Hanratty C, Cavalcante R,
Kappetein AP, Taggart DP, van Es GA, Morel MA, de Vries T, Onuma
Y, Farooq V, Serruys PW, Banning AP. Clinical outcomes of state of
the art percutaneous coronary revascularization in patients with de
novo three vessel disease: 1 year results of the SYNTAX II study.
Eur Heart J. 2017; 38(42): 3124-34. Article. IF: 23.425; D1
• Escobar C, Arceluz M, de Oca RM, Mori R, López-Sendón JL, Meri-
no JL. Concomitant rivaroxaban and dronedarone administration in
patients with nonvalvular atrial fibrillation. Rev Esp Cardiol. 2017;
70(2): 121-2. Letter. IF: 5.166; Q1
• Escobar C, Barrios V, Cosín-Sales J, Marzal D, Calderón A. Selection
of the best of 2016 in clinical cardiology: Continuum of care; re-
lationship between cardiology and primary care. Rev Esp Cardiol.
2017; 70(2): 122-3. Letter. IF: 5.166; Q1
• Escobar C, Castrejón S, de Oca RM, Ortega M, López-Sendón JL,
Merino JL. Common atrial flutter catheter ablation without discon-
tinuing oral anticoagulation. Future Cardiol. 2017; 13(5): 429-32. Ar-
ticle. Not Indexed
• Escobar C, Divisón JA. Cardiotoxicity. A reality that the primary
care physician should be aware. Semergen. 2017; 43(2): 149-50. Arti-
cle. Not Indexed
• Escobar C, Divisón JA. Current management of stable ischemic
heart disease. Semergen. 2017; 43(1): 57-8. Article. Not Indexed
• Escobar C, Divisón JA. Importance of medication adherence.
Semergen. 2017; 43(3):236-7-. Article. Not Indexed
• Escobar C, Divisón JA. LDL-cholesterol targets arrive at the Ameri-
can guidelines. Semergen. 2017; 43(3): 238-9. Article. Not Indexed
119
 3
Information Groups by Area
3.2 Cardiovascular Area
• Escobar C, Divisón JA. New recommendations of 2016 European
Guidelines for the diagnosis and treatment of heart failure. Semer-
gen. 2017; 43(4): 328-9. Article. Not Indexed
• Escobar C, Divisón JA. New recommendations of 2016 European
Guidelines on cardiovascular disease prevention. Semergen. 2017;
43(4): 330-1. Article. Not Indexed
• Ferreira-González I, Abu-Assi E, Arias MA, Gallego P, Sánchez-Re-
calde A. Revista Española de Cardiología: First year activity of the
new editorial team. Rev Esp Cardiol. 2017; 70(3): 199-207. Editorial
Material. IF: 5.166; Q1
• García E, Arzamendi D, Jiménez-Quevedo P, Samago F, Martí G,
Sánchez-Recalde A, Lasa-Larraya G, Sancho M, Íñiguez A, Goico-
lea J, García-San Román K, Alonso-Briales JH, Molina E, Calabuig J,
Freixa X, Berenguer A,Valdés-Chavarri M,Vázquez N, Díaz JF, Cruz-
González I. Outcomes and predictors of success and complications
for paravalvular leak closure: an analysis of the SpanisH realwOrld
paravalvular LEaks closure (HOLE) registry. Eurointervention. 2017;
12(16): 1962-8. Article. IF: 4.417; Q2
• Gemma D, Galeote García G, Sánchez-Recalde A. Effects of exci-
mer laser coronary atherectomy assessed by OCT. Rev Esp Cardiol
(Engl Ed). 2017; 70(2): 116. Article. IF: 5.166; Q1
• Guillén CRS, Peinado RP. ECG, April 2017. Rev Esp Cardiol. 2017;
70(4): 295. Editorial Material. IF: 5.166; Q1
• Guillén CRS, Peinado RP. Response to ECG, April 2017. Rev Esp
Cardiol. 2017; 70(5): 395. Editorial Material. IF: 5.166; Q1
• Irazusta FJ, Jiménez-Valero S, Gemma D, Meras P, Galeote G, Sán-
chez-Recalde A, Rial V, Moreno R, López-Sendón JL. Percutaneous
balloon pericardiotomy:Treatment of choice in patients with advan-
ced oncological disease and severe pericardial effusion. Cardiovasc
Revasc Med. 2017; 18(5): S14-7. Article. Not Indexed
• Irazusta FJ, Ramírez U, Caro-Codón J, Refoyo E, Garrido D, Pinilla I,
Mesa JM, López-Sendón JL. Extensive chest wall destruction secon-
dary to a large ventricle pseudoaneurysm: A surgical challenge. Ann
Thorac Surg. 2017; 103(3): E227-9. Article. IF: 3.779; Q1
• Junco RM, González-Gallarza RD, Conde AC, Fernández OG, Orte-
ga CA, Bermejo ZB, Furuya-Kanamoric L, Gómez RM, Arreses ELD.
Clinical outcomes in myocardial infarction and multivessel disease
after a cardiac rehabilitation programme: Partial versus complete
revascularization. Arch Cardiovasc Dis. 2017; 110(4): 234-41. Article.
IF: 2.37; Q2
• Kereiakes DJ, Meredith IT, Masotti M, Carrie D, Moreno R, Erglis A,
Mehta SR, Elhadad S, Berland J, Stein B, Airaksinen J, Jobe RL, Reit-
man A, Janssens L, Christen T, Dawkins KD, Windeeker S. Safety and
efficacy of a bioabsorbable polymer-coated, everolimus-eluting coro-
nary stent in patients with diabetes: the EVOLVE II diabetes substudy.
Eurointervention. 2017; 12(16): 1987-94. Article. IF: 4.417; Q2
• Lavi S, Iqbal J, Cairns JA, Cantor WJ, Cheema AN, Moreno R, Mee-
ks B, Welsh RC, Kedev S, Chowdhary S, Stankovic G, Schwalm JD,
Liu Y, Jolly SS, Dzavik V. Bare metal versus drug eluting stents for
ST-segment elevation myocardial infarction in the TOTAL trial. Int J
Cardiol. 2017; 248:120-3. Editorial Material. IF: 4.034; Q2
• Lindholm D, Hagstrom E, James SK, Becker RC, Cannon CP, Him-
melmann A, Katus HA, Maurer G, López-Sendón JL, Steg PG, Storey
RF, Siegbahn A, Wallentin L. Growth differentiation factor 15 at 1
month after an acute coronary syndrome is associated with increa-
sed risk of major bleeding. J Am Heart Assoc. 2017; 6(4): e005580.
Article. IF: 4.45; Q2
• Lindholm D, James SK, Bertilsson M, Becker RC, Cannon CP, Gian-
nitsis E, Harrington RA, Himmelmann A, Kontny F, Siegbahn A, Steg
PG, Storey RF,Velders MA, Weaver WD, Wallentin L, (López-Sendón
JL). Biomarkers and coronary lesions predict outcomes after re-
vascularization in non-ST-elevation acute coronary syndrome. Clin
Chem. 2017; 63(2): 573-84. Article. IF: 8.636; D1
• Llontop C, García-Quero C, Castro A, Dalmau R, Casitas R, Gale-
ra R, Iglesias A, Martínez-Cerón E, Soriano JB, García-Rio F. Small
120
airway dysfunction in smokers with stable ischemic heart disease.
Plos One. 2017; 12(8): e0182858. Article. IF: 2.766; Q1
• Lobos-Bejarano JM, Rodríguez AC, Barrios V, Escobar C, Polo-
García J, del Castillo-Rodríguez JC,Vargas-Ortega D, López-Pineda
A, Prieto-Valiente L, Lip GYH. Influence of renal function on anti-
coagulation control in patients with non-valvular atrial fibrillation
taking vitamin K antagonists. Int J Clin Pract. 2017; 71(9): e12974.
Article. IF: 2; Q2
• López-Fernández T, García AM, Beltrán AS, Luis AM, Sanz RG, Ramos
PM, del Castillo SV,Areses ELD, Barreiro-Pérez M, Baydes RH, de Isla
LP, López SCV, González-Gallarza RD, Calvo-Iglesias F, Ferrer JJG,
Fernández AC, González-Caballero E, Mitroi C, Arenas M, Echaburu
JAV, Vera PM, Romo AI, Zamorano JL, Gómez JCP, Henchel JLLS.
Cardio-onco-hematology in clinical practice. Position paper and re-
commendations. Rev Esp Cardiol. 2017; 70(6): 474-86. Article. IF:
5.166; Q1
• Lowenstern A, Storey RF, Neely M, Sun JL, Angiolillo DJ, Cannon CP,
Himmelmann A, Huber K, James SK, Katus HA, Morais J, Siegbahn
A, Steg PG, Wallentin L, Becker RC, (López-Sendón JL. ) Platelet-
related biomarkers and their response to inhibition with aspirin and
P2Y(12)-receptor antagonists in patients with acute coronary syn-
drome. J Thromb Thrombolys. 2017; 44(2): 145-53. Article. IF: 2.62; Q2
• Meras P, Caro J, Trigo E, Irazusta J, López-Sendón JL, Refoyo E. Diag-
nostic value of NT-proBNP for early identification of chagas car-
diomyopathy in non-endemic areas. Rev Esp Cardiol. 2017; 70(9):
783-5. Letter. IF: 5.166; Q1
• Merino JL.Tools or toys? The 20 year anniversary of the nonfluoros-
copic mapping system dilemma. Rev Esp Cardiol. 2017; 70(9): 690-3.
Editorial Material. IF: 5.166; Q1
• Moreno R, Mehta SR. Nonculprit vessel intervention: Let’s COM-
PLETE the evidence. Rev Esp Cardiol. 2017; 70(6): 418-20. Editorial
Material. IF: 5.166; Q1
• Moreno R. Antithrombotic therapy after transcatheter aortic valve
implantation. Am J Cardiovasc Drug. 2017; 17(4): 265-71. Article. IF:
2.643; Q2
• Oliver JM, Gallego P, González AE, García-Hamilton D, Ávila P,
Alonso A, Ruiz-Cantador J, Peinado R, Yotti R, Fernández-Avilés
F. Impact of age and sex on survival and causes of death in adults
with congenital heart disease. Int J Cardiol. 2017; 245:119-24. Ar-
ticle. IF: 4.034; Q2
• Ortiz M, Martín A, Arribas F, Coll-Vinent B, del Arco C, Peinado R,
Almendral J. Randomized comparison of intravenous procainamide
vs. intravenous amiodarone for the acute treatment of tolerated
wide QRS tachycardia: the PROCAMIO study. Eur Heart J. 2017;
38(17): 1329-35, Article. IF: 23.425; D1
• Pogosova N, Kotseva K, de Bacquer D, von Kanel R, de Smedt D,
Bruthans J, Dolzhenko M, (Castro Conde A). Psychosocial risk fac-
tors in relation to other cardiovascular risk factors in coronary
heart disease: Results from the EUROASPIRE IV survey. A registry
from the European Society of Cardiology. Eur J Prev Cardiol. 2017;
24(13): 1371-80. Article. IF: 4.542; Q1
• Pollack CV, Davoudi F, Diercks DB, Becker RC, James SK, Lim ST,
Schulte PJ, Spinar J, Steg PG, Storey RF, Himmelmann A, Wallentin L,
Cannon CP, (López Sendón JL). Relative efficacy and safety of tica-
gelor vs clopidogrel as a function of time to invasive management in
non-ST-segment elevation acute coronary syndrome in the PLATO
trial. Clin Cardiol. 2017; 40(6): 390-8. Article. IF: 2,733; Q2
• Rojas-González A, Cecconi A, Merino JL, Jiménez-Borreguero LJ, Al-
fonso F. Spike or not a spike? That is the question in a patient with
single lead pacemaker. J Electrocardiol. 2017; 50(6): 937-8. Article. IF:
1.421; Q4
• Royo-Bordonada MA, Armario P, Bejarano JML, Pedro-Botet J, Álva-
rez FV, Elosua R, Cuixart CB, Cortés O, Serrano B, Babkowski MC,
Núñez AG, Pérez A, Maiques A, Nocito AD, de Castro A, Alegria E,
Baeza C, Herranz M, Sans S, Campos P. Spanish adaptation of the
2016 European Guidelines on cardiovascular disease prevention in
clinical practice. Gac Sanit. 2017; 31(3) :255-68. Article. IF: 1.581; Q3
• Sanjurjo SC, Caro JLL, Fragoso AS, Díaz MAP, Cervantes CE, García
AB, Padial LR, Carratala VP, Pérez RV, Jiménez SM, Roca GCR, Badi-
món JJ. Characteristics of the metabolic syndrome in the patients of
IBERICAN Study (Identification of the Spanish Population at Car-
diovascular and Renal Risk). Metab Syndr Relat D. 2017; 15(9): 431-
8. Article. IF: 1.744; Q3
• Storm C, Nee J, Sunde K, Holzer M, Hubner P, Taccone FS, Friberg
H, López de Sa E, Cariou A, Schefold JC, Ristagno G, Noc M, Donker
DW, Andrés J, Krawczyk P, Skrifvars MB, Penketh J, Krannich A, Fries
M. A survey on general and temperature management of post car-
diac arrest patients in large teaching and university hospitals in 14
European countries-The SPAME trial results. Resuscitation. 2017;
116: 84-90. Article. IF: 5.863; D1
• Tamargo J, Rosano GMC, Delpon E, Ruilope L, López-Sendón J.
Pharmacological reasons that may explain why randomized clinical
trials have failed in acute heart failure syndromes. Int J Cardiol. 2017;
233: 1-11. Review. IF: 4.034; Q2
• Velilla-Zancada SM, Escobar-Cervantes C, Manzano-Espinosa L,
Prieto-Díaz MA, Ramalle-Gomara E, Vara-González LA. Impact of
variations in blood pressure with orthostatism on mortality: the
HOMO study. Blood Press Monit. 2017; 22(4): 184-90. Article. IF:
1.194; Q4
• Vidal-Petiot E, Stebbins A, Chiswell K, Ardissino D, Aylward PE, Can-
non CP, Corrales MAR, Held C, López-Sendón JL, Stewart RAH,
Wallentin L, White HD, Steg PG. Visit-to-visit variability of blood
pressure and cardiovascular outcomes in patients with stable coro-
nary heart disease. Insights from the STABILITY trial. Eur Heart J.
2017; 38(37): 2813-22. Article. IF: 23.425; D1
• Vinereanu D, Lopes RD, Mulder H, Gersh BJ, Hanna M, Silva PGMDE,
Atar D, Wallentin L, Granger CB, Alexander JH, (López Sendón JL).
Echocardiographic risk factors for stroke and outcomes in patients
with atrial fibrillation anticoagulated with apixaban or warfarin.
Stroke. 2017; 48(12): 3266-73. Article. IF: 6.239; D1
• Wagner M, Wanner C, Kotseva K, Wood D, de Bacquer D, Ryden L,
Stork S, Heuschmann PU, (Castro Conde A). Prevalence of chronic
kidney disease and its determinants in coronary heart disease pa-
tients in 24 European countries: Insights from the EUROASPIRE IV
survey of the European Society of Cardiology. Eur J Prev Cardiol.
2017; 24(11): 1168-80. Article. IF: 4.542; Q1
Public Projects
Jiménez Valero S. ABLAVIEW - Un sistema innovador de
ablación por radiofrecuencia guiado por imagen para el tra-
tamiento de la fibrilacion auricular (RTC-2016-2016-5445-1).
MINECO. 2016-2019.
Managment centre: FIBHULP
López-Sendón Hentschel JL. Red de Enfermedades Cardio-
vasculares (RECAVA) (RD12/0042/0063). ISCIII. 2013-2017.
Managment centre: FIBHULP
López-Sendón Hentschel JL. Toxicidad cardiovascular por
fármacos antitumorales. Valoración del riesgo y diagnóstico
precoz (PI13/00559). ISCIII. 2014-2017.
Managment centre: FIBHULP
Private Projects
Castro Conde A. II Encuentro nacional de investigación en
rehabilitación cardiaca. Laboratorio Menarini S.A. 2015-On-
going.
Managment centre: FIBHULP
Castro Conde A. Jornadas de formación en investigación en
la prevención secundaria y rehabilitación. Astrazeneca Farma-
ceutica Spain S.A. 2013-Ongoing.
Managment centre: FIBHULP
Castro Conde A. Tecnologías disruptivas para la rehabilita-
ción del futuro. Laboratorios Servier S.L. 2011-Ongoing.
Managment centre: FIBHULP
Dalmáu González-Gallerza R. Estudio de los beneficios de
la marcha nórdica dentro de un programa de rehabilitación
cardíaca en pacientes con síndrome coronario agudo recien-
te. Laboratorio Menarini S.A. 2011-Ongoing.
Managment centre: FIBHULP
Jiménez Valero S. Análisis de correlación entre los marcado-
res de inflamación y morfología de placas coronarias median-
te tomografía de coherencia óptica y TEC multicorte: eEtudio
IVI. Abbott Laboratories S.A. 2009-Ongoing.
Managment centre: FIBHULP
Jiménez Valero S. Estudio en modelo porcino para evaluar
la utilidad de la tomografía de coherencia óptica en el análisis
de las lesiones endocárdicas producidas por radiofrecuencia.
Medlumics S.L. 2015-Ongoing.
Managment centre: FIBHULP
López-Sendón Hentschel JL. Biomarcadores en la cardio-
toxicidad por agentes antineoplás: rendimiento dianóstico.
Bayer Hispania S.L. 2015-Ongoing.
Managment centre: FIBHULP
López-Sendón Hentschel JL. Jornada científica: Cardio-on-
cology 2017 new rules. Laboratorios Farmacéuticos Rovi S.A.
2017-Ongoing.
Managment centre: FIBHULP
López-Sendón Hentschel JL. La insuficiencia cardiaca en el
área 5. Laboratorios Servier S.L. 2017-Ongoing.
Managment centre: FIBHULP
López-Sendón Hentschel JL. Sesiones interhospitalarias de
formación en investigación en cardiología. Astrazeneca Far-
maceutica Spain S.A. 2016-Ongoing.
Managment centre: FIBHULP
López-Sendón Hentschel JL. Sesiones clínicas de cardiología.
Astrazeneca Farmaceutica Spain S.A. 2006-Ongoing.
Managment centre: FIBHULP
Merino Llorens JL.Actividades formativas de investigación en
cirugía cardiaca pediátrica. Bayer Hispania S.L. 2006-Ongoing.
Managment centre: FIBHULP
Merino Llorens JL. Formación en investigación en electrofi-
siología cardiaca. European Society of Cardiology. 2015-On-
going.
Managment centre: FIBHULP
Merino Llorens JL. Innovación tecnológica en cardiología:
mapas tridimensionales de ciclo de retorno para la abla-
ción de taquicardias macroreentrantes. Bayer Hispania S.L.
2007-Ongoing.
Managment centre: FIBHULP
Merino Llorens JL. Manejo práctico de la fibrilación auricu-
lar: de la investigación a la práctica clínica. Boehringer Ingel-
heim España S.A. 2017-Ongoing.
Managment centre: FIBHULP
121
 3
Information Groups by Area
3.2 Cardiovascular Area
Moreno Gómez JR. Evaluación clínica y seguimiento de los
pacientes con cardiopatía estructural sometidos a procedi-
mientos de tratamiento percutáneo. subproyecto: Análisis de
expresión de miRNAs relacionados con el proceso angio-
génico en cáncer mama. Abbott Laboratories S.A. 2011-On-
going.
Managment centre: FIBHULP
Peinado Peinado R. Influencia del remodelado eléctrico
del miocardio auricular en la recurrencia de fibrilación au-
ricular tras el aislamiento eléctrico de las venas pulmonares
por fibrilación auricular paroxística. Medtronic Iberica S.A.
2009-Ongoing.
Managment centre: FIBHULP
Peinado Peinado R. Síndrome de apneas-hipopneas obs-
tructivas del sueño y arritmias ventriculares en pacientes con
disfunción ventricular sistólica portadores de DAI. Boston
Scientific Iberica S.A. 2008-Ongoing.
Managment centre: FIBHULP
Peinado Peinado R. Utilidad de la estimulación programada
ventricular izquierda para la inducción de la taquicardia ven-
tricular monomórfica clínica en pacientes con infarto previo.
Boston Scientific Iberica S.A. 2009-Ongoing.
Managment centre: FIBHULP
Riera del Moral LF. Tratamiento celular de los aneurismas de
aorta abdominal en un modelo murino. Jotec Cardiovascular
S.L. 2017-Ongoing.
Managment centre: FIBHULP
INTERNATIONAL Projects
López-Sendón JL. International study of comparative health
effectiveness with medical and invasive approaches - estudio
internacional comparativo de la eficacia sanitaria con enfo-
ques médicos e invasivos (ISCHEMIA). UE. 2013-2020.
Managment centre: FIBHULP
CLINICAL TRIALS
Antorrena Miranda MI. Estudio no intervencionista sobre
el tratamiento con edoxaban en la práctica clínica habitual
para pacientes con fibrilación auricular no valvular. ETNA-
AF-EUROPE. Type: EPA-SP.
HULP code: PI-2559. Sponsored´s protocol code: DSE-EDO-2016-01.
Sponsored by: Daiichi-Sankyo Development Limited.
Signed date: 30/03/2017
Antorrena Miranda MI. Estudio observacional retrospectivo
del uso de evolocumab en unidades españolas de cardiolo-
gía (Retrospective observational study of evolocumab use in
spanish cardiology units). Type: EPA-OD.
HULP code: PI-2844. Sponsored´s protocol code: 20160139.
Sponsored by: Amgen S.A.
Signed date: 04/08/2017
Antorrena Miranda MI. Manejo de edoxaban en procedi-
mientos diagnósticos y terapéuticos. Estudio Emit-AF/VTE.
Type: EPA-SP.
HULP code: ANEXO-I PI-2679. Sponsored´s protocol code: DSE-
EDO-2016-02.
Sponsored by: Daiichi-Sankyo Development Limited.
Signed date: 08/05/2017
122
Antorrena Miranda MI. Manejo de edoxabán en procedi-
mientos diagnósticos y terapéuticos. Estudio EMIT-AF/VTE.
Type: EPA-SP.
HULP code: PI-2679. Sponsored´s protocol code: DSE-EDO-2016-02.
Sponsored by: Daiichi-Sankyo Development Limited.
Signed date: 08/05/2017
Castro Conde A. Pemafibrato para reducir los episodios car-
diovasculares mediante la reducción de los triglicéridos en
pacientes con diabetes (Prominent).Type: Clinical Trial, phase I.
HULP code: 4764. Sponsored´s protocol code: K-877-302.
Sponsored by: Kowa Research Institute Inc.
Signed date: 28/06/2017
Dalmau González-Gallerza R. Estudio multicéntrico tipo
probe (prospective, randomized, open, blinded for the end-
point evaluators): prospectivo, aleatorizado, abierto, ciego
para el evaluador, para comparar la adherencia a largo plazo
de las medidas de prevención secundaria tras un síndrome
coronario agudo después de un programa de rehabilitación
cardiaca intensivo de menor duración frente a un programa
estándar. Type: NO-EPA.
HULP code: ANEXO-I FIB-022. Sponsored´s protocol code: FIB-022.
Sponsored by: Fundación Casa del Corazón
Signed date: 25/04/2017
López de Sa Areces E. Estudio clínico unicéntrico de una
serie de casos para evaluar la viabilidad de integrar la hipoter-
mia terapéutica con el sistema IVTM de zoll como adjuvan-
te de la angioplastia coronaria percutánea en pacientes con
infarto agudo de miocardio. Type: Clinical Trial, phase PRO-
DUCTO SANITARIO.
HULP code: 4749. Sponsored´s protocol code: COOL-AMI.
Sponsored by: Zoll Circulation Inc.
Signed date: 24/07/2017
López de Sa Areces E. Estudio prospectivo abierto del an-
dexanet alfa en pacientes tratados con un inhibidor de factor
XA que presentan una hemorragia mayor aguda.Type: Clinical
Trial, phase III.
HULP code: ANEXO-I 4523. Sponsored´s protocol code: 14-505.
Sponsored by: Portola Pharmaceuticals Inc.
Signed date: 03/10/2017
López-Sendón Hentschel JL. Estudio aleatorizado, doble
ciego, controlado con placebo, de grupos paralelos, multi-
céntrico, para demostrar los efectos de sotagliflozina so-
bre los eventos cardiovasculares y renales en pacientes con
diabetes tipo 2, factores de riesgo cardiovascular y función
renal moderadamente reducida (SCORED). Type: Clinical
Trial, phase III.
HULP code: 4943. Sponsored´s protocol code: EFC14875.
Sponsored by: Sanofi-Aventis Recherche & Developpement.
Signed date: 27/11/2017
López-Sendón Hentschel JL. Registro global del tratamiento
antitrombótico oral a largo plazo en pacientes con fibrilación
auricular (fase II/III-estados mienbros de la UE/AEE). Type:
EPA-LA.
HULP code: ANEXO-II 3661. Sponsored´s protocol code: BOE-
DAB-2012-01.
Sponsored by: Boehringer Ingelheim España S.A.
Signed date: 30/10/2017
Merino Llorens JL. Anticoagulantes orales no antagonistas
de la vitamina K en pacientes con episodios de frecuencia
auricular rapida. Type: Clinical Trial, phase III.
HULP code: 4763. Sponsored´s protocol code: NOAH-AFNET 6.
Sponsored by: Kompetenznetz Vorhofflimmern E.V.
Signed date: 09/01/2017
Moreno Gómez JR. Edoxabán frente al tratamiento estándar
y sus efectos en los resultados clínicos de los pacientes que
se han sometido a una implantación de válvula aórtica trans-
catéter (en fibrilación auricular). Type: Clinical Trial, phase III.
HULP code: 4843. Sponsored´s protocol code: DU176B-C-U4001.
Sponsored by: Daiichi Sankyo Inc.
Signed date: 23/10/2017
Moreno Gómez JR. Estudio clínico unicéntrico de una serie
de casos para evaluar la viabilidad de integrar la hipotermia
terapéutica con el sistema IVTM de zoll como adjuvante de
la angioplastia coronaria percutánea en pacientes con infar-
to agudo de miocardio. Type: Clinical Trial, phase Producto
Sanitario.
HULP code: 4749. Sponsored´s protocol code: COOL-AMI.
Sponsored by: Zoll Circulation Inc.
Signed date: 24/07/2017
Moreno Gómez JR. Evaluación de la seguridad y eficacia del
tratamiento antitrombótico con edoxabán en comparación
con un antagonista de la vitamina K (AVK), tras una inter-
vención coronaria percutánea (ICP) con colocación de stent
satisfactoria (tratamiento con edoxabán comparado con AVK
en pacientes que padecen fibrilación auricular sometidos a
ICP. Entrust - FA ICP). Type: Clinical Trial, phase III.
HULP code: 4761. Sponsored´s protocol code: DSE-EDO-01-15-EU.
Sponsored by: Daiichi-Sankyo Europe GMBH.
Signed date: 15/02/2017
Moreno Gómez JR. Registro posterior a la comercialización
de Biomatrix Alpha™ (Stent Farmacoactivo A9™ (BA9™)
de biolimús, cobalto y cromo). Type: NO-EPA.
HULP code: PI-2579. Sponsored´s protocol code: BMXAlphaRegistry
16EU01.
Sponsored by: Biosensors Europe S.A.
Signed date: 01/07/2017
Moreno Gómez JR. Stent liberador de sirolimus de filamento
delgado en una población abierta a todos los candidatos inte-
resados frente a stent liberador de everolimus. Type: Clinical
Trial, phase Producto Sanitario.
HULP code: 4784. Sponsored´s protocol code: ECRI-007.
Sponsored by: European Cardiovascular Research Institute.
Signed date: 20/02/2017
Peinado Peinado R. Estudio observacional Smart Registry
– Estrategias de optimización de la respuesta a la terapia de
resincronización cardiaca. Type: NO-EPA.
HULP code: PI-2831. Sponsored´s protocol code: C1949
Sponsored by: Guidant Europe NV; Boston Scientific Com-
pany.
Signed date: 05/09/2017
Roldán Rabadán I. Estudio no intervencionista sobre el tra-
tamiento con edoxaban en la práctica clínica habitual para pa-
cientes con fibrilación auricular no valvular. Etna-AF-Europe.
Type: EPA-SP.
HULP code: PI-2559B. Sponsored´s protocol code: DSE-
EDO-2016-01.
Sponsored by: Daiichi-Sankyo Development Limited.
Signed date: 30/03/2017
Patents and Trademarks
Filgueiras Rama D, López de Sá y Areses E, Millet Roig J,
Calvo Saiz CJ, inventors; Centro Nacional de Investigacio-
nes Cardiovasculares Carlos III (CNIC), FIBHULP, Universi-
dad Politécnica de Valencia, assignees. Method of predicting
or prognosticating neurological performance in patients
who have suffered a cardiac arrest and optionally comato-
se status due to ventricular fibrillation. PCT/EP2015/076893,
EP3020333; 2014 November 17.
Riera del Moral LF, inventor; FIBHULP, assignee. Aortic en-
doprosthesis for the treatment of aneurysm. P201231638,
PCT/ES2013/070712; 2012 October 24.
123
 3
Information Groups by Area
3.2 Cardiovascular Area
Cardiovascular Epidemiology
and Nutrition Group
38 283.946 29
Fernando Rodríguez Artalejo. Catedrático de Medicina
Preventiva y Salud Pública. Facultad de Medicina. UAM
José Ramón Banegas Banegas. Catedrático de Medicina Preventiva
y Salud Pública. Facultad de Medicina. UAM
Auxiliadora Graciani Pérez-Regadera. Profesora Contratada de
Medicina Preventiva y Salud Pública. Facultad de Medicina. UAM
Pilar Guallar-Castillón. Profesora Titular de Medicina Preventiva y
Salud Pública. Facultad de Medicina. UAM
Juan Luis Gutiérrez Fisac. Profesor Asociado de Medicina
Preventiva y Salud Pública. Facultad de Medicina. UAM
Luz María León Muñoz. Colaboradora Docente de Medicina
Preventiva y Salud Pública. Facultad de Medicina. UAM
Esther López-García. Profesora Contratada. Doctora de Medicina
Preventiva y Salud Pública. Facultad de Medicina. UAM
Fernando Villar Álvarez. Profesor Asociado de Medicina Preventiva
y Salud Pública. Facultad de Medicina. UAM
Strategic Objective
Our strategic objective is to produce relevant infor-
mation to support clinical and population-based poli-
cies aimed at controlling CVD.
The results of our studies have been explicitly in-
corporated into the National Strategy for Ischemic
Heart Disease Control and into the National Strate-
gy for Obesity Prevention and Control, elaborated by
the Ministry of Health.
Moreover, our research results have also supported
the development of clinical guidelines in this field;
specifically, the guidelines of the Spanish Society for
Arterial Hypertension, and guidelines of the Spanish
Society of Family Medicine, the leading society devo-
ted to primary health care in Spain.
124
• Bayán-Bravo A, Pérez-Tasigchana RF, Sayón-Orea C, Martínez-Gó-
• Beltrán LM, Olmo-Fernández A, Banegas JR, García-Puig J. Electronic
• Campanini MZ, Guallar-Castillón P, Rodríguez-Artalejo F, López-
• Campanini MZ, López-García E, Rodríguez-Artalejo F, González AD,
• Cavero-Redondo I, Peleteiro B, Álvarez-Bueno C, Rodríguez-Arta-
• Chaparro M, Ramas M, Benítez JM, López-García A, Juan A, Guardio-
Research Lines
• de la Sierra A, Vinyoles E, Banegas JR, Segura J, Gorostidi M, de la
• Cardiovascular and nutritional epidemiology.
Research Activity
• Divisón-Garrote JA, Ruilope LM, de la Sierra A, de la Cruz JJ, Vinyo-
PUBLICATIONS
• Andrade-Gómez E, García-Esquinas E, Ortola R, Martínez-
Gómez D, Rodríguez-Artalejo F. Watching TV has a distinct
• Ezzati M, Bentham J, Di Cesare M, Bilano V, Bixby H, Zhou B, Stevens
sociodemographic and lifestyle profile compared with other
sedentary behaviors: A nationwide population-based study. Plos
One. 2017; 12(12): e0188836. Article. IF: 2.766; Q1
• Banegas JR, Rodríguez-Artalejo F. The StrongHeart Study:
adding biological plausibility to the red meat - cardiovascular
disease association. J Hypertens. 2017; 35(9): 1782-4. Editorial
Material. IF: 4.092; Q1
• Banegas JR, Ruilope LM, de la Sierra A, Vinyoles E, Gorostidi
M, de la Cruz JJ, Segura J, Oliveras A, Martell N, García-Puig J,
Williams B. Clinic versus daytime ambulatory blood pressure
difference in hypertensive patients the impact of age and clinic
blood pressure. Hypertension. 2017; 69(2): 211-9. Article. IF:
6.823; D1
• Banegas JR. Birth month, a simple demographic indicator of
early environmental exposures and risk of chronic diseases.
Med Clin-Barcelona. 2017; 148(11): 498-500. Editorial Material.
IF: 1.168; Q3
• Banegas JR. Lack of association between passive smoking and
blood pressure, lipids, and fasting glucose. J Hypertens. 2017;
35(10): 1952-4. Editorial Material. IF: 4.092; Q1
• Banegas JR. Mass starvation in early life and adult hypertension
in China. J Hypertens. 2017; 35(1): 29-32. Editorial Material. IF:
4.092; Q1
mez D, López-García E, Rodríguez-Artalejo F, Guallar-Castillón P.
Combined impact of traditional and non-traditional healthy beha-
viors on health-related quality of life: a prospective study in older
adults. Plos One. 2017; 12(1): e0170513. Article. IF: 2.766; Q1
clinical decision support system and multifactorial risk factor con-
trol in patients with type 2 diabetes in primary health care. Eur J
Intern Med. 2017; 44: E35-7. Letter. IF: 3.282; Q1
García E. Mediterranean diet and changes in sleep duration and in-
dicators of sleep quality in older adults. Sleep. 2017; 40(3): zsw083.
Article. IF: 5.135; Q1
Andrade SM, Mesas AE. Agreement between sleep diary and actigra-
phy in a highly educated Brazilian population. Sleep Med. 2017; 35:
27-34. Article. IF: 3.395; Q2
lejo F, Martínez-Vizcaino V. Glycated haemoglobin A1c as a risk fac-
tor of cardiovascular outcomes and all-cause mortality in diabetic
and nondiabetic populations: a systematic review and meta-analysis.
BMJ Open. 2017; 7(7): e015949. Review. IF: 2.413; Q2
la J, Mínguez M, Calvet X, Márquez L, Salazar LIF, Bujanda L, García
C, Zabana Y, Lorente R, Barrio J, Hinojosa E, Iborra M, Cajal MD,
Van Domselaar M, García-Sepulcre MF, Gomollón F, Piqueras M,
Alcain G, García-Sánchez V, Panes J, Domenech E, García-Esquinas
E, Rodríguez-Artalejo F, Gisbert JP. Extracolonic cancer in inflam-
matory bowel disease: Data from the GETECCU Eneida Registry.
Am J Gastroenterol. 2017; 112(7): 1135-43. Article. IF: 10.231; D1
Cruz JJ, Ruilope LM. Prevalence and clinical characteristics of white-
coat hypertension based on different definition criteria in untreated
and treated patients. J Hypertens. 2017; 35(12): 2388-94. Article. IF:
4.092; Q1
les E, Gorostidi M, Escobar-Cervantes C,Velilla-Zancada SM, Segura
J, Banegas JR. Magnitude of hypotension based on office and ambu-
latory blood pressure monitoring: results from a cohort of 5066
treated hypertensive patients aged 80 years and older. J Am Med Dir
Assoc. 2017; 18(5): 452.e1-e6. Article. IF: 5.325; D1
GA, Riley LM, Taddei C, Hajifathalian K, Lu Y, Savin S, Cowan MJ, Pa-
ciore CJ, Chiritaemandi A, Hayes AJ, Katz J, Kelishadi R, Kengne AP,
Khang YH, Laxmaiah A, Li YP, Ma J, Miranda JJ, Mostafa A, Neovius M,
Padez C, Rampal L, Zhu A, Bennet JE, Danaei G, Bhutta ZA, Ezzati M,
Abarca-Gómez L, Abdeen ZA, Hamid ZA, Abu-Rmeileh NM, Acosta-
Cazares B, Acuin C, Adams RJ, Aekplakorn W, Afsana K, Aguilar-Sali-
nas CA, Agyemng C, Ahmadvand A, Ahrens W, Ajlouni K, Akhtaeva N,
Al-Hazzaa HM, Al-Othman AR, Al-Raddadi R, AlBuhairan F, AlDhukai
S, Ali MM, Ali O, Alkerwi A, Álvarez-Pedrerol M, Aly E, Amarapurkar
DN, Amouyel P, Amuzu A, Andersen LB, Anderssen SA, Andrade DS,
Angquist LH, Anjana RM, Aounallah-Skhiri H, Araujo J, Arianse I, Aris
T, Arlappa N, Arveiler D, Aryal KK, Aspelund T, Assah FK, Assuncao
MCF, Aung MS, Avdicova M, Azevedo A, Azizi F, Babu BV, Bahijri S,
Baker JL, Balakrishna N, Bamoshmoosh M, Banach M, Bandosz P,
Banegas JR, Barbagallo CM, Barcelo A, Barkat A, Barros AJD, Barros
MVG, Bata I, Batieha AM, Batista RL, Batyrbek A, Baur LA, Beagleho-
le R, Ben Romdhane H, Benedics J, Benet M, Bennet JE, Bernabe A,
Bernotiene G, Bettiol H, Bhagyalaxmi A, Bharadwaj S, Bhargava SK,
Bhatti Z, Bhutta ZA, Bi HS, Bi YF, Biehl A, Bikbov M, Bista B, Bjelica
DJ, Bjerregaard P, Bjertnes E, Bjness MB, Bjorkelund C, Blokstra A,
Bo S, Bobak M, Boddy LM, Boehm BO, Boeing H, Boggia JG, Boisson-
net CP, Bonaccio M, Bongard V, Bovet P, Braeckevelt L, Braeckman L,
Bragt MCE, Brajkovich I, Branca F, Breckenkamp J, Breda J, Brenner
H, Brewster LM, Brian GR, Brinduse L, Bruno G, Bueno-de-Mesquita
HB, Bugge A, Buoncristiano M, Burazeri G, Burns C, de León AC,
Cacciottolo J, Cai H, Cama T, Cameron C, Camola J, Can G, Candido
APCC, Capanzana M, Capuano V, Cardoso VC, Carlsson AC, Carval-
ho MJ, Casanueva FF, Casas JP, Caserta CA, Chamukuttan S, Chan
AW, Chan Q, Chaturvedi HK, Chaturvedi N, Chen CJ, Chen FF,
Chen HS, Chen SH, Chen ZM, Cheng CY, Chetrit A, Chikova-Isce-
ner E, Chiolero A, Chiou ST, Chirita-Emandi A, Chirlaque MD, Cho
B, Cho Y, Christensen K, Christofaro DG, Chudek J, Cifkova R, Cin-
teza E, Claessens F, Clays E, Concin H, Confortin SC, Cooper C,
Cooper R, Coppinger TC, Costanzo S, Cottel D, Cowell C, Craig
CL, Crujeiras AB, Cucu A, D’Arrigo G, d’Orsi E, Dallongeville J, Da-
masceno A, Damsgaard CT, Danae G, Dankner R, Dantoft TM, Dast-
giri S, Dauchet L, Davletov K, De Backer G, De Bacquer D, De Cur-
tis A, de Gaetano G, De Henauw S, de Oliveira PD, De Ridder K, De
Smedt D, Deepa M, Deev AD, Dehghan A, Delisle H, Delpeuch F,
Deschamps V, Dhana K, Di Castelnuovo AF, Dias-da-Costa JS, Díaz A,
Dika Z, Djalalinia S, Do HTP, Dobson AJ, Donati MB, Donfrancesco
C, Donoso SP, Doring A, Dorobantu M, Dorosty AR, Doua K, Drygas
W, Duan JL, Duante C, Duleva V, Dulskiene V, Dzerve V, Dziankows-
ka-Zaborszczyk E, Egbagbe EE, Eggertsen R, Eiben G, Ekelund U, El
Ati J, Elliott P, Engle-Stone R, Erasmus RT, Erem C, Eriksen L, Eriksson
JG, Escobedo J, Evans A, Faeh D, Fall CH, Sant’Angelo VF, Farzadfar F,
Felix-Redondo FJ, Ferguson TS, Fernandes RA, Fernández-Berges D,
Ferrante D, Ferrari M, Ferreccio C, Ferrieres J, Finn JD, Fischer K,
Flores EM, Foger B, Foo LH, Forslund AS, Forsner M, Fouad HM,
Francis DK, Franco MD, Franco OH, Frontera G, Fuchs FD, Fuch SC,
Fujita Y, Furusawa T, Gaciong Z, Gafencu M, GaLeóne D, Galvano F,
García-de-la-Hera M, Gareta D, Garnett SP, Gaspoz JM, Gasull M,
Gates L, Geiger H, Geleijnse JM, Ghasemian A, Giampaoli S, Gianfag-
na F, Gill TK, Giovannelli J, Giwerman A, Godos J, Gogen S, Golds-
mith RA, Goltzman D, Goncalves H, González-León M, González-
Rivas JP, González-Gross M, Gottrand F, Graca AP, Graff-Iversen S,
Grafnetter D, Grajda A, Grammatikopoulou MG, Gregor RD, Gro-
dzicki T, Grontved A, Grosso G, Gruden G, Grujic V, Gu DF, Gualdi-
Russo E, Guallar-Castillón P, Guan OP, Gudmundsson EF, Gudnason
V, Guerrero R, Guessous I, Guimaraes AL, Gulliford MC, Gunnlaugs-
dottir J, Gunter M, Guo XH, Guo Y, Gupta PC, Gupta R, Gureje O,
Gurzkowska B, Gutiérrez L, Gutzwiller F, Hadaegh F, Hadjigeorgiou
CA, Si-Ramlee K, Halkjaer J, Hambleton IR, Hardy R, Kumar RH,
Hassapidou M, Hata J, Hayes AJ, He J, Heidinger-Felso R, Heinen M,
Hendriks ME, Henriques A, Cadena LH, Herrala S, Herrera VM, Her-
ter-Aeberli I, Heshmat R, Hihtaniemi IT, Ho SY, Ho SC, Hobbs M,
Hofman A, Hopman WM, Horimoto ARVR, Hormiga CM, Horta BL,
Houti L, Howitt C, Htay TT, Htet AS, Htike MMT, Hu YH, Huerta JM,
Petrescu CH, Huisman M, Husseini A, Huu CN, Huybrechts I, Hwalla
N, Hyska J, Iacoviello L, Iannone AG, Ibarluzea JM, Ibrahim MM, Ikeda
N, Ikram MA, Irazola VE, Islam M, Ismail AA, Ivkovic V, Iwasaki M,
Jackson RT, Jacobs JM, Jaddou H, Jafar T, Jamil KM, Jamrozik K, Janszky
I, Jarani J, Jasienska G, Jelakovic A, Jelakovic B, Jennings G, Jeong S.L.,
Jiang CQ, Jiménez-Acosta SM, Joffres M, Johansson M, Jonas JB, Tor-
ben J, Joshi P, Jovic DP, Jozwiak J, Juolevi A, Jurak G, Juresa V, Kaaks R,
Kafatos A, Kajantie EO, Kalter-Leibovici O, Kamaruddin NA, Kapan-
tais E, Karki KB, Kasaeian A, Katz J, Kauhanen J, Kaur P, Kavousi M,
Kazakbaeva G, Keil U, Boker LK, Keinanen-Kiukaanniemi S, Kelishadi
R, Kelleher C, Kemper HCG, Kengne AP, Kerimkulova A, Kersting M,
Key T, Khader OS, Khalili D, Khang YH, Khateeb M, Khaw KT, Khouw
IMS.L., Kiechl-Kohlendorfer U, Kiech S, Killewo J, Kim J, Kim YY, Kli-
mont J, Klumbiene J, Knoflach M, Koirala B, Kolle E, Kolsteren P,
Korrovits P, Kos J, Koskinen S, Kouda K, Kovacs VA, Kowlessur S,
Koziel S, Kratzer W, Kriemler S, Kristensen PL, Krokstad S,
Kromhout D, Kruger HS, Kubinova R, Kuciene R, Kuh D, Kujala UM,
Kulaga Z, Kumar RK, Kunesova M, Kurjata P, Kusuma YS, Kuulasmaa
K, Kyobutungi C, La QN, Laamiri FZ, Laatikainen T, Lachat C, Laid Y,
Lam TH, Landrove O, Lanska V, Lappas G, Larijani B, Laugsand LE,
Lauria L, Laxmaiah A, Bao KLN, Le TD, Lebanan MAO, Leclercq C,
Lee J, Lee J, Lehtimaki T, León-Muñoz LM, Levitt NS, Li YP, Lilly CL,
Lim WY, Lima-Costa MF, Lin HH, Lin X, Lind L, Linneberg A, Lissner
L, Litwin M, Liu J, Loit HM, Lopes L, Lorbeer R, Lotufo PA, Lozano JE,
125
 3
Information Groups by Area
3.2 Cardiovascular Area
Luksiene D, Lundqvist A, Lunet N, Lytsy P, Ma GS, Ma J, Machado-
Coelho GLL, Machado-Rodrigues AM, Machi S, Maggi S, Magliano DJ,
Magriplis E, Mahaletchumy A, Maire B, Majer M, Makdisse M, Malek-
zadeh R, Malhotra R, Rao KM, Malyutina S, Manios Y, Mann JI, Manza-
to E, Margozzini P, Markaki A, Markey O, Marques LP, Marques-Vidal
P, Marrugat J, Martin-Prevel Y, Martin R, Martorell R, Martos E, Mar-
ventano S, Masoodi SR, Mathiesen EB, Matijasevich A, Matsha TE,
Mazur A, Mbanya JCN, McFarlane SR, McGarvey ST, Mckee M, Mclac
S, McLean RM, McLean SB, McNulty BA,Yusof SM, Mediene-Benche-
kor S, Medzioniene J, Meirhaeghe A, Meisfjord J, Meisinger C, Mene-
zes AMB, Menon GR, Mensink GBM, Meshram II, Metspalu A, Meyer
HE, Mi J, Michaelsen KF, Michels N, Mikkel K, Miller JC, Minderico
CS, Miquel JF, Miranda JJ, Mirkopoulou D, Mirrakhimov E, Misigoj-
Durakovic M, Mistretta A, Mocanu V, Modesti PA, Mohamed MK,
Mohammad K, Mohammadifard N, Mohan V, Mohanna S,Yusoff MFM,
Molbo D, Mollehave LT, Moller NC, Molnar D, Momenan A, Mondo
CK, Monterrubio EA, Monyeki KDK, Moon JS, Moreira LB, Morejo
A, Moreno LA, Morgan K, Mortensen EL, Moschonis G, Mossakows-
ka M, Mostafa A, Mota J, Mota-Pinto A, Motlag ME, Motta J, Mu TT,
Muc M, Muiesan ML, Muller-Nurasyid M, Murphy N, Mursu J, Mur-
tagh EM, Musil V, Nabipour I, Nagel G, Naidu BM, Nakamura H, Na-
mesna J, Nang EEK, Nangia VB, Nankap M, Narake S, Nardone P,
Navarrete-Muñoz EM, Neal WA, Nenko I, Neovius M, Nervi F, Ngu-
yen CT, Nguyen ND, Nguye QN, Nieto-Martínez RE, Ning G, Nino-
miya T, Nishtar S, Noale M, Noboa OA, Norat T, Norie S, Noto D, Al
Nsour M, O’Reilly D, Obreja G, Oda E, Oehlers G, Oh K, Ohara K,
Olafsson O, Olinto MTA, Oliveira IO, Oltarzewski M, Omar MA,
Onat A, Ong SK, Ono LM, Ordunez P, Ornelas R, Ortiz AP, Osler M,
Osmond C, Ostojic SM, Ostovar A, Otero JA, Overvad K, Owusu-
Dabo E, Paccaud FM, Padez C, Pahomova E, Pajak A, Palli D, Palloni
A, Palmieri L, Pan WH, Panda-Jonas S, Pandey A, Panza F, Papandreou
D, Park SW, Parnell WR, Parsaeian M, Pascanu IM, Patel ND, Pecin I,
Pednekar MS, Peer N, Peeters PH, Peixoto SV, Peltonen M, Pereira
AC, Perez-Farinos N, Perez CM, Peters A, Petkeviciene J, Petrauskie-
ne A, Peykari N, Pham ST, Pierannunzio D, Pigeo I, Pikhart H, Pilav A,
Pilotto L, Pistelli F, Pitakaka F, Piwonska A, Plans-Rubio P, Poh BK,
Pohlabeln H, Pop RM, Popovic SR, Porta M, Portegies MLP, Posch G,
Poulimeneas D, Pouraram H, Pourshams A, Poustchi H, Pradeepa R,
Prashant M, Price JF, Puder JJ, Pudule I, Puiu M, Punab M, Qasrawi RF,
Qorbani M, Bao TQ, Radic I, Radisauskas R, Rahman M, Rahman M,
Raitakari O, Raj M, Rao SR, Ramachandran A, Ramke J, Ramos E,
Ramos R, Rampal L, Rampal S, Rascon-Pacheco RA, Redon J, Reganit
PFM, Ribas-Barba L, Ribeiro R, Riboli E, Rigo F, de Wit TFR, Rito A,
Ritti-Dias RM, Rivera JA, Robinson SM, Robitaille C, Rodrigues D,
Rodríguez-Artalejo F, Rodríguez-Perez MDC, Rodríguez-Villamizar
LA, Rojas-Martínez R, Rojroongwasinkul N, Romaguera D, Ronkai-
nen K, Rosengren A, Rouse I, Roy JGR, Rubinstein A, Ruhli FJ, Ruiz-
Betancourt BS, Russo P, Rutkowski M, Sabanayagam C, Sachdev HS,
Saidi O, Salanave B, Martínez ES, Salmeron D, Salomaa V, Salonen JT,
Salvetti M, Sánchez-Abanto J, Sandjaja, Sans S, Marina LS, Santos DA,
Santos IS, Santos O, dos Santos RN, Santos R, Saramies JL, Sardinha
LB, Sarrafzadegan N, Saum KU, Savva S, Savy M, Scazufca M, Rosario
AS, Schargrodsky H, Schienkiewitz A, Schipf S, Schmidt CO, Schmidt
IM, Schultsz C, Schutte AE, Sein AA, Sen A, Senbanjo IO, Sepanlou SG,
Serra-Majem L, Shalnova SA, Sharma SK, Shaw JE, Shibuya K, Shin
DW, Shin YC, Shiri R, Siani A, Siantar R, Sibai AM, Silva AM, Silva DAS,
Simon M, Simons J, Simons LA, Sjoberg A, Sjostrom M, Skovbjerg S,
Slowikowska-Hilczer J, Slusarczyk P, Smeeth L, Smith MC, Snijder
MB, So HK, Sobngwi E, Soderberg S, Soekatri MYE, Solfrizzi V, Sones-
tedt E, Song Y, Sorensen TIA, Soric M, Jerome CS, Soumare A, Spine-
lli A, Spiroski I, Staessen JA, Stamm H, Star G, Stathopoulou MG,
Staub K, Stavreski B, Steene-Johannessen J, Stehle P, Stein AD, Ster-
giou GS, Stessman J, Stieber J, Stockl D, Stocks T, Stokwisze J, Stratton
G, Stronks K, Strufaldi MW, Suarez-Medina R, Sun CA, Sundstrom J,
Sung YT, Sunyer J, Suriyawongpaisa P, Swinburn BA, Sy RG, Szponar
L, Tai ES, Tammesoo ML, Tamosiunas A, Tan EJ, Tang X, Tanser F, Tao Y,
Tarawneh MR, Tarp J, Tarqui-Mamani CB, Tautu OF, Braunerova RT,
Taylor A, Tchibindat F, Theobald H, Theodoridis X, Thijs L, Thuesen
126
BH,Tjonneland A,Tolonen HK,Tolstrup JS,Topbas M,Topor-Madry R,
Tormo MJ, Tornaritis MJ, Torrent M, Toselli S, Traissac P, Trichopoulos
D, Trichopoulou A, Trinh OTH, Atul T, Tshepo L, Tsigga M, Tsugane S,
Tulloch-Reid MK,Tullu F,Tuomainen TP,Tuomilehto J,Turley ML,Tyne-
lius P, Tzotzas T, Tzourio C, Ueda P, Ugel EE, Ukoli FAM, Ulmer H,
Unal B, Uusitalo HMT, Valdivia G, Vale S, Valvi D, van der Schouw YT,
Van Herck K, Minh VH, van Rossem L, Van Schoor NM, Van Valken-
goed IG,Vanderschueren D,Vanuzzo D,Vatten L,Vega T,Veidebaum T,
Velasquez-Melendez G, Velika B, Veronesi G, Verschuren WMM, Vic-
tora CG, Viegi G, Viet L, Viikari-Juntura E, Vineis P, Vioque J, Virtanen
JK, Visvikis-Siest S, Viswanathan B, Vlasoff T, Vollenweider P, Volzke H,
Voutilainen S, Vrijheid M, Wade AN, Wagner A, Waldhor T, Walton J,
Bebakar WMW, Mohamud WNW,Wanderley RS,Wang MD,Wan Q,
Wang YX,Wannamethee SG,Wareham N,Weber A,Wedderkopp N,
Weerasekera D, Whincup PH, Widhalm K, Widyahening IS, Wiecek
A, Wijga AH, Wilks RJ, Willeit J, Willeit P, Wilsgaard T, Wojtyniak B,
Wong-McClure RA,Wong JYY,Wong JE,Wong TY,Woo J,Woodward
M, Wu FC, Wu JF, Wu S.L., Xu HQ, Xu L,Yamborisut U,Yan WL,Yang
XU, Yardim N, Ye XW, Yiallouros PK, Yngve A, Yoshihara A, You QS,
Younger-Coleman NO,Yusoff F,Yusoff MFM, Zaccagni L, Zafiropulos
V, Zainuddin AA, Zambon S, Zampelas A, Zamrazilova H, Zdrojewski
T, Zeng Y, Zhao D, Zhao WH, Zheng W, Zheng YF, Zholdin B, Zhou
MG, Zhu D, Zhussupov B, Zimmermann E, Cisneros JZ. Worldwide
trends in body-mass index, underweight, overweight, and obesity
from 1975 to 2016: a pooled analysis of 2416 population-based
measurement studies in 128.9 million children, adolescents, and
adults. Lancet. 2017; 390(10113): 2627-42. Article. IF: 53.254; D1
• García-Esquinas E, Andrade E, Martínez-Gómez D, Caballero FF, Ló-
pez-García E, Rodríguez-Artalejo F. Television viewing time as a risk
factor for frailty and functional limitations in older adults: results
from 2 European prospective cohorts. Int J Behav Nutr Phy. 2017;
14: 54. Article. IF: 5.548; D1
• García-Esquinas E, Rodríguez-Artalejo F. Environmental pollutants,
limitations in physical functioning, and frailty in older adults. Curr
Environ Health Rep. 2017; 4(1): 44166. Review. Not Indexed
• Gijón-Conde T, Graciani A, López-García E, Guallar-Castillón P,
García-Esquinas E, Rodríguez-Artalejo F, Banegas JR. Short-term
variability and nocturnal decline in ambulatory blood pressure in
normotension, white-coat hypertension, masked hypertension and
sustained hypertension: a population-based study of older individuals
in Spain. Hypertens Res. 2017; 40(6): 613-9. Article. IF: 3.439; Q1
• Halcox JP, Banegas JR, Roy C, Dallongeville J, de Backer G, Guallar E,
Perk J, Hajage D, Henriksson KM, Borghi C. Prevalence and treatment
of atherogenic dyslipidemia in the primary prevention of cardiovascu-
lar disease in Europe: EURIKA, a cross-sectional observational study.
Bmc Cardiovasc Disor. 2017; 17: 160. Article. IF: 1.812; Q3
• Hernández-Aceituno A, Pérez-Tasigchana RF, Guallar-Castillón P,
López-García E, Rodríguez-Artalejo F, Banegas JR. Combined healthy
behaviors and healthcare services use in older adults. Am J Prev
Med. 2017; 53(6): 872-81. Article. IF: 4.127; Q1
• Higueras-Fresnillo S, Guallar-Castillón P, Cabañas-Sánchez V, Banegas
JR, Rodríguez-Artalejo F, Martínez-Gómez D. Changes in physical ac-
tivity and cardiovascular mortality in older adults. J Geriatr Cardiol.
2017; 14(4): 280-1. Letter. IF: 1.581; Q3
• Hurtado-Roca Y, Bueno H, Fernández-Ortiz A, Ordovas JM, Ibáñez
B, Fuster V, Rodríguez-Artalejo F, Laclaustra M. Oxidized LDL is as-
sociated with metabolic syndrome traits independently of central
obesity and insulin resistance. Diabetes. 2017; 66(2): 474-82. Article.
IF: 7.273; D1
• Lana A, Valdés-Becares A, Buño A, Rodríguez-Artalejo F, López-Gar-
cía E. Serum leptin concentration is associated with incident frailty
in older adults. Aging Dis. 2017;8 (2): 240-9. Article. IF: 5.058; Q1
• León-Muñoz LM, Guallar-Castillón P, García-Esquinas E, Galán I, Ro-
dríguez-Artalejo F. Alcohol drinking patterns and risk of functional
limitations in two cohorts of older adults. Clin Nutr. 2017; 36(3):
831-8. Article. IF: 5.496; D1
• López-García E, Guallar-Castillón P, García-Esquinas E, Rodríguez- • Zhou B, Bentham J, Di Cesare M, Bixby H, Danaei G, Cowan MJ,
Artalejo F. Metabolically healthy obesity and health-related quality Paciorek CJ, Singh G, Hajifathalian K, Bennett JE, Taddei C, Bilano V,
of life: A prospective cohort study. Clin Nutr. 2017; 36(3): 853-60. Carrillo-Larco RM, Djalalinia S, Khatibzadeh S, Lugero C, Peykari N,
Article. IF: 5.496; D1 Zhang WZ, Lu Y, Stevens GA, Riley LM, Bovet P, Elliott P, Gu DF, Ikeda
• Martínez-Gómez D, Guallar-Castillón P, García-Esquinas E, Bandi- N, Jackson RT, Joffres M, Kengne AP, Laatikainen T, Lam TH, Laxmaiah
nelli S, Rodríguez-Artalejo F. Physical activity and the effect of mul- A, Liu J, Miranda JJ, Mondo CK, Neuhauser HK, Sundstrom J, Smeeth
timorbidity on all-cause mortality in older adults. Mayo Clin Proc. L, Soric M, Woodward M, Ezzati M, Abarca-Gómez L, Abdeen ZA,
2017; 92(3): 376-82. Article. IF: 7.199; D1 Rahim HA, Abu-Rmeileh NM, Acosta-Cazares B, Adams R, Aek-
plakorn W, Afsana K, Aguilar-Salinas CA, Agyemang C, Ahmadvand A,
• Martínez-Gómez D, Guallar-Castillón P, Higueras-Fresnillo S, Rodrí-
Ahrens W, Al Raddadi R, Al Woyatan R, Ali MM, Alkerwi A, Aly E,
guez-Artalejo F. Concurrent validity of the historical leisure-time
Amouyel P, Amuzu A, Andersen LB, Anderssen SA, Angquist L, Anjana
physical activity question of the Spanish National Health survey in
RM,Ansong D,Aounallah-Skhiri H,Araujo J,Ariansen I,Aris T,Arlappa
older adults. Rev Esp Cardiol. 2017; 70(8): 669-70. Letter. IF: 5.166; Q1
N, Aryal K, Arveiler D, Assah FK, Assuncao MCF, Avdicova M, Azeve-
• Orozco Arbeláez E, Banegas JR, Rodríguez Artalejo F, López Gar-
do A, Azizi F, Babu BV, Bahijri S, Balakrishna N, Bandosz P, Banegas JR,
cía E. Influence of habitual chocolate consumption over the Mini-
Barbagallo CM, Barcelo A, Barkat A, Barros AJD, Barros MV, Bata I,
Mental State Examination in Spanish older adults. Nutr Hosp. 2017;
Batieha AM, Baur LA, Beaglehole R, Ben Romdhane H, Benet M, Ben-
34(4): 841-6. Article. Not Indexed
son LS, Bernabe-Ortiz A, Bernotiene G, Bettiol H, Bhagyalaxmi A,
• Ortola R, García-Esquinas E, Galán I, Guallar-Castillón P, López- Bharadwaj S, Bhargava SK, Bi YF, Bikbov M, Bjerregaard P, Bjertness E,
García E, Banegas JR, Rodríguez-Artalejo F. Patterns of alcohol con- Bjokelund C, Blokstra A, Bo S, Bobak M, Boeing H, Boggia JG, Bois-
sumption and risk of falls in older adults: a prospective cohort study. sonnet CP, Bongard V, Bovet P, Braeckman L, Brajkovich I, Branca F,
Osteoporosis Int. 2017; 28(11): 3143-52. Article. IF: 3.856; Q2 Breckenkamp J, Brenner H, Brewster LM, Bruno G, Bueno-de-Mes-
• Pérez-Hernández B, García-Esquinas E, Graciani A, Guallar-Castillón quita HB, Bugge A, Burns C, Bursztyn M, de León AC, Cameron C,
P, López-García E, León-Muñoz LM, Banegas JR, Rodríguez-Artale- Can G, Candido APC, Capuano V, Cardoso VC, Carlsson AC, Carval-
jo F. Social inequalities in cardiovascular risk factors among older ho MJ, Casanueva FF, Casanueva FF, Casas JP, Caserta CA, Cha-
adults in Spain: The seniors-ENRICA study. Rev Esp Cardiol. 2017; mukuttan S, Chan AW, Chan Q, Chaturvedi HK, Chaturvedi N, Chen
70(3): 145-54. Article. IF: 5.166; Q1 CJ, Chen FF, Chen HS, Chen S, Chen ZM, Cheng CY, Dekkaki IC,
• Pérez-Tasigchana RF, León-Muñoz LM, López-García E, Gutiérrez- Chetrit A, Chiolero A, Chiou ST, Chirita-Emandi A, Cho B, Cho Y,
Fisac JL, Laclaustra M, Rodríguez-Artalejo F, Guallar-Castillón P. Me- Chudek J, Cifkova R, Claessens F, Clays E, Concin H, Cooper C,
tabolic syndrome and insulin resistance are associated with frailty Cooper R, Coppinger TC, Costanzo S, Cottel D, Cowell C, Craig
in older adults: a prospective cohort study. Age Ageing. 2017; 46(5): CL, Crujeiras AB, Cruz JJ, D’Arrigo G, d’Orsi E, Dallongeville J, Da-
807-12. Article. IF: 4.013; Q1 masceno A, Danaei G, Dankner R, Dantoft TM, Dauchet L, De Bac-
• Recio A, Linares C, Banegas JR, Díaz J. Impact of road traffic noise on ker G, de Gaetano G, De Henauw S, De Smedt D, Deepa M, De-
cause-specific mortality in Madrid (Spain). Sci Total Environ. 2017; hghan A, Delisle H, Deschamps V, Dhana K, Di Castelnuovo AF,
Dias-da-Costa JS, Díaz A, Dickerson TT, Djalalinia S, Do HTP, Dob-
590: 171-3. Article. IF: 4.61; Q1
son AJ, Donfrancesco C, Donoso SP, Doring A, Doua K, Drygas W,
• Rodríguez-Mañas L, Rodríguez-Artalejo F, Sinclair AJ.The third tran-
Dulskiene V, Dzakula A, Dzerve V, Dziankowska-Zaborszczyk E,
sition: The clinical evolution oriented to the contemporary older
Eggertsen R, Ekelund U, El Ati J, Ellert U, Elliott P, Elosua R, Erasmus
patient. J Am Med Dir Assoc. 2017; 18(1): 8-9. Editorial Material. IF:
RT, Erem C, Eriksen L, Escobedo-de la Pena J, Evans A, Faeh D, Fall
5.325; D1
CH, Farzadfar F, Félix-Redondo FJ, Ferguson TS, Fernández-Berges D,
• Rodríguez-Pascual C, Paredes-Galán E, Ferrero-Martínez AI, Gon- Ferrante D, Ferrari M, Ferreccio C, Ferrieres J, Finn JD, Fischer K,
zález-Guerrero JL, Hornillos-Calvo M, Menéndez-Colino R, Torres-
Torres I,Vilches-Moraga A, Galán MC, Suárez-García F, Olcoz-Chiva
MT, Rodríguez-Artalejo F. The frailty syndrome is associated
with adverse health outcomes in very old patients with
stable heart failure: A prospective study in six Spanish
hospitals. Int J Cardiol. 2017; 236: 296-303. Article. IF:
4.034; Q2
• Ruiz-Hurtado G, Banegas JR, Sarafidis PA, Volpe M, Wi-
lliams B, Ruilope LM. Has the SPRINT trial introduced a
new blood-pressure goal in hypertension? Nat Rev Car-
diol. 2017; 14(9): 560-6. Article. IF: 15.162; D1
• Ueda P, Woodward M, Lu Y, Hajifathalian K, Al-Wotayan
R, Aguilar-Salinas CA, Ahmadvand A, Azizi F, Bentham J,
Cifkova R, Di Cesare M, Eriksen L, Farzadfar F, Ferguson
TS, Ikeda N, Khalili D, Khang YH, Lanska V, León-Muñoz L,
Magliano DJ, Margozzini P, Msyamboza KP, Mutungi G, Oh
K, Oum S, Rodríguez-Artalejo F, Rojas-Martínez R, Valdi-
via G, Wilks R, Shaw JE, Stevens GA, Tolstrup JS, Zhou B,
Salomon JA, Ezzati M, Danaei G. Laboratory-based and office-
based risk scores and charts to predict 10-year risk of cardio-
vascular disease in 182 countries: a pooled analysis of prospective
cohorts and health surveys. Lancet Diabetes Endocrinol. 2017; 5(3):
196-213. Article. IF: 19,313; D1
• Vinyoles E, de la Sierra A, Roso-Llorach A, Banegas JR, de la Cruz
JJ, Gorostidi M, Segura J, Divisón JA, Ruiz-Hurtado G, Ruilope LM.
24-h pulse pressure cutoff point definition by office pulse pressure
in a population of Spanish older hypertensive patients. J Hypertens.
2017; 35(5): 1011-8. Article. IF: 4.092; Q1
127
 3
Information Groups by Area
3.2 Cardiovascular Area
Foger B, Foo LH, Forslund AS, Forsner M, Fortmann SP, Fouad HM,
Francis DK, Franco MD, Franco OH, Frontera G, Fuchs FD, Fuchs
SC, Fujita Y, Furusawa T, Gaciong Z, Gareta D, Garnett SP, Gaspoz JM,
Gasull M, Gates L, Gavrila D, Geleijnse JM, Ghasemian A, Ghimire A,
Giampaoli S, Gianfagna F, Giovannelli J, Goldsmith RA, Goncalves H,
Gross MG, Rivas JPG, Gottrand F, Graff-Iversen S, Grafnetter D,
Grajda A, Gregor RD, Grodzicki T, Grontved A, Gruden G, Grujic V,
Gu DF, Guan OP, Gudnason V, Guerrero R, Guessous I, Guimaraes
AL, Gulliford MC, Gunnlaugsdottir J, Gunter M, Gupta PC, Gureje O,
Gurzkowska B, Gutiérrez L, Gutzwiller F, Hadaegh F, Halkjaer J,
Hambleton IR, Hardy R, Harikumar R, Hata J, Hayes AJ, He J, Hen-
driks ME, Henriques A, Cadena LH, Herqutanto, Herrala S, Heshmat
R, Hihtaniemi IT, Ho SY, Ho SC, Hobbs M, Hofman A, Dinc GH,
Hormiga CM, Horta BL, Houti L, Howitt C, Htay TT, Htet AS, Hu YH,
Huerta JM, Husseini AS, Huybrechts I, Hwalla N, Iacoviello L, Ianno-
ne AG, Ibrahim MM, Ikram MA, Irazola VE, Islam M, Ivkovic V, Iwasaki
M, Jackson RT, Jacobs JM, Jafar T, Jamrozik K, Janszky I, Jasienska G,
Jelakovic B, Jiang CQ, Johansson M, Jonas JB, Jorgensen T, Joshi P,
Juolevi A, Jurak G, Juresa V, Kaaks R, Kafatos A, Kalter-Leibovici O,
Kamaruddin NA, Kasaeian A, Katz J, Kauhanen J, Kaur P, Kavousi M,
Kazakbaeva G, Keil U, Boker LK, Keinanen-Kiukaanniemi S, Kelishadi
R, Kemper HCG, Kengne AP, Kersting M, Key T, Khader YS, Khalili D,
Khang YH, Khaw KT, Kiechl S, Killewo J, Kim J, Klumbiene J, Kolle E,
Kolsteren P, Korrovits P, Koskinen S, Kouda K, Koziel S, Kristensen
PL, Krokstad S, Kromhout D, Kruger HS, Kubinova R, Kuciene R,
Kuh D, Kujala UM, Kula K, Kulaga Z, Kumar RK, Kurjata P, Kusuma YS,
Kuulasmaa K, Kyobutungi C, Laatikainen T, Lachat C, Landrove O,
Lanska V, Lappas G, Larijani B, Laugsand LE, Laxmaiah A, Bao KLN, Le
TD, Leclercq C, Lee J, Lee J, Lehtimaki T, Lekhraj R, León-Muñoz LM,
Levitt NS, Li YP, Lilly CL, Lim WY, Lima-Costa MF, Lin HH, Lin X,
Linneberg A, Lissner L, Litwin M, Liu J, Lorbeer R, Lotufo PA, Lozano
JE, Luksiene D, Lundqvist A, Lunet N, Lytsy P, Ma GS, Ma J, Machado-
Coelho GLL, Machi S, Maggi S, Magliano DJ, Majer M, Makdisse M,
Malekzadeh R, Malhotra R, Rao KM, Malyutina S, Manios Y, Mann JI,
Manzato E, Margozzini P, Marques-Vidal P, Marrugat J, Martorell R,
Mathiesen EB, Matijasevich A, Matsha TE, Mbanya JCN, Posso AJM,
McFarlane SR, McFarlane SR, McGarvey ST, McLachlan S, McLean
RM, McNulty BA, Khir ASM, Mediene-Benchekor S, Medzioniene J,
Meirhaeghe A, Meisinger C, Menezes AMB, Menon GR, Meshram II,
Metspalu A, Mi J, Mikkel K, Miller JC, Miquel JF, Miranda JJ, Misigoj-
Durakovic M, Mohamed MK, Mohammad K, Mohammadifard N,
Mohan V, Yusoff MFM, Moller NC, Molnar D, Momenan A, Mondo
CK, Monyeki KDK, Moreira LB, Morejon A, Moreno LA, Morgan K,
Moschonis G, Mossakowska M, Mostafa A, Mota J, Motlagh ME,
Motta J, Muiesan ML, Muller-Nurasyid M, Murphy N, Mursu J, Musil V,
Nagel G, Naidu BM, Nakamura H, Namsna J, Nang EEK, Nangia VB,
Narake S, Navarrete-Muñoz EM, Ndiaye NC, Neal WA, Nenko I,
Nervi F, Neuhauser HK, Nguyen ND, Nguyen QN, Nieto-Martínez
RE, Niiranen TJ, Ning G, Ninomiya T, Nishtar S, Noale M, Noboa OA,
Noorbala AA, Norat T, Noto D, Al Nsour M, O’Reilly D, Oh K, Olin-
to MTA, Oliveira IO, Omar MA, Onat A, Ordunez P, Osmond C,
Ostojic SM, Otero JA, Overvad K, Owusu-Dabo E, Paccaud FM, Pa-
dez C, Pahomova E, Pajak A, Palli D, Palmieri L, Panda-Jonas S, Panza
F, Papandreou D, Parnell WR, Parsaeian M, Pecin I, Pednekar MS, Peer
N, Peeters PH, Peixoto SV, Pelletier C, Peltonen M, Pereira AC, Pérez
RM, Peters A, Petkeviciene J, Peykari N, Pham ST, Pigeot I, Pikhart H,
Pilav A, Pilotto L, Pitakaka F, Plans-Rubio P, Polakowska M, Polasek O,
Porta M, Portegies MLP, Pourshams A, Pradeepa R, Prashant M, Price
JF, Puiu M, Punab M, Qasrawi RF, Qorbani M, Radic I, Radisauskas R,
Rahman M, Raitakari O, Raj M, Rao SR, Ramos E, Rampal S, Reina
DAR, Rasmussen F, Redon J, Reganit PFM, Ribeiro R, Riboli E, Rigo F,
de Wit TFR, Ritti-Dias RM, Robinson SM, Robitaille C, Rodríguez-
Artalejo F, Rodríguez-Villamizar LA, Rojas-Martínez R, Rosengren A,
Rubinstein A, Rui O, Ruiz-Betancourt BS, Horimoto ARVR, Ru-
tkowski M, Sabanayagam C, Sachdev HS, Saidi O, Sakarya S, Salanave
B, Martínez ES, Salmeron D, Salomaa V, Salonen JT, Salvetti M, Sán-
chez-Abanto J, Sans S, Santos D, Santos IS, dos Santos RN, Santos R,
Saramies JL, Sardinha LB, Margolis GS, Sarrafzadegan N, Saum KU,
128
Savva SC, Scazufca M, Schargrodsky H, Schneider IJ, Schultsz C,
Schutte AE, Sen A, Senbanjo IO, Sepanlou SG, Sharma SK, Shaw JE,
Shibuya K, Shin DW, Shin YC, Siantar R, Sibai AM, Silva DAS, Simon
M, Simons J, Simons LA, Sjotrom M, Skovbjerg S, Slowikowska-Hilc- Coagulopathies
and Alterations
zer J, Slusarczyk P, Smeeth L, Smith MC, Snijder MB, So HK, Sobngwi
E, Soderberg S, Solfrizzi V, Sonestedt E, Song Y, Sorensen TIA, Soric M,
Jerome CS, Soumare A, Staessen JA, Starc G, Stathopoulou MG, Sta-
vreski B, Steene-Johannessen J, Stehle P, Stein AD, Stergiou GS,
Stessman J, Stieber J, Stockl D, Stocks T, Stokwiszewski J, Stronks K,
Strufaldi MW, Sun CA, Sundstrom J, Sung YT, Suriyawongpaisal P, Sy
of Haemostasis Group
RG, Tai ES, Tammesoo ML, Tamosiunas A, Tang L, Tang X, Tanser F, Tao
Y, Tarawneh MR, Tarqui-Mamani CB, Taylor A, Theobald H, Thijs L,
Thuesen BH, Tjonneland A, Tolonen HK, Topbas M, Topor-Madry R,
Tormo MJ, Torrent M, Traissac P, Trichopoulos D, Trichopoulou A,
Trinh OTH, Trivedi A, Tshepo L, Tulloch-Reid MK, Tuomainen TP, Tur-
ley ML,Tynelius P,Tzourio C, Ueda P, Ugel E, Ulmer H, Uusitalo HMT,
Valdivia G, Valvi D, van der Schouw YT, Van Herck K, van Rossem L,
van Valkengoed IGM, Vanderschueren D, Vanuzzo D, Vatten L, Vega T,
Velasquez-Melendez G,Veronesi G,Verschuren WMM,Verstraeten R,
Victora CG, Viet L, Viikari-Juntura E, Vineis P, Vioque J, Virtanen JK,
Visvikis-Siest S,Viswanathan B,Vollenweider P,Vrdoljak A,Vrijheid M,
Wade AN, Wagner A, Walton J, Mohamud WNW, Wang MD, Wang
Q,Wang YX,Wannamethee SG,Wareham N,Wederkopp N,Weera-
sekera D,Whincup PH,Widhalm K,Widyahening IS,Wiecek A,Wijga
AH, Wilks RJ, Willeit P, Williams EA, Wilsgaard T, Wojtyniak B, Wong
TY, Wong-McClure RA, Woo J, Woodward M, Wu AG, Wu FC, Wu
S.L., Xu HQ, Yan WL, Yang XG, Ye XW, Yiallouros PK, Yoshihara A,
Younger-Coleman NO, Yusoff AF, Zambon S, Zdrojewski T, Zeng Y, 13 53.677 5
Zhao D, Zhao WH, Zheng Y, Zhu D, Zimmermann E, Cisneros JZ.
Worldwide trends in blood pressure from 1975 to 2015: a pooled
analysis of 1479 population-based measurement studies with 19.1
million participants. Lancet. 2017; 389(10064): 37-55. Article. IF: Víctor Manuel Jiménez Yuste. Jefe de Servicio de • Risk factors for the development of factor FVIII/
53.254; D1 Hematología. HULP FIX inhibitors in patients with haemophilia A and
María Teresa Álvarez Román. Facultativo Especialista de Área en B. Individualised treatment adaptation based on
the nature of antigenic epitopes
Public Projects Hematología y Hemoterapia. HULP
• Epidemiological studies of congenital haemo-
Nora Viviana Butta Coll. Investigadora Senior (Contrato Miguel Servet
Rodríguez Artalejo F. Impacto de los principales patrones de philia A and B, acquired haemophilia A and von
- Tipo II). Jefa de Laboratorio. HULP
consumo de bebidas alcohólicas sobre la salud de los adultos Willebrand’s disease
Ihosvany Fernández Bello. Investigador Postdoctoral. HULP
mayores en españa (2014/002). Plan Nacional sobre Drogas.
Raquel Fernández Morata. Técnico de Laboratorio. HULP 2- Haemostasis disorders:
2015-2017.
Elena García Arias-Salgado. Investigadora asociada. Advenced Medical • Haemostasis in thrombocytopenic diseases (im-
Managment centre: UAM
Project Madrid mune thrombocytopenic purpura and myelodys-
Rodríguez Artalejo F. Centro de Investigación Biomédica plastic syndromes)
Sara García Barcenilla. Coordinadora de Estudios. HULP
en Red de Epidemiologíay Salud Pública (CIBEResp). ISCIII. • Haemostasis in inflammatory diseases
2006-2017. Mónica Martín Salces. Facultativo Especialista de Área en Hematología
y Hemoterapia. HULP
Managment centre: UAM
Research Activity
Isabel Rivas Pollmar. Médico Adjunto en Hematología. HULP
Rodríguez Artalejo F. El síndrome de fragilidad y los factores
psicosociales en las trayectorias de envejecimiento saluda-
ble: una cohorte comunitaria de adultos mayores en España. Strategic Objective Doctoral TheseS
proyectos de cohortes CIBER, en el marco de las estrategias
This group’s research activities address various rele-
en salud del Sistema Nacional de Salud. ISCIII. 2016-Ongoing. Rivas Pollmar MI. Estudio del efecto sobre la hemosta-
vant questions in the area of haematology and focus on
Managment centre: UAM sia de los distintos agentes terapéuticos utilizados en
the characterisation of the genetic and molecular basis
el tratamiento de la trombocitopenia inmune [disserta-
of coagulation and haemostatic function. Our group
tion]. Madrid: UAM: (20/09/2017).
INTERNATIONAL Projects investigates physiological processes such as coagula-
tion, haemostasis, innate immunity, inflammation, cell
Directors: Álvarez Román MT; Jiménez-Yuste V; Butta
Rodríguez Artalejo F. Utility of omic-based biomarkers in Col N.
adhesion and migration, and cell signalling, with special
characterizing older individuals at risk for frailty, its progres- emphasis on their relevance to pathological processes.
sion to disability and general consequences to health and well- In addition, we perform epidemiological studies to fa-
being - the frailomic initiative (FP7-HEALTH-2012-305483-2). cilitate patient data analysis and therapeutic treatment.
BOOKS AND BOOK CHAPTERS
European Union. 2013-2017. Álvarez Román MT. Recomendaciones para el diagnós-
Managment centre: UAM tico y tratamiento de la hemofilia adquirida en España.
Rodríguez Artalejo F. Ageing trajectories of health: longitu- Research Lines Barcelona: CA Ambos, 2017. p.7-59
dinal opportunities and synergies (ATHLOS). (H2020- PHC- 1- Haemophilia A and B: Jiménez-Yuste V. Enfermedades congénitas de la coa-
2014. 635316-2.). European Union. 2015-2019. • Genetic and molecular studies in patients with hae- gulación. In: Moraleda Jiménez JM. Pregrado de Hema-
Managment centre: UAM mophilia A and B tología. Madrid: Luzán5, 2017. p.615-26
129
 3
Information Groups by Area
3.2 Cardiovascular Area
Martín Salces M, Álvarez Román MT. Jiménez Yuste V. Sín-
dromes de hipocoagulabilidad. In: Cartón Sánchez AJ, Barreda
Bonis AC, Ruiz Domínguez JA, Guerrero-Fernández J. Manual
de Diagnóstico y Terapéutica en Pediatría. Madrid: Panameri-
cana, 2017. p.1193-8
Víctor Jiménez-Yuste. Nonacog gamma em hemofilia B
(Coord). Madrid: Aran, 2017. p.7-89
PUBLICATIONS
• Álvarez-Román MT, Fernández-Bello I, de la Corte-Rodríguez H,
Hernández-Moreno AL, Martín-Salces M, Butta-Coll N, Rivas-Poll-
mar MI, Rivas-Muñoz S, Jiménez-Yuste V. Experience of tailoring
prophylaxis using factor VIII pharmacokinetic parameters estimated
with my PKFiT (R) in patients with severe haemophilia A without
inhibitors. Haemophilia. 2017; 23(1): E50-4. Letter. IF: 2.768; Q2
• Bastida JM, González-Porras JR, Jiménez C, Benito R, Ordóñez GR,
Álvarez-Román MT, Fontecha ME, Janusz K, Castillo D, Fisac RM,
García-Frade LJ, Aguilar C, Martínez MP, Bermejo N, Herrero S, Ba-
lanzategui A, Martín-Antorán JM, Ramos R, Cebeiro MJ, Pardal E,
Aguilera C, Pérez-Gutiérrez B, Prieto M, Riesco S, Mendoza MC,
Benito A, Benito-Sendin AH, Jiménez-Yuste V, Hernández-Rivas JM,
García-Sanz R, González-Días M, Sarasquete ME. Application of a
molecular diagnostic algorithm for haemophilia A and B using next-
generation sequencing of entire F8, F9 and VWF genes. Thromb
Haemostasis. 2017; 117(1): 66-74. Article. IF: 4.952; D1
• Berntorp E, Dolan G, Hay C, Linari S, Santagostino E, Tosetto A,
Castaman G, Álvarez-Román M, López RP, Oldenburg J, Albert T,
Scholz U, Holmstrom M, Schved JF, Trossaert M, Hermans C, Boban
A, Ludlam C, Lethagen S. European retrospective study of real-life
haemophilia treatment. Haemophilia. 2017; 23(1): 105-14. Article. IF:
2.768; Q2
• Borrás N, Batllé J, Pérez-Rodríguez A, López-Fernández MF, Rodrí-
guez-Trillo A, Loures E, Cid AR, Bonanad S, Cabrera N, Moret A,
Parra R, Mingot-Castellano ME, Balda I, Altisent C, Pérez-Montes
R, Fisac RM, Iruin G, Herrero S, Soto I, de Rueda B, Jiménez-Yuste
V, Alonso N, Vilarino D, Arija O, Campos R, Paloma MJ, Bermejo N,
Berrueco R, Mateo J, Arribalzaga K, Marco P, Palomo A, Sarmien-
to L, Inigo B, Nieto MD, Vidal R, Martínez MP, Aguinaco R, César
JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J,
Rodríguez-González R, García-Candel F, Cornudella R, Aguilar C,
Vidal F, Corrales I. Molecular and clinical profile of von Willebrand
disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by
next-generation sequencing of 480 patients. Haematologica. 2017;
102(12): 2005-14. Article. IF: 9.09; D1
• Carrillo J, Calvete O, Pintado-Berninches L, Manguán-García C, Na-
varro JS, Arias-Salgado EG, Sastre L, Guenechea G, Granados EL, de
Villartay JP, Revy P, Benítez J, Perona R. Mutations in XLF/NHEJ1/
Cernunnos gene results in downregulation of telomerase genes ex-
pression and telomere shortening. Hum Mol Genet. 2017; 26(10):
1900-14. Article. IF: 4.902; Q1
• Fernández-Bello I, Stenmo C, Butta N, Lind V, Ezban M, Jiménez-Yus-
te V. The pharmacokinetics and pharmacodynamics of single-dose
and multiple-dose recombinant activated factor VII in patients with
haemophilia A or B. Haemophilia. 2017; 23(6): 868-76. Article. IF:
2.768; Q2
• González-López TJ, Álvarez-Román MT, Pascual C, Sánchez-Gonzá-
lez B, Fernández-Fuentes F, Pérez-Rus G, Hernández-Rivas JA, Ber-
nat S, Bastida JM, Martínez-Badas MP, Martínez-Robles V, Soto I, Oli-
vera P, Bolaños E, Alonso R, Entrena L, Gómez-Núñez M, Alonso A,
Cobo MY, Caparrós I,Tenorio M, Arrieta-Cerdán E, López-Ansoar E,
García-Frade J, González-Porras JR. Use of eltrombopag for secon-
dary immune thrombocytopenia in clinical practice. Brit J Haematol.
2017; 178(6): 959-70. Article. IF: 5.128; Q1
• González-López TJ, Fernández-Fuertes F, Hernández-Rivas J, Sán-
130
chez-González B, Martínez-Robles V, Álvarez-Román M, Pérez-Rus
G, Pascual C, Bernat S, Arrieta-Cerdán E, Aguilar C, Barez A, Pe-
narrubia MJ, Olivera P, Fernández-Rodríguez A, de Cabo E, García-
Frade L, González-Porras J. Efficacy and safety of eltrombopag in
persistent and newly diagnosed ITP in clinical practice. Int J Hema-
tol. 2017; 106(4): 508-16. Article. IF: 1.942; Q3
• Hermans C, Auerswald G, Benson G, Dolan G, Duffy A, Jiménez-
Yuste V, Ljung R, Morfini M, Lambert T, Osooli M, Salek SZ. Outcome
measures for adult and pediatric hemophilia patients with inhibitors.
Eur J Haematol. 2017; 99(2): 103-11. Review. IF: 2.595; Q3
• Mullins ES, Stasyshyn O, Álvarez-Román MT, Osman D, Liesner R, Engl
W, Sharkhawy M, Abbuehl BE. Extended half-life pegylated, full-length
recombinant factor VIII for prophylaxis in children with severe hae-
mophilia A. Haemophilia. 2017; 23(2): 238-46. Article. IF: 2.768; Q2
• Orsini S, Noris P, Bury L, Heller PG, Santoro C, Kadir RA, Butta NC,
Falcinelli E, Cid AR, Fabris F, Fouassier M, Miyazaki K, Lozano ML,
Zúñiga P, Flaujac C, Podda GM, Bermejo N, Favier R, Henskens Y, de
Maistre E, de Candia E, Mumford AD, Ozdemir GN, Eker I, Nurden P,
Bayart S, Lambert MP, Bussel J, Zieger B, Tosetto A, Melazzini F, Glem-
botsky AC, Pecci A, Cattaneo M, Schlegel N, Gresele P. Bleeding risk
of surgery and its prevention in patients with inherited platelet disor-
ders. Haematologica. 2017; 102(7): 1192-203. Article. IF: 9.09; D1
• Peyvandi F, Ettingshausen CE, Goudemand J, Jiménez-Yuste V, Santa-
gostino E, Makris M. New findings on inhibitor development: from
registries to clinical studies. Haemophilia. 2017; 23: 4-13. Review. IF:
2.768; Q2
• Salek SZ, Auerswald G, Benson G, Dolan G, Duffy A, Hermans C,
Jiménez-Yuste V, Ljung R, Morfini M, Santagostino E, Lambert T.
Beyond stopping the bleed: short-term episodic prophylaxis with
recombinant activated factor FVII in haemophilia patients with inhi-
bitors. Blood Transfus-Italy. 2017; 15(1): 77-84. Article. IF: 2.138; Q3
Public Projects
Butta Coll NV. Estudio prospectivo de pacientes con trom-
bocitopenia inmune: identificación de mecanismos fisiopato-
logicos que condicionan el fenotipo clínico y la respuesta a la
terapia (PI15/01457). ISCIII. 2016-2018.
Managment centre: FIBHULP
Butta Coll NV. Contrato de estabilización Miguel Servet Y II
(MSII11/000024). ISCIII. 2015-2017.
Managment centre: FIBHULP
Private Projects
Álvarez Román MT. Manejo de la patología urgente en pa-
cientes con hemofilia en el ambito extrahospitalario. Desa-
rrollo de un protocolo de actuación extrahospitalario. De-
sarrollo de un protocolo de actuación coordinado entre el
SUMMA 112 y el Servicio de Trombosis y Hemosta. Antares
Consulting S.A. 2014-Ongoing.
Managment centre: FIBHULP
Butta Coll NV. Estudio de la hemostasia en la enfermedad de
Behçet. Antares Consulting S.A. 2011-Ongoing.
Managment centre: FIBHULP
Jiménez Yuste VM. Field study to evaluate the assay varia-
bility of BAY 81-8973 measurements with methodologies,
reference standards and reagents routinely used in clinical
laboratories. Bayer Hispania S.L. 2015-Ongoing.
Managment centre: FIBHULP
Jiménez Yuste VM. Monitorización del tratamiento con agen-
tes “bypass”, en pacientes con hemofilia e inhibidor mediante
tres métodos de evaluación global de la hemostasia. Antares
Consulting S.A. 2007-Ongoing.
Managment centre: FIBHULP
Jiménez Yuste VM. Alteraciones citogenéticas en donantes
de sangre sanos. FIBHULP. 2004-Ongoing.
Managment centre: FIBHULP
Jiménez Yuste VM. Estudio retrospectivo de utilización de
Fanhdi en enfermedad de Von Willebrand y hemofilia A. Bax-
ter S.L. 2008-Ongoing.
Managment centre: FIBHULP
Jiménez Yuste VM. Evaluación de la disfunción endotelial
e identificación de factores de riesgo asociados a la enfer-
medad cardiovascular en el paciente con hemofilia. Antares
Consulting S.A. 2013-Ongoing.
Managment centre: FIBHULP
Jiménez Yuste VM. Desarrollo de un nuevo método de labo-
ratorio de alta sensibilidad para la detección cuantitativa de
anticuerpos contra el factor VIII. Pfizer S.L.U. 2012-Ongoing.
Managment centre: FIBHULP
Jiménez Yuste VM. Post-hemarthrosis sinovitis markers on
patients with haemophilia on prophilaxis. clinical, biological
and ultrasonographic stuyd. CAM. 2012-Ongoing.
Managment centre: FIBHULP
Jiménez Yuste VM. Field study to evaluate the activity a site
specific of b-domain deleted (BDD) pegylated recombinant
FVIII protein (BAY 94-9024) in plasma samples measured
with both chromogenic and one stage assays used in clinical
laboratories. Bayer Hispania S.L. 2015-Ongoing.
Managment centre: FIBHULP
Jiménez Yuste VM. Estudio del papel de los biomarcadores
de daño endotelial, hepatocelular y fibrosis hepática y la elas-
tografía de transición en el diagnóstico del síndrome de obs-
truccion sinusoidal. Eusa Pharma Iberia S.L.U. 2015-Ongoing.
Managment centre: FIBHULP
Jiménez Yuste VM. One-year training and research scholars-
hip programme in haemophilia and other haemostatic disor-
ders. Novo Nordisk Health Care AG. 2015-Ongoing.
Managment centre: FIBHULP
Jiménez Yuste VM. Curso de hematología: investigación y clí-
nica. Glaxosmithkline S.A. 2014-Ongoing.
Managment centre: FIBHULP
Jiménez Yuste VM. Individualización del régimen profiláctico
con agentes baipás en pacientes con hemofilia e inhibidor de
alta respuesta mediante tromboelastometría y trominografía.
Antares Consulting S.A. 2014-Ongoing.
Managment centre: FIBHULP
Jiménez Yuste VM. Tailoring prophylaxis in children with se-
vere haemophilia: impact of the trough procoagulant state
on the incidence of breakthrough bleeding. Novo Nordisk
Health Care AG. 2015-Ongoing.
Managment centre: FIBHULP
Jiménez Yuste VM. Curso en investigación y tratamiento de
la hemofilia. Laboratorios Pfizer Ltda. 2015-Ongoing.
Managment centre: FIBHULP
Jiménez Yuste VM. Estudio in vitro del efecto procoagu-
lante de factor VII recombinante activado y Vatreptacog
Alfa en sangre de pacientes con hemofilia grave mediante
tromboelastografía y test de generación de tromina. PI-1306.
Novo Nordisk AS. 2012-Ongoing.
Managment centre: FIBHULP
Jiménez Yuste VM. Case-control pilot study of the immune
modulating effect of feiba on patients with haemophilia a and
inhibitors. Baxter Healthcare Corporation. 2013-Ongoing.
Managment centre: FIBHULP
Jiménez Yuste VM. Individualización de la profilaxis: estudio
de los niveles valles mediante técnicas globales e impacto de
la actividad fisica. Baxalta GMBH. 2015-Ongoing.
Managment centre: FIBHULP
Jiménez Yuste VM. Formación orientada a la investigación
en el área de hematología. Profármaco-2 S.L. 2015-Ongoing.
Managment centre: FIBHULP
Jiménez Yuste VM. Head-us mobile app: desingn and imple-
mentation. Pfizer Inc. 2017-Ongoing.
Managment centre: FIBHULP
Jiménez Yuste VM. Iniciativas Confihe: profilaxis personaliza-
da: estudios prospectivos de la influencia de los parámetros
farmacocinéticos individuales, test globales de la coagulación
y actividad deportiva en la eficacia de la profilaxis. MK Media
S.L. 2017-Ongoing.
Managment centre: FIBHULP
CLINICAL TRIALS
Álvarez Román MT. Caracterización farmacocinética de la
población con hemofilia A en España, utilizando una aplica-
ción médica online basada en un modelo poblacional publica-
do y un algoritmo bayesiano. Type: EPA-SP.
HULP code: PI-2627. Sponsored´s protocol code: STH-OCT-2016-01.
Sponsored by: Fundación Seth.
Signed date: 20/11/2017
Álvarez Román MT. Estudio clínico de fase III, prospectivo,
aleatorizado y multicéntrico para comparar la seguridad y la
eficacia de BAX 855 tras la profilaxis guiada por FC dirigida
a dos concentraciones mínimas de FVIII distintas en sujetos
con hemofilia A grave. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4547. Sponsored´s protocol code: 261303.
Sponsored by: Baxter Innovations GMBH.
Signed date: 18/07/2017
Álvarez Román MT. Estudio de extensión de fase III, abierto,
multicéntrico para evaluar la seguridad y eficacia del factor
de la coagulación VIII recombinante (RVIII-cadena sencilla,
CSL627) en pacientes con hemofilia A severa. Type: Clinical
Trial, phase III.
HULP code: ANEXO-II 4179. Sponsored´s protocol code: CSL-3001.
Sponsored by: CSL Behring GMBH Clinical.
Signed date: 22/09/2017
Álvarez Román MT. Estudio de extension de fase IIIB, abier-
to, multicéntrico, sobre la seguridad y eficacia de una proteína
de fusión del factor IX recombinante de la coagulación con la
albumina (RIXFB) en pacientes con hemofilia B. Type: Clinical
Trial, phase IIIb.
HULP code: ANEXO-III 4011.
Sponsored´s protocol code: CSL654_3003.
Sponsored by: CSL Behring GMBH Clinical.
131
 3
Information Groups by Area
3.2 Cardiovascular Area
Signed date: 09/11/2017
Álvarez Román MT. Estudio de mercado sobre los diferentes
tratamientos para la hemofília A en la práctica clínica habitual.
Type: EPA-OD.
HULP code: PI-2766. Sponsored´s protocol code: PHA-HEM-2017-01.
Sponsored by: Phamax AG.
Signed date: 01/06/2017
Álvarez Román MT. Estudio epidemiológico internacional
para determinar la prevalencia de los anticuerpos neutralizan-
tes y las respuestas inmunitarias adaptativas a los virus ade-
noasociados (VAA) en adultos con hemofilia. Type: NO-EPA.
HULP code: PI-2904. Sponsored´s protocol code: 201601.
Sponsored by: Baxalta Innovations GMHB.
Signed date: 13/09/2017
Álvarez Román MT. Estudio multicéntrico de fase II, abier-
to, de un solo brazo, prospectivo, intervencional, del factor
derivado del plasma VIII/VWF (Alphanate®) en la terapia de
inducción de tolerancia inmune en sujetos con hemofilia con-
génita A. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4655. Sponsored´s protocol code: GBI1406.
Sponsored by: Grifols S.A.
Signed date: 06/04/2017
Álvarez Román MT. Estudio multicéntrico, abierto y de ad-
ministración repetida, para evaluar la seguridad y la eficacia
de UCB7665 en sujetos con trombocitopenia inmune prima-
ria. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4562. Sponsored´s protocol code: TP0001.
Sponsored by: UCB Biosciencies GMBH.
Signed date: 18/09/2017
Álvarez Román MT. Estudio prospectivo, multicéntrico, no
intervencional de 24 meses para evaluar la efectividad de
elocta en comparación con productos del factor convencio-
nal en el tratamiento profiláctico de pacientes con hemofilia
a (A-Sure). Type: EPA-SP.
HULP code: PI-2868. Sponsored´s protocol code: SOB-EFM-2016-01.
Sponsored by: Swedish Orphan Biovitrum AB.
Signed date: 20/10/2017
Álvarez Román MT. Evaluación en abierto y multicéntrico
de la seguridad y la eficacia a largo plazo de la proteína re-
combinante de fusión del factor VIII de coagulación humano
en la prevención y el tratamiento de episodios de sangrado
en sujetos con hemofilia tratados previamente. Type: Clinical
Trial, phase III.
HULP code: ANEXO-I 3543. Sponsored´s protocol code: 8HA01EXT.
Sponsored by: Bioverativ Therapeutics Inc.
Signed date: 24/08/2017
Jiménez Yuste VM. ECHO: expanding communications on
hemophilia A outcomes - estudio observacional, internacio-
nal, longitudinal, prospectivo en pacientes en tratamiento de
hemofilia A de moderada a grave para la evaluación de los
resultados comunicados por los pacientes y la asociación con
su enfermedad. Type: EPA-SP.
HULP code: 4727. Sponsored´s protocol code: BAY-FAC-2016-01.
132
Sponsored by: Bayer Hispania S.L.
Signed date: 08/02/2017
Jiménez Yuste VM. Ensayo clínico en fase IIIB multicéntrico,
con un solo grupo de tratamiento, para evaluar la seguridad
y tolerancia del tratamiento profiláctico con emicizumab en
pacientes con hemofilia A que presentan inhibidores. Type:
Clinical Trial, phase IIIb.
HULP code: 4811. Sponsored´s protocol code: MO39129.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 10/05/2017
Jiménez Yuste VM. Estudio abierto, multicéntrico y no con-
trolado de la eficacia de RFVIIIFC para la inducción de tole-
rancia inmune (ITI) en sujetos con hemofilia A grave con in-
hibidores que se someten al primer tratamiento de ITI. Type:
Clinical Trial, phase IV.
HULP code: 4899. Sponsored´s protocol code: 997HA402.
Sponsored by: Bioverativ Therapeutics Inc.
Signed date: 25/09/2017
Jiménez Yuste VM. Estudio post-autorizacion de tipo obser-
vacional de factor IX Grifols (concentrado de factor IX hu-
mano de alta pureza doblemente inactivado) en profilaxis o
tratamiento de pacientes con hemofilia B. Type: EPA-LA.
HULP code: 2007. Sponsored´s protocol code: INS-FAC-2004-01.
Sponsored by: Instituto Grifols S.A.
Signed date: 01/11/2017
Jiménez Yuste VM. Explorer ™4- ensayo multicéntrico, alea-
torizado, abierto y controlado para evaluar la eficacia y se-
guridad de la administración de concizumab en profilaxis en
pacientes con hemofilia A y B e inhibidores.Type: Clinical Trial,
phase II.
HULP code: 4822. Sponsored´s protocol code: NN7415-4310.
Sponsored by: Novo Nordisk A/S.
Signed date: 25/07/2017
Jiménez Yuste VM. Explorer ™5- ensayo multicéntrico para
evaluar la eficacia y seguridad de la administración de conci-
zumab en profilaxis en pacientes con hemofilia A grave sin
inhibidores. Type: Clinical Trial, phase II.
HULP code: 4821. Sponsored´s protocol code: NN7415-4255.
Sponsored by: Novo Nordisk A/S.
Signed date: 25/07/2017
Jiménez Yuste VM. Valoración del estatus articular de los pa-
cientes con hemofilia A en España mediante técnica ecográfi-
ca. Estudio Artiha. Type: EPA-OD.
HULP code: PI-2723. Sponsored´s protocol code: PFI-MOR-2017-01.
Sponsored by: Pfizer Inc.
Signed date: 18/10/2017
Martín Salces M. Estudio en fase III prospectivo, abierto, in-
ternacional y multicéntrico sobre la eficacia y la seguridad
de la profilaxis con RVWF en la enfermedad grave de Von
Willebrand. Type: Clinical Trial, phase III.
HULP code: 4884. Sponsored´s protocol code: 071102.
Sponsored by: Baxalta Innovations GMHB.
Signed date: 20/10/2017
Vascular Physiology and
Pharmacology Group
17 80.763 17
Mercedes Salaices Sánchez. Catedrática. Departamento
de Farmacología. UAM
Strategic Objective
Andrea Aguado Martínez. Investigadora Postdoctoral. UAM
María Jesús Alonso Gordo. Catedrática. Departamento de
Ciencias Básicas de la Salud. Facultad de Ciencias de la Salud.
Universidad Rey Juan Carlos
María Soledad Avendaño Herrador. Investigadora
Postdoctoral. UAM
Gloria Balfagón Calvo. Catedrática. Departamento de Fisiología.
Facultad de Medicina. UAM
Javier Blanco Rivero. Profesor Contratado Doctor. Departamento
de Fisiología. Facultad de Medicina. UAM
Ana María Briones Alonso. Investigadora Senior (Contrato
Ramón y Cajal). UAM
Laura Caracuel Cano. Investigadora Postdoctoral. UAM
Ana Belén García Redondo. Investigadora Postdoctoral. UAM
María González Amor. Investigadora Predoctoral. UAM
Raquel Hernanz Martín. Profesora Contratada Doctor.
Departamento de Ciencias Básicas de la Salud. Facultad de Ciencias
de la Salud. Universidad Rey Juan Carlos
Ángela Martín Cortés. Profesora Contratada Doctor.
Departamento de Ciencias Básicas de la Salud. Facultad de Ciencias
de la Salud. Universidad Rey Juan Carlos
Marta Miguel Castro. Científico Titular. Instituto de Investigación
en Ciencias de la Alimentación. CSIC - Instituto de Investigación en
Ciencias de la Alimentación
Research Lines
Roberto Palacios Ramírez. Investigador Predoctoral.
Universidad Rey Juan Carlos
Raquel Rodrigues Díez. Investigadora Postdoctoral. UAM
Our group is a well-established research group with
more than 30 years of experience in the study of the
mechanisms involved in the functional, structural and
mechanical alterations of the vasculature in various
cardiovascular pathologies such as ageing, diabetes and,
in particular, hypertension.
The group is located at the Faculty of Medicine (UAM)
and maintains research collaborations with investiga-
tors at various universities in Spain and in other coun-
tries. Our main objective is to gain further insight into
the physiological and molecular mechanisms involved
in alterations of resistance and conductance arteries
in cardiovascular pathologies.To conduct our research,
we generally use various experimental approaches in-
cluding in vivo animal models, ex vivo experiments and
in vitro cellbased studies combined with physiological,
pharmacological and molecular biology techniques. In
addition, we have begun to translate this knowledge
into human studies. In terms of the mediators involved,
we have a particular interest in the role of prostanoids
derived from the inducible isoform of cyclooxygenase
(COX-2) and reactive oxygen species (and their inte-
raction among each other or with other mediators
such as nitric oxide) in inflammatory conditions that
resemble those found in cardiovascular pathologies.
This research is important given the essential role the-
se mediators play in the control of vascular smooth
muscle tone and vascular structure.
• Inflammation and vascular function and remodelling.
Changes with hypertension and other cardiovascu-
lar pathologies.
133
 3
Information Groups by Area
3.2 Cardiovascular Area
• Adipose tissue and vascular alterations in cardiovascu-
lar pathologies.
• Neural control of vascular tone.
• Cardiovascular effects of heavy metals.
• Antioxidant and antihypertensive properties of food
bioactive compounds.
Research Activity
Doctoral TheseS
Martínez Silveira C. Feito do consumo de hidrolisado de clara
de ovo sobre as alterações neurológicas, reprodutivas e car-
diovasculares promovidas pela exposição ao clorato de alu-
minio em ratos[dissertation]. Uruguaiana, Brasi: Universidade
Federal do Pampa (l): 2017(13/12/2017).
Directors: Wiggers G; Miguel M.
Nieto Moral C. Encefalía hepática aguda sobre crónica en
la colestasis experimental microquirúrgica experimental:
Alteraciones metabólicas y vasculares[dissertation]. Madrid:
UCM: 2017(26/06/2017).
Directors: Blanco Rivero J; Aller MA; Higuera Matas A.
BOOKS AND BOOK CHAPTERS
Cat AN, Briones AM. Isolation of mature adipocytes from
white adipose tissue and gene expression studies by real-
time quantitative RT-PCR. In: Touyz R., Schiffrin E. (eds) . Hy-
pertension: Method in mlolecular biology. Nueva York, US:
Humana Press, 2017. p.283-95
PUBLICATIONS
• Gutiérrez-Tenorio J, Marín-Royo G, Martínez-Martínez E, Martín R,
Miana M, López-Andrés N, Jurado-López R, Gallardo I, Luaces M,
Román JAS, González-Amor M, Salaices M, Nieto ML, Cachofeiro
V. The role of oxidative stress in the crosstalk between leptin and
mineralocorticoid receptor in the cardiac fibrosis associated with
obesity. Sci Rep-Uk. 2017; 7: 16802. Article. IF: 4.122; Q1
• Martínez CS,Alterman CDC, Pecanha FM,Vassallo DV, Mello-Carpes
PB, Miguel M,Wiggers GA. Aluminum exposure at human dietary le-
vels for 60 days reaches a threshold sufficient to promote memory
impairment in rats. Neurotox Res. 2017; 31(1): 20-30. Article. IF:
3.186; Q2
• Martínez CS, Escobar AG, Uranga-Ocio JA, Pecanha FM,Vassallo DV,
Exley C, Miguel M, Wiggers GA. Aluminum exposure for 60 days at
human dietary levels impairs spermatogenesis and sperm quality in
rats. Reprod Toxicol. 2017; 73: 128-41. Article. IF: 2.58; Q2
• Martínez CS, Pecanha FM, Brum DS, Santos FW, Franco JL, Zemolin
APP, Anselmo-Franci JA, Junior FB, Alonso MJ, Salaices M, Vassallo
DV, Leivas FG,Wiggers GA. Reproductive dysfunction after mercury
exposure at low levels: evidence for a role of glutathione peroxidase
(GPx) 1 and GPx4 in male rats. Reprod Fert Develop. 2017; 29(9):
1803-12. Article. IF: 2.105; Q1
• Martínez CS, Piagette JT, Escobar AG, Martín A, Palacios R, Pecanha
FM, Vassallo DV, Exley C, Alonso MJ, Miguel M, Salaices M, Wiggers
GA. Aluminum exposure at human dietary levels promotes vascular
dysfunction and increases blood pressure in rats: A concerted ac-
tion of NAD(P)H oxidase and COX-2. Toxicology. 2017; 390: 10-21.
Article. IF: 3.265; Q2
• Martínez-Revelles S, García-Redondo AB, Avendaño MS, Varona S,
Palao T, Orriols M, Roque FR, Fortuno A, Touyz RM, Martínez-Gon-
134
zález J, Salaices M, Rodríguez C, Briones AM. Lysyl oxidase induces
vascular oxidative stress and contributes to arterial stiffness and
Salaices Sánchez M. Red de Investigación Cardiovascular INTERNATIONAL Projects
(RIC) (RD12/0042/0024). ISCIII. 2013-2017.
abnormal elastin structure in hypertension: Role of P38MAPK. Anti- Managment centre: UAM Briones Alonso AM. ADMIRE - aldosterone and mineralo-
oxid Redox Sign. 2017; 27(7): 379-97. Article. IF: 6.53; D1 corticoid receptor: pathophysiology, clinical implication and
• Martín-Ventura JL, Rodrigues-Díez R, Martínez-López D, Salaices
Salaices Sánchez M. Ciber Enfermedades Cardiovasculares therapeutic innovations (COST BM1301). European Union.
(CB16/11/00286). ISCIII. 2017-2022.
M, Blanco-Colio LM, Briones AM. Oxidative stress in human athe- 2014-2017.
rothrombosis: Sources, markers and therapeutic targets. Int J Mol Managment centre: UAM Managment centre: UAM
Sci. 2017; 18(11): 2315. Review. IF: 3.687; Q2 Salaices Sánchez M. Briones Alonso AM. Novel inflam- Miguel Castro M. Egg white hydrolysates as functional food
• Millán Longo A, Montero Saiz O, Sarro Fuente C, Aguado Martínez
A, Salaices Sánchez M. Mercury exposure induces proinflammatory
matory mechanisms of vascular damage in hypertension and
obesity. Role of pro-resolving lipid mediators as possible the-
ingredients to control the cardiometabolic complications
associated to oxidative stress induced by heavy metals ex-
enzymes in vascular fibroblasts. Clin Investig Arterioscler. 2017; rapeutic strategy. (SAF2016-80305-P). MINECO. 2017-2020. posure. (406715/2013-0). Conselho Nacional de Desemvol-
29(6): 231-8. Article. Not Indexed Managment centre: UAM vimiento Cientifico e Tecnologico del Gobierno de Brasil.
• Oller J, Méndez-Barbero N, Ruiz EJ, Villahoz S, Renard M, Canelas 2014-2017.
Alonos Gordo MJ. Modulación por NFR2 del daño vascu-
LI, Briones AM, Alberca R, Lozano-Vidal N, Hurle MA, Milewicz D, Managment centre: Universidad Federal do Espiritu Santo
Evangelista A, Salaices M, Nistal JF, Jiménez-Borreguero LJ, de Backer lar asociado a la patología hipertensiva. Relación con TLR4
J, Campanero MR, Redondo JM. Nitric oxide mediates aortic disease (SAF2015-69294-R). MINECO. 2016-2019.
in mice deficient in the metalloprotease Adamts1 and in a mouse Managment centre: URJC Patents and Trademarks
model of Marfan syndrome. Nat Med. 2017; 23(2): 200-12. Article. IF:
32.621; D1 González-Muñiz R, Pérez de Vega MJ, Miguel M, Balse-
• Requena T, Miguel M, Garcés-Rimón M, Martínez-Cuesta MC, Ló-
Private Projects ra-Paredes B, Moreno S, inventors; CSIC, assignee. Triazo-
lyl polyphenols with antioxidant activity and uses thereof;
pez-Fandino R, Peláez C. Pepsin egg white hydrolysate modulates Briones Alonso AM. Relación entre postranoides, especies
P201531450; 2015 November 08 .
gut microbiota in Zucker obese rats. Food Funct. 2017; 8(1): 437-43. reactivas de oxígeno y aldosterona del tejido adiposos y su
Article. IF: 3.289; Q1 papel en las alteraciones cardiovasculares asociadas a hiper- González-Muñiz R, Miguel Castro M, Pérez de Vega MJ,
• Rizzetti DA, Martín A, Corrales P, Fernández F, Simoes MR, Pecanha tension y obesidad. Roche Farma S.A. 2014-Ongoing. Balsera-Paredes B, Moreno S, inventors; CSIC, assignee.
FM, Vassallo DV, Miguel M, Wiggers GA. Egg white-derived pepti- Managment centre: FIBHULP Compounds with antioxidant activity and uses thereof.
des prevent cardiovascular disorders induced by mercury in rats: P201630362; 2016 March 29.PCT/ES2017/070179, 28 de
Role of angiotensin-converting enzyme (ACE) and NADPH oxidase.
Miguel Castro M. Estudio de los procesos de proteolisis en
el desarrollo de aromas y sabores en el jamón puro ibérico
Marzo de 2017
Toxicol Lett. 2017; 281: 158-74. Article. IF: 3.166; Q2
de bellota y caracterización de péptidos bioactivos. Arturo
• Rizzetti DA, Martínez CS, Escobar AG, da Silva TM, Uranga-Ocio
Sánchez E Hijos. 2016-2017.
JA, Pecanha FM, Vassallo DV, Castro MM, Wiggers GA. Egg white-
Managment centre: CSIC
derived peptides prevent male reproductive dysfunction induced by
mercury in rats. Food Chem Toxicol. 2017; 100: 253-64. Article. IF: Miguel Castro M. Participación en comité de expertos y ase-
3.977; D1 soramiento científico en materia de alimentación y bebidas:
• Rizzetti DA, Torres JGD, Escobar AG, da Silva TM, Moraes PZ, Her- cerveza 0,0% isotónica. Farfara Lab. 2016-2017.
nanz R, Pecanha FM, Castro MM, Vassallo DV, Salaices M, Alonso MJ, Managment centre: CSIC
Wiggers GA.The cessation of the long-term exposure to low doses
of mercury ameliorates the increase in systolic blood pressure and
vascular damage in rats. Environ Res. 2017; 155: 182-92. Article. IF:
4.732; D1
• Rodrigues-Díez R, Salaices M. Cardiovascular risk factors and oxi-
dative stress in young people. Clin Investig Arterioscler. 2017; 29(5):
216-7. Article. Not Indexed
• Toral M, Jiménez R, Romero M, Robles-Vera I, Sánchez M, Salaices
M, Sabio JM, Duarte J. Role of endoplasmic reticulum stress in the
protective effects of PPAR beta/delta activation on endothelial dys-
function induced by plasma from patients with lupus. Arthritis Res
Ther. 2017; 19: 268. Article. IF: 4.269; Q2
• Toscano CM, Simoes MR, Alonso MJ, Salaices M, Vassallo DV, Fio-
resi M. Sub-chronic lead exposure produces beta(1)-adrenoceptor
downregulation decreasing arterial pressure reactivity in rats. Life
Sci. 2017; 180: 93-101. Article. IF: 3.234; Q2
• Varona S, García-Redondo AB, Martínez-González J, Salaices M,
Briones AM, Rodríguez C. Vascular lysyl oxidase over-expression
alters extracellular matrix structure and induces oxidative stress.
Clin Investig Arterioscler. 2017; 29(4): 157-65. Article. Not Indexed
Public Projects
Briones Alonso AM. Relación entre postanoides, especies
reactivas de oxígeno y aldosterona del tejido adiposo y su
papel en las alteraciones cardiovasculares asociadas a hiper-
tensión y obesidad (PI13/01488). ISCIII. 2014-2017.
Managment centre: FIBHULP
135
 3
Information Groups by Area
3.2 Cardiovascular Area
Vascular Pharmacology
and Metabolism Group
(FARMAVSM)
5 33.181 4
Carlos Félix Sánchez Ferrer. Catedrático de Farmacología.
UAM
Elena Cercas Alonso. Técnico Especialista en Análisis Clínico. UAM
Jorge Francisco Gómez Cerezo. Jefe de Servicio de Medicina
Interna. Hospital Universitario Infanta Sofía
Concepción Peiró Vallejo. Profesora Titular de Farmacología. UAM
Mariella Ramos González. Investigador Predoctoral. UAM
Susana Vallejo Fernán. Investigador Postdoctoral. UAM
Strategic Objective
Our research deals with the challenge 1 of the Spa-
nish Strategy for Science and Technology and for
Innovation: “Health, demographic change and well-
being”. The main goal is to improve our understan-
ding of vascular ageing, both in healthy and patho-
logical conditions, like obesity and type 2 diabetes
Research Lines
mellitus. Vascular ageing is associated with complex
vascular structural and functional changes. It repre-
sents a crucial process for the health status of elderly
people and the main risk factor for the development
of cardiovascular diseases. Obesity and type 2 dia-
betes mellitus are extremely prevalent and closely
related diseases, so that the term “diabesity” has
been coined. Diabesity is among the highest health
and socioeconomic challenge in Western countries,
especially due to cardiovascular complications. Epi-
demiological studies indicate that these patients
have reduced life expectancy, in close relation to the
development of diseases, such as hypertension and
136
atherosclerosis. Diabesity is also considered an age-
related disease, as well as a progeric entity, sharing
similar cellular and molecular mechanisms than the
age-induced vascular dysfunction. Understanding the
pathways involved in vascular damage and premature
ageing associated to diabesity should help to delay
vascular complications. Furthermore, preservation of
vascular function in ageing should not only reduce
deaths and disabilities secondary to cardiovascular
events but should attenuate other negative aspects
of the ageing process that lead to loss of function
and/or disability, such as motor capacity and cognitive
frailty. Indeed, it seems now quite evident that ro-
bustness in advanced age cannot be achieved without
preservation of vascular function.
The main objective of FARMAVASM for the next 5
years is to determine how those called progeric car-
diometabolic diseases, particularly obesity, diabetes
mellitus and/or metabolic syndrome, can favour the
vascular aging process. In particular, we will analyse
the role for selected adipokines over-produced and
released by the inflamed adipose tissue in the de-
velopment of premature vascular ageing. We aim to
characterize the cellular and molecular mechanisms
of action of selected adipokines that may lead to al-
terations in the vascular function and/or structure,
as well as their interaction with other key factors in-
fluencing cardiometabolic diseases such is high gluco-
se. Moreover, as pharmacologists, we aspire to characte-
rize new pharmacological targets that could be relevant
to prevent or delay accelerated vascular ageing and the
associated cardiovascular risk. To achieve this global ob-
jective, we have now an active grant by the Plan Nacional
de I+D covering 2015 to 2017, and we expect to obtain
further financial support for the period 2018 to 2020.
Furthermore, we have active projects with pharmaceu-
tical companies (Boehringer Ingelgeim). Our strategy
will also include our incorporation to national networks
(CIBER or RETICS), and international programmes (Ho-
rizon 2020). Indeed, this is in fact one of the reasons
for asking our inclusion in IdiPAZ. Additionally, we aimed
to include new researchers into FARMAVASM, both at
pre- and postdoctoral level (FPU-MEC, FPU-UAM, Marie
Sklodowska-Curie Actions, Juan de La Cierva, Ramón y
Cajal).
Research Activity
PUBLICATIONS
• Domínguez H, Sánchez-Ferrer CF. The role of glycated proteins
on cardiovascular diabetic complications new findings. J Am Coll
Cardiol. 2017; 70(16): 2020-1. Editorial Material. IF: 16.834; D1
• Peiró C, Lorenzo O, Carraro R, Sánchez-Ferrer CF. IL-1 beta Inhi-
bition in cardiovascular complications associated to diabetes melli-
tus. Front Pharmacol. 2017; 8: 363. Review. IF: 3.831; Q1
• San Hipólito Luengo A, Alcaide A, Ramos-González M, Cercas E,Va-
llejo S, Romero A, Talero E, Sánchez-Ferrer CF, Motilva V, Peiró C.
Dual effects of resveratrol on cell death and proliferation of colon
cancer cells. Nutr Cancer. 2017; 69(7): 1019-27.Article. IF: 2.261; Q3
• Sobrino A,Vallejo S, Novella S, Lázaro-Franco M, Mompeón A, Bue-
no-Beti C, Walther T, Sánchez-Ferrer C, Peiró C, Hermenegildo C.
Mas receptor is involved in the estrogen-receptor induced nitric
oxide-dependent vasorelaxation. Biochem Pharmacol. 2017; 129:
67-72. Article. IF: 4.235; Q1
• Zhenyukh O, Civantos E, Ruiz-Ortega M, Sánchez MS, Vázquez C,
Peiró C, Egido J, Mas S. High concentration of branched-chain ami-
no acids promotes oxidative stress, inflammation and migration of
human peripheral blood mononuclear cells via mTORC1 activa-
tion. Free Radical Bio Med. 2017; 104: 165-77. Article. IF: 6.02; Q1
Public Projects
Peiró Vallejo C; Sánchez Ferrer CF. Adipoquinas y enve-
jecimiento vascular: mecanismos implicados y modulación
farmacológica (SAF2014-52762-R). MINECO. 2015-2017.
Managment centre: UAM
Private Projects
Sánchez Ferrer CF; Peiró Vallejo C. Endothelial dysfunction
induced by the adipokine dipeptidyl peptidase 4 (DPP-4) in
human mesenteric microvessels and its prevention by lina-
gliptin. Boehringer Ingelheim. 2015-Ongoing.
Managment centre: UAM
Sánchez Ferrer CF. Proinflammatory cell mechanisms in car-
diovascular diseases: targets for pharmacological interferen-
ce. UAM-Santander. 2016-Ongoing.
Managment centre: UAM
137
 3
Information Groups by Area

3.2 Cardiovascular Area

Cardiology Research Group

(HUF)

Alejandro Curcio Ruigómez. Jefe de Servicio. HUF

Strategic Objective
Javier Alonso Bello. Médico Adjunto. HUF
Cármen Cristobal Varela. Médico Adjunto. HUF
Adriana de la Rosa Riestra. Médico Adjunto. HUF
Silvia del Castillo Arrojo. Médico Adjunto. HUF
Nieves Estibal Ortega. Enfermera. HUF
Research Lines
Iria Andrea González García. Médico Adjunto. HUF
Catherine Graupner Abad. Médico Adjunto. HUF
Carlos Gutiérrez Landaluce. Médico Adjunto. HUF
Rosa María Jiménez Hernández. Médico Adjunto. HUF
Elena Moreno Merino. Enfermera. HUF
José María Serrano Antolín. Médico Adjunto. HUF
Pedro Talavera Calle. Médico Adjunto. HUF
Clinical research on cardiotoxicity in oncohaemato-
logical treatments, bioethical aspects of the manage-
ment of defibrillators at the end of life.
• Cardiotoxicity by chemotherapy, prognostic value
of biomarkers and echocardiographic parameters
in cardiotoxicity by chemotherapy
• Management of implantable defibrillators in the
terminally ill and in end-of-life care
• Prognostic value of new biomarkers in acute coro-
nary syndrome
• Predictive value for the development of atrial
fibrillation of atrial arrhythmias in cryptogenic
stroke

138 139
 3
Information Groups by Area

AIDS and Infectious

Diseases Group

3.3
Infectious
Diseases
and 39 350.099 23
Immunity Area
José Ramón Arribas López. Facultativo Especialista de Mario Mayoral Muñoz. Enfermero. HULP
Área en Medicina Interna (Contrato de Intensificación). Unidad Juan José Miguel Castro. Enfermero. HULP
Eduardo López-Collazo de VIH. HULP. Profesor Asociado. UAM Rocío Montejano Sánchez. Facultativo Especialista de Área en
Marta Arsuaga Vicente. Médico Adjunto en Medicina Interna. Medicina Interna. HULP
HULP - HCIII
243 1,123.881 María Luisa Montes Ramírez. Facultativo Especialista de Área en
José Ignacio Bernardino de la Serna. Facultativo Especialista Medicina Interna. Unidad de VIH. HULP
194 988.524 de Área en Medicina Interna. Unidad de VIH. HULP
Marta Mora Rillo. Facultativo Especialista de Área en Medicina Interna.
19.75% 46.09% Clara Crespillo Andújar. Médico Adjunto en Medicina Interna. Unidad de Enfermedades Infecciosas y Microbiología Clínica. HULP
Unidad de Medicina Tropical . HULP - HCIII
Francisco Moreno Ramos. Farmacéutico. HULP
Fernando de la Calle Prieto. Médico Adjunto en Medicina
Jose Francisco Pascual Pareja. Facultativo Especialista de Área en
Interna. Unidad de Medicina Tropical. HULP - HCIII. Profesor
AIDS and Infectious Diseases Group Colaborador. UAM
Medicina Interna. HULP - Hospital de Cantoblanco
Jose María Peña Sánchez de Rivera. Jefe de Sección de Plaza
Molecular Microbiology Group Rosa de Miguel Buckley. Facultativo Especialista Adjunto
Vinculada. HULP. Catedrático. Profesor Titular. UAM
(Contrato Río Hortega). HULP
Ignacio Pérez Valero. Investigador Postdoctoral. HULP
Immuno-Rheumatology Group Alicia de Pablo Olaiz. Técnico de Laboratorio (Contrato de
Técnico de Apoyo). HULP Juan Carlos Ramos Ramos. Facultativo Especialista de Área en
Innate Immune Response Group Marta Díaz Menéndez. Médico Adjunto en Medicina Interna.
Medicina Interna. HULP
Unidad de Medicina Tropical. HULP Berta Rodés Soldevila. Investigadora Senior (Contrato Miguel Servet-
Diagnosis and Treatment of Diseases associated with Andrés Esteban Cantos. Investigador Predoctoral. HULP
II). HULP
Abnormalities of the Complement System Group Marta Gálvez Charro. Enfermera. Unidad de VIH. HULP
Javier Rodríguez Centeno. Facultativo Especialista de Área. HULP
Elena Sendagorta Cudós. Facultativo Especialista de Área en
Lymphocyte Pathophysiology in Immunodeficiencies Group Francisco Gayá Moreno. Investigador Predoctoral (Contrato de
Dermatología. HULP
Estabilización de Técnicos de Apoyo). HULP
Lucía Serrano Morago. Investigadora Predoctoral. HULP
Drug Hypersensibility and Innate Immune Response Group Alicia González Baeza. Investigadora Predoctoral. HULP
Elena Trigo Esteban. Médico Ajunto en Medicina Interna. Unidad de
Juan Julián González García. Facultativo Especialista de Área
Pediatric Respiratory, Systemic and Neurological en Medicina Interna. Unidad de VIH. HULP
Medicina Tropical. HULP - HCIII
Infections & Host Immune Response Group Pedro Herranz Pinto. Facultativo Especialista de Área en

Pediatric Systemic Infections; HIV, Tuberculosis,

Imported and Emergent Diseases Group
Translational Research in Pediatric Oncology,
Hematopoietic Transplantation and Cell Therapy Group
Digestive Intestinal Diseases Research Group (HUF)
140
Dermatología. Jefe de Sección. HULP
Víctor Hontañón Antoñana. Investigador Predoctoral . HULP
María Concepción Ladrón de Guevara García.
Facultativo Especialista de Área en Microbiología y Parasitología.
HULP - HCIII
María del Mar Lago Núñez. Facultativo Especialista de Área en
Medicina Interna. Unidad de Medicina Tropical. HULP - HCIII
Raquel Martín Jara. Enfermera. Unidad de VIH. HULP
Strategic Objective
Worldwide projections of global mortality and the
burden of disease from 2002 to 2030 estimate that
by 2030 HIV infection will be the number one disease
in terms of overall burden and third in terms of ove-
rall mortality (Mathers, C. D.; Loncar, D. Projections of
global mortality and burden of disease from 2002 to
2030. PLOS MEDICINE. 2006; 3(11): e442.).
141
 3
Information Groups by Area
3.3 Infectious Diseases and Immunity Area
Although great progress has been made, HIV infection
remains an incurable disease. Even under the best cir-
cumstances, HIV-infected patients who receive current
antiretroviral therapy have a survival disadvantage com-
pared with the general non-infected population, which is
estimated to be a life expectancy of 15 years less than the
general population.
HIV infection is highly prevalent in Spain. Among wes-
tern European countries, Spain has the second highest
prevalence.
An important local characteristic of the HIV-infected po-
pulation in Spain is the high prevalence of hepatitis C
coinfection.
This research line covers four main topics of research
in HIV infection: antiretroviral treatment, HIV-HCV coin-
fection, metabolic complications and HIV-resistance to
antiretroviral drugs. In addition, we are planning to start
another research project on infections other than HIV.
The group has started a new research line regarding the
aging and HIV Infection.
Tropical diseases are increasing as a consequence og
global travel. These diseases continue to be relatively
rare however, and therefore, often sub-optimal treated
if managed by non-speciaslists. Furthermore, every year
an increasing amount of special travelers (pregnants, co-
morbidities, immunossupressed) travel abroad, adding
complexity in terms of a timely and effective diagnosis
and management. The Tropical and Travel Medicine Unit
provide both pre and postravel assistance in imported
infectious diseases. The aim of this Unit is to provide
efficient and effecrive specialist care with proven or sus-
pected tropical disease and a specific preventative travel
advice, togheter with international vaccines recommen-
ded for the trip.
Research Lines
• Antiretroviral therapy & resistance
• Metabolic complications of antiretroviral therapy
• Liver disease
• Neurocognitive impairment
• Paediatric HIV infection and MTCT
• Epigenetic and cellular factors related to HIV progres-
sion
• Optimisation of antibiotic therapy (ID no HIV)
• Tropical diseases
• Emerging and re-emerging virus
Research Activity
PUBLICATIONS
• Alsina M, Martín-Ancel A, Alarcón-Allen A, Arca G, Gaya F, García-
Alix A. The severity of hypoxic-ischemic encephalopathy correlates
with multiple organ dysfunction in the hypothermia era. Pediatr Crit
Care Me. 2017; 18(3): 234-40. Article. IF: 3.092; Q1
• Ara-Martín M, Pinto PH, Pascual-Salcedo D. Impact of immunogeni-
city on response to anti-TNF therapy in moderate-to-severe plaque
psoriasis: results of the PREDIR study. J Dermatol Treat. 2017; 28(7):
606-12. Article. IF: 2.144; Q2
• Arribas JR, de Jesús E, van Lunzen J, Zurawski C, Doroana M, Tow-
142
ner W, Lazzarin A, Nelson M, McColl D, Andreatta K, Swamy R,
Szwarcberg J, Nguyen T. Simplification to single-tablet regimen of
elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet
ritonavir-boosted protease inhibitor plus coformulated emtricita-
bine and tenofovir DF regimens: week 96 results of STRATEGY-PI.
HIV Clin Trials. 2017; 18(3): 118-25. Article. IF: 1.379; Q4
• Arribas JR, Thompson M, Sax PE, Haas B, McDonald C, Wohl DA, de
Jesús E, Clarke AE, Guo S, Wang H, Callebaut C, Plummer A, Cheng
A, Das M, McCallister S. Randomized, double-blind comparison of
tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF),
each coformulated with elvitegravir, cobicistat, and emtricitabine
(E/C/F) for Initial HIV-1 treatment: Week 144 Results. JAIDS-J Acq
Imm Def. 2017; 75(2): 211-8. Article. IF: 4.116; Q1
• Baker JV, Sharma S, Achhra AC, Bernardino JI, Bogner JR, Duprez
D, Emery S, Gazzard B, Gordin J, Grandits G, Phillips AN, Schwar-
ze S, Soliman EZ, Spector SA, Tambussi G, Lundgren J. Changes in
cardiovascular disease risk factors with immediate versus deferred
antiretroviral therapy initiation among HIV-positive participants in
the START (Strategic Timing of Antiretroviral Treatment) Trial. J Am
Heart Assoc. 2017; 6(5): e004987. Article. IF: 4.45; Q2
• Berenguer J, Rodríguez-Castellano E, Carrero A,Von Wichmann MA,
Montero M, Galindo MJ, Mallolas J, Crespo M, Ellez MJT, Quereda C,
Sanz J, Barros C, Tural C, Santos I, Pulido F, Guardiola JM, Rubio R,
Ortega E, Montes ML, Jusdado JJ, Gaspar G, Esteban H, Bellón JEM,
González-García J. Eradication of hepatitis C virus and non-liver-
related non-acquired immune deficiency syndrome-related events
in human immunodeficiency virus/hepatitis C virus coinfection. He-
patology. 2017; 66(2): 344-56. Article. IF: 14.079; D1
• Cahn P, Kaplan R, Sax PE, Squires K, Molina JM, Avihingsanon A, Rata-
nasuwan W, Rojas E, Rassool M, Bloch M, Vandekerckhove L, Ruane
P, Yazdanpanah Y, Katlama C, Xu X, Rodgers A, East L, Wenning L,
Rawlins S, Homony B, Sklar P, Nguyen BY, Leavitt R,Teppler H, (Arri-
bas JR). Raltegravir 1200 mg once daily versus raltegravir 400 mg
twice daily, with tenofovir disoproxil fumarate and emtricitabine, for
previously untreated HIV-1 infection: a randomised, double-blind,
parallel-group, phase 3, non-inferiority trial. Lancet HIV. 2017; 4(11):
E486-94. Article. IF: 11.355; D1
• de Arellano ER, Hernández L, Goyanes MJ, Arsuaga M, Cruz AF,
Negredo A, Sánchez-Seco MP. Phylogenetic characterization of Cri-
mean-Congo Hemorrhagic fever virus, Spain. Emerg Infect Dis. 2017;
23(12): 2078-80. Article. IF: 7.422; D1
• Díaz-Menéndez M, de la Calle-Prieto F, Arsuaga M, Trigo E, de Gue-
vara CL, Barreiro P, Lago CYM. Hotline for Zika virus: experience
of a tropical and travel medicine unit. Gac Sanit. 2017; 31(6): 531-34.
Article. IF: 1.581; Q3
• Díaz-Menéndez M,Trigo E, de la Calle-Prieto F, Arsuaga M. Zika virus
infection during the Olympic Games in Rio: A fear or an actual risk?
Rev Clin Esp. 2017; 217(3): 155-60. Review. IF: 1.184; Q3
• García-Bujalance S, Gutiérrez-Arroyo A, de la Calle F, Díaz-Menén-
dez M, Arribas JR, García-Rodríguez J, Arsuaga M. Persistence and in-
fectivity of Zika virus in semen after returning from endemic areas:
Report of 5 cases. J Clin Virol. 2017; 96: 110-5. Article. IF: 3.101; Q2
• Girard PM, Antinori A, Arribas JR, Ripamonti D, Bicer C, Netzle-
Sveine B, Hadacek B, Moecklinghoff C. Week 96 efficacy and safety
of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two
nucleoside reverse transcriptase inhibitors in the PROTEA trial. HIV
Med. 2017; 18(1): 5-12. Article. IF: 2.932; Q2
• González-Baeza A, Arribas JR, Pérez-Valero I, Monge S, Bayón C,
Martín P, Rubio S, Carvajal F. Vocal emotion processing deficits in
HIV-infected individuals. J Neurovirol. 2017; 23(2): 304-12. Article. IF:
3.228; Q2
• Goycochea-Valdivia WA, Moreno-Ramos F, Paño-Pardo JR, Aracil-
Santos FJ, Baquero-Artigao F, del Rosal-Rabes T, Mellado-Peña MJ,
Escosa-García L. Identifying priorities to improve. Paediatric in-hos-
pital antimicrobial use by cross-sectional evaluation of prevalence
and appropriateness of prescription. Enferm Infec Micr Cl. 2017;
35(9): 556-62. Article. IF: 1.707; Q3
• Halperin SA, Arribas JR, Rupp R, Andrews CP, Chu L, Das R, Simon
JK, Onorato MT, Liu K, Martín J, Helmond FA. Six-month safety data
of recombinant vesicular stomatitis virus-Zaire Ebola virus envelo-
pe glycoprotein vaccine in a phase 3 double-blind, placebo-contro-
lled randomized study in healthy adults. J Infect Dis. 2017; 215(12):
1789-98. Article. IF: 5.186; Q1
• Lazarus JV, Barton SE, Bernardino JI. Taking the long-view in a per-
sonalised approach to HIV care. Lancet HIV. 2017; 4(11): E483-5.
Editorial Material. IF: 11.355; D1
• Macías J, Mancebo M, Merino D,Téllez F, Montes-Ramírez ML, Pulido
F, Rivero-Juárez A, Raffo M, Pérez-Pérez M, Merchante N, Cotarelo
M, Pineda JA. Changes in liver steatosis after switching from efavi-
renz to raltegravir among human immunodeficiency virus-infected
patients with nonalcoholic fatty liver disease. Clin Infect Dis. 2017;
65(6): 1012-19. Article. IF: 9.117; D1
• Margolis DA, González-García J, Stellbrink HJ, Eron JJ, Yazdanpanah
Y, Podzamczer D, Lutz T, Angel JB, Richmond GJ, Clotet B, Gutiérrez
F, Sloan L, St Clair M, Murray M, Ford S.L., Mrus J, Patel P, Crauwels
H, Griffith SK, Sutton KC, Dorey D, Smith KY, Williams PE, Spreen
WR. Long-acting intramuscular cabotegravir and rilpivirine in adults
with HIV-1 infection (LATTE-2): 96-week results of a randomised,
open-label, phase 2b, non-inferiority trial. Lancet. 2017; 390(10101):
1499-510. Article. IF: 53.254; D1
• Meras P, Caro J, Trigo E, Irazusta J, López-Sendón JL, Refoyo E.
Diagnostic value of NT-proBNP for early identification of Cha-
gas cardiomyopathy in non-endemic areas. Rev Esp Cardiol. 2017;
70(9):783-5. Letter. IF: 5.166; Q1
• Montejano R, Stella-Ascariz N, Monge S, Bernardino JI, Pérez-Valero
I, Montes ML, Valencia E, Martín-Carbonero L, Moreno V, González-
García J, Arnalich F, Mingorance J, Berniches LP, Perona R, Arribas JR.
Impact of antiretroviral treatment containing tenofovir difumarate
on the telomere length of Aviremic HIV-infected patients. JAIDS-J
Acq Imm Def. 2017; 76(1): 102-9. Article. IF: 4.116; Q1
• Montes ML, Olveira A, Ahumada A, Aldámiz T, García-Samaniego J,
Clemente A, Berenguer J, González-García J, Martín-Carbonero L.
Similar effectiveness of direct-acting antiviral against hepatitis C vi-
rus in patients with and without HIV infection. AIDS. 2017; 31(9):
1253-60. Article. IF: 4.914; Q1
• Moreno S, Antela A, García F, del Amo J, Boix V, Coll P, Fortuny C,
Sirvent JLG, Gutiérrez F, Iribarren JA, Llibre JM, de Quirós JCLB,
Losa JE, Lozano A, Meulbroek M, Olalla J, Pujol F, Pulido F, Casal MC,
García JG, Aldeguer JL, Molina JAP, Palter DP, Román AR. Executive
summary: Pre-exposure prophylaxis for prevention of HIV infection
in adults in Spain: July 2016. Enferm Infec Micr Cl. 2017; 35(6): 377-
83. Article. IF: 1.707; Q3
• Negredo A, de la Calle-Prieto F, Palencia-Herrejón E, Mora-Rillo M,
Astray-Mochales J, Sánchez-Seco MP, López EB, Menárguez J, Fer-
nández-Cruz A, Sánchez-Artola B, Keough-Delgado E, de Arellano
ER, Lasala F, Milla J, Fraile JL, Gavin MO, de la Gandara AM, Pérez LL,
Díaz-Díaz D, López-García MA, Delgado-Jiménez P, Martín-Quirós
A, Trigo E, Figueira JC, Manzanares J, Rodríguez-Baena E, García-
Comas L, Rodríguez-Fraga O, García-Arenzana N, Fernández-Díaz-
MV, Cornejo VM, Emmerich P, Schmidt-Chanasit J, Arribas JR. Auto-
chthonous Crimean-Congo hemorrhagic fever in Spain. New Engl J
Med. 2017; 377(2): 154-61. Article. IF: 79.258; D1
• Norman FF, López-Polín A, Salvador F, Trevino B, Calabuig E, Torrus
D, Soriano-Arandes A, Ruiz-Giardín JM, Monge-Maillo B, Pérez-Mo-
lina JA, Pérez-Ayala A, García M, Rodríguez A, Martínez-Serrano M,
Zubero M, López-Velez R, (Diáz Menéndez M). Imported malaria
in Spain (2009-2016): results from the plus REDIVI Collaborative
Network. Malaria J. 2017; 16: 407. Article. IF: 2.845; Q1
• Paton NI, Kityo C, Thompson J, Nankya I, Bagenda L, Hoppe A, Ha-
kim J, Kambugu A, van Oosterhout JJ, Kiconco M, Bertagnolio S, Eas-
terbrook PJ, Mugyenyi P, Walker AS, (Arribas lópez JR). Nucleoside
reverse-transcriptase inhibitor cross-resistance and outcomes from
second-line antiretroviral therapy in the public health approach: an
observational analysis within the randomised, open-label, EARNEST
trial. Lancet HIV. 2017; 4(8): E341-8. Article. IF: 11.355; D1
• Pérez-Molina JA, López-Polín A, Trevino B, Molina I, Goikoetxea J,
Díaz-Menéndez M, Torrus D, Calabuig E, Benito A, López-Velez R.
6-year review of plus Redivi: a prospective registry of imported in-
fectious diseases in Spain. J Travel Med. 2017; 24(5): tax035. Review.
IF: 1.8; Q2
• Pérez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera
M, Estebánez M, Palacios R, Sanz-Moreno J, Troya J, Marino A, Antela
A, Navarro J, Esteban H, Moreno S. Simplification to dual therapy
(atazanavir/ritonavir plus lamivudine) versus standard triple therapy
[atazanavir/ritonavir plus two nucleos(t)ides] in virologically stable
patients on antiretroviral therapy: 96 week results from an open-
label, non-inferiority, randomized clinical trial (SALT study). J Anti-
microb Chemoth. 2017; 72(1): 246-53. Article. IF: 5.217; D1
• Pulido F, Ribera E, Lagarde M, Pérez-Valero I, Palacios R, Iribarren
JA, Payeras A, Domingo P, Sanz J, Cervero M, Curran A, Rodríguez-
Gómez FJ, Téllez MJ, Ryan P, Barrufet P, Knobel H, Rivero A, Alejos
B, Yllescas M, Arribas JR. Dual therapy with darunavir and ritonavir
plus lamivudine vs triple therapy with darunavir and ritonavir plus
tenofovir disoproxil fumarate and emtricitabine or abacavir and la-
mivudine for maintenance of human immunodeficiency virus type
1 viral suppression: Randomized, open-label, noninferiority DUAL-
GESIDA 8014-RIS-EST45 Trial. Clin Infect Dis. 2017; 65(12): 2112-8.
Article. IF: 9.117; D1
• Ramírez E, Bellón T, Tong HY, Borobia AM, de Abajo FJ, Lerma V, Hi-
dalgo MAM, Castaner JL, Cabañas R, Fiandor A, González-Ramos J,
Herranz P, Cachafeiro L, González-Herrada C, González O, Aram-
buru JA, Laosa O, Hernández R, Carcas AJ, Frías J. Significant HLA
class I type associations with aromatic antiepileptic drug (AED)-
induced SJS/TEN are different from those found for the same AED-
induced DRESS in the Spanish population. Pharmacol Res. 2017; 115:
168-78. Article. IF: 4.897; D1
• Ramírez E, Medrano-Casique N, Tong HY, Bellón T, Cabañas R, Fian-
dor A, González-Ramos J, Herranz P, Trigo E, Muñoz M, Borobia AM,
Carcas AJ, Frías J. Eosinophilic drug reactions detected by a prospec-
tive pharmacovigilance programme in a tertiary hospital. Brit J Clin
Pharmacol. 2017; 83(2): 400-15. Article. IF: 3.838; Q1
• Rivero A, Pérez-Molina JA, Blasco AJ, Arribas JR, Crespo M, Domin-
go P, Estrada V, Iribarren JA, Knobel H, Lazaro P, López-Aldeguer J,
Lozano F, Moreno S, Palacios R, Pineda JA, Pulido F, Rubio R, de la
Torre J, Tuset M, Gatell JM. Costs and cost-efficacy analysis of the
2016 GESIDA/Spanish AIDS National Plan recommended guidelines
for initial antiretroviral therapy in HIV-infected adults. Enferm Infec
Micr Cl. 2017;35(2):88-99. Article. IF: 1,707; Q3.0
• Rosado-Sánchez I, Herrero-Fernández I, Álvarez-Ríos AI, Genebat
M, Abad-Carrillo MA, Ruiz-Mateos E, Pulido F, González-García J,
Montero M, Bernal-Morell E, Vidal F, Leal M, Pacheco YM. A lower
baseline CD4/CD8 T-cell ratio is independently associated with im-
munodiscordant response to antiretroviral therapy in HIV-infected
subjects. Antimicrob Agents Ch. 2017; 61(8): e00605-17. Article. IF:
4.255; Q1
• Saumoy M, Llibre JM, Terrón A, Knobel H, Arribas JR, Domingo P,
Arroyo-Manzano D, Rivero A, Moreno S, Podzamczer D. Short
communication: Maraviroc once-daily: Experience in routine clini-
cal practice. AIDS Res Hum Retrov. 2017; 33(1): 29-32. Article. IF:
1.935; Q3
• Sax PE, Pozniak A, Montes ML, Koenig E, de Jesús E, Stellbrink HJ,
Antinori A, Workowski K, Slim J, Reynes J, Garner W, Custodio J,
White K, sen Gupta D, Cheng A, Quirk E. Coformulated bictegra-
vir, emtricitabine, and tenofovir alafenamide versus dolutegravir
with emtricitabine and tenofovir alafenamide, for initial treatment
of HIV-1 infection (GS-US-380-1490): a randomised, double-blind,
multicentre, phase 3, non-inferiority trial. Lancet. 2017; 390(10107):
2073-82. Article. IF: 53.254; D1
143
 3
Information Groups by Area
3.3 Infectious Diseases and Immunity Area
• Sobrino-Jiménez C, Jiménez-Nacher I, Moreno-Ramos F, González-
Fernández MA, Freire-González M, González-García J, Herrero-Am-
brosio A. Analysis of antiretroviral therapy modification in routine
clinical practice in the management of HIV infection. Eur J Hosp
Pharm-SP. 2017; 24(2): 96-100. Article. IF: 0.538; Q4
• Stella-Ascariz N, Arribas JR, Paredes R, Li JZ.The role of HIV-1 drug-
resistant minority variants in treatment failure. J Infect Dis. 2017;
216: S847-50. Article. IF: 5.186; Q1
• Stella-Ascariz N, Montejano R, Pintado-Berninches L, Monge S,
Bernardino JI, Pérez-Valero I, Montes ML, Mingorance J, Perona R,
Arribas JR. Differential effects of tenofovir, abacavir, emtricitabine,
and darunavir on telomerase activity in vitro. JAIDS-J Acq Imm Def.
2017; 74(1): 91-4. Article. IF: 4.116; Q1
• Toro C, Trevisi P, López-Quintana B, Amor A, Iglesias N, Subirats M,
de Guevara CL, Lago M, Arsuaga M, de la Calle-Prieto F, Herrero
D, Rubio M, Puente S, Baquero M. Imported Dengue infection in a
Spanish hospital with a high proportion of travelers from Africa: A
9-year retrospective study. Am J Trop Med Hyg. 2017; 96(3): 701-7.
Article. IF: 2.564; Q2
• Valencia-Ortega ME, García-Bujalance S, González-García J. Hepa-
titis with a multiple etiology in HIV-positive men who have sexual
relations with other men. Rev Esp Enferm Dig. 2017; 109(11): 801.
Letter. IF: 1.632; Q4
Public Projects
Arribas López JR. Contrato intensificación José Ramón Arri-
bas López (INT16/00136). ISCIII. 2017-2018.
Managment centre: FIBHULP
Arribas López JR. Ensayo clínico, randomizado, piloto, dise-
ñado para comparar, en sujetos infectados por el virus de in-
munodeficiencia humana que nunca han recibido tratamiento
antirretroviral, la evolución del funcionamiento cerebral y del
rendimiento neurocognitivo tras 24 semanas de tratamiento
(EC11-217). MSSSI. 2012-2017.
Managment centre: FIBHULP
Arribas López JR. Envejecimiento prematuro de pacientes
VIH+: evaluación in vivo e in vitro del impacto del tratamien-
to con análogos nucleosidos en la longitud de los telometros
(PI13/01467). ISCIII. 2014-2017.
Managment centre: FIBHULP
Arribas López JR. Identificación y caracterización de anti-
cuerpos monoclonales frente al virus Ébola para aplicaciones
diagnósticas y terapéuticas (DTS15/00143). ISCIII. 2016-2017.
Managment centre: FIBHULP
Arribas López JR. Impulso a la participación en H2020 de
IdiPAZ (ECT-2017-0347). MSSSI. 2017-2018.
Managment centre: FIBHULP
Arribas López JR. Tratamiento antiretroviral guiado por ge-
notipo proviral: ensayo clínico piloto de prueba de concepto
(TAR-PRO) (PI16/00837). ISCIII. 2017-2020.
Managment centre: FIBHULP
Gayá Moreno F. Contrato de técnico de apoyo (ECA07/013).
ISCIII, CAM. 2008-2019.
Managment centre: FIBHULP
González García JJ. Efectos de la erradicación del VHC en
pacientes con cirrosis avanzada por VHC. Una aproximación
traslacional (PI14/01581). ISCIII. 2015-2017.
Managment centre: FIBHULP
144
González García JJ. Erradicación del VHC en pacientes coin-
fectados por VIH/VHC: efectos sobre la inflamación, el daño
endotelial, la activación inmune y la aterosclerosis preclinica
(EC11-241). MSSSI. 2012-2017.
Managment centre: FIBHULP
González García JJ. Red de SIDA (RIS) (RD12/0017/0016).
ISCIII. 2013-2017.
Managment centre: FIBHULP
González García JJ. Red española de Investigación en SIDA
(RIS) (RD16/0025/0018). ISCIII. 2017-21.
Managment centre: FIBHULP
Montejano Sánchez R. Contrato Río Hortega. (CM14/00034).
ISCIII. 2015-2017.
Managment centre: FIBHULP
Mora Rillo M. Red de Investigación Colaborativa en Enfer-
medades Tropicales (RICET) (RD16/0027/0002). ISCIII. 2017-
2021.
Managment centre: FIBHULP
Mora Rillo M. Red de Investigación Cooperativa en Enfer-
medades Tropicales (RICET) (RD12/0018/0023). ISCIII. 2013-
2017.
Managment centre: FIBHULP
Pérez Valero I. Seguridad neurocognitiva de terapias anti-
rretrovirales no convencionales con inhibidores de proteasa
(IPS) (PI14/01876). ISCIII. 2015-2017.
Managment centre: FIBHULP
Rodés Soldevila B. Analisis de la expresión de los niveles
de proteínas modificadoras y otros mecanismos epigenéticos
asociados a la regulación de la transcripción del VIH en pa-
cientes LTPN/EC (PI12/00850). ISCIII. 2013-2017.
Managment centre: FIBHULP
Rodés Soldevila B. Contrato de estabilización I2 (CES11/021).
ISCIII, CAM. 2012-2019.
Managment centre: FIBHULP
Private Projects
Arribas López JR. Aplicación de la secuenciación de genomas
individuales (SGI) al estudio de la resistencia a antirretrovi-
rales en poblaciones minoritarias celulares y plasmáticas en
pacientes infectados por VIH. Fundación para la Investigación
y la Prevención del SIDA. 2009-Ongoing.
Managment centre: FIBHULP
Arribas López JR. Curso de actualización de la investigación
en simplificación con inhubidores de proteasa. Janssen Cilag
S.A. Colombia. 2014-Ongoing.
Managment centre: FIBHULP
Arribas López JR. Curso de actualización en investigación en
VIH: aprendizajes pasados y nuevos conceptos. Janssen Cilag
S.A. Colombia. 2014-Ongoing.
Managment centre: FIBHULP
Arribas López JR. Curso de avances en la investigación en
el tratamiento con inhibidores de proteasa. Janssen Cilag S.A.
Colombia. 2015-Ongoing.
Managment centre: FIBHULP
Arribas López JR. Estudio de longitud telomérica en pa- Díaz Menéndez M. Evaluación de la patología adquirida por
cientes infectados por el VIH expuestos a dos estrategias de viajeros de riesgo durante un viaje internacional: estudio
tratamiento antirretroviral diferente (Telomere Lenght Subs- prospectivo en un centro de referencia. International Society
tudy).The European treatment network for HIV, hepatitis and of Travel Medicine (ISTM).2017-Ongoing.
global infectious diseases. 2016-Ongoing. Managment centre: FIBHULP
Managment centre: FIBHULP
González García JJ. Características clínicas y epidemiológi-
Arribas López JR. II Curso de enfermedades por virus emer- cas de la coinfección VHC-VIH en la población española en
gentes: preparándonos para la siguiente crisis de la investiga- 2008.Varios Financiadores. 2008-Ongoing.
ción a la clínica. Janssen-Cilag España S.A 2017-Ongoing. Managment centre: FIBHULP
Managment centre: FIBHULP
González García JJ. Erradicación del virus de la hepatitis C en
Arribas López JR. Preparación y asesoramiento para el de- pacientes infectados por el VIH: efectos a largo plazo sobre
sarrollo del curso de investigación sobre VIH y deterioro la morbilidad y mortalidad no relacionada con la hepatopatía,
neurocognitivo, a traves del grupo SIDA y Enfermedades In- sobre la activación inmune y sobre marcadores metabólicos,
fecciosas. Bristol Myers Squibb S.A.U. 2012-Ongoing. de inflamación y de baño ENOT. Fundación para la Investiga-
Managment centre: FIBHULP ción y la Prevención del SIDA. 2011-Ongoing.
Managment centre: FIBHULP
Arribas López JR. Programa de actualización en investigación
sobre el envejecimiento en pacientes infectados por el VIH. González García JJ. Estudio de cohorte de pacientes con
Gilead Sciences S.L. 2017-Ongoing. infección por VIH del Hospital La Paz de Madrid (Cohorte
Managment centre: FIBHULP VIH-La Paz). Gilead Sciences S.L. 2008-Ongoing.
Managment centre: FIBHULP
Arribas López JR. Registro descriptivo longitudinal retrospec-
tivo de los pacientes naïve incluidos en la cohorte de pacientes Herranz Pinto P. Curso manejo global de la toxicidad muco-
con infección por VIH del Hospital La Paz de Madrid (Cohorte cutánea de las terapias antineoplásicas. De la investigación a
VIH-La Paz). Janssen-Cilag España S.A. 2010-Ongoing. la práctica clínica. Merck S.L. 2016-Ongoing.
Managment centre: FIBHULP Managment centre: FIBHULP
Arribas López JR. Research in boosted pi monotherapy.
Janssen-Cilag. 2012-Ongoing.
Managment centre: FIBHULP
Arribas López JR. VIII Jornadas de actualización científica
en enfermedades infecciosas. Novartis Farmaceutica S.A.
2012-Ongoing.
Managment centre: FIBHULP
Arribas López JR. XI Jornadas de Actualización
en enfermededades infecciosas: de la investiga-
ción a la práctica clínica. Varios Financiadores.
2016-Ongoing.
Managment centre: FIBHULP
Arribas López JR. XI Jornadas de Actuali-
zación en enfermedades infecciosas: de la
investigación a la práctica clínica. Gilead
Sciences S.L. 2015-Ongoing.
Managment centre: FIBHULP
Bernardino de la Serna JI. Biological age
and cardiovascular ischemic events or dia-
btes in HIV-infected patients. Gilead Scien-
ces S.L. 2017-Ongoing.
Managment centre: FIBHULP
Bernardino de la Serna JI. Cohorte ob-
servacional internacional coordinada por la
cohorte suiza de VIH (SHCS) sobre la contri-
bución de las variables genéticas asociadas a la
aparición de la enfermedad coronaria en pacien-
tes infectados por el virus de la inmunodeficiencia
humana. Kantonsspital Bruderholz. 2011-Ongoing.
Managment centre: FIBHULP
de la Calle Prieto F. Curso de consejo integral al viajero:
de la investigación a la práctica clínica. Varios Financiadores.
2016-Ongoing.
Managment centre: FIBHULP
145
 3
Information Groups by Area
3.3 Infectious Diseases and Immunity Area
Herranz Pinto P. Encuentro de actualización en psoriasis.
Novartis Farmaceutica S.A. 2017-Ongoing.
Managment centre: FIBHULP
Herranz Pinto P. Identificación precoz de buenos responde-
dores primarios a las terapias biológicas en la psoriasis mo-
derada a grave. Novartis Farmacéutica S.A.; Promega Corpo-
ration. 2014-Ongoing.
Managment centre: FIBHULP
Herranz Pinto P. Jornada científica: lucha antivenerea en el
siglo XXI. Gilead Sciences S.L. 2016-Ongoing.
Managment centre: FIBHULP
Herranz Pinto P. Preceptorship del Servicio de Dermatolo-
gia del Hospital Univesitario La Paz dirigido a dermatólogos.
Novartis Argentina. 2017-Ongoing.
Managment centre: FIBHULP
Herranz Pinto P. Terapia biológica con artritis psoriásica y
psoriasis y su investigación asociada. Merck Sharp and Doh-
me de España S.A. 2005-Ongoing.
Managment centre: FIBHULP
Ladrón de Guevara G. V Jornadas de medicina del viajero y
salud internacional: nuevas vacunas, nuevos viajeros, nuevas
medidas sanitarias: de la investigación a la práctica clínica. La-
drón de Guevara Jorn Viajero. 2017-Ongoing.
Managment centre: FIBHULP
Montes Ramírez ML. Estudio de hepatopatías en pacien-
tes infectados por VIH sin hepatitis víricas que reciben
tratamiento antirretroviral. Abbvie Spain S.L.U. 2016-On-
going.
Managment centre: FIBHULP
Paño Pardo JR. Evaluación de la utilización de antifúngicos
a través de datos agregados de consumo: elaboración de un
modelo. Gilead Sciences S.L. 2010-Ongoing.
Managment centre: FIBHULP
Peña Sánchez de Rivera JM. Estudio de cohorte de pacien-
tes con infección por VIH del Hospital La Paz de Madrid (Co-
horte VIH-La Paz). Glaxosmithkline S.A. 2008-Ongoing.
Managment centre: FIBHULP
Pérez Valero I. Jornada de actualización en infecciones de
transmisión sexual para atención primaria: de la investigación
a la práctica clínica. Gilead Sciences S.L. 2015-Ongoing.
Managment centre: FIBHULP
Rodes Soldevilla B. Convenio marco: prácticas de maría de
frutos del pozo: máster microbiología. UCM. 2016-Ongoing.
Managment centre: FIBHULP
Trigo Esteban E. Riesgo de infección por enfermedad de
Chagas tras viaje a zonas endémicas. Drugs for Neglected
Diseases Initiative. 2017-Ongoing.
Managment centre: Hospital Vall d´Hebron
CLINICAL TRIALS
Arribas López JR. Determinación de frecuencias de mutacio-
nes mediante genotipo provira. Type: EPA-OD.
HULP code: PI-2836.
Sponsored´s protocol code: GEN-PRO.
146
Sponsored by: Fundación para la Investigación Biomédica
Hospital Universitario La Paz.
Signed date: 13/09/2017
Arribas López JR. Ensayo clínico de fase III, multicéntrico, do-
ble ciego, aleatorizado, controlado con un comparador activo
para evaluar la seguridad y la eficacia de 100 mg de doravirina
(MK-1439) una vez al día frente a 800 mg de darunavir una
vez al día más 100 mg de ritonavir una vez al día, cada uno de
ellos en combinación con Truvada™ o Epzicom™/Kivexa™,
en sujetos infectados por el VIH 1 no tratados previamente.
Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4326. Sponsored´s protocol code: MK-1439-
018.
Sponsored by: Merck & Co. Inc.
Signed date: 14/03/2017
Arribas López JR. Ensayo clínico fase IIB, aleatorizado, con-
trolado con principio activo, doble ciego, para investigar la
seguridad, eficacia y dosis-respuesta de BMS-955176, admi-
nistrado con tenofovir/emtricitabina en adultos infectados
por VIH 1 naive a tratamiento. Type: Clinical Trial, phase II.
HULP code: ANEXO-II 4424. Sponsored´s protocol code: AI468-038.
Sponsored by: VIIV Healthcare UK Limited.
Signed date: 17/02/2017
Arribas López JR. Estudio de fase III, aleatorizado, controla-
do con tratamiento activo y abierto para evaluar el cambio
de tratamiento a un régimen en un solo comprimido admi-
nistrado una vez al día de darunavir/cobicistat/emtricitabina/
tenofovir alafenamida (D/C/F/TAF) frente a la continuación
del régimen actual formado por un inhibidor de la protea-
sa potenciado (IPP) combinado con emtricitabina/tenofovir
disoproxil fumarato (FTC/TDF) en sujetos infectados por el
virus de la inmunodeficiencia humana de tipo 1 (VIH-1) con
supresión virológica. Type: Clinical Trial, phase III.
HULP code: ANEXO-III 4300.
Sponsored´s protocol code: TMC114IFD3013.
Sponsored by: Janssen-Cilag España S.A.
Signed date: 15/06/2017
Arribas López JR. Estudio de fase III, aleatorizado, controla-
do con tratamiento activo y abierto para evaluar el cambio
de tratamiento a un régimen en un solo comprimido admi-
nistrado una vez al día de darunavir/cobicistat/emtricitabina/
tenofovir alafenamida (C/C/F/TAF) frente a la continuación
del régimen actual formado por un inhibidor de la protea-
sa potenciado (IPP) combinado con emtricitabina/tenofovir
disoproxil fumarato (FTC/TDF) en sujetos infectados por el
virus de la inmunodeficiencia humana de tipo 1 (VIH-1) con
supresión virológica. Type: Clinical Trial, phase III.
HULP code: ANEXO-II 4300.
Sponsored´s protocol code: TMC114IFD3013.
Sponsored by: Janssen-Cilag España S.A.
Signed date: 27/05/2017
Arribas López JR. Estudio de fase III, aleatorizado, multicén-
trico, con grupos paralelos y de ausencia de inferioridad para
evaluar la eficacia, la seguridad y la tolerabilidad del cambio a
dolutegravir más lamivudina en adultos infectados por el VIH
1 con supresión virológica. Type: Clinical Trial, phase III.
HULP code: 4885. Sponsored´s protocol code: 204862.
Sponsored by: VIIV Healthcare Uk Limited.
Signed date: 23/06/2017
Arribas López JR. Tratamiento antirretroviral guiado por ge-
notipo proviral: ensayo clínico piloto de prueba de concepto.
Type: Clinical Trial, phase II.
HULP code: 4874. Sponsored´s protocol code: TAR-PRO.
Sponsored by: Fundación para la Investigación Biomedica
Hospital Universitario La Paz.
Signed date: 13/09/2017
Bernardino de la Serna JI. Estudio de fase IIIB, abierto y
aleatorizado para evaluar el cambio de una pauta con te-
nofovir disoproxil fumarato (TDF) por una combinación
en dosis fijas (CDF) de elvitegravir/cobicistat/emtricitabina/
tenofovir alafenamida (E/C/F/TAF) en sujetos 60 años in-
fectados por el VIH 1 con supresión virológica. Type: Clinical
Trial, phase IIIb.
HULP code: ANEXO-I 4745. Sponsored´s protocol code: GS-
US-292-1826.
Sponsored by: Gilead Sciences Inc.
Signed date: 10/04/2017
Bernardino de la Serna JI. Estudio multicéntrico, aleatori-
zado, doble ciego y controlado con placebo para evaluar la
seguridad, tolerabilidad y eficacia de evolocumab (AMG 145)
en el C-LDL de sujetos con VIH e hiperlipidemia y/ó dislipi-
demia mixta. Type: Clinical Trial, phase III.
HULP code: 4804. Sponsored´s protocol code: 20130286.
Sponsored by: Amgen S.A.
Signed date: 21/04/2017
González García JJ. Estudio de seguimiento a largo plazo de
los sujetos que participaron en un ensayo clínico en el que se
administro asunaprevir (BMS-650032) y/o daclatasvir (BMS-
790052) para el tratamiento de la hepatitis C crónica. Type:
Clinical Trial, phase III.
HULP code: ANEXO-I 3956. Sponsored´s protocol code: AI444-046.
Sponsored by: Bristol Myers Squibb S.A.U.
Signed date: 25/05/2017
González García JJ. Estudio de seguimiento a largo plazo
para evaluar la durabilidad de la respuesta virológica y/o los
patrones de resistencia viral de sujetos con hepatitis C cró-
nica que han sido tratados previamente con MK-5172 en un
ensayo clínico previo. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4310. Sponsored´s protocol code: 5172-017.
Sponsored by: Merck Sharp and Dohme de España S.A.
Signed date: 06/04/2017
González García JJ. Estudio fase III aleatorizado, multicén-
trico, de grupos paralelos, de no inferioridad, para evaluar la
eficacia, seguridad y tolerabilidad del cambio de una terapia
antirretroviral basada en INI, ITINN o IP a dolutegravir más
rilpivirina en pacientes adultos infectados por el VIH-1 con
supresión de la carga viral. Type: Clinical Trial, phase III.
HULP code: ANEXO-III 4372. Sponsored´s protocol code: 201637.
Sponsored by: Laboratorios VIIV Healthcare S.L.
Signed date: 13/07/2017
González García JJ. Estudio fase III, aleatorizado, multicéntri-
co, abierto, de grupos paralelos, para evaluar la eficacia, segu-
ridad y tolerabilidad de una pauta de tratamiento intramus-
cular de acción prolongada con cabotegravir y rilpivirina en el
mantenimiento de la supresión virológica, tras una inducción
con un tratamiento de comprimido único con un inhibidor
de la integrasa en pacientes adultos infectados por el VIH-1
que no han recibido un tratamiento antirretroviral previo.
Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4679. Sponsored´s protocol code: 201584.
Sponsored by: Laboratorios VIIV Healthcare S.L.
Signed date: 12/12/2017
Herranz Pinto P. Ensayo fase III, aleatorizado, doble ciego,
controlado con placebo, para evaluar la eficacia y seguridad
de tralokinumab en monoterapia en pacientes con dermatitis
atópica moderada a grave que sean candidatos para un trata-
miento sistémico. Type: Clinical Trial, phase III.
HULP code: 4842. Sponsored´s protocol code: LP0162-1325.
Sponsored by: Leo Pharma A/S.
Signed date: 10/11/2017
Herranz Pinto P. Estudio abierto de dupilumab en pacientes
con dermatitis atópica que han participado en ensayos clíni-
cos previos con dupilumab. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4514. Sponsored´s protocol code: R668-
AD-1225 04.
Sponsored by: Regeneron Pharmaceuticals Inc.
Signed date: 12/02/2017
Herranz Pinto P. Estudio aleatorizado, doble ciego y contro-
lado con placebo, para demostrar la eficacia y la seguridad a
largo plazo de dupilumab en pacientes adultos con dermati-
tis atópica de grado moderado a severo. Type: Clinical Trial,
phase III.
HULP code: ANEXO-II 4170. Sponsored´s protocol code: R668-
AD-1224.
Sponsored by: Regeneron Pharmaceuticals Inc.
Signed date: 24/08/2015
Herranz Pinto P. Estudio clínico abierto para evaluar la efica-
cia y la seguridad a largo plazo de dimetilfumarato en adultos
con psoriasis crónica en placas moderada-grave en la práctica
clínica (Estudio Dimeskin 1). Type: Clinical Trial, phase IV.
HULP code: 4895. Sponsored´s protocol code: M-41-008-41.
Sponsored by: Almirall S.A.
Signed date: 03/10/2017
Herranz Pinto P. Estudio de fase III, multicéntrico, aleatori-
zado, doble ciego y comparado con placebo, para evaluar la
eficacia y la seguridad de baricitinib en pacientes con derma-
titis atópica de moderada a grave. Type: Clinical Trial, phase III.
HULP code: 4951. Sponsored´s protocol code: I4V-MC-JAHM.
Sponsored by: Lilly S.A.
Signed date: 20/12/2017
Herranz Pinto P. Estudio multicéntrico de fase III, aleato-
rizado, doble ciego para evaluar la eficacia comparativa de
guselkumab (CNTO1959) y secukinumab en el tratamiento
de la psoriasis en placa de moderada a grave. Type: Clinical
Trial, phase III.
HULP code: 4770. Sponsored´s protocol code: CNTO1959PSO3009.
Sponsored by: Janssen Cilag International NV.
Signed date: 03/02/2017
Montejano Sánchez R. Estudio de fase IIB, comparativo, mul-
ticéntrico, aleatorizado, doble ciego, para evaluar la eficacia y
seguridad de VIS410 por vía intravenosa administrado junto
con oseltamivir (Tamiflu®) en comparación con oseltamivir
en monoterapia en adultos hospitalizados con infección por
el virus de la gripe A que requieren soporte con oxígeno.
Type: Clinical Trial, phase II.
147
 3
Information Groups by Area

3.3 Infectious Diseases and Immunity Area

HULP code: 4903. Sponsored´s protocol code: VIS410-203. Sponsored by: Abbvie Spain S.L.U.
Sponsored by: Visterra Inc. Signed date: 03/02/2017

Molecular Microbiology Group

Signed date: 23/10/2017
Montes Ramírez ML. Estudio fase IIIB, aleatorizado, multi-
céntrico, abierto, de grupos paralelos, de no inferioridad que
evalúa la eficacia, seguridad y tolerabilidad de cabotegravir
de acción prolongada más rilpivirina de acción prolongada
administrados cada 8 semanas o cada 4 semanas en adul-
tos infectados por VIH-1 que presentan supresión virológica.
Type: Clinical Trial, phase IIIb.
HULP code: 4925. Sponsored´s protocol code: 207966.
Sponsored by: Laboratorios VIIV Healthcare S.L.
Signed date: 14/09/2017
Montes Ramírez ML. Evidencia en vida real de la efectividad
de paritaprevir/r/ombitasvir ± dasabuvir (régimen abbvie) ±
ribavirina en pacientes con hepatitis c crónica – estudio ob-
servacional retrospectivo en España. Estudio VIE-REAL. Type:
EPA-OD.
HULP code: PI-2508. Sponsored´s protocol code: ABB-OMB-2016-01.
Pérez Valero I. Ensayo clínico fase IV abierto, aleatorizado y
piloto diseñado para evalurar la potencial neurotoicidad de
dolutegravir/lamivudina/abacavir en paciente VIH neuro sin-
tomáticos y su revesibilidad tras el cambio a elvitegravir/co-
bicistat/emtricitabina/tenofovir alafenamida. Estudio Dream.
Type: Clinical Trial, phase IV.
HULP code: 4829. Sponsored´s protocol code: GESIDA 9016.
Sponsored by: Fundación SEIMC-GESIDA.
Signed date: 31/05/2017
Patents and Trademarks
Romero Gómez M, Solá Lamoglia R, González García JJ,
inventors; Servicio Andaluz de Salud, Universidad de Sevilla,
Fundació Institut Mar D’Investigacións Mèdiques, FIBHULP,
assignees. Kit for decision making in patients with Hepatitis
C genotypes 1 and 4. P201330731; 2013 May 21.

36 117.768 19

Jesús Mingorance Cruz. Investigador Senior (Contrato
Ramón y Cajal - I3). Jefe de Laboratorio. HULP
Emilio Cendejas Bueno. Investigador Postdoctoral (Contrato
Juan Rodés). HULP
María Teresa Corcuera Pindado. Técnico Grado Superior.
HULP
Manuela de Pablos Gómez. Facultativo Especialista de Área en
Microbiología. HULP
Silvia García Bujalance. Facultativo Especialista de Área en
Microbiología. HULP
Adelaida García Perea. Facultativo Especialista de Área en
Microbiología. HULP
Julio García Rodríguez. Jefe de Servicio de Microbiología. HULP
María Jesús García García. Profesora Titular del Departamento
de Medicina Preventiva y Salud Pública y Microbiología. Facultad de
Medicina. UAM
Paulino Gómez Puertas. Investigador Titular - Profesor
Honorario. UAM - CSIC - CBM Severo Ochoa
María Rosa Gómez-Gil Mira. Facultativo Especialista de Área
en Microbiología. HULP
Fernando Lázaro Perona. Facultativo Especialista de Área en
Microbiología. HULP
María Belén Loeches Yagüe. Médico Adjunto en Unidad de
Enfermedades Infecciosas. HULP
Elena López Camacho. Investigadora Postdoctoral. HULP
Carmen Menéndez Gómez. Profesora Honoraria del
Departamento de Medicina Preventiva y Salud Pública y
Microbiología. Facultad de Medicina. UAM
Dolores Montero Vega. Facultativo Especialista de Área en
Microbiología. HULP
Arturo Noguerado Asensio. Jefe de Servicio de Medicina
Interna. HULP - Hospital de Cantoblanco
148
Verónica Pérez Blanco. Facultativo Especialista de Área en Medicina
Preventiva. HULP
María Inmaculada Quiles Melero. Facultativo Especialista de Área
en Microbiología. HULP
Alicia Rico Nieto. Facultativo Especialista de Área en Microbiología.
HULP
María Pilar Romero Gómez. Facultativo Especialista de Área en
Microbiología. HULP
Guillermo Ruiz Carrascoso. Facultativo Especialista de Área en
Microbiología. HULP
Alma Lorena Guadalupe Sotillo Torquemada. Investigadora
Predoctoral. HULP
Natalia Stella Ascariz. Investigadora Predoctoral. HULP
Carlos Toro Rueda. Facultativo Especialista de Área en Microbiología.
HULP - HCIII
Strategic Objective
The Molecular Microbiology research group is integra-
ted into the Department of Microbiology at Hospital
La Paz, and a significant number of its members are
physicians in the department devoted to microbiolo-
gical diagnostic work. This integration determines the
group’s strategic approach and therefore, the different
lines of research revolve around several aspects of cli-
nical microbiology and infectious diseases.
An important line of activity (Clinical Microbiology)
is the result of the routine activities provided by the
department, but goes further and deeper into the
methodological, epidemiological and pathological cha-
llenges encountered in the daily routine.
One research line derived from the former is the de-
velopment of methods for the molecular characterisa-
149
 3
Information Groups by Area
3.3 Infectious Diseases and Immunity Area
tion of pathogenic microorganisms, including microbio-
logical diagnosis and epidemiological analysis, and more
recently, microbial genomics.
Another line focuses on the study of the evolution of
pathogenic microorganisms. As a model of opportunistic
pathogens, we study Escherichia coli, a microorganism
that is well characterised at the genetic level and that is
clinically relevant as the primary cause of urinary tract
infections and one of the most frequently involved in
bacteraemia.
As a model of viral pathogens, we study the dynamics
of HIV viral populations over time and in terms of the
response to antiretroviral treatment.
Another important focus, given the scarcity of new anti-
biotics, is the search for new therapeutic targets. In this
line, we study bacterial division as a promising target for
the development of new antibiotics.
Research Lines
• Molecular epidemiology and evolution of pathogens
• Molecular methods for diagnostics of infectious disea-
ses
• Microbial genomics
• Biochemistry and molecular biology of bacterial cell
division
• Clinical Microbiology
Research Activity
Doctoral TheseS
Sotillo Torquemada A. Estructura fina de la población de Kle-
bsiella pneumoniae ST11 productora de OXA-48 del Hos-
pital Universitario La Paz determinada por secuenciación
genómica[dissertation]. Madrid: UAM: 2017(15/12/2017).
Director: Mingorance Cruz J.
PUBLICATIONS
• Aguilera A, Navarro D, Rodríguez-Frías F, Viciana I, Martínez-Sapina
AM, Rodríguez MJ, Martro E, Lozano MC, Coletta E, Cardenoso L,
Suárez A, Trigo M, Rodríguez-Granjer J, Montiel N, de la Iglesia A,
Alados JC,Vegas C, Bernal S, Fernández-Cuenca F, Peña MJ, Reina G,
García-Bujalance S, Echevarría MJ, Benítez L, Pérez-Castro S, Ocete
D, García-Arata I, Guerrero C, Rodríguez-Iglesias M, Casas P, García
F. Prevalence and distribution of hepatitis C virus genotypes in Spain
during the 2000-2015 period (the GEHEP 005 study). J Viral Hepa-
titis. 2017; 24(9): 725-32. Article. IF: 4.237; Q1
• Ares MA, Ríos-Sarabia N, de la Cruz MA, Rivera-Gutiérrez S, Gar-
cía-Morales L, León-Solis L, Espitia C, Pacheco S, Cerna-Cortés JF,
Helguera-Repetto AC, García MJ, González-y-Merchand JA. The
sigma factor SigD of Mycobacterium tuberculosis putatively enhan-
ces gene expression of the septum site determining protein under
stressful environments. New Microbiol. 2017; 40(3): 199-204. Arti-
cle. IF: 1.412; Q4
• Arroyo-Fajardo A, San Juan-Delgado MF, García-Rodríguez J. Can-
dida glabrata vaginitis: The great ignored? Rev Iberoam Micol. 2017;
34(4): 246. Letter. IF: 0.989; Q4
• Buey RM, Fernández-Justel D, Marcos-Alcalde I, Winter G, Gómez-
Puertas P, Pereda JM, Revuelta JL. A nucleotide-controlled confor-
mational switch modulates the activity of eukaryotic IMP dehydro-
genases. SCI Rep-Uk. 2017; 7: 2648. Article. IF: 4.122; Q1
150
• Cabrerizo M, Díaz-Cerio M, Muñoz-Almagro C, Rabella N, Tarrago
D, Romero MP, Peña MJ, Calvo C, Rey-Cao S, Moreno-Docón A,
Martínez-Rienda I, Otero A, Trallero G. Molecular epidemiology of
enterovirus and parechovirus infections according to patient age
over a 4-year period in Spain. J Med Virol. 2017; 89(3): 435-42. Arti-
cle. IF: 1.988; Q3
• Castón JJ, Lacort-Peralta I, Martín-Dávila P, Loeches B, Tabares S,
Temkin L, Torre-Cisneros J, Paño-Pardo JR. Clinical efficacy of cef-
tazidime/avibactam versus other active agents for the treatment of
bacteremia due to carbapenemase-producing Enterobacteriaceae in
hematologic patients. Int J Infect Dis. 2017; 59: 118-23. Article. IF:
3.202; Q2
• Cendejas-Bueno E, Forastiero A, Ruiz I, Mellado E, Gavalda J, Gó-
mez-López A. Blood and tissue distribution of posaconazole in a
rat model of invasive pulmonary aspergillosis. Diagn Micr Infec Dis.
2017; 87(2): 112-7. Article. IF: 2.341; Q3
• Dahdouh E, Gómez-Gil R, Sanz S, González-Zorn B, Daoud Z, Min-
gorance J, Suárez M. A novel mutation in pmrB mediates colistin re-
sistance during therapy of Acinetobacter baumannii. Int J Antimicrob
Ag. 2017; 49(6): 727-33. Article. IF: 4.253; Q1
• Dandouh E, Gómez-Gil R, Pacho S, Mingorance J, Daoud Z, Suárez
M. Clonality, virulence determinants, and profiles of resistance of
clinical Acinetobacter baumannii isolates obtained from a Spanish
hospital. Plos One. 2017; 12(4): e0176824. Article. IF: 2.766; Q1
• Espinel-Ingroff A, Arendrup M, Cantón E, Córdoba S, Dannaoui E,
García-Rodríguez J, González GM, Govender NP, Martín-Mazuelos
E, Lackner M, Lass-Florl C, Sicilia MJL, Rodríguez-Iglesias MA, Peláez
T, Shields RK, García-Effron G, Guinea J, Sanguinetti M, Turnidger J.
Multicenter study of method-dependent epidemiological cutoff va-
lues for detection of resistance in candida spp. and aspergillus spp.
to amphotericin B and echinocandins for the etest agar diffusion
Method. Antimicrob Agents Ch. 2017; 61(1): e01792-16. Article. IF:
4.255; Q1
• Falcés-Romero I, Alastruey-Izquierdo A, García-Rodríguez J. First
isolation of Conidiobolus sp in a respiratory sample of a patient in
Europe. Clin Microbiol Infec. 2017; 23(11): 834. Editorial Material. IF:
5.394; D1
• Fernández-Ruíz M, Guinea J, Lora-Pablos D, Zaragoza O, Puig-Asen-
sio M, Almirante B, Cuenca-Estrella M, Aguado JM, (García Rodrí-
guez J). Impact of fluconazole susceptibility on the outcome of pa-
tients with candidaemia: data from a population-based surveillance.
Clin Microbiol Infec. 2017; 23(9): 672.e1-11. Article. IF: 5.394; D1
• García-Bujalance S, Gutiérrez-Arroyo A, de la Calle F, Díaz-Menén-
dez M, Arribas JR, García-Rodríguez J, Arsuaga M. Persistence and in-
fectivity of Zika virus in semen after returning from endemic areas:
Report of 5 cases. J Clin Virol. 2017; 96: 110-5. Article. IF: 3.101; Q2
• Gutiérrez-Arroyo A, Falcés-Romero I, Corcuera-Pindado MT, Ro-
mero-Gómez MP. Bacteraemia in a two month-old infant. Enferm
Infec Micr Cl. 2017; 35(10):676-7. Editorial Material. IF: 1.707; Q3
• Lázaro-Perona F, Sarria-Visa A, Ruiz-Carrascoso G, Mingorance J,
García-Rodríguez J, Gómez-Gil R. Klebsiella pneumoniae co-produ-
cing NDM-7 and OXA-48 carbapenemases isolated from a patient
with prolonged hospitalisation. Int J Antimicrob Ag. 2017; 49(1): 112-
3. Letter. IF: 4.253; Q1
• Lora-Tamayo J, Senneville E, Ribera A, Bernard L, Dupon M, Zeller
V, Li HK, Arvieux C, Clauss M, Uckay I, Vigante D, Ferry T, Iribarren
JA, Peel TN, Sendi P, Miksic NG, Rodríguez-Pardo D, del Toro MD,
Fernández-Sampedro M, Dapunt U, Huotari K, Davis JS, Palomino
J, Neut D, Clark BM, Gottlieb T, Trebse R, Soriano A, Bahamonde A,
Guio L, Rico A, Salles MJC, Pais MJG, Benito N, Riera M, Gómez L,
Aboltins CA, Esteban J, Horcajada JP, O’Connell K, Ferrari M, Skali-
czki G, Juan RS, Cobo J, Sánchez-Somolinos M, Ramos A, Giannitsioti
E, Jover-Sáenz A, Baraia-Etxaburu JM, Barbero JM, Choong PFM, As-
seray N, Ansart S, Le Moal G, Zimmerli W, Ariza J. The not-so-good
prognosis of streptococcal periprosthetic joint infection managed
by implant retention: The results of a large multicenter study. Clin
Infect Dis. 2017; 64(12): 1742-52. Article. IF: 9.117; D1
• Marcos-Alcalde I, Mendieta-Moreno JI, Puisac B, Gil-Rodríguez MC, center study. Eur J Clin Microbiol. 2017; 36(10): 1757-65. Article. IF:
Hernández-Marcos M, Soler-Polo D, Ramos FJ, Ortega J, Pie J, Men- 2.537; Q2
dieta J, Gómez-Puertas P. Two-step ATP-driven opening of cohesin • Stella-Ascariz N, Arribas JR, Paredes R, Li JZ.The role of HIV-1 drug-
head. SCI Rep-Uk. 2017; 7: 3266. Article. IF: 4.122; Q1 resistant minority variants in treatment failure. J Infect Dis. 2017;
• Maseda E, Salgado P, Anillo V, Ruiz-Carrascoso G, Gómez-Gil R, Mar- 216: S847-50. Article. IF: 5.186; Q1
tín-Funke C, Giménez MJ, Granizo JJ, Aguilar L, Gilsanz F. Risk factors
• Stella-Ascariz N, Montejano R, Pintado-Berninches L, Monge S,
for colonization by carbapenemase-producing enterobacteria at ad-
Bernardino JI, Pérez-Valero I, Montes ML, Mingorance J, Perona R,
mission to a Surgical ICU: A retrospective study. Enferm Infec Micr
Arribas JR. Differential effects of tenofovir, abacavir, mmtricitabine,
Cl. 2017; 35(6): 333-7. Article. IF: 1.707; Q3
and darunavir on telomerase activity in vitro. JAIDS-J Acq Imm Def.
• Montejano R, Stella-Ascariz N, Monge S, Bernardino JI, Pérez-Valero
2017; 74(1): 91-4. Article. IF: 4.116; Q1
I, Montes ML, Valencia E, Martín-Carbonero L, Moreno V, González-
• Temkin E, Torre-Cisneros J, Beovic B, Benito N, Giannella M, Gi-
García J, Arnalich F, Mingorance J, Berniches LP, Perona R, Arribas JR.
larranz R, Jeremiah C, Loeches B, Machuca I, Jiménez-Martín MJ,
Impact of antiretroviral treatment containing tenofovir difumarate
Martínez JA, Mora-Rillo M, Navas E, Osthoff M, Pozo JC, Ramos
on the telomere length of Aviremic HIV-infected patients. JAIDS-J
JCR, Rodríguez M, Sánchez-García M, Viale P, Wolff M, Carmeli
Acq Imm Def. 2017; 76(1): 102-9. Article. IF: 4.116; Q1
Y. Ceftazidime-avibactam as salvage therapy for infections caused
• Moreno-García E, Rodríguez JG, Paño-Pardo JR. Optimizing antimi- by carbapenem-resistant organisms. Antimicrob Agents Ch. 2017;
crobial prescribing: a practical decalogue. Rev Esp Quim. 2017; 30: 61(2): e01964-16. Article. IF: 4.255; Q1
56-60. Article. IF: 0.605; Q4
• Toro C, Trevisi P, López-Quintana B, Amor A, Iglesias N, Subirats M,
• Nogueira CL, de Almeida LGP, Menéndez MC, García MJ, Digiampie- de Guevara CL, Lago M, Arsuaga M, de la Calle-Prieto F, Herrero
tri LA, Chimara E, Cnockaert M, Palomino JC, Portaels F, Martín A,
Vandamme P, Leao SC. Characterization of mycobacterium chelo-
D, Rubio M, Puente S, Baquero M. Imported Dengue infection in a
Spanish hospital with a high proportion of travelers from Africa: A
nae-like strains by comparative genomics. Front Microbiol. 2017; 8:
9-year retrospective study. Am J Trop Med Hyg. 2017; 96(3): 701-7.
789. Article. IF: 4.019; Q1
Article. IF: 2.564; Q2
• Otal I, Pérez-Herrán E, García-Morales L, Menéndez MC, González-
• Valencia-Ortega ME, García-Bujalance S, González-García J. Hepa-
y-Merchand JA, Martín C, García MJ. Detection of a putative TetR-
titis with a multiple etiology in HIV-positive men who have sexual
like gene related to mycobacterium bovis BCG growth in choles-
relations with other men. Rev Esp Enferm Dig. 2017; 109(11): 801.
terol using a GFP-transposon mutagenesis system. Front Microbiol.
Letter. IF: 1.632; Q4
2017; 8: 315. Article. IF: 4.019; Q1
• Yao YC, Lázaro-Perona F, Falgenhauer L, Valverde A, Imirzalioglu C,
• Oviedo Briones M, Rico A, Grados M. Minocycline induced hyper-
Domínguez L, Cantón R, Mingorance J, Chakraborty T. Insights into
pigmentation. Rev Esp Geriatr Gerontol. 2017; 52(6): 353-4-. Letter.
a novel bla(KPC-2)-encoding IncP-6 plasmid reveal carbapenem-
Not Indexed
• Puisac B, Teresa-Rodrigo ME, Hernández-Marcos M, Baquero-Mon-
resistance circulation in several enterobacteriaceae species from
wastewater and a hospital source in Spain. Front Microbiol. 2017; 8:
toya C, Gil-Rodríguez MC,Visnes T, Bot C, Gómez-Puertas P, Kaiser
1143. Article. IF: 4.019; Q1
FJ, Ramos FJ, Strom L, Pie J. mRNA quantification of NIPBL isoforms
A and B in adult and fetal human tissues, and a potentially pathologi-
cal variant affecting only isoform A in two patients with Cornelia de
Lange syndrome. Int J Mol Sci. 2017; 18(3): 481. Article. IF: 3.687; Q2
Public Projects
• Ramos-Martínez A, Vicente-López N, Sánchez-Romero I, Padilla B, Cendejas Bueno E. Contrato Juan Rodés (JR14/00027 ).
Merino-Amador P, Garnacho-Montero J, Ruiz-Camps I, Montejo M, ISCIII. 2015-2018.
Salavert M, Mensa J, Cuenca-Estrella M, (García Rodríguez J). Epide- Managment centre: FIBHULP
miology and prognosis of candidaemia in elderly patients. Mycoses.
2017; 60(12): 808-17. Article. IF: 2.793; Q1 Mingorance Cruz J. Análisis cuantitativo de la colonización
• Ríos Germán PP, Loeches Yagues B, Rico Nieto A. Long-standing intestinal por enterobacterias productoras de carbapenema-
painful genital ulcers in a patient with chronic lymphocytic leukae- sas (PI16/01209). ISCIII. 2017-2020.
mia. Rev Esp Geriatr Gerontol. 2017; 52(2): 103-4. Letter. Not In- Managment centre: FIBHULP
dexed
Mingorance Cruz J. Contrato de estabilización Ramón y Ca-
• Robustillo-Rodela A, Pérez-Blanco V, Ruiz MAE, Carrascoso GR,
jal (I3) (). ISCIII, CAM. 2011-2018.
Iglesias JCF, Martín DA. Successful control of 2 simultaneous out-
breaks of OXA-48 carbapenemase-producing Enterobacteriaceae Managment centre: FIBHULP
and multidrug-resistant Acinetobacter baumannii in an intensive Stella Ascariz N. Contrato predoctoral (FI14/00391). ISCIII.
care unit. Am J Infect Control. 2017; 45(12): 1356-62. Article. IF:
2015-2018.
1.929; Q2
Managment centre: FIBHULP
• Romero-Gómez MP, Cendejas-Bueno E, Rodríguez JG, Mingorance J.
Impact of rapid diagnosis of Staphylococcus aureus bacteremia from Stella Ascariz N. Movilidad predoctoral (MV16/00021 ).
positive blood cultures on patient management. Eur J Clin Microbiol. ISCIII. 2017.
2017; 36(12): 2469-73. Article. IF: 2.537; Q2 Managment centre: FIBHULP
• Rueda C, Puig-Asensio M, Guinea J, Almirante B, Cuenca-Estrella M,
Zaragoza O. Evaluation of the possible influence of trailing and para-
doxical effects on the clinical outcome of patients with candidemia. Private Projects
Clin Microbiol Infec. 2017; 23(1): e8. Article. IF: 5.394; D1
García Bujalance S. Detección de variantes minoritarias de
• San-Juan R, Pérez-Montarelo D,Viedma E, Lalueza A, Fortun J, Loza E,
Pujol M, Ardanuy C, Morales I, de Cueto M, Resino-Foz E, Morales-
mutaciones de resistencia del VIH-1 mediante pirosecuen-
Cartagena MA, Fernández-Ruiz M, Rico A, Romero MP, de Mera MF, ciación y evaluación de su impacto sobre la eficacia de los
López-Medrano F, Orellana MA, Aguado JM, Chaves F. Pathogen-re- tratamientos antirretrovirales. Laboratorios VIIV Healthcare
lated factors affecting outcome of catheter-related bacteremia due S.L. 2010-Ongoing.
to methicillin-susceptible Staphylococcus aureus in a Spanish multi- Managment centre: FIBHULP
151
 3
Information Groups by Area
3.3 Infectious Diseases and Immunity Area
García Bujalance S. Evaluación del rendimiento del ensa-
yo aptima HIV-1 quant para la detección y cuantificación del
HIV-1 en muestras de plasma. Hologic Deuschland GMBH.
2016-Ongoing.
Managment centre: FIBHULP
García Rodríguez J. Colaboración para el desarrollo de
proyectos especificos entre el grupo de investigación de mi-
crobiología molecular del IdiPAZ en contreto: el desarrollo
de soluciones en el ámbito de la microbiología molecular
para atención en el punto de necesidad (POC). Epistem Ltd.
2016-Ongoing.
Managment centre: FIBHULP
García Rodríguez J. Diágnostico de aspergilosis invasora me-
diante detección de ácidos nucleicos de aspergillus SPP en
sangre. Gilead Sciences S.L. 2011-Ongoing.
Managment centre: FIBHULP
García Rodríguez J. Estudio de la sensibilidad in vitro y si-
nergia de anidulafungina y voriconazol frente a aislamientos
clínicos de especies de aspergillus del Hospital Universitario
La Paz.Varios Investigadores. 2010-Ongoing.
Managment centre: FIBHULP
García Rodríguez J. Estudio poblacional de las especies de
candida invasoras. Astellas Pharma S.A. 2010-Ongoing.
Managment centre: FIBHULP
García Rodríguez J. Evaluation infectious diseases panel en
cobas e801. Roche Diagnostics S.L. 2017-Ongoing.
Managment centre: FIBHULP
García Rodríguez J. Identificación de aspergillus a través del
sistema Malditof. Maldifumi. Varios Investigadores. 2012-On-
going.
Managment centre: FIBHULP
García Rodríguez J. Utilidad de la espectrometría de masas
Maldi-Tof para la tipificacion rapida de aislados microbiológi-
cos. Maldi-Tof. 2017-Ongoing.
Managment centre: FIBHULP
Gómez-Gil Mira MR. Aislamiento, identificación, estudio de
sensibilidad, control de calidad y envio al laboratorio central
de enterobacterias productoras de carbapenemasas. Astraze-
neca Farmacéutica Spain S.A. 2016-Ongoing.
Managment centre: FIBHULP
Gómez-Gil Mira MR. In vitro activities of ceftaroline, dap-
tomycin, linezolid, and vancomycin against bacteremic methi-
cillin-resistant staphylococcus aureus isolates. Astrazeneca
Farmaceutica Spain S.A. 2013-Ongoing.
Managment centre: FIBHULP
Mingorance Cruz J. Aplicación de los métodos de tipado ge-
nómico y molecular a la elaboración del mapa microbiológico
del Hospital Universitario La Paz. Epistem Ltd. 2012-Ongoing.
Managment centre: FIBHULP
Mingorance Cruz J. Desarrollo de un dispositivo lab on a
chip para la detección en POCT (points of care testing) de
la resistencia a antibióticos de muestras de orina. Diagnochip
SPA. 2014-Ongoing.
Managment centre: FIBHULP
Mingorance Cruz J. Identificación y caracterización de pa-
tógenos con interés intrahospitalario bajos sistemas auto-
matizables con potencial implantación hospitalaria. Biotools-
152
Biotechnological Medical Laboratori. 2009-Ongoing.
Managment centre: FIBHULP
Mingorance Cruz J. IDI-20101176-kits de diagnóstico basa-
dos en pirosecuenciación. Varios Investigadores. 2011-On-
going.
Immuno-Rheumatology Group
Managment centre: FIBHULP
Mingorance Cruz J. La utilidad clínica de Septifast para el
diagnóstico de sepsis en pacientes nefrológicos. Roche Diag-
nostics S.L. 2010-Ongoing.
Managment centre: FIBHULP
Mingorance Cruz J. Molecular epidemiology of resistance to
linezolid in gram positive cocci in a tertiary hospital. Varios
Investigadores. 2009-Ongoing.
Managment centre: FIBHULP
Mingorance Cruz J. SEPTIDRIVE. Development and evalua-
tion of a new sepsis test.Varios Investigadores. 2012-Ongoing.
Managment centre: FIBHULP
Mingorance Cruz J. Validación clínica de un biosensor
para la identificación de streptococcus pneumoniae. CSIC.
2013-Ongoing.
Managment centre: FIBHULP
Toro Rueda C. Evaluación del rendimiento de una prueba
en el punto de atencion (POCT) de QPCR para diagnóstico 29 110.828 10
biológico. Arcis Biotechnology Holdings Ltd. 2012-Ongoing.
Managment centre: FIBHULP
Toro Rueda C. Evaluación del rendimiento de una prueba en
el punto de atencion (POCT) de QPCR para el diagnóstico María Eugenia Miranda Carús. Facultativo Especialista Chamaida Plasencia Rodríguez. Facultativo Especialista de Área
microbilógico. Epistem Ltd. 2012-Ongoing. de Área en Reumatología. HULP. en Reumatología. HULP
Managment centre: FIBHULP Pilar Aguado Acín. Facultativo Especialista de Área en Alejandro Villalba Yllán. Facultativo Especialista de Área en
Reumatología. HULP Reumatología. HULP
INTERNATIONAL Projects Alejandro Balsa Criado. Jefe de Sección de Reumatología. HULP.
Mingorance Cruz J. Optomechanics for virology (VIRUS-
Profesor Asociado. Facultad de Medicina. UAM
María Gema Bonilla Hernán. Facultativo Especialista de Área
Strategic Objective
CAN). EU. 2016-2021. en Reumatología. HULP Our objective is to investigate the pathogenesis of
Managment centre: FIBHULP rheumatic diseases, specifically focusing on genetics,
Ana Castilla Plaza. Facultativo Especialista de Área en
metabolic pathways and immunopathogenesis.
Mingorance Cruz J. European gram negative antibacterial Reumatología. HULP
engine (ENABLE). GlaxoSmithKline. 2014-2020. Eugenio de Miguel Mendieta. Facultativo Especialista de Área
Managment centre: FIBHULP en Reumatología. HULP Research Lines
Paula Fortea Gordo. Investigadora Predoctoral. HULP
• Immunopathogenesis and genetics of inflammatory
Sara García Carazo. Facultativo Especialista de Área en
Patents and Trademarks Reumatología. HULP
and autoimmune arthritis
• Imaging of inflammatory and autoimmune arthritis
Vicente Muñoz M, Mingorance Cruz J, Rueda González MS, Francisco de Borja Hernández Breijo. Investigador • Immunopathogenesis and genetics of osteoporosis
inventors; CSIC, assignee. Method for determining state of Postdoctoral. HULP • Immunogenicity of biological therapies with mo-
growth and viability of bacterial FTsZ population, whether
Emilio Martín Mola. Jefe de Servicio de Reumatología. HULP. noclonal antibodies
natural or cultivated, is based on determining existence of
Profesor Asociado. Facultad de Medicina. UAM
FTsZ rings in actively growing individual cells. P200200370;
Ana Martínez Feíto. Investigadora Predoctoral. HULP
Research Activity
2002 February 15.
Irene Monjo Henry. Facultativo Especialista de Área en
Mingorance Cruz J, Castán García P, Franco de Sarabia
Reumatología. HULP
Rosado PM, inventors; BIOTOOLS BIOTECHNOLOGICAL
María Victoria Navarro Compán. Facultativo Especialista de
Doctoral TheseS
& MEDICAL LABORATORIES S.A., assignee. Composition,
method and kit for detecting bacteria by means of sequen- Área en Reumatología. HULP Castillo Gallego MC. Diagnostic imaging techniques
cing. PCT/ES2009/000507, EP2492352, US2013157265, Laura Nuño Nuño. Médico Adjunto Interino en Reumatología. and predictive factors in spondyloarthritis and psoriatic
CA2775273, MX2012004627; 2009 October 22. HULP arthritis[dissertation]. Madrid: UAM: 2017(12/06/2017).
María Dora Pascual-Salcedo Pascual. Químico Adjunto en Directors: de Miguel E, McGonnagle D,
Mingorance Cruz J, Castán García P, Franco de Sarabia
Inmunología. HULP Marzo-Ortega H.
Rosado PM, inventors; 2B BLACKBIO S.L., assignee. Compo-
sition, method and kit for detecting fungi and yeasts by means Diana Peiteado López. Facultativo Especialista de Área en Plasencia Rodríguez C. Immunogenicity of biological
of sequencing. PCT/ES2010/000248; 2010 June 02. Reumatología. HULP drugs in inflammatory rheumatic disease: Clinical rele-
153
 3
Information Groups by Area
3.3 Infectious Diseases and Immunity Area
vance and therapeutic drug monitoring[dissertation]. Madrid:
UAM: 2017(14/06/2017).
Directors: Balsa A, Wolbink G.
PUBLICATIONS
• Ara-Martín M, Pinto PH, Pascual-Salcedo D. Impact of immunogeni-
city on response to anti-TNF therapy in moderate-to-severe plaque
psoriasis: results of the PREDIR study. J Dermatol Treat. 2017; 28(7):
606-12. Article. IF: 2.144; Q2
• Bautista-Caro MB, de Miguel E, Peiteado D, Plasencia-Rodríguez C,
Villalba A, Monjo-Henry I, Puig-Kroger A, Sánchez-Mateos P, Mar-
tín-Mola E, Miranda-Carús ME. Increased frequency of circulating
CD19+CD24(hi) CD38(hi) B cells with regulatory capacity in pa-
tients with Ankylosing spondylitis (AS) naive for biological agents.
Plos One. 2017; 12(7): e0180726. Article. IF: 2.766; Q1
• Castillo-Gallego C, de Miguel E, García-Arias M, Plasencia C, Lojo-
Oliveira L, Martín-Mola E. Color Doppler and spectral Doppler
ultrasound detection of active sacroiliitis in spondyloarthritis com-
pared to physical examination as gold standard. Rheumatol Int. 2017;
37(12): 2043-7. Article. IF: 1.952; Q4
• de Miguel E, Pecondon-Español A, Castaño-Sánchez M, Corrales A,
Gutiérrez-Polo R, Rodríguez-Gómez M, Pinto-Tasende JA, Rivas J,
Ivorra-Cortes J. A reduced 12-joint ultrasound examination pre-
dicts lack of X-ray progression better than clinical remission criteria
in patients with rheumatoid arthritis. Rheumatol Int. 2017; 37(8):
1347-56. Article. IF: 1.952; Q4
• Dougados M, Sepriano A, Molto A, van Lunteren M, Ramiro S, de
Hooge M, van den Berg R, Compán VN, Demattei C, Landewe R, van
der Heijde D. Sacroiliac radiographic progression in recent onset
axial spondyloarthritis: the 5-year data of the DESIR cohort. Ann
Rheum Dis. 2017; 76(11): 1823-8. Article. IF: 12.35; D1
• Dreesen E, Bossuyt P, Mulleman D, Gils A, Pascual-Salcedo D. Practi-
cal recommendations for the use of therapeutic drug monitoring of
biopharmaceuticals in inflammatory diseases. Clin Pharmacol. 2017;
9: 101-11. Review. Not Indexed
• Fautrel B, Balsa A, Van Riel P, Casillas M, Capron JP, Cueille C, de la
Torre I. Influence of route of administration/drug formulation and
other factors on adherence to treatment in rheumatoid arthritis
(pain related) and dyslipidemia (non-pain related). Curr Med Res
Opin. 2017; 33(7): 1231-46. Review. IF: 2.665; Q1
• Fernández-Carballido C, Navarro-Compán V, Castillo-Gallego C,
Castro-Villegas MC, Collantes-Estévez E, de Miguel E. Disease ac-
tivity as a major determinant of quality of life and physical function
in patients with early axial spondyloarthritis. Arthrit Care Res. 2017;
69(1): 150-5. Article. IF: 4.149; Q2
• Joven BE, Navarro-Compán V, Rosas J, Dápica PF, Zarco P, de Miguel
E. Diagnostic value and validity of early spondyloarthritis features:
Results from a National Spanish Cohort. Arthrit Care Res. 2017;
69(6): 938-42. Article. IF: 4.149; Q2
• Kneepkens E, van den Oever IAM, Plasencia CH, Pascual-Salcedo D,
de Vries A, Hart M, Nurmohamed MT, Balsa A, Rispens T, Wolbink G.
Serum tocilizumab trough concentration can be used to monitor
systemic IL-6 receptor blockade in patients with rheumatoid arthri-
tis: a prospective observational cohort study. Scand J Rheumatol.
2017; 46(2): 87-94. Article. IF: 3.021; Q3
• López-Mejías R, Corrales A, Vicente E, Robustillo-Villarino M,
González-Juanatey C, Llorca J, Genre F, Remuzgo-Martínez S, Diers-
sen-Sotos T, Miranda-Filloy JA, Huaranga MAR, Pina T, Blanco R,
Alegre-Sancho JJ, Raya E, Mijares V, Ubilla B, Ferraz-Amaro I, Gómez-
Vaquero C, Balsa A, López-Longo FJ, Carreira P, González-Álvaro I,
Ocejo-Vinyals JG, Rodríguez-Rodríguez L, Fernández-Gutiérrez B,
Castañeda S, Martín J, González-Gay MA. Influence of coronary ar-
tery disease and subclinical atherosclerosis related polymorphisms
on the risk of atherosclerosis in rheumatoid arthritis. SCI Rep-Uk.
2017; 7: 40303. Article. IF: 4.122; Q1
154
• Márquez A,Vidal-Bralo L, Rodríguez-Rodríguez L, González-Gay MA,
Balsa A, González-Álvaro I, Carreira P, Ortego-Centeno N, Ayala-
Gutiérrez MM, García-Hernández FJ, González-Escribano MF, Sabio
JM, Tolosa C, Suárez A, González A, Padyukov L, Worthington J,Vyse
T, Alarcón-Riquelme ME, Martín J. A combined large-scale meta-
analysis identifies COG6 as a novel shared risk locus for rheuma-
toid arthritis and systemic lupus erythernatosus. Ann Rheum Dis.
2017; 76(1): 286-94. Article. IF: 12.35; D1
• Medina F, Plasencia C, Goupille P, Paintaud G, Balsa A, Mulleman D.
Current practice for therapeutic drug monitoring of biopharma-
ceuticals in spondyloarthritis. Ther Drug Monit. 2017; 39(4): 360-3.
Article. IF: 2.092; Q2
• Medina F, Plasencia C, Goupille P, Ternant D, Balsa A, Mulleman D.
Current practice for therapeutic drug monitoring of biopharmaceu-
ticals in rheumatoid arthritis. Ther Drug Monit. 2017; 39(4): 364-9.
Article. IF: 2.092; Q2
• Murias S, Magallares L, Albizuri F, Pascual-Salcedo D, Dreesen E,
Mulleman D. Current practices for therapeutic drug monitoring of
biopharmaceuticals in pediatrics.Ther Drug Monit. 2017; 39(4): 370-
8. Article. IF: 2.092; Q2
• Navarro-Compán V, Plasencia-Rodríguez C, de Miguel E, Díaz del
Campo P, Balsa A, Gratacos J. Switching biological disease-modifying
antirheumatic drugs in patients with axial spondyloarthritis: re-
sults from a systematic literature review. RMD Open. 2017; 3(2):
e000524. Article. Not Indexed
• Paintaud G, Passot C, Ternant D, Bertolotto A, Bejan-Angoulvant T,
Pascual-Salcedo D, Mulleman D. Rationale for therapeutic drug mo-
nitoring of biopharmaceuticals in inflammatory diseases. Ther Drug
Monit. 2017; 39(4): 339-43. Article. IF: 2.092; Q2
• Peiteado D, Villalba A, Martín-Mola E, Balsa A, de Miguel E. Ultra-
sound sensitivity to changes in gout: a longitudinal study after two
years of treatment. Clin Exp Rheumatol. 2017; 35(5): 746-51. Article.
IF: 3.201; Q2
• Ramos-Remus C, Barajas-Ochoa A, Ramírez-Gómez A, Castillo-
Ortiz JD, Brambila-Barba V, Adebajo AO, Espinoza LR, Aceves-Ávila
FJ, Sánchez-González JM, Boudersa N, Slimani S, Ladjouze-Rezig A,
Díaz MP, Kirmayr KI, Asnal CA, Catoggio LJ, Citera G, Casado GC,
Álvarez AP, Pisoni CN, Benavente E, López-Cabanillas A, Báez RM,
Pons-Estel BA, Sacnun MP, Cavallasca JA, Paniego RH, Proudman
SM, Thomas R, Major G, Mathers DM, Schrieber L, Islam N, Haq
SA, Dessein PH, von Muhlen CA, Bianchi WA, Castelar-Pinheiro
GD, Feldman-Pollak D, Cossermelli W, Bonfiglioli KR, Giorgi RD,
Zabsonre-Tiendrebeogo WJ, Olaru L, Karsh J, Castro-Esparza IH,
Fuentealba C, Aguilera S, Burgos PI, Neira O, Li ZG, Tam LS, Mok
MY, Medina YF, Zúñiga-Vera AE, Moreno-Álvarez MJ, Vera C, Queza-
da I, Moreno IM, Calapaqui W, El-Mardenly G, Salama MS, Ragab G,
Gado K, Hadidi T, Leirisalo-Repo M, Tuompo R, Koivuniemi R, Be-
renbaum F, Allanore Y, Constantin A, Buttgereit F, Schulze-Koops H,
Liz M, Dey D, Santiago-Pastelin CB, Alonzo-Borjas HD, Cuellar-Cruz
V, Dharmanand BG, Yathish GC, Akerkar SM, Malaviya AN, Ahmad-
zadeh A, Hasunuma T, Owino BO, Pacheco-Tena C, Frausto-Arenas
A, de la Madrid-Cernas AA, Cardona-Cabrera R, Centeno-Valadez
JD, Rodríguez-Torres IM,Vaidya B, Gupta AK, Harrison AA, Grainger
R, Nwankwo HM, Diamantopoulos AP, Maeland E, Besada E, Go-
rriz L, Duarte M, Cabrera-Villalba S, Albrecht MTRD, García-Poma
A, Segami MI, Ramos MP, Perez-Medina W, Dianongco ML, Lichauco
JJ, Racaza GZ, Navarra SV, Torralba TP, Manapat-Reyes BH, Penserga Sieper J, Sampaio-Barros P, Wiek D, Braun J. 2016 update of the
EG, Hammoudeh M, Al-Emadi S, Botchkova AG, AlSaeedi SH, Almoa- ASAS-EULAR management recommendations for axial spondyloar-
llim H, Al-Arfaj HF, Koh WH, Leung YY, Whitelaw DA, Hodkinson B, thritis. Ann Rheum Dis. 2017; 76(6): 978-91. Review. IF: 12.35; D1
García-Miguel J, Duro JC, Martín-Mola E, Ahijon-Lana M, Andreu JL, • van Schie KA, Heer POD, Kruithof S, Plasencia C, Jurado T, Salcedo
Finckh A, Alpizar-Rodríguez D, Osiri M, Kasitanon N, Louthrenoo DP, Brandse JF, d’Haens GRAM,Wolbink GJ, Rispens T. Infusion reac-
W, van Vollenhoven RF, de Vries N, van Denderen C, Gerritsen M, tions during infliximab treatment are not associated with IgE anti-
Jansen TL, van Riel P, Núñez-Sotelo CM, Villegas-Morales S. Latitu- infliximab antibodies.Ann Rheum Dis. 2017; 76(7): 1285-8.Article. IF:
de gradient influences the age of onset of rheumatoid arthritis: a 12.35; D1
worldwide survey. Clin Rheumatol. 2017; 36(3): 485-97. Article. IF:
• Vargas RR, Madrid EM, Rodríguez CG, Sarabia FN, Quesada CD, Ari-
2.141; Q3
za RA, Compán VN. Association between serum dickkopf-1 levels
• Regueiro C, Nuño L, Ortiz AM, Peiteado D, Villalba A, Pascual-Sal- and disease duration in axial spondyloarthritis. Reumatol Clin. 2017;
cedo D, Martínez-Feito A, González-Álvaro I, Balsa A, González A. 13(4): 197-200. Article. Not Indexed
Value of measuring anti-carbamylated protein antibodies for clas-
• Wilburn J, McKenna SP, Kutlay A, Bender T, Braun J, Castillo-Gallego
sification on early arthritis patients. SCI Rep-Uk. 2017; 7: 12023.
C, Favero M, Geher P, Kiltz U, Martín-Mola E, Ramonda R, Rouse M,
Article. IF: 4.122; Q1
Tennant A, Kucukdeveci AA. Adaptation of the osteoarthritis-speci-
• Reinisch W, Jahnsen J, Schreiber S, Danese S, Panes J, Balsa A, Park W, fic quality of life scale (the OAQoL) for use in Germany, Hungary,
Kim J, Lee JU,Yoo DH. Evaluation of the cross-reactivity of antidrug Italy, Spain and Turkey. Rheumatol Int. 2017; 37(5): 727-34. Article. IF:
antibodies to CT-P13 and Infliximab reference product (Remicade):
1.952; Q4
An analysis using immunoassays tagged with both agents. Biodrugs.
• Zamarrón-de Lucas E, Carrera LG, Bonilla G, Petit D, Mangas A,
2017; 31(3): 223-7. Article. IF: 3.825; Q1
Álvarez-Sala R. Antisynthetase syndrome: Analysis of 11 cases. Med
• Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Clin-Barcelona. 2017; 148(4): 166-9. Editorial Material. IF: 1.168; Q3
Lula S, Hawes C, Kola B, Marshall L. Immunogenicity of biologics in
chronic inflammatory diseases: A systematic review. Biodrugs. 2017;
31(4): 299-316. Review. IF: 3.825; Q1 Public Projects
• Terslev L, Iagnocco A, Bruyn GAW, Naredo E, Vojinovic J, Collado
de Miguel Mendieta E. Curso natural y factores predictivos
P, Damjanov N, Filer A, Filippou G, Finzel S, Gandjbakhch F, Ikeda K,
de la espondiloartritis de inicio (PI13/02034). ISCIII. 2014-
Keen HI, Kortekaas MC, Magni-Manzoni S, Ohrndorf S, Pineda C,
Ravagnani V, Richards B, Sahbudin I, Schmidt WA, Siddle HJ, Stoenoiu 2017.
MS, Szkudlarek M, Tzaribachev N, D’Agostino MA, (de Miguel E). Managment centre: FIBHULP
The OMERACT ultrasound group: A report from the OMERACT
2016 meeting and perspectives. J Rheumatol. 2017; 44(11): 1740-3. Miranda Carús ME. Frecuencia, fenotipo y función de las cé-
lulas B reguladoras (BREG) en pacientes con artritis reuma-
Article. IF: 3.47; Q2
toide (AR) preclínica, temprana y establecida (PI16/01189).
• Torices S, Álvarez-Rodríguez L, Varela I, Muñoz P, Balsa A, López-
ISCIII. 2017-2020.
Hoyos M, Martínez-Taboada V, Fernández-Luna JL. Evaluation of
Managment centre: FIBHULP
Toll-like-receptor gene family variants as prognostic biomarkers
in rheumatoid arthritis. Immunol Lett. 2017; 187: 35-40. Article. IF:
2.436; Q3
• van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van
den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud
H, Dougados M, van Gaalen F, Geher P, van der
Horst-Bruinsma I, Inman RD, Jongkees M,
Kiltz U, Kvien TK, Machado PM, Marzo-
Ortega H, Molto A, Navarro-Compán
V, Ozgocmen S, Pimentel-Santos
FM, Reveille J, Rudwaleit M,
155
 3
Information Groups by Area
3.3 Infectious Diseases and Immunity Area
Miranda Carús ME. Frecuencia, fenotipo y función de las cé-
lulas T helper foliculares en sangre periférica de pacientes
con artritis reumatoide (PI13/00084). ISCIII. 2014-2017.
Managment centre: FIBHULP
Miranda Carús ME. Red de Investigación en Inflamación y
Enfermedades Reumaticas (RIER) (RD12/0009/0012). ISCIII.
2013-2017.
Managment centre: FIBHULP
Pascual-Salcedo Pascual MD. Desarrollo y validación de
herramientas para la monitorización del tratamiento de la
enfermedad inflamatoria intestinal con fármacos biológicos
(IBD-monitor). (RTC-2015-4004-1). MINECO. 2015-2018.
Managment centre: FIBHULP
Plasencia Rodríguez C. Identificación precoz de respues-
ta clínica a la terapia anti-TNF en la artritis reumatoide
(PI16/00474). ISCIII. 2017-2020.
Managment centre: FIBHULP
Private Projects
Aguado Acín P. Caracterización e historia natural de la hi-
pofosfatasia en pacientes adultos con confirmación genética
frente a pacientes con fosfatasa alcalina baja y test genéti-
co negativo. Hipofosfatasia del adulto. Aguado Acín PI-2995.
2017-Ongoing.
Managment centre: FIBHULP
Balsa Criado A. Actualización y renovación de la actividad
investigadora en el Servicio de Reumatologia del Hospital
Universitario La Paz.Varios. 2016-Ongoing.
Managment centre: FIBHULP
Balsa Criado A. Desarrollo de biochips para monitorización
de infliximab y la presencia de anticuerpos frente a infliximab
en sangre. PI-2629 Dr.Balsa. 2017-Ongoing.
Managment centre: FIBHULP
Balsa Criado A. Estudio de las comorbilidades en la artritis
reumatoide. Roche Farma S.A. 2011-Ongoing.
Managment centre: FIBHULP
Balsa Criado A. Estudio para determinar la correlación entre
la calprotectina sérica y la actividad de la artritis reumatoide.
Arepaz. 2010-Ongoing.
Managment centre: FIBHULP
Balsa Criado A. Preceptorship de investigación: Individuali-
zed medicine: anti-TFN monitoring and clinical practice. Pro-
teomika S.L. 2013-Ongoing.
Managment centre: FIBHULP
Balsa Criado A. Preceptorship del Servicio de Reumatologia
del HULP dirigido a reumatólogos. Dr. Balsa-Novartis Argen-
tina. 2017-Ongoing.
Managment centre: FIBHULP
Balsa Criado A. Preceptorship excelencia en reumatología.
Synergy Medical Comunications LTD. 2013-Ongoing.
Managment centre: FIBHULP
Balsa Criado A. Relación entre los niveles de fármaco circu-
lante, la aparición de anticuerpos anti idiotipo y la respuesta
clínica, en pacientes con enfermedades articulares inflama-
torias (artritis reumatoide, artritis idiopática juvenil, artritis
psoriática). Pfizer S.L.U. 2011-Ongoing.
156
Managment centre: FIBHULP
de Miguel Mendieta E. Carga de la enfermedad en pacientes
con espondiloartritis de reciente comienzo. Assessment In
Spondyloarthritis International Society. 2014-Ongoing.
Managment centre: FIBHULP
Martín Mola E. Estudio COP. Arepaz. 2007-Ongoing.
Managment centre: FIBHULP
Martín Mola E. Formación en investigación en el área de in-
munología/reumatología. Jannsen Cilaj-Bélgica. 2014-Ongoing.
Managment centre: FIBHULP
Martín Mola E. Formación en investigación en pacientes
con artritis de reciente comienzo, factores diagnósticos y
pronósticos a tener en cuenta. Bristol Myers Squibb S.A.U.
2016-Ongoing.
Managment centre: FIBHULP
Martín Mola E. Preceptorship excelencia en reumatología.
Janssen Cilag S.A Colombia. 2012-Ongoing.
Managment centre: FIBHULP
Martín Mola E. Preceptoship on immunogenicity. Pfizer APS.
2014-Ongoing.
Managment centre: FIBHULP
Martín Mola E. Proyecto COP. Hoffman La Roche. 2010-On-
going.
Managment centre: FIBHULP
Miranda Carús Me. Frequency and function of B cells with
regulatory capacity present in the peripheral blood and syno-
vial tissues of RA patients. Roche Farma S.A. 2009-Ongoing.
Managment centre: FIBHULP
Pascual-Salcedo Pascual MD. Estudio de los niveles de fár-
macos biológicos en la cohorte española con enfermedades
inflamatorias sistémicas. Establecimiento de los rangos tera-
péuticos óptimos.Varios. 2015-Ongoing.
Managment centre: FIBHULP
Pascual-Salcedo Pascual MD. Identificación precoz de bue-
nos respondedores primarios a las terapias biológicas en
la psoriasis moderada a grave. Novartis Farmaceutica S.A.
2014-Ongoing.
Managment centre: FIBHULP
Pascual-Salcedo Pascual MD. Relación entre los niveles de
fármaco circulantes, la aparición de anticuerpos anti idiotipo
y la respuesta clínica, en pacientes con artritis reumatoide
tratados con biológicos anti-TNF. 2008-Ongoing.
Managment centre: FIBHULP
CLINICAL TRIALS
Balsa Criado A. Ensayo de fase II, exploratorio, aleatorizado,
en doble ciego y con doble simulación, controlado con place-
bo y con producto activo, para evaluar la eficacia y la seguri-
dad de la aplicación tópica de GRT7019 en sujetos con dolor
crónico por gonartrosis. Type: Clinical Trial, phase II.
HULP code: 4819. Sponsored´s protocol code: KF7019-01.
Sponsored by: Grünenthal GMBH.
Signed date: 06/07/2017
Balsa Criado A. Ensayo de fase IV, aleatorizado, doble cie-
go, controlado con placebo y de grupos paralelos para eva-
luar la eficacia y la seguridad de golimumab (MK-8259 [SCH
900259]) tras la retirada del tratamiento, en comparación
con su continuación (pauta completa o reducida), en sujetos
con espondiloartritis axial no radiológica. Type: Clinical Trial,
phase IV.
HULP code: 4859. Sponsored´s protocol code: 8259-038.
Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 14/06/2017
Balsa Criado A. Ensayo fase IIIb, aleatorizado, doble ciego
para evaluar la eficacia y seguridad de abatacept SC en com-
binación con metotrexato comparado con metotrexato en
monoterapia para conseguir la remisión clínica en adultos
con artritis reumatoide temprana sin tratamiento previo con
metotrexato. Type: Clinical Trial, phase IIIb.
HULP code: ANEXO-II 4470. Sponsored´s protocol code: IM101-550.
Sponsored by: Bristol Myers Squibb International Corpora-
tion.
Signed date: 03/05/2017
Balsa Criado A. Estudio abierto de seguimiento a largo plazo
de CP-690, 550, un inhibidor de la janus quinasa 3 moderada-
mente selectivo, para el tratamiento de la artritis reumatoide.
Type: Clinical Trial, phase II.
HULP code: ANEXO-IV 2372. Sponsored´s protocol code: A3921024.
Sponsored by: Pfizer S.L.U.
Signed date: 28/02/2017
Balsa Criado A. Estudio de fase IIB multicéntrico, aleatori-
zado, doble ciego, controlado con placebo, de intervalos de
dosis y grupos paralelos, para evaluar la eficacia y la seguridad
de bimekizumab en pacientes con espondilitis anquilosante
activa. Type: Clinical Trial, phase II.
HULP code: 4788. Sponsored´s protocol code: AS0008.
Sponsored by: UCB Biosciencies GMBH.
Signed date: 13/03/2017
Balsa Criado A. Estudio de fase III, aleatorizado, con com-
parador activo, doble ciego para comparar ABT-494 con
abatacept en sujetos con artritis reumatoide de actividad
moderada a grave con respuesta insuficiente o intoleran-
cia a los farme biológicos (Farmeb) en tratamiento estable
con fármacos antirreumáticos modificadores de la enfer-
medad sintéticos convencionales (Farmesc). Type: Clinical
Trial, phase III.
HULP code: 4868. Sponsored´s protocol code: M15-925.
Sponsored by: Abbvie Deutschland GMBH.
Signed date: 21/11/2017
Balsa Criado A. Estudio en fase I/III, aleatorizado y de grupos
paralelos para evaluar la eficacia, la farmacocinética y la segu-
ridad de CT-P13 subcutáneo y CT-P13 intravenoso en pacien-
tes con artritis reumatoide activa. Type: Clinical Trial, phase I.
HULP code: 4825. Sponsored´s protocol code: CT-P13 3.5.
Sponsored by: Celltrion Inc.
Signed date: 30/05/2017
Balsa Criado A. Estudio fase IIA, aleatorizado, doble-ciego,
paralelo, controlado con placebo y naproxeno para evaluar
la eficacia analgésica de ASP7962 en pacientes con dolor se-
cundario a osteoartritis en rodilla. Type: Clinical Trial, phase II.
HULP code: ANEXO-II 4561.
Sponsored´s protocol code: 7962-CL-0022.
Sponsored by: Astellas Pharma Europe B.V.
Signed date: 30/07/2017
Balsa Criado A. Estudio fase IIA, aleatorizado, doble-ciego,
paralelo, controlado con placebo y naproxeno para evaluar
la eficacia analgésica de ASP7962 en pacientes con dolor se-
cundario a osteoartritis en rodilla. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4561.
Sponsored´s protocol code: 7962-CL-0022.
Sponsored by: Astellas Pharma Europe B.V.
Signed date: 16/01/2017
Balsa Criado A. Estudio retrospectivo sobre la eficacia en
práctica clínica de golimumab tras el fracaso de un primer
anti-TNF-a en pacientes con espondiloartritis. Go-Beyond
Spain. Type: EPA-OD.
HULP code: PI-2706. Sponsored´s protocol code: MSD-
GOL-2016-01.
Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 08/05/2017
Patents and Trademarks
Pascual-Salcedo Pascual MD, Balsa Criado A, Plasencia
Rodríguez C, authors; FIBHULP, assignee. Trademark name:
BioDrug Analysis BIDA. CM 13.808.531, 2015 March 10.
157
 3
Information Groups by Area
3.3 Infectious Diseases and Immunity Area
Innate Immune Response Group
30 180.84 18
Eduardo Manuel López-Collazo. Director Científico de
IdiPAZ. Investigador Senior (Contrato Miguel Servet - II). Jefe de
Laboratorio. HULP
Luis Augusto Aguirre Pérez. Investigadora Postdoctoral. HULP
Susana Alemany de la Peña. Investigadora Senior. Jefe de
Laboratorio. IIB Alberto Sols
José Avendaño Ortiz. Ayudante de Investigación. HULP
José Manuel Baena Martínez. Investigador Asociado. Universidad
de Granada
Lisardo Boscá Gomar. Investigador Senior. Jefe de Laboratorio. IIB
Alberto Sols
Ramón Cantero Cid. Facultativo Especialista de Área en Cirugía
General y de Aparato Digestivo. HULP
José Germán Casas Martín. Investigador Predoctoral. HULP
Antonio Castrillo Viguera. Investigador Senior. Jefe de
Laboratorio. IIB Alberto Sols
María Fernández Velasco. Investigadora Senior (Contrato Miguel
Servet- Tipo I). IIB Alberto Sols
Paloma Gómez Campelo. Investigadora Postdoctoral. HULP
Santiago Gómez Ruiz. Profesor Titular. Universidad Rey Juan Carlos
María Susana Guerra García. Investigadora Postdoctoral. UAM
Charbel Antonio Maroun Eid. Facultativo Especialista de Área
en Urgencias. Hospital del Norte
Eduardo Martín Arranz. Facultativo Especialista de Área en
Gastroenterología. HULP
María Dolores Martín Arranz. Jefa de Sección. HULP. Profesora
Asociada. UAM
Paloma Martín Sanz. Investigadora Senior. Jefe de Laboratorio. IIB
Alberto Sols
Aurora Muñoz Jiménez. Técnico de Laboratorio. HULP
Rebeca Pérez de Diego. Investigadora Senior (Contrato Ramón y
Cajal). HULP
158
Sanjiv Prashar. Profesor Titular. Universidad Rey Juan Carlos
Victor Manuel Toledano Real. Técnico de Laboratorio (Contrato de
Técnico de Apoyo). HULP
Aníbal Ramón Varela Serrano. Técnico de Laboratorio. HULP
Strategic Objective
This group focuses on the study of the reprogramming
of the innate immune response in the context of in-
flammatory diseases (e.g., sepsis, cystic fibrosis, acute
coronary syndrome, lung cancer) using the description
of the various molecular mechanisms that underlie the
reprogramming of monocytes/macrophages during re-
fractory states.
The innate immune response is activated in various
clinical contexts that can be modelled in vitro. The ini-
tial reaction of the Innate Immune System is marked
by an inflammatory response that is similar in different
contexts.
However, after the initial response, a “deviation” is
produced towards an “alternative” response that may,
in many cases, lead to refractory states such as endo-
toxin and tumour tolerance. These refractory states
may have undesirable clinical consequences and their
study is the objective of our research.
Research Lines
• Molecular mechanisms of the innate immune system
tolerance to tumours in several clinical contexts.
• Molecular mechanisms of endotoxin tolerance in
several clinical contexts: respiratory diseases (OSA
and cystic fibrosis), acute coronary syndrome, sepsis
and septic shock and leukaemias.
• Role of the innate immune system in metastasis.
• Myeloid cell polarization and atherogenesis.
• Role of some mediators of the innate immune system
in cardiovascular diseases.
Research Activity
Doctoral TheseS
Ramón Vázquez A. Estudio del perfil transcripcional de los
receptores nucleares LXR en un modelo celular de ma-
crófago murino inmortalizado[dissertation]. Madrid: UCM:
2017(01/07/2017).
DirectorS: Castrillo A; Boscá Gomar L.
Rosales Mendoza CE. Papel de la pro-proteína convertasa
subtilisina kexina de tipo 9 (PCSK9) en el macrófago. Implica-
ciones en el desarrollo de aterosclerosis[dissertation]. Ma-
drid: UAM: 2017(01/09/2017).
DirectorS: Boscá Gomar L, Martínez Valverde A.
PUBLICATIONS
• A-González N, Quintana JA, García-Silva S, Mazariegos M, de la Aleja
AG, Nicolás-Ávila JA, Walter W, Adrover JM, Crainiciuc G, Kuchroo
VK, Rothlin CV, Peinado H, Castrillo A, Ricote M, Hidalgo A. Phago-
cytosis imprints heterogeneity in tissue-resident macrophages. J Exp
Med. 2017; 214(5): 1281-96. Article. IF: 10.79; D1
• lvárez E, Toledano V, Morilla F, Hernández-Jiménez E, Cubillos-Zapata
C,Varela-Serrano A, Casas-Martín J, Avendaño-Ortiz J, Aguirre LA, Ar-
nalich F, Maroun-Eid C, Martín-Quirós A, Díaz MQ, López-Collazo E.
A system dynamics model to predict the human monocyte response
to endotoxins. Front Immunol. 2017; 8: 915. Article. IF: 5.511; Q1
• Baldanta S, Fernández-Escobar M, Acín-Pérez R, Albert M, Camafeita
E, Jorge I,Vázquez J, Enríquez JA, Guerra S. ISG15 governs mitochon-
drial function in macrophages following vaccinia virus infection. Plos
Pathog. 2017; 13(10): e1006651. Article. IF: 6.158; D1
• Brea R, Motino O, Frances D, García-Monzón C,Vargas J, Fernández-
Velasco M, Boscá L, Casado M, Martín-Sanz P, Agra N. PGE2 induces
apoptosis of hepatic stellate cells and attenuates liver fibrosis in
mice by downregulating miR-23a-5p and miR-28a-5p. Biochim Bio-
phys Acta. 2017; 1864(2): 325-37-. Article. IF: 5.108; Q1
• Cubillos-Zapata C, Avendaño-Ortiz J, Hernández-Jiménez E, To-
ledano V, Casas-Martín J, Varela-Serrano A, Torres M, Almendros I,
Casitas R, Fernández-Navarro I, García-Sánchez A, Aguirre LA, Fa-
rre R, López-Collazo E, García-Río F. Hypoxia-induced PD-L1/PD-1
crosstalk impairs T-cell function in sleep apnoea. Eur Respir J. 2017;
50(4): 1700833. Article. IF: 12.242; D1
• Cubillos-Zapata C, Córdoba R, Avendaño-Ortiz J, López-Collazo E.
Thalidomide analog CC-122 induces a refractory state in mono-
cytes from patients with diffuse large B cell lymphoma. Leukemia
Lymphoma. 2017; 58(8): 1999-2001. Letter. IF: 2.644; Q2
• Cuevas VD, Anta L, Samaniego R, Orta-Zavalza E, de la Rosa JV, Bau-
jat G, Domínguez-Soto A, Sánchez-Mateos P, Escribese MM, Cas-
trillo A, Cormier-Daire V, Vega MA, Corbi AL. MAFB determines
human macrophage anti-inflammatory polarization: Relevance for
the pathogenic mechanisms operating in multicentric carpotarsal
osteolysis. J Immunol. 2017; 198(5): 2070-81. Article. IF: 4.539; Q2
• de la Muela MH, López EG, Aldeguer LF, Gómez-Campelo P. Proto-
col for the BRECAR study: a prospective cohort follow-up on the
impact of breast reconstruction timing on health-related quality of
life in women with breast cancer. BMJ Open. 2017 ;7(12): e018108.
Article. IF: 2.413; Q2
• Díaz MQ, Borobia AM, Erce JAG, Maroun-Eid C, Fabra S, Carcas A,
Frías J, Muñoz M. Appropriate use of red blood cell transfusion in
emergency departments: A study in five emergency departments.
Blood Transfus-Italy. 2017; 15(3): 199-206. Article. IF: 2.138; Q3
• Esteso G, Guerra S, Valés-Gómez M, Reyburn HT. Innate immune
recognition of double-stranded RNA triggers increased expression
of NKG2D ligands after virus infection. J Biol Chem. 2017; 292(50):
20472-80. Article. IF: 4.01; Q2
• Fernández-Paredes L, Casrouge A, Decalf J, de Andrés C, Villar LM,
de Diego RP, Alonso B, Cermeno JCA, Arroyo R, Tejera-Alhambra
M, Navarro J, Oreja-Guevara C, Trascasa ML, Seyfferth A, Martínez
MAG, Lafuente RA, Albert ML, Sánchez-Ramon S. Multimarker risk
stratification approach at multiple sclerosis onset. Clin Immunol.
2017; 181: 43-50. Article. IF: 3.557; Q2
• Ferrer-Mayorga G, Gómez-López G, Barbachano A, Fernández-Ba-
rral A, Peña C, Pisano DG, Cantero R, Rojo F, Muñoz A, Larriba MJ.
Vitamin D receptor expression and associated gene signature in
tumour stromal fibroblasts predict clinical outcome in colorectal
cancer. Gut. 2017; 66(8): 1449-62. Article. IF: 17.016; D1
• García-Martín A, Maroun-Eid C, Campino-Villegas A, Oliva-Manuel
B, Herrero-Ambrosio A, Quintana-Díaz M. Perception survey on
the value of the hospital pharmacist at the emergency department.
Farm Hosp. 2017; 41(3): 357-70. Article. Not Indexed
• Gómez-Hurtado N, Domínguez-Rodríguez A, Mateo P, Fernández-
Velasco M, Val-Blasco A, Aizpun R, Sabourin J, Gómez AM, Benitah JP,
Delgado C. Beneficial effects of leptin treatment in a setting of car-
diac dysfunction induced by transverse aortic constriction in mouse.
J Physiol-London. 2017; 595(13): 4227-43. Article. IF: 4.54; Q1
• Hernández-Jiménez E, Cubillos-Zapata C, Toledano V, de Diego RP,
Fernández-Navarro I, Casitas R, Carpio C, Casas-Martín J, Valentin
J, Varela-Serrano A, Avendaño-Ortiz J, Álvarez E, Aguirre LA, Pérez-
Martínez A, de Miguel MP, Belda-Iniesta C, García-Río F, López-Co-
llazo E. Monocytes inhibit NK activity via TGF-beta in patients with
obstructive sleep apnoea. Eur Respir J. 2017; 49(6): 1602456. Article.
IF: 12.242; D1
• Hernández-Jiménez E, Gutiérrez-Fernández M, Cubillos-Zapata C,
Otero-Ortega L, Rodríguez-Frutos B, Toledano V, Martínez-Sánchez
P, Fuentes B, Varela-Serrano A, Avendaño-Ortiz J, Blázquez A, Man-
gas-Guijarro MA, Díez-Tejedor E, López-Collazo E. Circulating mo-
nocytes exhibit an endotoxin tolerance status after acute ischemic
Stroke: Mitochondrial DNA as a putative explanation for poststroke
infections. J Immunol. 2017; 198(5): 2038-46. Article. IF: 4.539; Q2
• Lambertucci F, Motino O, Villar S, Rigalli JP, Álvarez MD, Catania VA,
Martín-Sanz P, Carnovale CE, Quiroga AD, Frances DE, Ronco MT.
Benznidazole, the trypanocidal drug used for Chagas disease, indu-
ces hepatic NRF2 activation and attenuates the inflammatory res-
ponse in a murine model of sepsis. Toxicol Appl Pharm. 2017; 315:
12-22. Article. IF: 3.616; Q1
• Martínez VG, Rubio C, Martínez-Fernández M, Segovia C, López-
Calderón F, Garín MI,Teijeira A, Munera-Maravilla E,Varas A, Sacedón
R, Guerrero F,Villacampa F, de la Rosa F, Castellano D, López-Collazo
E, Paramio JM, Vicente A, Dueñas M. BMP4 induces M2 macrophage
polarization and favors tumor progression in bladder cancer. Clin
Cancer Res. 2017; 23(23): 7388-99. Article. IF: 10.199; D1
• Martín-Sanz P, Casado M, Boscá L. Cyclooxygenase 2 in liver dys-
function and carcinogenesis: Facts and perspectives. World J Gas-
troentero. 2017; 23(20): 3572-80. Editorial Material. IF: 3.3; Q2
• Matalonga J, Glaria E, Bresque M, Escande C, Carbo JM, Kiefer K,
Vicente R, León TE, Beceiro S, Pascual-García M, Serret J, Sanjurjo L,
Morón-Ros S, Riera A, Paytubi S, Juárez A, Sotillo F, Lindbom L, Cae-
lles C, Sarrias MR, Sancho J, Castrillo A, Chini EN, Valledor AF. The
nuclear receptor LXR limits bacterial infection of host macrophages
through a mechanism that impacts Cellular NAD metabolism. Cell
Rep. 2017; 18(5): 1241-55. Article. IF: 8.032; Q1
• Paniagua-Herranz L, Gil-Redondo JC, Queipo MJ, González-Ramos
159
 3
Information Groups by Area
3.3 Infectious Diseases and Immunity Area
S, Boscá L, Pérez-Sen R, Mirás-Portugal MT, Delicado EG. Prosta-
glandin E-2 impairs P2Y(2)/P2Y(4) receptor signaling in cerebellar
astrocytes via EP3 receptors. Front Pharmacol. 2017; 8: 937. Article.
IF: 3.831; Q1
• Rodríguez M, Márquez S, de la Rosa JV, Alonso S, Castrillo A, Crespo
MS, Fernández N. Fungal pattern receptors down-regulate the in-
flammatory response by a cross-inhibitory mechanism independent
of interleukin-10 production. Immunology. 2017; 150(2): 184-98. Ar-
ticle. IF: 3.358; Q2
• Ruiz-Hurtado G, García-Prieto CF, Pulido-Olmo H, Velasco-Martín
JP, Villa-Valverde P, Fernández-Valle ME, Boscá L, Fernández-Velasco
M, Regadera J, Somoza B, Fernández-Alfonso MS. Mild and short-
term caloric restriction prevents obesity-induced cardiomyopathy
in young zucker rats without changing in metabolites and fatty acids
cardiac profile. Front Physiol. 2017; 8: 42. Article. IF: 3.394; Q1
• Sánchez A, Relano C, Carrasco A, Contreras-Jurado C, Martín-Duce
A, Aranda A, Alemany S. Map3k8 controls granulocyte colony stimu-
lating factor production and neutrophil precursor proliferation in
lipopolysaccharide-induced emergency granulopoiesis. SCI Rep-Uk.
2017; 7: 5010. Article. IF: 4.122; Q1
• Sanz-García C, Sánchez A, Contreras-Jurado C, Calés C, Barranque-
ro C, Muñoz M, Merino R, Escudero P, Sanz MJ, Osada J, Aranda A,
Alemany S. Map3k8 modulates monocyte state and atherogenesis in
ApoE(-/-) mice. Arterioscl Throm Vas. 2017; 37(2): 237-46. Article. IF:
6.086; D1
• Tamayo M, Manzanares E, Bas M, Martín-Nunes L, Val-Blasco A, La-
rriba MJ, Fernández-Velasco M, Delgado C. Calcitriol (1,25-dihydro-
xyvitamin D3) increases L-type calcium current via protein kinase A
signaling and modulates calcium cycling and contractility in isolated
mouse ventricular myocytes. Heart Rhythm. 2017; 14(3): 432-9. Ar-
ticle. IF: 4.743; Q1
• Val-Blasco A, Piedras MJGM, Ruiz-Hurtado G, Suárez N, Prieto
P, González-Ramos S, Gómez-Hurtado N, Delgado C, Pereira L,
Benito G, Zaragoza C, Domenech N, Crespo-Leiro MG, Vásquez-
Echeverri D, Núñez G, López-Collazo E, Boscá L, Fernández-Velas-
co M. Role of NOD1 in heart failure progression via regulation of
Ca2+ handling. J Am Coll Cardiol. 2017; 69(4): 423-33. Article. IF:
16.834; D1
• Val-Blasco A, Prieto P, González-Ramos S, Benito G, Vallejo-Crema-
des MT, Pacheco I, González-Peramato P, Agra N, Terrón V, Delgado
C, Martín-Sanz P, Boscá L, Fernández-Velasco M. NOD1 activation in
cardiac fibroblasts induces myocardial fibrosis in a murine model of
type 2 diabetes. Biochem J. 2017; 474: 399-410. Article. IF: 3.857; Q2
• Villarroya-Beltri C, Guerra S, Sánchez-Madrid F. ISGylation - a key
to lock the cell gates for preventing the spread of threats. J Cell Sci.
2017; 130(18): 2961-9. Review. IF: 4.401; Q2
• Zhang L, Rajbhandari P, Priest C, Sandhu J, Wu XH, Temel R, Cas-
trillo A, Vallim TQD, Sallam T, Tontonoz P. Inhibition of cholesterol
biosynthesis through RNF145-dependent ubiquitination of SCAP.
Elife. 2017 ;6: e28766. Article. IF: 7.616; D1
Public Projects
Avendaño Ortiz J. Contrato ayuda investigación (PEJ15/BIO/
AI-0021). CAM. 2016-2018.
Managment centre: FIBHULP
Fernández Velasco M. Implicación de los receptores NOD1
en el desarrollo de la insuficiencia cardiaca (PI14/01078).
ISCIII. 2015-2017.
Managment centre: FIBHULP
Fernández Velasco M. Contrato Miguel Servet tipo II. ISCIII.
(2017-2020).
160
Managment centre: FIBHULP para el tratamiento personalizado del cáncer de páncreas. Pérez de Diego R. Medicina de precisión en inmunodefi-
Hospital Universitario de Fuenlabrada. 2017-Ongoing. ciencias primarias: desentrañando nuevas etiologías genéticas
Gómez Campelo P. Biobanks Platform. (PT13/0010/0003).
Managment centre: FIBHULP mediante aproximaciones ómicas. Fundación Ramón Areces.
ISCIII. (2014-2017).
2015-Ongoing.
Managment centre: FIBHULP López-Collazo EM. Estudio de la interacción entre las células
troncales de cáncer colorrectal y el sistema inmune innato. Managment centre: FIBHULP
López-Collazo EM. Contrato de estabilización Miguel Servet
Roche Farma S.A. 2015-Ongoing.
(I2). ISCIII, CAM. 2009-2017.
Managment centre: FIBHULP
Managment centre: FIBHULP INTERNATIONAL Projects
López-Collazo EM. Estudio del sistema inmune infiltrado en
López-Collazo EM. The risk of infections in severalpatho- López-Collazo EM, Belda Iniesta C. Massive screening
el cáncer de pulmón y búsqueda de marcadores pronósticos
logies: a thorough study with clinical tools development for methodology to discard doping. COI. 2015-Ongoing.
en células circulantes de pacientes que sufren esta enferme-
personalised medicine (PIE15/00065). ISCIII. 2016-2018. Managment centre: COE
dad. Encinar. 2014-Ongoing.
Managment centre: FIBHULP
Managment centre: FIBHULP López-Collazo EM. Transplantation (SOT & HSCT) in chil-
López-Collazo EM. Tolerancia a endotoxinas: ¿una puerta López-Collazo EM. Programa específico de investigación dren transchild. (TRANSCHILD). FIBHULP. 2016-Ongoing.
hacia el tratamiento eficaz de la sepsis? (PI14/01234). ISCIII. para al obtención y validación de un método de muestreo
Managment centre: FIBHULP
2015-2017. (Screening) masivo para descartar el dopaje en el deporte.
Managment centre: FIBHULP Fundación Hospital de Madrid. 2013-Ongoing.
Pérez de Diego R. Contrato Ramón y Cajal (RyC 2011- Managment centre: FIBHULP Patents and Trademarks
07597). MINECO. 2011-2017. López-Collazo EM. Transplantation (SOT & HSCT) in chil- Llamas Matías MA, López-Collazo E, inventors; FIBHULP,
Managment centre: FIBHULP dren transchild. Fundación para la Investigación Biomédica Llamas Matías MA, Empireo S.L., assignees. Method for deter-
Hospital Universitario La Paz. 2016-Ongoing.
Pérez de Diego R. Respuesta inmune celular y humoral de la mine the risk of developing an infectious disease. P201330768,
enfermedad inflamatoria intestinal. Papel de los patrones mo- Managment centre: FIBHULP PCT/ES2014/070434, EP3006570; 2013 May 27.
leculares asociados a patógenos en la etiología y evolución
clínica (PI14/00616). ISCIII. 2015-2017.
Managment centre: FIBHULP
Toledano Real VM. Contrato PTA (PTA2013-8265-I). MINE-
CO. 2015-2018.
Managment centre: FIBHULP
Private Projects
Cantero Cid R. Cultivo y estudio de células troncales (STEM)
de adenocarcinoma de recto humano pre y post-tratamiento
con radiobioquimioterapia. Usos potenciales en terapia on-
cológica. Fundacion Mutua Madrileña. 2014-Ongoing.
Managment centre: FIBHULP
Cantero Cid R. Generación de microtejidos de colon tridi-
mensionales automatizada para Evaluación de fármacos anti-
tumorales. Roche Farma S.A. 2017-Ongoing.
Managment centre: FIBHULP
Cantero Cid R. Premio por la publicación del artículo: ne-
gative pressure therapy to reduce risk of wound infection
following diverting loop ileostomy reversal. an initial study.
KCI Uk Holdings Limited. 2016-Ongoing.
Managment centre: FIBHULP
Gómez Campelo P. Calidad de vida y satisfacción con la ciru-
gía en mujeres con cáncer de mama con reconstrucción con
mastectomía: estudio BRECAR. (2015-Ongoing).
Managment centre: FIBHULP
Gómez Campelo P. Nodo científico Biobanco HULP. FI-
BHULP. 2014-Ongoing.
Managment centre: FIBHULP
Gómez Ruiz S. Phosphorus-rich early transition metal and
rare earth metal complexes as precursors for metal phosphi-
des. DAAD-Fundación Universidad ES. 2014-Ongoing.
Managment centre: URJC
López-Collazo EM. Desarrollo de modelos experimentales
161
 3
Information Groups by Area
3.3 Infectious Diseases and Immunity Area
Diagnosis and Treatment of
Diseases Associated with
Abnormalities of the
Complement System Group
6 19.212 1
Margarita López Trascasa. Facultativo Especialista de Área
en Inmunología. HULP. Profesor Asociado de la Facultad de
Medicina. HULP
Pilar Sánchez-Corral Gómez. Investigadora Senior
(Contrato Miguel Servet - II). Jefe de Laboratorio. HULP
Fernando Corvillo Rodríguez. Investigador Predoctoral. HULP
Irene Gómez Delgado. Investigador Predoctoral. HULP
Alberto López Lera. Investigador Postdoctoral. Contratado CIBERER.
HULP
Marta Melgosa Hijosa. Facultativo Especialista de Área en
Nefrología Infantil. HULP
Pilar Nozal Aranda. Investigadora Predoctoral. HULP
Antonia Peña Carrión. Facultativo Especialista de Área en
Nefrología Infantil. HULP
César Pérez Casanova. Técnico de Laboratorio. HULP
Strategic Objective
This is a national reference group for the study of pri-
mary or acquired defects in the complement system.
The main aim is to gain an understanding of the mo-
lecular mechanisms underlying in complement defi-
ciency or dysregulation in several human diseases,
the majority of which are classified as rare diseases.
In this context, the group implements and applies
various methodological strategies (immunological,
biochemical, proteomic and genetic) to detect cli-
nically relevant deficiencies or functional defects
in complement components. By following a clearly
translational approach, the group also develops new
diagnostic tests which are implemented in the clini-
162
cal practice, especially for treatment adjustment and
patient follow-up.
The research lines could be classified as: screening
and characterization of genetic or acquired comple-
ment defects that cause renal pathology (I), functio-
nal and molecular diagnosis of deficiencies affecting
individual components of the complement system
(II), diagnosis and molecular studies in Hereditary
Angioedema and screening for disease modifying ge-
nes (III), study of pathogenic mechanisms in acquired
lipodystrophies (IV).
Research Lines
• Screening and characterization of genetic and
acquired Complement defects in renal disease.
• Biochemical and molecular diagnosis of isolated
Complement deficiencies.
• Screening and molecular characterization of disea-
se modifying genes in Hereditary Angioedema.
• Genetic and immunological mechanisms associa-
ted with Complement dysregulation in partial li-
podistrophy.
Research Activity
Doctoral TheseS
Mena de la Cruz R. Splicing alternativo en SERPING1: Ex-
presión del ARNm total y de dos variantes alternativas
del mensajero del gen del inhibidor de C1 en pacien-
tes con angioedema hereditario[dissertation]. Madrid: UAM: Sánchez-Corral Gómez P. Diagnóstico, caracterización y re-
2017(27/03/2017).
Director: López Trascasa M.
levancia clínica de defectos en la familia factor H/CFHRS del
complemento en patologia renal (PI12/00597). ISCIII. 2013-
PUBLICATIONS
2017.
Managment centre: FIBHULP
• Fernández-Paredes L, Casrouge A, Decalf J, de Andrés C, Villar LM,
Sánchez-Corral Gómez P. Línea de incorporación estable de
investigadores (I3). ISCIII, CAM. 2008-2017.
de Diego RP, Alonso B, Cermeno JCA, Arroyo R, Tejera-Alhambra Managment centre: FIBHULP
M, Navarro J, Oreja-Guevara C, Trascasa ML, Seyfferth A, Martínez
MAG, Lafuente RA, Albert ML, Sánchez-Ramón S. Multimarker risk Sánchez-Corral Gómez P. Nefropatías asociadas con des-
stratification approach at multiple sclerosis onset. Clin Immunol. regulación del complemento: estudio de factores de riesgo
2017; 181: 43-50. Article. IF: 3.557; Q2 y evolución mediante proteómica traslacional (PI16/00723).
• Hidalgo MS, Merinero HM, López A, Anter J, García SP, González- ISCIII. 2017-2019.
Fernández FA, Fores R, López-Trascasa M, Villegas A, Ojeda E, de Managment centre: FIBHULP
Córdoba SR. Extravascular hemolysis and complement consump-
tion in Paroxysmal Nocturnal Hemoglobinuria patients undergoing
eculizumab treatment. Immunobiology. 2017; 222(2): 363-71. Article. Private Projects
IF: 2.873; Q3
López Trascasa M. Búsqueda de los mecanismos inmuno-
• Rodríguez-Jiménez C, Santos-Simarro F, Campos-Barros A, Camare-
lógicos comunes en glomerulonefritis y lipodistrofias. Fun-
na C, Lledin D, Vallespín E, del Pozo A, Mena R, Lapunzina P, Rodrí-
dación de la Sociedad Española de Nefrología (SENEFRO).
guez-Novoa S. A new variant in PHKA2 is associated with glycogen
storage disease type IXa. Mol Genet Metab Rep. 2017; 10: 52-5.
2016-2017.
Article. Not Indexed Managment centre: FUAM
• Rodríguez-Sanz A, Sánchez-Villanueva R, Domínguez-Ortega J, Fian- López Trascasa M. Complementest. Déficits y alteraciones
dor AM, Ruiz MP, Trocoli F, Díaz-Tejeiro R, Cadenillas C, González E, del sistema del complemento en patología humana. Secugen
Martínez V, López-Trascasa M, Quirce S, Selgás R, Bellón T. Mecha- Sl. 2011-Ongoing.
nisms involved in hypersensitivity reactions to polysulfone hemo- Managment centre: FIBHULP
dialysis membranes. Artif Organs. 2017; 41(11): E285-95. Article. IF:
2.111; Q2 López Trascasa M. Estudio de las bases moleculares del sín-
• Tortajada A, Gutiérrez E, de Jorge EG, Anter J, Segarra A, Espinosa M, drome hemolítico urémico atípico y creación de un registro
Blasco M, Román E, Marco H, Quintana LF, Gutiérrez J, Pinto S, Ló- español de SHU-atípico. Secugen Sl. 2011-Ongoing.
pez-Trascasa M, Praga M, de Córdoba SR. Elevated factor H-related Managment centre: FIBHULP
protein 1 and factor H pathogenic variants decrease complement
Sánchez-Corral Gómez P. Convenio marco: prácticas de Ire-
regulation in IgA nephropathy. Kidney Int. 2017; 92(4): 953-63. Arti-
ne Gómez Delgado: Máster en investigación e inmunología.
cle. IF: 8.429; D1
UCM. 2017-Ongoing.
• Deschenes G, Vivarelli M, Peruzzi L. Variability of diagnostic criteria
Managment centre: FIBHULP
and treatment of idiopathic nephrotic syndrome across European
countries (Peña Carrión A). Eur J Pediatr. 2017; 176(5): 647. Article.
IF: 2.242; Q2
Patents and Trademarks
López Trascasa M, authors; FIBHULP, assignee. Trademark
Public Projects name: COMPLEMENTest; CM 009.658.791; 2011, January 14.
López Trascasa M. Nuevos biomarcadores en enfermedades
mediadas por el sistema del complemento (PI15/00255). MI-
NECO. 2016-2018.
Managment centre: FIBHULP
163
 3
Information Groups by Area
3.3 Infectious Diseases and Immunity Area
Lymphocyte Pathophysiology in
Immunodeficiencies Group
10 40.648 5
Eduardo López Granados. Coordinador de Inmunología.
HULP
Strategic Objective
Rita Francisca Álvarez Doforno. Facultativo Especialista de
Área en Inmunología. HULP
Francisco Javier Alves Ferreira. Facultativo Especialista de
Área en Anatomía Patológica. HULP
Laura Casamayor Polo. Facultativo Especialista de Área. HULP
Lucía del Pino Molina. Investigadora Predoctoral. HULP
Antonio Ferreira Cerdán. Facultativo Especialista de Área en
Inmunología. HULP
María Cruz García Rodríguez. Facultativo Especialista de Área
en Inmunología. HULP
Julia Leal de la Rosa. Facultativo Especialista de Área en Pediatría
General. HULP
Montserrat Lozano Doncel. Técnico de Laboratorio. HULP
Diego Plaza López de Sabando. Facultativo Especialista de
Área en Hemato-Oncología Pediátrica. HULP
Ángel Julian Robles Marhuenda. Facultativo Especialista de
Área en Medicina Interna. HULP
Rebeca Rodríguez Peña. Facultativo Especialista de Área en
Inmunología. HULP
María Carmen Salcedo Moreno. Técnico de Laboratorio.
HULP
Laura Sánchez Zapardiel. Facultativo Especialista de Área en
Inmunología. HULP
Ana Sastre Urguelles. Facultativo Especialista de Área en
Hemato-Oncología Pediátrica. HULP
Esther Tato Gutiérrez. Técnico de Laboratorio. HULP
Juan Manuel Torres Canizales. Médico Interno Residente en
Inmunología. HULP
164
Defective molecular events driving the differentiation,
activation and homeostasis of lymphocytes underli-
ne the pathophysiology of numerous immunological
and haematological diseases. In primary immunodefi-
ciencies (PIDs), intrinsic impairments of immune cells
lead to infection and, in some cases, autoimmunity
and cancer.
Common variable immunodeficiency disorders
(CVIDs) are the most frequent but least understood
types of PID and are a major focus of our research.
Our group attempts to unravel the molecular basis for
functional defects of lymphocytes in several PIDs as
well as the basis for autoimmune and lymphoprolifera-
tive complications. We take a multidisciplinary clinical,
anatomic, genetic, epigenetic and functional approach.
By correlating clinical and experimental data, we aim
to achieve a better understanding of the syndro-
mes and lay the groundwork for new, more effective
treatments.
We have recently been concentrating our efforts on
understanding differentiation and survival cell signa-
lling pathways and the control of gene transcription
in B cells from affected individuals. The B cell receptor
(BCR), the TNF-R family members and the Toll-like
receptors (TLRs) are fundamental to the synergistic
action of B cell function. It is increasingly evident that
innate and adaptive pathways intersect and reinforce
each other and that TLRs play a fundamental role in
this relationship.
Methodological and conceptual approaches applied to
the study of PIDs can be applied to monitoring more
prevalent secondary immunodeficiency states such as
immunological reconstitution in haematopoietic stem
cell transplantation (HSCT), acute viral infection, and use
of immunosuppressive treatments in transplantation and
autoimmunity. We validate new biological markers and
assays for a patient-based rather than a disease-based
therapeutic approach in the latest clinical scenarios, to
facilitate clinical decisions and to maximise the clinical
efficiency and safety of treatments.
Research Lines
• The study of the anatomical, genetic, epigenetic and
biochemical bases for lymphoid function deficiency in
immunodeficiencies of antibody formation and their
autoimmune and lymphoproliferative complications
• Role of Toll Like Receptors (TLRs) and signalling
pathways in lymphoid maturation and immune respon-
se to infection in primary immunodeficiencies
• Identification of new biomarkers for lymphoid function
for monitoring in states of immunodeficiency secon-
dary to: acute viral infection, immune reconstitution af-
ter transplantation of haematopoietic progenitors and
use of immunosuppressive therapies in transplantation,
autoimmunity and chronic inflammation
Research Activity
PUBLICATIONS
• Altmuller F, Lissewski C, Bertola D, Flex E, Stark Z, Spranger S, Bay-
nam G, Buscarilli M, Dyack S, Gillis J, Yntema HG, Pantaleoni F, van
Loon RLE, MacKay S, Mina K, Schanze I, Tan TY, Walsh M, White SM,
Niewisch MR, García-Miñaur S, Plaza D, Ahmadian MR, Cave H, Tar-
taglia M, Zenker M. Genotype and phenotype spectrum of NRAS
germline variants. Eur J Hum Genet. 2017; 25(7): 823-31. Article. IF:
3.636; Q2
• Bautista F, Gallego S, Cañete A, Mora J, de Heredia CD, Cruz O,
Fernández JM, Rives S, Berlanga P, Hladun R, Ribelles AJ, Madero L,
Ramírez M, Delgado RF, Pérez-Martínez A, Mata C, Llort A, Broto
JM, Cela ME, Ramírez G, Sabado C, Acha T, Astigarraga I, Sastre A,
Muñoz A, Guibelalde M, Moreno L. Early clinical trials in paediatric
oncology in Spain: a nationwide perspective. An Pediatr. 2017; 87(3):
155-63. Article. IF: 1.318; Q
• Blanco-Sánchez AI, Méndez-Echevarría A, Alonso-Quintela P, García-
Perea A, Baquero-Artigao F. Fever, parotid swelling, otorrhea and
retroauricular fistula in a child. Enferm Infec Micr Cl. 2017; 35(1):
54-5. Editorial Material. IF: 1.707; Q3
• Carrillo J, Calvete O, Pintado-Berninches L, Manguán-García C, Na-
varro JS, Arias-Salgado EG, Sastre L, Guenechea G, Granados EL, de
Villartay JP, Revy P, Benítez J, Perona R. Mutations in XLF/NHEJ1/
Cernunnos gene results in downregulation of telomerase genes ex-
pression and telomere shortening. Hum Mol Genet. 2017; 26(10):
1900-14. Article. IF: 4.902; Q1
• Cidre-Aranaz F, Grunewald TGP, Surdez D, García-García L, Láza-
ro JC, Kirchner T, González-González L, Sastre A, García-Miguel P,
López-Pérez SE, Monzón S, Delattre O, Alonso J. EWS-FLI1-media-
ted suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers
aggressiveness to Ewing sarcoma. Oncogene. 2017; 36(6): 766-76.
Article. IF: 6.854; Q1
• García-Morato MB, García-Miñaur S, Garicano JM, Simarro FS,
Molina LDP, López-Granados E, Cerdán AF, Peña RR. Mutations in
PIK3R1 can lead to APDS2, SHORT syndrome or a combination of
the two. Clin Immunol. 2017; 179: 77-80. Article. IF: 3.557; Q2
• García-Morato MB, Nevado J, González-Granado LI, Urgelles AS,
Peña RR, Cerdán AF. Chronic granulomatous disease caused by
maternal uniparental isodisomy of chromosome 16. J Allergy Clin
Immunol Pract. 2017 ;5(4): 1146-8. Letter. IF: 6.966; D1
• Gutiérrez-Camino A, Martín-Guerrero I, de Andoin NG, Sastre A,
Baneres AC, Astigarraga I, Navajas A, García-Orad A. Confirmation
of involvement of new variants at CDKN2A/B in pediatric acute
lymphoblastic leukemia susceptibility in the Spanish population. Plos
One. 2017; 12(5): e0177421. Article. IF: 2.766; Q1
• Huertas-Martínez J, Court F, Rello-Varona S, Herrero-Martín D,
Almacellas-Rabaiget O, Sainz-Jaspeado M, García-Monclus S, Laga-
res-Tena L, Buj R, Hontecillas-Prieto L, Sastre A, Azorin D, Sanjuán
X, López-Alemany R, Morán S, Roma J, Gallego S, Mora J, del Muro
XG, Giangrande PH, Peinado MA, Alonso J, de Alava E, Monk D,
Esteller M,Tirado OM. DNA methylation profiling identifies PTRF/
Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-
expressed with caveolin-1. Cancer Lett. 2017; 386: 196-207. Arti-
cle. IF: 6.491; Q1
• Martínez-Sánchez N, Pérez-Pinto S, Robles-Marhuenda A, Arnalich-
Fernández F, Camean MM, Zalvide EH, Bartha JL. Obstetric and pe-
rinatal outcome in anti-Ro/SSA-positive pregnant women: a pros-
pective cohort study. Immunol Res. 2017; 65(2): 487-94. Article. IF:
2.487; Q3
Public Projects
López Granados E. Desregulación de la expresión génica del
linfocito B en la inmunodeficiencia comun variable: papel de
la epigenetica y los microRNAs (PI16/01605). ISCIII. 2017-
2020.
Managment centre: FIBHULP
Private Projects
López Granados E. Actualización y renovación de la activi-
dad en el Servicio de Inmunología del Hospital Universitario
La Paz. CSL Behring S.A. 2012-Ongoing.
Managment centre: FIBHULP
López Granados E. Aplicaciones clínicas de la monitoriza-
ción inmunológica avanda en el trasplante de órgano sólido
infantil. Fundación Mutua Madrileña. 2014-Ongoing.
Managment centre: FIBHULP
López Granados E. Cáncer, fallo medular e inmunodeficien-
cia en niños, un esfuerzo integrado para comprender sus ba-
ses moleculares y mejorar su diagnóstico y pronóstico clínico.
Fundación Asociación Española Contra el Cáncer. 2014-2018.
Managment centre: FIBHULP
López Granados E. Estudio de la respuesa antiviral T me-
diante ensayo de OX40 y su correlación con la terapia inmu-
nosupresora para una monitorizacion individualizada del niño
trasplantado. Cytognos. 2015-Ongoing.
Managment centre: FIBHULP
López Granados E. XII Reunión del registro español inmu-
nodeficiencias primaria. CAM. 2015-Ongoing.
Managment centre: FIBHULP
Robles Marhuenda AJ. Relevancia clínica y problemática te-
rapéutica del síndrome de los anticuerpos antifosfolípidos.
Sanofi Aventis S.A. 2006-Ongoing.
Managment centre: FIBHULP
165
 3
Information Groups by Area
3.3 Infectious Diseases and Immunity Area
CLINICAL TRIALS
Sastre Urgüelles A. Ensayo adaptativo de fase 3 aleatorizado,
abierto y controlado para investigar la eficacia, seguridad y
tolerabilidad del anticuerpo Bite® blinatumomab como tra-
tamiento de consolidación frente a la quimioterapia de con-
solidación convencional en sujetos pediátricos con leucemia
linfoblástica aguda (LLA) de precursores B en primera recaí-
da de alto riesgo. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4416. Sponsored´s protocol code: 20120215.
Sponsored by: Amgen S.A..
Signed date: 20/09/2017
166
Patents and Trademarks
Van Dongen JJM, Orfao de Matos Correia E Vale JA, Van
Der Burg M, Pérez Andrés M, Van Zelm MC, Kalina T, Vlko- Drug Hypersensibility
and Innate Immune
va M, López Granados E, Blanco Álvarez E, Kienzler AK,
inventors; Erasmus University Medical Center Rotterdam,
assignee. Reagents, methods, and kits for diagnosing primary
immunodeficiencies. PCT/NL2015/050762, US62/072,498;
2014 Oct 30. Response Group
17 36.948 5
Teresa Bellón Heredia. Investigadora Senior (Contrato
Miguel Servet - II). Jefa de Laboratorio. HULP
María del Rosario Cabañas Moreno. Facultativo Especialista de
Área en Alergología. HULP
Francisco José de Abajo Iglesias. Facultativo Especialista de Área
en Farmacología. Hospital Universitario Principe de Asturias. Profesor
Titular. Facultad de Medicina. UAH
Jéssica González Ramos. Médico Interno Residente en
Dermatología. HULP
Victoria Lerma Hambleton. Coordinadora de Casos del Estudio
PIELenReD. Hospital Universitario Principe de Asturias
Aranzazú Isabel Rodríguez Sanz. Investigadora Postdoctoral.
HULP
Gastón Roustan Gullón. Profesor Asociado. Facultad de Medicina.
UAM. Facultativo Especialista de Área en Dermatología. Hospital
Universitario Puerta de Hierro
Strategic Objective
Cutaneous adverse drug reactions are unpredictable
and represent a plethora of skin diseases with va-
rious degrees of severity. The spectrum ranges from
mild to potentially fatal multisystem maladies. Those
of most concern are usually referred to as severe
cutaneous adverse reactions (SCARs), and include
acute generalized exanthematous pustulosis (AGEP),
drug reaction with eosinophilia and systemic symp-
toms (DRESS), also known as drug induced hyper-
sensitivity syndrome or hypersensitivity syndrome
(DIHS/HSS), Stevens-Johnson’s syndrome (SJS), and
toxic epidermal necrolysis (TEN). Among them, SJS
and TEN are the most severe clinical entities and are
nowadays considered as variants of the same disease
characterized by keratinocyte necrosis and epider-
mal detachment with the formation of subepidermal
bullae. From the immunopatohogenic point of view,
SCARs are T-cell mediated type IV hypersensitivity
reactions. However, T cells can orchestrate different
types of immune responses and this functional hetero-
geneity has led to a further sub-classification into type
IVa-IVd hypersensitivity that considers the distinct
cytokine production pattern by T cell subpopulations,
and emphasizes the participation of different effector
cells causing inflammation and tissue damage. Current
knowledge supports the active participation of cyto-
toxic lymphocytes in different clinical entities.
Our project aims to a better understanding of the
immune mechanisms underlying the etiopathogene-
sis of these diseases. The study is performed in the
framework of the consortium PIELenRed (Plataforma
interdisciplinar para el estudio de reacciones cutáneas
graves en red) integrated by researchers belonging to
different hospitals in Madrid.
Reactivation of latent herpesvirus has been described
during the development of some of the previously
mentioned clinical entities. In order to improve our
understanding of the behaviour of the immune system
during viral replication, collaboration has been esta-
blished with the Kidney Transplant Unit (Nephrology
Service, HULP). Kidney transplant recipients are being
followed immediately before and after transplant in
order to identify patients with active CMV replication.
General objectives for the next 5 years
The main objectives are:
I) Biobanking of samples of severe cutaneous adverse
reactions to medications (DRESS, AGEP and SJS/TEN)
associated to the registry PIELenRed, and integrated in
the international registry RegiSCAR.
II) To investigate in vitro test for drug causality asses-
sement.
167
 3
Information Groups by Area

3.3 Infectious Diseases and Immunity Area

III) To explore the involvement of the innate immune res-
ponse (in particular natural cytotoxic activity) during the
development of SCARs.
IV) Identification of biomarkers of susceptibility .
V) To find biomarkers for disease and response to
treatments.
VI) To explore the potential of microRNAs in SJS/TEN as
biomarkers of disease and of response to treatments, as
well as their relationship with pathogenic mechanisms.
VII) To analyze the evolution of the cytotoxic response in
patients with CMV replication.
VIII) Compare the innate immune response in patients
with CMV replication after kidney transplant and in pa-
tients with SCARs.
tan-Gullón L G, Kovtun I. Sarcoidosis developing after treatment
with interferon alpha in a patient with hepatitis C: An association
every physician should know. Rev Gastroenterol Mex. 2017; 82(2):
185-6-. Article. Not Indexed
• García-Lledo A, de Santiago-Nocito AM, de Abajo FJ. Cardiovascular
safety of noninsulin antidiabetic drugs: facts and promises. Rev Clin
Esp. 2017; 217(8): 473-7. Review. IF: 1.184; Q3
• González-Herrada C, Rodríguez-Martín S, Cachafeiro L, Lerma
V, González O, Lorente JA, Rodríguez-Miguel A, González-Ramos
J, Roustan G, Ramírez E, Bellón T, de Abajo FJ. Cyclosporine use
in epidermal necrolysis Is associated with an important mortality
reduction: Evidence from three different approaches. J Invest Der-
matol. 2017; 137(10): 2092-100. Article. IF: 6.448; D1
• López-Oliva MO, Flores J, Madero R, Escuín F, Santana MJ, Bellón T,
Selgas R, Jiménez C. Cytomegalovirus infection after kidney trans-
plantation and long-term graft loss. Nefrología. 2017; 37(5): 515-25.
e Identificación de posibles marcadores biológicos: análi-
sis de microRNAs como biomarcadores de enfermedad
(PI13/01768). ISCIII. 2014-2017.
Managment centre: FIBHULP
Bellón Heredia T. Contrato de estabilización Miguel Servet
(I2). ISCIII, CAM. 2007-2019.
Managment centre: FIBHULP
Private Projects
Bellón Heredia T. Enfermedad por CMV después del trans-
plante renal. Importancia de la monitorización inmunológica:
respuesta específica t CD8 y expresión de CD94/NKG2C en
relación con el rechazo. Roche Farma. 2010-Ongoing.
Managment centre: FIBHULP
de Abajo Iglesias Fj. Convenios de colaboración Registro
Poblacional de Trastornos Cutáneos Graves Asociados a Me-
dicamentos. Agenca Española de Medicamentos y Productos
Sanitarios. 2015-2016.
Managment centre: FIB-HUPA
Bellón Heredia T. Creación de un centro de referencia para
el estudio de los mecanismos implicados en las reacciones de
hipersensibilidad a las membranas de hemodialisis basadas en
Polysulfona. 2017-Ongoing.
Managment centre: FIBHULP
Patents and Trademarks
Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI,
Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alaja-

Research Lines
Article. IF: 1.167; Q4
• Martorell A, Wortsman X, Alfageme F, Roustan G, Arias-Santiago S,
• Biobanking of biological samples from patients with Catalano O, di Santolo MS, Zarchi K, Bouer M, Gaitini D, González
severe cutaneous adverse reactions to medications C, Bard R, García-Martínez FJ, Mandava A. Ultrasound evaluation
(DRESS, AGEP and SJS/TEN). as a complementary test in hidradenitis suppurativa: Proposal of a
standarized report. Dermatol Surg. 2017; 43(8): 1065-73. Article. IF:
• Development and evaluation of in vtro tests for drug
2.471; Q2
causality assessment.
• Monge-Ortega OP, Domínguez-Ortega J, González-Muñoz M, Caba-
• Identification of biomarkers of susceptibility.
ñas R, Lluch-Bernal M, Fiandor A, Bravo-Gallego LY, Quirce S. Delayed
• Involvement of NK receptors in the etiopathogenesis allergic reaction to amlodipine with a positive lymphocyte transfor-
of Stevens-Johnson syndrome /Toxic epidermal necro-
mation test. Rev Alerg Mex. 2017; 64(4): 505-8-. Article. Not Indexed
lysis (SJS/TEN).
• Ossorio M, Bajo MA, del Peso G, Martínez V, Fernández M, Castro
• Differential analysis of the cytokine pattern involved in
MJ, Rodríguez-Sanz A, Madero R, Bellón T, Selgas R. Sustained low
different SCARs (AGEP, DRESS and SJS/TEN). peritoneal effluent CCL18 levels are associated with preservation
• Analysis of miRNAs as biomarkers of disease and res- of peritoneal membrane function in peritoneal dialysis. Plos One.
ponse to treatments. 2017; 12(4): e0175835. Article. IF: 2.766; Q1
• Ramírez E, Bellón T, Tong HY, Borobia AM, de Abajo FJ, Lerma V, Hi-
Bellón Heredia T. Reacciones de hipersensibilidad cutánea
graves asociadas a medicamentos: biobanco de muestras bio-
lógicas asociadas a un registro de casos para el estudio de los
determinantes y mecanismos biológicos y realización del test
de transformación linfocitaria. Fundacion para la Investigación
Biomedica del Hospital Universitario Principe de Asturias.
2014-Ongoing.
Managment centre: FIBHULP
Bellón Heredia T. Formación en la investigación. SYF Galenus
Center S.L. 2015-Ongoing.
Managment centre: FIBHULP
de Abajo Iglesias FJ. Cáncer colorrectal y medicamentos: es-
tudio de casos y controles en la base de datos BIFAP. Instituto
Teófilo Hernando. 2014-2017.
Managment centre: FIB-HUPA
rín Fernández R, inventors; FIBHULP, Universidad de Alcalá,
assignees. Use of compounds derived from salts of pyrida-
zine[1’,6’:1,2]pyrido[3,4-b]indolinium as anti-inflammatory
agents. P201331143, PCT/ES2014/070603; 2013 July 25.
Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz
AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P,
Alajarín Fernández R, inventors; FIBHULP, Universidad
de Alcalá, assignees. Use of compounds derived from salts
of piridazine[3,2-b]benzimidazolium as anti-inflammatory
agents. P201430411, PCT/ES2014/070603; 2013 July 25.
Sánchez Niño MD, Ortiz Arduán A; FIBHULP, Instituto de
Investigación Sanitaria Fundación Jiménez Díaz. Phar-
maceutical composition and its use in the manufacture of a
medicament for treating chronic kidney disease and method
for screening compounds. P201430081, PCT/ES2015/070039;
2014 January 27.

Research Activity
Doctoral TheseS
López-Oliva MO. Manejo de la infección y enfermedad
por CMV en el trasplante renal. Importancia de la moni-
torización inmunológica: respuesta específica T CD8 y ex-
presión de CD94/NKG2C[dissertation]. Madrid: UAM:
2017(04/04/2017).
Directors: Bellón Heredia T, Selgas Gutiérrez R.
PUBLICATIONS
• de Abajo FJ, Albanell J, Sánchez OD, Klein K, Moreno-Muelas JV, Ruiz
S, Ferrando MJS, Thorpe R, Zaragoza F. Roundtable on biosimilars:
pharmacovigilance, traceability, immunogenicity, 15 November 2016,
Madrid, Spain. Gabi J. 2017; 6(1):31-7. Article. Not Indexed
• de Abajo FJ, Rodríguez-Martín S, Rodríguez-Miguel A, Gil MJ. Risk
of ischemic stroke associated with calcium supplements with or
without vitamin D: A nested case-control study. J Am Heart Assoc.
2017; 6(5): e005795. Article. IF: 4.45; Q2
• Fernández IS, Roldán FA, Gullón GR. Greater detection of small
caliber blood vessels in port wine stain with X mode than with con-
ventional doppler: A pilot study. Actas Dermosifiliogr. 2017; 108(7):
690-2. Letter. Not Indexed
• Fernández IS, Roldán FA, Massa DS, Gullón GR. Rapidly progressi-
ve infiltrated plaques in a transplant recipient. Actas Dermosifiliogr.
2017; 108(3): 255-6. Editorial Material. Not Indexed
• Fernández LS, Sanz MMS, Botello LN, Gullón GR. Not as good as it
looks. Actas Dermosifiliogr. 2017; 108(9): 876-8. Letter. Not indexed
• Flores-Robles B J, Sanguesa-Gómez C P, Barbadillo Mateos C, Rous-
168
dalgo MAM, Castaner JL, Cabañas R, Fiandor A, González-Ramos J,
Herranz P, Cachafeiro L, González-Herrada C, González O, Aram-
buru JA, Laosa O, Hernández R, Carcas AJ, Frías J. Significant HLA
class I type associations with aromatic antiepileptic drug (AED)-
induced SJS/TEN are different from those found for the same AED-
induced DRESS in the Spanish population. Pharmacol Res. 2017;
115:168-78. Article. IF: 4.897; D1
• Ramírez E, Medrano-Casique N, Tong HY, Bellón T, Cabañas R, Fian-
dor A, González-Ramos J, Herranz P, Trigo E, Muñoz M, Borobia AM,
Carcas AJ, Frías J. Eosinophilic drug reactions detected by a prospec-
tive pharmacovigilance programme in a tertiary hospital. Brit J Clin
Pharmaco. 2017; 83(2): 400-15. Article. IF: 3.838; Q1
• Rodríguez-Sanz A, Sánchez-Villanueva R, Domínguez-Ortega J, Fian-
dor AM, Ruiz MP, Trocoli F, Díaz-Tejeiro R, Cadenillas C, González E,
Martínez V, López-Trascasa M, Quirce S, Selgas R, Bellón T. Mecha-
nisms involved in hypersensitivity reactions to polysulfone hemo-
dialysis membranes. Artif Organs. 2017; 41(11):E285-95. Article. IF:
2.111; Q2
• Salguero Fernández I, Alfageme Roldán F, López Negrete E, Cabezas
R, Suárez Massa D, Roustan Gullón G. Hyperkeratotic nodule with
rapid growth. Med Clin (Barc). 2017; 148(1): e5. Article. IF: 1.168; Q3
• Su SC, Mockenhaupt M, Wolkenstein P, Dunant A, Le Gouvello S,
Chen CB, Chosidow O,Valeyrie-Allanore L, Bellón T, Sekula P, Wang
CW, Schumacher M, Kardaun SH, Hung SI, Roujeau JC, Chung WH.
Interleukin-15 is associated with severity and mortality in Stevens-
Johnson syndrome/toxic epidermal necrolysis. J Invest Dermatol.
2017; 137(5): 1065-73. Article. IF: 6.448; D1
Public Projects
Bellón Heredia T. Lesiones cutáneas graves asociadas a me-
dicamentos. Mantenimiento de un biobanco de muestras
169
 3
Information Groups by Area
3.3 Infectious Diseases and Immunity Area
Pediatric Respiratory,
Systemic and Neurological
Infections & Host Group
36 101.672 11
Cristina Calvo Rey. Jefe de Sección del Servicio de Pediatría
Hospitalaria, Enfermedades Infecciosas y Tropicales. HULP
María Rosa Albañil Ballesteros. Pediatra Titular. Atención
Primaria - Centro de Salud de Cuzco
María Mercedes Bueno Campaña. Facultativo Especialista de
Área en Pediatría. Hospital Fundación de Alcorcón
María Cabrerizo Sanz. Investigador titular. ISCIII
Ana María Calderón Reyón. Ayudante de Investigación. ISCIII
Inmaculada Casas Flecha. Científico Titular. ISCIII
Teresa del Rosal Rabes. Médico Adjunto de Pediatría Hospitalaria y
Enfermedades Infecciosas y Tropicales. HULP
María Luz García García. Jefe de Servicio de Pediatría. Hospital
Severo Ochoa
Mónica González Esguevillas. Ayudante de Investigación. ISCIII -
Centro Nacional de Microbiología
María de la Montaña Iglesias Caballero. Titulado Superior ATP.
ISCIII - Centro Nacional de Microbiología
Ana María Méndez Echevarria. Facultativo Especialista de Área
en Pediatría General. HULP
Mar Molinero Calamita. Colaboradora I+D+I. ISCIII - Centro
Nacional de Microbiología
Almudena Otero Sánchez. Ayudante de Investigación I+D+I.
ISCIII - Centro Nacional de Microbiología
Juan Francisco Pozo Sánchez. Investigador Titular. ISCIII - Centro
Nacional de Microbiología
Strategic Objective
Infectious diseases are the most frequent pathology
in childhood. Our group is focused in the study of
170
paediatric infections with special attention to those
associated to viruses.
The acute respiratory infections (ARIs) of lower res-
piratory tract are the most frequent infectious disea-
ses in humans and these suppose at least 4 million of
deaths yearly in the world. A high proportion of these
infections are related with viral aetiology and particu-
larly in children. In our country, the viral ARIs are one
of the most frequent causes of hospitalization in chil-
dren less than 2 years old. Using the metagenomics
and applying an adapted method designed and develo-
ped for ARIs study, we will have achieve an increased
knowledge of viral infections in hospitalized children
of all ages, as well as in outpatients. Metagenomics
could allow recognizing new viruses and also permits
a deeper knowledge of traditional respiratory virus
groups. Any new technological tool and its application
to respiratory infection will mean an improvement in
the diagnosis and monitoring of these types of infec-
tions and their immediate use is specified for resol-
ving alerts in public health associated with respiratory
viral infections is like the case of MERS-CoV, avian flu,
or other influenza pandemics. We are also interested
in the study of the immunological response of the in-
fants to the viral infections, and the mechanisms that
allow develop recurrent wheezing, or asthma (the
most frequent chronic disease in children).
Emerging viral infections have also an important role
in the pathology in childhood. Recently picornaviru-
ses, mainly human parechovirus and enterovirus are
causing outbreaks and several neurological infections,
morbidity and mortality. They were associated with a
wide range of pathologies, from febrile syndrome to res-
piratory, neurological or systemic diseases. In newborns,
these infections can be severe, even fatal. Surveillance of
these polio-like diseases is a public health concern and it
is one of our group objectives.
Finally, to study viral infections in high risk group of chil-
dren (newborn, chronic lung diseases, immunodefiencies,
oncologic patients, rheumatic deseases…) is also a prio-
rity in our group.
Research Lines
• Respiratory viral infections in hospitalized children. Vi-
ral metagenomic methods applied to the severe infec-
tions of the lower respiratory tract.
• Respiratory viral infections in children in Primary Care.
• Respiratory viral infections in high risk group of chil-
dren (newborn, chronic lung diseases, immunodefien-
cies, oncologic patients…).
• Applying of new technologies as echography to value
risk conditions in viral infections.
• Immune response of the children and interleukins pro-
file in infants with respiratory viral infections and co-
rrelation with the development of recurrent wheezing
in the first years of life.
• Detection and characterization of enterovirus (EV)
and parechovirus (PeV) systemic and neurological in-
fections in children.
• Neurological development in children with EV and PeV
infections.
• Kawasaki disease
• Osteoarticular infections
• Infections in children with rheumatic diseases.
Research Activity
Doctoral TheseS
Salas Aizpurúa C. El papel de la comunicación médico-pa-
ciente en la satisfacción del usuario y del profesional de la
medicina[dissertation]. Madrid: UAX: 2017(19/01/2017).
Directors: Calvo Rey C; García García ML.
Olabarrieta Arnal I. Infecciones respiratorias de origen vírico
en recién nacidos prematuros moderados y tardíos durante
sus dos primeros años de vida[dissertation]. Madrid: UAM:
2017(24/04/2017).
Directors: Calvo Rey C; García García ML.
Martín del Valle F. Infecciones neurológicas y sistémi-
cas por parechovirus humano en niños menores de 3
años[dissertation]. Madrid: UAM: 2017(22/06/2017).
Directors: Calvo Rey C; Cabrerizo M.
González Carrasco E. Infecciones respiratorias virales en el
niño prematuro: morbilidad a corto y medio plazo [disserta-
tion]. Madrid: UAX: 2017(06/06/2017).
Directors: Calvo Rey C; García García ML.
Quevedo Teruel S. Papel de las interleucinas en el desarrollo
de sibilancias recurrentes tras un episodio de bronquiolitis
grave[dissertation]. Madrid: UAX: 2017(05/05/2017).
Directors: Calvo Rey C; García García ML.
Climent Alcalá FJ. Utilidad de una unidad especiali-
zada en la atención de niños con patología crónica
compleja[dissertation]. Madrid: UAM: 2017(18/09/2017).
Directors: Calvo Rey C, Albajara Velasco L, Mellado Peña MJ
Fernández Rincón A. Infecciones por virus respiratorios en
una cohorte de recién nacidos y desarrollo de sibilancias
recurrentes[dissertation]. Madrid: UAM: 2017(21/09/2017).
Directors: Calvo Rey C; García García ML.
Escosa García L. Cribado de la infección congénita por cito-
megalovirus en prematuros de peso adecuado y neonatos
de bajo peso para la edad gestacional[dissertation]. Madrid:
UAM: 2017(06/07/2017).
Directors: del Rosal Rabes T; Mellado MJ.
García Fernández-Villalta M. Adherencia al calendario va-
cunal infantil y cumplimiento de las recomendaciones de
inmunización adicional en niños con patología crónica
compleja[dissertation]. Madrid: UAM: 2017(22/09/2017).
Directors: Méndez Echevarría A; Mellado MJ.
Rojas Inastrillas M. Niveles de anticuerpos frente a enfer-
medades infecciosas prevenibles mediante vacunación y con
impacto en la salud infantil en mujeres embarazadas en la
Comunidad Autónoma de Madrid[dissertation]. Malaga: Uni-
versidad de Málaga: 2017(15/09/2017).
Directors: Méndez Echevarría A; Moreno Pérez D.
BOOKS AND BOOK CHAPTERS
Román C, Calvo C . Encefalitis. In: Guerrero J, Carón A, Barre-
da A, Menéndez J, Ruiz J. Manual de diagnóstico y terapéutica
en pediatría del Hospital Infantil La Paz. Madrid: Editorial Pa-
namericana, 2017. p.1443-6
García-Mauriño C, Calvo Rey C, Laplaza González M. Neu-
monía de origen comunitario. Neumonía nosocomial. Com-
plicaciones. In: Guerrero J, Carón A, Barreda A, Menéndez J,
Ruiz J. Manual de diagnóstico y terapéutica en pediatría del
Hospital Infantil La Paz. Madrid: Editorial Panamericana, 2017.
p.1387-98
Sánchez Martín M, Calvo C. Bronquiolitis. In: Guerrero J,
Carón A, Barreda A, Menéndez J, Ruiz J. Manual de diagnóstico
y terapéutica en pediatría del Hospital Infantil La Paz. Madrid:
Editorial Panamericana, 2017. p.1379-85
Bustamante J, Méndez Echevarría A, Mellado MJ . Tubercu-
losis. In: Guerrero J, Carón A, Barreda A, Menéndez J, Ruiz J.
Manual de diagnóstico y terapéutica en pediatría del Hospital
Infantil La Paz. Madrid: Editorial Panamericana, 2017. p.1613-23
Gual Sánchez M, del Rosal Rabes T. Infecciones de piel y
partes blandas. In: Guerrero J, Carón A, Barreda A, Menéndez
J, Ruiz J. Manual de diagnóstico y terapéutica en pediatría del
Hospital Infantil La Paz. Madrid: Editorial Panamericana, 2017.
p.1301-6
Baez Santana S, del Rosal Rabes T. Parotiditis aguda.
Parotiditis recurrente. In: Guerrero J, Carón A, Barreda A,
Menéndez J, Ruiz J. Manual de diagnóstico y terapéutica en
pediatría del Hospital Infantil La Paz. Madrid: Editorial Pana-
mericana, 2017. p.1335-8
González Gómez B, del Rosal Rabes T. Piomiositis. In: Gue-
rrero J, Carón A, Barreda A, Menéndez J, Ruiz J. Manual de
diagnóstico y terapéutica en pediatría del Hospital Infantil La
Paz. Madrid: Editorial Panamericana, 2017. p.1489-92
171
 3
Information Groups by Area
3.3 Infectious Diseases and Immunity Area
Martín Jiménez L, del Rosal T, de José MI (in memoriam).
Síndrome pertusoide. Tosferina. In: Guerrero J, Carón A, Ba-
rreda A, Menéndez J, Ruiz J. Manual de diagnóstico y terapéu-
tica en pediatría del Hospital Infantil La Paz. Madrid: Editorial
Panamericana, 2017. p.1373-8
Martín Jiménez L, del Rosal Rabes T. Adenopatías. Diagnós-
tico diferencial. In: Guerrero J, Carón A, Barreda A, Menéndez
J, Ruiz J. Manual de diagnóstico y terapéutica en pediatría del
Hospital Infantil La Paz. Madrid: Editorial Panamericana, 2017.
p.121-6
Méndez-Echevarría A, del Rosal Rabes T. Sospecha de in-
munodeficiencia primaria. Orientación diagnóstica y manejo
básico. In: Guerrero J, Carón A, Barreda A, Menéndez J, Ruiz J.
Manual de diagnóstico y terapéutica en pediatría del Hospital
Infantil La Paz. Madrid: Editorial Panamericana, 2017. p.161-8
Baquero-Artigao F, del Rosal T. Tratamiento antibiotico em-
pírico de las principales infecciones en la infancia. In: Gue-
172
rrero J, Carón A, Barreda A, Menéndez J, Ruiz J. Manual de
diagnóstico y terapéutica en pediatría del Hospital Infantil La
Paz. Madrid: Editorial Panamericana, 2017.
Castilla A, Méndez-Echevarría A. Fiebre de origen desco-
nocido. Síndrome febril prolongado. In: Guerrero J, Carón
A, Barreda A, Menéndez J, Ruiz J. Manual de diagnóstico y
terapéutica en pediatría del Hospital Infantil La Paz. Madrid:
Editorial Panamericana, 2017. p.247-63
Calzado I, Méndez Echevarría A. Gastroenteritis aguda. In:
Guerrero J, Carón A, Barreda A, Menéndez J, Ruiz J . Manual
de diagnóstico y terapéutica en pediatría del Hospital Infantil
La Paz. Madrid: Editorial Panamericana, 2017. p.1399-408
Bustamante J, Méndez Echevarría A. Infección relacionada
con cateter venoso central. In: Guerrero J, Carón A, Barreda
A, Menéndez J, Ruiz J. Manual de diagnóstico y terapéutica en
pediatría del Hospital Infantil La Paz. Madrid: Editorial Pana-
mericana, 2017. p.1497-503
Sánchez Martín M, Calvo C. Laringitis, epiglotitis y traqueo-
bronquitis. In: Guerrero J, Carón A, Barreda A, Menéndez J,
Ruiz J. Manual de diagnóstico y terapéutica en pediatría del
Hospital Infantil La Paz. Madrid: Editorial Panamericana, 2017.
p.1365-72
Ramírez Balza O, Albañil Ballesteros R. Rabia. In: Hidal-
go I, Montón JL. Vacunas, algo más que el calendario vacunal.
Cuestiones y respuestas. 3ª edición. Madrid: Undergraf, 2017.
p.289-99
PUBLICATIONS
• Alcobendas R, Murias S, Remesal A, Calvo C. The contemporary
microbiology of osteoarticular infections in young children. Pediatr
Infect Dis J. 2017; 36(6): 621. Article. IF: 2.305; Q2
• Baquero-Artigao F, Michavila A, Suárez-Rodríguez A, Hernández A,
Martínez-Campos L, Calvo C. Spanish Society of Pediatric Infectious
Diseases, Spanish Society of Paediatric Clinical Immunology and
Allergy, Spanish Association of Paediatric Primary Care, and the Spa-
nish Society of Extra-hospital Paediatrics and Primary Health Care
consensus document on antibiotic treatment in penicillin or amoxi-
cillin allergy. An Pediatr. 2017; 86(2): 99.e1-9. Article. IF: 1.318; Q3
• Blanco-Sánchez AI, Mendéz-Echevarría A, Alonso-Quintela P, García-
Perea A, Baquero-Artigao F. Fever, parotid swelling, otorrhea and
retroauricular fistula in a child. Enferm Infec Micr Cl. 2017; 35(1):
54-5. Editorial Material. IF: 1.707; Q3
• Bustamante J, Calzado I, Sainz T, Calvo C, del Rosal T, Mendéz-Eche-
varría A. Epidemiological factors related to hospitalization due to
influenza in children below 6 months of age. Eur J Pediatr. 2017;
176(10): 1425-8. Article. IF: 2.242; Q2
• Cabrerizo M. Importance of enteroviruses in neuropaediatrics:
from polioviruses to other enteroviruses. Rev Neurología. 2017; 64:
S35-8. Article. IF: 0.601; Q4
• Cabrerizo M, Díaz-Cerio M, Muñoz-Almagro C, Rabella N, Tarrago
D, Romero MP, Peña MJ, Calvo C, Rey-Cao S, Moreno-Docón A,
Martínez-Rienda I, Otero A, Trallero G. Molecular epidemiology of
enterovirus and parechovirus infections according to patient age
over a 4-year period in Spain. J Med Virol. 2017; 89(3):
435-42. Article. IF: 1.988; Q3
• Cabrerizo M, García-Íñiguez JP, Munell F, Ama-
do A, Madurga-Revilla P, Rodrigo C, Pérez S,
Martínez-Sapina A, Anóon A, Suárez G, Rabe-
lla N, del Campo V, Otero A, Masa-Calles J.
First cases of severe flaccid paralysis asso-
ciated with enterovirus D68 infection in
Spain, 2015-2016. Pediatr Infect Dis J. 2017;
36(12): 1214-6. Article. IF: 2.305; Q2
• Calderón A, Pozo F, Calvo C, García-Gar-
cía M, González-Esguevillas M, Molinero
M, Casas I. Genetic variability of respi-
ratory syncytial virus A in hospitalized
children in the last five consecutive
winter seasons in central Spain. J
Med Virol. 2017; 89(5): 767-74. Ar-
ticle. IF: 1.988; Q3
• Calvo C, Aguado I, García-García
ML, Ruiz-Chércoles E, Díaz-Mar-
tínez E, Albañil RM, Campelo O,
Olivas A, Muñoz-González L,
Pozo F, Fernández-Arroyo R,
Fernández-Rincón A, Calde-
rón A, Casas I. Respiratory
viral infections in a cohort
of children during the first
year of life and their role
in the development of wheezing. An Pediatr. 2017; 87(2): 104-10.
Article. IF: 1.318; Q3
• Calvo C, de Ceano-Vivas M. Fever without source in infants less
than 3 months of age. What’s new? An Pediatr. 2017; 87(1): 1-2. Edi-
torial Material. IF: 1.318; Q3
• Casas-Alba D, de Sevilla MF, Valero-Rello A, Fortuny C, García-Gar-
cía JJ, Ortez C, Muchart J, Armangue T, Jordán I, Luaces C, Barrabeig
I, González-Sanz R, Cabrerizo M, Muñoz-Almagro C, Launes C. Out-
break of brainstem encephalitis associated with enterovirus-A71 in
Catalonia, Spain (2016): a clinical observational study in a children’s
reference centre in Catalonia. Clin Microbiol Infec. 2017; 23(11):
874-81. Article. IF: 5.394; D1
• Castilla J, Navascues A, Casado I, Díaz-González J, Pérez-García A,
Fernandino L, Martínez-Baz I,Aguinaga A, Pozo F, Ezpeleta C. Combi-
ned effectiveness of prior and current season influenza vaccination
in northern Spain: 2016/17 mid-season analysis. Eurosurveillance.
2017; 22(7): 11-6. Article. IF: 7.127; D1
• Domínguez-Carral J, López-Pisón J, Macaya A, Campana MB, García-
Pérez MA, Natera-de Benito D. Genetic testing among Spanish pe-
diatric neurologists: Knowledge, attitudes and practices. Eur J Med
Genet. 2017; 60(2): 124-9. Article. IF: 2.004; Q3
• Duran MJP, Sanz-Gadea BM, Raves TD, Peña MJM, Baquero-Artigao
F. Osteoarticular tuberculosis in paediatrics: A review of 20 years of
cases in a tertiary hospital. An Pediatr. 2017; 87(5): 291-2. Letter. IF:
1.318; Q3
• García-García ML, Calvo C, Moreira A, Canas JA, Pozo F, Sastre B,
Quevedo S, Casas I, del Pozo V.Thymic stromal lymphopoietin, IL-33,
and periostin in hospitalized infants with viral bronchiolitis. Medici-
ne. 2017; 96(18): e6787. Article. IF: 2.028; Q2
• García-García ML, Calvo C, Rey C, Díaz B, Molinero MD, Pozo F,
Casas I. Human metapnuemovirus infections in hospitalized children
and comparison with other respiratory viruses. 2005-2014 pros-
pective study. Plos One. 2017; 12(3): e0173504. Article. IF: 2.766; Q1
• García-García ML, Calvo C, Ruiz S, Pozo F, del Pozo V, Remedios L,
Expósito N, Téllez A, Casas I. Role of viral coinfections in asthma
development. Plos One. 2017; 12(12): 189083. Article. IF: 2.766; Q1
• Goycochea-Valdivia WA, Baquero-Artigao F, del Rosal T, Frick MA,
Rojo P, Echeverra MJ, Noguera-Julián A, Bringue X, Saavedra-Lo-
zano J, Vives-Onos I, Moliner E, Cilleruelo MJ, Cuadrado I, Colino
E, Castells L, Tagarro A, Vilas J, Soler-Palacín P, Blázquez-Gamero D.
Cytomegalovirus DNA detection by polymerase chain reaction in
cerebrospinal fluid of infants with congenital infection: Associations
with clinical evaluation at birth and implications for follow-up. Clin
Infect Dis. 2017; 64(10): 1335-42. Article. IF: 9.117; D1
• Goycochea-Valdivia WA, Moreno-Ramos F, Paño-Pardo JR, Aracil-
Santos FJ, Baquero-Artigao F, del Rosal-Rabes T, Mellado-Peña MJ,
Escosa-García L. Identifying priorities to improve.paediatric in-hos-
pital antimicrobial use by cross-sectional evaluation of prevalence
and appropriateness of prescription. Enferm Infec Micr Cl. 2017;
35(9): 556-62. Article. IF: 1.707; Q3
• Kissling E, Rondy M. Early 2016/17 vaccine effectiveness estimates
against influenza A(H3N2): I-MOVE multicentre case control stu-
dies at primary care and hospital levels in Europe. Eurosurveillance.
2017; 22(7): 2-10. Article. IF: 7.127; D1
• Launes C, Casas-Alba D, Fortuny C, Valero-Rello A, Cabrerizo M,
Muñoz-Almagro C. Utility of filmarray meningitis/encephalitis panel
during outbreak of brainstem encephalitis caused by enterovirus
in Catalonia in 2016. J Clin Microbiol. 2017; 55(1): 336-8. Letter. IF:
4.054; Q1
• Mendéz-Echevarría A, Amador JB, Fernández-Miranda MD. Immu-
nization of pregnant women against pertussis. Are we using the
best approach? Med Clin-Barcelona. 2017; 148(10): 475-6. Letter. IF:
1.168; Q3
• Mendéz-Echevarría A, Coronado-Poggio M, Baquero-Artigao F, del
Rosal T, Rodado-Marina S, Calvo C, Domínguez-Gadea L. Septic
pulmonary emboli detected by F-18-FDG PET/CT in children with
173
 3
Information Groups by Area
3.3 Infectious Diseases and Immunity Area
S-aureus catheter-related bacteremia. Infection. 2017; 45(5): 691-6.
Article. IF: 2.773; Q2
• Nieto A, Pozo F, Vidal-García M, Omeñaca M, Casas I, Falcón A. Iden-
tification of rare PB2-D701N mutation from a patient with severe
influenza: Contribution of the PB2-D701N mutation to the patho-
genicity of human influenza. Front Microbiol. 2017; 8: 575. Article. IF:
4.019; Q1
• Quesada U, Cabello J, Morán GG, Calvo C. Neuropathic physeal
injury: Differential diagnosis with osteomyelitis. An Pediatr. 2017;
87(4): 240-1. Editorial Material. IF: 1.318; Q3
• Rabes TD, Baquero-Artigao F, Mendéz-Echevarría AM, Peña MJM.Tu-
berculosis in infants less than 3 months of age. Enferm Infec Micr Cl.
2017; 35(4): 243-5. Article. IF: 1.707; Q3
• Rabes TDR, Baquero-Artigao F, Mendéz-Echevarría AM, Peña MJM.
Reply to Tuberculosis in infants less than 3 months of age of Risa-
ralda, Colombim. Enferm Infec Micr Cl. 2017; 35(5): 328-9. Letter. IF:
1.707; Q3
• Reina J, Cabrerizo M. Age distribution of acute respiratory infec-
tions caused by enteroviruses in the child population. Enferm Infec
Micr Cl. 2017; 35(9): 608-9. Letter. IF: 1.707; Q3
• Reina J, Cabrerizo M, Aliaga F. Community acute respiratory infec-
tions caused by enterovirus in the paediatric population. Enferm
Infec Micr Cl. 2017; 35(2): 133-5. Letter. IF: 1.707; Q3
• Reina J, Cabrerizo M, Ferres F. Analysis of the clinical features of
infections caused by enterovirus A71 (EV-A71) in Balearic Islands.
An Pediatr. 2017; 87(5): 289-90. Letter. IF: 1.318; Q3
• Reina J, Cabrerizo M, Ferres F. Infecciones respiratorias agudas
comunitarias causadas por enterovirus D68 (EV-D68). An Pediatr.
2017; 86(3): 158-9. Letter. IF: 1.318; Q3
• Rondy M, Gherasim A, Casado I, Launay O, Rizzo C, Pitigoi D, Mickie-
ne A, Marbus SD, Machado A, Syrjanen RK, Pem-Novose I, Horvath
JK, Larrauri A, Castilla J, Vanhems P, Alfonsi V, Ivanciuc AE, Kuliese M,
van Gageldonk-Lafeber R, Gómez V, Ikonen N, Lovric Z, Ferenczi
A, Moren A, (Pozo F). Low 2016/17 season vaccine effectiveness
against hospitalised influenza A(H3N2) among elderly: awareness
warranted for 2017/18 season. Eurosurveillance. 2017; 22(41): 8-13.
Article. IF: 7.127; D1
• Salas A, Pardo-Seco J, Cebey-López M, Gómez-Carballa A, Obando-
Pacheco P, Rivero-Calle I, Curras-Tuala MJ, Amigo J, Gómez-Rial J, Mar-
tinón-Torres F, (Calvo-Rey C). Whole exome sequencing reveals new
candidate genes in host genomic susceptibility to respiratory syncytial
virus disease. SCI Rep-Uk. 2017; 7: 15888. Article. IF: 4.122; Q1
• Salas-Mera D, Sainz T, Mira MRGG, Mendéz-Echevarría A. Gentami-
cin resistant E. coil as a cause of urinary tract infections in children.
Enferm Infec Micr Cl. 2017; 35(7): 465-6. Letter. IF: 1.707; Q3
• Vacas B, Rosal T, Mendéz-Echevarría A, Royo A. Asymmetry of the
tongue. An Pediatr. 2017; 86(5): 290-1. Editorial Material. IF: 1.318; Q3
• Vasilijevic J, Zamarreno N, Oliveros JC, Rodríguez-Frandsen A, Gó-
mez G, Rodríguez G, Pérez-Ruiz M, Rey S, Barba I, Pozo F, Casas I,
Nieto A, Falcón A. Reduced accumulation of defective viral genomes
contributes to severe outcome in influenza virus infected patients.
Plos Pathog. 2017; 13(10): e1006650. Article. IF: 6.158; D1
Public Projects
Casas Flechas I. Metagenómica viral aplicada al estudio de
la infección aguda grave del tracto respiratorio inferior en
pacientes pediátricos (PI15/00028). ISCIII. 2016-2018.
Managment centre: Centro Nacional de Microbiología
174
Cabrerizo Sanz M. Investigación en infecciones por ente-
Pediatric Systemic
rovirus y parechovirus que causan patologías neurológicas y
sistémicas graves en población infantil (PI15/00020). ISCIII.
2016-2018.
Managment centre: Centro Nacional de Microbiología
Infections; HIV,Tuberculosis,
Private Projects
Calvo Rey C. Infecciones en niños con artritis idiopática juve-
Imported and Emergent Group
nil. Fundación SEIP. 2017.
Managment centre: FIBHULP
del Rosal T. Infecciones por virus respiratorios y células
NK en vías respiratorias en niños receptores de trasplan-
te de progenitores hematopoyéticos. Estudio prospectivo.
European Society Of Pediatric Infectious Diseases (ESPID).
2017.
Managment centre: FIBHULP
Calvo Rey C. Infecciones respiratorias virales en recién naci-
dos de muy bajo peso. Fundación SEIP. 2017.
Managment centre: FIBHULP
Calvo Rey C. Infecciones osteoarticulares en pediatría. es-
tudio prospectivo multicéntrico. Fundación de la Asociación
Española de Pediatría, Fundación SEIP. 2017.
Managment centre: FIBHULP 29 89.654 10
Calvo Rey C. KAWA-RACE. Estudio retrospectivo y pros-
pectivo multicéntrico sobre factores de riesgo y pronóstico
de la respuesta al tratamiento en la enfermedad de Kawasaki
María José Mellado Peña. Jefe de Servicio. HULP 5. Immunization strategies in children: immune res-
en niños menores de 14 años. SERPE. 2016. ponse in high risk patient’s vaccine effectiveness
Fernando Baquero Artigao. Facultativo Especialista de Área de
Managment centre: Fundación SEIP and barriers.
Pediatría. HULP. Profesor asociado. UAM
García García Ml. Perfil de interleucinas en aspirado naso- Francisco José Climent Alcalá. Facultativo Especialista de Área
Research Lines
faríngeo en niños con bronquiolitis aguda grave y otros cua- de Pediatría. Unidad de Patología Compleja. HULP. Clínico colaborador
dros respiratorios y desarrollo de sibilancias recurrentes . docente. UAM
UAX. 2017. Luis Escosa García. Facultativo Especialista de Área en Pediatría. HULP Vertically acquired HIV infection in children
Managment centre: UAX
María Milagros García López de Hortelano. Médico Adjunto • Immuno-pathogenesis: Immune-activation, inflam-
Calvo Rey C. Nuevas tecnologías al servicio del niño con de Pediatría Hospitalaria y Enfermedades Infecciosas y Tropicales. HULP mation and biomarkers
problemas complejos de salud: telemedicina. Plataforma Den- Marta García Fernández de Villalta. Facultativo Especialista de • Epidemiology, immuno-virological factors
drita. No Financiado. 2016. Área de Pediatría. HULP. Clínico colaborador docente. UAM • Comorbidities, long term follow-up, cardiovascular
Managment centre: HULP Roi Piñeiro Pérez. Jefe Asociado del Servicio de Pediatría. Hospital risk, bone disorders, metabolic abnormalities, neu-
General de Villalba rocognitive impairment, renal dysfunction.
Calvo Rey C. Desarrollo neurológico en niños con infección
del SNC por parechovirus humano. Cristina Calvo. 2016. Talía Sainz Acosta. Facultativo Especialista de Área en Pediatría. HULP. • Antiretroviral treatment: new drugs, resistances,
Profesor colaborador. UAM
Managment centre: HULP dosage, toxicity in children, simplification strate-
gies.
CLINICAL TRIALS Strategic Objective • HIV eradication: barriers, HIV reservoir, new an-
tiretroviral drugs and other strategies to achieve
1. Vertically acquired HIV infection in children: Co- HIV replication control.
Méndez Echevarría AM. Estudio multicéntrico, abierto, alea-
morbidities, biomarkers, HIV reservoir, new the- • Gut Microbiota and bacterial traslocation intes-
torizado, de fase II/III para determinar la seguridad y eficacia
rapeutic approaches. tinal as modulating factors for inflammation and
de la solitromicina en adolescentes (de 12 a 17 años de
2. Epidemiology of Paediatric Tuberculosis is Spain: Immune-activation in HIV-infected children.
edad, ambos inclusive) y niños (2 meses a < 12 años de edad)
con neumonía bacteriana adquirida en la comunidad sospe-
molecular epidemiology of drug resistant strains, • Transition to adult care: barriers, strategies to
new diagnostic tools and new drugs for TB: Phar- maintain adherence to care.
chada o confirmada. Type: Clinical Trial, phase II.
macodynamics in children and TB-drugs Off-label
HULP code: ANEXO-I 4599. Sponsored´s protocol code: CE01-203. Epidemiology of paediatric Tuberculosis (TB).
use in paediatrics.
Sponsored by: Chiltern International Spain S.A. • Epidemiology of paediatric TB. paediatric cases as
3. Congenital infections: burden of disease, prompt
Signed date: 16/08/2017 diagnosis and in-utero and postnatal management, as a sentinel for burden of diseases.
host immune response. • Molecular Epidemiology of paediatric TB: resistant
4. Epidemiology of imported and emergent disea- strains.
ses in children: Identification and management of • Immuno-pathogenesis: New diagnostic tools in
emergent outbreaks. Immuno-pathogenesis, pre- special Populations: HIV-infected, ID patients, mi-
ventive measures and management. grants and Internationally adopted children
175
 3
Information Groups by Area
3.3 Infectious Diseases and Immunity Area
• Management of critical situations. Neonatal TB, multi-
drug resistant and extra-pulmonary TB.
• New fixed-dosed combinations. Off label drugs in chil-
dren. Pharmacodinamic and pharmacokinetic.
Congenital infectious diseases
• Congenital Citomegalovirus and Toxoplasma infec-
tions: diagnostic barriers, prognostic factors, new the-
rapeutic approaches.
• CHAGAS disease and congenital TB: diagnostic ba-
rriers, prognostic factors, pharmacokinetics in new-
borns and new drugs.
Epidemiology of imported and emergent disea-
ses in children
• Paediatric International Outbreaks: Epidemiology and
public health impact: Zika. Rabies. Dengue. Chikungun-
ya. Haemorragic fevers, Mers-co.
• Imported diseases in Spain: epidemiology and special
populations: adopted, migrant, refugees, travelers and
ID children.Tropical and parasitic infections in children.
Immunization strategies in children, including
high risk patients
• Immunization and vaccine response in special popula-
tions: immunocompromised children, transplant reci-
pients, chronic patients, HIV-infected, migrants.
• Vaccine immunogenicity: barriers in paediatric popula-
tions.
Research Activity
Doctoral TheseS
García Fernández de Villalta M. Adecuación del calenda-
rio de inmunizaciones y cumplimiento de las recomenda-
ciones adicionales por su patología de base en niños con
problemas complejos de salud.[dissertation]. Madrid: UAM:
2017(22/09/2017).
Directors: Mellado MJ; Méndez Echeverría A.
García López Hortelano M. Experiencia epidemiológica, clí-
nica y preventiva en una unidad de referencia de vacunación
internacional pediátrica y niño viajero[dissertation]. Madrid:
UAM: 2017(21/12/2017).
Directors: Mellado Peña MJ; Díaz J.
Escosa García L. Cribado de la infección congénita por cito-
megalovirus en prematuros de peso adecuado y neonatos
de bajo peso para la edad gestacional[dissertation]. Madrid:
UAM: 2017(22/07/2017).
Directors: Mellado Peña MJ; del Rosal Rabés T
Climent Alcalá FJ. Utilidad de una unidad especiali-
zada en la atención de niños con patología crónica
compleja[dissertation]. Madrid: UAM: 2017(18/09/2017).
Directors: Calvo Rey C, Albajara Velasco L, Mellado Peña MJ
BOOKS AND BOOK CHAPTERS
Almaráz Garzón E, Alonso Lebrero E, Astray San Martín
A, Álvarez Calatayud G, Arriola Pereda G, Arroba Basan-
ta ML, Ballester Herrea MJ, Baquero Artigao F, Benítez
Maestre AM, Boira Sanz L, Bravo Marcos V, Cabo Bravo
176
MJ, Cañete Díaz A, Ceñal González-Fierro MJ, Corredor
Andrés B, Dago Elorza MR, Duelo Marcos M, Fernández
Escribano A, García-Sicilia López J, Giralt Muiña P, Gon-
zález Mateos JA, González Ojeda V, González Serrano MP,
Hernández Palomo R, Jiménez García JJ, Maraña Pérez AI,
Muñoz Calonge A, Muñoz Calvo MT, Natalini Martínez S,
Pascual Marcos MJ, Romero Blanco I, Rosal Rabes T, Tolín
Hernani M, Vázquez Gómez F, Vázquez López LA, Velasco
Bernardo RM, Velasco Casares M, Zafra Anta M. Chuletario
de la Sociedad de Pediatría de Madrid y Castilla La Mancha
2017. Madrid: Aries Innovación Gráfica, 2017.
Alos M, Climent Alcalá FJ. Tromboflebitis y linfangitis. In:
Guerrero J, Carón A, Barreda A, Menéndez J, Ruiz J . Manual
de diagnóstico y terapéutica en pediatría del Hospital Infantil
La Paz. 6ª Edición. Madrid: Editorial Panamericana S.L., 2017.
Ara MF, Baquero-Artigao F. Meningitis aguda. Meningitis re-
currente. In: Guerrero J, Carón A, Barreda A, Menéndez J, Ruiz
J . Manual de diagnóstico y terapéutica en pediatría del Hos-
pital Infantil La Paz. 6ª Edición. Madrid: Editorial Panamericana
S.L., 2017.
Bravo Gallego LY, Escosa García L, García López Hortelano
M. Enfermedad de Chagas. In: Guerrero J, Carón A, Barreda
A, Menéndez J, Ruiz J. Manual de diagnóstico y terapéutica
en pediatría del Hospital Infantil La Paz. 6ª Edición. Madrid:
Editorial Panamericana S.L., 2017.
Bustamante J, García López Hortelano M. Sindrome febril
en el niño viajero. In: Guerrero J, Carón A, Barreda A, Menén-
dez J, Ruiz J. Manual de diagnóstico y terapéutica en pediatría
del Hospital Infantil La Paz. 6ª Edición. Madrid: Editorial Pana-
mericana S.L., 2017. p.1513-9
Bustamante J, Méndez Echevarría A, Mellado MJ. Tubecu-
losis. In: Guerrero J, Carón A, Barreda A, Menéndez J, Ruiz J.
Manual de diagnóstico y terapéutica en pediatría del Hospital
Infantil La Paz. 6ª Edición. Madrid: Editorial Panamericana S.L.,
2017.
Climent FJ, Rodríguez de Tembleque C. Profilaxis y tra-
tamiento de la enfermedad tromboembólica. In: Guerrero J,
Carón A, Barreda A, Menéndez J, Ruiz J. Manual de diagnóstico
y terapéutica en pediatría del Hospital Infantil La Paz. 6ª Edi-
ción. Madrid: Editorial Panamericana S.L., 2017.
Daoud Pérez Z, Mellado MJ. Infecciones por Arbovirus. In:
Guerrero J, Carón A, Barreda A, Menéndez J, Ruiz J. Manual
de diagnóstico y terapéutica en pediatría del Hospital Infantil
La Paz. 6ª Edición. Madrid: Editorial Panamericana S.L., 2017
Francisco González L, Mellado MJ. Eosinofilia en niño via-
jero. In: Guerrero J, Carón A, Barreda A, Menéndez J, Ruiz J.
Manual de diagnóstico y terapéutica en pediatría del Hospital
Infantil La Paz. 6ª Edición. Madrid: Editorial Panamericana S.L.,
2017.
García M, Climent FJ, Albajara LA. Generalidades en el niño
con patología crónica compleja. In: Guerrero J, Carón A, Ba-
rreda A, Menéndez J, Ruiz J . Manual de diagnóstico y tera-
péutica en pediatría del Hospital Infantil La Paz. 6ª Edición.
Madrid: Editorial Panamericana S.L., 2017.
García Mauriño C, Escosa García L, Mellado MJ. Infección
Pediàtrica por el VIH. In: Guerrero J, Carón A, Barreda A, Me-
néndez J, Ruiz J . Manual de diagnóstico y terapéutica en pe-
diatría del Hospital Infantil La Paz. 6ª Edición. Madrid: Editorial
Panamericana S.L., 2017.
García-Mauriño C, Aracil Santos FJ, García López Hortela-
no M. Malaria. In: Guerrero J, Carón A, Barreda A, Menéndez
J, Ruiz J. Manual de diagnóstico y terapéutica en pediatría del
Hospital Infantil La Paz. 6ª Edición. Madrid: Editorial Paname-
ricana S.L., 2017. p.1529-38
Goycoechea Valdivia WA, García López Hortelano M. Infec-
ciones tropicales emergentes. In: Guerrero J, Carón A, Barre-
da A, Menéndez J, Ruiz J. Manual de diagnóstico y terapéutica
en pediatría del Hospital Infantil La Paz. 6ª Edición. Madrid:
Editorial Panamericana S.L., 2017.
Goycoechea Valdivia WA, García López Hortelano M. Vacu-
nas.Vacunas Internacionales. In: Guerrero J, Carón A, Barreda
A, Menéndez J, Ruiz J. Manual de diagnóstico y terapéutica
en pediatría del Hospital Infantil La Paz. 6ª Edición. Madrid:
Editorial Panamericana S.L., 2017.
Martín M, Sotomayor CS, García M. Alergias. Orientación
del diagnóstico etiológico y recomendaciones básicas. In:
Guerrero J, Carón A, Barreda A, Menéndez J, Ruiz J. Manual
de diagnóstico y terapéutica en pediatría del Hospital Infantil
La Paz. 6ª Edición. Madrid: Editorial Panamericana S.L., 2017.
Mellado Peña MJ, García López Hortelano M. Vacunación
en inmigrantes, adoptados, acogimiento, viajeros y convivien-
tes. In: Hidalgo I, Monton JL. Algo más que el calendario vacu-
nal. Cuestiones y respuestas.Madrid: Undergraf, 2017.
Pérez MJ, Baquero-Artigao F. Faringoamigdalitis aguda y sus
complicaciones. In: Guerrero J, Carón A, Barreda A, Menén-
dez J, Ruiz J. Manual de diagnóstico y terapéutica en pediatría
del Hospital Infantil La Paz. 6ª Edición. Madrid: Editorial Pana-
mericana S.L., 2017.
Pérez Muñoz S, García López Hortelano M, Mellado Peña
MJ. Adopcion Internacional. In: Guerrero J, Carón A, Barreda
A, Menéndez J, Ruiz J. Manual de diagnóstico y terapéutica
en pediatría del Hospital Infantil La Paz. 6ª Edición. Madrid:
Editorial Panamericana S.L., 2017.
Pérez Muñoz S, Mellado Peña MJ. Parasitosis Intestinales. In:
Guerrero J, Carón A, Barreda A, Menéndez J, Ruiz J. Manual
de diagnóstico y terapéutica en pediatría del Hospital Infantil
La Paz. 6ª Edición. Madrid: Editorial Panamericana S.L., 2017.
p.1419-30
Quesada U, Baquero-Artigao F. Sinusitis. In: Guerrero J, Ca-
rón A, Barreda A, Menéndez J, Ruiz J . Manual de diagnóstico
y terapéutica en pediatría del Hospital Infantil La Paz. 6ª Edi-
ción. Madrid: Editorial Panamericana S.L., 2017.
Reyero A, García M. Episodio aparentemente letal. Síndrome
de muerte súbita del lactante. In: Guerrero J, Carón A, Barre-
da A, Menéndez J, Ruiz J. Manual de diagnóstico y terapéutica
en pediatría del Hospital Infantil La Paz. 6ª Edición. Madrid:
Editorial Panamericana S.L., 2017.
Rimbau I, Baquero-Artigao F. Celulitis preseptal y orbitaria.
In: Guerrero J, Carón A, Barreda A, Menéndez J, Ruiz J. Manual
de diagnóstico y terapéutica en pediatría del Hospital Infantil
La Paz. 6ª Edición. Madrid: Editorial Panamericana S.L., 2017.
Sainz Acosta MJ, Torres C. Pinchazo accidental. In: Guerrero J,
Carón A, Barreda A, Menéndez J, Ruiz J . Manual de diagnóstico
y terapéutica en pediatría del Hospital Infantil La Paz. 6ª Edi-
ción. Madrid: Editorial Panamericana S.L., 2017. p.1599-1603
Salas D, Baquero Artigao F. Otitis media aguda y otitis ex-
terna. Complicaciones. In: Guerrero J, Carón A, Barreda A,
Menéndez J, Ruiz J. Manual de diagnóstico y terapéutica en
pediatría del Hospital Infantil La Paz. 6ª Edición. Madrid: Edi-
torial Panamericana S.L., 2017.
PUBLICATIONS
• Asmuth DM, Thompson CG, Chun TW, Ma ZM, Mann S, Sainz T,
Serrano-Villar S, Utay NS, García JC, Troia-Cancio P, Pollard RB, Mi-
ller CJ, Landay A, Kashuba AD. Tissue pharmacologic and virologic
determinants of duodenal and rectal gastrointestinal-associated
lymphoid tissue immune reconstitution in HIV-infected patients ini-
tiating antiretroviral therapy. J Infect Dis. 2017; 216(7): 813-8. Article.
IF: 5.186; Q1
• Baquero-Artigao F. Update on congenital and neonatal herpes in-
fections: infection due to cytomegalovirus and herpes simplex. Rev
Neurología. 2017; 64: S29-33. Article. IF: 0.601; Q4
• Baquero-Artigao F, Michavila A, Suárez-Rodríguez A, Hernández
A, Martínez-Campos L, Calvo C. Spanish Society of Pediatric In-
fectious Diseases, Spanish Society of Paediatric Clinical Immuno-
logy and Allergy, Spanish Association of Paediatric Primary Care,
and the Spanish Society of Extra-hospital Paediatrics and Primary
Health Care consensus document on antibiotic treatment in peni-
cillin or amoxicillin allergy. An Pediatr. 2017; 86(2): 99.e1-9. Article.
IF: 1.318; Q3
• Blanco-Sánchez AI, Méndez-Echevarría A, Alonso-Quintela P, García-
Perea A, Baquero-Artigao F. Fever, parotid swelling, otorrhea and
retroauricular fistula in a child. Enferm Infec Micr Cl. 2017; 35(1):
54-5. Editorial Material. IF: 1.707; Q3
• Bustamante J, Calzado I, Sainz T, Calvo C, del Rosal T, Méndez-Eche-
varría A. Epidemiological factors related to hospitalization due to
influenza in children below 6 months of age. Eur J Pediatr. 2017;
176(10): 1425-8. Article. IF: 2.242; Q2
• de Ory SJ, González-Tome MI, Fortuny C, Mellado MJ, Soler-Palacín
P, Bustillo M, Ramos JT, Muñoz-Fernández MA, Navarro ML. New
diagnoses of human immunodeficiency virus infection in the Spa-
nish pediatric HIV Cohort (CoRISpe) from 2004 to 2013. Medicine.
2017; 96(39): e7858. Article. IF: 2.028; Q2
• Durán MJP, Sanz-Gadea BM, Raves TD, Pena MJM, Baquero-Artigao
F. Osteoarticular tuberculosis in paediatrics: A review of 20 years of
cases in a tertiary hospital. An Pediatr. 2017; 87(5): 291-2. Letter. IF:
1.318; Q3
• Gómez BG, Pérez MV, Rabes TD, Santos FJA, Baquero-Artigao F.
Pyomyositis in a non-tropical area. 12 years of cased-based expe-
rience. An Pediatr. 2017; 87(6): 350-1. Letter. IF: 1.318; Q3
• Goycochea-Valdivia WA, Baquero-Artigao F, del Rosal T, Frick MA,
Rojo P, Echeverra MJ, Noguera-Julián A, Bringue X, Saavedra-Lo-
zano J, Vives-Onos I, Moliner E, Cilleruelo MJ, Cuadrado I, Colino
E, Castells L, Tagarro A, Vilas J, Soler-Palacín P, Blázquez-Gamero D.
Cytomegalovirus DNA detection by polymerase chain reaction in
cerebrospinal fluid of infants with congenital infection: Associations
with clinical evaluation at birth and implications for follow-up. Clin
Infect Dis. 2017; 64(10): 1335-42. Article. IF: 9.117; D1
• Goycochea-Valdivia WA, Moreno-Ramos F, Paño-Pardo JR, Aracil-
Santos FJ, Baquero-Artigao F, del Rosal-Rabes T, Mellado-Pena MJ,
Escosa-García L. Identifying priorities to improve.paediatric in-hos-
pital antimicrobial use by cross-sectional evaluation of prevalence
and appropriateness of prescription. Enferm Infec Micr Cl. 2017;
35(9): 556-62. Article. IF: 1.707; Q3
• Jiménez B, Sainz T, Díaz L, Mellado MJ, Navarro ML, Rojo P, Gon-
zález-Tome MI, Prieto L, Martínez J, de José MI, Ramos JT, Muñoz-
Fernández MA. Low bone mineral density in vertically HIV-infected
children and adolescents. Pediatr Infect Dis J. 2017; 36(6): 578-83.
Article. IF: 2.305; Q2
• Méndez-Echevarría A, Coronado-Poggio M, Baquero-Artigao F, del
Rosal T, Rodado-Marina S, Calvo C, Domínguez-Gadea L. Septic
177
 3
Information Groups by Area
3.3 Infectious Diseases and Immunity Area
pulmonary emboli detected by F-18-FDG PET/CT in children with
S-aureus catheter-related bacteremia. Infection. 2017; 45(5): 691-6.
Article. IF: 2.773; Q2
• Moresco MV, Hortelano MGL, Arrieta JV, Núñez MS. Guinean child
with Calabar swelling: Loiasis. An Pediatr. 2017; 86(6): 359-60. Letter.
IF: 1.318; Q3
• Pérez RP, Aguado IC. High-frequency users of Emergency De-
partments. Experience and failure of health education counselling.
An Pediatr. 2017; 87(6): 362. Letter. IF: 1.318; Q3
• Pérez RP, Martín DH, Rodríguez MAC, Cancho MD,Verrier EC, Are-
valo SG, Aguado IC. Vaccination counselling: The meeting point is
possible. An Pediatr. 2017; 86(6): 314-20. Article. IF: 1.318; Q3
• Pérez RP, Sainz-Costa T, Mellado-Peña MJ. It may be too early to try
to prove the effect of deworming on tuberculin reactivity. Pediatr
Infect Dis J. 2017; 36(2): 241. Letter. IF: 2.305; Q2
• Picazo J, Ruiz-Contreras J, Casado-Flores J, Negreira S, Baquero F,
Hernández-Sampelayo T, Otheo E, Méndez C. Effect of the different
13-valent pneumococcal conjugate vaccination uptakes on the inva-
sive pneumococcal disease in children: Analysis of a hospital-based
and population-based surveillance study in Madrid, Spain, 2007-
2015. Plos One. 2017; 12(2): e0172222. Article. IF: 2.766; Q1
• Prieto LM, McPhee CF, Rojas P, Mazariegos D, Muñoz E, Mellado
MJ, Holguin A, Navarro ML, González-Tome M, Ramos JT. Pregnancy
outcomes in perinatally HIV-infected young women in Madrid, Spain:
2000-2015. Plos One. 2017; 12(8): e0183558. Article. IF: 2.766; Q1
• Rabes TD, Baquero-Artigao F, Méndez-Echevarría AM, Peña MJM.Tu-
berculosis in infants less than 3 months of age. Enferm Infec Micr Cl.
2017; 35(4): 243-5. Article. IF: 1.707; Q3
• Rabes TDR, Baquero-Artigao F, Méndez-Echevarría AM, Peña MJM.
Reply to Tuberculosis in infants less than 3 months of age of Risa-
ralda, Colombim. Enferm Infec Micr Cl. 2017; 35(5): 328-9. Letter. IF:
1.707; Q3
• Ruiz-Contreras J, Picazo J, Casado-Flores J,
Baquero-Artigao F, Hernández-
Sampelayo T, Otheo E,
Méndez C,
178
del Amo M, Balseiro C. Impact of 1.3-valent pneumococcal con-
jugate vaccine on pneumococcal meningitis in children. Vaccine.
2017; 35(35): 4646-51. Article. IF: 3.285; Q2
• Sainz T, Navarro ML. HIV-infected youths: Transition in Spain com-
pared to the netherlands. Clin Infect Dis. 2017; 64(2): 230. Letter. IF:
9.117; D1
• Salas-Mera D, Sainz T, Mira MRGG, Méndez-Echevarría A. Gentami-
cin resistant E coli as a cause of urinary tract infections in children.
Enferm Infec Micr Cl. 2017; 35(7): 465-6. Letter. IF: 1.707; Q3
• Sánchez BS, Tato LMP, Martín SG, Pérez E, Grasa C,Valderrama S, de
Augusto I, Sierra M, Ros MG, Aguado I, Hortelano MGL. Imported
malaria in children in Madrid, Spain, 2007-2013. Enferm Infec Micr
Cl. 2017; 35(6): 348-53. Article. IF: 1.707; Q3
• Serrano-Villar S, Vásquez-Domínguez E, Pérez-Molina JA, Sainz T, de
Benito A, Latorre A, Moya A, Gosalbes MJ, Moreno S. HIV, HPV, and
microbiota: partners in crime? AIDS. 2017; 31(4): 591-4. Letter. IF:
4.914; Q1
• Serrano-Villar S, Vázquez-Castellanos JF, Vallejo A, Latorre A, Sainz
T, Ferrando-Martínez S, Rojo D, Martínez-Botas J, del Romero J,
Madrid N, Leal M, Mosele JI, Motilva MJ, Barbas C, Ferrer M, Moya
A, Moreno S, Gosalbes MJ, Estrada V. The effects of prebiotics on
microbial dysbiosis, butyrate production and immunity in HIV-in-
fected subjects. Mucosal Immunol. 2017; 10(5): 1279-93. Article. IF:
7.36; Q1
• Serrano-Villar S, Sainz T, Ma ZM, Utay NS, Wook-Chun T, Mann S,
Kashuba AD, Siewe B, Albanese A,Troia-Cancio P, Sinclair E, So-
masunderam A, Yotter T, Deeks SG, Landay A, Pollard RB,
Miller CJ, Moreno S, Asmuth DM. Correction: Effects
of Combined CCR5/Integrase Inhibitors-Based
Regimen on Mucosal Immunity in HIV-Infec-
ted Patients Naive to Antiretroviral The-
rapy: A Pilot Randomized Trial. Plos Pathog. 2017; 13(5): e1006368.
Article. IF: 6.158; D1
• Tagarro A, Otheo E, Baquero-Artigao F, Navarro ML,Velasco R, Ruiz
M, Penín M, Moreno D, Rojo P, Madero R. Dexamethasone for pa-
rapneumonic pleural effusion: A randomized, double-blind, clinical
trial. J Pediatr-US. 2017; 185: 117-23. Article. IF: 3.667; Q1
• Thorne C, Turkova A, Indolfi G, Venturini E, Giaquinto C, Goetghe-
buer T, Hainaut M,Van der Kelen E, Konigs C, Mantzsch K, Baumann
U, de Martino M, Galli L, Giacomet V, Nicolini LA, del Puente F, Ga-
biano C, Guarino A, Martinazzi S, Miniaci A, Dobsz S, Marczynska M,
Ene L, Duiculescu D, Miloenko M, Dodonov K, Latysheva I,Voronin E,
Rojo P, Ramos JT, Navarro M, de Ory SJ, Sainz T, Mellado MJ, García
M, Pérez C, Moreno D, Núñez E, Gracia M,Terol P, Neth O, Falcón L,
Otero C, Rincón E, López C, Santos JL, Couceiro J, Noguera-Julián
A, Fortuny C, Soler-Palacín P, Espiau M, Mur A, Coll MT,Valmanya MT,
Mayol L, Méndez MJ, Rodrigo C, Escribano J, Rius N, Rovira N, Cala-
via O, García L, Pineda V, Soriano-Arandes A, Rudin C, Duppenthaler
A, Judd A, Malyuta R, Volokha A, Raus I, Kaleeva T, Baryshnikova Y,
Soloha S, Bashkatova N, Glutshenko O, Ruban Z, Primak N, Kiseleva
G. Coinfection with HIV and hepatitis C virus in 229 children and
young adults living in Europe. AIDS. 2017; 31(1): 127-35. Article. IF:
4.914; Q1
Public Projects
Sainz Costa T. Contrato Juan Rodés (JR16/00021). ISCIII.
2017-2018.
Managment centre: FIBHULP
Sainz Costa T. Evaluación de factores determinantes del re-
servorio viral en niños infectados por el VIH: avanzando hacia
la erradicación (ICI14/00207 ). ISCIII. 2015-2017.
Managment centre: FIBHULP
Private Projects
Mellado Peña MJ. Valoración de riesgo cardiovascular en ni-
ños y adolescentes infectados por el VIH. Asociación para el
Estudio de Lls Enfermedades Infecciosas. 2014-Ongoing.
Managment centre: FIBHULP
Mellado Peña MJ. Proyecto COCCUN: Respuesta a vacunas
en niños y adolescentes infectados por el vih en tratamiento
antirretroviral: el cociente CD4/CD8 como predictor de res-
puesta.Varios Investigadores. 2017-Ongoing.
Managment centre: FIBHULP
INTERNATIONAL Projects
Saiz Acosta T. Utilidad de la ecografía torácica en la indi-
cación de ventilación no invasiva en la bronquiolitis aguda
del lactante hospitalizado. Estudio de Cohorte. (PI-2525).
European Society of Pediatric Infectious Diseases (ESPID).
2017-Ongoing.
Managment centre: FIBHULP
Mellado Peña MJ. Efecto de una intervención nutricional
inmunomoduladora sobre la microbiota, translocación bac-
teriana, inflamación/activación inmune y respuesta a vacunas
en la infección por el VIH en niños. Estudio piloto pediabiota.
European Society of Pediatric Infectious Diseases (ESPID).
2014-Ongoing.
Managment centre: FIBHULP
Mellado Peña MJ. Zikaction: Preparedness, research and
action network on maternal-paediatric axis of zika infection
in latin america and the caribbean (H2020-SC1-2016-RTD-
Zika). UE. 2017-Ongoing.
Managment centre: Fundación PENTA
Mellado Peña MJ. INFRADEV - European Paediatric Transla-
tional Research Infrastructure (H2020-ID-EPTRI). UE. 2017-
2019.
Managment centre: FIBHULP
CLINICAL TRIALS
Mellado Peña MJ. Estudio de la infección por virus influenza
en niños hospitalizados en España en dos estaciones gripa-
les consecutivas. Análisis de costos médicos directos. Type:
NO-EPA.
HULP code: PI-2794. Sponsored´s protocol code: HOSPIGRIP-2016.
Sponsored by: Fundación Vasca de Innovación e Investigación
Sanitarias.
Signed date: 08/06/2017
179
 3
Information Groups by Area
3.3 Infectious Diseases and Immunity Area
Translational Research
in Pediatric Oncology,
Hematopoietic Group
10 41.558 5
Antonio Pérez Martínez. Facultativo Especialista de Área
en Pediatría, Oncología y Hematología. HULP
David Bueno Sánchez. Facultativo Especialista de Área en Pediatría,
Oncología y Hematología. HULP
Pilar Carrasco Salas. Diagnóstico Molecular. HULP
Adela Escudero López. Investigadora Postdoctoral. HULP
Berta González Martínez. Facultativo Especialista de Área en
Pediatría. HULP
Pablo González Navarro. Técnico en Laboratorio. HULP
Pedro María Rubio Aparicio. Facultativo Especialista de Área en
Pediatría, Oncología y Hematología. HULP
Sonsoles San Román Pacheco. Facultativo Especialista de Área
en Pediatría, Oncología y Hematología. HULP
Jaime Valentín Quiroga. Investigador Predoctoral . HULP
María Vela Cuenca. Investigador Postdoctoral . HULP
Strategic Objective
Our research program focuses on the molecular and
immunological characterization of childhood cancer;
the development of cell therapies, primarily through
the susceptibility of tumor cells to Natural Killer
cells; and the optimization of hematopoietic stem
cells transplantation.
Research Lines
• Analysis of solid/hematological tumors samples to
determine their susceptibility to cell therapy, at
functional, protein expression and genetic level.
180
• Cell therapy with activated NK cells in childhood
cancer.
• Hematopoietic progenitor transplantation as a
platform for cell therapy.
• Cell therapy with memory T lymphocytes as adop-
tive immunotherapy in transplantation of haema-
topoietic progenitors.
• Optimization of cell therapy by the generation of
an NKG2D antigenic chimeric receptor (NKG2D-
CAR). Evaluation of its specificity, persistence and
activity (in vitro and in vivo) for the treatment of
childhood cancer.
• Optimization of NK cell therapy using nanotech-
nology and antigenic chimeric receptors (CAR).
• Induction of immunological tolerance in solid or-
gan transplantation through the induction of he-
matopoietic mixed chimerism by cell therapy.
• Development of academic clinical trials and co-
llaborations with the pharmaceutical industry as
a strategy for the development of new therapies
more effective and with fewer side effects in child-
hood cancer.
Research Activity
Doctoral TheseS
Gómez Santos C. Análisis comparativo de los resulta-
dos del trasplante de sangre de cordón umbilical y ha-
ploidéntico en pacientes pediátricos con hemopatías
malignas[dissertation]. Madrid: UAM: 2017(07/09/2017).
Director: Pérez Martínez A.
Molina Angulo B. Patrón de recaída postrasplante hemato-
poyético en pacientes pediátricos con hemopatías malignas.
Evaluación del efecto aloinmune[dissertation]. Madrid: UAM:
2017(01/09/2017).
Director: Pérez Martínez A.
PUBLICATIONS
• Bautista F, Gallego S, Canete A, Mora J, de Heredia CD, Cruz O,
Fernández JM, Rives S, Berlanga P, Hladun R, Ribelles AJ, Madero L,
Ramírez M, Delgado RF, Pérez-Martínez A, Mata C, Llort A, Broto
JM, Cela ME, Ramírez G, Sabado C, Acha T, Astigarraga I, Sastre A,
Muñoz A, Guibelalde M, Moreno L. Early clinical trials in paediatric
oncology in Spain: a nationwide perspective. An Pediatr. 2017; 87(3):
155-63. Article. IF: 1.318; Q3
• Carpio MC, Álvarez DN, Marqués CH, Martínez AP, Atienza AL, Ló-
pez LM. Intracranial germ cell tumours: A 21-year review. An Pediatr.
2017; 86(1): 20-27. Article. IF: 1.318; Q3
• Chamorro-Vina C, Valentín J, Fernández L, González-Vicent M, Pé-
rez-Ruiz M, Lucía A, Culos-Reed SN, Díaz MA, Pérez-Martínez A.
Influence of a moderate-intensity exercise program on early NK
cell immune recovery in pediatric patients after reduced-intensity
hematopoietic stem cell transplantation. Integr Cancer Ther. 2017;
16(4): 464-72. Article. IF: 2.657; Q1
• Fernández L, Metais JY, Escudero A,Vela M,Valentín J,Vallcorba I, Lei-
vas A, Torres J, Valeri A, Patiño-García A, Martínez J, Leung W, Pérez-
Martínez A. Memory T cells expressing an NKG2D-CAR efficiently
target osteosarcoma cells. Clin Cancer Res. 2017; 23(19): 5824-35.
Article. IF: 10.199; D1
• Fiuza-Luces C, Padilla JR, Soares-Miranda L, Santana-Sosa E, Quiroga
JV, Santos-Lozano A, Pareja-Galeano H, Sanchís-Gomar F, Lorenzo-
González R, Verde Z, López-Mojares LM, Lassaletta A, Fleck SJ, Pé-
rez M, Pérez-Martínez A, Lucía A. Exercise intervention in pediatric
patients with solid tumors: The physical activity in pediatric cancer
trial. Med Sci Sport Exer. 2017; 49(2): 223-30. Article. IF: 4.291; D1
• Fiuza-Luces C, Padilla JR, Valentín J, Santana-Sosa E, Santos-Lozano
A, Sanchís-Gomar F, Pareja-Galeano H, Morales JS, Fleck SJ, Pérez
M, Lassaletta A, Soares-Miranda L, Pérez-Martínez A, Lucía A. Effects
of exercise on the immune function of pediatric patients with solid
tumors insights from the PAPEC randomized trial. Am J Phys Med
Rehab. 2017; 96(11): 831-7. Article. IF: 1.843; Q2
• García M, Barrio R, García-Lavandeira M, García-Rendueles AR, Es-
cudero A, Díaz-Rodríguez E, del Blanco DG, Fernández A, de Rijke
YB, Vallespín E, Nevado J, Lapunzina P, Matre V, Hinkle PM, Hokken-
Koelega ACS, de Miguel MP, Cameselle-Teijeiro JM, Nistal M, Álvarez
CV, Moreno JC. The syndrome of central hypothyroidism and ma-
croorchidism: IGSF1 controls TRHR and FSHB expression by diffe-
rential modulation of pituitary TGF beta and Activin pathways. SCI
Rep-Uk. 2017; 7: 42937. Article. IF: 4.122; Q1
• Hernández-Jiménez E, Cubillos-Zapata C, Toledano V, de Diego RP,
Fernández-Navarro I, Casitas R, Carpio C, Casas-Martín J, Valentín
J, Varela-Serrano A, Avendaño-Ortiz J, Álvarez E, Aguirre LA, Pérez-
Martínez A, de Miguel MP, Belda-Iniesta C, García-Rio F, López-Co-
llazo E. Monocytes inhibit NK activity via TGF-beta in patients with
obstructive sleep apnoea. Eur Respir J. 2017; 49(6): 1602456. Article.
IF: 12.242; D1
• Ruiz-Pinto S, Pita G, Patiño-García A, Alonso J, Pérez-Martínez A,
Cartón AJ, Gutiérrez-Larraya F, Alonso MR, Barnes DR, Dennis J,
Michailidou K, Gómez-Santos C, Thompson DJ, Easton DF, Benítez
J, González-Neira A. Exome array analysis identifies GPR35 as a no-
vel susceptibility gene for anthracycline-induced cardiotoxicity in
childhood cancer. Pharmacogenet Genomics. 2017; 27(12): 445-53.
Article. IF: 2.25; Q2
• Salas PC, Lapunzina P, Pérez-Martínez A. Genetic predisposition to
childhood cancer. An Pediatr. 2017; 87(3): 125-7. Editorial Material.
IF: 1.318; Q3
Public Projects
Pérez Martínez A. Ayudas para la movilidad de profesiona-
les sanitarios e investigadores del SNS (BA16/00048). ISCIII.
2017.
Managment centre: FIBHULP
Pérez Martínez A. Diseño del receptor antigénico quimérico
NKG2D (CAR-NKG2D) como terapia celular en los sarco-
mas infantiles (PI15/00973). ISCIII. 2016-2018.
Managment centre: FIBHULP
Pérez Martínez A. Realización de contratos para técnicos de
laboratorio (PEJ16/MED/TL-0713). CAM. 2017-2019.
Managment centre: FIBHULP
Private Projects
Pérez Martínez A. Estudio mediante tecnología de alto ren-
dimiento de la predisposición hereditaria al cáncer infantil.
Fundación Cris Contra el Cáncer, CAM. 2017.
Managment centre: FIBHULP
Pérez Martínez A. Infusión de células natual killer como tra-
tamiento de consolidacion en niños y adolescentes con leu-
cemia mieloblástica aguda. Fundación Mutua Madrileña. 2015.
Managment centre: FIBHULP
Pérez Martínez A. Inmunoterapia en sarcomas: combinación
del anticuerpo anticxcr4 y la terapia celular NK. Fundación La
Sonrisa de Alex, Fundación Mari Paz Jiménez Casado, CAM.
2016.
Managment centre: FIBHULP
Pérez Martínez A. NK cell team-2: inmunoterapia con célu-
las natural killer en el niño. Fundación Cris Contra el Cáncer.
2014.
Managment centre: FIBHULP
Pérez Martínez A. Optimización de la terapia celular NK en
sarcomas pediátricos mediante el uso nanopartículas multi-
funcionalizadas. Fundación Cris Contra el Cáncer. 2013.
Managment centre: FIBHULP
Pérez Martínez A. Programa de educación médica en tras-
plante pediátrico. Gilead Sciences S.L. 2017.
Managment centre: FIBHULP
Pérez Martínez A. Terapia celular basada en el receptor
quimérico NKG2D (CAR-NKG2D) para la leucemia infantil.
Fundación Uno Entre Cien Mil. 2015.
Managment centre: FIBHULP
Pérez Martínez A. Terapia celular con el receptor antigénico
quimérico NKG2D(CAR-NKG2D) para los tumores sólidos
infantiles. Fundación Asociación Española Contra el Cáncer.
2016.
Managment centre: FIBHULP
Pérez Martínez A. Unidad de investigación y de terapias
avanzadas en hematooncologia infantil. Fundación Cris Con-
tra el Cáncer. 2016.
Managment centre: FIBHULP
181
 3
Information Groups by Area
3.3 Infectious Diseases and Immunity Area
Rubio Aparicio PM. Actualización y renovación de la activi-
dad en el Servicio de Oncología Pediátrica del Hospital Uni-
versitario La Paz.Varios Financiadores. 2012.
Managment centre: FIBHULP
CLINICAL TRIALS
Pérez Martínez A. Estudio abierto, multicéntrico, de grupos
paralelos para comparar la farmacocinética (FC), la farmaco-
dinámica (FD) y la seguridad de febuxostat entre pacientes
pediátricos (de 6 y <18 años de edad) y adultos.Type: Clinical
Trial, phase II.
HULP code: ANEXO-I 4717. Sponsored´s protocol code: FLO-02.
Sponsored by: Menarini Ricerche S.P.A.
Signed date: 07/06/2017
Pérez Martínez A. Estudio adaptativo y aleatorizado de fase
III para comparar la eficacia y la seguridad de defibrotide
frente al mejor tratamiento de soporte en la prevención de
la enfermedad venooclusiva hepática en pacientes adultos y
pediátricos sometidos a un trasplante hematopoyético de cé-
lulas madre. Type: Clinical Trial, phase IIIa.
HULP code: ANEXO-I 4696. Sponsored´s protocol code: 15-007.
Sponsored by: Jazz Pharmaceuticals Ireland Ltd.
Signed date: 26/04/2017
Pérez Martínez A. Estudio adaptativo y aleatorizado de fase
III para comparar la eficacia y la seguridad de defibrotide
frente al mejor tratamiento de soporte en la prevención de
182
la enfermedad venooclusiva hepática en pacientes adultos y
pediátricos sometidos a un trasplante hematopoyético de cé-
lulas madre. Type: Clinical Trial, phase IIIa.
HULP code: 4696. Sponsored´s protocol code: 15-007.
Sponsored by: Jazz Pharmaceuticals Ireland Ltd.
Signed date: 10/01/2017
Pérez Martínez A. Incidence and outcomes associated with
the management of adenovirus infections in allogeneic hemato-
poietic cell transplant recipients: advance. Type: EPA-OD.
HULP code: PI-2592. Sponsored´s protocol code: CHI-ADE-2016-01.
Sponsored by: Chimerix Inc.
Signed date: 11/01/2017
Pérez Martínez A. LCH-IV international collaborative
treatment protocol for children and adolescents with langer-
hans cell histiocytosis. Type: Clinical Trial, phase IV.
HULP code: 4709. Sponsored´s protocol code: LCH-IV 042011.
Sponsored by: Sociedad Española de Oncología y Hematolo-
gía Pediátricas.
Signed date: 17/02/2017
Rubio Aparicio PM. Ensayo clínico en fase III multicéntri-
co, aleatorizado, doble ciego, controlado por placebo, con
grupos paralelos para investigar la eficacia, seguridad y to-
lerabilidad de naloxona HCL LP comprimidos en pacientes
con estreñimiento inducido por opioides. Type: Clinical Trial,
phase I.
HULP code: 4898. Sponsored´s protocol code: BAY 73-4506/15906.
Sponsored by: Bayer AG.
Intestinal Diseases
Research Group (HUF)
Fernando Bermejo San José. Jefe Servicio de
Digestivo. HUF
Alicia Algaba García. Investigadora Servicio de Digestivo.
HUF
María del Mar Aller Zamanillo. Enfermera del Servicio
de Digestivo. HUF
Carolina Aulló González. Médico Adjunto Servicio de
Radiología. HUF
Daniel Bonillo Cambrodón. Médico Adjunto Servicio de
Digestivo. HUF
Antonio Guardiola Arévalo. Médico Adjunto Servicio de
Digestivo. HUF
Iván Guerra Marina. Médico Adjunto Servicio de Digestivo. HUF
Estíbaliz Pérez Viejo. Médico Adjunto Servicio de Cirugía General
y Digestiva. HUF
Alfredo Rivera Díaz. Médico Adjunto Servicio de Cirugía General
y Digestiva. HUF
Ángel Serrano del Moral. Médico Adjunto Servicio de Cirugía
General y Digestiva. HUF
Strategic Objective
The research group is formed by gastroenterolo-
gists, surgeons, radiologist, biologist and nurse, and
its research area focuses on intestinal pathology, with
special emphasis on chronic inflammatory bowel
disease, which mainly includes two clinical entities,
ulcerative colitis and Crohn’s disease. Also our group
has as areas of interest other intestinal diseases such
as colorectal cancer.
Research Lines
The main lines of research include the participa-
tion and implementation of clinical and basic stu-
dies in ulcerative colitis and Crohn’s disease, as
well as epidemiological studies and clinical trials
with new drugs and new therapies (such as
stem cells) for the treatment of inflammatory
bowel disease. Additionally, participation in
basic, clinical and epidemiological studies in
colorectal cancer.
183
 3
Information Groups by Area

Internal Medicine and

Systemic Diseases Group

3.4
Large System
Pathologies
Area 23 169.065 11

Francisco García Río

Francisco Arnalich Fernández. Jefe de Servicio de
Medicina Interna. HULP. Catedrático. Facultad de Medicina. UAM
354 1,664.556
Gema Atienza Toledo. Técnico de Laboratorio. UAM
271 1,329.417 Anna Bordas Sánchez. Investigadora Predoctoral. UAM
11.86% 31.92% José Luis Cedillo Mireles. Becario Predoctoral (Contrato FPU). UAM
María del Carmen Fernández Capitán. Jefa de Sección de
Medicina Interna. HULP
Internal Medicine and Systemic Diseases Group Carolina Martín Sánchez. Becaria Predoctoral (Contrato FPI). UAM
Organic Dysfunction and Failure in the Aggression Group Carmen Montiel López. Catedrática. Facultad de Medicina. UAM
María Angustias Quesada Simón. Facultativo Especialista de
Respiratory Diseases Group Área en Medicina Interna. HULP. Profesora Honoraria. UAM
Jaime Renart Pita. Investigador Científico. IIB Alberto Sols
Regulation of Gene Expression and by Hypoxia Group
Juan José Ríos Blanco. Subdirector Médico. HULP
Nephrology Group
Neonatology Group Strategic Objective
In the setting of the systemic response frequently
Aging and Fragility in the Elderly Group found in patients attended in Internal Medicine wards,
Molecular Hepatology Group our group has studied some regulatory mechanisms
of the innate immune response in patients with sepsis
Diagnosis and Treatment of Allergic Diseases Group and other inflammatory states such as acute coro-
nary syndromes (ACS), cystic fibrosisand cancer.
Gynecologic Oncology Group The first line of our research is the link between the
parasympathetic and innate immune systems, that is
Patient Blood Management Group the molecular mechanisms by which acetylcholine
Endocrine Diseases Group can influence the immune system via the “cholinergic
anti-inflammatory pathway”.
Urology Group This pathway is mediated by the vagus nerve whichre-
leases acetylcholine to interact with the α7 subunit
Health Care Nurses Research Group of the nicotinic acetylcholine receptor (α7nAChR).
We firstly reported that the neuronal α7 nicotinic
Maternal and Fetal Medicine Group receptor subunit gene (CHRNA7) is partially dupli-
Emergency and Critical Pathology Group cated in the human genome forming a hybrid gene
(CHRFAM7A) with the novel FAM7A gene, and pro-
184
vided experimental data showing that dupα7 could
modulate α7 receptor-mediated synaptic transmis-
sion and cholinergic anti-inflammatory response (J
Biol Chem 2011). The Toll-like receptor (TLR) plays
an important role in the induction of the hyperin-
flammatory response and tissue injury in sepsis. We
found that the α7 gene expression level in septic pa-
tients’ peripheral blood mononuclear cells (PBMC) is
a clinically relevant marker to assess the magnitude
of the patient’s inflammatory state, disease severity,
and clinical outcome (J Infect Dis 2015).
Another exciting line of our research is the involve-
ment of the α7-nicotinic receptor and its endoge-
nous modulator dupα7 in human smoking- related
tumors, and particularly their involvement in to-
bacco carcinogen-induced tumor development and
chemotherapy resistence. This topic has attracted a
grant from the Ministerio de Economia y Compe-
titividad from 2014-2017. Besides, professor Jaime
Renart who works in our team group, is doing new
research on the molecular mechanisms of podopla-
nin, a type I transmembrane mucin widely known as
a marker for lymphatic endothelial cells that has a
critical role during development of the heart, lungs
and lymphatic endothelial system. The expression of
podoplanin is significantly enhanced during tissue-
remodelling processes and in several types of human
cancer, including squamous cell carcinomas.
Research Lines
Applied research lines:
• Molecular mechanisms involved in the innate im-
mune response.
• Link between the parasympathetic and innate im-
mune systems.
185
 3
Information Groups by Area
3.4 Large System Pathologies Area
Collaborative research line:
• Adaptative imnune response in human immunodefi-
ciency virus (HIV) infection.
• Multicentric group: RIETE group (Registro Español de
Enfermedad Trombo-Embólica).
• Molecular mechanisms of podoplanin during tissue-
remodelling processes and in several types of human
cancer.
• Mechanisms and clinical features of systemic autoimm-
ne diseases.
Lines of study framed in basic research
projects:
• Study of the pathophysiological role of nicotinica7 and
dup-a7 receptors expressed in human macrophages,
neurons and lung carcinoma cells.
• Identification of signalling pathways connecting nicoti-
nic alpha7 receptors and negative regulators of TLR-
mediated inflammation in human macrophages.
Research Activity
Doctoral TheseS
Cedillo Mireles JL. Implicación fisiopatológica del receptor ni-
cotínico α7 y de su duplicado parcial dupα7 en sepsis y cán-
cer de pulmón[dissertation]. Madrid: UAM: 2017(05/09/2017).
Directors: Montiel López C; Arnalich Fernández F.
Martín Sánchez C. Identificación de un nuevo receptor nico-
tínico α7dup/α7 mixto y su papel fisiopatológico en la neuro-
transmisión y neuroinflamación[dissertation]. Madrid: UAM:
2017(20/09/2017).
Directors: Montiel López C; Arnalich Fernández F.
PUBLICATIONS
• Alonso-Fernández A, de la Peña M, Carrera M, Suquía AG, Casitas
R, García-Rio F, Martínez-Cerón E, Pierola J, Barcelo A, Soriano JB,
Fernández-Capitán C. OSA and recurrent VTE causality or cause?
Response. Chest. 2017; 151(2): 515-6. Letter. IF: 7.652; Q1
• Álvarez E, Toledano V, Morilla F, Hernández-Jiménez E, Cubillos-Za-
pata C, Varela-Serrano A, Casas-Martín J, Avendaño-Ortiz J, Aguirre
LA, Arnalich F, Maroun-Eid C, Martín-Quirós A, Díaz MQ, López-
Collazo E. A system dynamics model to predict the human monocy-
te response to endotoxins. Front Immunol. 2017; 8: 915. Article. IF:
5.511; Q1
• Arandia NI, Simeón-Aznar CP, del Castillo AG, Arguelles DC, Ru-
bio-Rivas M, Martínez LT, Hernández FJG, Comet LS, Arberas MVE,
Ortego-Centeno N, Freire M, Alfonso BM, Hitos JAV, Blanco JJR,
Parra JAT, Rodríguez-Carballeira M, Ballve AM, Fernández AJC, Salas
XP, Vuelta ABM, Muñoz MR, Pla VF, Espinosa G. Influence of antibo-
dy profile in clinical features and prognosis in a cohort of Spanish
patients with systemic sclerosis. Clin Exp Rheumatol. 2017; 35(4):
S98-105. Article. IF: 3.201; Q2
• Barrios D, Chavant J, Jiménez D, Bertoletti L, Rosa-Salazar V, Muriel
A, Viallón A, Fernández-Capitán C, Yusen RD, Monreal M. Treatment
of right heart thrombi associated with acute pulmonary embolism.
Am J Med. 2017; 130(5): 588-95. Article. IF: 5.117; Q1
• Bordas A, Cedillo JL,Arnalich F, Esteban-Rodríguez I, Guerra-Pastrián
L, de Castro J, Martín-Sánchez C, Atienza G, Fernández-Capitán C,
Ríos JJ, Montiel C. Expression patterns for nicotinic acetylcholine
186
receptor subunit genes in smoking-related lung cancers. Oncotar-
get. 2017; 8(40): 67878-90. Article. Not Indexed
• da Silva IL, Montero-Montero L, Martín-Villar E, Martín-Pérez J, Sainz
B, Renart J, Simoes RT,Veloso ES,Teixeira CS, de Oliveira MC, Ferrei-
ra E, Quintanilla M. Reduced expression of the murine HLA-G ho-
molog Qa-2 is associated with malignancy, epithelial-mesenchymal
transition and stemness in breast cancer cells. SCI Rep-Uk. 2017; 7:
6276. Article. IF: 4.122; Q1
• Freire M, Rivera A, Sopena B, Vilella CT, Guillén-del Castillo A, Ar-
güelles DC, Rubio JLC, Rivas MR, Martínez LT, Parra JAT, Carballeira
MR, Arandia NI, Hernández FJG, Arberas MVE, Comet LS, Hitos JAV,
Blanco JJR, Ballve AM, Salas XP,Vuelta ABM, Muñoz MR, Pla VF, Aznar
CPS. Clinical and epidemiological differences between men and wo-
men with systemic sclerosis: a study in a Spanish systemic sclerosis
cohort and literature review. Clin Exp Rheumatol. 2017; 35(4): S89-
97. Review. IF: 3.201; Q2
• González-Suárez I, Ríos-Blanco JJ, Arpa J. Accelerated atherosclero-
sis in ANCA-associated vasculitis. Acta Neurol Scand. 2017; 136(6):
688-93. Article. IF: 3.126; Q2
• Gouin B, Blondón M, Jiménez D, Fernández-Capitán C, Bounameaux
H, Soler S, Duce R, Sahuquillo JC, Ruiz-Giménez N, Monreal M. Cli-
nical prognosis of nonmassive central and noncentral pulmonary
embolism a registry-based cohort study. Chest. 2017; 151(4): 829-
37. Article. IF: 7.652; Q1
• Jara-Palomares L, Otero R, Jiménez D, Carrier M, Tzoran I, Bren-
ner B, Margeli M, Praena-Fernández JM, Grandone E, Monreal M,
(Fernández-Capitán C). Development of a risk prediction score for
occult cancer inpPatients with VTE. Chest. 2017; 151(3): 564-71. Ar-
ticle. IF: 7.652; Q1
• Mahe I, Chidiac J, Bertoletti L, Font C, Trujillo-Santos J, Peris M,
Ductor CP, Nieto S, Grandone E, Monreal M, (Fernández-Capitán
C). The clinical course of venous thromboembolism may differ ac-
cording to cancer site. Am J Med. 2017; 130(3): 337-47. Article. IF:
5.117; Q1
• Martínez-Sánchez N, Pérez-Pinto S, Robles-Marhuenda A, Arnalich-
Fernández F, Camean MM, Zalvide EH, Bartha JL. Obstetric and pe-
rinatal outcome in anti-Ro/SSA-positive pregnant women: a pros-
pective cohort study. Immunol Res. 2017; 65(2): 487-94. Article. IF:
2.487; Q3
• Montejano R, Stella-Ascariz N, Monge S, Bernardino JI, Pérez-Valero
I, Montes ML, Valencia E, Martín-Carbonero L, Moreno V, González-
García J, Arnalich F, Mingorance J, Berniches LP, Perona R, Arribas JR.
Impact of antiretroviral treatment containing tenofovir difumarate
on the telomere length of Aviremic HIV-infected patients. JAIDS-J
Acq Imm Def. 2017; 76(1): 102-9. Article. IF: 4.116; Q1
• Moustafa F, Fernández S, Fernández-Capitán C, Nieto JA, Pedrajas
JM, Visona A, Valero B, Marchena PJ, Braester A, Monreal M. Uterine
bleeding during anticoagulation in women with venous thromboe-
mbolism. Thromb Res. 2017; 151 Suppl 1: S1-5. Article. IF: 2.779; Q2
• Negredo A, de la Calle-Prieto F, Palencia-Herrejón E, Mora-Rillo M,
Astray-Mochales J, Sánchez-Seco MP, López EB, Menárguez J, Fer-
nández-Cruz A, Sánchez-Artola B, Keough-Delgado E, de Arellano
ER, Lasala F, Milla J, Fraile JL, Gavín MO, de la Gandara AM, Pérez LL,
Díaz-Díaz D, López-García MA, Delgado-Jiménez P, Martín-Quirós
A, Trigo E, Figueira JC, Manzanares J, Rodríguez-Baena E, García-
Comás L, Rodríguez-Fraga O, García-Arenzana N, Fernández-Díaz
MV, Cornejo VM, Emmerich P, Schmidt-Chanasit J, Arribas JR. Auto-
chthonous Crimean-Congo hemorrhagic fever in Spain. New Engl J
Med. 2017; 377(2): 154-61. Article. IF: 79.258; D1
• Newton DH, Bosch MM, Amendola M, Wolfe L, Ductor CP, Lecum-
berri R, Levy MM, (Fernández-Capitán C). Analysis of noncatheter-
associated upper extremity deep venous thrombosis from the RIE-
TE registry. J Vasc Surg Venous Lymphat Disord. 2017; 5(1): 18-24.
Article. IF: 1,619; Q3.0
• Roldán T, Ríos JJ, Villamañán E, Waxman AB. Complications associa-
ted with the use of oral anticoagulation in patients with pulmonary
arterial hypertension from two referral centers. Pulm Circ. 2017;
7(3): 692-701. Article. IF: 2.283; Q2
• Roldán T,Villamañán E, Ríos JJ,Waxman AB. Assessment of the quality
of anticoagulation management in patients with pulmonary arterial
hypertension. Thromb Res. 2017; 160: 83-90. Article. IF: 2.779; Q2
• Rubio-Rivas M, Simeón-Aznar CP, Velasco C, Mari-Alfonso B, Espi-
nosa G, Corbella X, Colunga-Argüelles D, Egurbide-Arberas MV,
Ortego-Centeno N, Vargas-Hitos JA, Freire M, Ríos-Blanco JJ, Tra-
piella-Martínez L, Rodríguez-Carballeira M, Fonollosa-Pla V. Chan-
ges in the pattern of death of 987 patients with systemic sclerosis
from 1990 to 2009 from the nationwide Spanish Scleroderma Re-
gistry (RESCLE). Clin Exp Rheumatol. 2017; 35(4): S40-7. Article. IF:
3.201; Q2
• Solans-Laque R, Fraile G, Rodríguez-Carballeira M, Caminal L, Casti-
llo MJ, Martínez-Valle F, Sáez L, Ríos JJ, Solanich X, Oristrell J, Pasquau
F, Fonseca E, Zamora M, Callejas JL, Frutos B, Abdilla M, Fanlo P,
García-Sánchez I, López-Dupla M, Sopena B, Pérez-Iglesias A, Bosch
JA. Clinical characteristics and outcome of Spanish patients with
ANCA-associated vasculitides Impact of the vasculitis type, ANCA
specificity, and treatment on mortality and morbidity. Medicine.
2017; 96(8): e6083. Article. IF: 2.028; Q2
• Tong HY, Borobia AM, Ávila JCM, Lubomirov R, Muñoz M, Banares
MJB, Hernández R, Capitán CF, Ramírez E, Frías J, Carcas AJ. Influen-
ce of two variants of CYP450 oxidoreductase on the stable dose of
acenocoumarol in a Spanish population. Pharmacogenomics. 2017;
18(8): 797-805. Article. IF: 2.302; Q3
• Trapiella-Martínez L, Díaz-López JB, Caminal-Montero L, Tolosa-
Vilella C, Castillo AGD, Colunga-Argüelles D, Rubio-Rivas M, Inies-
ta-Arandia N, Castillo-Palma MJ, Saez-Comet L, Egurbide-Arberas
MV, Ortego-Centeno N, Freire M, Vargas-Hitos JA, Ríos-Blanco JJ,
Todoli-Parra JA, Rodríguez-Carballeira M, Marin-Ballve A, Chamo-
rro-Fernández AJ, Pla-Salas X, Madronero-Vuelta AB, Ruiz-Muñoz
M, Fonollosa-Pla V, Simeón-Aznar CP. Very early and early systemic
sclerosis in the Spanish scleroderma Registry (RESCLE) cohort. Au-
toimmun Rev. 2017; 16(8): 796-802. Review. IF: 8.745; D1
• Tzoran I, Papadakis M, Brenner B, Fidalgo A, Rivas A, Wells PS, Ga-
vin O, Adarraga MD, Moustafa F, Monreal M, (Fernández-Capitán C).
Outcome of patients with venous thromboembolism and factor V
leiden or prothrombin 20210 carrier mutations during the cour-
se of anticoagulation. Am J Med. 2017; 130(4): 482.e1-9 . Article. IF:
5.117; Q1
Public Projects
Montiel López C; Arnalich Montiel F. The alpha7-nicotinic
receptor and its endogenous modulator dup-alpha7 in hu-
man smoking-related tumors: their involvement in tobacco
carcinogen-induced tumor development and chemotherapy
resistence (SAF2014-56623-R). MINECO. 2014-2017.
Managment centre: UAM
Private Projects
Arnalich Fernández F. Gestión multidisciplinar de la asisten-
cia al paciente con insuficiencia cardiaca. Academia de Estu-
dios Mir S.L. 2008-Ongoing.
Managment centre: FIBHULP
Arnalich Fernández F. Papel del dup-alfa7, un duplicado par-
cial de la subunidad alfa7 del receptor nicotínico humano, en
el desarrollo tumoral asociado al consumo de tabaco. Funda-
ción Mutua Madrileña. 2011-Ongoing.
Managment centre: FIBHULP
Arnalich Fernández F. Plan de difusión de la enfermedad de
Fabry. Almirall S.A. 2015-Ongoing.
Managment centre: FIBHULP
Arnalich Fernández F. Servicio de Urgencias. 2006-Ongoing.
Managment centre: FIBHULP
Fernández Capitán MC. Estudio longitudinal predictivo de
hipertensión pulmonar postrombótica basado en la creación
de una red de biobancos vinculados a datos clínicos de em-
bolismo pulmonar (Estudio Osiris). Laboratorios Farmacéu-
ticos Rovi S.A. 2015-Ongoing.
Managment centre: FIBHULP
Ríos Blanco JJ. Estudio de disfunción ventricular precoz en
pacientes con esclerodermia. Glaxosmithkline S.A. 2011-On-
going.
Managment centre: FIBHULP
Ríos Blanco JJ. Estudio de hipertensión pulmonar en la co-
horte de pacientes con infección VIH del Hospital La Paz.
Glaxosmithkline S.A. 2010-Ongoing.
Managment centre: FIBHULP
Ríos Blanco JJ. Estudio de la relación entre la rigidez arterial
y la función endotelial en pacientes con hipertensión de bata
blanca. Menarini Diagnósticos S.A. 2009-Ongoing.
Managment centre: FIBHULP
CLINICAL TRIALS
Quesadas Simón A. Estudio fase IV para evaluar la eficacia y
la seguridad de la nueva insulina glargina 300 u/ml (GLA-300)
durante la hospitalización y la intensificación al alta en pacien-
tes con diabetes tipo 2. Type: Clinical Trial, phase IV.
HULP code: 4697. Sponsored´s protocol code: GLARGL07710.
Sponsored by: Sanofi Aventis S.A.
Signed date: 15/05/2017
Quesadas Simón A. Ensayo clínico aleatorizado, controlado
con placebo, para evaluar los resultados clínicos cardiovascu-
lares tras el tratamiento con exenatida una vez a la semana
en pacientes con diabetes mellitus de tipo II. Type: Clinical
Trial, phase III.
HULP code: ANEXO-III 4103. Sponsored´s protocol code: BCB109.
Sponsored by: Bristol Myers Squibb International Corpora-
tion.
Signed date: 10/04/2017
Quesadas Simón A. Revisión observacional en serie de his-
torias clínicas del uso de Repatha® en sujetos europeos con
hiperlipidemia. Type: EPA-SP.
HULP code: PI-2828. Sponsored´s protocol code: AMG-EVO-2016-01.
Sponsored by: Amgen S.A.
Signed date: 17/07/2017
Quesadas Simón A. Ensayo clínico exploratorio fase II/III,
aleatorizado, doble ciego, controlado con placebo, de grupos
paralelos para evaluar la eficacia, seguridad y farmacodinamia
de dapagliflozina y combinación de dapagliflozina con saxa-
gliptina en pacientes con diabetes mellitus tipo 2, insuficiencia
renal crónica 3 y albuminuria tratados con inhibidores de la
enzima convertidora de angiotensina (IECA) o bloqueantes
del receptor de angiotensina II. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4493.
Sponsored´s protocol code: D1690C00023.
187
 3
Information Groups by Area

3.4 Large System Pathologies Area

Sponsored by: Astrazeneca AB.

Signed date: 26/04/2017
Quesadas Simón A. Estudio a largo plazo, aleatorizado, doble
ciego, controlado con placebo para determinar el efecto de
Organic Dysfunction and
albiglutida, cuando se añade al tratamiento hipoglucemiante
estándar, sobre eventos cardiovasculares mayores en pacien- Failure in the Aggression
Group
tes con diabetes mellitus tipo 2. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4396.
Sponsored´s protocol code: GLP116174
Sponsored by: Lilly Research Laboratories.
Signed date: 28/03/2017
Quesadas Simón A. Ensayo multicéntrico, rando-
mizado, doble ciego, controlado con placebo para
evaluar el efecto de dapagliflozina 10mg una vez al
día en la incidencia de muerte cardiovascular, in-
farto de miocardio o ictus isquémico en pacientes
con diabetes tipo 2. Type: Clinical Trial, phase IV.
HULP code: ANEXO-I 3919.
Sponsored´s protocol code: D1693C0001.
Sponsored by: Astrazeneca AB.
Signed date: 28/03/2017
Quesadas Simón A. Estudio multicéntrico, alea-
torizado, doble ciego, de grupos paralelos, con
control activo, para evaluar la eficacia y segu-
ridad de LCZ696 comparado con valsartan,
sobre la morbilidad y mortalidad en pacientes 16 137.429 7
con insuficiencia cardiaca (clase II-IV NYHA)
con fracción de eyección preservada.Type: Cli-
nical Trial, phase III.
HULP code: ANEXO-I 3990.
Abelardo García de Lorenzo y Mateos. Jefe de Itziar Pozuelo Echegaray. Facultativo Especialista de Área en
Sponsored´s protocol code: CLCZ696D2301.
Servicio de Medicina Intensiva. HULP. Profesor Titular. Facultad de Medicina Intensiva. Hospital de Collado Villalba
Sponsored by: Novartis Farmacéutica S.A. Medicina. UAM Santos Manuel Sánchez Sánchez. Facultativo Especialista de
Signed date: 31/05/2017 Alexander Agrifoglio Rotaeche. Facultativo Especialista de Área Área en Medicina Intensiva. HULP
Quesadas Simón A. Estudio aleatorizado, en Medicina Intensiva. HULP
Santiago Yus Teruel. Coordinador de Trasplante. HULP
doble ciego, motivado por los aconteci- José Manuel Añón Elizalde. Jefe de Sección en Medicina Intensiva.
mientos, controlado con placebo y multi- HULP
céntrico, de los efectos de la canagliflozina
en los resultados renales y cardiovascula-
María Antonia Arce Mendiburu. Facultativo Especialista de Área
en Medicina Intensiva. HULP Strategic Objective
res en sujetos con diabetes mellitus tipo María José Asensio Martín. Facultativo Especialista de Área en The global objective of the investigation team on
2 y nefropatía diabética. Type: Clinical Trial, Medicina Intensiva. HULP Dysfunction and Organ Failure in Aggression is the
phase III.
Lucía Cachafeiro Fuciños. Facultativo Especialista de Área en optimization of the patient management in the rea-
HULP code: ANEXO-II 4160. Medicina Intensiva. HULP lly critical ill patients who can develop organ dys-
Sponsored´s protocol code:
Belén Civantos Martín. Facultativo Especialista de Área en function or organ failure. Multiorgan Dysfuntion &
28431754DNE3001. Medicina Intensiva. HULP Multiorgan Failure Syndrome (MOF-MOD Syndro-
Sponsored by: Janssen Cilag International
María Belén Estebánez Montiel. Facultativo Especialista de Área en me) are correlated with bad prognostic and high
NV. Medicina Intensiva. HULP
Signed date: 03/07/2017 mortality rates.
Juan Carlos Figueira Iglesias. Facultativo Especialista de Área en D-FMO Syndrome is correlated both with the di-
Medicina Intensiva. HULP
sease severity and the therapeutic efforts.The thera-
Eva Mercedes Flores Cabeza. Facultativo Especialista de Área en
peutic management of the patient must be early and
Medicina Intensiva. HULP
directed to specific objectives.
Ricardo García Hernández. Facultativo Especialista de Área en
Medicina Intensiva. HULP Otherwise, the support measures must be directed
Mónica Hernández Bernal. Médico Adjunto Especialista en Unidad to the specific situations (like sepsis, trauma…) and
de Cuidados Intensivos. HULP to the Organs or Systems in Dysfunction or Failure
Eva Herrero de Lucas. Facultativo Especialista de Área en Medicina (coagulation, haemodynamic, respiratory or renal...)
Intensiva. HULP Finally, the detection or D-FMO Syndrome emplo-
Jesús Javier Manzanares Gómez. Facultativo Especialista de Área ying not only single markers (clinic) but early and
en Medicina Intensiva. HULP organ specific biomarkers (basic or advanced bio-
Eva Perales Ferrera. Facultativo Especialista de Área en Medicina chemical markers, molecular markers…) can bring a
Intensiva. HULP higher efficacy and better results.
188 189
 3
Information Groups by Area
3.4 Large System Pathologies Area
Research Lines
• Biomarkers
• Resuscitation income
• Therapeutic support
Research Activity
Doctoral TheseS
Cachafeiro Fuciños L. La influencia del síndrome de inhala-
ción en la evolución y el pronóstico del paciente quemado
crítico[dissertation]. Madrid: UAM: 2017(13/07/2017).
Directors: García de Lorenzo y Mateos A, Sánchez Sánchez M.
Herrero de Lucas E. Lactato y parámetros hemodinámicos
en el paciente quemado crítico[dissertation]. Madrid: UAM:
2017(19/01/2017).
Directors: García de Lorenzo y Mateos A, Sánchez Sánchez SM.
Pozuelo Echegaray I. Coagulopatía temprana del paciente que-
mado crítico[dissertation]. Madrid: UAM: 2017(19/09/2017).
Directors: Sánchez Sánchez SM, Quintana Díaz M.
Rosado Caracena R. Síntomas neurológicos postoperatorios
tras dos abordajes de plexo braquial en cirugía de miembro
superior[dissertation]. Madrid: UAM: 2017(20/09/2017).
Directors: García de Lorenzo y Mateos A, Olarra Nuel J.
Valero González N. Valor de los biomarcadores en el diag-
nóstico diferencial entre síndrome de respuesta inflamatoria
sistémica y sepsis en el paciente gran quemado[dissertation].
Madrid: UAM: 2017(27/06/2017).
Directors: Lorente Balanza JA, García de Lorenzo y Mateos A.
BOOKS AND BOOK CHAPTERS
Añón JM, Escuela MP. Enfermedad pulmonar obstructiva
crónica reagudizada. In: Montejo JC, García de Lorenzo A,
Marco P, Ortiz C. Manual de medicina intensiva. Barcelona:
Elsevier España, 2017. p.164-7
Añón JM, Escuela MP. Síndrome de distres respiratorio
agudo. In: Montejo JC, García de Lorenzo A, Marco P, Ortiz
C. Manual de medicina intensiva. Barcelona: Elsevier España,
2017. p.171-3
Asensio MJ, García R. Intubación orotraqueal y traqueo-
tomía. In: Montejo JC, García de Lorenzo A, Marco P, Ortiz
C. Manual de medicina intensiva. Barcelona: Elsevier España,
2017. p.39-42
de la Cerda G, Yus S. Traumatismo cráneoencefálico. In: Mon-
tejo JC, García de Lorenzo A, Marco P, Ortiz C. Manual de
medicina intensiva. Barcelona: Elsevier España, 2017. p.375-8
Figueira JC, Guallar C. Crisis asmática. In: Montejo JC, García
de Lorenzo A, Marco P, Ortiz C. Manual de medicina intensiva.
Barcelona: Elsevier España, 2017. p.167-70
Galván B, Pozuelo I. Prevención de la infección nosocomial
en UCI. In: Montejo JC, García de Lorenzo A, Marco P, Ortiz
C. Manual de medicina intensiva. Barcelona: Elsevier España,
2017. p.269-73
García de Lorenzo A, Montejo JC. Requerimientos nutri-
cionales y metabólicos. In: Montejo JC, García de Lorenzo A,
190
Marco P, Ortiz C. Manual de medicina intensiva. Barcelona:
Elsevier España, 2017. p.401-4
García de Lorenzo A. Manzanares W. Síndrome de respues-
ta inflamatoria sistémica y síndrome de disfunción multior-
gánica. In: Montejo JC, García de Lorenzo A, Marco P, Ortiz
C. Manual de medicina intensiva. Barcelona: Elsevier España,
2017. p.1-4
Garijo MA, Añón JM. Hemoptisis masiva. In: Montejo JC, Gar-
cía de Lorenzo A, Marco P, Ortiz C. Manual de medicina in-
tensiva. Barcelona: Elsevier España, 2017. p.174-81
Grill F, Civantos B. Hipertensión intraabdominal y síndrome
compartimental. In: Montejo JC, García de Lorenzo A, Marco
P, Ortiz C. Manual de medicina intensiva. Barcelona: Elsevier
España, 2017. p.237-341
Herrero E, Hernández M. Monitorización de la perfusión
tisular. In: Montejo JC, García de Lorenzo A, Marco P, Ortiz
C. Manual de medicina intensiva. Barcelona: Elsevier España,
2017. p.56-8
López J, Cambronero JA. Valoración de la insuficiencia res-
piratoria aguda. In: Montejo JC, García de Lorenzo A, Marco
P, Ortiz C. Manual de medicina intensiva. Barcelona: Elsevier
España, 2017. p.161-3
Manzanares J, Agrifoglio A. Pancreatitis aguda grave. In: Mon-
tejo JC, García de Lorenzo A, Marco P, Ortiz C. Manual de
medicina intensiva. Barcelona: Elsevier España, 2017. p.260-4
Montejo JC, García de Lorenzo A, Marco P, Ortiz C. Manual
de Medicina Intensiva. Barcelona: Elsevier España, 2017.
Montejo JC, García de Lorenzo A. Nutrición enteral. In: Mon-
tejo JC, García de Lorenzo A, Marco P, Ortiz C. Manual de
medicina intensiva. Barcelona: Elsevier España, 2017. p.408-11
Ortiz C, García de Lorenzo A. Nutrición parenteral. In: Mon-
tejo JC, García de Lorenzo A, Marco P, Ortiz C. Manual de
medicina intensiva. Barcelona: Elsevier España, 2017. p.404-8
Perales E, Estébanez B. Hipertensión arterial asociada a
embarazo. In: Montejo JC, García de Lorenzo A, Marco P, Or-
tiz C. Manual de medicina intensiva. Barcelona: Elsevier Espa-
ña, 2017. p.469-73
Sánchez SM, Flores E. Quemados críticos y necrolisis epi-
dérmica toxica. In: Montejo JC, García de Lorenzo A, Marco
P, Ortiz C. Manual de medicina intensiva. Barcelona: Elsevier
España, 2017. p.435-40
Soriano C, Millán P. Síndromes embólicos de riesgo vital.
In: Montejo JC, García de Lorenzo A, Marco P, Ortiz C. Ma-
nual de medicina intensiva. Barcelona: Elsevier España, 2017.
p.181-5
PUBLICATIONS
• Camps VL, García MAG, García MAG, Elizalde JMA, Burrallo NM,
Sánchez OR, García AE, Marín JLM. National survey on the indica-
tors of quality in Bioethics of the SEMICYUC in the departments of
Intensive Care Medicine in Spain. Med Intensiva. 2017; 41(9): 523-31.
Article. IF: 1.755; Q4
• Delgado MCM, Mateos AGDY. Surviving the intensive care units
looking through the family’s eyes. Med Intensiva. 2017; 41(8): 451-3.
Editorial Material. IF: 1.755; Q4
• Estrella-Alonso A, Aramburu JA, González-Ruiz MY, Cachafeiro L,
Sánchez SM, Lorente JA. Toxic epidermal necrolysis: a paradigm of
critical illness. Rev Bras Ter Intensiva. 2017; 29(4): 499-508. Article.
Not Indexed
• Fernández MM, González-Castro A, Magret M, Bouza MT, Ibáñez
M, García C, Balerdi B, Mas A, Arauzo V, Añón JM, Ruiz F, Ferreres
J, Tomás R, Alabert M, Tizón AI, Altaba S, Llamas N, Fernández R.
Reconnection to mechanical ventilation for 1 h after a successful
spontaneous breathing trial reduces reintubation in critically ill pa-
tients: a multicenter randomized controlled trial. Intens Care Med.
2017; 43(11): 1660-7. Article. IF: 15.008; D1
• González-Herrada C, Rodríguez-Martín S, Cachafeiro L, Lerma
V, González O, Lorente JA, Rodríguez-Miguel A, González-Ramos
J, Roustan G, Ramírez E, Bellon T, de Abajo FJ. Cyclosporine use
in epidermal necrolysis is associated with an important mortality
reduction: Evidence from three different approaches. J Invest Der-
matol. 2017; 137(10): 2092-100. Article. IF: 6.448; D1
• Herruzo R, Ruiz G, Vizcaíno M J, Rivas L, Pérez-Blanco V, Sánchez
M. Microbial competition in environmental nosocomial reservoirs
and diffusion capacity of OXA48-Klebsiella pneumoniae: potential
impact on patients and possible control methods. J Prev Med Hyg.
2017; 58(1): E34-41. Review. Not Indexed
• Herruzo R, Vizcaíno MJ, Herruzo I, Sánchez M. Surface disinfectants
for burn units evaluated by a new double method, using microor-
ganisms recently isolated from patients, on a surface germ-carrier
model. J Burn Care Res. 2017; 38(3): E663-9. Article. IF: 1.923; Q2
• Mateos AGDY. Seventh Jesus Culebras lecture. Systemic inflam-
matory response and multi organic dysfunction/failure following
aggression: metabolic implications. Nutr Hosp. 2017; 34(1): 244-50.
Article. Not Indexed
• Negredo A, de la Calle-Prieto F, Palencia-Herrejón E, Mora-Rillo M,
Astray-Mochales J, Sánchez-Seco MP, López EB, Menárguez J, Fer-
nández-Cruz A, Sánchez-Artola B, Keough-Delgado E, de Arellano
ER, Lasala F, Milla J, Fraile JL, Gavin MO, de la Gandara AM, Pérez LL,
Díaz-Díaz D, López-García MA, Delgado-Jiménez P, Martín-Quirós
A, Trigo E, Figueira JC, Manzanares J, Rodríguez-Baena E, García-
Comas L, Rodríguez-Fraga O, García-Arenzana N, Fernández-Díaz
MV, Cornejo VM, Emmerich P, Schmidt-Chanasit J, Arribas JR. Auto-
chthonous Crimean-Congo hemorrhagic fever in Spain. New Engl J
Med. 2017; 377(2): 154-61. Article. IF: 79.258; D1
• Raimondi N,Vial MR, Calleja J, Quintero A, Alban AC, Celis E, Pache-
co C, Ugarte S, Añón JM, Hernández G, Vidal E, Chiappero G, Ríos
F, Castilleja F, Matos A, Rodríguez E, Antoniazzi P, Teles JM, Duñas C,
Sinclair J, Martínez L,Von der Osten I,Vergara J, Jiménez E, Arroyo M,
Rodríguez C, Torres J, Fernández-Bussy S, Nates JL. Evidence-based
guides in tracheostomy use in critical patients. Med Intensiva. 2017;
41(2): 94-115. Article. IF: 1.755; Q4
• Raimondi N,Vial MR, Calleja J, Quintero A, Cortés A, Celis E, Pache-
co C, Ugarte S, Añón JM, Hernández G,Vidal E, Chiappero G, Ríos F,
Castilleja F, Matos A, Rodríguez E, Antoniazzi P, Teles JM, Dueñas C,
Sinclair J, Martínez L, von der Osten I,Vergara J, Jiménez E, Arroyo M,
Rodríguez C, Torres J, Fernández-Bussy S, Nates JL. Evidence-based
guidelines for the use of tracheostomy in critically ill patients. J Crit
Care. 2017; 38: 304-18. Article. IF: 2.872; Q2
• Ramírez E, Bellón T, Tong HY, Borobia AM, de Abajo FJ, Lerma V, Hi-
dalgo MAM, Castaner JL, Cabañas R, Fiandor A, González-Ramos J,
Herranz P, Cachafeiro L, González-Herrada C, González O, Aram-
buru JA, Laosa O, Hernández R, Carcas AJ, Frías J. Significant HLA
class I type associations with aromatic antiepileptic drug (AED)-
induced SJS/TEN are different from those found for the same AED-
induced DRESS in the Spanish population. Pharmacol Res. 2017; 115:
168-78. Article. IF: 4.897; D1
• Rodríguez A, Ferri C, Martín-Loeches I, Díaz E, Masclans JR, Gordo
F, Sole-Violan J, Bodi M, Avilés-Jurado FX, Trefler S, Magret M, Mo-
reno G, Reyes LF, Marín-Corral J, Yébenes JC, Esteban A, Anzueto
A, Aliberti S, Restrepo MI. Risk factors for noninvasive ventilation
failure in critically Ill subjects with confirmed influenza infection.
Resp Care. 2017; 62(10): 1307-15. Article. IF: 2.073; Q3
• Sánchez-Sánchez M, Herrero E, Cachafeiro L, Flores E, Agrifoglio A,
Civantos B, García-de-Lorenzo A. Main limitations of transpulmo-
nary thermodilution: set targets. Crit Care. 2017; 21: 242. Letter. IF:
6.425; Q1
• Villar J, Martín-Rodríguez C, Domínguez-Berrot AM, Fernández L,
Ferrando C, Soler JA, Díaz-Lamas AM, González-Higueras E, No-
gales L, Ambros A, Carriedo D, Hernández M, Martínez D, Blanco J,
Belda J, Parrilla D, Suárez-Sipmann F, Tarancón C, Mora-Ordóñez JM,
Blanch L, Pérez-Mendez L, Fernández RL, Kacmarek RM, (Civantos
B). A quantile analysis of plateau and driving pressures: Effects on
mortality in patients with acute respiratory distress syndrome re-
ceiving lung-protective ventilation. Crit Care Med. 2017; 45(5): 843-
50. Article. IF: 6.63; Q1
• Sakr Y, Birri PNR, Kotfis K, Nanchal R, Shah B, Kluge S, Schroeder
ME, Marshall JC, Vincent JL, (Yus S). Higher fluid balance increases
the risk of death from sepsis: Results from a large international au-
dit. Crit Care Med. 2017; 45(3): 386-94. Article. IF: 6.63; Q1
CLINICAL TRIALS
Añón Elizalde JM. Estudio de fase IB/IIA, aleatorizado, doble
ciego, de grupos paralelos, controlado con placebo y mul-
ticéntrico para evaluar la seguridad y eficacia de las células
madre alogénicas expandidas derivadas del tejido adiposo
(EASC) CX611 para el tratamiento intravenoso de pacien-
tes adultos con neumonía bacteriana grave adquirida en la
comunidad e ingresados en unidades de cuidados intensivos
(Estudio Sepcell). Type: Clinical Trial, phase Ib.
HULP code: 4754. Sponsored´s protocol code: Cx611-0204.
Sponsored by: Tigenix S.A.U..
Signed date: 18/09/2017
Sánchez Sánchez M. Estudio comparativo de fase III de gru-
pos paralelos, aleatorizado y doble ciego sobre la eficacia y
seguridad de FB-1201-LYO (interferón beta-1A recombinan-
te humano) y placebo en el tratamiento de pacientes con
síndrome de dificultad respiratoria aguda grave o moderado.
Type: Clinical Trial, phase III.
HULP code: 4906. Sponsored´s protocol code: FPCLI002.
Sponsored by: Faron Pharmaceuticals Ltd.
Signed date: 13/09/2017
Sánchez Sánchez M. Prospective, randomized, controlled,
double-blind, multi-centric, international study on the effica-
cy and safety of an early target controlled plasma volume
replacement therapy with a balanced gelatin solution vs a
balanced electrolyte solution in patients with severe sepsis/
septic shock. Type: Clinical Trial, phase IV.
HULP code: 4894. Sponsored´s protocol code: GENIUS.
Sponsored by: Braun Melsungen AG.
Signed date: 23/11/2017
Patents and Trademarks
Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez
Rodríguez J, Asensio Martín MJ, Gonzá-
lez Sánchez ML, Moro Agud M, Lorente
Romeo M, López Nieto M, Gómez Rioja
R, authors; FIBHULP, assignee. Trademark
name: SINOIRES; CM 13.080.056; 2014
July 14.
191
 3
Information Groups by Area
3.4 Large System Pathologies Area
Respiratory Diseases Group
22 203.605 11
Strategic Objective
Francisco José García Río. Jefe de Sección de Neumología
(Contrato de Intensificación). HULP. Profesor Titular. Facultad de
Medicina. UAM
Cristina Aguado Cruz. Investigador Predoctoral. HULP
Sergio Alcolea Batres. Facultativo Especialista de Área en
Neumología. HULP
Rodolfo Álvarez-Sala Walther. Jefe de Servicio de Neumología.
HULP. Catedrático. Facultad de Medicina. UAM
Juan José Cabanillas Martín. Facultativo Especialista de Área en
Neumología. HULP
Carlos Javier Carpio Segura. Facultativo Especialista de Área en
Neumología. HULP
Raquel Casitas Mateo. Facultativo Especialista de Área en
Neumología. HULP
Carolina Cubillos Zapata. Investigadora Posdoctoral. HULP
Raúl Galera Martínez. Facultativo Especialista de Área en
Neumología. HULP
Luis Gómez Carrera. Facultativo Especialista de Área en
Neumología. HULP
María Antonia Gómez Mendieta. Facultativo Especialista de
Área en Neumología. HULP
Elisabet Martínez Cerón. Facultativo Especialista de Área en
Neumología. HULP
José María Pino García. Facultativo Especialista de Área en
Neumología. HULP
Concepción Prados Sánchez. Jefe de Sección de Neumología. HULP
David Romero Ribate. Facultativo Especialista de Área en
Neumología. HULP
Ana Santiago Recuerda. Facultativo Especialista de Área en
Neumología. HULP
Carlos Villasante Fernández-Montes. Jefe de Sección de
Neumología. HULP
192
Our group studies the molecular mechanisms of car-
diovascular morbidity associated with sleep breathing
disorders, in particular, the sleep apnoeahypopnea
syndrome(SAHS).
We also provide evidence for making clinical deci-
sions on patients with these disorders. We conduct
studies to evaluate the mechanisms involved in the
development of arterial hypertension, arrhythmias,
heart failure, ischaemic heart disease, pulmonary hy-
pertension, pulmonary embolism, and carbohydrate
metabolism disorders.
In terms of the pathogenesis of airflow limitations,
several of our projects have focused on small airway
function, bronchial hyperresponsiveness and exercise
adaptation in a number of obstructive diseases, par-
ticularly COPD, asthma and cystic fibrosis. We also
evaluate the objective measurement of daily physical
activity in these patients and contribute to the best
definition of its determinants and its clinical and prog-
nostic usefulness.We collaborate with other research
groups to study the contribution of the innate immu-
ne system to the evolution of these diseases and the
relationship between the response to hypoxia and the
clinical expression of COPD and SAHS.
Finally, in the field of the systematisation of lung
function testing, we create reference values for va-
rious population groups and define the methodolo-
gical aspects of the measurement of exhaled breath
condensate and nitric oxide.
Research Lines
• Morbidity of sleep-disordered breathing
• Pathogenesis of airflow limitation
• Systematization of lung function testing
Research Activity
Doctoral TheseS
Fernández Rodríguez L.Análisis de la utilidad de la tomografía
computarizada volumétrica de tórax en la evaluación de ope-
rabilidad de pacientes con cáncer de pulmón[dissertation].
Madrid: UAM: 2017(23/10/2017).
Directors: García Río FJ; Torres Sánchez I.
Diana Bobolea I. Fenotipos y endotipos de asma grave: me-
canismos moleculares implicados en la patogénesis y en la
desensibilización a aspirina[dissertation]. Madrid: UAM:
2017(19/09/2017).
Directors: Quirce Gancedo S; Álvarez-Sala Walther R.
Jurado Palomo J. Eficacia y seguridad de la profilaxis a cor-
to plazo con andrógenos atenuados y/o concentrado plas-
mático de C1 inhibidor en la realización de procedimientos
odontoestomatológicos, maxilofaciales y otorrinolaringoló-
gicos en pacientes con angioedema hereditario por déficit
de la proteína inhibidor de la C1 esterasa funcionalmente
activa[dissertation]. Madrid: UAM: 2017(17/10/2017).
Directors: Caballero MT; Álvarez-Sala Walther R.
PUBLICATIONS
• Almendros I, García-Río F. Sleep apnoea, insulin resistance and dia-
betes: the first step is in the fat. Eur Respir J. 2017; 49(4): 1700179.
Editorial Material. IF: 12.242; D1
• Alonso-Fernández A, de la Peña M, Carrera M, Suquía AG, Casitas
R, García-Río F, Martínez-Cerón E, Pierola J, Barcelo A, Soriano JB,
Fernández-Capitán C. OSA and recurrent VTE causality or cause?
Response. Chest. 2017; 151(2): 515-6. Letter. IF: 7.652; Q1
• Álvarez E, Toledano V, Morilla F, Hernández-Jiménez E, Cubillos-Za-
pata C, Varela-Serrano A, Casas-Martín J, Avendaño-Ortiz J, Aguirre
LA, Arnalich F, Maroun-Eid C, Martín-Quiros A, Díaz MQ, López-
Collazo E. A system dynamics model to predict the human monocy-
te response to endotoxins. Front Immunol. 2017; 8: 915. Article. IF:
5.511; Q1
• Athanazio R, Pereira MC, Gramblicka G, Cavalcanti-Lundgren F, de
Figueiredo MF, Arancibia F, Rached S, de la Rosa D, Maiz-Carro L,
Girón R, Olveira C, Prados C, Martínez-García MA. Latin America
validation of FACED score in patients with bronchiectasis: an analy-
sis of six cohorts. BMC Pulm Med. 2017; 17: 73. Article. IF: 2.721; Q2
• Bastir M, García-Martínez D,Torres-Tamayo N, Sanchís-Gimeno JA,
O’Higgins P, Utrilla C, Sánchez IT, Río FG. In vivo 3D analysis of
thoracic kinematics: Changes in size and shape during breathing
and their implications for respiratory function in recent humans
and fossil hominins. Anat Rec. 2017; 300(2): 255-64. Article. IF:
1.373; Q3
• Bastir M, García-Martínez D, Williams SA, Recheis W, Torres-Sán-
chez I, Río FG, Oishi M, Ogihara N. 3D geometric morphometrics
of thorax variation and allometry in Hominoidea. J Hum Evol. 2017;
113: 10-23. Article. IF: 3.992; D1
• Caballero JDD, Girón R, del Campo R, Prados C, Barrio MI, Salcedo
A, Cantón R. Antibiotic prescription patterns in Spanish cystic fibro-
sis patients: results from a national multicenter study. Farm Hosp.
2017; 41(3): 391-400. Article. Not Indexed
• Casitas R, Martínez-Cerón E, Galera R, Cubillos-Zapata C, Gon-
zález-Villalba MJ, Fernández-Navarro I, Sánchez B, García-Sánchez
A, Zamarrón E, García-Río F. The effect of treatment for sleep ap-
noea on determinants of blood pressure control. Eur Respir J. 2017;
50(5): 1701261. Article. IF: 12.242; D1
• Cubillos-Zapata C, Avendaño-Ortiz J, Hernández-Jiménez E, To-
ledano V, Casas-Martín J, Varela-Serrano A, Torres M, Almendros I,
Casitas R, Fernández-Navarro I, García-Sánchez A, Aguirre LA, Fa-
rre R, López-Collazo E, García-Río F. Hypoxia-induced PD-L1/PD-1
crosstalk impairs T-cell function in sleep apnoea. Eur Respir J. 2017;
50(4): 1700833. Article. IF: 12.242; D1
• Cubillos-Zapata C, Córdoba R, Avendaño-Ortiz J, López-Collazo E.
Thalidomide analog CC-122 induces a refractory state in mono-
cytes from patients with diffuse large B cell lymphoma. Leukemia
Lymphoma. 2017; 58(8): 1999-2001. Letter. IF: 2.644; Q2
• García-Río F, Soler-Cataluña JJ, Alcázar B, Viejo JL, Miravitlles M. Re-
quirements, strengths and weaknesses of inhaler devices for COPD
patients from the expert prescribers’ point of view: Results of the
EPOCA delphi consensus. COPD. 2017; 14(6): 573-80. Article. IF:
2.604; Q3
• Hernández-Jiménez E, Cubillos-Zapata C, Toledano V, de Diego RP,
Fernández-Navarro I, Casitas R, Carpio C, Casas-Martín J, Valentín
J, Varela-Serrano A, Avendaño-Ortiz J, Álvarez E, Aguirre LA, Pérez-
Martínez A, de Miguel MP, Belda-Iniesta C, García-Río F, López-Co-
llazo E. Monocytes inhibit NK activity via TGF-beta in patients with
obstructive sleep apnoea. Eur Respir J. 2017; 49(6): 1602456. Article.
IF: 12.242; D1
• Hernández-Jiménez E, Gutiérrez-Fernández M, Cubillos-Zapata C,
Otero-Ortega L, Rodríguez-Frutos B, Toledano V, Martínez-Sánchez
P, Fuentes B, Varela-Serrano A, Avendaño-Ortiz J, Blázquez A, Man-
gas-Guijarro MA, Díez-Tejedor E, López-Collazo E. Circulating mo-
nocytes exhibit an endotoxin tolerance status after acute ischemic
stroke: Mitochondrial DNA as a putative explanation for poststroke
Infections. J Immunol. 2017; 198(5): 2038-46. Article. IF: 4.539; Q2
• Horner A, Soriano JB, Puhan MA, Studnicka M, Kaiser B,Vanfleteren
LEGW, Gnatiuc L, Burney P, Miravitlles M, García-Río F, Ancochea J,
Menezes AM, Pérez-Padilla R, de Oca MM, Torres-Duque CA, Caba-
llero A, González-García M, Buist S, Flamm M, Lamprecht B. Altitude
and COPD prevalence: analysis of the PRrepocol-Platino-Bold-Epi-
Scan Study. Resp Res. 2017; 18: 162. Article. IF: 3,751; Q2
• Llontop C, García-Quero C, Castro A, Dalmáu R, Casitas R, Gale-
ra R, Iglesias A, Martínez-Cerón E, Soriano JB, García-Río F. Small
airway dysfunction in smokers with stable ischemic heart disease.
Plos One. 2017; 12(8): e0182858. Article. IF: 2.766; Q1
• Martínez-Cerón E, García-Río F. Does continuous positive airway
pressure have the “Power” to improve glycemic control in patients
with type II diabetes and obstructive sleep apnea? Reply. Am J Resp
Crit Care. 2017; 195(3): 407-8. Letter. IF: 15.239; D1
• Martínez-Cerón E, García-Río F. Mortality and cardiovascular disea-
se in type 1 and type 2 diabetes. New Engl J Med. 2017; 377(3):300.
Letter. IF: 79.258; D1
• Martínez-García MA, Athanazio RA, Girón R, Maiz-Carro L, de
la Rosa D, Olveira C, de Gracia J, Vendrell M, Prados-Sánchez C,
Gramblicka G, Corso PM, Lundgren FL, Fernandes de Figueiredo
M, Arancibia F, Rached SZ. Predicting high risk of exacerbations in
bronchiectasis: the E-FACED score. Int J Chron Obstruct Pulmon
Dis. 2017; 12: 275-84. Article. IF: 2.917; Q2
• Mediano O, Casitas R, Villasante C, Martínez-Cerón E, Galera R,
Zamarrón E, García-Río F. Dynamic hyperinflation in patients with
asthma and exercise-induced bronchoconstriction. Ann Allerg Asth-
ma Im. 2017; 118(4): 427-32. Article. IF: 3.263; Q2
• Prados C, Lerín M, Cabanillas JJ, Gómez-Carrera L, Álvarez-Sala R.
How are the ancient cystic fibrosis patients? Cystic fibrosis diagno-
193
 3
Information Groups by Area
3.4 Large System Pathologies Area
sed over 60 years-old. Respir Med Case Rep. 2017; 21: 49-51.Article.
Not Indexed
• Tejero E, Prats E, Casitas R, Galera R, Pardo P, Gavilán A, Martínez-
Cerón E, Cubillos-Zapata C, del Peso L, García-Río F. Classification
of airflow limitation based on z-score underestimates mortality in
patients with chronic obstructive pulmonary disease. Am J Resp
Crit Care. 2017; 196(3): 298-305. Article. IF: 15.239; D1
• Zamarrón-de Lucas E, Carrera LG, Bonilla G, Petit D, Mangas A,
Álvarez-Sala R. Antisynthetase syndrome: Analysis of 11 cases. Med
Clin-Barcelona. 2017; 148(4): 166-9. Editorial Material. IF: 1.168; Q3
Public Projects
García Río FJ. Efecto de la CPAP nasal sobre la reducción de
la albuminuria en pacientes con nefropatía diabética y apnea
obstructiva del sueño (PI16/00201). ISCIII. 2017-2019.
Managment centre: FIBHULP
García Río FJ. Contrato de Intensificación (INT15/00076).
ISCIII. 2016-2017.
Managment centre: FIBHULP
García Río FJ. Papel de las alteraciones de las dianas gé-
nicas de HIF y del sistema inmune innato en el desarrollo
del SAHS. Su implicación en cáncer y cardiopatía isquémica
(PI13/01512). ISCIII. 2014-2017.
Managment centre: FIBHULP
Ruiz Pérez D. Contrato Predoctoral (FPU13/01638). MINE-
CO. 2014-2017.
Managment centre: FIBHULP
Private Projects
Álvarez-Sala Walther R. Actualización y renovación de la ac-
tividad investigadora en el Servicio de Neumologia del Hos-
pital Universitario La Paz. Chiesi España S.A. 2015-Ongoing.
Managment centre: FIBHULP
Álvarez-Sala Walther R. Puesta al día en asma grave para
atención primaria: de la investigación a la práctica clinica. San-
doz Farmacéutica S.A. 2016-Ongoing.
Managment centre: FIBHULP
García Río FJ. Analisis de la actividad del sistema inmune
innato en pacientes con síndrome de apneas-hipopneas del
sueño grave. Roche Pharma S.A. 2014-Ongoing.
Managment centre: FIBHULP
García Río FJ. Caracterización clínica de distintos fenoti-
pos de exacerbación de EPOC. Evaluación de sus factores
de riesgo, pronóstico y persistencia a medio plazo. Sociedad
Madrileña de Neumología y Cirugía Torácica. 2016-Ongoing.
Managment centre: Fundación Neumomadrid
García Río FJ. Contribución de las alteraciones de la percep-
ción de la disnea al diagnóstico de asma ficticio en obesos.
Astrazeneca Farmaceutica Spain S.A. 2009-Ongoing.
Managment centre: FIBHULP
García Río FJ. Efecto de la CPAP nasal sobre la progresión
de la enfermedad vascular retiniana en pacientes con apnea
obstructiva del sueño y retinopatía diabética no proliferativa
(Estudio Retinas). Sociedad Española de Neumología y Ciru-
gía Torácica (SEPAR). 2017-Ongoing.
Managment centre: SEPAR
194
García Río FJ. Regulación de la expresión génica por hipoxia: describir el perfil clínico de los pacientes diagnosticados con Sponsored by: Fundación Española del Pulmón (SEPAR).
identificación de polimorfismos que afectan a los sitios de FPI tratados con nintedanib (OFWV®) en la práctica clínica Signed date: 22/06/2017
unión del factor inducible por hipoxia (HIF) en pacientes de habitual en España. Type: EPA-OD.
EPOC y pacientes de SAHS. Sociedad Española de Neumolo- García Río FJ. Ensayo clínico, aleatorizado, doble ciego, con
HULP code: PI-2832. Sponsored´s protocol code: 1199-0295.
gía y Cirugía Torácica. 2014-Ongoing. control activo y de grupos paralelos para evaluar el efecto so-
Sponsored by: Boehringer Ingelheim España S.A.
bre las exacerbaciones del tratamiento una vez al día oral in-
Managment centre: Fundación Respira Signed date: 19/07/2017
halado de la combinación a dosis fijas de tiotropio+olodaterol
García Río FJ. Valores de referencia para el consumo de García Río FJ. Carga de la enfermedad en pacientes con comparado con tiotropio durante 52 semanas en pacientes
oxígeno máximo, umbral de acidosis, reserva ventilatoria y EPOC eosinofílica en España: estudio observacional multi- con enfermedad pulmonar obstructiva crónica grave a muy
reserva cardiaca en la población madrileña de ascendientes céntrico. Type: EPA-OD. grave. Type: Clinical Trial, phase III.
europeos. Sociedad Española de Neumología y Cirugía Torá- HULP code: PI-2903. Sponsored´s protocol code: HO-16-16447. HULP code: ANEXO-I 4327.
cica. 2014-Ongoing. Sponsored´s protocol code: 1237.19.
Sponsored by: Glaxosmithkline S.A.
Managment centre: Fundación Respira
Signed date: 20/12/2017 Sponsored by: Boehringer Ingelheim España S.A.
Gómez Carrera L. Auditoria clínica sobre manejo de fibrosis Signed date: 09/01/2017
Gómez Carrera L. Estudio retrospectivo para evaluar el
pulmonar idiopatica (FPI) en el área sanitaria del Hospital La
perfil clínico de pacientes con fibrosis pulmonar idiopática
Paz. Boehringer Ingelheim España S.A. 2016-Ongoing.
tratados y no tratados, con pirfenidona en España. Estudio
Managment centre: FIBHULP Aeras. Type: EPA-OD.
Santiago Recuerda A. Efecto del tratamiento con ventila- HULP code: PI-2807.
ción mecánica no invasora y humidificación en las complica- Sponsored´s protocol code: SEP-PIR-2016-01.
ciones infecciosas respiratorias. Menarini Diagnósticos S.A.
2014-Ongoing.
Managment centre: FIBHULP
Villasante Fernández-Montes C. Programa docente en
clínica e investigación. Astrazeneca Farmaceutica Spain S.A.
2017-Ongoing.
Managment centre: FIBHULP
CLINICAL TRIALS
Gómez Carrera L. Estudio aleatorizado, doble ciego y con-
trolado con placebo para evaluar la eficacia y la seguridad del
tratamiento con nintedanib durante 52 semanas en pacientes
con enfermedad pulmonar intersticial fibrosante progresiva
(EPI-FP). Type: Clinical Trial, phase III.
HULP code: 4740. Sponsored´s protocol code: 1199.247.
Sponsored by: Boehringer Ingelheim España S.A.
Signed date: 25/01/2017
Prados Sánchez C. Ensayo clínico con enmascara-
miento doble, multicéntrico y controlado con pla-
cebo para investigar la eficacia y seguridad de 12
meses de terapia con Promixin® inhalado (colisti-
metato de sodio) para el tratamiento de pacientes
con bronquiectasia no debida a fibrosis quística
con infección crónica por pseudomonas aerugi-
nosa (p. aeruginosa). Type: Clinical Trial, phase III.
HULP code: 4779.
Sponsored´s protocol code: Z7224L01.
Sponsored by: Zambon S.A.
Signed date: 08/06/2017
Prados Sánchez C. Estudio en fase IIA, aleatori-
zado, doble ciego, controlado con placebo para
evaluar varias dosis de GLPG2222 en sujetos
con fibrosis quística que son homocigotos para
la mutación F508DEL. Type: Clinical Trial, phase II.
HULP code: 4780.
Sponsored´s protocol code: GLPG2222-CL-202.
Sponsored by: Galapagos NV.
Signed date: 01/06/2017
Gómez Carrera L. Estudio retrospectivo, de
revisión de historias clínicas, multicéntrico para
195
 3
Information Groups by Area
3.4 Large System Pathologies Area
Regulation of Gene Expression
and by Hypoxia Group
1 15.239 1
Luis del Peso Ovalle. Profesor Titular. Departamento de
Bioquímica. Facultad de Medicina. UAM
Benilde Jiménez Cuenca. Profesor Titular. Departamento de
Bioquímica. Facultad de Medicina. UAM
María Tiana Cerrolaza. Investigador Predoctoral. UAM
Strategic Objective
The elucidation of the cellular and molecular respon-
ses to changes in oxygen tension constitutes an exci-
ting research topic given the dependence of virtually
all human tissues on appropriate oxygen supply and
the involvement of hypoxia in high-incidence patho-
logies such as cardiopulmonary diseases and cancer.
The Hypoxia Inducible transcription Factor (HIF)
plays a pivotal role in this response by controlling
the expression of most of the genes involved in the
adaptation to hypoxia. Our research group aims to
provide novel insight into transcriptional response to
hypoxia and to exploit this knowledge to improve
clinical management of pathologies in which hypoxia
is a common feature. To this end we are currently
involved in the following.
Research Lines
• Identification of network motifs within the gene
regulatory network regulated by HIF and study of
their role in the adaptation to hypoxia.
196
• Characterization of the effect of hypoxia/HIF on
endothelial cell proliferation and integration of this
response in the induction of angiogenesis.
• Analysis of the functional effect of polymorphisms
affecting HIF binding and investigation of their co-
rrelation with the different phenotypes in chronic
respiratory diseases and cancer
Research Activity
PUBLICATIONS
• Tejero E, Prats E, Casitas R, Galera R, Pardo P, Gavilán A, Martí-
nez-Cerón E, Cubillos-Zapata C, del Peso L, García-Río F. Clas-
sification of airflow limitation based on z-score underestimates
mortality in patients with chronic obstructive pulmonary di-
sease. Am J Resp Crit Care. 2017; 196(3): 298-305. Article. IF:
15.239; D1
Public Projects
del Peso Ovalle L. Estudio genómico, bioinfomático y
funcional del papel de la hipoxia en angiogénesis y el sín-
drome de Von Hippel-Lindau (SAF2014-53819-R). MINE-
CO. 2015-2017.
Managment centre: UAM
Nephrology Group
38 359.461 19
Rafael Selgas Gutiérrez. Jefe de Servicio de Nefrología.
HULP. Profesor Asociado. Facultad de Medicina. UAM
María Auxiliadora Bajo Rubio. Facultativo Especialista de Área en
Nefrología. HULP. Profesora Asociado. Facultad de Medicina. UAM
María Jose Castro Notario. Enfermera. HULP
Olga Costero Fernández. Facultativo Especialista de Área en
Nefrología. HULP
Gloria del Peso Gilsanz. Facultativo Especialista de Área en
Nefrología. HULP
María José Fernández Reyes. Facultativo Especialista de Área en
Nefrología. Hospital de Segovia
Helena García Llana. Psicóloga Investigadora. HULP
María Elena González García. Facultativo Especialista de Área en
Nefrología. HULP
Guadalupe González Mateo. Investigadora Predoctoral. HULP
Carlos Jiménez Martín. Facultativo Especialista de Área en
Nefrología. HULP
María Ovidia López Oliva. Facultativo Especialista de Área en
Nefrología. HULP
Virginia Martínez Cabeza. Técnico de Laboratorio. HULP
Teresa Olea Tejero. Facultativo Especialista de Área en Nefrología.
HULP
Ramón Peces Serrano. Facultativo Especialista de Área en
Nefrología. HULP
Begoña Rivas Becerra. Facultativo Especialista de Área en
Nefrología. HULP
Almudena Pérez Torres. Dietista-Nutricionista. HULP
María Dolores Sánchez Niño. Investigadora Postdoctoral
(Contrato Sara Borrell). HULP
Rafael Jesús Sánchez Villanueva. Facultativo Especialista de Área
en Nefrología. HULP
Maximino Alberto Torre Carballada. Facultativo Especialista de
Área en Nefrología. HULP
Strategic Objective
The strategic objective of this care-research group is
to enable, by developing a deep understanding of the
various components that make up nephrology (kidney
diseases in initial stages, progression of kidney disease,
particular and general complications of dialysis and
kidney transplantation), access by affected patients
to the best diagnostic and therapeutic interventions
available at any time. Each of the areas must ensure a
minimum level of research and development activity
representing the innovation in these areas. The lines
of research are at times cross-sectional to the four
components indicated for overall nephrology.
Research Lines
The lines of research are occasionally cross-sectional
to the four components indicated for nephrology as
a whole.
A) Incipient nephropathies and kidney
disease progression:
• Glomerular and tubular nephropathies. New diag-
nostic markers and interventions.
• Organisational Research (computerisation, organi-
sation of generational change in the department
and network).
• Morbidity, mortality and progression of Diabetic
Nephropathy and other glomerular nephropathies.
197
 3
Information Groups by Area
3.4 Large System Pathologies Area
• Autosomal Dominant Polycystic Kidney Disease. Fa-
mily Studies and treatment approaches with Tolvaptan.
• Association of cardiovascular disease with the pro-
gress of nephropathies (NEFRONA multicenter study,
REDinREN).
• Incorporation of a psychologist into the department of
nephrology: criteria and process. Issues on monitoring
therapeutic adherence, inparticular among transplan-
ted patients
• Occult Hepatits C virus in different kidney disease si-
tuations.
B) Complications of dialysis
• Establishment of normal peritoneal functional in hu-
mans. Implications for patient survival and long-term
treatment. New dialysis fluids. Aquaporin 1 (AQP1)
and its genetic polymorphisms: relationship with peri-
toneal transport of water. Multicentre European study.
• The alternatively activated macrophage in peritoneal
effluent (AAM): its relationship with defence and peri-
toneal fibrosis. CCL18 as a chemokine of AAM and a
mediator of peritoneal fibrosis.
• Peritoneal biopsy for the complete evaluation of the
peritoneal membrane. A correspondence study with
cell and components findings in peritoneal effluent du-
ring kidney transplantation is ongoing (Multicenter).
• Cardiovascular risk in patients with advanced kidney
disease and on dialysis. Endocrine aspects.The abdomi-
nal adipocyte and adipocytokines. FABP antagonists as
blockers of the adipocyte-macrophage response. Non-
thyroidal diseases, influence on CKD patients. FGF 21
role in uremic insulin resistance.
• Mouse model for peritoneal dialysis: exploration of the
effects of dialysis fluids, pharmacological interventions
and genetic manipulation (KO, transgenic).
• Allergic reactions to hemodialysis membranes: mecha-
nisms and alternatives.
C) Complications of kidney transplantation:
• Toxicity due to immunosuppressants. Ultrasound con-
trast in the analysis of renal microvasculature in kidney
transplantation and complications.
• The involvement of CMV in the renal graft response:
anticipated diagnosis.
• Kidney graft response. Thymoglobulin administered to
a cadaver donor: effects on the expression of HLA an-
tigens by tubular cells (clinical trial).
• Post-transplant monitorization of anti-HLA antibodies.
Local development.
• The transplantation career since the values of the pa-
tient: health outcome repercussion.
Research Activity
Doctoral TheseS
González García E. Papel del estrés oxidativo y del FGF21
en la progresión de la arteriosclerosis y el síndrome meta-
bólico en pacientes en diálisis[dissertation]. Madrid: UAM:
2017(03/04/2017).
Directors: Bajo Rubio MA, Díez JJ
López Oliva MO. Manejo de la infección y enfermedad por
citomegalovirus en el trasplante renal. Importancia de la
198
monitorización inmunológica: respeusta específica T CD8
y expresión de CD94/NKG2C[dissertation]. Madrid: UAM:
2017(04/04/2017).
Directors: Selgas Gutiérrez R, Jiménez Martín C, Bellón
Heredia T
Pérez Torres A. Efectos a corto plazo de un programa de edu-
cación nutricional sobre el estado nutricional de pacientes
con enfermedad renal crónica avanzada[dissertation]. Madrid:
UCM: 2017(20/06/2017).
Directors: Selgas Gutiérrez R, López Sobaler AM
PUBLICATIONS
• Bajo MA, del Peso G, Teitelbaum I. Peritoneal membrane preserva-
tion. Semin Nephrol. 2017; 37(1): 77-92. Review. IF: 3.35; Q1
• Barber RM, Fullman N, Sorensen RJD, Bollyky T, McKee M, Nolte E,
Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulle
AM, Abdurahman AA, Abera SF, Abraham B, Abreha GF, Adane K,
Adelekan AL, Adetifa IMO, Afshin A, Agarwal A, Agarwal SK, Agarwal
S, Agrawal A, Kiadaliri AA, Ahmadi A, Ahmed KY, Ahmed MB, Akinye-
mi RO, Akinyemiju TF, Akseer N, Al-Aly Z, Alam K, Alam N, Alam SS,
Alemu ZA, Alene KA, Alexander L, Ali R, Ali SD, Alizadeh-Navaei R,
Alkerwi A, Alla F, Allebeck P, Allen C, Al-Raddadi R, Alsharif U, Al-
tirkawi KA, Martín EA, Alvis-Guzmán N, Amare AT, Amini E, Ammar
W, Amo-Adjei J, Amoako YA, Anderson BO, Androudi S, Ansari H,
Ansha MG, Antonio CAT, Arnlov J, Al Artaman, Asayesh H, Assadi R,
Astatkie A, Atey TM, Atique S, Atnafu NT, Atre SR, Avila-Burgos L,
Avokpaho EFGA, Quintanilla BPA, Awasthi A, Ayele NN, Azzopardi P,
Saleem HOB, Baernighausen T, Bacha U, Badawi A, Banerjee A, Barac
A, Barboza MA, Barker-Collo S.L., Barrero LH, Basu S, Baune BT,
Baye K, Bayou YT, Bazargan-Hejazi S, Bedi N, Beghi E, Bejot Y, Bello
AK, Bennett DA, Bensenor IM, Berhane A, Bernabe E, Bernal OA,
Beyene AS, Beyene TJ, Bhutta ZA, Biadgilign S, Bikbov B, Birlik SM,
Birungi C, Biryukov S, Bisanzio D, Bizuayehu HM, Bose D, Brainin M,
Brauer M, Brazinova A, Breitborde NJK, Brenner H, Butt ZA, Carde-
nas R, Cahuana-Hurtado L, Campos-Nonato IR, Car J, Carrero JJ,
Casey D, Caso V, Castaneda-Orjuela CA, Rivas JC, Catala-López F,
Cecilio P, Cercy K, Charlson FJ, Chen AZ, Chew A, Chibalabala M,
Chibueze CE, Chisumpa VH, Chitheer AA, Chowdhury R, Christen-
sen H, Christopher DJ, Ciobanu LG, Cirillo M, Coggeshall MS, Coo-
per LT, Cortinovis M, Crump JA, Dalal K, Dandona L, Dandona R,
Dargan PI, das Neves J, Davey G, Davitoiu DV, Davletov K, De Leo D,
Del Gobbo LC, del Pozo-Cruz B, Dellavalle RP, Deribe K, Deribew
A, Jarlais DCD, Dey S, Dharmaratne SD, Dicker D, Ding EL, Dokova
K, Dorsey ER, Doyle KE, Dubey M, Ehrenkranz R, Ehrenkranz R,
Ellingsen CL, Elyazar I, Enayati A, Ermakov SP, Eshrati B, Esteghamati
A, Estep K, Fuerst T, Faghmous IDA, Fanuel FBB, Faraon EJA, Farid TA,
Farinha CSES, Faro A, Farvid MS, Farzadfar F, Feigin VL, Feigl AB, Fe-
reshtehnejad SM, Fernandes JG, Fernandes JC, Feyissa TR, Fischer F,
Fitzmaurice C, Fleming TD, Foigt N, Foreman KJ, Forouzanfar MH,
Franklin RC, Frostad J, Hiwot TTG, Gakidou E, Gambashidze K, Ga-
mkrelidze A, Gao W, García-Basteiro AL, Gebre T, Gebremedhin AT,
Gebremichael MW, Gebru AA, Gelaye AA, Geleijnse JM, Genova-
Maleras R, Gibney KB, Giref AZ, Gishu MD, Giussani G, Godwin
WW, Gold A, Goldberg EM, Gona PN, Goodridge A, Gopalani SV,
Goto A, Graetz N, Greaves F, Griswold M, Guban PI, Gugnani HC,
Gupta PC, Gupta R, Gupta R, Gupta T, Gupta V, Habtewold TD, Ha-
fezi-Nejad N, Haile D, Hailu AD, Hailu GB, Hakuzimana A, Hamadeh
RR, Hambisa MT, Hamidi S, Hammami M, Hankey GJ, Hao Y, Harb HL,
Hareri HA, Haro JM, Hassanvand MS, Havmoeller R, Hay RJ, Hay SI,
Hendrie D, Heredia-Pi IB, Hoek HW, Horino M, Horita N, Hosgood
HD, Htet AS, Hu G, Huang H, Huang JJ, Huntley BM, Huynh C, Iburg
KM, Ileanu BV, Innos K, Irenso AA, Jahanmehr N, Jakovljevic MB, Ja-
mes P, James S.L., Javanbakht M, Jayaraman SP, Jayatilleke AU, Jeemon
P, Jha V, John D, Johnson C, Johnson SC, Jonas JB, Juel K, Kabir Z,
Kalkonde Y, Kamal R, Kan H, Karch A, Karema CK, Karimi SM, Ka-
saeian A, Kassebaum NJ, Kastor A, Katikireddi SV, Kazanjan K, Keiyo-
ro PN, Kemmer L, Kemp AH, Kengne AP, Kerbo AA, Kereselidze M,
Kesavachandran CN, Khader YS, Khalil I, Khan AR, Khan EA, Khan G,
Khang YH, Khoja ATA, Khonelidze I, Khubchandani J, Kibret GD, Kim
D, Kim P, Kim YJ, Kimokoti RW, Kinfu Y, Kissoon N, Kivipelto M,
Kokubo Y, Kolk A, Kolte D, Kopec JA, Kosen S, Koul PA, Koyanagi A,
Kravchenko M, Krishnaswami S, Krohn KJ, Defo BK, Bicer BK, Kui-
pers EJ, Kulkarni VS, Kumar GA, Kumsa FA, Kutz M, Kyu HH, Lager
ACJ, Lal A, Lal DK, Lalloo R, Lallukka T, Lan Q, Langan SM, Lansingh
VC, Larson HJ, Larsson A, Laryea DO, Latif AA, Lawrynowicz AEB,
Leasher JL, Leigh J, Leinsalu M, Leshargie CT, Leung J, Leung R, Levi
M, Liang X, Lim SS, Lind M, Linn S, Lipshultz SE, Liu P, Liu Y, Lo LT,
Logroscino G, López AD, Lorch SA, Lotufo PA, Lozano R, Lunevicius
R, Lyons RA, Macarayan ERK, Mackay MT, El Razek HMA, El Razek
MMA, Mahdavi M, Majeed A, Malekzadeh R, Malta DC, Mantovani
LG, Manyazewal T, Mapoma CC, Marcenes W, Marks GB, Marquez N,
Martínez-Raga J, Marzan MB, Massano J, Mathur MR, Maulik PK, Ma-
zidi M, McAlinden C, McGrath JJ, McNellan C, Meaney PA, Mehari A,
Mehndiratta MM, Meier T, Mekonnen AB, Meles KG, Memish ZA,
Mengesha MM, Mengiste DT, Mengistie MA, Menota BG, Mensah
GA, Mereta ST, Meretoja A, Meretoja TJ, Mezgebe HB, Micha R, Mi-
llear A, Mills EJ, Minnig S, Mirarefin M, Mirrakhimov EM, Mock CN,
Mohammad KA, Mohammed S, Mohanty SK, Mokdad AH, Mola GLD,
Molokhia M, Monasta L, Montico M, Moradi-Lakeh M, Moraga P, Mo-
rawska L, Mori R, Moses M, Mueller UO, Murthy S, Musa KI, Nache-
ga JB, Nagata C, Nagel G, Naghavi M, Naheed A, Naldi L, Nangia V,
Nascimento BR, Negoi I, Neupane SP, Newton CR, Ng M, Ngalesoni
FN, Ngunjiri JW, Nguyen G, Ningrum DNA, Nolte S, Nomura M,
Norheim OF, Norrving B, Noubiap JJN, Obermeyer CM, Ogbo FA,
Oh IH, Okoro A, Oladimeji O, Olagunju AT, Olivares PR, Olsen HE,
Olusanya BO, Olusanya JO, Opio JN, Oren E, Ortiz A, Osborne RH,
Osman M, Owolabi MO, Mahesh PA, Pain AW, Pakhale S, Castillo EP,
Pana A, Papachristou C, Parsaeian M, Patel T, Patton GC, Paudel D,
Paul VK, Pearce N, Pereira DM, Pérez-Padilla R, Pérez-Ruiz F, Perico
N, Pesudovs K, Petzold M, Phillips MR, Pigott DM, Pillay JD, Pinho C,
Polinder S, Pond CD, Prakash V, Purwar M, Qorbani M, Quistberg
DA, Radfar A, Rafay A, Rahimi K, Rahimi-Movaghar V, Rahman M,
Rahman MHU, Rai RK, Ram U, Rana SM, Rankin Z, Rao PV, Rao PC,
Rawaf S, Rego MAS, Reitsma M, Remuzzi G, Renzaho AMNN, Res-
nikoff S, Rezaei S, Rezai MS, Ribeiro AL, Roba HS, Rokni MB, Ronfani
L, Roshandel G, Roth GA, Rothenbacher D, Roy NK, Sachdev PS,
Sackey BB, Saeedi MY, Safiri S, Sagar R, Sahraian MA, Saleh MM, Salo-
mon JA, Samy AM, Sanabria JR, Sánchez-Niño MD, Sandar L, Santos
IS, Santos JV, Milicevic MMS, Sarmiento-Suárez R, Sartorius B, Sat-
pathy M, Savic M, Sawhney M, Saylan MI, Schottker B, Schutte AE,
Schwebel DC, Seedat S, Seid AM, Seifu CN, Sepanlou SG, Serdar B,
Servan-Mori EE, Setegn T, Shackelford KA, Shaheen A, Shahraz S,
Shaikh MA, Shakh-Nazarova M, Shamsipour M, Islam SMS, Sharma J,
Sharma R, She J, Sheikhbahaei S, Shen JB, Shi P, Shigematsu M, Shin MJ,
Shiri R, Shoman H, Shrime MG, Sibamo ELS, Sigfusdottir ID, Silva
DAS, Silveira DGA, Sindi S, Singh A, Singh JA, Singh OP, Singh PK,
Singh V, Sinke AH, Sinshaw AE, Skirbekk V, Sliwa K, Smith A, Sobngwi
E, Soneji S, Soriano JB, Sousa TCM, Sposato LA, Sreeramareddy CT,
Stathopoulou V, Steel N, Steiner C, Steinke S, Stokes MA, Stranges S,
Strong M, Stroumpoulis K, Sturua L, Sufiyan MB, Suliankatchi RA, Sun
JD, Sur P, Swaminathan S, Sykes BL, Tabares-Seisdedos R, Tabb KM,
Taffere GR, Talongwa RT, Tarajia M, Tavakkoli M, Taveira N, Teeple S,
Tegegne TK, Tehrani-Banihashemi A, Tekelab T, Tekle DY, Shifa GT,
Terkawi AS, Tesema AG, Thakur JS, Thomson AJ, Tillmann T, Tiruye TY,
Tobe-Gai R, Tonelli M, Topor-Madry R, Tortajada M, Troeger C, Truel-
sen T, Tura AK, Uchendu US, Ukwaja KN, Undurraga EA, Uneke CJ,
Uthman OA, van Boven JFM,Van Dingenen R,Varughese S,Vasankari
T,Venketasubramanian N,Violante FS,Vladimirov SK,Vlassov VV,Voll-
set SE, Vos T, Wagner JA, Wakayo T, Waller SG, Walson JL, Wang H,
Wang YP, Watkins DA, Weiderpass E, Weintraub RG, Wen CP, Wer-
decker A, Wesana J, Westerman R, Whiteford HA, Wilkinson JD, Wi-
ysonge CS, Woldeyes BG, Wolfe CDA, Won S, Workicho A, Workie
SB, Wubshet M, Xavier D, Xu GL,Yadav AK,Yaghoubi M,Yakob B,Yan
LL, Yano Y, Yaseri M, Yimam HH, Yip P, Yonemoto N, Yoon SJ, Younis
MZ, Yu CH, Zaidi Z, Zaki MES, Zambrana-Torrelio C, Zapata T, Ze-
nebe ZM, Zodpey S, Zoeckler L, Zuhlke LJ, Murray CJL. Healthcare
Access and Quality Index based on mortality from causes amenable
to personal health care in 195 countries and territories, 1990-2015:
a novel analysis from the Global Burden of Disease Study 2015.
Lancet. 2017; 390(10091): 231-66. Article. IF: 53.254; D1
• Carmona A, Aguera ML, Luna-Ruiz C, Buendía P, Calleros L, García-
Jerez A, Rodríguez-Puyol M, Arias M, Arias-Guillén M, de Arriba G,
Ballarin J, Bernis C, Fernández E, García-Rebollo S, Mancha J, del
Peso G, Pérez E, Poch E, Portoles JM, Rodríguez-Puyol D, Sánchez-
Villanueva R, Sarro F, Torres A, Martín-Malo A, Aljama P, Ramírez R,
Carracedo J. Markers of endothelial damage in patients with chronic
kidney disease on hemodialysis. Am J Physiol-Renal. 2017; 312(4):
F673-81. Article. IF: 3.164; Q2
• Castillo-Rodríguez E, Fernández-Prado R, Martín-Cleary C, Pizarro-
Sánchez MS, Sánchez-Niño MD, Sanz AB, Fernández-Fernández B,
Ortiz A. Kidney injury marker 1 and neutrophil gelatinase-associa-
ted lipocalin in chronic kidney disease. Nephron. 2017; 136(4): 263-
7. Review. IF: 2.203; Q2
• Castillo-Rodríguez E, Pizarro-Sánchez S, Sanz AB, Ramos AM, Sán-
chez-Niño MD, Martín-Cleary C, Fernández-Fernández B, Ortiz A.
Inflammatory cytokines as uremic toxins: “Ni Son Todos Los Que
Estan, Ni Estan Todos Los Que Son”. Toxins. 2017; 9(4): 114. Review.
IF: 3.273; D1
• da Costa BM, del Peso G, Bajo MA, Carreno G, Ferreira M, Ferreira
C, Selgas R. Relationship between bioimpedance-determined body
composition and peritoneal transport in peritoneal dialysis. Int J Ar-
tif Organs. 2017; 40(5): 212-8. Article. IF: 1.133; Q4
• Fernández-Prado R, Esteras R, Pérez-Gómez MV, Gracia-Iguacel C,
González-Parra E, Sanz AB, Ortiz A, Sánchez-Niño MD. Nutrients tur-
ned into toxins: Microbiota modulation of nutrient properties in chro-
nic kidney disease. Nutrients. 2017; 9(5): 489. Review. IF: 4.196; Q1
• Gakidou E, Afshin A, Abajobir AA, Abate KH, Abbafati C, Abbas KM,
Abd-Allah F, Abdulle AM, Abera SF, Aboyans V, Abu-Raddad LJ, Abu-
Rmeileh NME, Abyu GY, Adedeji IA, Adetokunboh O, Afarideh M,
Agrawal A, Agrawal S, Kiadaliri AA, Ahmadieh H, Ahmed MB, Aichour
AN, Aichour I, Aichour MTE, Akinyemi RO, Akseer N, Alahdab F, Al-
Aly Z, Alam K, Alam N, Alam T, Alasfoor D, Alene KA, Ali K, Alizadeh-
Navaei R, Alkerwi A, Alla F, Allebeck P, Al-Raddadi R, Alsharif U, Al-
tirkawi KA, Alvis-Guzmán N, Amare AT, Amini E, Ammar W, Amoako
YA, Ansari H, Anto JM, Antonio CAT, Anwari P, Arian N, Arnlov J,
Artaman A, Aryal KK, Asayesh H, Asgedom SW, Atey TM, Avila-Bur-
gos L, Avokpaho EFGA, Awasthi A, Azzopardi P, Bacha U, Badawi A,
Balakrishnan K, Ballew SH, Barac A, Barber RM, Barker-Collo S.L.,
Barnighausen T, Barquera S, Barregard L, Barrero LH, Batis C, Battle
KE, Baune BT, Beardsley J, Bedi N, Beghi E, Bell ML, Bennett DA,
Bennett JR, Bensenor IM, Berhane A, Berhe DF, Bernabe E, Betsu
BD, Beuran M, Beyene AS, Bhansali A, Bhutta ZA, Bikbov B, Birungi
C, Biryukov S, Blosser CD, Boneya DJ, Bou-Orm IR, Brauer M, Breit-
borde NJK, Brenner H, Brugha TS, Bulto LNB, Baumgarner BR, Butt
ZA, Cahuana-Hurtado L, Cardenas R, Carrero JJ, Castaneda-Orjuela
CA, Catala-López F, Cercy K, Chang HY, Charlson FJ, Chimed-Ochir
O, Chisumpa VH, Chitheer AA, Christensen H, Christopher DJ, Ciri-
llo M, Cohen AJ, Comfort H, Cooper C, Coresh J, Cornaby L, Cor-
tesi PA, Criqui MH, Crump JA, Dandona L, Dandona R, das Neves
J, Davey G, Davitoiu DV, Davletov K, de Courten B, Degenhardt L,
Deiparine S, Dellavalle RP, Deribe K, Deshpande A, Dharmaratne
SD, Ding EL, Djalalinia S, Do HP, Dokova K, Doku DT, Dorsey ER,
Driscoll TR, Dubey M, Duncan BB, Duncan S, Ebert N, Ebrahimi H,
El-Khatib ZZ, Enayati A, Endries AY, Ermakov SP, Erskine HE, Eshrati
B, Eskandarieh S, Esteghamati A, Estep K, Faraon EJA, Farinha CSES,
Faro A, Farzadfar F, Fay K, Feigin VL, Fereshtehnejad SM, Fernandes
JC, Ferrari AJ, Feyissa TR, Filip I, Fischer F, Fitzmaurice C, Flaxman
AD, Foigt N, Foreman KJ, Frostad JJ, Fullman N, Furst T, Furtado JM,
Ganji M, García-Basteiro AL, Gebrehiwot TT, Geleijnse JM, Geleto A,
Gemechu BL, Gesesew HA, Gething PW, Ghajar A, Gibney KB, Gill
PS, Gillum RF, Giref AZ, Gishu MD, Giussani G, Godwin WW, Gona
PN, Goodridge A, Gopalani SV, Goryakin Y, Goulart AC, Graetz N,
Gugnani HC, Guo JW, Gupta R, Gupta T, Gupta V, Gutiérrez RA, Ha-
199
 3
Information Groups by Area
3.4 Large System Pathologies Area
chinski V, Hafezi-Nejad N, Hailu GB, Hamadeh RR, Hamidi S, Ham-
mami M, Handal AJ, Hankey GJ, Harb HL, Hareri HA, Hassanvand MS,
Havmoeller R, Hawley C, Hay SI, Hedayati MT, Hendrie D, Heredia-
Pi IB, Hoek HW, Horita N, Hosgood HD, Hostiuc S, Hoy DG, Hsairi
M, Hu GQ, Huang H, Huang JJ, Iburg KM, Ikeda C, Inoue M, Irvine
CMS, Jackson MD, Jacobsen KH, Jahanmehr N, Jakovljevic MB, Jau-
regui A, Javanbakht M, Jeemon P, Johansson LRK, Johnson CO, Jonas
JB, Jurisson M, Kabir Z, Kadel R, Kahsay A, Kamal R, Karch A, Karema
CK, Kasaeian A, Kassebaum NJ, Kastor A, Katikireddi SV, Kawakami
N, Keiyoro PN, Kelbore SG, Kemmer L, Kengne AP, Kesavachandran
CN, Khader YS, Khalil IA, Khan EA, Khang YH, Khosravi A, Khub-
chandani J, Kieling C, Kim D, Kim JY, Kim YJ, Kimokoti RW, Kinfu Y,
Kisa A, Kissimova-Skarbek KA, Kivimaki M, Knibbs LD, Knudsen AK,
Kopec JA, Kosen S, Koul PA, Koyanagi A, Kravchenko M, Krohn KJ,
Kromhout H, Defo BK, Bicer BK, Kumar GA, Kutz M, Kyu HH, Lal
DK, Lalloo R, Lallukka T, Lan Q, Lansingh VC, Larsson A, Lee A, Lee
PH, Leigh J, Leung J, Levi M, Li YC, Li YM, Liang XF, Liben ML, Linn S,
Liu P, Lodha R, Logroscino G, Looker KJ, López AD, Lorkowski S, Lo-
tufo PA, Lozano R, Lunevicius R, Macarayan ERK, Abd el Razek HM,
Abd el Razek MM, Majdan M, Majdzadeh R, Majeed A, Malekzadeh
R, Malhotra R, Malta DC, Mamun AA, Manguerra H, Mantovani LG,
Mapoma CC, Martín RV, Martínez-Raga J, Martíns-Melo FR, Mathur
MR, Matsushita K, Matzopoulos R, Mazidi M, McAlinden C, McGrath
JJ, Mehata S, Mehndiratta MM, Meier T, Melaku YA, Memiah P, Memish
ZA, Mendoza W, Mengesha MM, Mensah GA, Mensink GBM, Mereta
ST, Meretoja A, Meretoja TJ, Mezgebe HB, Micha R, Millear A, Miller
TR, Minnig S, Mirarefin M, Mirrakhimov EM, Misganaw A, Mishra SR,
Mohammad KA, Mohammed KE, Mohammed S, Ibrahim NM, Mohan
MBV, Mokdad AH, Monasta L, Hernández JCM, Montico M, Moradi-
Lakeh M, Moraga P, Morawska L, Morrison SD, Mountjoy-Venning C,
Mueller UO, Mullany EC, Muller K, Murthy GVS, Musa KI, Naghavi
M, Naheed A, Nangia V, Natarajan G, Negoi I, Negoi RI, Nguyen CT,
Nguyen G, Nguyen M, Le Nguyen Q, Nguyen TH, Nichols E, Nin-
grum DNA, Nomura M, Nong VM, Norheim OF, Norrving B, Nou-
biap JJN, Obermeyer CM, Ogbo FA, Oh H, Oladimeji O, Olagunju
AT, Olagunju TO, Olivares PR, Olsen HE, Olusanya BO, Olusanya
JO, Opio JN, Oren E, Ortiz A, Ota E, Owolabi MO, Pa M, Pacella
RE, Pana A, Panda BK, Panda-Jonas S, Pandian JD, Papachristou C,
Park EK, Parry CD, Patten SB, Patton GC, Pereira DM, Perico N,
Pesudovs K, Petzold M, Phillips MR, Pillay JD, Piradov MA, Pishgar F,
Plass D, Pletcher MA, Polinder S, Popova S, Poulton RG, Pourmalek F,
Prasad N, Purcell C, Qorbani M, Radfar A, Rafay A, Rahimi-Movaghar
A, Rahimi-Movaghar V, Rahman M, Rahman MHU, Rahman MA, Rai
RK, Rajsic S, Ram U, Rawaf S, Rehm CD, Rehm J, Reiner RC, Reitsma
MB, Reynales-Shigematsu LM, Remuzzi G, Renzaho AMN, Resnikoff
S, Rezaei S, Ribeiro AL, Rivera JA, Roba KT, Rojas-Rueda D, Roman
Y, Room R, Roshandel G, Roth GA, Rothenbacher D, Rubagotti E,
Rushton L, Sadat N, Safdarian M, Safi S, Safiri S, Sahathevan R, Salama
J, Salomon JA, Samy AM, Sanabria JR, Sánchez-Niño MD, Sánchez-Pi-
mienta TG, Santomauro D, Santos IS, Milicevic MMS, Sartorius B, Sa-
tpathy M, Sawhney M, Saxena S, Schaeffner E, Schmidt MI, Schneider
IJC, Schutte AE, Schwebel DC, Schwendicke F, Seedat S, Sepanlou SG,
Serdar B, Servan-Mori EE, Shaddick G, Shaheen A, Shahraz S, Shaikh
MA, Levy TS, Shamsipour M, Shamsizadeh M, Islam SMS, Sharma J,
Sharma R, She J, Shen J, Shi PL, Shibuya K, Shields C, Shiferaw MS,
Shigematsu M, Shin MJ, Shiri R, Shirkoohi R, Shishani K, Shoman H,
Shrime MG, Sigfusdottir ID, Silva DAS, Silva JP, Silveira DGA, Singh
JA, Singh V, Sinha DN, Skiadaresi E, Slepak EL, Smith DL, Smith M,
Sobaih BHA, Sobngwi E, Soneji S, Sorensen RJD, Sposato LA, Sree-
ramareddy CT, Srinivasan V, Steel N, Stein DJ, Steiner C, Steinke S,
Stokes MA, Strub B, Subart M, Sufiyan MB, Strub B, Subart M, Sufiyan
MB, Suliankatchi RA, Sur PJ, Swaminathan S, Sykes BL, Szoeke CEI,
Tabares-Seisdedos R, Tadakamadla SK, Takahashi K, Takala JS, Tandon
N, Tanner M, Tarekegn YL, Tavakkoli M, Tegegne TK, Tehrani-Banihas-
hemi A, Terkawi AS, Tesssema B, Thakur JS, Thamsuwan O, Thanka-
ppan KR, Theis AM, Thomas ML, Thomson AJ, Thrift AG, Tillmann T,
Tobe-Gai R, Tobollik M, Tollanes MC, Tonelli M, Topor-Madry R, To-
rre A, Tortajada M, Touvier M, Tran BX, Truelsen T, Tuem KB, Tuzcu
EM, Tyrovolas S, Ukwaja KN, Uneke CJ, Updike R, Uthman OA, van
200
Boven JFM, van Donkelaar A, Varughese S, Vasankari T, Veerman LJ,
Venkateswaran V,Venketasubramanian N,Violante FS,Vladimirov SK,
Vlassov VV, Vollset SE, Vos T, Wadilo F, Wakayo T, Wallin MT, Wang YP,
Weichenthal S, Weiderpass E, Weintraub RG, Weiss DJ, Werdecker
A, Westerman R, Whiteford HA, Wiysonge CS, Woldeyes BG, Wolfe
CDA, Woodbrook R, Workicho A, Hanson SW, Xavier D, Xu GL,
Yadgir S, Yakob B, Yan LLJ, Yaseri M, Yimam HH, Yip P, Yonemoto N,
Yoon SJ,Yotebieng M,Younis MZ, Zaidi Z, Zaki MES, Zavala-Arciniega
L, Zhang XY, Zimsen SRM, Zipkin B, Zodpey S, Lim SS, Murray CJL.
Global, regional, and national comparative risk assessment of 84
behavioural, environmental and occupational, and metabolic risks
or clusters of risks, 1990-2016: a systematic analysis for the Global
Burden of Disease Study 2016. Lancet. 2017; 390(10100): 1345-22.
Article. IF: 53.254; D1
• García-Llana H, Bajo MA, Barbero J, Selgas R, del Peso G. The Com-
munication and Bioethical Training (CoBiT) program for assisting
dialysis decision-making in Spanish ACKD units. Psychol Health
Med. 2017; 22(4): 474-82. Article. IF: 1.589; Q3
• Goicoechea M, Sánchez-Niño MD, Ortiz A, de Vinuesa SG, Quiroga
B, Bernis C, Morales E, Fernández-Juárez G, de Sequera P, Verdalles
U, Verde E, Luno J. Low dose aspirin increases 15-epi-lipoxin A4 le-
vels in diabetic chronic kidney disease patients. Prostag Leukotr Ess.
2017; 125: 8-13. Article. IF: 2.437; Q3
• González E, Díez JJ, Torres AP, Bajo MA, del Peso G, Sánchez-Vi-
llanueva R, Grande C, Rodríguez O, Coronado M, Candela CG,
Díaz-Almirón M, Iglesias P, Selgas R. Body composition analysis and
adipocytokine concentrations in haemodialysis patients: abdominal
fat gain as an additional cardiovascular risk factor. Nefrología. 2017;
37(2): 138-48. Article. IF: 1.167; Q4
• González N, Prieto I, del Puerto-Nevado L, Portal-Núñez S, Ardura
JA, Cortón M, Fernández-Fernández B, Aguilera O, Gómez-Guerre-
ro C, Mas S, Moreno JA, Ruiz-Ortega M, Sanz AB, Sánchez-Niño
MD, Rojo F, Vivanco F, Esbrit P, Ayuso C, Álvarez-Llamas G, Egido J,
Gairca-Foncillas J, Ortiz A. 2017 update on the relationship between
diabetes and colorectal cancer: epidemiology, potential molecular
mechanisms and therapeutic implications. Oncotarget. 2017; 8(11):
18456-85. Review. Not Indexed
• Hay SI, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F,
Abdulle AM, Abebo TA, Abera SF, Aboyans V, Abu-Raddad LJ, Acker-
man IN, Adedeji IA, Adetokunboh O, Afshin A, Aggarwal R, Agrawal S,
Agrawal A, Kiadaliri AA, Ahmed MB, Aichour AN, Aichour I, Aichour
MTE, Aiyar S, Akinyemiju TF, Akseer N, Al Lami FH, Alahdab F, Al-Aly
Z, Alam K, Alam N, Alam T, Alasfoor D, Alene KA, Ali R, Alizadeh-Na-
vaei R, Alkaabi JM, Alkerwi A, Alla F, Allebeck P, Allen C, Al-Maskari F,
AlMazroa MA, Al-Raddadi R, Alsharif U, Alsowaidi S, Althouse BM,
Altirkawi KA,Alvis-Guzmán N,Amare AT,Amini E,Ammar W,Amoako
Y, Ansha MG, Antonio CAT, Anwari P, Arnlov J, Arora M, Al Artaman,
Aryal KK, Asgedom SW, Atey TM, Atnafu NT, Avila-Burgos L,
Avokpaho EFGA,Awasthi A,Awasthi S, Quintanilla BPA,Azarpazhooh
MR, Azzopardi P, Babalola TK, Bacha U, Badawi A, Balakrishnan K,
Bannick MS, Barac A, Barker-Collo S.L., Barnighausen T, Barquera S,
Barrero LH, Basu S, Battista R, Battle KE, Baune BT, Bazargan-Hejazi
S, Beardsley J, Bedi N, Bejot Y, Bekele BB, Bell ML, Bennett DA, Ben-
nett JR, Bensenor IM, Benson J, Berhane A, Berhe DF, Bernabe E,
Betsu BD, Beuran M, Beyene AS, Bhansali A, Bhatt S, Bhutta ZA, Biad-
gilign S, Bienhoff K, Bikbov B, Birungi C, Biryukov S, Bisanzio D, Bizua-
yehu HM, Blyth FM, Boneya DJ, Bose D, Bou-Orm IR, Bourne RRA,
Brainin M, Brayne CEG, Brazinova A, Breitborde NJK, Briant PS,
Britton G, Brugha TS, Buchbinder R, Bulto LNB, Bumgarner B, Butt
ZA, Cahuana-Hurtado L, Cameron E, Campos-Nonato IR, Carabin
H, Cardenas R, Carpenter DO, Carrero JJ, Carter A, Carvalho F, Ca-
sey D, Castaneda-Orjuela CA, Rivas JC, Castle CD, Catala-López F,
Chang JC, Charlson FJ, Chaturvedi P, Chen HL, Chibalabala M, Chi-
bueze CE, Chisumpa VH, Chitheer AA, Chowdhury R, Christopher
DJ, Ciobanu LG, Cirillo M, Colombara D, Cooper LT, Cooper C, Cor-
tesi PA, Cortinovis M, Criqui MH, Cromwell EA, Cross M, Crump JA,
Dadi AF, Dalal K, Damasceno A, Dandona L, Dandona R, das Neves J,
Davitoiu DV, Davletov K, de Courten B, de Leo D, De Steur H, Deg-
enhardt L, Deiparine S, Dellavalle RP, Deribe K, Deribew A, Des Jar-
lais DC, Dey S, Dharmaratne SD, Dhillon PK, Dicker D, Djalalinia S,
Do HP, Dokova K, Doku DT, Dorsey ER, dos Santos KPB, Driscoll
TR, Dubey M, Duncan BB, Ebel BE, Echko M, El-Khatib ZZ, Enayati A,
Endries AY, Ermakov SP, Erskine HE, Eshetie S, Eshrati B, Esteghamati
A, Estep K, Fanuel FBB, Farag T, Sofia C, Farinha S, Faro A, Farzadfar F,
Fazeli MS, Feigin VL, Feigl AB, Fereshtehnejad SM, Fernandes JC, Fe-
rrari AJ, Feyissa TR, Filip I, Fischer F, Fitzmaurice C, Flaxman AD, Foigt
N, Foreman KJ, Franklin RC, Frostad JJ, Fullman N, Furst T, Furtado
JM, Futran ND, Gakidou E, García-Basteiro AL, Gebre T, Gebregergs
GB, Gebrehiwot TT, Geleijnse JM, Geleto A, Gemechu BL, Gesesew
HA, Gething PW, Ghajar A, Gibney KB, Gillum RF, Ginawi IAM, Gishu
MD, Giussani G, Godwin WW, Goel K, Goenka S, Goldberg EM,
Gona PN, Goodridge A, Gopalani SV, Gosselin RA, Gotay CC, Goto
A, Goulart AC, Graetz N, Gugnani HC, Gupta R, Gupta PC, Gupta T,
Gupta V, Gupta R, Gutiérrez RA, Hachinski V, Hafezi-Nejad N, Hailu
AD, Hailu GB, Hamadeh RR, Hamidi S, Hammami M, Handal AJ,
Hankey GJ, Hao YT, Harb HL, Hareri HA, Haro JM, Harun KM, Har-
vey J, Hassanvand MS, Havmoeller R, Hay RJ, Hedayati MT, Hendrie D,
Henry NJ, Heredia-Pi IB, Heydarpour P, Hoek HW, Hoffman HJ, Ho-
rino M, Horita N, Hosgood HD, Hostiuc S, Hotez PJ, Hoy DG, Htet
AS, Hu GQ, Huang JJ, Huynh C, Iburg KM, Igumbor EU, Ikeda C, Irvi-
ne CMS, Jacobsen KH, Jahanmehr N, Jakovljevic MB, James P, Jassal
SK, Javanbakht M, Jayaraman SP, Jeemon P, Jensen PN, Jha V, Jiang GH,
John D, Johnson CO, Johnson SC, Jonas JB, Jurisson M, Kabir Z, Kadel
R, Kahsay A, Kamal R, Kar C, Karam NE, Karch A, Karema CK, Karimi
SM, Karimkhani C, Kasaeian A, Kassa GM, Kassebaum NJ, Kassaw
NA, Kastor A, Katikireddi SV, Kaul A, Kawakami N, Keiyoro PN, Kem-
mer L, Kengne AP, Keren A, Kesavachandran CN, Khader YS, Khalil IA,
Khan EA, Khang YH, Khoja AT, Khosravi A, Khubchandani J, Kieling C,
Kim YJ, Kim D, Kimokoti RW, Kinfu Y, Kisa A, Kissimova-Skarbek KA,
Kissoon N, Kivimaki M, Knudsen AK, Kokubo Y, Kolte D, Kopec JA,
Kosen S, Kotsakis GA, Koul PA, Koyanagi A, Kravchenko M, Krohn KJ,
Defo BK, Bicer BK, Kumar GA, Kumar P, Kyu HH, Lager ACJ, Lal DK,
Lalloo R, Lallukka T, Lambert N, Lan Q, Lansingh VC, Larsson A, Leas-
her JL, Lee PH, Leigh J, Leshargie CT, Leung J, Leung R, Levi M, Li YC,
Li YM, Liang XF, Liben ML, Lim SS, Linn S, Liu A, Liu PY, Liu SW, Liu Y,
Lodha R, Logroscino G, Looker KJ, López AD, Lorkowski S, Lotufo
PA, Lozano R, Lucas TCD, Lunevicius R, Lyons RA, Macarayan ERK,
Maddison ER, Abd el Razek HM, Magis-Rodríguez C, Mahdavi M, Ma-
jdan M, Majdzadeh R, Majeed A, Malekzadeh R, Malhotra R, Malta
DC, Mamun AA, Manguerra H, Manhertz T, Mantovani LG, Ma-
poma CC, March LM, Marczak LB, Martínez-Raga J, Henri-
que P, Martíns V, Martíns-Melo FR, Martopullo I, Marz
W, Mathur MR, Mazidi M, McAlinden C, Mc-
Gaughey M, McGrath JJ, Mckee M, Mehata
S, Meier T, Meles KG, Memiah P, Me-
mish ZA, Mendoza W, Mengesha MM,
Mengistie MA, Mengistu DT, Mensah
GA, Meretoja A, Meretoja TJ, Mezge-
be HB, Micha R, Millear A, Miller TR,
Minnig S, Mirarefin M, Mirrakhimov
EM, Misganaw A, Mishra SR, Mitchell
PB, Mohammad KA, Mohammadi A,
Mohammed S, Mohammed KE, Mo-
hammed MSK, Mohan MBV, Mokdad
AH, Mollenkopf SK, Monasta L, Her-
nández JCM, Montico M, Moradi-
Lakeh M, Moraga P, Morawska L, Mori
R, Morrison SD, Moses M, Mountjoy-
Venning C, Mruts KB, Mueller UO,
Muller K, Mudoch ME, Murthy S,
Murthy GVS, Musa KI, Nachega JB,
Nagel G, Naghavi M, Naheed A, Nai-
doo KS, Nangia V, Nasher JT, Natara-
jan G, Negasa DE, Negoi I, Negoi RI,
Newton CR, Ngunjiri JW, Nguyen
CT, Le Nguyen Q, Nguyen G, Nguyen
TH, Nguyen M, Nichols E, Ningrum
DNA, Nong VM, Norheim OF, Norrving B, Noubiap JJN, Nyandwi A,
Obermeyer CM, O’Donnell MJ, Ogbo FA, Oh IH, Okoro A, Oladime-
ji O, Olagunju AT, Olagunju TO, Olsen HE, Olusanya BO, Olusanya JO,
Ong KY, Opio JN, Oren E, Ortiz A, Osborne RH, Osgood-Zimmer-
man A, Osman M, Ota E, Owolabi MO, Pa M, Pacella RE, Panda BK,
Pandian JD, Papachristou C, Park EK, Parry CD, Parsaeian M, Patil ST,
Patten SB, Patton GC, Paudel D, Paulson K, Pearce N, Pereira DM,
Pérez KM, Perico N, Pesudovs K, Peterson CB, Petri WA, Petzold M,
Phillips MR, Phipps G, Pigott DM, Pillay JD, Pinho C, Piradov MA, Plass
D, Pletcher MA, Popova S, Poulton RG, Pourmalek F, Prabhakaran D,
Prasad N, Purcell C, Purwar M, Qorbani M, Rabiee RHS, Radfar A,
Rafay A, Rahimi K, Rahimi-Movaghar A, Rahimi-Movaghar V, Rahman
M, Rahman MA, Rahman MHU, Rai RK, Rajsic S, Ram U, Ranabhat CL,
Rangaswamy T, Rankin Z, Rao PV, Rao PC, Rawaf S, Ray SE, Reiner RC,
Reinig N, Reitsma M, Remuzzi G, Renzaho AMN, Resnikoff S, Rezaei
S, Ribeiro AL, Roba HS, Robinson SR, Rojas-Rueda D, Rokni MB, Ron-
fani L, Roshandel G, Roth GA, Rothenbacher D, Roy A, Rubagotti E,
Ruhago GM, Saadat S, Safdarian M, Safiri S, Sagar R, Sahathevan R,
Sahraian MA, Salama J, Saleh MM, Salomon JA, Salvi SS, Samy AM, Sa-
nabria JR, Sánchez-Niño MD, Santomauro D, Santos JV, Santos IS, Mi-
licevic MMS, Sartorius B, Satpathy M, Sawhney M, Saxena S, Schelonka
K, Schmidt MI, Schneider IJC, Ben Schottker, Schutte AE, Schwebel
DC, Schwendicke F, Seedat S, Sepanlou SG, Servan-Mori EE, Shaheen
A, Shaikh MA, Shamsipour M, Islam SMS, Sharma R, Sharma J, She J,
Shi PL, Shibuya K, Shields C, Shiferaw MS, Shigematsu M, Shiri R,
Shirkoohi R, Shirude S, Shishani K, Shoman H, Siabani S, Sibai AM, Si-
gfusdottir ID, Silberberg DH, Silva JP, Silva DAS, Silveira DGA, Singh
JA, Singh V, Singh OP, Singh NP, Sinha DN, Skiadaresi E, Skirbekk V,
Slepak EL, Smith DL, Smith M, Sobaih BHA, Sobngwi E, Soljak M, So-
rensen RJD, Sousa TCM, Sposato LA, Sufiyan MB, Abdulkader RS,
Sunguya BF, Sur PJ, Swaminathan S, Sykes BL, Sylte D, Szoeke CEI, Ta-
bares-Seisdedos R, Tadakamadla SK, Taffere GR, Takala JS, Tandon N,
Tanne D, Tarekegn YL, Tavakkoli M, Taveira N, Taylor HR, Tegegne TK,
Tehrani-Banihashemi A, Tekelab T, Shifa GT, Terkawi AS, Tesfaye DJ,
Tesssema B, Thakur JS, Thamsuwan O, Theadom AM, Theis AM, Tho-
mas KE, Thomas N, Thompson R, Thrift AG, Tobe-Gai R, Tobollik M,
Tonelli M,Topor-Madry R,Tortajada M,Touvier M,Traebert J,Tran BX,
Troeger C, Truelsen T, Tsoi D, Tuzcu EM, Tymeson H, Tyrovolas S,
Ukwaja KN, Undurraga EA, Uneke CJ, Updike R, Uthman OA, Uzo-
chukwu BSC, van Boven JFM, Varughese S, Vasankari T, Veerman LJ,
Venkatesh S, Venketasubramanian N, Vidavalur R, Vijayakumar L, Vio-
201
 3
Information Groups by Area
3.4 Large System Pathologies Area
lante FS, Vishnu A, Vladimirov SK, Vlassov VV, Vollset SE, Vos T, Wadilo
F, Wakayo T, Wallin MT, Wang YP, Weichenthal S, Weiderpass E, Wein-
traub RG, Weiss DJ, Werdecker A, Westerman R, Whiteford HA, Wi-
jeratne T, Williams HC, Wiysonge CS, Woldeyes BG, Wolfe CDA,
Woodbrook R, Woolf AD, Workicho A, Xavier D, Xu GL, Yadgir S,
Yaghoubi M, Yakob B, Yan LLJ, Yano Y, Ye PP, Yihdego MG, Yimam HH,
Yip P, Yonemoto N, Yoon SJ, Yotebieng M, Younis MZ, Yu CH, Zaidi Z,
Zaki MES, Zegeye EA, Zenebe ZM, Zhang XY, Zheng YF, Zhou MG,
Zipkin B, Zodpey S, Zoeckler L, Zuhlke LJ, Murray CJL. Global, regio-
nal, and national disability-adjusted life-years (DALYs) for 333 disea-
ses and injuries and healthy life expectancy (HALE) for 195 coun-
tries and territories, 1990-2016: a systematic analysis for the Global
Burden of Disease Study 2016. Lancet. 2017; 390(10100): 1260-344.
Article. IF: 53.254; D1
• Iglesias P, Bajo MA, Selgas R, Díez JJ. Thyroid dysfunction and kidney
disease: An update. Rev Endocr Metab Dis. 2017; 18(1): 131-44. Re-
view. IF: 4.963; Q1
• López-Oliva MO, Álvarez L,Testillano ML, Pérez T, Nieto MF, Santana
MJ, González E, Herrero A, Selgas R, Jiménez C. Switch to belatacept
in kidney graft recipients. Nefrología. 2017; 37(5): 550-2. Letter. IF:
1.167; Q4
• López-Oliva MO, Flores J, Madero R, Escuín F, Santana MJ, Bellón T,
Selgas R, Jiménez C. Cytomegalovirus infection after kidney trans-
plantation and long-term graft loss. Nefrología. 2017; 37(5): 515-25.
Article. IF: 1.167; Q4
• Magalhaes P, Pejchinovski M, Markoska K, Banasik M, Klinger M,
Svec-Billa D, Rychlik I, Rroji M, Restivo A, Capasso G, Bob F, Schiller
A, Ortiz A, Pérez-Gómez MV, Cannata P, Sánchez-Niño MD, Nau-
movic R, Brkovic V, Polenakovic M, Mullen W, Vlahou A, Zurbig P,
Pape L, Ferrario F, Denis C, Spasovski G, Mischak H, Schanstra JP.
Association of kidney fibrosis with urinary peptides: a path towards
non-invasive liquid biopsies? Sci Rep-Uk. 2017; 7: 16915. Article. IF:
4.122; Q1
• Martín-Lorenzo M, González-Calero L, Ramos-Barrón A, Sánchez-
Niño MD, Gómez-Alamillo C, García-Segura JM, Ortiz A, Arias M,
Vivanco F, Álvarez-Llamas G. Urine metabolomics insight into acute
kidney injury point to oxidative stress disruptions in energy genera-
tion and H2S availability. J Mol Med. 2017; 95(12): 1399-409. Article.
IF: 4.938; Q1
• Martín-Sánchez D, Gallegos-Villalobos A, Fontecha-Barriuso M, Ca-
rrasco S, Sánchez-Niño MD, López-Hernández FJ, Ruiz-Ortega M,
Egido J, Ortiz A, Sanz AB. Deferasirox-induced iron depletion pro-
motes BclxL downregulation and death of proximal tubular cells. Sci
Rep-Uk. 2017; 7: 41510. Article. IF: 4.122; Q1
• Martín-Sánchez D, Ruiz-Andrés O, Poveda J, Carrasco S, Cannata-
Ortiz P, Sánchez-Niño MD, Ortega MR, Egido J, Linkermann A, Ortiz
A, Sanz AB. Ferroptosis, but not necroptosis, is important in nephro-
toxic folic acid-induced AKI. J Am Soc Nephrol. 2017; 28(1): 218-29.
Article. IF: 8.655; D1
• Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera
SF, Aboyans V, Adetokunboh O, Arnlov J, Afshin A, Agrawal A, Kiadaliri
AA, Ahmadi A, Ahmed MB, Aichour AN, Aichour I, Aichour MTE, Ai-
yar S, Al-Eyadhy A, Alahdab F, Al-Aly Z, Alam K, Alam N, Alam T, Alene
KA, Ali SD, Alizadeh-Navaei R, Alkaabi JM, Alkerwi A, Alla F, Allebeck
P, Allen C, Al-Raddadi R, Alsharif U, Altirkawi KA, Alvis-Guzmán N,
Amare AT, Amini E, Ammar W, Amoako YA, Anber N, Andersen HH,
Andrei CL, Androudi S, Ansari H, Antonio CAT, Anwari P, Arora M,
Artaman A, Aryal KK, Asayesh H, Asgedom SW, Atey TM, Avila-Bur-
gos L, Avokpaho EFGA, Awasthi A, Paulina B, Quintanilla A, Bejot Y,
Babalola TK, Bacha U, Balakrishnan K, Barac A, Barboza MA, Bar-
ker-Collo S.L., Barquera S, Barregard L, Barrero LH, Baune BT, Bedi
N, Beghi E, Bekele BB, Bell ML, Bennett JR, Bensenor IM, Berhane
A, Bernabe E, Betsu BD, Beuran M, Bhatt S, Biadgilign S, Bienhoff
K, Bikbov B, Bisanzio D, Bourne RRA, Breitborde NJK, Negesa L,
Bulto B, Bumgarner BR, Butt ZA, Cardenas R, Cahuana-Hurtado L,
Cameron E, Campuzano JC, Car J, Carrero JJ, Carter A, Casey DC,
Castaneda-Orjuela CA, Catala-López F, Charlson FJ, Chibueze CE,
202
Chimed-Ochir O, Chisumpa VH, Chitheer AA, Christopher DJ, Cio-
banu LG, Cirillo M, Cohen AJ, Colombara D, Cooper C, Cowie BC,
Criqui MH, Dandona L, Dandona R, Dargan PI, das Neves J, Davitoiu
DV, Davletov K, de Courten B, Degenhardt L, Deiparine S, Deribe
K, Deribew A, Dey S, Dicker D, Ding EL, Djalalinia S, Do HP, Doku
DT, Douwes-Schultz D, Driscoll TR, Dubey M, Duncan BB, Echko
M, El-Khatib ZZ, Ellingsen CL, Enayati A, Erskine HE, Eskandarieh S,
Esteghamati A, Ermakov SP, Estep K, Farinha CSES, Faro A, Farzadfar
F, Feigin VL, Fereshtehnejad SM, Fernandes JC, Ferrari AJ, Feyissa TR,
Filip I, Finegold S, Fischer F, Fitzmaurice C, Flaxman AD, Foigt N, Frank
T, Fraser M, Fullman N, Furst T, Furtado JM, Gakidou E, García-Bas-
teiro AL, Gebre T, Gebregergs GB, Gebrehiwot TT, Gebremichael DY,
Geleijnse JM, Genova-Maleras R, Gesesew HA, Gething PW, Gillum
RF, Ginawi IAM, Giref AZ, Giroud M, Giussani G, Godwin WW, Gold
AL, Goldberg EM, Gona PN, Gopalani SV, Gouda HN, Goulart AC,
Griswold M, Gupta PC, Gupta R, Gupta T, Gupta V, Haagsma JA, Ha-
fezi-Nejad N, Hailu AD, Hailu GB, Hamadeh RR, Hambisa MT, Hamidi
S, Hammami M, Hancock J, Handal AJ, Hankey GJ, Hao Y, Harb HL,
Hareri HA, Hassanvand MS, Havmoeller R, Hay SI, He F, Hedayati MT,
Henry NJ, Heredia-Pi IB, Herteliu C, Hoek HW, Horino M, Horita
N, Hosgood HD, Hostiuc S, Hotez PJ, Hoy DG, Huynh C, Iburg KM,
Ikeda C, Ileanu BV, Irenso AA, Irvine CMS, Irenso AA, Irvine CMS,
Jurisson M, Jacobsen KH, Jahanmehr N, Jakovljevic MB, Javanbakht
M, Jayaraman SP, Jeemon P, Jha V, John D, Johnson CO, Johnson SC,
Jonas JB, Kabir Z, Kadel R, Kahsay A, Kamal R, Karch A, Karimi SM,
Karimkhani C, Kasaeian A, Kassaw NA, Kassebaum NJ, Katikireddi
SV, Kawakami N, Keiyoro PN, Kemmer L, Kesavachandran CN, Kha-
der YS, Khan EA, Khang YH, Khoja ATA, Khosravi A, Khosravi MH,
Khubchandani J, Kieling C, Kievlan D, Kim D, Kim YJ, Kimokoti RW,
Kinfu Y, Kissoon N, Kivimaki M, Knudsen AK, Kopec JA, Kosen S, Koul
PA, Koyanagi A, Defo BK, Kulikoff XR, Kumar GA, Kumar P, Kutz M,
Kyu HH, Lal DK, Lalloo R, Lallukka T, Lambert N, Lan Q, Lansingh VC,
Larsson A, Lee PH, Leigh J, Leung J, Levi M, Li Ym, Kappe DL, Liang
XF, Liben ML, Lim SS, Liu A, Liu PY, Liu Y, Lodha R, Logroscino G,
Lorkowski S, Lotufo PA, Lozano R, Lucas TCD, Ma S, Macarayan ERK,
Maddison ER, Abd el Razek MM, Majdan M, Majdzadeh R, Majeed A,
Malekzadeh R, Malhotra R, Malta DC, Manguerra H, Manyazewal T,
Mapoma CC, Marczak LB, Markos D, Martínez-Raga J, Martíns-Melo
FR, Martopullo I, McAlinden C, McGaughey M, McGrath JJ, Mehata
S, Meier T, Meles KG, Memiah P, Memish ZA, Mengesha MM, Men-
gistu DT, Menota BG, Mensah GA, Meretoja A, Meretoja TJ, Millear
A, Miller TR, Minnig S, Mirarefin M, Mirrakhimov EM, Misganaw A,
Mishra SR, Mohammad KA, Mohammadi A, Mohammed S, Mokdad
AH, Mola GLD, Mollenkopf SK, Molokhia M, Monasta L, Hernández
JCM, Montico M, Mooney MD, Moradi-Lakeh M, Moraga P, Morawska
L, Morrison SD, Morozoff C, Mountjoy-Venning C, Mruts KB, Muller
K, Murthy GVS, Musa KI, Nachega JB, Naheed A, Naldi L, Nangia V,
Nascimento BR, Nasher JT, Natarajan G, Negoi I, Ngunjiri JW, Ngu-
yen CT, Nguyen G, Nguyen M, Le Nguyen Q, Nguyen TH, Nichols E,
Ningrum DNA, Nong VM, Noubiap JJN, Ogbo FA, Oh IH, Okoro A,
Olagunju AT, Olsen HE, Olusanya BO, Olusanya JO, Ong KY, Opio JN,
Oren E, Ortiz A, Osman M, Ota E, Pa M, Pacella RE, Pakhale S, Pana A,
Panda BK, Panda-Jonas S, Papachristou C, Park EK, Patten SB, Patton
GC, Paudel D, Paulson K, Pereira DM, Pérez-Ruiz F, Perico N, Pervaiz
A, Petzold M, Phillips MR, Pigott DM, Pinho C, Plass D, Pletcher MA,
Polinder S, Postma MJ, Pourmalek F, Purcell C, Qorbani M, Radfar A,
Rafay A, Rahimi-Movaghar V, Rahman M, Rahman MHU, Rai RK, Rana-
bhat CL, Rankin Z, Rao PC, Rath GK, Rawaf S, Ray SE, Rehm J, Reiner
RC, Reitsma MB, Remuzzi G, Rezaei S, Rezai MS, Rokni MB, Ronfani L,
Roshandel G, Roth GA, Rothenbacher D, Ruhago GM, Saadat RSAS,
Sachdev PS, Sadat N, Safdarian M, Safi S, Safiri S, Sagar R, Sahathevan
R, Salama J, Salamati P, Salomon JA, Samy AM, Sanabria JR, Sánchez-
Niño MD, Santomauro D, Santos IS, Milicevic MMS, Sartorius B, Sa-
tpathy M, Shahraz S, Schmidt MI, Schneider IJC, Schulhofer-Wohl S,
Schutte AE, Schwebel DC, Schwendicke F, Sepanlou SG, Servan-Mori
EE, Shackelford KA, Shaikh MA, Shamsipour M, Shamsizadeh M, Is-
lam SMS, Sharma J, Sharma R, She J, Sheikhbahaei S, Shey M, Shi PL,
Shields C, Shields C, Shigematsu M, Shiri R, Shirude S, Shiue I, Sho-
man H, Shrime MG, Sigfusdottir ID, Silpakit N, Silva JP, Singh A, Singh
JA, Skiadaresi E, Sligar A, Smith A, Smith DL, Smith M, Sobaih BHA,
Soneji S, Sorensen RJD, Soriano JB, Sreeramareddy CT, Srinivasan
V, Stanaway JD, Stathopoulou V, Steel N, Stein DJ, Steiner C, Steinke
S, Stokes MA, Strong M, Strub B, Subart M, Sufiyan MB, Sunguya BF,
Sur PJ, Swaminathan S, Sykes BL, Tabares-Seisdedos R, Tadakamadla
SK, Takahashi K, Takala JS, Talongwa RT, Tarawneh MR, Tavakkoli M,
Taveira N, Tegegne TK, Tehrani-Banihashemi A, Temsah MH, Terkawi
AS, Thakur JS, Thamsuwan O, Thankappan KR, Thomas KE, Thomp-
son AH, Thomson AJ, Thrift AG, Tobe-Gai R, Topor-Madry R, Torre A,
Tortajada M, Towbin JA, Tran BX, Troeger C, Truelsen T, Tsoi D, Tuzcu
EM, Tyrovolas S, Ukwaja KN, Undurraga EA, Updike R, Uthman OA,
Uzochukwu BSC, van Boven JFM,Vasankari T,Venketasubramanian N,
Violante FS, Vlassov VV, Vollset SE, Vos T, Wakayo T, Wallin MT, Wang
YP,Weiderpass E,Weintraub RG,Weiss DJ,Werdecker A,Westerman
R, Whetter B, Whiteford HA, Wijeratne T, Wiysonge CS, Woldeyes
BG, Wolfe CDA, Woodbrook R, Workicho A, Xavier D, Xiao QY, Xu
GL, Yaghoubi M, Yakob B, Yano Y, Yaseri M, Yimam HH, Yonemoto N,
Yoon SJ, Yotebieng M, Younis MZ, Zaidi Z, Zaki MES, Zegeye EA, Ze-
nebe ZM, Zerfu TA, Zhang AL, Zhang XY, Zipkin B, Zodpey S, López
AD, Murray CJL. Global, regional, and national age-sex specific mor-
tality for 264 causes of death, 1980-2016: a systematic analysis for
the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100):
1151-210. Article. IF: 53.254; D1
• Ortiz A, Husi H, González-Lafuente L,Valino-Rivas L, Fresno M, Sanz
AB, Mullen W, Albalat A, Mezzano S, Vlahou T, Mischak H, Sánchez-
Niño MD. Mitogen-activated protein kinase 14 promotes AKI. J Am
Soc Nephrol. 2017; 28(3): 823-36. Article. IF: 8.655; D1
• Ortiz A, Sánchez-Niño MD. Diagnosis and treatment of Fabry disea-
se. Med Clin-Barcelona. 2017; 148(3): 132-8. Editorial Material. IF:
1.168; Q3
• Ortiz A, Sánchez-Niño MD. Differences between agalsidase alpha
and agalsidase beta in the treatment of Fabry disease Reply. Med
Clin-Barcelona. 2017; 149(6): 271-2. Letter. IF: 1.168; Q3
• Ossorio M, Bajo MA, del Peso G, Martínez V, Fernández M, Castro
MJ, Rodríguez-Sanz A, Madero R, Bellon T, Selgas R. Sustained low
peritoneal effluent CCL18 levels are associated with preservation
of peritoneal membrane function in peritoneal dialysis. Plos One.
2017; 12(4): e0175835. Article. IF: 2.766; Q1
• Peces R, Afonso S, Peces C, Nevado J, Selgas R. Living kidney trans-
plantation between brothers with unrecognized renal amyloidosis
as the first manifestation of familial Mediterranean fever: a case re-
port. BMC Med Genet. 2017; 18: 97. Article. IF: 1.913; Q3
• Pérez-Torres A, García EG, García-Llana H, del Peso G, López-Soba-
ler AM, Selgas R. Improvement in nutritional status in patients with
chronic kidney disease-4 by a nutrition education program with no
impact on renal function and determined by male sex. J Renal Nutr.
2017; 27(5): 303-10. Article. IF: 2.651; Q2
• Poveda J, Sanz AB, Carrasco S, Ruiz-Ortega M, Cannata-Ortiz P, Sán-
chez-Niño MD, Ortiz A. Bcl3: a regulator of NF-kappa B inducible
by TWEAK in acute kidney injury with anti-inflammatory and anti-
apoptotic properties in tubular cells. Exp Mol Med. 2017; 49: e352.
Article. IF: 5.584; Q1
• Poveda J, Sanz AB, Fernández-Fernández B, Carrasco S, Ruiz-Ortega
M, Cannata-Ortiz P, Ortiz A, Sánchez-Niño MD. MXRA5 is a TGF-
1-regulated human protein with anti-inflammatory and anti-fibrotic
properties. J Cell Mol Med. 2017; 21(1):154-64. Article. IF: 4.302; Q1
• Rodríguez-Sanz A, Sánchez-Villanueva R, Domínguez-Ortega J, Fian-
dor AM, Ruiz MP, Trocoli F, Díaz-Tejeiro R, Cadenillas C, González E,
Martínez V, López-Trascasa M, Quirce S, Selgas R, Bellón T. Mecha-
nisms involved in hypersensitivity reactions to polysulfone hemo-
dialysis membranes. Artif Organs. 2017; 41(11): E285-95. Article. IF:
2.111; Q2
• Ruiz-Carpio V, Sandoval P, Aguilera A, Albar-Vizcaino P, Pérez-Lozano
ML, González-Mateo GT, Acuña-Ruiz A, García-Cantalejo J, Botías
P, Bajo MA, Selgas R, Sánchez-Tomero JA, Passlick-Deetjen J, Piecha
D, Buchel J, Steppan S, López-Cabrera M. Genomic reprograming
analysis of the mesothelial to mesenchymal transition identifies bio-
markers in peritoneal dialysis patients. Sci Rep-Uk. 2017; 7: 44941.
Article. IF: 4.122; Q1
• Sánchez-Niño MD, Ortiz A. Does wealth make health? Cherchez la
renal replacement therapy. Clin Kidney J. 2017; 10(1): 45-8. Editorial
Material. Not Indexed
• Sánchez-Niño MD, Sanz AB, Ramos AM, Fernández-Fernández B,
Ortiz A. Clinical proteomics in kidney disease as an exponential te-
chnology: heading towards the disruptive phase. Clin Kidney J. 2017;
10(2): 188-91. Editorial Material. Not Indexed
• Sánchez-Niño MD, Sanz AB, Ramos AM, Ruiz-Ortega M, Ortiz
A. Translational science in chronic kidney disease. Clin Sci. 2017;
131(14): 1617-29. Review. IF: 5.22; Q1
• Sánchez-Niño MD, Zheng-Lin B, Valino-Rivas L, Sanz AB, Ramos AM,
Luno J, Goicoechea M, Ortiz A. Lesinurad: what the nephrologist
should know. Clin Kidney J. 2017; 10(5):679-7. Article. Not Indexed
• Selgas R, Rodríguez L, Julián JC, Remon C, Prieto-Velasco M, Pérez-
Contreras J, Fontan MP. How a bottom-up multi-stakeholder initia-
tive helped transform the renal replacement therapy landscape in
spain. Appl Health Econ Health Policy. 2017; 15(6): 755-2. Article. IF:
1.885; Q2
• Trimarchi H, Canzonieri R, Schiel A, Politei J, Costales-Collaguazo
C, Stern A, Paulero M, Rengel T,Valino-Rivas L, Forrester M, Lombi F,
Pomeranz V, Iriarte R, Muryan A, Ortiz A, Sánchez-Niño MD, Zotta
E. Expression of uPAR in urinary podocytes of patients with Fabry
disease. Int J Nephrol. 2017: 1287289. Article. Not Indexed
• Wang HD, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah
F, Abera SF, Abraha HN, Abu-Raddad LJ, Abu-Rmeileh NME, Adedeji
IA, Adedoyin RA, Adetifa IMO, Adetokunboh O, Afshin A, Aggarwal R,
Agrawal A, Agrawal S, Kiadaliri AA, Ahmed MB, Aichour AN, Aichour
I,Aichour MTE,Aiyar S,Akanda S,Akinyemiju TF,Akseer N,Al-Eyadhy
A,Al Lami FH,Alabed S,Alahdab F,Al-Aly Z,Alam K,Alam N,Alasfoor
D, Aldridge RW, Alene KA, Alhabib S, Ali R, Alizadeh-Navaei R, Aljunid
SM, Alkaabi JM, Alkerwi A, Alla F, Allam SD, Allebeck P, Al-Raddadi R,
Alsharif U, Altirkawi KA, Martín EA, Alvis-Guzmán N, Amare AT,
Ameh EA, Amini E, Ammar W, Amoako YA, Anber N, Andrei CL, An-
droudi S, Ansari H, Ansha MG, Antonio CAT, Anwari P, Arnlov J, Aro-
ra M, Al Artaman, Aryal KK, Asayesh H, Asgedom SW, Asghar RJ, As-
sadi R, Atey TM, Atre SR, Avila-Burgos L, Avokpaho EFGA, Awasthi A,
Quintanilla BPA, Babalola TK, Bacha U, Badawi A, Balakrishnan K,
Balalla S, Barac A, Barber RM, Barboza MA, Barker-Collo S.L., Bar-
nighausen T, Barquera S, Barregard L, Barrero LH, Baune BT, Bazar-
gan-Hejazi S, Bedi N, Beghi E, Bejot Y, Bekele BB, Bell ML, Bello AK,
Bennett DA, Bennett JR, Bensenor IM, Benson J, Berhane A, Berhe
DF, Bernabe E, Beuran M, Beyene AS, Bhala N, Bhansali A, Bhaumik S,
Bhutta ZA, Bikbov B, Birungi C, Biryukov S, Bisanzio D, Bizuayehu
HM, Bjerregaard P, Blosser CD, Boneya DJ, Boufous S, Bourne RRA,
Brazinova A, Breitborde NJK, Brenner H, Brugha TS, Bukhman G,
Negesa L, Bulto B, Bumgarner BR, Burch M, Butt ZA, Cahill LE, Ca-
huana-Hurtado L, Campos-Nonato IR, Car J, Car M, Crdenas R,
Carpenter DO, Carrero JJ, Carter A, Castaneda-Orjuela CA, Rivas
JC, Castro FF, Castro RE, Catala-López F, Chen HL, Chiang PPC,
Chibalabala M, Chisumpa VH, Chitheer AA, Choi JYJ, Christensen H,
Christopher DJ, Ciobanu LG, Cirillo M, Cohen AJ, Colquhoun SM,
Coresh J, Criqui MH, Cromwell EA, Crump JA, Dandona L, Dandona
R, Dargan PI, das Neves J, Davey G, Davitoiu DV, Davletov K, de
Courten B, De Leo D, Degenhardt L, Deiparine S, Dellavalle RP, De-
ribe K, Deribew A, Des Jarlais DC, Dey S, Dharmaratne SD, Dherani
MK, Díaz-Torne C, Ding EL, Dixit P, Djalalinia S, Do P, Doku DT,
Donnelly CA, Priscila K, dos Santos B, Douwes-Schultz D, Driscoll
TR, Duan L, Dubey M, Duncan BB, Dwivedi LK, Ebrahimi H, El Bche-
raoui C, Ellingsen CL, Enayati A, Endries AY, Ermakov SP, Eshetie S,
Eshrati B, Eskandarieh S, Esteghamati A, Estep K, Fanuel FBB, Faro A,
Farvid MS, Farzadfar F, Feigin VL, Fereshtehnejad SM, Fernandes JG,
Fernandes JC, Feyissa TR, Filip I, Fischer F, Foigt N, Foreman KJ, Frank
T, Franklin RC, Fraser M, Friedman J, Frostad JJ, Fullman N, Furst T,
Furtado JM, Futran ND, Gakidou E, Gambashidze K, Gamkrelidze A,
Gankpe FG, García-Basteiro AL, Gebregergs GB, Gebrehiwot TT,
Gebrekidan KG, Gebremichael MW, Gelaye AA, Geleijnse JM, Ge-
203
 3
Information Groups by Area
3.4 Large System Pathologies Area
mechu BL, Gemechu KS, Genova-Maleras R, Gesesew HA, Gething
PW, Gibney KB, Gill PS, Gillum RF, Giref AZ, Girma BW, Giussani G,
Goenka S, Gómez B, Gona PN, Gopalani SV, Goulart AC, Graetz N,
Gugnani HC, Gupta PC, Gupta R, Gupta R, Gupta T, Gupta V, Haags-
ma JA, Hafezi-Nejad N, Bidgoli HH, Hakuzimana A, Halasa YA, Hama-
deh RR, Hambisa MT, Hamidi S, Hammami M, Hancock J, Handal AJ,
Hankey GJ, Hao YT, Harb HL, Hareri HA, Harikrishnan S, Haro JM,
Hassanvand MS, Havmoeller R, Hay RJ, Hay SI, He F, Heredia-Pi IB,
Herteliu C, Hilawe EH, Hoek HW, Horita N, Hosgood HD, Hostiuc
S, Hotez PJ, Hoy DG, Hsairi M, Htet AS, Hu GQ, Huang H, Huang JJ,
Iburg KM, Igumbor EU, Ileanu BV, Inoue M, Irenso AA, Irvine CMS,
Islam N, Jacobsen KH, Jaenisch T, Jahanmehr N, Jakovljevic MB, Ja-
vanbakht M, Jayatilleke AU, Jeemon P, Jensen PN, Jha V, Jin Y, John D,
John O, Johnson SC, Jonas JB, Jurisson M, Kabir Z, Kadel R, Kahsay A,
Kalkonde Y, Kamal R, Kan HD, Karch A, Karema CK, Karimi SM,
Karthikeyan G, Kasaeian A, Kassaw NA, Kassebaum NJ, Kastor A,
Katikireddi SV, Kaul A, Kawakami N, Kazanjan K, Keiyoro PN, Kelbo-
re SG, Kemp AH, Kengne AP, Keren A, Kereselidze M, Kesavachan-
dran CN, Ketema EB, Khader YS, Khalil IA, Khan EA, Khan G, Khang
YH, Khera S, Khoja ATA, Khosravi MH, Kibret GD, Kieling C, Kim CI,
Kim D, Kim P, Kim S, Kim YJ, Kimokoti RW, Kinfu Y, Kishawi S, Kissi-
mova-Skarbek KA, Kissoon N, Kivimaki M, Knudsen AK, Kokubo Y,
Kopec JA, Kosen S, Koul PA, Koyanagi A, Kravchenko M, Krohn KJ,
Defo BK, Bicer BK, Kuipers EJ, Kulikoff XR, Kulkarni VS, Kumar GA,
Kumar P, Kumsa FA, Kutz M, Lachat C, Lagat AK, Lager ACJ, Lal DK,
Lalloo R, Lambert N, Lan Q, Lansingh VC, Larson HJ, Larsson A,
Laryea DO, Lavados PM, Laxmaiah A, Lee PH, Leigh J, Leung J, Leung
R, Levi M, Li YM, Liao Y, Liben ML, Lim SS, Linn S, Lipshultz SE, Liu SW,
Lodha R, Logroscino G, Lorch SA, Lorkowski S, Lotufo PA, Lozano
R, Lunevicius R, Lyons RA, Ma S, Macarayan ERK, Machado IE, Mac-
kay MT, Abd el Razek MM, Magis-Rodríguez C, Mahdavi M, Majdan M,
Majdzadeh R, Majeed A, Malekzadeh R, Malhotra R, Malta DC, Man-
tovani LG, Manyazewal T, Mapoma CC, Marczak LB, Marks GB,
Martínez-Raga J, Martíns-Melo FR, Massano J, Maulik PK, Mayosi BM,
Mazidi M, McAlinden C, McGarvey ST, McGrath JJ, Mckee M, Mehata
S, Mehndiratta MM, Mehta KM, Meier T, Mekonnen TC, Meles KG,
Memiah P, Memish ZA, Mendoza W, Mengesha MM, Mengistie MA,
Tadese D, Menon MGR, Menota BG, Mensah GA, Meretoja A, Mere-
toja TJ, Mezgebe HB, Micha R, Mikesell J, Miller TR, Mills EJ, Minnig S,
Mirarefin M, Mirrakhimov EM, Misganaw A, Mishra SR, Mohammad
KA, Mohammadi A, Mohammed KEMS, Mohan MBV, Mohanty SK,
Mokdad AH, Assaye AM, Mollenkopf SK, Molokhia M, Monasta L,
Hernández JCM, Montico M, Mooney MD, Moore AR, Moradi-Lakeh
M, Moraga P, Morawska L,Velasquez IM, Mori R, Morrison SD, Mruts
KB, Mueller UO, Mullany E, Muller K,Venkata G, Murthy S, Murthy S,
Musa KI, Nachega JB, Nagata C, Nagel G, Naghavi M, Naidoo KS,
Nanda L, Nangia V, Nascimento BR, Natarajan G, Negoi I, Nguyen
CT, Ningrum DNA, Nisar MI, Nomura M, Nong VM, Norheim OF,
Norrving B, Noubiap JJN, Nyakarahuka L, Obermeyer CM,
O’Donnell MJ, Ogbo FA, Oh IH, Okoro A, Oladimeji O, Olagunju AT,
Olusanya BO, Olusanya JO, Oren E, Ortiz A, Osgood-Zimmerman A,
Ota E, Owolabi MO, Oyekale AS, Pa M, Pacella RE, Pakhale S, Pana A,
Panda BK, Panda-Jonas S, Park EK, Parsaeian M, Patel T, Patten SB,
Patton GC, Paudel D, Pereira DM, Pérez-Padilla R, Pérez-Ruiz F, Pe-
rico N, Pervaiz A, Pesudovs K, Peterson CB, Petri WA, Petzold M,
Phillips MR, Piel FB, Pigott DM, Pishgar F, Plass D, Polinder S, Popova
S, Postma MJ, Poulton RG, Pourmalek F, Prasad N, Purwar M, Qor-
bani M, Rabiee RHS, Radfar A, Rafay A, Rahimi-Movaghar A, Rahimi-
Movaghar V, Rahman M, Rahman MHU, Rahman SU, Rai RK, Rajsic S,
Ram U, Rana SM, Ranabhat CL, Rao PV, Rawaf S, Ray SE, Rego MAS,
Rehm J, Reiner RC, Remuzzi G, Renzaho AMNN, Resnikoff S, Rezaei
S, Rezai MS, Ribeiro AL, Rokni MB, Ronfani L, Roshandel G, Roth GA,
Rothenbacher D, Roy A, Rubagotti E, Ruhago GM, Saadat S, Sabde
YD, Sachdev PS, Sadat N, Safdarian M, Safiri SSS, Sagar R, Sahathevan
R, Sahebkar A, Sahraian MA, Salama J, Salamati P, Salomon JA, Salvi SS,
Samy AM, Sanabria JR, Sánchez-Niño MD, Santos IS, Milicevic MMS,
Sarmiento-Suárez R, Sartorius B, Satpathy M, Sawhney M, Saxena S,
Saylan MI, Schmidt MI, Schneider IJC, Schutte AE, Schwebel DC,
204
Schwendicke F, Seedat S, Seid AM, Sepanlou SG, Servan-Mori EE,
Shackelford KA, Shaheen A, Shahraz S, Shaikh MA, Shamsipour M,
Shamsizadeh M, Islam SMS, Sharma J, Sharma R, She J, Shen JB, Shetty
BP, Shi P, Shibuya K, Shigematsu M, Shiri R, Shiue I, Shrime MG, Sigfus-
dottir ID, Silberberg DH, Silpakit N, Silva DAS, Silva JP, Silveira DGA,
Sindi S, Singh A, Singh JA, Singh PK, Singh V, Sinha DN, Skiadaresi E,
Sligar A, Smith DL, Sobaih BHA, Sobngwi E, Soneji S, Soriano JB,
Sreeramareddy CT, Srinivasan V, Stathopoulou V, Steel N, Stein DJ,
Steiner C, Stockl H, Stokes MA, Strong M, Sufiyan MB, Suliankatchi
RA, Sunguya BF, Sur PJ, Swaminathan S, Sykes BL, Szoeke CEI, Taba-
res-Seisdedos R, Tadakamadla SK, Tadese F, Tandon N, Tanne D, Tara-
jia M, Tavakkoli M, Taveira N, Tehrani-Banihashemi A, Tekelab T, Tekle
DY, Shifa GT, Temsah MH, Terkawi AS, Tesema CL, Tesssema B, Theis
A,Thomas N,Thompson AH,Thomson AJ,Thrift AG,Tiruye TY,Tobe-
Gai R, Tonelli M, Topor-Madry R, Topouzis F, Tortajada M, Tran BX,
Trujillo TTU, Tsilimparis N, Tuem KB, Tuzcu EM, Tyrovolas S, Ukwaja
KN, Undurraga EA, Uthman OA, Uzochukwu BSC, van Boven JFM,
Varakin YY, Varughese S, Vasankari T, Vasconcelos AMN, Venketasu-
bramanian N, Vidavalur R, Violante FS, Vishnu A, Vladimirov SK, Vlas-
sov VV, Vollset SE, Vos T, Waid JL, Wakayo T, Wang YP, Weichenthal S,
Weiderpass E, Weintraub RG, Werdecker A, Wesana J, Wijeratne T,
Wilkinson JD,Wiysonge CS,Woldeyes BG,Wolfe CDA,Workicho A,
Workie SB, Xavier D, Xu GL,Yaghoubi M,Yakob B,Yalew AZ,Yan LLJ,
Yano Y, Yaseri M, Ye PP, Yimam HH, Yip P, Yirsaw BD, Yonemoto N,
Yoon SJ,Yotebieng M,Younis MZ, Zaidi Z, Zaki MES, Zeeb H, Zenebe
ZM, Zerfu TA, Zhang AL, Zhang XY, Zodpey S, Zuhlke LJ, López AD,
Murray CJL. Global, regional, and national under-5 mortality, adult
mortality, age-specific mortality, and life expectancy, 1970-2016: a
systematic analysis for the Global Burden of Disease Study 2016.
Lancet. 2017; 390(10100): 1084-150. Article. IF: 53.254; D1
Public Projects
Selgas Gutiérrez R. Red de Investigación Renal (RedinRED)
(RD16/0009/0008). ISCIII. 2017-2021.
Managment centre: FIBHULP
Selgas Gutiérrez R. Vasculopatía hialinizante en diálisis pe-
ritoneal. Relación con la transición endotelio-mesenquimal
y la disfunción del endotelio y del músculo liso vascular
(PI15/00120). ISCIII. 2016-2018.
Managment centre: FIBHULP
Private Projects
Jiménez Martín C. Grupos emergentes. Wyeth Farma S.A.
2009-Ongoing.
Managment centre: FIBHULP
Selgas Gutiérrez R. Actualización y renovación de la acti-
vidad investigadora en nefrología clínica hospitalaria. Abbvie
Spain S.L.U. 2009-Ongoing.
Managment centre: FIBHULP
Selgas Gutiérrez R. Atención domiciliaria continuada para
pacientes en diálisis domiciliaria y biología celular del macró-
fago peritoneal y su relación con la fibrosis peritoneal. Baxter
S.L. 2009-Ongoing.
Managment centre: FIBHULP
Selgas Gutiérrez R. Cardiovascular disease and peritoneal
membrane damage in peritoneal dialysis as concurrent con-
sequences of a common mechanism dependent on the glu-
cose effect in peritoneal adipocytes. extramural. Baxter S.L.
2008-Ongoing.
Managment centre: FIBHULP
Selgas Gutiérrez R. Determinación de la nefrotoxicidad in-
ducida por la ecografía con burbujas en un modelo animal
como fase previa para su aplicación en transplante renal. No-
vartis Farmacéutica S.A. 2008-Ongoing.
Managment centre: FIBHULP
Selgas Gutiérrez R. Evaluación e intervención en el bienes-
tar emocional del personal y pacientes del Servicio de Ne-
frología: atención integral e interdisciplinar. Wyeth Farma S.A.
2007-Ongoing.
Managment centre: FIBHULP
Selgas Gutiérrez R. Historia natural de la microcirculación
del injerto renal mediante ecografía resaltada por contraste.
Análisis en el paciente trasplantado, tratado con/sin anti-cal-
cineurínicos.Varios. 2009-Ongoing.
Managment centre: FIBHULP
Selgas Gutiérrez R. I Campus cientifico Síndrome Hemolí-
tico Urémico Atípico(SHUA) en nefrología. Alexion Pharma
Spain S.L. 2017-Ongoing.
Managment centre: FIBHULP
Selgas Gutiérrez R. IV Jornadas científicas sobre novedades
socio-sanitarias en el trasplante renal de donante vivo.Varios.
2016-Ongoing.
Managment centre: FIBHULP
Selgas Gutiérrez R. La donación de vivo en el trasplante
renal: representaciones y prácticas sociales en la toma de de-
cisión. Un estudio socio-antropológico.Varios. 2013-Ongoing.
Managment centre: FIBHULP
Selgas Gutiérrez R. Las células mesoteliales del efluente cre-
cidas ex vivo reflejan las alteraciones peritoneales encontra-
das en la biopsia peritoneal. Oportunidades adicionales para
biomarcadores en el efluente. Fundación Senefro. 2016-On-
going.
Managment centre: FIBHULP
Selgas Gutiérrez R. Monitorización del rechazo humoral
del receptor de trasplante renal. Novartis Farmacéutica S.A.
2015-Ongoing.
Managment centre: FIBHULP
Selgas Gutiérrez R. Quinto curso de formación científica de
educadores en enfermedad renal crónica avanzada (ERCA).
Vifor Fresenius Medical Care Renal Pharma España S.L.
2017-Ongoing.
Managment centre: FIBHULP
INTERNATIONAL Projects
Selgas Gutiérrez R. Clinical validation of miniature wearable
dialysys machine (WEAKID). UE. 2017-2019.
Managment centre: FIBHULP
CLINICAL TRIALS
Bajo Rubio MA. Estudio de la enfermedad de Fabry en pa-
cientes en diálisis peritoneal. Type: NO-EPA.
HULP code: ANEXO-I PI-1920. Sponsored´s protocol code: GSS-
FBZ-2014-04.
Sponsored by: Sanofi Aventis S.A.
Signed date: 30/05/2017
Bajo Rubio MA. VEIFIE. Evaluación de la seguridad, efectivi-
dad y adherencia de velphoro en la vida real. Estudio no in-
tervencionista para investiga la seguridad, la efectividad y la
adherencia de velphoro a corto y a largo plazo en la vida real
en pacientes con hiperfosfatenia sometidos a hemodiálisis o
al adialisis peritoneal. Type: EPA-LA.
HULP code: PI-2593. Sponsored´s protocol code: VFMCRP-MEAF-
PA21-EU.
Sponsored by: Kantar Health.
Signed date: 17/02/2017
Jiménez Martín C. Estudio piloto de evaluación de una nueva
prueba diagnóstica en sangre basada en el análisis del perfil
de respuesta inmunitaria, para la identificación de biomar-
cadores asociados con la tolerancia o el rechazo crónico al
trasplante de riñón. Type: NO-EPA.
HULP code: PI-2446. Sponsored´s protocol code: PI-2446.
Sponsored by: Biohope Scientific Solutions For Human
Health S.L.
Signed date: 09/02/2017
López Oliva MO. Suspensión de la profilaxis con valganciclo-
vir en trasplantados renales CMV-seropositivo que mantie-
nen la inmunidad celular CD8+ CMV-específica tras recibir
timoglobulina. Type: Clinical Trial, phase III.
HULP code: 4892. Sponsored´s protocol code: FCO-TIM-2015-01.
Sponsored by: Fundación para la Investigación Biomédica de
Córdoba (FIBICO-IMIBIC).
Signed date: 19/06/2017
Patents and Trademarks
Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI,
Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alaja-
rín Fernández R, inventors; FIBHULP, Universidad de Alcalá,
assignees. Use of compounds derived from salts of pyrida-
zine[1’,6’:1,2]pyrido[3,4-b]indolinium as anti-inflammatory
agents. P201331143, PCT/ES2014/070603; 2013 July 25.
Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz
AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P,
Alajarín Fernández R, inventors; FIBHULP, Universidad
de Alcalá, assignees. Use of compounds derived from salts
of piridazine[3,2-b]benzimidazolium as anti-inflammatory
agents. P201430411, PCT/ES2014/070603; 2013 July 25.
Aguilera Peralta AI, López-Cabrera M, Selgas Gutiérrez
R, Steppan S, Passlickdeetjen J, inventors; Fresenius Me-
dical Care Deutschland GMBH, assignee. Pharmaceutical
compositions containing steviosides. PCT/EP2015/074955,
EP3212199, US2017304335, CN107073022; 2014 October
31.
López-Cabrera M, Aguilera Peralta AI, Selgas Gutiérrez R,
Passlickdeetjen J. Buechel J, Steppan S, inventors; Frese-
nius Medical Care AG & Co. KGaA, assignee. Method and
kit for diagnosing epitelial to mesenchymal transition of the
peritoneum (EMT-Chip). WO2017042253, DE102015115158;
2015 September 09.
Sánchez Niño MD, Ortiz Arduán A; FIBHULP, Instituto de
Investigación Sanitaria Fundación Jiménez Díaz. Phar-
maceutical composition and its use in the manufacture of a
medicament for treating chronic kidney disease and method
for selecting compounds. P201430081, PCT/ES2015/070039;
2014 January 27.
205
 3
Information Groups by Area
3.4 Large System Pathologies Area
Neonatology Group
21 132.204 9
Adelina Pellicer Martínez. Facultativo Especialista de Área
en Neonatología. HULP
Susana Ares Segura. Facultativo Especialista de Área en
Neonatología. HULP
Juan Bernal Carrasco. Jefe de Departamento de Fisiopatología
Endocrina y Sistema Nervioso. IIB Alberto Sols
María Carmen Bravo Laguna. Facultativo Especialista de Área en
Neonatología. HULP
Antonio Buño Soto. Jefe de Servicio de Laboratorio de Urgencias.
HULP
Fernando Cabañas González. Facultativo Especialista de Área en
Neonatología. Hospital Universitario Quirón Madrid
María Jesus del Olmo. Profesora Contratada. UAM
María Dolores Elorza Fernández. Jefe de Sección en
Neonatología. HULP
Miriam Martínez Biarge. Facultativo Especialista de Área. Hospital
Hammer Smith
María Teresa Montes Bueno. Enfermera. HULP
María Natividad Pastrana Pérez. Enfermera. HULP
María Luisa Prieto Postigo. Auxiliar de Enfermería. HULP
Miguel Sáenz de Pipaón Marcos. Facultativo Especialista de Área
en Neonatología. HULP. Profesor Asociado. UAM
Belén Sáenz-Rico de Santiago. Profesor Contratado Doctor. UCM
Laura Sánchez García. Médico Adjunto en Neonatología. HULP
Eva Valverde Nuñez. Facultativo Especialista de Área en
Neonatología. HULP. Profesor Asociado. UAM
Strategic Objective
Prevent structural damage to organs and systems in
the high risk newborn.
206
Reduce the impact of the processes that occurred in
the peri-neonatal stage in later life.
Research Lines
• Developmental Neurobiology.
• Neonatal pulmonary and cardiovascular pathology.
• Thyroid in term and preterm neonates.
• Nutrition. Breast feeding. Mycrobiota.
• Perinatal and neonatal infectology. Inmunology and
vaccines.
• Neurodevelopmental. Follow–up.
Research Activity
Doctoral TheseS
García Díaz EF. El violín: un instrumento para el desa-
rrollo musical y cognitivo desde la infancia[dissertation].
Madrid: UAM: 2017(22/09/2017).
Director: del Olmo Barros MJ; Gutiérrez Rivas E.
Riera Banal J. Nuevos métodos no invasivos para
el estudio del flujo sanguíneo cerebral en recién
nacidos[dissertation]. Madrid: UPM: 2017(19/07/2017).
Director: Pellicer Martínez A; Serrano JJ.
PUBLICATIONS
• Balbas LAB, Amaro MS, Rioja RG, Martín MJA, Soto AB. Stabi-
lity of plasma electrolytes in Barricor and PST II tubes under
different storage conditions. Biochem Medica. 2017; 27(1): 225-30.
Article. IF: 3.653; Q1
• Bravo MC, Valverde E. Reliability in cerebellar size assessment by
2D cranial ultrasonography in neonates. Eur J Paediatr Neuro. 2017;
21(4): 610-3. Article. IF: 2.362; Q2
• de Pipaón MS, Closa R, Gormaz M, Lines M, Narbona E, Rodíguez-
Martínez G, Uberos J, Zozaya C, Couce ML. Nutritional practices
in very low birth weight infants: a national survey. Nutr Hosp. 2017;
34(5):71-6. Article. Not Indexed
• de Pipaón MS, Dorronsoro I, Álvarez-Cuervo L, Butte NF, Madero R,
Barrios V, Coya J, Martínez-Biarge M, Martos-Moreno GA, Fewtrell
MS, Argente J, Quero J. The impact of intrauterine and extrauterine
weight gain in premature infants on later body composition. Pediatr
Res. 2017; 82(4): 658-64. Article. IF: 3.123; Q1
• Ergenekon E, Rojas-Anaya H, Bravo MC, Kotidis C, Mahoney L, Rabe
H. Cardiovascular drug therapy for human newborn: Review of
pharmacodynamic data. Curr Pharm Design. 2017; 23(38): 5850-60.
Review. IF: 2.757; Q2
• Herruzo R, Ruiz G, Pérez-Blanco V, Gallego S, Mora E, Vizcaino MJ,
Omeñaca F. Bla-OXA48 gene microorganisms outbreak, in a tertiary
Children’s Hospital, Over 3 years (2012-2014) Case Report. Medici-
ne. 2017; 96(40): e7665. Article. IF: 2.028; Q2
• Jiménez BC, Parada YA, Marín AV, Marcos MSD. Short, medium and
long-term benefits of human milk intake in very-low-birth-weight
infants. Nutr Hosp. 2017; 34(5): 63-70. Article. Not Indexed
• Kyriakopoulou V, Vatansever D, Davidson A, Patkee P, Elkommos S,
Chew A, Martínez-Biarge M, Hagberg B, Damodaram M, Allsop J, Fox
M, Hajnal JV, Rutherford MA. Normative biometry of the fetal brain
using magnetic resonance imaging. Brain Struct Funct. 2017; 222(5):
2295-307. Article. IF: 4.231; D1
• Lana A, Valdes-Becares A, Buño A, Rodríguez-Artalejo F, López-Gar-
cía E. Serum leptin concentration is associated with incident frailty
in older adults. Aging Dis. 2017; 8(2): 240-9. Article. IF: 5.058; Q1
• López-Maestro M, Sierra-García P, Díaz-González C, Torres-Valdi-
vieso MJ, Lora-Pablos D, Ares-Segura S, Pallas-Alonso CR. Quality
of attachment in infants less than 1500 g or less than 32 weeks.
Related factors. Early Hum Dev. 2017; 104: 1-6. Article. IF: 2.025; Q2
• Loureiro B, Martínez-Biarge M, Foti F, Papadaki M, Cowan FM,
Wusthoff CJ. MRI Patterns of brain injury and neurodevelopmental
outcomes in neonates with severe anaemia at birth. Early Hum Dev.
2017; 105: 17-22. Article. IF: 2.025; Q2
• Martínez M, Romero MG, Guereta LG, Cabrera M, Regojo RM, Alba-
jara L, Couce ML, de Pipaón MS. Infantile-onset Pompe disease with
neonatal debut: A case report and literature review. Medicine. 2017;
96(51): e9186. Review. IF: 2.028; Q2
• Moreno-Núñez A, Rodíguez C, del Olmo MJ. Rhythmic ostensive
gestures: How adults facilitate infants’ entrance into early triadic
interactions. Infant Behav Dev. 2017; 49: 168-81.Article. IF: 1.669; Q3
• Negredo A, de la Calle-Prieto F, Palencia-Herrejón E, Mora-Rillo M,
Astray-Mochales J, Sánchez-Seco MP, López EB, Menárguez J, Fer-
nández-Cruz A, Sánchez-Artola B, Keough-Delgado E, de Arellano
ER, Lasala F, Milla J, Fraile JL, Gavin MO, de la Gandara AM, Pérez LL,
Díaz-Díaz D, López-García MA, Delgado-Jiménez P, Martín-Quirós
A, Trigo E, Figueira JC, Manzanares J, Rodíguez-Baena E, García-Co-
mas L, Rodíguez-Fraga O, García-Arenzana N, Fernández-Díaz MV,
Cornejo VM, Emmerich P, Schmidt-Chanasit J, Arribas JR, (Buño Soto
A). Autochthonous Crimean-Congo hemorrhagic fever in Spain.
New Engl J Med. 2017; 377(2): 154-61. Article. IF: 79.258; D1
• Perales A, Delgado JL, de la Calle M, García-Hernández JA, Escu-
dero AI, Campillos JM, Sarabia MD, Laiz B, Duque M, Navarro M,
Calmarza P, Hund M, Álvarez FV, (Buño Soto A). sFlt-1/PlGF for
prediction of early-onset pre-eclampsia: STEPS (Study of Early Pre-
eclampsia in Spain). Ultrasound Obst Gyn. 2017; 50(3): 373-82. Ar-
ticle. IF: 5.654; Q1
• Salinas M, López-Garrigos M, Flores E, Leiva-Salinas C. Primary care
requests for anaemia chemistry tests in Spain: potential iron, trans-
ferrin and folate over-requesting. J Clin Pathol. 2017; 70(9): 760-5.
Article. IF: 2.894; Q2
• Sánchez-Illana A, Núñez-Ramiro A, Cernada M, Parra-Llorca A, Val-
verde E, Blanco D, Moral-Pumarega MT, Cabañas F, Boix H, Pavón A,
Chaffanel M, Benavente-Fernández I, Tofe I, Loureiro B, Fernández-
Lorenzo JR, Fernández-Colomer B, García-Robles A, Kuligowski J,
Vento M. Evolution of energy related metabolites in plasma from
newborns with hypoxic-ischemic encephalopathy during hypother-
mia treatment. Sci Rep-Uk. 2017; 7: 17039. Article. IF: 4.122; Q1
• Martinón-Torres F, Wysocki J, Center KJ, Czajka H, Majda-Stanis-
lawska E, Omeñaca F, Concheiro-Guisan A, Giménez-Sánchez F,
Szenborn L, Blázquez-Gamero D, Moreno-Galarraga L, Giardina PC,
Sun G, Gruber WC, Scott DA, Gurtman A. Circulating antibody 1
and 2 years after vaccination with the 13-valent pneumococcal con-
jugate vaccine in preterm compared with term infants. Pediatr Infect
Dis J. 2017; 36(3): 326-32. Article. IF: 2.305; Q2
• Nieto CZ, Caamano BF, Bartolo GM, Suso JJM, Remacha EF, Núñez
EV. Presenting features and prognosis of ischemic and nonischemic
neonatal liver failure. J Pediatr Gastr Nutr. 2017; 64(5): 754-9. Arti-
cle. IF: 2.752; Q1
• Plomgaard AM, Alderliesten T, Austin T, van Bel F, Benders M, Claris
O, Dempsey E, Fumagalli M, Gluud C, Hagmann C, Hyttel-Sorensen
S, Lemmers P, van Oeveren W, Pellicer A, Petersen TH, Pichler G,
Winkel P, Greisen G. Early biomarkers of brain injury and cerebral
hypo- and hyperoxia in the SafeBoosC II trial. Plos One. 2017; 12(3):
e0173440. Article. IF: 2.766; Q1
• Zozaya C, Triana M, Madero R, Abrams S, Martínez L, Amesty MV,
de Pipaón MS. Predicting full enteral feeding in the postoperative
period in infants with congenital diaphragmatic hernia. Eur J Pediatr
Surg. 2017; 27(5): 431-6. Article. IF: 1.494; Q3
Public Projects
Cabañas González F. Red de Salud Materno-Infantil y del
Desarrollo (SAMID) (RD16/0022/0004). ISCIII. 2017-2021.
Managment centre: FIBHULP
Laguna Bravo MC. Ensayo clínico multicéntrico sobre el tra-
tamiento del ductus arterioso persistente ecocardiográfica-
mente guiado en el recién nacido prematuro con ibuprofeno
en perfusión continua intravenosa frente a bolos intraveno-
sos: impacto en el pronóstico intestinal (PI16/00644). ISCIII.
2017-2019.
Managment centre: FIBHULP
Sáenz de Pipaón Marcos M. Efecto de la suplementación
precoz con ácido docosahexanoico y ácido araquidónico so-
bre la incidencia de displasia broncopulmonar en niños extre-
madamente prematuros: ensayo clínico (PI16/00606). ISCIII.
2017-2019.
Managment centre: FIBHULP
Private Projects
Ares Segura S. Exceso de yodo: consecuencias en la función
tiroidea y en el neurodesarrollo. Universidad de Akershus de
Ciencias Aplicadas. 2013-Ongoing.
Managment centre: FIBHULP
Bravo Laguna MC. Valoración cuantitativa de la repercusión
hemodinámica del ductus arterioso persistente y su trata-
miento en el recién nacido de bajo peso. Neonatcare S.L.
2008-Ongoing.
Managment centre: FIBHULP
207
 3
Information Groups by Area

3.4 Large System Pathologies Area

Bravo Laguna MC. Ensayo clínico multicéntrico sobre el tra- CLINICAL TRIALS Sánchez García L. Estudio multicéntrico aleatorizado y Sponsored by: Glaxosmithkline S.A.
tamiento del ductus arterioso persistente ecocardiográfica- abierto en fase IIB para comparar la eficacia, seguridad y far- Signed date: 16/05/2017
mente guiado en el recién nacido prematuro con ibuprofeno Sáenz de Pipaón Marcos M. Estudio aleatorizado, en doble macocinetica (PK) de la dosis óptima y la dosis estándar de
con perfusión continua intravenosa frente a bolos intrave- ciego, controlado, con grupos paralelos y multinacional, para vancomicina en neonatos y niños menores o iguales a 90 días Sáenz de Pipaón Marcos M. Estudio multicéntrico, aleatori-
nosos: impacto en el pronóstico intestinal. Fundación Mutua investigar el efecto sobre la composición de la microbiota de vida con sospecha de sepsis o sepsis confirmada por ger- zado, doble ciego controlado con placebo para evaluar la efi-
Madrileña. 2016-Ongoing. intestinal de una leche infantil parcialmente hidrolizada, su- menes gram-positivos. Type: Clinical Trial, phase II. cacia y seguridad del uso de NTRA-2112 para tratar la mala
plementada con simbióticos, y su efectividad clínica en lactan- HULP code: 4729. Sponsored´s protocol code: NEOVANC. absorción intestinal causada por inmadurez gastrointestinal
Managment centre: FIBHULP
tes con gran riesgo de desarrollar alergia. Type: Health care en niños prematuros. Type: Clinical Trial, phase III.
Sponsored by: Fondazione Penta Onlus.
Buño Soto A. Actualización y renovación de la actividad in- product. HULP code: ANEXO-I 4231. Sponsored´s protocol code: FIT-EU-04.
vestigadora en el Servicio de Análisis Clínicos del Hospital Signed date: 17/02/2017
HULP code: 4850. Sponsored´s protocol code: EBB15BL89859. Sponsored by: Nutrinia Ltd.
Universitario La Paz. Radiometer Iberica S.L. 2012-Ongoing. Sponsored by: Nutricia Reseach B.V. (Danone). Ares Segura S. Estudio de fase IIB aleatorizado, doble ciego,
Signed date: 26/07/2017
Managment centre: FIBHULP Signed date: 24/07/2017 controlado con placebo para evaluar la seguridad y la eficacia
de MEDI8897, un anticuerpo monoclonal con una semivida Sáenz de Pipaón Marcos M. Estudio multicéntrico, aleatori-
Buño Soto A. Method comparison evaluation between the Cabañas González F. Ensayo clínico fase III, aleatorizado, mul- prolongada frente al virus respiratorio sincitial, en prematu- zado, doble ciego controlado con placebo para evaluar la efi-
radiometer procalitonin (PCT) assay on the AQT90 flex ticéntrico, doble ciego para evaluar dos pautas de administra- ros sanos. Type: Clinical Trial, phase II. cacia y seguridad del uso de NTRA-2112 para tratar la mala
analyzer and the elecsys B.R.A.M.S. pct on an automated ción del ibuprofeno en el tratamiento del ductus arterioso HULP code: ANEXO-I 4660. absorción intestinal causada por inmadurez gastrointestinal
roche immunoassay analyzer. Radiometer Medical APS. persistente eco-guiado: impacto en el pronóstico intestinal.
Sponsored´s protocol code: D5290C00003. en niños prematuros. Type: Clinical Trial, phase III.
2015-Ongoing. Type: Clinical Trial, phase III.
Sponsored by: Medimmune. HULP code: ANEXO-II 4231. Sponsored´s protocol code: FIT-EU-04.
Managment centre: FIBHULP HULP code: 4711C. Sponsored´s protocol code: IBU24h-EchoG.
Signed date: 09/01/2017 Sponsored by: Nutrinia Ltd.
Buño Soto A. Recogida de muestras en deportistas de alto Sponsored by: Fundación para la Investigación Biomédica
Hospital Universitario La Paz. Omeñaca Terés F. Estudio para evaluar la seguridad, la reac- Signed date: 19/10/2017
rendimiento para la evaluación de su variación biológica.
FIBHULP. 2016-Ongoing. Signed date: 03/04/2017 togenicidad y la inmunogenicidad de la vacuna experimental
frente al virus respiratorio sincitial (VRS) de GSK biologicals
Managment centre: FIBHULP
basada en proteínas virales codificadas por un adenovector
Patents and Trademarks
Cabañas González F. Impacto de las técnicas de reproduc- derivado del chimpancé (CHAD155RSV) (GSK3389245A) en Segovia Iñigo C, Montes Bueno MT, inventors; Segovia Iñigo
ción asistida en la salud del recién nacido. Varios. 2011-On- niños seropositivos frente al VRS. Type: Clinical Trial, phase II. C, assignee. Positioning device for neonates (Utility model).
going. HULP code: 4668. Sponsored´s protocol code: 204838 (RSV PED-002). U201330102; 2013 January 31.
Managment centre: FIBHULP
del Olmo Barros MJ. Jornadas de investigación y atención
directo en musicoterapia hospitalaria. Varios Financiadores.
2015-Ongoing.
Managment centre: FIBHULP
Omeñaca Terés F. Leche materna en niños prematuros: ca-
racterísticas nutricionales e infección por citomegalovirus.
Infacare Pharmaceutical Corporation. 2010-Ongoing.
Managment centre: FIBHULP
Salas Hernández S. I Curso multidisciplinar en la atención
al seguimiento de niños nacidos con peso < 1.500 g. Varios
Financiadores. 2011-Ongoing.
Managment centre: FIBHULP
Buño Soto A. Estudio en población cognitivamente sana (sin
demencia) para la determinación de valores de referencia de
una nueva técnica diagnóstica basada en espectroscopia Ra-
man. Raman Health Technologies S.L. 2016-Ongoing.
Managment centre: FIBHULP
Pellicer Martínez A. Online cerebral pressure autoregu-
lation continuous monitorin as a neurobiomarker to guide
assessment and intervention to prevent or minimise brain
injury in the high-risk preterm infant. Chiesi Found. 2017-On-
going.
Managment centre: FIBHULP
Sáenz de Pipaón Marcos M. Efecto de la suplementación
precoz con ácido araquidónico y ácido docosahexanoico
(DHA) en la evolución de las concentraciones plasmáticas y
eritrocitarias de DHA en recién nacidos prematuros: ensayo
controlado aleatorizado. Nestle España S.A. 2016-Ongoing.
Managment centre: FIBHULP
Pellicer Martínez A. Servicios grupo de investigación de
neonatología.Varios Financiadores. 2017-Ongoing.
Managment centre: FIBHULP
208 209
 3
Information Groups by Area
3.4 Large System Pathologies Area
Aging and Fragility in
the Elderly Group
21 50.528 5
Juan Ignacio González Montalvo. Jefe de Servicio de
Geriatría. HULP. Profesor Asociado. UAM
Juan Carlos Abánades Herranz. Subdirector Médico. Responsable
de la Unidad de Formación e Investigación. Atención Primaria
María Teresa Alarcón Alarcón. Jefe de Sección de Geriatría. HULP
Juan Cárdenas Valladolid. Técnico de la Gerencia Adjunta de
Planificación y Calidad de Atención Primaria. Atención Primaria
María Victoria Castell Alcalá. Facultativo Especialista de Área en
Medicina Familiar y Comunitaria. Atención Primaria
Carmen de Burgos Lunar. Facultativo Especialista de Área en
Medicina Preventiva. HULP
Macarena Díaz de Bustamante de Ussía. Médico Interno
Residente. HULP
Araceli Garrido Barral. Facultativo Especialista de Área en
Medicina Familiar y Comunitaria. Atención Primaria
Pilar Gotor Pérez. Enfermera. Unidad de Valoración Geriátrica y
Ortogeriatría. HULP
Alicia Gutiérrez Misis. Profesor Ayudante Doctor. UAM
Rosa Julián Viñals. Facultativo Especialista de Área en Medicina
Familiar y Comunitaria. Atención Primaria - Centro de Salud Raúl
Castroviejo
Rocío Menéndez Colino. Facultativo Especialista de Área en
Geriatría. HULP - Hospital de Cantoblanco
Débora Moral Cuesta. Médico Interno Residente en Geriatría
Ángel Otero Puime. Profesor Titular Medicina Preventiva y Salud
Pública. UAM. Médico Adjunto Medicina Preventiva. HULP
Rocío Queipo Mata. Investigadora Predoctoral. UAM
Raquel Ramírez Martín. Médico Interno Residente. HULP
Ana María Rosas Hernández. Investigadora Predoctoral. UAM
María del Pilar Sáez López. Facultativo Especialista de Área en
Geriatría. Complejo Asistencial de Ávila
210
Miguel Ángel Salinero Fort. Gerente adjunto de Planificación y
Calidad. Atención Primaria
Mercedes Sánchez Martínez. Profesor Asociado. UAM
Strategic Objective
• To promote and improve the quality of research in
the field of Primary Health Care and Geriatrics in
the area of influence of IdiPAZ.
• To continue the follow-up of the Cohorts of the
Group: elderly people with population-based (Pe-
ñagrande Study), patients with frailty syndrome
(FONDA) and patients with Type 2 Diabetes Melli-
tus (MADiabetes).
• Progress in the epidemiological study of frailty in
the elderly.
• To consolidate clinical studies related to hip frac-
ture and chronic diseases in the elderly, specially
the Diabetes Mellitus.
Research Lines
• Frailty syndrome in the elderly.To promote the de-
tection of frailty syndrome in elderly people above
75 years that consults at the Primary Heatlh Care
Center of the Hospital La Paz Setting and create a
new cohort of those patients with functional im-
pairment. Additionally, to develop and evaluate an
intervention program with these patients, focused
on the physical exercise, the geriatric evaluation,
management of comorbidity, in the medication
adjustment y in nutritional supplementation when
necessary.
• Hip fracture in the frail elderly. To evaluated the im-
plementation and evaluation of the FONDA interven-
tion with frail elderly patients hospitalized at the La
Paz Hospital based on: physical exercise program (ac-
tive and passive), early normalization of plasma levels
of VitD, nutritional supplementation in patients with
hypoproteinemia, low or vitamin D deficiency, and
control of the pain and anemia.
• Follow-up of patients with Type 2 Diabetes Mellitus
(MADiabetes Cohort, more than 3.500 patients) and
prediabetes patients (SPREDIA Cohort, n=600) of
Madrid, to analyze clinical and psychosocial factors
related to clinical outcomes (cardiovascular events,
chronic kidney disease, retinopathy, and mortality), we
are developing predictive models for main outcomes
(chronic kidney disease, all-cause mortality and cardio-
vascular mortality).
Research Activity
PUBLICATIONS
• Aguilera-Correa JJ, Urruzuno P, Barrio J, Martínez MJ, Agudo S, So-
modevilla A, Llorca L, Alarcón T. Detection of helicobacter pylori
and the genotypes of resistance to clarithromycin and the hetero-
geneous genotype to this antibiotic in biopsies obtained from symp-
tomatic children. Diagn Micr Infec Dis. 2017; 87(2): 150-3. Article. IF:
2.341; Q3
• Alarcón T, Llorca L, Pérez-Pérez G. Impact of the microbiota and
gastric disease development by helicobacter pylori. Curr Top Micro-
biol. 2017; 400: 253-75. Review. IF: 5.829; Q1
• Alarcón T, Urruzuno P, Martínez MJ, Domingo D, Llorca L, Correa A,
López-Brea M. Antimicrobial susceptibility of 6 antimicrobial agents
in Helicobacter pylori clinical isolates by using EUCAST breakpoints
compared with previously used breakpoints. Enferm Infec Micr Cl.
2017; 35(5): 278-82. Article. IF: 1.707; Q3
• Alba C, Blanco A, Alarcón T. Antibiotic resistance in Helicobacter
pylori. Curr Opin Infect Dis. 2017; 30(5): 489-97. Review. IF: 3.782; Q2
• Condorhuaman-Alvarado PY, Menéndez-Colino R, Mauleón-Ladre-
ro C, Díez-Sebastián J, Alarcón T, González-Montalvo JI. Predictive
factors of functional decline at hospital discharge in elderly patients
hospitalised due to acute illness. Rev Esp Geriatr Gerontol. 2017;
52(5): 253-6. Article. Not Indexed
• del Río VC, Mostaza J, Lahoz C, Sánchez-Arroyo V, Sabín C, López S,
Patrón P, Fernández-García P, Fernández-Puntero B, Vicent D, Mon-
tesano-Sánchez L, García-Iglesias F, González-Alegre T, Estirado E,
Laguna F, de Burgos-Lunar C, Gómez-Campelo P, Abanades-Herranz
JC, de Miguel-Yanes JM, Salinero-Fort MA. Prevalence of periphe-
ral artery disease (PAD) and factors associated: An epidemiological
analysis from the population-based Screening PRE-diabetes and type
2 DIAbetes (SPREDIA-2) study. Plos One. 2017; 12(10): e0186220.
Article. IF: 2.766; Q1
• González-Montalvo JI, Alarcón T, Menéndez-Colino R, Ríos-German
PP, Queipo R, Otero A. Fequency of sarcopenia and characteristics
of the patients studied using uniform EWGSOP criteria in Spanish
studies. Rev Esp Geriatr Gerontol. 2017; 52(5): 293-4. Letter. Not
Indexed
• Jiménez-García R, López-de-Andrés A, Hernández-Barrera V,
Gómez-Campelo P, Andrés-Rebollo FJS, de Burgos-Lunar C,
Cárdenas-Valladolid J, Abanades-Herranz JC, Salinero-Fort MA.
Influenza vaccination in people with type 2 diabetes, coverage,
predictors of uptake, and perceptions. Result of the MADIABE-
TES cohort a 7 years follow up study.Vaccine. 2017; 35(1): 101-8.
Article. IF: 3.285; Q2
• Jiménez-Trujillo I, Jiménez-García R, de Miguel-Díez J, de Miguel-
Yanes JM, Hernández-Barrera V, Méndez-Bailón M, Pérez-Farinos N,
Salinero-Fort MA, López-de-Andrés A. Incidence, characteristic and
outcomes of ventilator-associated pneumonia among type 2 diabe-
tes patients: An observational population-based study in Spain. Eur J
Intern Med. 2017; 40: 72-8. Article. IF: 3.282; Q1
• Llorca L, Pérez-Pérez G, Urruzuno P, Martínez MJ, Iizumi T, Gao Z,
Sohn J, Chung J, Cox L, Simón-Soro A, Mira A, Alarcón T. Characteri-
zation of the gastric microbiota in a pediatric population according
to helicobacter pylori status. Pediatr Infect Dis J. 2017; 36(2): 173-8.
Article. IF: 2.305; Q2
• López EG, Lázaro MIG, Puime AO. Family medicine in the training of
the doctors of the future, and nowadays. Med Clin-Barcelona. 2017;
148(4): 192-3. Letter. IF: 1.168; Q3
• López-de-Andrés A, de Miguel-Díez J, Jiménez-Trujillo I, Hernández-
Barrera V, de Miguel-Yanes JM, Méndez-Bailón M, Pérez-Farinós N,
Salinero-Fort MA, Jiménez-García R. Hospitalisation with commu-
nity-acquired pneumonia among patients with type 2 diabetes: an
observational population-based study in Spain from 2004 to 2013.
BMJ Open. 2017; 7(1): e013097. Article. IF: 2.413; Q2
• López-de-Andrés A, de Miguel-Yanes JM, Hernández-Barrera V, Mén-
dez-Bailón M, González-Pascual M, de Miguel-Díez J, Salinero-Fort
MA, Pérez-Farinós N, Jiménez-Trujillo I, Jiménez-García R. Renal
transplant among type 1 and type 2 diabetes patients in Spain: A
population-based study from 2002 to 2013. Eur J Intern Med. 2017;
37: 64-8. Article. IF: 3.282; Q1
• Pérez MDC, Alcalá MVC, Menéndez-Asenjo AA, Puime AO.Variabili-
ty in the use of health services by the elderly related to the medical
list to which they belong. Aten Prim. 2017; 49(10): 620-1. Letter. IF:
1.148; Q3
• Ramírez-Martín R, Alcalá MVC, Alarcón T, Queipo R, Germán PPR,
Puime AO, González-Montalvo JI. Comprehensive geriatric as-
sessment for identifying older people at risk of hip fracture: cross-
sectional study with comparative group. Fam Pract. 2017; 34(6): 679-
84. Article. IF: 1.675; Q2
• Rodríguez-Pascual C, Paredes-Galán E, Ferrero-Martínez AI, Gon-
zález-Guerrero JL, Hornillos-Calvo M, Menéndez-Colino R, Torres-
Torres I, Vilches-Moraga A, Galán MC, Suárez-García F, Olcoz-Chiva
MT, Rodríguez-Artalejo F. The frailty syndrome is associated with
adverse health outcomes in very old patients with stable heart failu-
re: A prospective study in six Spanish hospitals. Int J Cardiol. 2017;
236: 296-303. Article. IF: 4.034; Q2
• Rodríguez-Sánchez I, Moral-Cuesta D, Menéndez-Colino R, Gonzá-
lez-Montalvo JI. Severe chronic hypocalcaemia in an asymptomatic
patient. Rev Esp Geriatr Gerontol. 2017; 52(3): 171-2. Letter. Not
Indexed
• Sáez-López P, Branas F, Sánchez-Hernández N, Alonso-García N,
González-Montalvo JI. Hip fracture registries: utility, description,
and comparison. Osteoporosis Int. 2017; 28(4): 1157-66. Article. IF:
3.856; Q2
• Salinero-Fort MA, Andrés-Rebollo FJS, Gómez-Campelo P, de
Burgos-Lunar C, Cárdenas-Valladolid J, Abanades-Herranz JC,
Otero-Puime A, Jiménez-García R, López-de-Andres A, de Miguel-
Yanes JM. Body mass index and all-cause mortality among type
2 diabetes mellitus patients: Findings from the 5-year follow-up
of the MADIABETES cohort. Eur J Intern Med. 2017; 43: 46-52.
Article. IF: 3.282; Q1
• Salinero-Fort MA, San Andrés-Rebollo J, Gómez-Campelo P, de
Andrés AL, Jiménez-García R. Response to cardiovascular and all-
cause mortality in patients with type 2 diabetes mellitus and chro-
nic kidney disease. J Diabetes Complicat. 2017; 31(3): 647. Letter.
IF: 2.792; Q3
• Zunzunegui MV, Belanger E, Benmarhnia T, Gobbo M, Otero A, Be-
land F, Zunzunegui F, Ribera-Casado JM. Financial fraud and health:
the case of Spain. Gac Sanit. 2017; 31(4): 313-9. Article. IF: 1.581; Q3
211
 3
Information Groups by Area

3.4 Large System Pathologies Area

Public Projects Private Projects

de Burgos Lunar C. Validación de los diagnósticos de fi-
brilacion articular, infarto agudo de miocardio, ictus y exitus
registrados en la historia clinica informatizadad de la atención
primaria (PI13/00632). ISCIII. 2014-2018.
Managment centre: FIBHULP
Otero Puime A. Red de Investigación Cooperativa en Enve-
jecimiento y Fragilidad (RETICEF) (RD12/0043/0019). ISCIII.
2013-2017.
Managment centre: FIBHULP
Salinero Fort MA. Análisis de evolución temporal de las tasas
y causas de mortalidad de una cohorte de diabetes mellitus
tipo 2 y comparación con estadísticas oficiales (PI12/01806).
ISCIII. 2013-2017.
Managment centre: FIBHULP
González Montalvo JI. Proyecto de actualización bibliográ-
fica básica de temas de investigación, documentación, actua-
lización y transmisión bibliográfica en sesiones conjuntas de Molecular Hepatology Group
servicio. EISAI Farmaceutica S.A. 2008-Ongoing.
Managment centre: FIBHULP
González Montalvo JI. Estudio de la evolución a medio y
largo plazo tras el tratamiento integral de los pacientes con
fractura de cadera. Evaluación de los factores predictivos del
pronóstico funcional y vital (Estudio Fonda). Conforem S.L.
2012-Ongoing.
Managment centre: FIBHULP
González Montalvo JI. Proyecto del registro nacional de
fracturas de cadera por fragilidad en el anciano. Amgen S.A.;
UCB Biopharma SPRL. 2017-Ongoing.
Managment centre: FIBHULP

8 20.743 5

Paloma Jara Vega. Jefe de Servicio de Hepatología Pediátrica.
HULP
Sara Andueza Salazar. Técnico de Investigación. HULP
Carmen Camarena Grande. Facultativo Especialista de Área en
Hepatología Pediátrica. HULP
Angela de la Vega Bueno. Facultativo Especialista de Área en
Hepatología Pediátrica. HULP
María Carmen Díaz Fernández. Jefe de Sección de Hepatología
Pediátrica. HULP
Esteban Frauca Remacha. Facultativo Especialista de Área en
Hepatología Pediátrica. HULP
Loreto Hierro Llanillo. Facultativo Especialista de Área en
Hepatología Pediátrica. HULP
Gema Muñoz Bartolo. Facultativo Especialista de Área en
Hepatología Pediátrica. HULP
María Angeles Pajares Tarancón. Investigador Científico. CSIC
Luiz Guilherme Stark Aroeira. Investigador Postdoctoral. HULP
David Vicent López. Investigador Senior (Contrato Miguel Servet -
I2). HULP
Strategic Objective
Our research interest is focused on the study of the
molecular mechanisms underlying the most severe
paediatric liver disorders, namely cholestasis, which
results from the
impaired secretion of bile from the liver to the in-
testine. As such, it represents a clinical and bioche-
mical syndrome that is produced by a wide variety
Research Lines
of disease processes that affect the liver. Individuals
with cholestasis manifest jaundice, severe itching, ma-
212
labsorption of fats and lipidsoluble vitamins and, in
many cases, progressive liver damage. These clinical
manifestations are due to the accumulation in blood
and tissues of substances normally secreted in the
bile, such as bilirubin, bile acids, and cholesterol and
to the absence of bile from the intestine.
When manifested in early infancy, cholestasis is of-
ten life threatening and usually requires liver trans-
plantation. Extrahepatic biliary atresia (EHBA), Ala-
gille syndrome and progressive familial intrahepatic
cholestasis (PFIC) constitute the main paediatric
cholestatic disorders. EHBA is an enigmatic disease
of unknown aetiology, characterised by a precocious
and accelerated obstruction of the biliary tree. Alagi-
lle syndrome is associated with mutations in the Jag1
gene and is characterised by a paucity or absence of
intrahepatic bile ducts. PFIC encompasses a hetero-
geneous group of autosomal recessive diseases that
exhibit similar clinical features. These diseases are
caused by mutations in proteins located in the cana-
licular membrane of the hepatocyte and in proteins
involved in bile secretion, such as the bile salt export
pump (BSEP; ABCB11), the phospholipid transport
protein MDR3 (ABCB4) and the aminophospholipid
translocase FIC1 (ATP8B1). These cholestatic disor-
ders constitute the most common indication for liver
transplantation in childhood.
• Molecular basis of paediatric liver diseases
• Liver Pathobiology
213
 3
Information Groups by Area
3.4 Large System Pathologies Area
Research Activity
PUBLICATIONS
• Camarena C,Aldamiz-Echevarría LJ, Polo B, Barba Romero MA, Gar-
cía I, Cebolla JJ, Ros E. Update on lysosomal acid lipase deficiency:
Diagnosis, treatment and patient management. Med Clin-Barcelona.
2017; 148(9): 429.e1-10. Article. IF: 1.168; Q3
• del Río VC, Mostaza J, Lahoz C, Sánchez-Arroyo V, Sabín C, López S,
Patrón P, Fernández-García P, Fernández-Puntero B, Vicent D, Mon-
tesano-Sánchez L, García-Iglesias F, González-Alegre T, Estirado E,
Laguna F, de Burgos-Lunar C, Gómez-Campelo P, Abanades-Herranz
JC, de Miguel-Yanes JM, Salinero-Fort MA. Prevalence of periphe-
ral artery disease (PAD) and factors associated: An epidemiological
analysis from the population-based Screening PRE-diabetes and type
2 DIAbetes (SPREDIA-2) study. Plos One. 2017; 12(10): e0186220.
Article. IF: 2.766; Q1
• Jahnel J, Zohrer E, Fischler B, D’Antiga L, Debray D, Dezsofi A, Haas
D, Hadzic N, Jacquemin E, Lamireau T, Maggiore G, McKiernan PJ,
Calvo PL,Verkade HJ, Hierro L, McLin V, Baumann U, Gonzales E. At-
tempt to determine the prevalence of two inborn errors of primary
bile acid synthesis: Results of a European survey. J Pediatr Gastr
Nutr. 2017; 64(6): 864-8. Article. IF: 2.752; Q1
• Mclin VA, Allen U, Boyer O, Bucuvalas J, Colledan M, Cuturi MC,
d’Antiga L, Debray D, Dezsofi A, de Goyet JD, Dhawan A, Durmaz
O, Falk C, Feng S, Fischler B, Franchi-Abella S, Frauca E, Ganschow
R, Gottschalk S, Hadzic N, Hierro L, Horslen S, Hubscher S, Karam
V, Kelly D, Maecker-Kolhoff B, Mazariegos G, McKiernan P, Melk A,
Nobili V, Ozgenc F, Reding R, Sciveres M, Sharif K, Socha P, Toso C,
Vajro P, Verma A, Wildhaber BE, Baumann U. Early and late factors
impacting patient and graft outcome in pediatric liver transplanta-
tion: Summary of an ESPGHAN monothematic conference. J Pediatr
Gastr Nutr. 2017; 65(3): E53-9. Article. IF: 2.752; Q1
• Nieto CZ, Caamaño BF, Bartolo GM, Suso JJM, Remacha EF, Núñez
EV. Presenting features and prognosis of ischemic and nonischemic
neonatal liver failure. J Pediatr Gastr Nutr. 2017; 64(5): 754-9. Arti-
cle. IF: 2.752; Q1
• Partearroyo T, Vallecillo N, Pajares MA, Varela-Moreiras G, Varela-
Nieto I. Cochlear homocysteine metabolism at the crossroad of
nutrition and sensorineural hearing loss. Front Mol Neurosci. 2017;
10: 107. Review. IF: 3.902; Q2
• Pérez-Miguelsanz J, Vallecillo N, Garrido F, Reytor E, Pérez-Sala D,
Pajares MA. Betaine homocysteine S-methyltransferase emerges as
a new player of the nuclear methionine cycle. BBA-Mol Cell Res.
2017; 1864(7): 1165-82. Article. IF: 4.651; Q1
• Rodríguez-Jiménez C, Santos-Simarro F, Campos-Barros A, Camare-
na C, Lledin D, Vallespín E, del Pozo A, Mena R, Lapunzina P, Rodrí-
guez-Novoa S. A new variant in PHKA2 is associated with glycogen
storage disease type IXa. Mol Genet Metab Rep. 2017; 10: 52-5.
Article. Not Indexed
Public Projects
Hierro Lanillo L. Identificación de causas genéticas y epi-
genéticas en enfermedades colestasicas infantiles idiopáticas
(PI15/01127). ISCIII. 2016-2018.
Managment centre: FIBHULP
Vicent López D. Contrato de estabilización Miguel Servet
(I2) (CES06/007). ISCII/CAM. 2008-2025.
Managment centre: FIBHULP
Vicente Capa C. Contrato de técnico de apoyo. Garantía
juvenil (PEJ15/BIO/TL-0238). CAM. 2016-2018.
Managment centre: FIBHULP
214
Private Projects
Díaz Fernández MC. Superando
barreras... hacia una mejor calidad
de vida: estado actual del trasplante
pediátrico en el Hospital Infantil La
Paz. Astellas Pharma S.A. 2014-On-
going.
Managment centre: FIBHULP
Hierro Llanillo L. Desarrollo de mé-
todos de diagnóstico molecular de
enfermedades hepáticas infantiles de
carácter hereditario. Fundación Maria
Francisca de Roviralta. 2005-Ongoing.
Managment centre: FIBHULP
Hierro Llanillo L. Diagnóstico mo-
lecular de enfermedades hepáticas
infantiles de carácter hereditario.
Asociación Española del Síndrome de
Sotos. 2012-Ongoing.
Managment centre: FIBHULP
Hierro Llanillo L. Identificación de nuevos genes respon-
sables de enfermedades hepáticas infantiles. 2015-Ongoing.
Managment centre: FIBHULP
Jara Vega P. Estudio epidemiológico, observacional sobre el
riesgo de desarrollo de síndrome linfoproliferativo en pacien-
tes pediátricos 3p-2007. Roche Farma S.A. 2008-Ongoing.
Managment centre: FIBHULP
Vicent López D. Caracterización clínica del nuevo factor de
riesgo cardiovascular trimetilamina-n-oxido en pacientes dia-
béticos obesos. Sendimad. 2015-Ongoing.
Managment centre: FIBHULP
CLINICAL TRIALS
Hierro Llanillo L. Estudio abierto y multicéntrico para eva-
luar la farmacocinética, la seguridad y la eficacia de glecapre-
vir/pibrentasvir en pacientes pediátricos con infección cróni- Sponsored´s protocol code: LUM001-304.
ca por el virus de la hepatitis C (VHC) de genotipo 16. Type:
Sponsored by: Lumena Paharmaceuticals Inc.
Clinical Trial, phase III.
Signed date: 11/10/2017
HULP code: 4847. Sponsored´s protocol code: M16-123.
Sponsored by: Abbvie Deutschland GMBH. Jara Vega P. Estudio abierto, no comparativo, a largo plazo,
Signed date: 28/08/2017 para evaluar la eficacia y la seguridad de un régimen de in-
munosupresor basado en modigraf en pacientes pediátricos
Camarena Grande C. Registro observacional de enfermedad receptores de un aloinjerto de organo sólido. Type: Clinical
y resultados clínicos de pacientes con deficiencia de lipasa Trial, phase IV.
ácida lisosomal (LAL) (enfermedad de Wolman y enfermedad HULP code: ANEXO-IV 3252. Sponsored´s protocol code: F506-
por almacenamiento de ésteres de colesterol) y portadores CL-0404.
del trastorno. Type: NO-EPA. Sponsored by: Astellas Pharma Europe B.V.
HULP code: PI-2497. Sponsored´s protocol code: LAL DEFICIENCY. Signed date: 02/08/2017
Sponsored by: Pharmaceuticals Inc.
Díaz Fernández MC. Estudio postautorización de seguridad
Signed date: 28/11/2017
(EPAS) no intervencional para evaluar la seguridad a largo
Díaz Fernández MC. Estudio abierto y a largo plazo con plazo del tratamiento con orfadin en la tirosinemia heredita-
ria tipo 1 (TH-1) en la práctica clínica estándar. Type: EPA-SP.
un periodo de retirada farmacológica aleatorizado, contro-
lado con placebo y doble ciego de LUM001, un inhibidor del HULP code: ANEXO-I 3986. Sponsored´s protocol code: SOBI.
NTBC-005.
trasportador apical de ácidos biliares depenciente de sodio
(ASBTI), en pacientes con síndrome de Alagille. Type: Clinical Sponsored by: Swedish Orphan Biovitrum AB.
Trial, phase III. Signed date: 05/09/2017
HULP code: ANEXO-III 4187.
215
 3
Information Groups by Area

3.4 Large System Pathologies Area

• Studies on bronchial hyperresponsiveness to direct rrin A, Bouillet L, Andresen I. The Icatibant Outcome Survey: expe-
and indirect agents and airway inflammation rience of hereditary angioedema management from six European

Diagnosis and Treatment of • Eosinophilic diseases of the respiratory tract (eosino- countries. J Eur Acad Dermatol. 2017; 31(7): 1214-22. Article. IF:
philic bronchitis) and digestive system (eosinophilic 4.287; Q1
esophagitis) • Caballero T, Prior N. Burden of illness and quality-of-life measures in

Allergic Diseases Group
41 222. 988
Santiago Eugenio Quirce Gancedo. Jefe de Servicio de
Alergología. HULP
María Pilar Encarnación Barranco Sanz. Facultativo
Especialista de Área en Alergología. HULP
María Teresa Boyano Martínez. Facultativo Especialista de Área
en Alergología. HULP
María Teresa Caballero Molina. Facultativo Especialista de Área
en Alergología. HULP
María Luisa Caballero Soto. Facultativo Especialista de Área en
Inmunología. HULP
Francisco Javier Contreras Porta. Facultativo Especialista de
Área en Alergología. HULP
Franciso Javier Domínguez Ortega. Facultativo Especialista de
Área en Alergología. HULP
Ana María del Carmen Fiandor Román. Jefe de Sección de
Alergología. HULP
Carmen Gómez Traseira. Facultativo Especialista de Área en
Alergología. HULP
María Magdalena Lluch Bernal. Facultativo Especialista de Área
en Alergología. HULP
Juan Alberto Luna Porta. Facultativo Especialista de Área en
Alergología. HULP
María Flora Martín Muñoz. Facultativo Especialista de Área en
Alergología. HULP
Santiago Olalde Sánchez. Facultativo Especialista de Área en
Alergología. HULP
María Pedrosa Delgado. Facultativo Especialista de Área en
Alergología. HULP
María Rosa Rodríguez Pérez. Investigadora Senior (Contrato
Miguel Servet- Tipo 2). HULP
Margarita Tomás Pérez. Facultativo Especialista de Área en
Alergología. HULP
Ana María Umpiérrez Rodríguez. Facultativo Especialista de
Área en Alergología. HULP
216
15
Strategic Objective
These group members are specialists in various areas
of allergic diseases, which enable them to perform
clinical studies and basic research on the main aller-
gic diseases (food allergies, asthma and rhinitis, urti-
caria/ angiooedema and drug allergies). The group’s
strategic research objectives include:
• The development of new techniques to improve
the diagnosis of food allergies by determining the
molecular sensitisation profile
• The treatment of food allergies with oral desensi-
tisation protocols
• The study of hyperresponsiveness and airway in-
flammation in asthma, as well as the role of aller-
gen exposure and comorbidities in this disease
• The study of the pathogenesis and treatment of
eosinophilic diseases of the airways (eosinophilic
bronchitis) and the gastrointestinal tract (eosino-
philic oesophagitis)
• The characterisation of various types of an-
giooedema caused by Bradykinin (hereditary and
acquired) and improvements in their diagnosis and
treatment
• Research on the epidemiology and pathomecha-
nisms of severe adverse reactions caused by im-
mune hypersensitivity reactions to drugs
Research Lines
• Food allergy (milk, egg, fruit, cereals): molecu-
lar diagnosis (by allergenic components) and
treatment with oral desensitisation
• Epidemiology, physiopathology, diagnosis and
treatment of angioedema and urticaria
• Persistent and difficult to control asthma: study on the
influence of common and occupational allergens, co-
morbidities and new therapies
• Aspirin-exacerbated respiratory disease (AERD): in-
flammatory markers and desensitisation protocol
• Adverse immunologic reactions to drugs: study on the
cellular and molecular mechanisms involved.
• Molecular basis of allergy: characterization of allergens
and modulating factors of allergenicity. Novel allergy
biomarkers: microRNAs and mRNAs. Seeking the di-
fferences of specific IgE between allergic patients and
asymptomatic individuals.
Research Activity
Doctoral TheseS
Bobolea I. Fenotipos y endotipos de asma grave: Mecanismos
moleculares implicados en la patogénesis y en la desensibiliza-
ción a aspirina[dissertation]. Madrid: UAM: 2017(19/09/2017).
Director:s Quirce Gancedo S; Álvarez Sala R.
Jurado Palomo J. Eficacia y seguridad de la profilaxis a cor-
to plazo con andrógenos atenuados y/o concentrado plas-
mático de C1 inhibidor en la realización de procedimientos
odontoestomatológicos, maxilofaciales y otorrinolaringológi-
cos en pacientes con angioedema hereditario por déficit de
la proteína inhibidor de la C1 esterasa funcionalmente activa
[dissertation]. Madrid: UAM: 2017(17/10/2017).
Directors: Caballero Molina MT; Álvarez Sala R.
BOOKS AND BOOK CHAPTERS
Jurado-Palomo J, Bobolea ID, Vlagea AD, Caballero T.
Bradykinin-mediated angioedema across the history. In: Pelin
Kartal S, Kutlubay Z. A comprehensive review of urticaria
and angioedema. Rijeka, Croacia: InTechOpen, 2017. p.205-25
Jurado-Palomo J, Caballero T. Pathophysiology of Bradyki-
nin-mediated angioedema: The role of the complement sys-
tem. In: Pelin Kartal S, Kutlubay Z. A comprehensive review of
urticaria and angioedema. Rijeka, Croacia: InTechOpen, 2017.
p.151-76
Jurado-Palomo J, Caballero T. Short-term prophylaxis in
odontostomatological, maxillofacial and ENT procedures in
patients with hereditary angioedema due to C1-inhibitor
deficiency. In: Pelin Kartal S, Kutlubay Z. A comprehensive re-
view of urticaria and angioedema. Rijeka, Croacia: InTechO-
pen, 2017. p.177-204
PUBLICATIONS
• Buhl R, Humbert M, Bjermer L, Chanez P, Heaney LG, Pavord I, Quir-
ce S, Virchow JC, Holgate S. Severe eosinophilic asthma: a roadmap
to consensus. Eur Respir J. 2017; 49(5): 1700634. Editorial Material.
IF: 12.242; D1
• Caballero T, Aberer W, Longhurst HJ, Maurer M, Zanichelli A, Pe-
angioedema conditions. Immunol Allergy Clin. 2017; 37(3): 597-616.
Article. IF: 3.694; Q2
• Canas JA, Sastre B, Mazzeo C, Fernández-Nieto M, Rodrigo-Muñoz
JM, González-Guerra A, Izquierdo M, Barranco P, Quirce S, Sastre J,
del Pozo V. Exosomes from eosinophils autoregulate and promote
eosinophil functions. J Leukocyte Biol. 2017; 101(5): 1191-9. Article.
IF: 4.224; Q2
• Domínguez-Ortega J, Delgado J, Blanco C, Prieto L, Arroabarren
E, Cimarra M, Henríquez-Santana A, Iglesias-Souto J, Vega-Chicote
JM, Tabar AL. Specific allergen immunotherapy for the treatment of
allergic asthma: a review of current evidence. J Invest Allerg Clin.
2017; 27: 1-35. Review. IF: 3.457; Q2
• Farkas H, Reshef A, Aberer W, Caballero T, McCarthy L, Hao J,
Nothaft W, Schranz J, Bernstein JA, Li HH.Treatment effect and safe-
ty of icatibant in pediatric patients with hereditary angioedema. J
Allergy Clin Immunol Pract. 2017; 5(6): 1671-8. Article. IF: 6.966; D1
• García-Ara C, Pedrosa M, Quirce S, Caballero T, Boyano-Martínez
T. Sensitization to microarrayed species-specific plant components
precedes that of cross-reacting allergens. Pediat Allerg Imm-UK.
2017; 28(3): 288-91. Letter. IF: 4.137; D1
• Gómez-Traseira C, Caballero T. Angioedema after caesarean deli-
very in a patient with hereditary angioedema with normal C1 in-
hibitor and P.THR309LYS mutation in the F12 gene - is it always
bradykinin-mediated? Curr Allergy Clin Im. 2017; 30(2): 94-6. Arti-
cle. Not Indexed
• González-Cavero L, Domínguez-Ortega J, González-Muñoz M,
Mayor-Ibarguren A, Tomás M, Fiandor A, Quirce S. Delayed allergic
reaction to terbinafine with a positive lymphocyte transformation
test. J Invest Allerg Clin. 2017;2 7(2): 136-7. Article. IF: 3.457; Q2
• González-Mancebo E, Domínguez-Ortega J, Blanco-Bermejo S,
González-Seco E, Trujillo MJ, de la Torre F. Comparison of two diag-
nostic techniques, skin-prick test and component resolved diagnosis
in the follow-up of a cohort of paediatric patients with pollinosis.
Multicentre pilot study in a highly exposed allergenic area. Allergol
Immunopath. 2017; 45(2): 121-6. Article. IF: 1.644; Q4
• Grabenhenrich LB, Reich A, Bellach J, Trendelenburg V, Sprikkelman
AB, Roberts G, Grimshaw KEC, Sigurdardottir S, Kowalski ML, Pa-
padopoulos NG, Quirce S, Dubakiene R, Niggemann B, Fernández-
Rivas M, Ballmer-Weber B, van Ree R, Schnadt S, Mills ENC, Keil
T, Beyer K. A new framework for the documentation and inter-
pretation of oral food challenges in population-based and clinical
research. Allergy. 2017; 72(3): 453-61. Article. IF: 6.048; Q1
• Hochwallner H, Schulmeister U, Swoboda I, Focke-Tejkl M, Rei-
ninger R, Civaj V, Campana R, Thalhamer J, Scheiblhofer S, Balic N,
Horak F, Ollert M, Papadopoulos NG, Quirce S, Szepfalusi Z, Herz
U, van Tol EAF, Spitzauer S, Valenta R. Infant milk formulas differ re-
garding their allergenic activity and induction of T-cell and cytokine
responses. Allergy. 2017; 72(3): 416-24. Article. IF: 6.048; Q1
• Longhurst H, Cicardi M, Craig T, Bork K, Grattan C, Baker J, Li HH,
Reshef A, Bonner J, Bernstein JA, Anderson J, Lumry WR, Farkas H,
Katelaris CH, Sussman GL, Jacobs J, Riedl M, Manning ME, Hebert J,
Keith PK, Kivity S, Neri S, Levy DS, Baeza ML, Nathan R, Schwartz
LB, Caballero T, Yang W, Crisan I, Hernández MD, Hussain I, Tarzi M,
Ritchie B, Kralickova P, Guilarte M, Rehman SM, Banerji A, Gower
RG, Bensen-Kennedy D, Edelman J, Feuersenger H, Lawo JP, Mach-
nig T, Pawaskar D, Pragst I, Zuraw BL. Prevention of hereditary an-
gioedema attacks with a subcutaneous C1 inhibitor. New Engl J Med.
2017; 376(12): 1131-40. Article. IF: 79.258; D1
• Longhurst HJ, Zanichelli A, Caballero T, Bouillet L, Aberer W, Maurer
M, Fain O, Fabien V, Andresen I. Comparing acquired angioedema
217
 3
Information Groups by Area
3.4 Large System Pathologies Area
with hereditary angioedema (types I/II): findings from the Icatibant
Outcome Survey. Clin Exp Immunol. 2017; 188(1):148-53. Article. IF:
3.542; Q2
• López-Vina A, Giner J, Molina J, Palicio J, Plaza J, Quintano JA, Quir-
ce S, Soria C, Uréndez AM, Plaza V. Multidisciplinary consensus on
the nonadherence to clinical management of inhaled therapy in
Spanish asthma patients. Clin Ther. 2017; 39(8): 1730-45. Article. IF:
3.185; Q2
• Martínez-Moragón E, Entrenas LM, Plaza V, Quirce S. Attitudes and
barriers uncontrolled asthma in Spain. Abanico study. Rev Clin Esp.
2017; 217(1): 60-2. Letter. IF: 1.184; Q3
• Martínez-Moragón E, Plaza V, Torres I, Rosado A, Urrutia I, Casas X,
Hinojosa B, Blanco-Aparicio M, Delgado J, Quirce S, Sabadell C, Ce-
bollero P, Muñoz-Fernández A. Fibromyalgia as a cause of uncontro-
lled asthma: a case-control multicenter study. Curr Med Res Opin.
2017; 33(12): 2181-6. Article. IF: 2.665; Q1
• Miravitlles M, Álvarez-Gutiérrez FJ, Calle M, Casanova C, Cosío BG,
López-Vina A, de Llano LP, Quirce S, Román-Rodríguez M, Soler-
Cataluña JJ, Plaza V. Algorithm for identification of asthma-COPD
overlap: consensus between the Spanish COPD and asthma guideli-
nes. Eur Respir J. 2017; 49(5): 1700068. Letter. IF: 12.242; D1
• Murillo-Cuesta S, Vallecillo N, Cediel R, Celaya AM, Lassaletta L,
Varela-Nieto I, Contreras J. A comparative study of drug delivery
methods targeted to the mouse inner ear: Bullostomy versus
transtympanic injection. J Vis Exp. 2017; (121): e54951. Article. IF:
1.184; Q2
• Phillips-Angles E, Barranco P, Lluch-Bernal M, Domínguez-Ortega J,
López-Carrasco V, Quirce S. Aspirin tolerance in patients with nons-
teroidal anti-inflammatory druge exacerbated respiratory disease
following treatment with omalizumab. J Allergy Clin Immunol Pract.
2017; 5(3): 842-5. Letter. IF: 6.966; D1
• Plaza V, Álvarez F, Calle M, Casanova C, Cosío BG, López-Vina A,
de Llano LP, Quirce S, Román-Rodríguez M, Soler-Cataluña JJ, Mi-
ravitlles M. Consensus on the Asthma-COPD Overlap Syndrome
(ACOS) between the Spanish COPD Guidelines (GesEPOC) and
the Spanish Guidelines on the Management of Asthma (GEMA).
Arch Bronconeumol. 2017; 53(8): 443-9. Article. IF: 2.633; Q2
• Pola-Bibian B, Domínguez-Ortega J, Vila-Nadal G, Entrala A, Gonzá-
lez-Cavero L, Barranco P, Cancelliere N, Díaz-Almirón M, Quirce S.
Asthma exacerbations in a tertiary Hospital: Clinical features, tri-
ggers, and risk factors for hospitalization. J Invest Allerg Clin. 2017;
27(4): 238-45. Article. IF: 3.457; Q2
• Quirce S, Campo P, Domínguez-Ortega J, Fernández-Nieto M,
Gómez-Torrijos E, Martínez-Arcediano A, Mur P, Delgado J. New
developments in work-related asthma. Expert Rev Clin Immu. 2017;
13(3): 271-81. Review. IF: 3.436; Q2
• Quirce S, Delgado J, Entrenas LM, Grande M, Llorente C, Vina AL,
Moragón EM, Mascaros E, Molina J, Olaguibel JM, de Llano LAP, Tor-
dera MP, Quintano JA, Rodríguez M, Román-Rodríguez M, Sastre J,
Trigueros JA, Valero AL, Zoni AC, Plaza V. Quality indicators of asth-
ma care derived from the Spanish Guidelines for Asthma Manage-
ment (GEMA 4.0): A multidisciplinary team report. J Invest Allerg
Clin. 2017; 27(1): 69-73. Editorial Material. IF: 3.457; Q2
• Ramírez E, Bellón T, Tong HY, Borobia AM, de Abajo FJ, Lerma V, Hi-
dalgo MAM, Castaner JL, Cabañas R, Fiandor A, González-Ramos J,
Herranz P, Cachafeiro L, González-Herrada C, González O, Aram-
buru JA, Laosa O, Hernández R, Carcas AJ, Frías J. Significant HLA
class I type associations with aromatic antiepileptic drug (AED)-
induced SJS/TEN are different from those found for the same AED-
induced DRESS in the Spanish population. Pharmacol Res. 2017; 115:
168-78. Article. IF: 4.897; D1
• Ramírez E, Medrano-Casique N, Tong HY, Bellón T, Cabañas R, Fian-
dor A, González-Ramos J, Herranz P, Trigo E, Muñoz M, Borobia AM,
Carcas AJ, Frias J. Eosinophilic drug reactions detected by a prospec-
tive pharmacovigilance programme in a tertiary hospital. Brit J Clin
218
Pharmacol. 2017; 83(2): 400-15. Article. IF: 3.838; Q1
• Rodríguez-Sanz A, Sánchez-Villanueva R, Domínguez-Ortega J, Fian-
dor AM, Ruiz MP, Trocoli F, Díaz-Tejeiro R, Cadenillas C, González E,
Martínez V, López-Trascasa M, Quirce S, Selgas R, Bellón T. Mecha-
nisms involved in hypersensitivity reactions to polysulfone hemo-
dialysis membranes. Artif Organs. 2017; 41(11): E285-95. Article. IF:
2.111; Q2
• Tripodi S, Pingitore G, Calvani M, Scala G, Rodríguez-Pérez R, Sfika I,
Asero R. Anisakis sensitivity in Italian children: A prospective study. J
Invest Allerg Clin. 2017; 27(2): 142-3. Article. IF: 3.457; Q2
• Valero A, Quirce S, Dávila I, Delgado J, Domínguez-Ortega J. Allergic
respiratory disease: Different allergens, different symptoms. Allergy.
2017; 72(9): 1306-16. Article. IF: 6.048; Q1
• van Kampen V, de Biay F, Folletti I, Kobierski P, Moscato G, Olivieri
M, Quirce S, Sastre J, Walusiak-Skorupa J, Raulf M. Skin prick testing
in the diagnosis of occupational type I allergies - a EAACI position
paper. Allergologie. 2017; 40(1): 29-36. Article. IF: 0.22; Q4
• Zanichelli A, Maurer M, Aberer W, Caballero T, Longhurst HJ, Boui-
llet L, Fabien V, Andresen I. Long-term safety of icatibant treatment
of patients with angioedema in real-world clinical practice. Allergy.
2017; 72(6): 994-8. Article. IF: 6.048; Q1
• Quirce S, Phillips-Angles E, Domínguez-Ortega J, Barranco P. Bio-
logics in the treatment of severe asthma. Allergol Immunopathol
(Madr). 2017; 45 Suppl 1: 45-9. Review. IF: 1.644; Q4
• Aberer W, Maurer M, Bouillet L, Zanichelli A, Caballero T, Longhurst
HJ, Perrin A, Andresen I. Breakthrough attacks in patients with here-
ditary angioedema receiving long-term prophylaxis are responsive
to icatibant: findings from the Icatibant Outcome Survey. Allergy
Asthma Clin Immunol. 2017; 13: 31. Article. IF: 2.051; Q3
• Jindal NL, Harniman E, Prior N, Pérez-Fernández E, Caballero T,
Betschel S. Hereditary angioedema: health-related quality of life in
Canadian patients as measured by the SF-36. Allergy Asthma Clin
Immunol. 2017; 13: 4. Article. IF: 2.051; Q3
• Navarro AM, Delgado J, Muñoz-Cano RM, Dordal MT, Valero A,
Quirce S. Allergic respiratory disease (ARD), setting forth the ba-
sics: proposals of an expert consensus report. Clin Transl Allergy.
2017; 7: 16. Article. IF: 3.539; Q2
• Ventura MT, Rodríguez-Pérez R, Caballero ML, García-Alonso M,
Antonicelli L, Asero R. IgE, IgG(1) and IgG(4) response to specific
allergens in sensitized subjects showing different clinical reactivity
to Anisakis simplex. Eur Ann Allergy Clin Immunol. 2017; 49(2): 52-8.
Article. Not Indexed
• Martín-Muñoz MF, Díaz-Perales A, Cannabal J, Quirce S. Anaphylaxis
to hidden potato allergens in a peach and egg allergic boy. Eur Ann
Allergy Clin Immunol. 2017; 49(1): 45-8. Article. Not Indexed
• Sánchez-García S, Mena AH, Quirce S. Biomarkers in inflammome-
try pediatric asthma: utility in daily clinical practice. Eur Clin Respir
J. 2017; 4: 1356160. Review. Not Indexed
• Bygum A, Busse P, Caballero T, Maurer M. Disease severity, activity,
impact, and control and how to assess them in patients with here-
ditary angioedema. Front Med (Lausanne). 2017; 4: 212. Review. Not
Indexed
• Barranco P, Phillips-Angles E, Domínguez-Ortega J, Quirce S. Dupilu-
mab in the management of moderate-to-severe asthma: the data so
far. Ther Clin Risk Manag. 2017; 13: 1139-49. Review. IF: 1.995; Q3
• Sánchez-Borges M, Fernández-Caldas E, Thomas WR, Chapman MD,
Lee BW, Caraballo L, Acevedo N, Chew FT, Ansotegui IJ, Behrooz L,
Phipatanakul W, van Wijk RG, Pascal D, Rosario N, Ebisawa M, Geller
M, Quirce S, Vrtala S, Valenta R, Ollert M, Canonica GW, Calderón
MA, Barnes CS, Custovic A, Benjaponpitak S, Capriles-Hulett A. In-
ternational consensus (ICON) on: clinical consequences of mite hy-
persensitivity, a global problem. World Allergy Organ J. 2017; 10: 14.
Article. IF: 5.676; Q1
Public Projects
Caballero Soto Ml. Estudio de tumorigenesis asociada a ani-
sakis simple (PI12/00888). ISCIII. 2013-2017.
Managment centre: FIBHULP
Rodríguez Pérez MR. Contrato Miguel Servet tipo II
(MSII13/000022). ISCIII. 2014-2020.
Managment centre: FIBHULP
Rodríguez Pérez MR. Identificación de genes y de microR-
NAs implicados en la función de los linfocitos T y B como
nuevos biomarcadores para el diagnóstico in vitro de la aler-
gia a anisakis (PI12/00581). ISCIII. 2013-2017.
Managment centre: FIBHULP
Private Projects
Barranco Sanz MPE. Jornada de investigación sobre asma de
difícil control.Varios Financiadores. 2011-Ongoing.
Managment centre: FIBHULP
Caballero Molina MT. Curso teórico-práctico de formación
en investigación en angioedema. Shire Pharmaceuticals Ibéri-
ca S.L. 2017-Ongoing.
Managment centre: FIBHULP
Caballero Molina MT. Development and trans-cultural vali-
dation of an international specific questionnaire (IHAE-QOL)
for assessment of health related quality of life in adult pa-
tients with hereditary angioedema due to C1 inhibitor defi-
ciency (HAE) and quality of lifes. Hereditary Angio-Edema In.
2009-Ongoing.
Managment centre: FIBHULP
Domínguez Ortega FJ. Asesoramiento para el diseño del
estudio clínico: ensayo clínico prospectivo multicéntrico
aleatorizado de doble simulación controlado con placebo de
búsqueda de la dosis más eficaz para el tratamiento de rini-
tis/rinoconjuntivitis por alergia frente al polen de gramínea.
Inmunotek. 2015-Ongoing.
Managment centre: FIBHULP
Domínguez Ortega FJ. Conocimientos básicos en patologia
alérgica para un médico residente e investigadores del Hospi-
tal Universitario La Paz. Glaxosmithkline S.A. 2017.
Managment centre: FIBHULP
Quirce Gancedo SE. Relación entre asma y obesidad en la
población española mayor o igual a 18 años. Laboratorio Me-
narini S.A. 2009.
Managment centre: FIBHULP
Quirce Gancedo SE. Sesiones en investigación del diagnósti-
co molecular como herramienta de identificación de perfiles
de respuesta en pacientes con enfermedad respiratoria alér-
gica y alergia a alimentos. Thermo Fisher Diagnostics S.L.U.
2017-Onoging.
Managment centre: FIBHULP
Rodríguez Pérez MR. Desarrollo de un programa formativo
de formación en investigación en centros de trabajo. Colegio
Valle del Miro. 2016-Ongoing.
Managment centre: FIBHULP
INTERNATIONAL Projects
Quirce Gancedo SE. Integrated approaches for food allergen
and allergy risk management (iFAAM). UE. 2013-2017.
Managment centre: FIBHULP
CLINICAL TRIALS
Quirce Gancedo SE. Estudio piloto de reslizumab en pacien-
tes con asma grave que no han respondido a omalizuma.Type:
Clinical Trial, phase II.
HULP code: 4805. Sponsored´s protocol code: SEP-RES-20196-01.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 10/03/2017
Patents and Trademarks
Valenta R, Constantin C, Quirce Gancedo, SE, inven-
tors; Phadia AB, assignee. Novel wheat allergens. PCT/
SE2008/051377, EP2225266, US2010305049, AU2008330230,
CA2707190, CN101932597, JP2011505134, RU2010126590;
2007 November 30.
Caballero Molina MT, Prior Gómez N, Remor Bitencourt
EA, authors, FIBHULP, assignee. Trademark name: HAE-QoL
HEREDITARY ANGIOEDEMA QUALITY OF LIFE. CM
13.083.068; 2014 July 15.
Sánchez Herreros R, Martínez Fernández J, Castro Morera
A, Gasset Vega M, Rodríguez Pérez RM, Pedrosa Delgado
M, Quirce Gancedo S, inventors; FIBHULP, CSIC, assignees.
Food allergen extracts and methods of producing and using
the same. EP16382413.9 (Publication Number pending); 2016
September 06.
del Pozo Abejón V, Sastre Dominguez J, Rodrigo-Muñoz JM,
Sastre Turrión B, Quirce Gancedo S, Cañas Mañas JA, in-
ventors; FIISFJD, Centro de Investigación Biomédica en Red
(CIBER), FIBHULP, Fundación Conchita Rábago de Jiménez
Díaz, assignees. In vitro method for identifying severity levels
in bronchial asthma patients. P201730739; 2017 May 29.
219
 3
Information Groups by Area
3.4 Large System Pathologies Area
Gynecologic Oncology Group
15 35.457 3
Ignacio Zapardiel Gutiérrez. Facultativo Especialista
de Área en Ginecología y Obstetricia. Unidad de Ginecología
Oncológica. HULP. Profesor Asociado. Facultad de Medicina.
UAM
Diana Alecsandru Danceanu. Médico Especialista en
Inmunología. IVI Madrid
Covadonga Álvarez López. Facultativo Especialista de Área en
Ginecología y Obstetricia. HULP
Ónica María Armijo Suárez. Facultativo Especialista de Área
en Ginecología y Obstetricia. Unidad de Reproducción Asistida. HULP
María Cerrillo Martínez. Ginecologa Especialista en
Reproducción Humana. IVI Madrid
María Dolores Diestro Tejeda. Facultativo Especialista de
Área en Ginecología y Obstetricia. Unidad de Ginecología Oncológica.
HULP
Juan Antonio García Velasco. Profesor Titular. Universidad Rey
Juan Carlos
Cristina González Benítez. Facultativo Especialista de Área en
Ginecología y Obstetricia. HULP
Alicia Hernández Gutiérrez. Facultativo Especialista de Área
en Ginecología y Obstetricia. Unidad de Ginecología Oncológica. HULP.
Profesor Asociado. Facultad de Medicina. UAM
María Josefa Herrera de la Muela. Facultativo Especialista
de Área en Ginecología y Obstetricia. Unidad de Patología Mamaria.
HULP
Ana López Carrasco. Facultativo Especialista de Área en
Ginecología y Obstetricia. HULP
Israel Ortega Sánchez. Coordinador del Departamento
Internacional. IVI Madrid
Margarita Sánchez-Pastor Ruiz. Facultativo Especialista de
Área en Ginecología y Obstetricia. Profesor Asociado. Facultad de
Medicina. HULP - UAM
María Serrano Velasco. Facultativo Especialista de Área en
Ginecología y Obstetricia. HULP
María Elisa Varela Sanz. Investigadora Postdoctoral. CNIO
220
Strategic Objective
The main objective of our group is to study all as-
pects related to gynaecologic malignancies. It inclu-
des from diagnosis to treatment and follow-up. For
the next years we will focus our research on the ma-
lignancies affecting female uterus, including cervical
and endometrial cancer as well as uterine sarcomas.
We will develop at least two stable and comprehen-
sive specific research lines trying to pay attention to
molecular aspects as well as clinical features of the
Gynaecological cancers. But we will support the rest
of aspects of the subspecialty.
Research Lines
• Evaluation, treatment and surgery of oncologic di-
seases in gynecology.
• Pelvic floor reconstructive surgery.
• Molecular disorders in preeclamsia, placenta and
other obstetrical diseases.
Research Activity
PUBLICATIONS
• Álvarez-López C, de Santiago J, Pinera A, Rodríguez R, Herrero
B, Herrera M, Pillado J, Zapardiel I. Utility of three-dimensional
ultrasonography to assess the position of essure tubal occlu-
sion device and Its complications. Gynecol Obstet Inves. 2017;
82(2): 170-4. Article. IF: 1.183; Q4
• Carrasco AL, Gutiérrez AH, Gutiérrez PAH, González RR, Mar-
tín JLM, Zapardiel I, García JD. Ileocecal endometriosis: diagno-
sis and management. Taiwan J Obstet Gyne. 2017; 56(2): 243-6.
Article. IF: 1.029; Q4
• di Martino G, Crivellaro C, de Ponti E, Bussi B,
Papadia A, Zapardiel I,Vizza E, Elisei F, Diestro
MD, Locatelli L, Gasparri ML, di Lorenzo
P, Mueller M, Buda A. Indocyanine green
versus radiotracer with or without blue
dye for sentinel lymph node mapping in
stage >IB1 cervical cancer (>2 cm). J
Minim Invas Gyn. 2017; 24(6): 954-9.
Article. IF: 3.061; Q1
• Gan C, Bossart M, Piek J, Halaska M, Hai-
dopoulos D, Zapardiel I, Grabowski JP, Kesic V, Kimmig
R, Cibula D, Lambaudie E, Verheijen R, Manchanda R. Robotic and
advanced laparoscopic surgical training in European gynecological
oncology trainees. Int J Gynecol Cancer. 2017; 27(2): 375-81. Ar-
ticle. IF: 2.192; Q2
• Halaska MJ, Haidopoulos D, Guyon F, Morice P, Zapardiel I, Kesic
V. European Society of Gynecological Oncology statement on fi-
broid and uterine morcellation. Int J Gynecol Cancer. 2017; 27(1):
189-92. Article. IF: 2.192; Q2
• Herrera de la Muela M, García López E, Frías Aldeguer L, Gómez-
Campelo P. Protocol for the BRECAR study: a prospective co-
hort follow-up on the impact of breast reconstruction timing on
health-related quality of life in women with breast cancer. BMJ
Open. 2017; 7(12): e018108. Article. IF: 2.413; Q2
• Iacoponi S, Zapardiel I. European nationality influence in the ma-
nagement of squamous cell vulvar cancer. Gynecol Obstet Inves.
2017; 82(4): 349-54. Article. IF: 1.183; Q4
• Lara-Domínguez MD, López-Jiménez A, Grabowski JP, Arjona-
Berral JE, Zapardiel I. Prospective observational study comparing
traditional laparoscopy and three-dimensional laparoscopy in
gynecologic surgery. Int J Gynecol Obstet. 2017; 136(3): 320-4.
Article. IF: 2.072; Q2
• Leal MA, Pinera A, de Santiago J, Zapardiel I. Novel technique
for contained power morcellation through umbilicus with
insufflated bag. Gynecol Obstet Inves. 2017; 82(2):
205-7. Article. IF: 1.183; Q4
• Minig L, Heitz F, Cibula D, Bakkum-Gámez JN, Germa-
nova A, Dowdy SC, Kalogera E, Zapardiel I, Lindemann K,
Harter P, Scambia G, Petrillo M, Zorrero C, Zanagnolo V, Re-
bollo JMC, du Bois A, Fotopoulou C. Patterns of lymph node
metastases in apparent stage I low-grade epithelial ovarian cancer:
A multicenter study. Ann Surg Oncol. 2017; 24(9): 2720-6. Article.
IF: 3.857; D1
• Papadia A, Zapardiel I, Bussi B, Ghezzi F, Ceccaroni M, de Ponti E,
Elisei F, Imboden S, de la Noval BD, Gasparri ML, Di Martino G,
de Santiago J, Mueller M,Vecchione F, Dell’Orto F, Buda A. Sentinel
lymph node mapping in patients with stage I endometrial carci-
noma: a focus on bilateral mapping identification by comparing
radiotracer TC99(m) with blue dye versus indocyanine green
fluorescent dye. J Cancer Res Clin. 2017; 143(3): 475-80. Article.
IF: 3.282; Q2
• Polterauer S, Schwameis R, Grimm C, Macuks R, Iacoponi S, Za-
lewski K, Zapardiel I. Prognostic value of lymph node ratio and
number of positive inguinal nodes in patients with vulvar cancer.
Gynecol Oncol. 2017; 147(1): 92-7. Article. IF: 4.54; D1
• Zalewski K, Lindemann K, Halaska MJ, Zapardiel I, Laky R, Chereau
E, Lindquist D, Polterauer S, Sukhin V, Dursun P. A call for new
communication channels for gynecological oncology trainees: A
survey on social media use and educational needs by the Euro-
pean Network of Young Gynecological Oncologists. Int J Gynecol
Cancer. 2017; 27(3): 620-6. Article. IF: 2.192; Q2
• Zapardiel I, Blancafort C, Cibula D, Jaunarena I, Gorostidi M, Gil-
Moreno A, de Santiago J. Utility and actual use of European and
Spanish Guidelines on the Management of Endometrial Cancer
Among Gynecologic Oncologists in Spain. Int J Gynecol Cancer.
2017; 27(6):1293-7. Article. IF: 2.192; Q2
• Zapardiel I, Gorostidi M, Ravaggi A, Allende MT, Silveira M, Macuks
R. Utility of human epididymis protein 4 serum marker for the
detection of adnexal malignancy: a multicentric prospective study.
Eur J Cancer Prev. 2017; 26(4): 346-50. Article. IF: 2.886; Q3
Private Projects
Herrera de la Muela MJ. Correlación de los hallazgos radio-
lógicos y clínico-exploratorios con las características citoló-
gicas del fluido mamario obtenido mediante aspiración con
el sistema halo en una cohorte de mujeres sanas portado-
ras de mutaciones delteteras en los genes BRCA. FIBHULP.
2015-Ongoing.
Managment centre: FIBHULP
Zapardiel Gutiérrez I. Ultraestadificación molecular ganglio
centinela en cáncer de cérvix: MRNA e6/e7 hpv. FIBHULP.
2013-Ongoing.
Managment centre: FIBHULP
Zapardiel Gutiérrez I. III Curso de investigación en laparos-
cópia avanzada en cadáveres. Karl Storz Endoscopia Ibética
S.A. 2015-Ongoing.
221
 3
Information Groups by Area
3.4 Large System Pathologies Area
Managment centre: FIBHULP
Zapardiel Gutiérrez I. Curso de investigación en laparosco-
pia ginecológica avanzada en cadáveres. Varios Financiadores.
2013-Ongoing.
Managment centre: FIBHULP
Zapardiel Gutiérrez I. Evaluación del antígeno epididimal
humano -HE4 - en el diagnóstico diferencial y seguimiento de
la endometriosis superficial y profunda. Abbott Laboratories
S.A. 2012-Ongoing.
Managment centre: FIBHULP
Zapardiel Gutiérrez I. Valor de la linfadectomía en el cán-
cer de endometrio de riesgo intermedio (LICERI). FIBHCSC.
2014-Ongoing.
Managment centre: Hospital Clínico San Carlos
CLINICAL TRIALS
Diestro Tejeda MD. Estudio observacional, prospectivo y
multicéntrico para evaluar el uso clínico de la prueba mo-
lecular Gynec®-DX para el descarte de cáncer de endome-
trio y posterior seguimiento en mujeres asintomáticas con
formaciones polipoideas endometriales. Type: Health care
product.
HULP code: PI-2847. Sponsored´s protocol code: RJ-GYN-01.
Sponsored by: Laboratorio Reig Jofre S.A.
Signed date: 28/08/2017
Hernández Gutiérrez A. Seguridad y beneficios del dispositi-
vo de captura de células tumorales metastásicas en pacientes
con cáncer de ovario avanzado. Type: Health care product.
HULP code: 4723. Sponsored´s protocol code: MTRAP-2016-01.
Sponsored by: Mtrap Inc.
Signed date: 10/01/2017
222
López Carrasco A. Estudio aleatorizado, controlado con
Patient Blood
placebo, doble ciego, de grupos paralelos, multicéntrico, de
dosis-respuesta para evaluar la eficacia y seguridad de dife-
rentes dosis orales de BAY1128688 en mujeres con endo-
Management Group
metriosis sintomática durante un tratamiento de 12 semanas.
Type: Clinical Trial, phase II.
HULP code: 4904. Sponsored´s protocol code: BAY 1128688/17472.
Sponsored by: Bayer AG.
Signed date: 20/10/2017
Patents and Trademarks
Zapardiel Gutiérrez I, de Santiago García J, inven-
tors; FIBHULP, assignee. Laparoscopic surgical instrument.
P201230950, PCT/ES2013/000139; 2012 June 18.
Zapardiel Gutiérrez I, de Santiago García J, inventors;
FIBHULP, assignee. Surgical device. P201330532, PCT/
ES2014/070277; 2013 April, 15.
18 35.306 5
Manuel Quintana Díaz. Facultativo Especialista de Área en • Try to diagnose the potentially ill politraumatized
Medicina Intensiva. HULP. Profesor Asociado. Facultad de Medicina. patient at the emergency room
UAM
Enhance the use of blood products
María José Alcaide Martín. Facultativo Especialista de Área en
Análisis Clínicos. Tutora de residentes de Análisis Clínicos. HULP • Critically ill patient coagulopathy
• Early diagnose of anemia at the emergency room
Sara Fabra Cadenas. Facultativo Especialista de Área en Medicina
Familiar y Comunitaria. HULP • Intravenous ironusage
Pilar Fernández Calle. Facultativo Especialista de Área en Análisis Anticoagulation Reserval
Clínicos. Coordinadora de Calidad de Análisis Clínicos. HULP
Jose Antonio García Erce. Facultativo Especialista de Área en Patient Blood Mangement Implementation
Hematología. HULP
Milagros Martí de Gracia. Facultativo Especialista de Área en
Radiodiagnóstico. Jefa de Sección de Radiología de Urgencias. HULP Research Lines
Ana María Martínez Virto. Facultativo Especialista de Área en • Critical Bleeding
Medicina Familiar y Comunitaria. Coordinadora Adjunta de Urgencias.
• Anticoagulation reversal
HULP
Paloma Oliver Sáez. Facultativo Especialista de Área en Análisis
Clínicos. Tutora de Residentes de Análisis Clínicos. HULP
María Inmaculada Pinilla Fernández. Facultativo Especialista de Research Activity
Área en Radiodiagnóstico. HULP
María Angélica Rivera Núñez. Facultativo Especialista de Área en Doctoral TheseS
Medicina Interna. HULP Ballesteros Ortega D. Características de los pacientes
Marcelino Sánchez Casado. Facultativo Especialista de Área en con infarto de miocardio con enfermedad coronaria no
Medicina Intensiva. Hospital Virgende la Salud obstructiva (IMECNO). Registro ARIAM-SEMICYUC.
Elaboración de Score predictivo de IMECNO.[disserta-
Strategic Objective tion]. Madrid: UAX: 2017(22/06/2017).
Directors: Blancas Gómez-Casero R, Quintana Díaz M.
Stratifying risk in the critically ill patient Díaz Tascón A. Valoración de escalas pronósticas basadas
• Stratify pulmonary thromboembolis risk en hallazgos la tomografía computarizada en pacientes
223
 3
Information Groups by Area
3.4 Large System Pathologies Area
con trauma cráneo encefálico grave[dissertation]. Madrid:
UAM: 2017(21/09/2017).
Directors: Quintana Díaz M, Martí de Gracia M.
Martínez Virto AM. Servicios de urgencias hospitalarias: in-
fluencia de la caracterización de los pacientes y su proceso
asistencial durante su tiempo de permanencia[dissertation].
Madrid: UAM: 2017(27/09/2017).
Directors: Quintana Díaz M; Sarriá Santamera A.
Pozuelo Echegaray I. Coagulopatía temprana del paciente que-
mado crítico[dissertation]. Madrid: UAM: 2017(19/09/2017).
Directors: Quintana Díaz M, Sánchez Sánchez MS.
Rivera Núñez MA. Escalas de valoración de riesgo
tromboembólico y tromboprofilaxis en el paciente de
urgencias[dissertation]. Madrid: UAM: 2017(19/05/2017).
Directors: Quintana Díaz M, Huerta Álvarez C.
Torres Santos-Olmo RM. Evaluación de una intervención
docente en la formación de residentes rotantes en un ser-
vicio de urgencias de un hospital universitario de tercer
nivel[dissertation]. Madrid: UAM: 2017(13/09/2017).
Directors: Quintana Díaz M, Huerta Álvarez C.
BOOKS AND BOOK CHAPTERS
Arenaza Choporena G. Actualización en Radiología de Ur-
gencias. Madrid: Martí de Gracia M, 2017.
Choperena G, de Araujo Martins-Romeo D, Blanco Ba-
rrio A, Borruel Nacenta S, Carreras Aja M, Cortés León C,
Dosda Muñoz R, Estellés Muñoz P, Grau García M, Martí
de Gracia M, Parra Gordo L, Vicente BártulosA, Martínez
Chamorro E. Casos TOP en Radiología de urgencias. Madrid:
Serau, 2017.
Quintana Díaz M, Cachafeiro Fuciños L. Coagulopatía ligada
a la hemorragia crítica. In: García de Lorenzo y Mateos A,
Montejo JC. Manual de medicina intensiva. Barcelona: Elsevier
España, 2017. p.469-473
PUBLICATIONS
• Álvarez E, Toledano V, Morilla F, Hernández-Jiménez E, Cubillos-Za-
pata C,Varela-Serrano A, Casas-Martín J, Avendaño-Ortiz J, Aguirre
LA, Arnalich F, Maroun-Eid C, Martín-Quirós A, Díaz MQ, López-
Collazo E. A system dynamics model to predict the human mono-
cyte response to endotoxins. Front Immunol. 2017; 8: 915. Article.
IF: 5.511; Q1
• Balbás LAB, Amaro MS, Rioja RG, Martín MJA, Soto AB. Stability of
plasma electrolytes in Barricor and PST II tubes under different
storage conditions. Biochem Medica. 2017; 27(1): 225-30. Article. IF:
3.653; Q1
• Barni S, Gascón P, Petrelli F, García-Erce JA, Pedrazzoli P, Rosti G,
Giordano G, Mafodda A, Muñoz M. Position paper on management
of iron deficiency in adult cancer patients. Expert Rev Hematol.
2017; 10(8): 685-95. Review. IF: 1.937; Q3
• Chico-Fernández M, Llompart-Pou JA, Sánchez-Casado M, Balleste-
ros-Sanz MA. Severe traumatic disease register in Spain. Med Inten-
siva. 2017; 41(5): 324-5. Letter. IF: 1.755; Q4
• Díaz AM, Rodríguez LF, de Gracia MM. Is urgent CT angiography
necessary in cases of acute lower gastrointestinal bleeding? Radio-
logia. 2017; 59(3): 249-52. Article. Not Indexed
• Díaz MQ, Borobia AM, Erce JAG, Maroun-Eid C, Fabra S, Carcas A,
Frías J, Muñoz M. Appropriate use of red blood cell transfusion in
224
emergency departments: a study in five emergency departments. en los servicios de urgencias hospitalarios. Proyecto Mapac- Quintana Díaz M. Adecuación de las dosis de HBPM me-
Blood Transfus-Italy. 2017; 15(3): 199-206. Article. IF: 2.138; Q3 Imagen II (PI16/01828). ISCIII. 2017-2019. diante la monitorización de los niveles de factor anti-XA en
• Erce JAG, Díaz MQ. Acute respiratory distress secondary to blood Managment centre: FIBHULP pacientes que reciben tromboprofilaxis ampliada desde ur-
transfusion. Med Intensiva. 2017; 41(7): 444-5. Letter. IF: 1.755; Q4 gencias. Laboratorios Farmacéuticos Rovi S.A. 2013-Ongoing.
Quintana Díaz M. Proyecto de innovación docente: taller de
• Erce JAG, Morales MJL. Patient blood management in the enhanced Managment centre: FIBHULP
trabajo en equipo (PID2016/17). UAM. 2017-Ongoing.
recovery program after abdominal surgery. Cir Espan. 2017; 95(9):
Managment centre: UAM Quintana Díaz M. Estudio de monitorización de heparinas
552-4. Letter. IF: 0.841; Q4
de bajo peso molecular como profilaxis en un Servicio de
• García-Martin A, Maroun-Eid C, Campino-Villegas A, Oliva-Manuel
Urgencias. Bayer Hispania S.L. 2011-Ongoing.
B, Herrero-Ambrosio A, Quintana-Díaz M. Perception survey on Private Projects Managment centre: FIBHULP
the value of the hospital pharmacist at the emergency department.
Farm Hosp. 2017; 41(3): 357-70. Article. Not Indexed Oliver Sáez P. Estudio de gasometría en el lugar de asistencia. Quintana Díaz M. Identificaión de factores de gravedad en el
• Lagerstedt L, Egea-Guerrero JJ, Bustamante A, Montaner J, Rodrí- Beneficio para el paciente. Asociación Española de Farma- paciente con traumatismo potencialmente grave. Fundación
guez-Rodríguez A, El Rahal A, Turck N, Quintana M, García-Armen- céuticos Analistas (AEFA). 2012-Ongoing. para la Investigación Biomédica Hospital Universitario La Paz.
gol R, Prica CM, Andereggen E, Rinaldi L, Sarrafzadeh A, Schaller K, Managment centre: FIBHULP 2013-Ongoing.
Sánchez JC. H-FABP: A new biomarker to differentiate between
Oliver Sáez P. Estudio comparativo multicéntrico sobre Managment centre: FIBHULP
CT-positive and CT-negative patients with mild traumatic brain in-
contaminación por microorganismos de las tiras reactivas
jury. Plos One. 2017; 12(4): e0175572. Article. IF: 2.766; Q1
de glucemia de uso hospitalario. Abbott Laboratories S.A.
• Llompart-Pou JA, Pérez-Barcena J, Chico-Fernández M, Sánchez-
2012-Ongoing.
Casado M, Raurich JM. Severe trauma in the geriatric population.
Managment centre: FIBHULP
World J Crit Care Med. 2017; 6(2):99-106-. Review. Not Indexed
• Mateos-Panero B, Sánchez-Casado M, Castano-Moreira B, Paredes-
Astillero I, López-Almodovar L F, Bustos-Molina F. Assessment of
Euroscore and SAPS III as hospital mortality predicted in cardiac
surgery. Rev Esp Anestesiol Reanim. 2017; 64(5): 273-81-. Article.
Not Indexed
• Muñoz M, Laso-Morales MJ, Gómez-Ramírez S, Cadellas M, Núñez-
Matas MJ, García-Erce JA. Pre-operative haemoglobin levels and
iron status in a large multicentre cohort of patients undergoing
major elective surgery. Anaesthesia. 2017; 72(7): 826-34. Article. IF:
5.431; Q1
• Parra-Salinas I, González-Rodríguez VP, Pina JAG, Lozano JJG,
García-Erce JA. Benefit in long-term response and mortality of
treatment with intravenous immunoglobulin prior to plasmaphe-
resis in peripheral polyneuropathies. Transfus Clin Biol. 2017; 24(1):
9-14. Article. IF: 0.936; Q4
• Pérez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I,
Riera M, Estebánez M, Palacios R, Sanz-Moreno J, Troya J, Mari-
no A, Antela A, Navarro J, Esteban H, Moreno S. Simplification to
dual therapy (atazanavir/ritonavir plus lamivudine) versus standard
triple therapy [atazanavir/ritonavir plus two nucleos(t)ides] in vi-
rologically stable patients on antiretroviral therapy: 96 week re-
sults from an open-label, non-inferiority, randomized clinical trial
(SALT study). J Antimicrob Chemoth. 2017; 72(1): 246-53. Article.
IF: 5.217; D1
• Quintana-Díaz M, Muñoz-Romo R, Gómez-Ramírez S, Pavia J, Boro-
bia AM, García-Erce JA, Muñoz M. A fast-track anaemia clinic in the
Emergency Department: cost-analysis of intravenous iron adminis-
tration for treating iron-deficiency anaemia. Blood Transfus-Italy.
2017; 15(5): 438-46. Article. IF: 2.138; Q3
• Rodríguez-Villar S, Rodríguez-García J L, Arévalo-Serrano J, Sán-
chez-Casado M, Fletcher H. Clinical residual symptomatology and
associated factors in multiple organ failure survivors: A long-term
mortgage. Rev Esp Anestesiol Reanim. 2017; 64(10): 550-9. Article.
Not Indexed
• Tong HY, Medrano N, Borobia AM, Ruiz JA, Martínez AM, Mar-
tín J, Quintana M, García S, Carcas AJ, Ramírez E. Hepatotoxicity
induced by acute and chronic paracetamol overdose in children:
Where do we stand? World J Pediatr. 2017; 13(1): 76-83. Article. IF:
1.228; Q3
Public Projects
Martí de Gracia M. Mejora de la adecuación en la solicitud
de pruebas de imagen con radiación ionizante (TC y RX)
225
 3
Information Groups by Area
3.4 Large System Pathologies Area
Endocrine Diseases Group
8 23.231 4
Lucrecia Herranz de la Morena. Jefe de Sección de
Diabetes. Servicio de Endocrinología y Nutrición. HULP
María Cristina Álvarez Escola. Facultativo Especialista de Área
en Endocrinología y Nutrición. HULP
Beatriz Barquiel Alcalá. Médico Adjunto Especialista en
Endocrinología y Nutrición. HULP
Isabel Calvo Viñuelas. Enfermera en Endocrinología y Nutrición.
HULP. Profesora Asociada. UAM
Ana Isabel de Cos Blanco. Facultativo Especialista de Área en
Endocrinología y Nutrición. HULP. Profesora Asociada. UAM
Sonia del Río Prados. Enfermera Educadora en la Unidad de
Diabetes. HULP
Gumersindo Fernández Vázquez. Facultativo Especialista de
Área en Endocrinología y Nutrición. HULP
Ruth Gaspar Lafuente. Enfermera Educadora en la Unidad de
Diabetes. HULP
Noemi González Pérez de Villar. Facultativo Especialista de
Área en Endocrinología y Nutrición. HULP
Natalia Hillman Gadea. Facultativo Especialista de Área en
Endocrinología y Nutrición. Unidad de Diabetes. HULP
Beatriz Lecumberri Santamaría. Médico Adjunto Especialista
en Endocrinología y Nutrición. HULP
Luis Felipe Pallardo Sánchez. Jefe de Servicio de
Endocrinología y Nutrición. HULP. Catedrático Departamento de
Medicina. UAM
Paola Andrea Parra Ramírez. Facultativo Especialista de Área
en Endocrinología y Nutrición. HULP
Lourdes Sáez de Ibarra de Medizábal. Enfermera Educadora
en la Unidad de Diabetes. HULP
226
Strategic Objective
The objective of this group is both basic and applied
investigation, with its interest focused on transla-
tional investigation, comprising two specific areas
within the speciality of Endocrinology and Nutrition.
The first, within metabolic pathology, includes diabe-
tes and obesity. The second is focused on endocrine
organ-specific pathology (thyroid, pituitary gland,
neuro-endocrinology and rare endocrine disorders).
Research Lines
Metabolic pathology
• Diabetes and pregnancy.
• Diabetes related complications.
• Advanced technologies in diabetes.
• Epidemiological, clinical and comprehensive thera-
peutic approach to obesity.
• Adipose brown tissue metabolism.
Organ-specific pathology
• Molecular biology applied to the diagnosis and
treatment of neuroendocrine disorders.
• Prognosis and treatment of differentiated thyroid
cancer.
• Study of GnRH deficiency.
• GH secretion alterations and cardiometabolic
pathology.
• Clinical-genetic characterizations of rare endocri-
ne disorders and imprinting syndromes.
Research Activity
Doctoral TheseS
Ben Abdelhanin M. Evaluación del eje entero-insular en
relación a la forma de la curva durante la sobrecarga
oral de glucosa en gestantes[dissertation]. Madrid: UAM:
2017(18/09/2017).
Directors: Gómez Rioja R; Herranz de la Morena L.
BOOKS AND BOOK CHAPTERS
Álvarez Escolá C, Cárdenas Salas JJ. Carcinoma medular de
tiroides. In: Galofré Ferratter JC. Cáncer de tiroides guía de
consulta rápida. Madrid: Ergón Creación, 2017. p.185-9
Barquiel B, Parra P. Hypertensive disorders of pregnancy
in gestational diabetes. In: Rajendram R, Preedy VR, Patel VB.
Nutrition and diet in maternal diabetes. An evidence -based
approach. London: Humana Press/Springer Nature, 2017.
p.177-88
PUBLICATIONS
• Alvarado-Martel D, Fernández MAR, Vigaray MC, Carrillo A, Boro-
nat M, Montesdeoca AE, Chávez LN, Sánchez MP, Quevedo PL, Suá-
rez ADS, Hillman N, Subias D,Vaquero PM, de Ibarra LS, Mauricio D,
de Pablos-Velasco P, Novoa FJ, Wagner AM.ViDa1: The development
and validation of a new questionnaire for measuring health-related
quality of life in patients with type 1 diabetes. Front Psychol. 2017; 8:
904. Article. IF: 2.089; Q2
• Badiu C, Bonomi M, Borshchevsky I, Cools M, Craen M, Ghervan C,
Hauschild M, Hershkovitz E, Hrabovszky E, Juul A, Kim SH, Kumanov
P, Lecumberri B, Lemos MC, Neocleous V, Niedziela M, Djurdjevic
SP, Persani L, Phan-Hug F, Pignatelli D, Pitteloud N, Popovic V, Quin-
ton R, Skordis N, Smith N, Stefanija MA, Xu C, Young J, Dwyer AA.
Developing and evaluating rare disease educational materials co-
created by expert clinicians and patients: the paradigm of congenital
hypogonadotropic hypogonadism. Orphanet J Rare Dis. 2017; 12: 57.
Article. IF: 3.607; Q2
• Bieler BM, Gerber SM, de Nanclares GP, Hardisson D, Lecumberri B.
Intratumoral activating GNAS (R201C) mutation in two unrelated
patients with virilizing ovarian Leydig cell tumors. Endocrinol Dia-
betes Nutr. 2017; 64(6): 335-7. Letter. Not Indexed
• Curras-Freixes M, Piñeiro-Yánez E, Montero-Conde C, Apellaniz-
Ruiz M, Calsina B, Mancikova V, Remacha L, Richter S, Ercolino T,
Rogowski-Lehmann N, Deutschbein T, Calatayud M, Guadalix S,
Álvarez-Escola C, Lamas C, Aller J, Sastre-Marcos J, Lázaro C,
Galofre JC, Patino-García A, Meoro-Avilés A, Balmana-Gelpi J, de
Miguel-Novoa P, Balbin M, Matias-Guiu X, Leton R, Inglada-Pérez L,
Torres-Pérez R, Roldán-Romero JM, Rodríguez-Antona C, Fliedner
SMJ, Opocher G, Pacak K, Korpershoek E, de Krijger RR, Vroonen
L, Mannelli M, Fassnacht M, Beuschlein F, Eisenhofer G, Cascon A,
Al-Shahrour F, Robledo M. A Targeted next-generation sequencing
assay for pheochromocytoma and paraganglioma diagnostics. J Mol
Diagn. 2017; 19(4): 575-88. Article. IF: 4.88; Q1
• Lecumberri B, López E, Coronado M, Rodado S, Castelo B. Thyroid
metastasis as first manifestation of a colon adenocarcinoma with
KRAS mutation usefulness of F-18-FDG PET/CT. Clin Nucl Med.
2017; 42(10): 795-7. Article. IF: 6.281; D1
• Martín AA, Pascual EL, Sanfiel MAB, Melero VA, Chávez LN, López IS,
Molina GC, Blanco FA, del Villar NGP. Clinical and metabolic profile
of patients with latent autoimmune diabetes in adults in specialized
care in Madrid. Endocrinol Diabetes Nutr. 2017; 64(1): 34-9. Article.
Not Indexed
• Pinto RC, Álvarez-Rodríguez E, de Villar NGP, Artola-Menéndez S,
Borras JG, Mata-Cases M, Rubio MG, Larrosa JP, Albert RM, Pérez
JAD. Managing the discharge of diabetic patients from the emergen-
cy department: a consensus paper. Emergencias. 2017; 29(5): 343-51.
Article. IF: 3.608; Q1
• Sesmilo G, Resmini E, Sambo M, Blanco C, Calvo F, Pazos F, Fernán-
dez-Catalina P, de Icaya PM, Páramo C, Fajardo C, Marazuela M, Ál-
varez-Escola C, Díez JJ, Perea V. Prevalence of acromegaly in patients
with symptoms of sleep apnea. Plos One. 2017; 12(9): e0183539.
Article. IF: 2.766; Q1
Private Projects
de Cos Blanco AI. Tratamiento interdisciplinar de diabetes
gestacional y obesidad. Banco de Castilla-La Mancha S.A.
2011-Ongoing.
Managment centre: FIBHULP
Herranz de la Morena L. Actualización y proyección de la
unidad funcional de la obesidad en la actividad clínica hospi-
talaria del Servicio de Endocrinología. Abbott Laboratories
S.A. 2008-Ongoing.
Managment centre: FIBHULP
Herranz de la Morena L. Jornadas de formación en investi-
gación sobre diabetes y obesidad. Astrazeneca Farmacéutica
Spain S.A. 2013-Ongoing.
Managment centre: FIBHULP
227
 3
Information Groups by Area

3.4 Large System Pathologies Area

• New immunomodulatory treatments in bladder can- BOOKS AND BOOK CHAPTERS

cer.

Urology Group
30 90. 881
Luis Martínez-Piñeiro Lorenzo. Jefe de Servicio en
Urología. HULP
Alfredo Aguilera Bazán. Facultativo Especialista de Área en
Urología. HULP
José María Alonso Dorrego. Facultativo Especialista de Área en
Urología. HULP
Mario Álvarez Maestro. Facultativo Especialista de Área en
Urología. HULP
Luisa María Botella Cubells. Investigadora Científica. CISC - Centro
de Investigaciones Biológicas
José Ramón Cansino Alcaide. Facultativo Especialista de Área en
Urología. HULP
Crisitina de Castro Guerin. Facultativo Especialista de Área en
Urología. HULP
Mercedes Ferrer Parra. Profesora Titular. Facultad de Medicina.
UAM
Eugenia García Fernández. Facultativo Especialista de Área en
Anatomía Patológico. HULP
María Justa García-Matres y Cortés. Facultativo Especialista de
Área en Urología. HULP
Juan Gómez Rivas. Facultativo Especialista de Área en Urología.
HULP
Estefanía Esperanza Linares Espinós. Facultativo Especialista de
Área en Urología. HULP
Pedro López Pereira. Jefe de Servicio de Urología Pediátrica. HULP
Nuria Malats Riera. Investigadora Senior. CNIO
José Antonio Moreno Valle. Facultativo Especialista de Área en
Urología. HULP
José Ramón Pérez-Carral García. Médico Adjunto en Urología.
HULP
Francisco Real Arribas. Investigador Senior. CNIO
Emilio Ríos González. Médico Adjunto en Urología. Hospital
Universitario Infanta Sofía
228
10
Fermín Rodríguez de Bethancourt Codés. Facultativo
Especialista de Área en Urología. HULP
Ángel Tabernero Gómez. Facultativo Especialista de Área en
Urología. HULP
María del Mar Valés Gómez. Científico Titular. CSIC - Centro
Nacional de Biotecnología
Strategic Objective
We aim to consolidate a strong research group into:
• Urologic Oncology
• Reconstructive surgery
• Endurologic and minimally invasive surgery
• Lithiasis
• Incontinence / Neuro-urology
• Andrology / Reproduction
Through basic and experimental research, clinical re-
search, translational research and clinical trials.
The results of this projects should be translated into
doctoral theses, publications in high impact journals
and visibility factor, as to finally achieve patents and
trademarks.
Research Lines
Urological Oncology
The group’s efforts will focus on the following fields
of research:
BLADDER CANCER
• Immunological response in patients with bladder
cancer treated with BCG.
• Urinary markers in diagnosis and prediction of res-
ponse in patients with bladder cancer.
• New imaging methods for the diagnosis of bladder
cancer.
• Efficacy of combined chemo and immunotherapy hy-
perthermia in bladder cancer.
PROSTATE CANCER
• Castration resistant prostate carcinoma, immune res-
ponse, and evaluation of predictive markers of thera-
peutic response.
• Medical treatment of locally advanced and metastatic
prostate cancer.
• Development of new surgical minimally invasive tech-
niques for localized prostate cancer.
KIDNEY CANCER
• Development of new surgical minimally invasive tech-
niques for localized kidney cancer.
• Research of new therapeutic lines in hereditary renal
cancer.
• Medical treatment of locally advanced and metastatic
renal carcinoma.
Reconstructive surgery
• Development and improvement of new reconstructive
surgery techniques for complex urethral  strictures,
genitourinary congenital malformations and genitouri-
nary fistulas.
• Development of a Regenerative Medicine Unit and Tis-
sue Bioengineering applied to reconstructive urologic
surgery.
Endurologic and minimally invasive surgery
• Development of new endourological surgery techni-
ques for minimally invasive treatment of benign pros-
tatic hyperplasia and urinary lithiasis.
• Development of a learning program in laparoscopy and
other minimally invasive surgeries.
Lithiasis
• Study of new inhibitors of crystallization of urine solu-
tes as prevention of lithogenesis.
• Metabolic study of renal lithiasis.
Incontinence and Neuro-urology
• Study and treatment of chronic pelvic pain.
• Development and improvement of new systems for
the treatment of urinary incontinence.
Andrology / Reproduction
• Study of new medical and surgical treatments for male
infertility.
• Development of new medical and surgical treatments
for erectile dysfunction.
Research Activity
Doctoral TheseS
Gómez Rivas J. Pérdida de función androgénica y vulnera-
bilidad vascular. Potencial efecto protector de extractos de
espirulina[dissertation]. Madrid: UAM: 2017(19/09/2017).
Directors: Rodríguez Bethancourt F; Ferrer Parra M.
Gómez Rivas J, Emberton M. Tissue preservation: Active
surveillance and focal therapy as complimentary strategies.
In: Klotz L (ed). Active surveillance for localized prostate
cancer. Helsinki: Springuer International Publishing, 2017.
p.217-227
Witjes JA, Bruins M, Compérat E, Cowan NC, Gakis G, Her-
nández V, Lebret T, Lorch A, Ribal MJ, van der Heijden
AG, Veskimäe E, Linares Espinós E, Rouanne M, Neuzillet
Y. EAU Guidelines MIBC and metastasic. London: European
Association of Urology, 2017.
PUBLICATIONS
• Alcaraz A, Martínez-Piñeiro L, Rodríguez A, Rubio J, Borque A, Bur-
gos J, Carballido J, Cozar JM, Crespo I, Esquena S, Gómez-Veiga L,
López D, Miñana B, Morote J, Ribal MJ, Solsona E, Suárez JF, Unda M.
Consensus on castration-resistant prostate cancer management in
Spain. Arch Esp Urol. 2017; 70(9): 777-91. Article. IF: 0.465; Q4
• Blanco LT, Socarras MR, Montero RF, Díez EL, Calvo AO, Gregorio
SAY, Cansino JR, Galán JA, Rivas JG. Renal colic during pregnancy:
Diagnostic and therapeutic aspects. Literature review. Cent Euro-
pean J Urol. 2017; 70(1): 93-100. Review. Not Indexed
• Blázquez-Moreno A, Pérez-Portilla A, Agúndez-Llaca M, Dukovska
D, Vales-Gómez M, Aydogmus C, Ikinciogullari A, Regueiro JR, Re-
yburn HT. Analysis of the recovery of CD247 expression in a PID
patient: insights into the spontaneous repair of defective genes.
Blood. 2017; 130(10): 1205-8. Article. IF: 15.132; D1
• Borgmann H, Socarras MR, Salem J, Tsaur I, Rivas JG, Barret E, Tor-
tolero L. Feasibility and safety of augmented reality-assisted uro-
logical surgery using smartglass. World J Urol. 2017; 35(6): 967-72.
Article. IF: 2.981; Q2
• Cansino R, Portilla A, Rivas JG. Performing easy prone punction.
Cent European J Urol. 2017; 70(2): 170-4. Review. Not Indexed
• Carrión DM, Álvarez Maestro M, Gómez Rivas J, González-Pera-
mato P, Cisneros Ledo J. Extramedullary plasmacytoma of the tes-
ticle. Arch Esp Urol. 2017; 70(10): 845-7. Article. IF: 0.465; Q4
• Carrión DM, Gregorio SAY, Rivas JG, Bazán AA, Sebastián JD,
Martínez-Piñeiro L. The role of hemostatic agents in preventing
complications in laparoscopic partial nephrectomy. Cent European
J Urol. 2017; 70(4): 362-7. Article. Not indexed
• Castellucci R, Linares Quevedo AI, Sánchez Gómez FJ, Díez
Rodríguez J, Cogorno L, Cogollos Acuña I, Salmerón BI, Muñoz
Fernández de Legaria M, Martínez Piñeiro L. Prospective nonran-
domized study of diagnostic accuracy comparing prostate cancer
detection by transrectal ultrasound-guided biopsy to magnetic
resonance imaging with subsequent MRI-guided biopsy in biopsy-
naive patients. Minerva Urol Nefrol. 2017; 69(6): 589-95. Article.
IF: 1.449; Q3
• de la Taille A, Martínez-Piñeiro L, Cabri P, Houchard A, Schalken J.
Factors predicting progression to castrate-resistant prostate can-
cer in patients with advanced prostate cancer receiving long-term
androgen-deprivation therapy. BJU Int. 2017; 119(1): 74-81. Article.
IF: 4.688; Q1
• Esteso G, Guerra S, Valés-Gómez M, Reyburn HT. Innate immune
recognition of double-stranded RNA triggers increased expres-
sion of NKG2D ligands after virus infection. J Biol Chem. 2017;
292(50): 20472-80. Article. IF: 4.01; Q2
• Faba OR, Brookman-May SD, Linares E, Breda A, Pisano F, Subiela
JD, Sanguedolce F, Brausi M, Palou J. Cytoreductive nephrectomy in
patients with metastatic renal cell carcinoma in the era of targeted
therapy: a bibliographic review. World J Urol. 2017; 35(12): 1807-
16. Review. IF: 2.981; Q2
229
 3
Information Groups by Area
3.4 Large System Pathologies Area
• García-Cuesta EM, Esteso G, Ashiru O, López-Cobo S, Álvarez-
Maestro M, Linares A, Ho MM, Martínez-Piñeiro L, Reyburn HT,
Valés-Gómez M. Characterization of a human anti-tumoral NK cell
population expanded after BCG treatment of leukocytes. Oncoim-
munology. 2017; 6(4): e1293212. Article. IF: 5.503; Q1
• Gómez-Rivas J, Rodríguez-Socarra ME, Tortotero-Blanco L, Gar-
cía-Sanz M, Álvarez-Maestro M, Ribal MJ, Coar-Olmo M. Influence
of social networks on congresses of urological societies and as-
sociations: Results of the 81th National Congress of the Spanish
Urological Association. Actas Urol Esp. 2017; 41(3): 181-7. Article.
IF: 1.26; Q4
• Hernández V, Espinós EL, Dunn J, MacLennan S, Lam T, Yuan YH,
Compeerat E, Cowan NC, Gakis G, Lebret T, van der Heijden AG,
Witjes JA, Ribal MJ. Oncological and functional outcomes of sexual
function-preserving cystectomy compared with standard radical
cystectomy in men: A systematic review. Urol Oncol-Semin Ori.
2017; 35(9): 539.e17. Review. IF: 3.397; Q1
• Hernández-Vivanco A, Sanz-Lazaro S, Jiménez-Pompa A, García-
Magro N, Carmona-Hidalgo B, Pérez-Álvarez A, Caba-González JC,
Tabernero A, Gregorio SAY, Passas J, Blázquez J, González-Enguita
C, de Castro-Guerín C, Albillos A. Human native Ca(v)1 channels
in chromaffin cells: contribution to exocytosis and firing of sponta-
neous action potentials. Eur J Pharmacol. 2017; 796: 115-21. Article.
IF: 3.04; Q2
• Hone AJ, McIntosh JM, Rueda-Ruzafa L, Passas J, de Castro-Guerín
C, Blázquez J, González-Enguita C, Albillos A. Therapeutic concen-
trations of varenicline in the presence of nicotine increase action
potential firing in human adrenal chromaffin cells. J Neurochem.
2017; 140(1): 37-52. Article. IF: 4.609; Q1
• Kallidonis P, Ntasiotis P, Knoll T, Sarica K, Papatsoris A, Somani BK,
Greco F, Aboumarzouk OM, Álvarez-Maestro M, Sanguedolce F.
Minimally invasive surgical ureterolithotomy versus ureteroscopic
lithotripsy for large ureteric stones: A systematic review and meta-
analysis of the literature. Eur Urol Focus. 2017; 3(6): 554-66. Review.
Not Indexed
• Morote J, Tabernero AJ, Ossorio JLA, Ciria JP, Domínguez-Escrig JL,
Vázquez F, Angulo J, López FJ, de La Iglesia R, Romero J. Cognitive
function in patients with prostate cancer receiving luteinizing hor-
mone-releasing hormone analogues: A prospective, observational,
multicenter study. Int J Radiat Oncol. 2017; 98(3): 590-4. Article. IF:
5.554; D1
• Orejón RU, Martínez IH, Torres EM, Escudero CJ, Rivas JG, Sebas-
tián JD, Tolsada MDU. Impact of a goal directed therapy in the im-
plementation of an ERAS (Enhanced recovery after surgery) pro-
tocol in laparoscopic radical cystectomy.Arch Esp Urol. 2017; 70(8):
707-14. Article. IF: 0.465; Q4
• Perusquia M, Herrera N, Ferrer M, Stallone JN. Antihypertensive
effects of androgens in conscious, spontaneously hypertensive rats.
J Steroid Biochem. 2017; 167: 106-14. Article. IF: 4.095; Q1
• Ríos E, Martínez-Piñeiro L. Re: Mid-term outcomes after advan-
ceXP male sling implantation. Eur Urol. 2017; 72(2): 318-9. Editorial
Material. IF: 17.581; D1
• Rivas JG, Carrión DM, Gregorio SAY, Álvarez-Maestro M, Gómez
AT, Ledo JC. A novel heterozygous mutation in the birt-hogg-dube
syndrome. Arch Esp Urol. 2017; 70(7): 675-8. Article. IF: 0.465; Q4
• Rivas JG, Gregorio SAY, Ledo JC, Orejón RU, Doslada P, Sebastián
J, Gómez A, Barthel JJD. Early recovery protocol in patients under-
going laparoscopic radical cystectomy. Urol Sci. 2017; 28(1): 2-5.
Review. Not Indexed
• Rivas JG, Ledo JC. Principles of urinary tract reconstructive surgery.
Arch Esp Urol. 2017; 70(4): 379-84. Article. IF: 0.465; Q4
• Rodríguez-Socarrás ME, Rivas JG, García-Sanz M, Pesquera L,Torto-
lero-Blanco L, Ciappara M, Melnick A, Colombo J, Patruno G, Serra-
no-Pascual A, Bachiller-Burgos J, Cozar-Olmo JM. Medical-surgical
activity and the current state of training of urology residents in
230
Spain: Results of a national survey. Actas Urol Esp. 2017; 41(6): 391- López Pereira P. Curso CRM (Crisis Resource Management) Martínez-Piñeiro Lorenzo L. Actualización y renovación de
9. Article. IF: 1.26; Q4 en Urología Pediátrica.Varios Financiadores. 2016-Ongoing. la actividad investigadora en el Servicio de Urología del Hos-
• Secín FP, Castillo OA, Rozanec JJ, Featherston M, Holst P, Milfont Managment centre: FIBHULP pital Universitario La Paz. Almirall S.A.2017-Ongoing.
JCA, Marchinena PG, Navarro AJ, Autran A, Rovegno AR, Faba OR, Managment centre: FIBHULP
Palou J, Dubeux VT, Bragayrac LN, Sotelo R, Zequi S, Guimares GC, López Pereira P. Estudio del desarrollo vesical en un mo-
Álvarez-Maestro M, Martínez-Piñeiro L, Villoldo G, Villaronga A, delo de mielomeningocele corregido prenatalmente. Q-Med. Martínez-Piñeiro Lorenzo L. Convenio de colaboración
Clavijo DA, Decia R, Frota R, Vidal-Mora I, Finkelstein D, Gardiner 2009-Ongoing. para el fomento de la formación. Tyco. 2006-Ongoing.
JIM, Schatloff O, Hernández-Porrás A, Santaella-Torres F, Quesada Managment centre: FIBHULP Managment centre: FIBHULP
ET, Sánchez-Salas R, Dávila H, Mavric HV. American Confederation
López Pereira P. Utilización de constructos de mucosa uro- Martínez-Piñeiro Lorenzo L; Álvarez Maestro M. Utilidad
of Urology (CAU) experience in minimally invasive partial ne-
telial autóloga obtenidos mediante ingeniería tisular para la de bladder Epicheck para la detección de recidivas de car-
phrectomy. World J Urol. 2017; 35(1): 57-65. Article. IF: 2.981; Q2
realización uretroplastias reconstructivas en un modelo ex- cinoma urotelial: estudio multicéntrico, prospectivo y ciego.
• Valverde-Martínez S, Ramírez-Backhaus M, Rubio-Briones J, Martí- perimental de hipospadias proximal en conejos. Fundación Nucleix Ltd. 2017-Ongoing.
nez-Piñeiro L, Dominguez-Escrig J. Indocyanine green guided pelvic
para la Investigación en Urología. 2016-Ongoing. Managment centre: FIBHULP
lymphadenectomy. Arch Esp Urol. 2017; 70(8): 748-9. Editorial Ma-
Managment centre: FIBHULP
terial. IF: 0.465; Q4
• Veneziano D, Ahmed K, Van Cleynenbreugel B, Gozen A, Palou J, CLINICAL TRIALS
Sarica K, Liatsikos E, Sanguedolce F, Honeck P, Álvarez-Maestro
M, Papatsoris A, Kallidonis P, Greco F, Breda A, Somani BK. Cansino Alcaide JR. Ensayo multicéntrico, controlado y alea-
Development methodology of the novel endoscopic torizado para evaluar el uso combinado de un dispositivo
stone treatment step 1 training/assessment curri- médico y un complemento alimenticio en el control del PH
culum: An international collaborative work by urinario de pacientes con un catéter doble J implantado.Type:
european association of urology sections. J Clinical Trial, phase Health Care Product.
Endourol. 2017; 31(9): 934-41. Article. IF: HULP code: 4944. Sponsored´s protocol code: DEV-LCD-02-17.
2.038; Q2 Sponsored by: Devicare S.L.
• Villalpando DM, Navarro R, del Campo Signed date: 17/11/2017
L, Largo C, Muñoz D, Tabernero M,
Baeza R, Otero C, García HS, Ferrer Martínez Piñeiro L. Estudio prospectivo no intervencional
M. Docosahexaenoic acid supple- poscomercialización para evaluar los criterios sobre qué re-
mented diet influences the orchidec- novación del tratamiento con análogos de la LHRH se realiza
tomy-induced vascular dysfunction en pacientes con cáncer de próstata localmente avanzado o
in rat mesenteric arteries. Plos One. metastásico (Estudio Anaren). Type: EPA-SP.
2017; 12(1): e0168841. Article. IF: HULP code: PI-2853. Sponsored´s protocol code: IPS-TRI-2016-02.
2.766; Q1 Sponsored by: Ipsen Pharma S.A.
• Villalpando DM, Rojas MM, García HS, Signed date: 13/09/2017
Ferrer M. Dietary docosahexaenoic acid
supplementation prevents the formation
of cholesterol oxidation products in arte-
ries from orchidectomized rats. Plos One.
2017; 12(10): e0185805. Article. IF: 2.766; Q1
Public Projects
Ferrer Parra M. Aplicaciones industriales de la espirulina
(S2013/ABI-2783). CAM. 2014-2018.
Managment centre: UAM
Private Projects
Gómez Rivas J. Cáncer de pene-PIEM. Fundación para la In-
vestigación en Urología. 2014-Ongoing.
Managment centre: Fundación para la Investigación en Urología
Gómez Rivas J. Cáncer de testiculo-PIEM. Fundación para la
Investigación en Urología. 2015-Ongoing.
Managment centre: Fundación para la Investigación en Urología
Gómez Rivas J. Identify. The investigastion and detection of
urological neoplasia in fast track patients referred with hae-
maturia: a multicenter analysis. 2017-Ongoing.
Managment centre: Fundación para la Investigación en Urología
Linares Espinós E. Análisis de biomarcadores en exosomas
de plasma y orina de pacientes con cáncer de próstata re-
sistente a la castración. Astellas Pharma S.A. 2017-Ongoing.
Managment centre: FIBHULP
231
 3
Information Groups by Area
3.4 Large System Pathologies Area
Health Care Nurses
Research Group
3 82.024 2
Jesús Castro Toro. Supervisor de Área Asistencial. HULP
Laura Alonso Recio. Profesora Contratada. UNED
Alicia Cerón Serrano. Enfermera Asistencial. HULP
María Nélida Conejo Pérez. Enfermera en Servicio Cuidados
Intesivos Pediátricos. HULP
Víctor Manuel Cornejo del Río. Supervisor de Unidad. HULP
María Ricardina Delgado Sandoval. Enfermera en Servicio de
Consultas Externas. HULP
María Luisa Díaz Martínez. Profesora Contratada. UAM
Maria Duran Agüi. Enfermera en Servicio de Medicina Interna. HULP
Matilde Fernández y Fernández-Arroyo. Profesora de la
Unidad Docente de Matronas. HULP
Salomé Herrero Cerceda. Enfermera Área Quirúgica. HULP
Patricia Luna Castaño. Enfermera en Servicio Cuidados Intesivos
Pediátricos. HULP
Jesús Morente López. Enfermero en Unidad de Cuidados Críticos.
HULP
Pedro Piqueras Rodríguez. Supervisor de Enfermería en Unidad
de Neonatología. HULP
Ana Ramos Cruz. Supervisor de Enfermería en Reanimación
Maternidad. HULP. Profesora Asociada de Grado de Enfermería. Centro
Universitario de Ciencias de la Salud San Rafael Nebrija
María Carmen Sellán Soto. Profesora Contratada. UAM
Gema Tapia Serrano. Enfermera Asistencial. HULP
Adrián Torres Hidalgo. Supervisor de Enfermería en Urgencias.
HULP
Strategic Objective
Care is an indispensable activity for survival, since
humanity exists. Care has been relevant as a primary
232
function to promote and develop all those activities
that make people live.
This research group aims to collaborate on growing
clinical evidence on health care. The real gap bet-
ween what generates scientific knowledge and the
decisions that are made in the day to day is ethi-
cally unacceptable. Between 30 and 40% of patients
do not receive care consistent with the results of
the research and around 20-25% of care may be
unnecessary or potentially harmful. Evidence-Based
Practice (PBE) or Evidence is based on the fact that
greater knowledge and use of research results in cli-
nical practice will contribute to improving the health
of the population. Today, it is well known that the im-
plementation of the best scientific evidence available
in the clinical practice improves quality of care and
clinical outcomes.
In addition, decision-makers based on available evi-
dence tend to be more satisfied with their role and
focus on improving the quality of care given to pa-
tients.
Finally, it should be noted that using evidence in daily
practice can achieve health goals at a minimum cost.
Cost-effectiveness studies have been conducted in
which evidence-based care is linked to a reduction in
health costs compared to traditional care.
At the same time, society is facing new economic,
political, demographic, social and cultural challenges
that require health services capable of meeting the
growing health needs of the population.
It is necessary to investigate in clinical practice the
most advanced care in order to achieve the full de-
velopment of care and ensure the achievement of
the best results in terms of overall health and quality
of life of patients, Effectiveness of interventions, greater
cohesion of health care teams, and of course, all contri-
bute to the sustainability of the health system and user
satisfaction.
Research Lines
• Vital Processes and complex care.
• Technological innovation and its application in health
care.
• Management of care and results of professional prac-
tice.
Research Activity
Doctoral TheseS
Conejo Pérez MN. Eficacia de la formación y mentoría so-
bre las competencias, práctica y barreras percibidas por las
enfermeras, en la Práctica Basada en Evidencias[dissertation].
Madrid: UAH: 2017(27/06/2017).
Directors: Casas Martínez MF; Molina Arias M.
Luna Castaño P. La valoración del dolor en los pacientes pre-
verbales: indicadores fisiológicos y conductuales utilizados
por las enfermeras en las UCI pediátricas[dissertation]. Ma-
drid: UAH: 2017(29/06/2017).
Directors: Casa Martínez MF; Gómez González JL.
BOOKS AND BOOK CHAPTERS
Fernández M, Muñoz I, Cerón GA, Delgado M, Cornejo del
Río V, Boal G. Estudio piloto para elaborar un cuestionario
de evaluación del Programa de Educación Maternal después
del parto. In: Libro de Ponencias. XXI Encuentro Internacio-
nal de Investigación en Cuidados. Madrid: Instituto de Salud
Carlos III, 2017. p.405-6
Fernández M, Pedraza A, Alcolea T, Oter C, Goberna J.
Aprendizaje y satisfacción de los padres con la simulación de
los cuidados del recién nacido en la Educación Maternal. In:
Libro de Ponencias. XXI Encuentro Internacional de Inves-
tigación en Cuidados. Madrid: Instituto de Salud Carlos III,
2017. p.385-6
Alcolea M, Espinosa MA, Otero C, Fernández M, Martín A.
Las estrategias frente al llanto en las consultas enfermeras
del niño sano en Atención Primaria. In: Libro de Ponencias.
XXI Encuentro Internacional de Investigación en Cuidados.
Madrid: Instituto de Salud Carlos III, 2017. p.4-5
Alcolea M, Otero C, Fernández M. El comienzo de la vida:
nuevo recurso docente para aprender el cuidado del niño
hasta los 3 años. In: Innovación emprendimiento y responsa-
bilidad social en enfermería. Zaragoza: Conferencia Nacional
de Decanos de Enfermería. (CNDE), 2017. p.272-3
Luna Castaño P, Piqueras Rodríguez P, Hernández Ave-
llaneda JM. Canalizaciones habituales en el recién nacido.
In: Sellán Soto MC,Vázquez Sellán A. Cuidados neonatales en
enfermería. Barcelona: Elsevier, 2017. p.241-50
Sellán Soto MC, Vázquez Sellán A. Cuidados neonatales en
enfermería. Barcelona: Elsevier, 2017.
Blanco Trejo F, Sellán Soto MC, Vázquez Sellán A. Los cui-
dados neonatales como canon de la cultura enfermera: Pre-
sencia, vulnerabilidad y reciprocidad. In: Sellán Soto MC, Váz-
quez Sellán A. Cuidados neonatales en enfermería. Barcelona:
Elsevier, 2017. p.3-11
Sellán Soto MC, Díaz Martínez ML, Vázquez Sellán A. Apli-
cación de la teoría y la metodología a la práctica clínica. In:
Sellán Soto MC, Vázquez Sellán A. Cuidados neonatales en
enfermería. Barcelona: Elsevier, 2017. p.269-273
Díaz Martínez ML, Albarrán Medrano G, Avilés Martínez
M. Planes de cuidados para la atención del neonato y la fami-
lia. In: Sellán Soto MC,Vázquez Sellán A. Cuidados Neonatales
en Enfermería. Barcelona: Elsevier, 2017. p.275-295
Ramos Cruz A, Utrilla Rojo AC. Manejo Respiratorio. In:
Sellán Soto MC, Vázquez Sellán A. Cuidados Neonatales en
Enfermería. Barcelona: Elsevier, 2017. p.85-103
Cobo González D, Neria Agujetas MS,Rey Cuevas ME, Fer-
nández Acevedo MR, Castro Toro J, Gómez González JL,
Santamaría García JM, Jiménez Rodríguez ML. Disminu-
ción de costes sanitarios tras la introuducción de sistemas
electrónicos de control de temperatura en el transporte de
componentes sanguineos. In: 28 Jornadas Nacionales de En-
fermeras Gestoras. Cáceres: Asociación Nacional de Directi-
vos de Enfermería, 2017.
Sevilla Ramírez Y, Castro Toro J, González Romero MJ,
Manzano Ocaña M, Sánchez Arroyo P. Eficiencia en la auto-
matización de la gestión del almacén en el Servicio de Análi-
sis Clínicos del Hospital Universitario La Paz. In: 28 Jornadas
Nacionales de Enfermeras Gestoras. Cáceres: Asociación
Nacional de Directivos de Enfermería, 2017
González Herrero MA ,Castro Toro J, Fernández Acevedo
MR, Rey Vuevas E. Cambio de modelo en la promoción de la
donación de sangre en el Hospital Universitario La Paz. In: 28
Jornadas Nacionales de Enfermeras Gestoras. Cáceres: Aso-
ciación Nacional de Directivos de Enfermería, 2017.
Castro Toro J, Durán Agüí M, Herrero Cereceda S, Morente
López J, Torres Hidalgo A. Desarrollo de la APP Vivir con
EPOC. In: 28 Jornadas Nacionales de Enfermeras Gestoras.
Cáceres: Asociación Nacional de Directivos de Enfermería,
2017
Pascáu González Garzón MJ, Rey Cuevas ME, Ramos Ro-
mán H, Muñoz Pintor J, Piqueras Rodríguez P, González
Pérez MP, Leiva Salgado JC, García de Miguel Gallego M.
Transplantchild: novedad, oportunidad y reto. In: 28 Jornadas
Nacionales de Enfermeras Gestoras. Cáceres: Asociación Na-
cional de Directivos de Enfermería, 2017.
Piqueras Rodríguez P, Rey Cuevas ME, Ramos Román
H, Muñoz Pintor J, Pascau González-Garzón MJ, Asensio
Fariza MA, López González MP. Visibilidad de la figura del
supervisor desde la visión de los estudiantes de enfermería.
In: 28 Jornadas Nacionales de Enfermeras Gestoras. Cáceres:
Asociación Nacional de Directivos de Enfermería, 2017.
Alonso-Recio L. Dorsal pathway. In: Vonk J, Shackelford
TK (Eds.). Encyclopedia of animal cognition and behaviour.
Berlin: Springer International Publishing, 2017.
Alonso Recio L, Colmenares Gil F, Desfilis Barceló E. Bases
biológicas de la conducta. Madrid: Ediciones CEF, 2017.
233
 3
Information Groups by Area
3.4 Large System Pathologies Area
PUBLICATIONS
• del Río VC, Mostaza J, Lahoz C, Sánchez-Arroyo V, Sabín C, López
S, Patrón P, Fernández-García P, Fernández-Puntero B, Vicent D,
Montesano-Sánchez L, García-Iglesias F, González-Alegre T, Estirado
E, Laguna F, de Burgos-Lunar C, Gómez-Campelo P, Abanades-He-
rranz JC, de Miguel-Yanes JM, Salinero-Fort MA. Prevalence of pe-
ripheral artery disease (PAD) and factors associated: An epidemio-
logical analysis from the population-based Screening PRE-diabetes
and type 2 DIAbetes (SPREDIA-2) study. Plos One. 2017; 12(10):
e0186220. Article. IF: 2.766; Q1
• Negredo A, de la Calle-Prieto F, Palencia-Herrejón E, Mora-Rillo M,
Astray-Mochales J, Sánchez-Seco MP, López EB, Menárguez J, Fer-
nández-Cruz A, Sánchez-Artola B, Keough-Delgado E, de Arellano
ER, Lasala F, Milla J, Fraile JL, Gavín MO, de la Gandara AM, Pérez LL,
Díaz-Díaz D, López-García MA, Delgado-Jiménez P, Martín-Quirós
A, Trigo E, Figueira JC, Manzanares J, Rodríguez-Baena E, García-
Comas L, Rodríguez-Fraga O, García-Arenzana N, Fernández-Díaz
MV, Cornejo VM, Emmerich P, Schmidt-Chanasit J, Arribas JR. Auto-
chthonous Crimean-Congo hemorrhagic fever in Spain. New Engl J
Med. 2017; 377(2): 154-61. Article. IF: 79.258; D1
• Cerón-Serrano A, Jiménez-Castellano R, Gómez-Campos AM. Pre-
vention and nursing care in the first case of Ebola virus disease
contracted outside Africa. Enferm Clin. 2017; 27(2): 125-31. Article.
Not Indexed
234
Private Projects
Castro Toro J. APP para mejorara la adherencia al tratamien-
to en pacientes EPOC. Vivir con EPOC. Vodafone. 2016-On-
Maternal and Fetal
going.
Managment centre: Reto Salud Andalucía
Medicine Group
12 23.954 2
José Luis Bartha Rasero. Jefe de Servicio de Obstetricia y
Ginecología. HULP. Catedrático de Obstetricia y Ginecología. UAM
Eugenia Antolín Alvarado. Jefe de Sección de Obstetricia y
Ginecología. HULP. Profesor asociado. UAM
Marta Cortés León. Médico Especialista en Ginecología y
Obstetricia. HULP
María de la Calle Fernández-Miranda. Jefa de Sección de la
Tocología de Alto Riesgo y Obstetricia Medica. HULP. Profesor Asociado.
Facultad de Medicina. UAM
Inmaculada Duyós Mateo. Facultativo Especialista de Área en
Ginecología y Obstetricia. HULP
María Amparo Gimeno Sanmartín. Médico Especialista en
Ginecología y Obstetricia. HULP
María del Mar González Arlazón. Facultativo Especialista de
Área en Ginecología y Obstetricia. HULP
María de la Cruz González Álvarez. Facultativo Especialista
de Área en Ginecología y Obstetricia. HULP
Beatriz Herrero Ruiz. Médico Adjunto de la Sección de Ecografía y
Medicina Fetal. HULP
Sara López Magallón. Facultativo Especialista de Área en
Ginecología y Obstetricia. HULP
Francisco López Sánchez. Facultativo Especialista de Área en
Ginecología y Obstetricia. HULP
Fernando Magdaleno Dans. Jefe de Sección de Obstetricia y
Ginecología. HULP. Profesor asociado. UAM
María Elena Martín Boado. Facultativo Especialista de Área en
Ginecología y Obstetricia. HULP
Nuría Martínez Sánchez. Facultativo Especialista de Área en
Ginecología y Obstetricia. HULP
Inmaculada Orensanz Fernández. Facultativo Especialista de
Área en Ginecología y Obstetricia. HULP
Roberto Rodríguez González. Facultativo Especialista de Área
en Ginecología y Obstetricia. HULP
Laura Sotillo Mallo. Facultativo Especialista de Área en Ginecología
y Obstetricia. HULP
Strategic Objective
1. To evaluate the involvement of placental energy
metabolism in obstetric disorders
2. To find new biomarkers in gestational diabetes
mellitus and macrosomia
3. To find new biomarkers of fetal and perinatal neu-
rological damage establishing new prevention stra-
tegies
4. To improve our understanding of the pathophysio-
logy fetal heart damage in Anti-Ro positivewomen
and to find new lines of treatment in these cases
Research Lines
• Diabetes mellitus, obesity and metabolic syndrome
during pregnancy
• Energy metabolism during pregnancy
• Fetal neurodevelopment
• Inflammation, autoimmunity and pregnancy
Research Activity
Doctoral TheseS
Herrero Ruiz B. Crecimiento longitudinal fetal en el tercer
trimestre como predictor de la aparición de eventos peri-
natales y hallazgos placentarios significativos[dissertation].
Madrid: UAM: 2017(26/09/2017).
Directors: Bartha Rasero Jl; de la Calle Fernández Miran-
da M.
Martínez Sánchez N. Implicaciones clínicas, resultados
obstétrico-perinatales y complicaciones fetales en ges-
tantes portadoras de anticuerpos anti-RO/SS-A y ANTI-
235
 3
Information Groups by Area
3.4 Large System Pathologies Area
LA/SS-B[dissertation]. Madrid: UAM: 2017(27/09/2017).
Director: Bartha Rasero JL.
Revello Álvarez R. Redicción multivariante del síndrome
de respuesta inflamatoria fetal a partir del uso combinado
de marcadores bioquímicos [dissertation]. Madrid: UAM:
2017(08/09/2017).
Director: Bartha Rasero JL
Silva Zaragueta P. Abordaje del hidrosalpinx mediante dis-
positivo essure previo al tratamiento de fecundación in
vitro[dissertation]. Madrid: UAM: 2017(22/06/2017).
Directors: Bartha Rasero JL; Hernández Gutiérrez A.
PUBLICATIONS
• Álvarez-López C, de Santiago J, Pinera A, Rodríguez R, Herrero B,
Herrera M, Pillado J, Zapardiel I. Utility of three-dimensional ultra-
sonography to assess the position of essure tubal occlusion device
and its complications. Gynecol Obstet Inves. 2017; 82(2): 170-4. Ar-
ticle. IF: 1.183; Q4
• Bugatto F, Quintero-Prado R,Vilar-Sánchez JM, Perdomo G,Torrejón
R, Bartha JL. Prepregnancy body mass index influences lipid oxi-
dation rate during pregnancy. Acta Obstet Gyn Scan. 2017; 96(2):
207-15. Article. IF: 2.649; Q2
• Carrasco AL, Gutiérrez AH, Gutiérrez PAH, González RR, Martín
JLM, Zapardiel I, García JD. Ileocecal endometriosis: diagnosis and
management. Taiwan J Obstet Gyne. 2017;56(2):243-246. Article. IF:
1,029; Q4.0
• de la Calle M,Vidaurrazaga C, Martínez N, González-Beato M, Anto-
lín E, Bartha JL. Successful treatment of a severe early onset case of
pemphigoid gestationis with intravenous immunoglobulin in a twin
pregnancy conceived with in vitro fertilisation in a primigravida. J
Obstet Gynaecol. 2017; 37(2): 246-7. Article. IF: 0.545; Q4
• Dore Reyes M, Triana Junco P, Encinas Hernández J L, Alvarado An-
tolín E, Bartha Rasero JL, Núñez Cerezo V, Romo Muñoz M, Gómez
Cervantes M, Sánchez Galán A, Martínez Martínez L, López Santa-
maría M. Mesenteric edema as a prenatal ultrasound sign of poor
prognosis in gastroschisis. Cir Pediatr. 2017; 30(3): 131-7. Article.
Not Indexed
• Martínez-Sánchez N, Pérez-Pinto S, Robles-Marhuenda A, Arnalich-
Fernández F, Camean MM, Zalvide EH, Bartha JL. Obstetric and pe-
rinatal outcome in anti-Ro/SSA-positive pregnant women: a pros-
pective cohort study. Immunol Res. 2017; 65(2): 487-94. Article. IF:
2.487; Q3
• Palacio M, Bonet-Carne E, Cobo T, Pérez-Moreno A, Sabria J, Richter
J, Kacerovsky M, Jacobsson B, García-Posada RA, Bugatto F, Santis-
teve R, Vives A, Parra-Cordero M, Hernández-Andrade E, Bartha
JL, Carretero-Lucena P, Tan KL, Cruz-Martínez R, Burke M, Vavilala
S, Iruretagoyena I, Delgado JL, Schenone M, Vilanova J, Botet F, Yeo
GSH, Hyett J, Deprest J, Romero R, Gratacos E. Prediction of neo-
natal respiratory morbidity by quantitative ultrasound lung texture
analysis: a multicenter study. Am J Obstet Gynecol. 2017; 217(2):
196.e1-14. Article. IF: 5.732; D1
• Palacio M, Cobo T, Antolín E, Ramírez M, Cabrera F, de Rosales FM,
Bartha JL, Juan M, Martí A, Oros D, Rodríguez A, Scazzocchio E, Oli-
vares JM, Varea S, Rios J, Gratacos E. Vaginal progesterone as main-
tenance treatment after an episode of preterm labour (PROMISE)
Study: A multicentre, double-blind, randomised, placebo-controlled
trial. Obstet Gynecol Surv. 2017; 72(3): 151-3. Editorial Material. IF:
2.014; Q3
• Perales A, Delgado JL, de la Calle M, García-Hernández JA, Escudero
AI, Campillos JM, Sarabia MD, Laiz B, Duque M, Navarro M, Calmarza
P, Hund M, Álvarez FV. sFlt-1/PlGF for prediction of early-onset pre-
eclampsia: STEPS (Study of Early Pre-eclampsia in Spain). Ultrasound
Obst Gyn. 2017; 50(3): 373-82. Article. IF: 5.654; D1
236
• Revello R, Alcaide MJ, Abehsera D, Martín-Camean M, Sousa E, Faro
Gomes M, Alonso-Luque B, Bartha JL. Prediction of chorioamnio-
nitis in cases of intraamniotic infection by ureaplasma urealyticum
in women with very preterm premature rupture of membranes or
preterm labour. J Matern Fetal Neonatal Med. 2017: 1-6. Article. IF:
1.493; Q4
• Sánchez-Galán A, Encinas J L, Antolín E, Vilanova A, Dore M, Triana
P, Bartha J L, López-Santamaría M. Intestinal complications in twin-
to-twin transfusion syndrome (TTTS) treated by laser coagulation
(LC). Cir Pediatr. 2017; 30(1): 33-8. Article. Not Indexed
• Suela J, López-Expósito I, Querejeta ME, Martorell R, Cuatrecasas
E, Armengol L, Antolín E, Domínguez Garrido E, Trujillo-Tiebas MJ,
Rosell J, García Planells J, Cigudosa JC. Recommendations for the
use of microarrays in prenatal diagnosis. Med Clin-Barcelona. 2017;
148(7): 328.e1-8. Article. IF: 1.168; Q3
Public Projects
Antolín Alvarado E. Desarrollo de métodos predictivos ba-
sados en la integración de factores prenatales y postnatales
para la detección de neurodesarrollo anómalo en cardiopa-
tías congénitas (PI13/02364). ISCIII. 2014-2017.
Managment centre: FIBHULP
Bartha Rasero JL. Aplicación de la biología de sistemas al
conocimiento de la fisiopatologia e Identificación de nuevos
biomarcadores de la diabetes gestacional (PI15/01563). ISCIII.
2016-2018.
Managment centre: FIBHULP
Private Projects
Bartha Rasero JL. Implicación de la oxidación mitocon-
drial de ácidos grasos placentaria en la patogénesis y clíni-
ca de la preeclampsia. Laboratorios Farmacéuticos Rovi S.A.
2016-Ongoing
Managment centre: FIBHULP
CLINICAL TRIALS
Bartha Rasero JL. Ensayo clínico controlado, aleatorizado,
doble ciego con prevastatina versus placebo para la preven-
ción de preclampsia. STATIN. Type: Clinical Trial, phase III.
HULP code: 4838. Sponsored´s protocol code: FFIS/2016/02/ST
STATIN.
Sponsored by: Fundación para la Formación e Investigación
Sanitarias de la Región de Murcia.
Signed date: 12/05/2017
Bartha Rasero JL. Estudio observacional, multicéntrico,
prospectivo, abierto, para evaluar la seguridad de Nife-Par®
en el tratamiento de la amenaza de parto pretérmino. Type:
EPA-OD.
HULP code: PI-2536. Sponsored´s protocol code: REI-NIF-2016-01.
Sponsored by: Laboratorio Reig Jofre S.A.
Signed date: 18/01/2017
de la Calle Fernández-Miranda M. Estudio en fase III, alea-
torizado, enmascarado para el observador, controlado con
placebo y con grupos secuenciales para determinar la inmu-
nogenicidad y la seguridad de una vacuna. Type: Clinical Trial,
phase III.
HULP code: ANEXO-I 4663. Sponsored´s protocol code: RSV-M-301.
Sponsored by: Novavax Inc.
Signed date: 13/07/2017
Emergency and Critical
Pathology Group
10 103.003 5
César Carballo Cardona. Facultativo Especialista de Área
en Ginecología y Obstetricia. HULP
María Teresa Ayuso Aragonés. Médico Interno Residente en
Urgencias. HULP
Gillermina Bejarano Redondo. Médico Adjunto en Urgencias.
HULP
Labna Dani Ben Abdel-Iah. Facultativo Especialista de Área en
Urgencias. HULP
Guadalupe Buitrago Weiland. Facultativo Especialista de Área en
Urgencias. HULP
María Elena Calvín García. Facultativo Especialista de Área en
Urgencias. HULP
Julio Cobo Mora. Jefe de la Unidad de Urgencias. HULP
Isabel Gallego Mínguez. Facultativo Especialista de Área en
Urgencias. HULP
María de los Ángeles García Martín. Facultativo Especialista
de Área en Farmacia Hospitalaria. HULP
Manuel Jesús González Viñolis. Facultativo Especialista de Área
en Urgencias. HULP
Olga González Peña. Facultativo Especialista de Área en Medicina
Familiar y Comunitaria. HULP
María Milagros Jaén Cañadas. Facultativo Especialista de Área
en Medicina Interna. HULP
Macarena Lerín Baratas. Facultativo Especialista de Área en
Urgencias. HULP
Cristina López Paredes. Facultativo Especialista de Área en
Urgencias. HULP
María Lorena López Corcuera. Facultativo Especialista de Área
en Medicina Interna. HULP
Alejandro Martín Quirós. Unidad de Aislamiento de Alto Nivel.
HULP
Carlos Martínez Caballero. Facultativo Especialista de Área en
Urgencias. HULP
Raúl Muñoz Romo. Técnico Superior de Salud Pública. SUMMA 112
Mikel Rico Briñas. Facultativo Especialista de Área en Urgencias.
HULP
Paloma Isabel Romero Gallego-Acho. Facultativo Especialista
de Área en Medicina Interna. HULP
María José Simón Merlo. Facultativo Especialista de Área en
Radiología. HULP
Yale Tung Chen. Facultativo Especialista de Área en Urgencias. HULP
Strategic Objective
Our group will investigate new strategies to address
very different pathologies that are presented in our
emergency department, national referent in different
fields of diagnosis and treatment.This heterogeneous
group of specialists, will approach 6 main lines of re-
search, which aim to contribute to the better defini-
tion of clinical, diagnostic and treatment strategies.
We collaborate with other research groups, to study
clinical and prognostic usefulness tests in cardiolo-
gy, to develop new strategies for the treatment and
diagnosis of infectious diseases, and to investigate
new antibiotics with the pneumology group.
We develop a new and pioneering line of imagingdiag-
nostic, with the line of emergency ultrasound, being
national referents in research in this field, in which
we have the active support of private enterprise.
We will investigate the possibility of supporting us in
new technologies that help the clinician in the deci-
sion making in the field of the treatment of the dia-
betes, impelling global initiatives both at the hospital
and the population level.
Finally, we will develop a line of toxicological re-
search, focusing both on the early recognition of the
237
 3
Information Groups by Area

3.4 Large System Pathologies Area

intoxicated patient, as well as their adequate treatment,
in collaboration with the clinical toxicology unit (CTU),
with the aim of becoming a national reference center in
the Management of the intoxicated patient, as well as in
the development of protocols of attention to multiple
victims of biological attack.
• Prados C, Lerín M, Cabanillas JJ, Gómez-Carrera L, Álvarez-Sala R.
How are the ancient cystic fibrosis patients? Cystic fibrosis diagno-
sed over 60 years-old. Respir Med Case Rep. 2017; 21: 49-51.Article.
Not Indexed
• Tung-Chen Y, Álvarez GG, Carballo-Cardona C. Swollen arms due
to acute rhabdomyolysis: An easily missed diagnosis. Med Clin-Bar-
celona. 2017; 148(11): 527-8. Letter. IF: 1.168; Q3
• Tung-Chen Y, Carballo-Cardona C. Nontuberculous mycobacteria
Carballo Cardona C. Revisión de la implantación de la
ecografía clínica en un hospital terciario. GE Healthcare.
2017-Ongoing.
Managment centre: FIBHULP
Carballo Cardona C. Sesiones formativas científicas de dia-
betes en el proyecto de investigación “Hospital Sin Azúcar”.
Astrazeneca Farmaceutica Spain S.A. 2016-Ongoing.
inhalado, en comparación con el protocolo actual para el
tratamiento del dolor de origen traumático, en adultos aten-
didos en unidades de urgencias españolas. Type: Clinical Trial,
phase IIIb.
HULP code: 4803. Sponsored´s protocol code: InMEDIATE.
Sponsored by: Mundipharma Pharmaceuticals S.L.
Signed date: 31/05/2017

Research Lines infection after aesthetic surgery. Med Clin-Barcelona. 2017; 149(5): Managment centre: FIBHULP

• Integral management of the treatment and follow-up

227-8. Letter. IF: 1.168; Q3
• Yusuf E, Ong DSY, Martín-Quirós A, Skevaki C, Cortez J, Dedic K,
Patents and Trademarks
of the diabetic patient. Maraolo AE, Dusek D, Maver PJ, Sanguinetti M, Tacconelli E. A large CLINICAL TRIALS Carballo Cardona C; author; FIBHULP, assignee. Trademark
• Emergency ultrasound. survey among European trainees in clinical microbiology and infec- name: Diagether. CM15869911, 2016 September 29.
Carballo Cardona C. Ensayo clínico fase IIIb, aleatorizado,
• Care of infectious diseases in the emergency room. tious disease on training systems and training adequacy: identifying
abierto, para evaluar el alivio del dolor con metoxiflurano
the gaps and suggesting improvements. Eur J Clin Microbiol. 2017;
• Optimization of the management of the acute intoxi-
36(2): 233-42. Article. IF: 2.537; Q2
cated patient and use of chemical substances for terro-
rist purposes.
• Attention to cardiovascular pathology of emergencies. Public Projects
• Attention to respiratory pathology.
Carballo Cardona C. Evaluación de la probabilidad clínica
pre-test de cardiopatía isquémica en pacientes con DTA en
los servicios de urgencias. Proyecto MAPAC-CARDIOTC
Research Activity (PI16/01045). ISCIII. 2017-2019.
Managment centre: FIBHULP
PUBLICATIONS
• Álvarez E, Toledano V, Morilla F, Hernández-Jiménez E, Cubillos-Za-
pata C, Varela-Serrano A, Casas-Martín J, Avendaño-Ortiz J, Aguirre
Private Projects
LA, Arnalich F, Maroun-Eid C, Martín-Quirós A, Díaz MQ, López- Carballo Cardona C. Adecuación de las dosis de HBPM me-
Collazo E. A system dynamics model to predict the human monocy- diante la monitorización de los niveles de factor anti-XA
te response to endotoxins. Front Immunol. 2017; 8: 915. Article. IF: en pacientes que reciben tromboprofilaxis ampliada desde
5.511; Q1 urgencias. Laboratorios Farmacéuticos Rovi S.A. 2013-On-
• Chen YT, Candalija AC, Lerín M, Siles JC, Cardona CC. On D-dimer going.
level and the Wells scale: a case of unexpected pulmonary throm-
Managment centre: FIBHULP
boembolism. Emergencias. 2017; 29(3): 204. Letter. IF: 3.608; Q1
• Chen YT, Saleh WE. Usefulness of bedside ultrasound in body pac-
ker syndrome. Emergencias. 2017; 29(6): 432-3. Letter. IF: 3,608; Q1
• Galán CD, Miranda BR, del Castillo JG, Grinspan MSR, Carballo C,
Guillén CB, Artillo S, Miro O, Martín-Sánchez FJ. Physical structure,
human resources, and health care quality indicators in public
hospital emergency departments in the autonomous communities
of Madrid and Catalonia: a comparative study. Emergencias. 2017;
29(6): 373-83. Article. IF: 3.608; Q1
• Maraolo AE, Ong DSY, Cortez J, Dedic K, Dusek D, Martín-Quirós
A, Maver PJ, Skevaki C, Yusuf E, Poljak M, Sanguinetti M, Tacconelli
E. Personal life and working conditions of trainees and young spe-
cialists in clinical microbiology and infectious diseases in Europe:
a questionnaire survey. Eur J Clin Microbiol. 2017; 36(7): 1287-95.
Article. IF: 2.537; Q2
• Negredo A, de la Calle-Prieto F, Palencia-Herrejón E, Mora-Rillo M,
Astray-Mochales J, Sánchez-Seco MP, López EB, Menárguez J, Fer-
nández-Cruz A, Sánchez-Artola B, Keough-Delgado E, de Arellano
ER, Lasala F, Milla J, Fraile JL, Gavin MO, de la Gandara AM, Pérez LL,
Díaz-Díaz D, López-García MA, Delgado-Jiménez P, Martín-Quirós
A, Trigo E, Figueira JC, Manzanares J, Rodríguez-Baena E, García-
Comas L, Rodríguez-Fraga O, García-Arenzana N, Fernández-Díaz
MV, Cornejo VM, Emmerich P, Schmidt-Chanasit J, Arribas JR. Auto-
chthonous Crimean-Congo hemorrhagic fever in Spain. New Engl J
Med. 2017; 377(2):154-61. Article. IF: 79.258; D1

238 239
 3
Information Groups by Area

3.5 INGEMM- Institute of Medical

and Molecular Genetics Group
Cancer
and
Human
Molecular
Genetics 34 101.026 11

Area
Pablo Daniel Lapunzina Badía. Coordinador INGEMM Víctor Manuel Martínez González. Investigador Postdoctoral.
Genetista. HULP HULP
Amparo Cano García Cinthia Amiñoso Carbonero. Técnico de Laboratorio. HULP Isabel Martínez María. Enfermera. HULP
Pedro Arias Lajara. Técnico de Laboratorio. HULP María Cruz Martínez Martínez. Técnico de Laboratorio. HULP
Veronica Barca Tierno. Investigadora Predoctoral. HULP Paloma Martínez Montero. Facultativo Especialista de Área en
183 904.712 Análisis Bioquímicos. HULP
Eva Barroso Ramos. Investigadora Postdoctoral. HULP
153 794.333 Alberta Belinchón Martínez. Investigadora Postdoctoral. HULP
Sonia María Martínez Novoa. Facultativo Especialista de Área.
Responsable del Laboratorio de Genética de Enfermedades Metabólicas.
18.03% 48.09% Sara Benito Sanz. Investigadora Postdoctoral. HULP HULP
Angel Campos Barros. Investigador Senior (Contrato Miguel Servet- Jesús Molano Mateos. Jefe de Sección. HULP
I2). Jefe de Laboratorio. HULP
María Ángeles Mori Álvarez. Bioquímico Adjunto. HULP
INGEMM- Institute of Medical and Molecular Felipe de Frutos Pérez María. Técnico de Laboratorio. HULP
Julián Nevado Blanco. Biólogo. HULP
Genetics Group Angela del Pozo Mate. Técnico Informático. HULP
María Palomares Bralo. Bióloga. HULP
Alicia Delicado Navarro. Genetista. HULP
María Sol Pérez Coto. Técnico de Laboratorio. HULP
Translational Oncology Group María Ángeles Domínguez Díaz. Técnico de Laboratorio. HULP
Teresa Ramos Álvarez. Enfermera. HULP
Begoña Ezquieta Zubicaray. Bioquímico Adjunto. HULP
Experimental Therapies and Biomarkers in Cancer Group Luis Fernández García-Moya. Biólogo. HULP
Víctor Luis Ruiz Pérez. Investigador Postdoctoral. IIB “Alberto Sols”
Carmen Sánchez Gómez. Técnico de Laboratorio. HULP
Oto-Neurosurgery Research Group Blanca Nieves Fernández Martínez. Técnico de Laboratorio. Fernando Santos Simarro. Médico Adjunto de Pediatría. HULP
HULP
Juan Carlos Silla Castro. Bioinformático de Sistemas. HULP
Cancer Molecular Pathology and Therapeutic Targets Group María Victoria Fernández Montaña. Técnico de Laboratorio.
Jesús Solera García. Facultativo Especialista de Área en Análisis
HULP
Bioquímicos. HULP
Mechanisms of Tumour Progression Group Amparo García Cardenal. Técnico de Laboratorio. HULP
Constanza Solis Villa. Farmacéutica Adjunto. HULP
Fe Amalia García Santiago. Bióloga. HULP
Animal and Cell Models for Detection and Sixto García-Miñaur Rica. Genetista. HULP
María Luisa de Torres Pérezhidalgo. Bióloga Adjunto. HULP

Characterization of Leukemic Stem Cells Group Isabel Gómez Nieto. Técnico de Laboratorio. HULP

Research and Diagnosis of Inherited Metabolic Diseases
Group
Regulation of Ciliary Structure and Function by
Phosphoinositides Group
Onco-Hematology Research Group (HUF)
240
Héctor González-Pecellín Rosa. Técnico de Laboratorio. HULP
Karen Elise Heath . Investigadora Senior (Contrato Ramón y Cajal -
I3). Jefa de Laboratorio. HULP
Alicia Llorente Alonso. Técnico de Laboratorio. HULP
Teresa López Timénez. Técnico de Laboratorio. HULP
María Elena Mansilla Aparicio. Genetista. HULP
María Soledad Martín Rodríguez. Técnico de Laboratorio. HULP
Pilar Martínez González. Bióloga. HULP
Strategic Objective
This is a clinical and basic research team that con-
ducts several lines of research into early diagnosis,
disease mechanisms and new therapeutic strategies
for genetic diseases, developmental disorders and
congenital defects.
It is a heterogeneous group consisting of physicians,
pharmacists, molecular biologists, bioinformaticians,
technicians and administrative officers.
241
 3
Information Groups by Area
3.5 Cancer and Human Molecular Genetics Area
Research Lines
• Subtelomeric rearrangements in patients with idio-
pathic mental retardation.
• Genetic and functional analysis of the SHOX and
SHOX2 genes in human growth.
• Overgrowth syndromes. Clinical and molecular analysis.
• Genetic aspects of harmonic short stature.
• Genetic aspects of monogenic diabetes mellitus.
• Genetics of the GHrelin axis in infantil onset obesity.
• SNPs arrays in pharmacogenetics of HIV patients.
• CGHarrays and genomic rearrangements in patients
with congenital malformations, intelectual disability
and tumores.
• Molecular genetics of hypertrophic myocardiopathy.
• Functional analysis of CLCN1 mutations in congenital
myotonia.
• Molecular study of endothelial dysfunction in diabetes
and ageing.
• Molecular characterization of the 22q11.2 región by
MLPA, microsatélites and FISH.
• Pharmacogenetics and pharcogenomics.
• Autosomal recessive osteogénesis imperfecta.
• Genomic tools for diagnosis: BAC, oligos and SNP
arrays.
• Macrocephaly-capillary malformations and syndromes
with macrocephaly.
• Next generation sequencing as a new tool in the diag-
nosis of genetic diseases.
• Dravet syndrome.
Research Activity
PUBLICATIONS
• Altmuller F, Lissewski C, Bertola D, Flex E, Stark Z, Spranger S, Bay-
nam G, Buscarilli M, Dyack S, Gillis J, Yntema HG, Pantaleoni F, van
Loon RLE, MacKay S, Mina K, Schanze I, Tan TY, Walsh M, White SM,
Niewisch MR, García-Miñaur S, Plaza D, Ahmadian MR, Cave H, Tar-
taglia M, Zenker M. Genotype and phenotype spectrum of NRAS
germline variants. Eur J Hum Genet. 2017; 25(7): 823-31. Article. IF:
3.636; Q2
• Andrade RC, dos Santos ACE, Neto JCD, Nevado J, Lapunzina P,
Vargas FR. TP53 and CDKN1A mutation analysis in families with Li-
Fraumeni and Li-Fraumeni like syndromes. Fam Cancer. 2017;1 6(2):
243-8. Article. IF: 1,943; Q3
• Barraza-García J, Rivera-Pedroza CI, Hisado-Oliva A, Belinchón-
Martínez A, Sentchordi-Montane L, Duncan EL, Clark GR, del Pozo
A, Ibáñez-Garikano K, Offiah A, Prieto-Matos P, Cormier-Daire V,
Heath KE. Broadening the phenotypic spectrum of POP1-skeletal
dysplasias: identification of POP1 mutations in a mild and severe
skeletal dysplasia. Clin Genet. 2017; 92(1): 91-8. Article. IF: 3.512; Q2
• Benito-Sanz S, Belinchón-Martínez A, Aza-Carmona M, de la Torre
C, Huber C, González-Casado I, Ross JL, Thomas NS, Zinn AR,
Cormier-Daire V, Heath KE. Identification of 15 novel partial SHOX
deletions and 13 partial duplications, and a review of the literature
reveals intron 3 to be a hotspot region. J Hum Genet. 2017; 62(2):
229-34. Review. IF: 2.942; Q2
• Blanco-Kelly F, Palomares M,Vallespín E,Villaverde C, Martín-Arenas
R, Vélez-Monsalve C, Lorda-Sánchez I, Nevado J, Trujillo-Tiebas MJ,
Lapunzina P, Ayuso C, Corton M. Improving molecular diagnosis of
aniridia and WAGR syndrome using customized targeted array-
242
based CGH. Plos One. 2017; 12(2): e0172363. Article. IF: 2.766; Q1
• Blanco-Lago R, Malaga-Diéguez I, Granizo-Martínez JJ, Carrera-
García L, Barruz-Galián P, Lapunzina P, Nevado-Blanco J. Wolf-Hirs-
chhorn syndrome. Description of a Spanish cohort of 51 cases and
a literature review. Rev Neurología. 2017; 64(9): 393-400. Review. IF:
0.601; Q4
• Caparrós-Martín JA, Aglan MS, Temtamy S, Otaify GA, Valencia M,
Nevado J, Vallespín E, del Pozo A, de Castro CP, Calatrava-Ferreras
L, Gutiérrez P, Bueno AM, Sagastizabal B, Guillén-Navarro E, Balles-
ta-Martínez M, González V, Basaran SY, Buyukoglan R, Sarikepe B,
Espinoza-Valdéz C, Cammarata-Scalisi F, Martínez-Glez V, Heath
KE, Lapunzina P, Ruiz-Pérez VL. Molecular spectrum and differential
diagnosis in patients referred with sporadic or autosomal recessive
osteogenesis imperfecta. Mol Genet Genomic Med. 2017; 5(1): 28-
39. Article. IF: 2.695; Q2
• García M, Barrio R, García-Lavandeira M, García-Rendueles AR, Es-
cudero A, Díaz-Rodríguez E, del Blanco DG, Fernández A, de Rijke
YB, Vallespín E, Nevado J, Lapunzina P, Matre V, Hinkle PM, Hokken-
Koelega ACS, de Miguel MP, Cameselle-Teijeiro JM, Nistal M, Álvarez
CV, Moreno JC. The syndrome of central hypothyroidism and ma-
croorchidism: IGSF1 controls TRHR and FSHB expression by diffe-
rential modulation of pituitary TGF beta and Activin pathways. SCI
Rep-Uk. 2017; 7: 42937. Article. IF: 4.122; Q1
• García-Morato MB, García-Miñaur S, Garicano JM, Simarro FS,
Molina LDP, López-Granados E, Cerdán AF, Peña RR. Mutations in
PIK3R1 can lead to APDS2, SHORT syndrome or a combination of
the two. Clin Immunol. 2017; 179: 77-80. Article. IF: 3.557; Q2
• García-Morato MB, Nevado J, González-Granado LI, Urgelles AS,
Peña RR, Cerdán AF. Chronic granulomatous disease caused by
maternal uniparental isodisomy of chromosome 16. J Allergy Clin
Immunol Pract. 2017; 5(4): 1146-8. Letter. IF: 6.966; D1
• Gkourogianni A,Andrew M,Tyzinski L, Crocker M, Douglas J, Dunbar
N, Fairchild J, Funari MFA, Heath KE, Jorge AAL, Kurtzman T, LaFran-
chi S, Lalani S, Lebl J, Lin YZ, Los E, Newbern D, Nowak C, Olson M,
Popovic J, Pruhova S, Elblova L, Quintos JB, Segerlund E, Sentchordi
L, Shinawi M, Stattin EL, Swartz J, del Ángel AG, Cuellar SD, Hosono
H, Sánchez-Lara PA, Hwa V, Baron J, Nilsson O, Dauber A. Clinical
characterization of patients with autosomal dominant short stature
due to Aggrecan mutations. J Clin Endocr Metab. 2017; 102(2): 460-
9. Article. IF: 5.789; Q1
• Gómez-González C, Esteban-Rodríguez MI, Ruano Y,Vallespín E, La-
punzina P, Martínez P, Pascual SI, Molano J, Prior C. Molecular diag-
nosis of limb-girdle muscular dystrophy type 2A by next-generation
sequencing. Ann Indian Acad Neur. 2017; 20(2): 164-5. Letter. IF:
1.131; Q4
• Ibarra-Ramírez M, Campos-Acevedo LD, Lugo-Trampe J, Martínez-
Garza LE, Martínez-Glez V, Valencia-Benítez M, Lapunzina P, Ruiz-
Pérez V. Phenotypic variation in patients with homozygous c.1678G
> T mutation in EVC gene: Report of two mexican families with
Ellis-van Creveld syndrome. Am J Case Rep. 2017; 18: 1325-9. Arti-
cle. Not Indexed
• Kalish JM, Biesecker LG, Brioude F, Deardorff MA, Di Cesare-Merlo-
ne A, Druley T, Ferrero GB, Lapunzina P, Larizza L, Maas S, Macchiaio-
lo M, Maher ER, Maitz S, Martínez-Agosto JA, Mussa A, Robinson P,
Russo S, Selicorni A, Hennekam RC. Nomenclature and definition
in asymmetric regional body overgrowth. Am J Med Genet A. 2017;
173(7): 1735-8. Article. IF: 2.264; Q3
• Leiter SM, Parker VER, Welters A, Knox R, Rocha N, Clark G, Pay-
ne F, Lotta L, Harris J, Guerrero-Fernández J, González-Casado I,
García-Miñaur S, Gordo G, Wareham N, Martínez-Glez V, Allison M,
O’Rahilly S, Barroso I, Meissner T, Davies S, Hussain K, Temple K, Ba-
rreda-Bonis AC, Kummer S, Semple RK. Hypoinsulinaemic, hypoke-
totic hypoglycaemia due to mosaic genetic activation of PI3-kinase.
Eur J Endocrinol. 2017; 177(2): 175-86. Article. IF: 4.333; Q1
• Márquez-Rodas I, Lobo M, Flores-Sánchez C, Sanz M, Luque S, Liza-
rraga S, González-Asanza C, Pajares JA, Peligros MI, Bueno O, Mata
C, López C, López-Tarruella S, Jérez Y, Muñoz-Martin A, Blanco M,
Die-Trill M, Justel JP, Solera J, Martín M. Five years of multidisciplinary
care in hereditary cancer: Our experience in a Spanish university
hospital. Oncology-Basel. 2017; 92(2): 68-74. Article. Not Indexed
• Mediero S, Mardero OD, de los Bueis AB, Martín SN, García-Miñaur
S. Keratoconus associated with Williams-Beuren syndrome: a new
case report. Int J Ophthalmol-Chi. 2017; 10(4): 658-60. Letter. IF:
1,166; Q4
• Meerschaut I, Rochefort D, Revencu N, Petre J, Corsello C, Rouleau
GA, Hamdan FF, Michaud JL, Morton J, Radley J, Ragge N, García-Mi-
ñaur S, Lapunzina P, Bralo MP, Mori MA, Moortgat S, Benoit V, Mary S,
Bockaert N, Oostra A,Vanakker O,Velinov M, de Ravel TJL, Mekahli D,
Sebat J,Vaux KK, DiDonato N, Hanson-Kahn AK, Hudgins L, Dallapic-
cola B, Novelli A, Tarani L, Andrieux J, Parker MJ, Neas K, Ceulemans
B, Schoonjans AS, Prchalova D, Havlovicova M, Hancarova M, Budis-
teanu M, Dheedene A, Menten B, Dion PA, Lederer D, Callewaert B.
FOXP1-related intellectual disability syndrome: a recognisable entity.
J Med Genet. 2017; 54(9): 613-23. Article. IF: 5.751; Q1
• Palencia-Campos A, Ullah A, Nevado J, Yildirim R, Unal E, Ciorraga
M, Barruz P, Chico L, Piceci-Sparascio F, Guida V, de Luca A, Kayse-
rili HL, Ullah I, Burmeister M, Lapunzina P, Ahmad W, Morales AV,
Ruiz-Pérez VL. GLI1 inactivation is associated with developmental
phenotypes overlapping with Ellis-van Creveld syndrome. Hum Mol
Genet. 2017; 26(23): 4556-71. Article. IF: 4.902; Q1
• Palomares-Bralo M,Vallespín E, del Pozo A, Ibáñez K, Silla JC, Galán E,
Gordo G, Martínez-Glez V,Alba-Valdivia LI, Heath KE, García-Miñaur
S, Lapunzina P, Santos-Simarro F. Pitfalls of trio-based exome se-
quencing: imprinted genes and parental mosaicism-MAGEL2 as an
example. Genet Med. 2017; 19(11): 1283-5. Letter. IF: 9.937; D1
• Peces R, Afonso S, Peces C, Nevado J, Selgas R. Living kidney trans-
plantation between brothers with unrecognized renal amyloidosis
as the first manifestation of familial Mediterranean fever: a case re-
port. BMC Med Genet. 2017; 18: 97. Article. IF: 1.913; Q3
• Rivera-Pedroza CI, Barraza-García J, Paumard-Hernández B, Ne-
vado J, Orbea-Gallardo C, del Pozo JS, Heath KE. Chromosome
1p31.1p31.3 deletion in a patient with craniosynostosis, central
cervous system and renal malformation: Case report and review of
the literature. Mol Syndromol. 2017; 8(1): 30-5. Article. Not Indexed
• Rodríguez F,Vallejos C, Giraudo F, Unanue N, Hernández MI, Godoy
P, Celis S, Martín-Arenas R, Palomares-Bralo M, Heath KE, López
MT, Cassorla F. Copy number variants of Ras/MAPK pathway genes
in patients with isolated cryptorchidism. Andrology-Us. 2017; 5(5):
923-30. Article. IF: 2.734; Q2
• Rodríguez-Jiménez C, Santos-Simarro F, Campos-Barros A, Camare-
na C, Lledin D, Vallespín E, del Pozo A, Mena R, Lapunzina P, Rodrí-
guez-Novoa S. A new variant in PHKA2 is associated with glycogen
storage disease type IXa. Mol Genet Metab Rep. 2017; 10:52-5. Ar-
ticle. Not Indexed
• Rodríguez-Zabala M, Aza-Carmona M, Rivera-Pedroza CI, Belinchón
A, Guerrero-Zapata I, Barraza-García J,Vallespín E, Lu M, del Pozo A,
Glucksman MJ, Santos-Simarro F, Heath KE. FGF9 mutation causes
craniosynostosis along with multiple synostoses. Hum Mutat. 2017;
38(11): 1471-6. Article. IF: 5.359; Q1
• Salas PC, Lapunzina P, Pérez-Martínez A. Genetic predisposition to
childhood cancer. An Pediatr. 2017; 87(3): 125-7. Editorial Material.
IF: 1.318; Q3
• Sánchez-Montenegro C, Vilanova-Sánchez A, Barrena-Delfa S, Te-
norio J, Santos-Simarro F, García-Miñaur S, Lapunzina P, Martínez-
Martínez L. Costello syndrome and umbilical ligament rhabdom-
yosarcoma in two pediatric patients: Case reports and review of
the literature. Case Rep Genet. 2017; 2017: 1587610. Article. Not
Indexed
• Santos-Simarro F, Vallespín E, del Pozo A, Ibáñez K, Silla JC, Fer-
nández L, Nevado J, González-Pecellín H, Montano VEF, Martín R,
Valdivia LA, García-Miñaur S, Lapunzina P, Palomares-Bralo M. Eye
coloboma and complex cardiac malformations belong to the clinical
spectrum of PUF60 variants. Clin Genet. 2017; 92(3): 350-1. Letter.
IF: 3.512; Q2
• Tardivo A, Masotto B, Espeche L, Solari AP, Nevado J, Rozental S.
16p11.2 microdeletion: first report in Argentina. Arch Argent Pedia-
tr. 2017; 115(6): E449-53. Article. IF: 0.405; Q4
• Tenorio J, Álvarez I, Riancho-Zarrabeitia L, Martos-Moreno GA,
Mandrile G, Crespo MD, Sukchev M, Sherif M, Kramer I, Darnaude-
Ortiz MT, Arias P, Gordo G, Dapia I, Martínez-Villanueva J, Gómez
R, Iturzaeta JM, Otaify G, García-Unzueta M, Rubinacci A, Riancho
JA, Aglan M, Temtamy S, Hamid MA, Argente J, Ruiz-Pérez VL, Heath
KE, Lapunzina P. Molecular and clinical analysis of ALPL in a cohort
of patients with suspicion of Hypophosphatasia. Am J Med Genet A.
2017; 173(3): 601-10. Article. IF: 2.264; Q3
• Teresa MAG, Abal RP, Torres SR, Urabayen DG, Martínez SG, Trang
H, Barros AC. Spanish patients with central hypoventilation syndro-
me included in the European Registry. The 2015 data. An Pediatr.
2017; 86(5): 255-63. Article. IF: 1.318; Q3
• Vasques GA, Hisado-Oliva A, Funari MFA, Lerario AM, Quedas EPS,
Solberg P, Heath KE, Jorge AAL. Long-term response to growth hor-
mone therapy in a patient with short stature caused by a novel
heterozygous mutation in NPR2. J Pediatr Endocr Met. 2017; 30(1):
111-6. Article. IF: 1.086; Q4
• Villarejo-López L, Jiménez E, Bartolomé-Martin D, Zafra F, Lapunzi-
na P, Aragón C, López-Corcuera B. P2X receptors up-regulate the
cell-surface expression of the neuronal glycine transporter GlyT2.
Neuropharmacology. 2017; 125: 99-116. Article. IF: 4.249; Q1
• Writzl K, Maver A, Kovacic L, Martínez-Valero P, Contreras L, Sa-
trustegui J, Castori M, Faivre L, Lapunzina P, van Kuilenburg ABP,
Radovic S,Thauvin-Robinet C, Peterlin B, del Arco A, Hennekam RC.
de Novo Mutations in SLC25A24 cause a disorder characterized by
early aging, bone dysplasia, characteristic face, and early demise. Am
J Hum Genet. 2017; 101(5): 844-55. Article. IF: 8.855; D1
Public Projects
Aparicio Herranz V. Contrato de garantía juvenil (PEJ15/BIO/
AI-045). CAM. 2016-2018.
Managment centre: FIBHULP
Barroso Ramos E. Identificación de nuevos genes respon-
sables del síndrome de Dravet y de espectros asociados de
encefalopatías epilépticas febriles (PI14/01753). ISCIII. 2015-
2017.
Managment centre: FIBHULP
Campos Barros A. Aplicación de nuevas estrategias de análi-
sis genómico a la identificación de los determinantes genéti-
cos de la deficiencia idiopática de GH y deficiencia primaria
de IGF-I en hipocrecimiento (PI12/00649). ISCIII. 2013-2017.
Managment centre: FIBHULP
Campos Barros A. Contrato de Estabilización Miguel Servet
(I2). ISCIII/CAM. 2008-2025.
Managment centre: FIBHULP
Dapia García I. Contrato de garantía juvenil (PEJ15/BIO/AI-
0222). CAM. 2016-2018.
Managment centre: FIBHULP
del Pozo Amate A. Determinación de la expresión alélica
específica para establecer la patogenicidad de las variantes
genómicas determinadas por NGS en pacientes con cardio-
patías congénitas (PI16/01444). ISCIII. 2017-2019.
Managment centre: FIBHULP
Fernández Elvira M. Contrato de garantía juvenil (PEJ15/
BIO/TL-0158). CAM. 2016-2018.
243
 3
Information Groups by Area
3.5 Cancer and Human Molecular Genetics Area
Managment centre: FIBHULP
García Santiago FA. Desarrollo de la detección de aneu-
ploidias fetales en sangre materna mediante secuenciación
masiva (PI13/01964). ISCIII. 2014-2017.
Managment centre: FIBHULP
Heath KE. Identificación y caracterización funcional de nue-
vos genes y Loci genomicos implicados en displasias esquelé-
tica (SAF2015-66831-R). MINECO. 2016-2017.
Managment centre: FIBHULP
Heath KE. Contrato de Estabilización Ramón y Cajal (I3).
CAM. 2009-2025.
Managment centre: FIBHULP
Lapunzina Badia PD. Búsqueda de nuevos genes y nuevas
patologías mediante la aplicación de secuenciación masiva
en una cohorte de pacientes con síndromes de sobrecreci-
miento bien caracterizados clínicamente (PI15/01481). ISCIII.
2016-2018.
Managment centre: FIBHULP
Lobato Vidal N. Contrato de garantía juvenil (PEJ15/BIO/
AI-0286). CAM. 2016-2018.
Managment centre: FIBHULP
Palomares Bralo M. Secuenciación del exoma para el diag-
nóstico de niños con trastorno del desarrolllo neurólogico
o discapacidad intelectual severa-moderada (PI13/02010).
ISCIII. 2014-2017.
Managment centre: FIBHULP
Rodríguez Novoa S. Diagnóstico genético de hipercolestero-
lemia familiar mediante next generation sequencing: estudio
funcional de nuevas variantes.Transcriptómica y miRNAs y su
impacto en el fenotipo (PI15/00122). ISCIII. 2016-2018.
Managment centre: FIBHULP
Santos Simarro F. Clinical characterization and molecu-
lar genetic analysis of the baf complex related syndromes
(PI14/01922). ISCIII. 2015-2017.
Managment centre: FIBHULP
Private Projects
Campos Barros A. Análisis genético de la deficiencia idiopá-
tica de GH y deficiencia primaria de IGF-1 en talla baja. Ipsen
Pharma SPS. 2012-Ongoing.
Managment centre: FIBHULP
Heath KE. Estudio comprensivo de la genética de las displa-
sias esqueléticas. Biomarin International Limited . 2017-On-
going.
Managment centre: FIBHULP
Lapunzina Badía PD. Análisis genético y genómico en pa-
cientes afectados por la enfermedad de Gorham-Stout y
por anomalías generales. Limphatic Malformation Institute.
2012-Ongoing.
Managment centre: FIBHULP
Lapunzina Badía PD. Análisis genómico global en el sin-
drome de Invdupdel (8p): evaluación de la dosis genómica
mediante microarrays personalizados de SNPS y estudio de
genes candidatos del fenotipo. Asdid. 2015-Ongoing.
Managment centre: FIBHULP
244
Lapunzina Badía PD. Análisis genómico global en el sín- nóstico rápido y eficaz de las patologías de origen genético. Lapunzina Badía PD. Screening of high-risk pediatric po-
drome de Sotos: evaluación de la dosis genómica mediante Construcción de un centro de excelencia de investigación pulation using an epilepsy gene panel for early diagnosis of
microarrays personalizados de SNPS y estudio de genes can- en bioinformática que permita el desarrollo de la tecnología neuronal ceroid lipofuscinosis type 2 (CLN2) disease.Varios.
en proyectos de investigación que mediante la implantación 2017-Ongoing.
didatos mediante secuenciación masiva de nueva generación
de sistemas de secuenciación de nueva generación que per-
en pacientes negativos para NSD1. Asociación Española del Managment centre: FIBHULP
Síndrome de Sotos. 2013-Ongoing. mita proporcionar diagnóstico avanzado a las patologías ge-
nética. Dravet Syndrome Foundation (Delegación en España). Nevado Blanco J. Aproximación genómica en el síndrome
Managment centre: FIBHULP de Phelanmc Dermid [síndrome de microdeleción 22Q13]:
2012-Ongoing.
Lapunzina Badía PD. Análisis global de la hipofosfatasia: eva- microarrays personalizados de SNPS y evaluación de los
Managment centre: FIBHULP
luación de la dosis genómica mediante MLPA y estudio del genes candidatos. Asociación Síndrome Phelan-Mcdermid.
gen ALPL en pacientes con sospecha clínica. Alexion Pharma Lapunzina Badía PD. Investigar y desarrollar un sistema diag- 2017-Ongoing.
Spain S.L. 2014-Ongoing. nóstico rápido y eficaz de las patologías de origen genético. Managment centre: FIBHULP
Managment centre: FIBHULP Construcción de un centro de excelencia de investigación en
Nevado Blanco J. Evaluación genómica en el síndrome de
bioinformática que permita el desarrollo de la tecnología en
Lapunzina Badía PD. Análisis mutacional del gen SCNA1 Wolf-Hirschhorn [sindrome 4p]: microarrays personalizados
proyectos de investigación que mediante la implantación de
en pacientes con diganóstico clínico de síndrome de Dravet. de SNPS y estudio de genes candidatos. Asociacion Española
sistemas de secuenciación de nueva generación que permita
Abyntek Biopharma S.L. 2011-Ongoing. del Síndrome de Wolf Hirschhom. 2017-Ongoing.
proporcionar diagnóstico avanzado a las patologías genéticas.
Managment centre: FIBHULP Managment centre: FIBHULP
CAM. 2013-Ongoing.
Lapunzina Badía PD. Determi- Managment centre: FIBHULP Rodríguez Novoa SM. Renalal tubular and markers of bone
nación genómica de muestras del turnover in HBV monoinfected patients during long term
Lapunzina Badía PD. Organización jornadas de investiga- tretament with entecavir or tenofovir. Bristol-Myers Squibb
biomarcador del gen KRAS y NRAS. ción: XXVII Congreso Nacional de la Asociación Española de International Corporation. 2011-Ongoing.
Amgen S.A. 2014-Ongoing. Genética Humana. Tilesa Kenes Spain S.L. 2013-Ongoing.
Managment centre: FIBHULP
Managment centre: FIBHULP Managment centre: FIBHULP
Solera García J. Estudio de microRNAs en pacientes con
Lapunzina Badía PD. Estudio clínico citogené- Lapunzina Badía PD. Patrocinio Jornadas de DNA day. Va- glucogenosis tipo II (enfermedad de Pompe) como marcado-
tico y molecular del síndrome de microdelección rios. 2012-Ongoing.
res de diagnóstico, progresión de la enfermedad y respuesta
22Q11,2 caracterización molecular de la región. Managment centre: FIBHULP
al tratamiento. Fundación Genzyme. 2013-Ongoing.
Genycell Biotech España S.L. 2013-Ongoing.
Managment centre: FIBHULP
Managment centre: FIBHULP
Lapunzina Badía PD. Estudio clínico
molecular en pacientes con síndrome Patents and Trademarks
de sobrecrecimiento (SSC). Estu- Friedman S, Li D, Narla G, Martignetti J, Heath K, inven-
dio de los genes NCD1, NIZP1, tors; Mount Sinai School of Medicine, assignee; Kruppel-like
HRAS, CDKN1C, GLP3, y de factor 6 (klf6), a tumor suppressor protein, and diagnostics,
las regiones cromosómi- therapeutics, and screening based on this protein. PCT/
cas 5Q35, XQ26 y 11P en US2001/025046, EP1332362, US2005181374, US2011059899,
pacientes con SSC. Effice AU8479001, CA2419064; 2000 August
Servicios para la Inves- 09.
tigación S.L. 2005-On-
going.
Managment centre:
FIBHULP
Lapunzina Badía PD.
Estudio genético-mole-
cular de genes candidatos
en pacientes con hiperten-
sión pulmonar idiopática.
Actelion Pharmaceuticals Es-
paña. 2011-Ongoing.
Managment centre: FIBHULP
Lapunzina Badía PD. Estudios citoge-
néticas y moleculares en población con
enfermedades de base genética en el Hos-
pital La Paz. Agilent Technologies Spain S.L.
2007-Ongoing.
Managment centre: FIBHULP
Lapunzina Badía PD. Genexpert (Gene
and Expert analysis). Microsoft Ibérica
S.L.R. 2017-Ongoing.
Managment centre: FIBHULP
Lapunzina Badía PD. Investigar
y desarrollar un sistema diag-
245
 3
Information Groups by Area
3.5 Cancer and Human Molecular Genetics Area
INGEMM, author; FIBHULP, assignee. Trademark name: IN-
GEMM Instituto de Genética Médica y Molecular del Hos-
pital Universitario La Paz; ESM 2.884.849, USM 77.891.143,
CM 8.746.869; 2009 July 16, 2009 December 11, 2009 De-
cember 10.
INGEMM, author; FIBHULP, assignee. Trademark name: Kar-
yoArray; USM 79.078.751, CM 8.512.907; 2010 January 07,
2009 August 27.
INGEMM, author; FIBHULP, assignee. Trademark name:
OverGrowthArray; ESM 2.958.709-3, USM 85.334.932, CM
10.009.256; 2010 December 02, 2011 June 01, 2011 May 31.
INGEMM, author; FIBHULP, assignee. Trademark name: Meta-
bolArray; ESM 2.958.711-5, USM 85.334.903, CM 10.009.348;
2010 December 02, 2011 June 01, 2011 May 31.
Palomares M, Lapunzina P, Nevado J, Vallespín E, Vallcorba
I, Melero J, authors; FIBHULP, Hospital Infanta Cristina (Ba-
dajoz) Fundesalud, assignees. Trademark name: OncoHema-
toArray; ESM 2.958.703-4, USM 85.334.842, CM 10.009.181;
2010 December 02, 2011 June 01, 2011 May 31.
246
INGEMM, author; FIBHULP, assignee. Trademark name: On-
coArray; ESM 2.962.910, USM 85.363.107, CM 10.091.882;
2011 January 05, 2011 July 05, 2011 July 01.
Lapunzina P, Nevado J, Solera J, Vallespín E, Martínez P,
Martínez-González V, authors; FIBHULP, assignee.Trademark
name: ONCOSeq; USM 85.457.843, CM 9.969.064; 2011 Oc-
tober 27, 2011 May 16.
Moreno JC, Moya CM, Vallespín E, Lapunzina P, Nevado
J, authors; FIBHULP, assignee. Trademark name: ThyroArray;
USM 85.686.688, CM 10.904.951; 2012 July 25, 2012 May 23.
Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ,
Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R,
authors; FIBHULP, UAM, assignees. Trademark name: Phar-
mArray; USM 86.004.412, CM 11.608.403; 2013 July 08, 2013
February 27.
Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán
AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Da-
pia García I, Muñoz M, authors; FIBHULP, UAM, assignees.
Trademark name: ClinPharmarray., CM15489511; 2016 May
31, 2016 September 07.
Translational Oncology Group
41 166.782 22
Jaime Feliú Batlle. Jefe de Servicio de Oncología Médica. HULP.
Profesor Titular de Oncología. UAM
Strategic Objective
Jorge Barriuso Feijoó. Facultativo Especialista de Área en Oncología.
HULP
Borja Belandía Gómez. Científico Titular. IIB Alberto Sols
Beatriz Castelo Fernández. Facultativo Especialista de Área en
Oncología. HULP
Paloma Cejas Guerrero. Investigadora Postdoctoral. HULP
Roberto Crespo San Pedro. Técnico Superior en Anatomía
Patológica. HULP
Ana Belén Custodio Carretero. Facultativo Especialista de Área
en Oncología. HULP
Enrique Espinosa Arranz. Facultativo Especialista de Área en
Oncología. HULP. Profesor Asociado. UAM
Juan Angel Fresno Vara. Investigador Senior (Contrato Miguel Servet
- I2). Jefe de Laboratorio. HULP
Angelo Gámez Pozo. Investigador Postdoctoral. HULP
Ismael Ghanem Cañete. Médico Adjunto en Oncología Médica. HULP
Victoria María Heredia Soto. Investigador Postdoctoral. HULP
Juan Carlos Lacal Sanjuan. Profesor de Investigación. IIB Alberto
Sols
Rocío López Vacas. Técnico de Laboratorio. HULP
Virginia Martínez Marín. Facultativo Especialista de Área en
Oncología. HULP
Ignacio Palmero Rodríguez. Científico Titular. IIB Alberto Sols
Álvaro Pinto Marín. Facultativo Especialista de Área en Oncología.
HULP
Andrés Redondo Sánchez. Facultativo Especialista de Área en
Oncología. HULP. Profesor Asociado. UAM
Nuria Rodríguez Salas. Facultativo Especialista de Área en
Oncología. HULP
Pilar Zamora Auñon. Facultativo Especialista de Área en Oncología.
HULP. Profesor Asociado. UAM
The aim of cancer research is to improve unders-
tanding of all aspects of the disease, including deepe-
ning our understanding of the biology of the tumour,
developing new treatments, analysing the efficacy of
diagnostic tests and performing studies aimed at pre-
vention and early diagnosis.
The Translational Oncology group’s objective is to
conduct highly scientific applied research in such a
way that basic research can be rapidly translated to
clinical practice. In other words, cancer patients at La
Paz University Hospital benefit almost immediately
from the results of research conducted by their own
physicians.
Although important advances have been made in
recent years in our understanding of the origin and
evolution of cancer, their implementation in healthca-
re takes too much time. The Translational Oncology
Unit (TOU) was established with the objective of
facilitating the incorporation into clinical practice of
new advances in molecular biology and the technolo-
gy developed in this field.
The main lines of study are based on tumours with
the greatest incidence and impact on survival, such as
lung, colorectal, breast and ovarian cancer, although
other types of neoplasms have been incorporated
such as gastric and renal cancer. A series of funda-
mental objectives have been established for these
neoplasms that can be summarised as early diagno-
sis, molecular classification for therapeutic goals and
the search for individualised treatments.The majority
of TOU projects have as their primary objective the
search for predictors of susceptibility or resistance
to anticancer agents and the search for prognostic
factors related to the evolution of the tumour.
247
 3
Information Groups by Area
3.5 Cancer and Human Molecular Genetics Area
Research Lines
• Identification of prognostic factors Clinical Genomic
Proteomic.
• Identification of mechanisms of resistance to drugs.
• Efficacy and toxicity of antineoplastic therapies.
• Palliative care and supportive treatments.
Research Activity
Doctoral TheseS
Casado Abad MG. Evaluación de la implantación de un
sistema de trazabilidad mediante lectura de código de
barras en el proceso farmacoterapéutico del paciente
oncológico[dissertation]. Madrid: UAM: 2017(01/05/2017).
Directors: Zamora Auñon P, Romero JA, Benedi J.
Díaz Almirón M. Desarrollo del algoritmo CAPRI para la
estimación de la abundancia de complejos enzimáticos y su
aplicación en la modelización del metabolismo en cáncer de
mama[dissertation]. Madrid: UAM: 2017(15/09/2017).
Directors: Gámez-Pozo A, Fresno Vara JA.
Martínez Jáñez N. Estudio de concordancia entre el 8-Gene
Score y otros test moleculares comerciales (Mammaprint,
Oncotype DX) para decidir la necesidad de quimiotera-
pia adyuvante en pacientes con cáncer de mama positivo
para receptores hormonales[dissertation]. Madrid: UAM:
2017(22/06/2017).
Directors: Espinosa Arranz E, Carrato Mena A.
Prieto Muñoz I. Cáncer y diabetes: influencia del estado pro-
inflamatorio diabético en las características del cáncer de
colon[dissertation]. Madrid: UAM: 2017(26/06/2017).
Directors: Rodríguez Salas N, Cassinello Plaza F.
Vilches Aguirre Y. Desarrollo de un modelo predictivo de su-
pervivencia en pacientes con cáncer avanzado[dissertation].
Madrid: UAM: 2017(01/06/2017).
Directors: Alonso A, Feliú Batlle J.
PUBLICATIONS
• Ajani JA, Abramov M, Bondarenko I, Shparyk Y, Gorbunova V, Hontsa
A, Otchenash N, Alsina M, Lazarev S, Feliú J, Elme A, Esko V, Abdalla
K, Verma U, Benedetti F, Aoyama T, Mizuguchi H, Makris L, Rosati G.
A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluo-
rouracil/cisplatin in patients with untreated diffuse gastric cancer.
Ann Oncol. 2017; 28(9): 2142-8. Article. IF: 13.926; D1
• Algarra SM, Soriano V, Fernández-Morales L, Berciano-Guerrero
MA, Mujika K, Manzano JL, Hernández TP, Soria A, Rodríguez-Abréu
D, Arranz EE, Martínez JM, Márquez-Rodas I, Rubio-Casadevall J, Or-
tega ME, García JMJ, Biurrun MJL, Palacio I, Artacho MRD, Altozano
JP, Rubio VEC, García A, Luna P, Ballesteros A, Fernández O, Martín
JAL, Berrocal A, Arance A. Dabrafenib plus trametinib for compas-
sionate use in metastatic melanoma: A STROBE-compliant retros-
pective observational postauthorization study. Medicine. 2017;
96(52): e9523. Article. IF: 2.028; Q2
• Almhanna K, Wright D, Mercade TM, Laethem JL, Gracián AC, Gui-
llén-Ponce C, Faris J, López CM, Hubner RA, Bendell J, Bols A, Feliú
J, Starling N, Enzinger P, Mahalingham D, Messersmith W, Yang HY,
Fasanmade A, Danaee H, Kalebic T. A phase II study of antibody-
248
drug conjugate, TAK-264 (MLN0264) in previously treated patients
with advanced or metastatic pancreatic adenocarcinoma expressing
guanylyl cyclase C. Invest New Drug. 2017; 35(5): 634-41. Article. IF:
3.502; Q1
• Apellaniz-Ruiz M, Tejero H, Inglada-Pérez L, Sánchez-Barroso L,
Gutiérrez-Gutiérrez G, Calvo I, Castelo B, Redondo A, García-
Donas J, Romero-Laorden N, Sereno M, Merino M, Curras-Freixes
M, Montero-Conde C, Mancikova V, Avall-Lundqvist E, Green H, Al-
Shahrour F, Cascon A, Robledo M, Rodríguez-Antona C. Targeted
sequencing reveals low frequency variants in EPHA genes as mar-
kers of paclitaxel induced peripheral neuropathy. Clin Cancer Res.
2017; 23(5): 1227-35. Article. IF: 10.199; D1
• Aranda E, Aparicio J, Bilbao JI, Alfonso PG, Maurel J, Rodríguez J,
Sangro B,Vieitez JM, Feliú J. Recommendations for SIR-Spheres Y-90
resin microspheres in chemotherapy-refractory/intolerant colorec-
tal liver metastases. Future Oncol. 2017; 13(23): 2065-82. Article. IF:
2.369; Q3
• Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, del Vecchio
M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Sileni VC,
Mandala M, Gogas H, Espinosa E, Hospers GAP, Miller WH, Robson S,
Makrutzki M, Antic V, Brown MP. Open-label, multicentre safety study
of vemurafenib in 3219 patients with BRAF(V600) mutation-positive
metastatic melanoma: 2 year follow up data and long term respon-
ders’ analysis. Eur J Cancer. 2017; 79: 176-84. Article. IF: 7.191; Q1
• Calderón C, Ferrando PJ, Carmona-Bayonas A, Lorenzo-Seva U, Jara
C, Beato C, García T, Ramchandani A, Castelo B, Muñoz MM, Gar-
cía S, Higuera O, Mangas-Izquierdo M, Jiménez-Fonseca P. Validation
of SDM-Q-Doc Questionnaire to measure shared decision-making
physician’s perspective in oncology practice. Clin Transl Oncol.
2017; 19(11): 1312-9. Article. IF: 2.392; Q3
• Calderón C, Ferrando PJ, Lorenzo-Seva U, Carmona-Bayonas A, Jara
C, de la Pena FA, Beato C, Ramchandani A, García T, Mangas-Izquier-
do M, Castelo B, Donnay O, Muñoz MD, de Castro EM, García S,
Ghanem I, Mellen T, Jiménez-Fonseca P. Psychometric properties of
Liverpool Stoicism Scale (LSS) in a cohort of patients with resected
cancer in adjuvant treatment. An Psicol-Spain. 2017; 33(3): 621-9.
Article. IF: 0.756; Q4
• Carmona-Bayonas A, Jiménez-Fonseca P, Castañón E, Ramchandani-
Vaswani A, Sánchez-Bayona R, Custodio A, Calvo-Temprano D, Viri-
zuela JA. Chronic opioid therapy in long-term cancer survivors. Clin
Transl Oncol. 2017; 19(2): 236-50. Article. IF: 2.392; Q3
• Carmona-Bayonas A, Jiménez-Fonseca P, Custodio A, Grande E, Ca-
pdevila J, López C, Teule A, García-Carbonero R. Optimizing soma-
tostatin analog use in well or moderately differentiated gastroen-
teropancreatic neuroendocrine tumors. Curr Oncol Rep. 2017;
19(11): 72. Review. IF: 3.122; Q3
• Carmona-Bayonas A, Jiménez-Fonseca P,Virizuela J, Antonio M, Font
C, Biosca M, Ramchandani A, Martínez-García J, Hernando J, Espino-
sa J, de Castro EM, Ghanem I, Beato C, Blasco A, Garrido M, Mondé-
jar R, Arcusa MA, Aragón I, Manzano A, Sevillano E, Castañón E, Ayala
F. Performance of the clinical index of stable febrile neutropenia
(CISNE) in different types of infections and tumors. Clin Transl On-
col. 2017; 19(3): 386-95. Article. IF: 2.392; Q3
• Cejas P, Cavazza A, Yandava CN, Moreno V, Horst D, Moreno-Rubio
J, Burgos E, Mendiola M, Taing L, Goel A, Feliú J, Shivdasani RA. Trans-
criptional regulator CNOT3 defines an aggressive colorectal cancer
subtype. Cancer Res. 2017; 77(3): 766-79. Article. IF: 9.13; D1
• Codony-Servat J, Cuatrecasas M, Asensio E, Montironi C, Martínez-
Cardus A, Marín-Aguilera M, Horndler C, Martínez-Balibrea E, Ru-
bini M, Jares P, Reig O, Victoria I, Gaba L, Martín-Richard M, Alonso
V, Escudero P, Fernández-Martos C, Feliú J, Méndez JC, Méndez M,
Gallego J, Salud A, Rojo F, Castells A, Prat A, Rosell R, García-Albéniz
X, Camps J, Maurel J. Nuclear IGF-1R predicts chemotherapy and
targeted therapy resistance in metastatic colorectal cancer. Brit J
Cancer. 2017; 117(12): 1777-86. Article. IF: 5.922; Q1
• Crespo G, Jiménez-Fonseca P, Custodio A, López C, Carmona-Ba-
yonas A, Alonso V, Navarro M, Aller J, Sevilla I, Grande E, Gajate P,
Alonso-Gordoa T, Matos I, Capdevila J, Nieto B, Barriuso J. Capeci-
tabine and temozolomide in grade 1/2 neuroendocrine tumors: a
Spanish multicenter experience. Future Oncol. 2017; 13(7): 615-24.
Article. IF: 2.369; Q3
• Custodio A, Carmona-Bayonas A, Jiménez-Fonseca P, Sánchez ML,
Viúdez A, Hernández R, Cano JM, Echavarría I, Pericay C, Mangas M,
Visa L, Buxo E, García T, Palomo AR, Mancenido FA, Lacalle A, Macías
I, Azkarate A, Ramchandani A, Montes AF, López C, Longo F, Bayona
RS, Limon ML, Díaz-Serrano A, Hurtado A, Madero R, Gómez C,
Gallego J. Nomogram-based prediction of survival in patients with
advanced oesophagogastric adenocarcinoma receiving first-line
chemotherapy: a multicenter prospective study in the era of trastu-
zumab. Brit J Cancer. 2017; 116(12): 1526-35. Article. IF: 5.922; Q1
• de Cedrón MG, Pérez RA, Sánchez-Martínez R, Molina S, Herranz J,
Feliú J, Reglero G, Enríquez JA, de Molina AR. MicroRNA-661 modu-
lates redox and metabolic homeostasis in colon cancer. Mol Oncol.
2017; 11(12): 1768-87. Article. IF: 5.264; Q1
• de Velasco G, Trilla-Fuertes L, Gámez-Pozo A, Urbanowicz M, Ruiz-
Ares G, Sepulveda JM, Prado-Vázquez G, Arevalillo JM, Zapater-Mo-
ros A, Navarro H, López-Vacas R, Manneh R, Otero I, Villacampa F,
Paramio JM, Vara JAF, Castellano D. Urothelial cancer proteomics
provides both prognostic and functional information. Sci Rep-Uk.
2017; 7: 15819. Article. IF: 4.122; Q1
• del Alba AG, Arranz JA, Puente J, Méndez-Vidal MJ, Gallardo E, Gran-
de E, Pérez-Valderrama B, González-Billalabeitia E, Lazaro-Quintela
M, Pinto A, Láinez N, Piulats JM, Esteban E, Rey JPM, García JA, Suárez
C. Recent advances in genitourinary tumors: A review focused on
biology and systemic treatment. Crit Rev Oncol Hemat. 2017; 113:
171-90. Review. IF: 4.495; Q1
• Espinosa E, Márquez-Rodas I, Soria A, Berrocal A, Manzano JL, Gon-
zález-Cao M, Martín-Algarra S. Predictive factors of response to im-
munotherapy-a review from the Spanish Melanoma Group (GEM).
Ann Transl Med. 2017; 5(19): 389. Review. Not Indexed
• Feliú J, de Corcuera ID, Manzano JL, Valladares-Ayerbes M, Alcaide J,
García TG,Vera R, Sastre J. Effectiveness and safety of aflibercept for
metastatic colorectal cancer: retrospective review within an early
access program in Spain. Clin Transl Oncol. 2017; 19(4): 498-507.
Review. IF: 2.392; Q3
• Fonseca PJ, Carmona-Bayonas A, Hernández R, Custodio A, Cano
JM, Lacalle A, Echavarría I, Macías I, Mangas M, Visa L, Buxo E, Man-
cenido FA, Viúdez A, Pericay C, Azkarate A, Ramchandani A, López
C, de Castro EM, Montes AF, Longo F, Bayona RS, Limón ML, Díaz-
Serrano A, Carnicero AM, Arias D, Cerdá P, Rivera F, Vieitez JM, Ca-
novas MS, Garrido M, Gallego J. Lauren subtypes of advanced gastric
cancer influence survival and response to chemotherapy: real-world
data from the AGAMENON National Cancer Registry. Brit J Can-
cer. 2017; 117(6): 775-82. Article. IF: 5.922; Q1
• Gámez-Pozo A, Trilla-Fuertes L, Berges-Soria J, Selevsek N, Ló-
pez-Vacas R, Díaz-Almirón M, Nanni P, Arevalillo JM, Navarro H,
Grossmann J, Moreno FG, Rioja RG, Prado-Vázquez G, Zapater-Mo-
ros A, Main P, Feliú J, del Prado PM, Zamora P, Ciruelos E, Espinosa
E,Vara JAF. Functional proteomics outlines the complexity of breast
cancer molecular subtypes. Sci Rep-Uk. 2017; 7: 10100. Article. IF:
4.122; Q1
• Gámez-Pozo A, Trilla-Fuertes L, Prado-Vázquez G, Chiva C, López-
Vacas R, Nanni P, Berges-Soria J, Grossmann J, Díaz-Almirón M, Ci-
ruelos E, Sabido E, Espinosa E, Vara JAF. Prediction of adjuvant che-
motherapy response in triple negative breast cancer with discovery
and targeted proteomics. Plos One. 2017; 12(6): e0178296. Article.
IF: 2.766; Q1
• González A, Lluch A, Aba E, Albanell J, Antón A, Álvarez I, Ayala F,
Barnadas A, Calvo L, Ciruelos E, Cortes J, de la Haba J, López-Vega
JM, Martínez E, Muñoz M, Peláez I, Redondo A, Rodríguez A, Rodrí-
guez CA, Ruiz A, Llombart A. A definition for aggressive disease in
patients with HER-2 negative metastatic breast cancer: an expert
consensus of the Spanish Society of Medical Oncology (SEOM). Clin
Transl Oncol. 2017; 19(5): 616-24. Article. IF: 2.392; Q3
• González-Cao M, Arance A, Piulats JM, Márquez-Rodas I, Manzano
JL, Berrocal A, Crespo G, Rodríguez D, Pérez-Ruiz E, Berciano M,
Soria A, Castaño AG, Espinosa E, Montagut C, Alonso L, Puertolas
T, Aguado C, Royo MA, Blanco R, Rodríguez JF, Muñoz E, Mut P,
Barrón F, Martín-Algarra S. Pembrolizumab for advanced melanoma:
experience from the Spanish Expanded Access Program. Clin Transl
Oncol. 2017; 19(6): 761-8. Article. IF: 2.392; Q3
249
 3
Information Groups by Area
3.5 Cancer and Human Molecular Genetics Area
• González-Cao M, Berrocal A, Puig S, Karachaliou N, de Matos-
Arruda L, Seoane J, Escors D, Álvarez C, Vaque JP, Prat A, Wellbrock
C, Arozarena I, Márquez-Rodas I, Espinosa E, Molina MA, Puertolas
T, Juan-Otero M, Malagrida R, Jantus-Lewintre E, Soriano V, Arance
A, Manzano JL, Lorigan P, Gajewski TF, Rosell R, Martín-Algarra S.
Report from the II Melanoma Translational Meeting of the Spanish
Melanoma Group (GEM). Ann Transl Med. 2017; 5(19): 390. Article.
Not Indexed
• Guo Q, Burgess S, Turman C, Bolla MK, Wang Q, Lush M, Abraham
J, Aittomaki K, Andrulis IL, Apicella C, Arndt V, Barrdahl M, Benítez J,
Berg CD, Blomqvist C, Bojesen SE, Bonanni B, Brand JS, Brenner H,
Broeks A, Burwinkel B, Caldas C, Campa D, Canzian F, Chang-Claude
J, Chanock SJ, Chin SF, Couch FJ, Cox A, Cross SS, Cybulski C, Czene
K, Darabi H, Devilee P, Diver WR, Dunning AM, Earl HM, Eccles DM,
Ekici AB, Eriksson M, Evans DG, Fasching PA, Figueroa J, Flesch-Janys
D, Flyger H, Gapstur SM, Gaudet MM, Giles GG, Glendon G, Grip
M, Gronwald J, Haeberle L, Haiman CA, Hall P, Hamann U, Hankin-
son S, Hartikainen JM, Hein A, Hiller L, Hogervorst FB, Holleczek
B, Hooning MJ, Hoover RN, Humphreys K, Hunter DJ, Husing A,
Jakubowska A, Jukkola-Vuorinen A, Kaaks R, Kabisch M, Kataja V,
Knight JA, Koppert LB, Kosma VM, Kristensen VN, Lambrechts D, Le
Marchand L, Li JM, Lindblom A, Lindstrom S, Lissowska J, Lubinski J,
Machiela MJ, Mannermaa A, Manoukian S, Margolin S, Marme F, Mar-
tens JWM, McLean C, Menendez P, Milne RL, Mulligan AM, Muranen
TA, Nevanlinna H, Neven P, Nielsen SF, Nordestgaard BG, Olson
JE, Pérez JIA, Peterlongo P, Phillips KA, Poole CJ, Pylkas K, Radice
P, Rahman N, Rudiger T, Rudolph A, Sawyer EJ, Schumacher F, Sei-
bold P, Seynaeve C, Shah M, Smeets A, Southey MC,Tollenaar RAEM,
Tomlinson I, Tsimiklis H, Ulmer HU, Vachon C, van den Ouweland
AMW, Van’t Veer LJ, Wildiers H, Willett W, Winqvist R, Zamora MP,
Chenevix-Trench G, Dork T, Easton DF, García-Closas M, Kraft P,
Hopper JL, Zheng W, Schmidt MK, Pharoah PDP. Body mass index
and breast cancer survival: a Mendelian randomization analysis. Int J
Epidemiol. 2017; 46(6): 1814-22. Article. IF: 8.36; D1
• Jiménez-Fonseca P, Carmona-Bayonas A, Lorenzo MLS, Plazas
JG, Custodio A, Hernández R, Garrido M, García T, Echavarría I,
Cano JM, Palomo AR, Mangas M, Declara IM, Ramchandani A, Visa
L, Viúdez A, Buxo E, Díaz-Serrano A, López C, Azkarate A, Longo
F, Castañón E, Bayona RS, Pimentel P, Limon ML, Cerda P, Llosa
RA, Serrano R, Lobera MPF, Alsina M, Nuño A, Gómez-Martín C.
Prognostic significance of performing universal HER2 testing in
cases of advanced gastric cancer. Gastric Cancer. 2017; 20(3): 465-
4. Article. IF: 5.045; Q1
• Lecumberri B, López E, Coronado M, Rodado S, Castelo B. Thyroid
metastasis as first manifestation of a colon adenocarcinoma with
KRAS mutation usefulness of F-18-FDG PET/CT. Clin Nucl Med.
2017; 42(10): 795-7. Article. IF: 6.281; D1
• Manos M, Giralt J, Rueda A, Cabrera J, Martínez-Trufero J, Marruecos
J, López-Pousa A, Rodrigo JP, Castelo B, Martínez-Galán J, Arias F,
Chaves M, Herranz JJ, Arrazubi V, Baste N, Castro A, Mesia R. Mul-
tidisciplinary management of head and neck cancer: First expert
consensus using Delphi methodology from the Spanish Society for
Head and Neck Cancer (part 1). Oral Oncol. 2017; 70: 58-64. Re-
view. IF: 4.636; D1
• Martín M, Chacón JI, Antón A, Plazaola A, García-Martínez E, Seguí
MA, Sánchez-Rovira P, Palacios J, Calvo L, Esteban C, Espinosa E, Bar-
nadas A, Batista N, Guerrero A, Muñoz M, Romio E, Rodríguez-Mar-
tín C, Caballero R, Casas MI, Rojo F, Carrasco E, Antolín S. Neoad-
juvant therapy with weekly nanoparticle albumin-bound paclitaxel
for luminal early breast cancer patients: Results from the NABRAX
Study (GEICAM/2011-02), a multicenter, non-randomized, phase II
trial, with a companion biomarker analysis. Oncologist. 2017; 22(11):
1301-8. Article. IF: 5.306; Q1
• Martín-Broto J, Redondo A, Valverde C, Vaz MA, Mora J, del Muro
XG, Gutiérrez A, Tous C, Carnero A, Marcilla D, Carranza A, Sancho
P, Martínez-Trufero J, Díaz-Beveridge R, Cruz J, Encinas V, Tarón M,
Moura DS, Luna P, Hindi N, López-Pousa A. Gemcitabine plus si-
250
rolimus for relapsed and progressing osteosarcoma patients after
standard chemotherapy: a multicenter, single-arm phase II trial of
Spanish Group for Research on Sarcoma (GEIS). Ann Oncol. 2017;
28(12): 2994-9. Article. IF: 13.926; D1
• Mestres JA, IMolins AB, Martínez LC, López-Muñiz JIC, Gil EC, Ferre
AD, Berrón SD, Pérez YF, Mata JG, Palomo AG, Gregori JG, Pardo
PG, Manas JJI, Hernández AL, de Dueñas EM, Jánez NM, Murillo SM,
Bofill JS, Auñón PZ, Sánchez-Rovira P. Defining the optimal sequence
for the systemic treatment of metastatic breast cancer. Clin Transl
Oncol. 2017; 19(2): 149-61. Article. IF: 2.392; Q3
• Orgaz MS, Pessolani TG, Kreilinger JJP, Zamora P, Álvarez CM, Boto-
de-los-Bueis A. Orbital and conjunctival metastasis from lobular
breast carcinoma. Orbit. 2017; 36(4): 197-200. Article. Not Indexed
• Peláez-García A, Yébenes L, Berjón A, Angulo A, Zamora P, Sán-
chez-Méndez JI, Espinosa E, Redondo A, Heredia-Soto V, Mendiola
M, Feliú J, Hardisson D. Comparison of risk classification between
EndoPredict and MammaPrint in ER-positive/HER2-negative pri-
mary invasive breast cancer. Plos One. 2017; 12(9): e0183452. Ar-
ticle. IF: 2.766; Q1
• Pineda E, Salud A,Vila-Navarro E, Safont MJ, Llorente B, Aparicio J,Vera
R, Escudero P, Casado E, Bosch C, Bohn U, Pérez-Carrion R, Carmona
A, Ayuso JR, Ripolles T, Bouzas R, Gironella M, García-Albeniz X, Fe-
liú J, Maurel J. Dynamic soluble changes in sVEGFR1, HGF, and VEGF
promote chemotherapy and bevacizumab resistance: A prospective
translational study in the BECOX (GEMCAD 09-01) trial.Tumor Biol.
2017; 39(6): 1010428317705500. Article. Not Indexed
• Redondo A, Bague S, Bernabéu D, Ortiz-Cruz E,Valverde C, Álvarez
R, Martínez-Trufero J, López-Martín JA, Correa R, Cruz J, López-
Pousa A, Santos A, del Muro XG, Martín-Broto J. Malignant bone tu-
mors (other than Ewing’s): clinical practice guidelines for diagnosis,
treatment and follow-up by Spanish Group for Research on Sarco-
mas (GEIS). Cancer Chemoth Pharm. 2017; 80(6): 1113-31. Article.
IF: 2.808; Q2
• Rodríguez-Salas N, Domínguez G, Barderas R, Mendiola M, García-
Albéniz X, Maurel J, Batlle JF. Clinical relevance of colorectal cancer
molecular subtypes. Crit Rev Oncol Hemat. 2017; 109: 9-19. Review.
IF: 4.495; Q1
• Sereno M, Gutiérrez-Gutiérrez G, Rubio JM, Apellániz-Ruiz M,
Sánchez-Barroso L, Casado E, Falagán S, López-Gómez M, Merino
M, Gómez-Raposo C, Rodríguez-Salas N, Tebar FZ, Rodríguez-
Antona C. Genetic polymorphisms of SCN9A are associated with
oxaliplatin-induced neuropathy. BMC Cancer. 2017; 17: 63. Article.
IF: 3.288; Q2
• Soria A, Manzano JL, Berrocal A, Espinosa E, Márquez-Rodas I, Gon-
zález-Cao M, Martín-Algarra S. Highlights of the season 2016-2017
by the Spanish Melanoma Group (GEM). Ann Transl Med. 2017;
5(19): 391. Article. Not Indexed
• Valdés-Mora F, Locke WJ, Bandres E, Gallego-Ortega D, Cejas P,
García-Cabezas MA, Colino-Sanguino Y, Feliú J, del Pulgar T, Lacal
JC. Clinical relevance of the transcriptional signature regulated by
CDC42 in colorectal cancer. Oncotarget. 2017; 8(16): 26755-70. Ar-
ticle. Not Indexed
Public Projects
Álvarez Castelao B. Análisis mutacional en cáncer epidermoi-
de de cabeza y cuello. Implicaciones pronósticas y predictivas
de respuesta en el ensayo clínico fase III TTCC(PI14/00071).
ISCIII. 2015-2017.
Managment centre: Fundación Instituto de Estudios de Ciencias
Cejas Guerrero P. Nuevos mecanismos de regulación epi-
genética de la expresión implicados en la respuesta a los es-
quemas de quimioterapia en cáncer colorrectal (PI13/01818).
ISCIII. 2014-2017.
Managment centre: FIBHULP
Custodio Carretero AB. Implicación de los cambios dinámi-
cos de la cromatina en la progresión tumoral y la predicción
de respuesta a quimioterapia neoadyuvante en adenocar-
cinoma gástrico localmente avanzado (PI16/01646). ISCIII.
2017-2019.
Managment centre: FIBHULP
Espinosa Arranz E. Alimentos funcionales y estrategias nu-
tricioales eficaces para la prevención y tratamiento de enfer-
medades crónicas (S2013/ABI-2728-ALIBIRD ). CAM. 2014-
2018.
Managment centre: FIBHULP
Feliú Batlle J. Análisis de biomarcadores relacionados
con la eficacia de las terapias dirigidas al cáncer colorectal
(PI13/01659). ISCIII. 2014-2017.
Managment centre: FIBHULP
Fresno Vara JA. Caracterizacion molecular del cáncer de
mama triple negativo (PI12/00444). ISCIII. 2013-2017.
Managment centre: FIBHULP
Fresno Vara JA. Evaluación del metaboloma sanguíneo como
fuente de biomarcadores para el manejo del paciente de cán-
cer de mama (PI15/01310). ISCIII. 2016-2018.
Managment centre: FIBHULP
Fresno Vara JA. Contrato de Estabilización Miguel Servet
(I2). ISCIII, CAM. 2012-2019.
Managment centre: FIBHULP
Private Projects
Barriuso Feijoó J. Estudio de biomarcadores predictores
de resistencia a fármacos antiangiogénicos e inhibidores de
MTOR en tumores neuroendocrinos gastro-entero-pancreá-
ticos. Fundación Eugenio Rodríguez Pascual. 2013-Ongoing.
Managment centre: FIBHULP
Barriuso Feijoó J. Puesta a punto de la técnica de PCR cuan-
titativa y determinación de grupos de genes que permitirán
el desarrollo del conocimiento de los tumores neuroendo-
crinos pancreáticos. Pfizer S.L.U. 2012-Ongoing.
Managment centre: FIBHULP
Feliú Batlle J. 2ª Jornada de debates fármaco-económicos en
oncología e investigación auditorio Hospital Universitario La
Paz. Astellas Pharma S.A. 2015-2017.
Managment centre: FIBHULP
Feliú Batlle J. 3ª Jornada de debates fármaco-económicos en
oncologia. Roche Farma S.A. 2015-Ongoing.
Managment centre: FIBHULP
Feliú Batlle J. Actividades y trabajos realizados por el grupo
de investigación de oncología traslacional de IdiPAZ. Univer-
sidad Europea de Madrid S.L. 2017-Ongoing.
Managment centre: FIBHULP
Feliú Batlle J. Actualización en oncología y nuevos retos en
investigación. Janssen-Cilag España S.A. 2014-Ongoing.
Managment centre: FIBHULP
Feliú Batlle J. Estudio de biomarcadores pronósticos y pre-
dictivos en adenocarcinoma de páncreas. Varios. 2015-On-
going.
Managment centre: FIBHULP
Feliú Batlle J. Estudio de factores predictivos de toxicidad
grave (grado 3-4) en anciano. CAM. 2012-Ongoing.
Managment centre: FIBHULP
Feliú Batlle J. Foro iberoamericano de investigación oncoló-
gica. Lapharcon L.L.C. 2017-Ongoing.
Managment centre: FIBHULP
Feliú Batlle J. Identificación de una huella genética para el
pronóstico en pacientes con cáncer de colon en estado II
operados con intención curativa.Varios. 2013-Ongoing.
Managment centre: FIBHULP
Feliú Batlle J. Implicaciones clínicas y terapeúticas de la
expresión génica diferencial de las células madre tumorales
procedentes de carcinomas de colon en estadíos operables.
Cephalon Pharma S.L.U. 2008-Ongoing.
Managment centre: FIBHULP
Feliú Batlle J. Jornadas científicas sobre investigación y ac-
tualización en oncología. Astrazeneca Farmacéutica Spain S.A.
2016-Ongoing.
Managment centre: FIBHULP
Feliú Batlle J. Jornadas científicas sobre investigación y ac-
tualización en oncología. Astrazeneca Farmaceutica Spain S.A.
2017-Ongoing.
Managment centre: FIBHULP
Feliú Batlle J. Jornadas investigación traslacional en oncolo-
gía. Pfizer S.L.U. 2016-Ongoing.
Managment centre: FIBHULP
Feliú Batlle J. MTA: procesamiento y tratamiento de mues-
tras.Varios. 2016-Ongoing.
Managment centre: FIBHULP
Feliú Batlle J. Promover la actividad investigadora en el Ser-
vicio de Oncología. Amgen S.A. 2010-Ongoing.
Managment centre: FIBHULP
Feliú Batlle J. Proyecto desarrollo de consulta de psicoon-
cología en el Hospital Universitario La Paz. Varios. 2012-On-
going.
Managment centre: FIBHULP
Feliú Batlle J. Sesiones de formación en oncología clínica e
investigación. Lilly S.A. 2016-Ongoing.
Managment centre: FIBHULP
Feliú Batlle J. Utilidad de la determinación del DNA circu-
lante para monitorizar la respuesta al tratamiento neoadyu-
vante en los pacientes con cáncer de recto localmente avan-
zado. Fundación Salud 2000. 2014-Ongoing.
Managment centre: FIBHULP
Fresno Vara JA. Aplicación de ensayos funcionales con mini-
genes como estrategia para determinar la implicación de va-
riantes de significado desconocido en el desarrollo de cáncer
hereditario. FMMA. 2012-Ongoing.
Managment centre: FIBHULP
Fresno Vara JA. Caracterización molecular del cáncer de
mama mediante Taqman Low Density Arrays: aplicación al
diagnósitico. FUAM. 2014-Ongoing.
Managment centre: FIBHULP
Fresno Vara JA. Extracción y análisis de la expresión de miR-
251
 3
Information Groups by Area
3.5 Cancer and Human Molecular Genetics Area
NA en 160 biopsias de cáncer renal embebias en parafina
y su correlación con la evaluación clínica de los pacientes.
Fundación para la Investigación Biomédica del Hospital Uni-
versitario 12 de Octubre. 2010-Ongoing.
Managment centre: FIBHULP
Fresno Vara JA. Extracción y análisis de la expresión miRNA
en biopsias de cáncer de mama embebidas en parafina y su
correlación con la evolución clínica de los pacientes. Funda-
ción para la Investigación Biomédica del Hospital Universita-
rio 12 de Octubre. 2012-Ongoing.
Managment centre: FIBHULP
Ghanem I. Alteraciones genómicas en carcinoma escamoso
de ano. Secuenciación del exoma completo. Grupo Español
Multidisciplinar de Cáncer de Aparato Digestivo. 2014-On-
going.
Managment centre: FIBHULP
Martínez Marín V. Estudio perfil mutacional e inmunohisto-
químico en Gist: búsqueda de factores pronósticos y predic-
tivos. Grupo Español de Investigación en Sarcomas. 2013-On-
going.
Managment centre: FIBHULP
Pinto Marín A. Evaluación del metaboloma sanguíneo como
fuente de biomarcadores para el manejo del paciente con
cáncer: el caso del cáncer de próstata metastásico. FIBHULP.
2015-Ongoing.
Managment centre: FIBHULP
Redondo Sánchez A. Análisis de expresión de miRNAs rela-
cionados con el proceso angiogénico en cáncer mama. Roche
Farma S.A. 2014-Ongoing.
Managment centre: FIBHULP
Redondo Sánchez A. Cáncer de mama y angiogénesis: estu-
dio de perfiles de expresión génica en muestras parafinadas.
Roche Farma S.A. 2009-Ongoing.
Managment centre: FIBHULP
Redondo Sánchez A. Caracterización de la acción de trabec-
tedina y análogos, lurbinectedina y análogos y PM60184 en
modelos celulares en dos y tres dimensiones de carcinoma
de ovario. Pharmamar S.A. 2016-Ongoing.
Managment centre: FIBHULP
Redondo Sánchez A. Estudio in vitro de modelos en tres
dimensiones de cáncer de interacción entre las células tumo-
rales y células del microambiente tumoral. Roche Farma S.A.
2017-Ongoing.
Managment centre: FIBHULP
Redondo Sánchez A. International sarcoma scientifica mee-
ting. EISAI Farmacéutica S.A. 2017-Ongoing.
Managment centre: FIBHULP
Rodríguez Salas N. Correlación de los hallazgos radiológicos
y clínico-exploratorios con las características citológicas del
fluido mamario obtenido mediante aspiración con el sistema
Halo en una cohorte de mujeres SNAS portadoras de muta-
ciones delteteras en los genes BRCA.Varios. 2015-Ongoing.
Managment centre: FIBHULP
Zamora Auñón P. VII Curso de investigación en diagnós-
tico y tratamiento del cáncer de mama. Roche Farma S.A.
2014-Ongoing.
Managment centre: FIBHULP
252
CLINICAL TRIALS
Castelo Fernández B. Caracterización y epidemiología en
España del dolor irruptivo oncológico. Type: NO-EPA.
HULP code: PI-2596B. Sponsored´s protocol code: CARPE-DIO.
Sponsored by: Takeda Farmacéutica España S.A.U.
Signed date: 16/01/2017
Castelo Fernández B. Estudio de fase III, aleatorizado y
abierto para evaluar pembrolizumab como tratamiento
neoadyuvante y en combinación con la asistencia habitual
como tratamiento adyuvante en el carcinoma epidermoide
de cabeza y cuello locorregionalmente avanzado (CECCLA),
extirpable, en estadio III-VA. Type: Clinical Trial, phase III.
HULP code: 4953. Sponsored´s protocol code: MK-3475-689.
Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 22/11/2017
Castelo Fernández B. Estudio epidemiológico, retrospectivo,
longitudinal para caracterizar la historia natural de los pa-
cientes con carcinoma diferenciado de tiroides avanzado en
España y Portugal. Estudio Erudit. Type: EPA-OD.
HULP code: PI-2895. Sponsored´s protocol code: EIS-CDT-2017-01.
Sponsored by: Eisai Farmaceutica S.A.
Signed date: 11/09/2017
Custodio Carretero AB. Ensayo clínico ensayo clínico de fase
III, aleatorizado, doble ciego y controlado con placebo, de
pembrolizumab (MK-3475) en combinación con cisplatino y
5-fluorouracilo frente a un placebo en combinación con cis-
platino y 5-fluorouracilo como tratamiento de primera línea
en sujetos con carcinoma esofágico avanzado/metastásico
(Keynote-590). Type: Clinical Trial, phase III.
HULP code: 4823. Sponsored´s protocol code: MK3475-590.
Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 04/05/2017
Custodio Carretero AB. Ensayo en fase III, abierto y multi-
céntrico del avelumab (MSB0010718C) como tratamiento de
tercera línea del adenocarcinoma de la unión gastroesofágica
o gástrico, metastásico, recurrente o irresecable. Type: Clini-
cal Trial, phase III.
HULP code: ANEXO-I 4704.
Sponsored´s protocol code: EMR100070-008.
Sponsored by: Merck KGAA.
Signed date: 24/01/2017
Custodio Carretero AB. Estudio clínico de fase II de durva-
lumab (MEDI4736) mas tremelumumab para el tratamiento
de pacientes con tumores neuroendocrinos avanzados de
origen gastroenteropáticos o pulmonares (DUNE). Type: Cli-
nical Trial, phase II.
HULP code: 4777. Sponsored´s protocol code: ESR 15-11561-61
DUNElo.
Sponsored by: Icapem.
Signed date: 06/03/2017
Custodio Carretero AB. Estudio para evaluar el uso de re-
cursos y los costes asociados al síndrome carcinoide contro-
lado y no controlado en pacientes con tumores neuroendo-
crinos (NETS) en España. Estudio Recosy. Type: EPA-OD.
HULP code: PI-2793. Sponsored´s protocol code: IPS-SOM-2017-01.
Sponsored by: Ipsen Pharma S.A.
Signed date: 12/06/2017
Espinosa Arranz E. Combi-AD: estudio de fase III, aleatori-
zado y doble ciego de dabrafenib (GSK2118436) en combi-
nacioón con trametinib (GSK1120212) frente a dos placebos
en el tratamiento adyuvante de melanoma de alto riesgo con
la mutación BRAF V600 tras resección quirúrgica. Type: Clini-
cal Trial, phase III.
HULP code: ANEXO-II 3855.
Sponsored´s protocol code: BRF115532.
Sponsored by: Novartis Farmacéutica S.A.
Signed date: 20/07/2017
Espinosa Arranz E. Ensayo de fase II, multicéntrico, interna-
cional, no controlado para identificar los mecanismos mole-
culares de resistencia y sensibilidad a la reexposición a pal-
bociclib tras la progresión a una combinación de palbociclib
en pacientes con cáncer de mama metastásico HER positivo
(Bioper). Código: Medopp089. Type: Clinical Trial, phase II.
HULP code: 4778. Sponsored´s protocol code: MEDOPP089.
Sponsored by: Medica Scientia Innovation Research.
Signed date: 25/04/2017
Espinosa Arranz E. Estudio de fase III multicéntrico, abierto,
randomizado, con dos grupos de tratamiento para evaluar la
eficacia y la seguridad de cobimetinib en combinación con
atezolizumab frente a pembrolizumab en pacientes con me-
lanoma BRAFV600 tipo salvaje avanzado, no tratados previa-
mente. Type: Clinical Trial, phase III.
HULP code: 4862. Sponsored´s protocol code: CO39722.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 06/10/2017
Espinosa Arranz E. Estudio de fase III, multicéntrico, aleato-
rizado, controlado, de dos grupos, para evaluar la seguridad y
eficacia de MK-3475 en comparación con ipilimumab en pa-
cientes con melanoma avanzado. Type: Clinical Trial, phase III.
HULP code: ANEXO-II 3830. Sponsored´s protocol code: 3475-006.
Sponsored by: Merck Sharp and Dohme de España S.A.
Signed date: 02/06/2017
Espinosa Arranz E. Estudio en fase III, aleatorizado, doble
ciego que compara la combinación del inhibidor de BRAF
(dabrafenib) y el inhibidor de MEK (trametinib) frente a
dabrafenib y placebo como terapia de primera línea en pa-
cientes con melanoma cutáneo no-resecable (estadío IIIC)
o metastásico (estadio IV) con la mutación BRAF V600E/K.
Type: Clinical Trial, phase III.
HULP code: ANEXO-II 3606. Sponsored´s protocol code: MEK 115306.
Sponsored by: Glaxosmithkline S.A.
Signed date: 07/09/2017
Feliú Batlle J. Elección de terapias personalizadas en pacien-
tes con carcinoma de páncreas metastásico de acuerdo al
análisis genético del tumor y al modelo avatar. Type: Clinical
Trial, phase III.
HULP code: ANEXO-I 4607. Sponsored´s protocol code: ERCAVA-
TAR2015.
Sponsored by: Hospital Universitario de Fuenlabrada.
Signed date: 24/10/2017
Feliú Batlle J. Ensayo de fase II para evaluar la eficacia y
seguridad de Folfiri + panitumumab como tratamiento de
primera línea en pacientes ancianos con cáncer colorrectal
metastásico no resecable, RAS/BRAF no mutado y buen esta-
do funcional. Type: Clinical Trial, phase II.
HULP code: 4875. Sponsored´s protocol code: GEMCAD-16-03.
Sponsored by: Grupo GEMCAD.
Signed date: 26/07/2017
Feliú Batlle J. Ensayo de fase III, multicéntrico y no enmasca-
rado sobre el tratamiento de mantenimiento con avelumab
(MSB0010718C) frente a la continuación de la quimioterapia
de primera línea en sujetos con un adenocarcinoma gástrico,
o de la zona de unión gastroesofágica, irresecable, localmente
avanzado o metastásico. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4643.
Sponsored´s protocol code: EMR100070-007.
Sponsored by: Merck KGAA.
Signed date: 15/09/2017
Feliú Batlle J. Estudio aleatorizado, multicéntrico, doble
ciego, controlado con placebo, de fase II/III del inhibidor de
la tirosina quinasa de Bruton, ibrutinib, en combinación con
nab-paclitaxel y gemcitabina frente a placebo en combina-
ción con nab-paclitaxel y gemcitabina, en el tratamiento de
primera línea de pacientes con adenocarcinoma de páncreas
metastásico. Type: Clinical Trial, phase II.
HULP code: 4913. Sponsored´s protocol code: PH1603.
Sponsored by: Ph Research S.L.
Signed date: 11/11/2017
Feliú Batlle J. Estudio de fase III de BBI-608 más nab-pacli-
taxel con gemcitabina en pacientes adultos con adenocarci-
noma pancreático metastásico. Type: Clinical Trial, phase III.
HULP code: 4830. Sponsored´s protocol code: CanStem111P.
Sponsored by: Boston Biomedical Inc.
Signed date: 30/06/2017
Feliú Batlle J. Estudio en fase III, aleatorizado, doble ciego y
controlado con placebo para evaluar la eficacia y seguridad
de GS-5745 en combinación con MFOLFOX6 como trata-
miento de primera línea en pacientes con adenocarcinoma
gástrico avanzado o de la unión gastroesofágica. Type: Clinical
Trial, phase III.
HULP code: ANEXO-II 4569.
Sponsored´s protocol code: GS-US-296-1080.
Sponsored by: Gilead Sciences Inc.
Signed date: 04/08/2017
Feliú Batlle J. Estudio fase I-II, en estudio preliminar de efi-
cacia, en abierto, de determinación de la dosis, en fase I-II
y llevado a cabo en humanos por primera vez para evaluar
la seguridad, la tolerabilidad, la farmacocinética y la farma-
codinámica de CX-2009 en adultos con tumores sólidos
irresecables metastásicos o localmente avanzados (Proclaim-
CX-2009). Type: Clinical Trial, phase I.
HULP code: 4867.
Sponsored´s protocol code: CTMX-M-2009-001.
Sponsored by: Cytomx Thereapeutics Inc.
Signed date: 19/07/2017
Feliú Batlle J. Estudio preliminar de eficacia, en abierto y
de determinación de la dosis de Probody™ (Probody TX)
therapeutics en pacientes con tumores sólidos irresecables
localmente o linfomas metastásicos o en estadío avanzado.
Type: Clinical Trial, phase II.
HULP code: 4731. Sponsored´s protocol code: CTMX-M-072-001.
Sponsored by: Cytomx Thereapeutics Inc.
Signed date: 24/01/2017
253
 3
Information Groups by Area
3.5 Cancer and Human Molecular Genetics Area
Feliú Batlle J. S-Avant seguimiento del estudio Avant hasta 8
y 10 años (mediana de seguimiento) en pacientes con carci-
noma de colón. Type: EPA-OD.
HULP code: PI-2730. Sponsored´s protocol code: C13-01.
Sponsored by: Grupo Tratamiento Tumores Digestivos (GER-
COR).
Signed date: 26/04/2017
Martínez Marín V. Caracterización del riesgo de trombosis
en pacientes con cáncer (Estudio Cartago). Type: EPA-SP.
HULP code: PI-2849. Sponsored´s protocol code: AJT-ACO-2016-01.
Sponsored by: Trujillo Santos, Antonio Javier.
Signed date: 18/09/2017
Martínez Marín V. Caracterización del riesgo de trombosis
en pacientes con cáncer. Estudio Cartago. Type: EPA-SP.
HULP code: ANEXO-I PI-2849.
Sponsored´s protocol code: AJT-ACO-2016-01.
Sponsored by: Trujillo Santos, Antonio Javier.
Signed date: 15/12/2017
Martínez Marín V. Retrospective observational study of pa-
tients with metastatic, unresectable or locally advanced gas-
trointestinal stromal tumours (GIST) treated with sunitinib.
exploratory analysis of prognostic and predictive factors in
long-term responder patients. Type: EPA-OD.
HULP code: PI-2798. Sponsored´s protocol code: GEIS 43.
Sponsored by: Grupo Español de Investigación en
Sarcomas.
Signed date: 17/07/2017
254
Pinto Marín A. Estudio de fase Ib/II, randomizado, doble cie-
go, controlado con placebo, multicéntrico, de grupos para-
lelos de B-701 más docetaxel en comparación con placebo
más docetaxel en el tratamiento del carcinoma urotelial lo-
calmente avanzado o metastásico en pacientes con recidiva
tras el tratamiento de referencia o que no hayan respondido
a este. Type: Clinical Trial, phase Ib.
HULP code: 4857. Sponsored´s protocol code: B-701-U21.
Sponsored by: Bioclin Therapeutics Inc.
Signed date: 25/09/2017
Pinto Marín A. Estudio de fase III multicéntrico, randomi-
zado, controlado con placebo de atezolizumab (anticuerpo
anti-DP-L1) en monterapia y en combinación con quimiote-
rapia basada en platino en placientes con carcinoma urotelial
localmente avanzado o metastásico no tratado previamente.
Type: Clinical Trial, phase III.
HULP code: 4771. Sponsored´s protocol code: WO30070.
Sponsored by: Daiichi-Sankyo Development Limited.
Signed date: 23/03/2017
Pinto Marín A. Estudio de fase III, aleatorizado, doble cie-
go y controlado con placebo, de dicloruro de radio 223
en combinación con acetato de abiraterona y prednisona/
prednisolona en el tratamiento de pacientes con metastasis
predominantemente óseas en pacientes asintomáticos o con
síntomas leves, que nunca han recibido quimioterapia. Type:
Clinical Trial, phase III.
HULP code: ANEXO-I 4086. Sponsored´s protocol code: BAY 88-
8223/153.
Sponsored by: Bayer AG.
Signed date: 17/10/2017
Pinto Marín A. Estudio de fase III, multicéntrico, multinacio-
nal, aleatorizado, abierto, con grupos paralelos sobre avelu-
mab (MSB0010718c) más los mejores cuidados paliativos
frente a los mejores cuidados paliativos solos como trata-
miento de mantenimiento en pacientes con cáncer urotelial
localmente avanzado o mestastásico sin progresión de la en-
fermedad tras completar la quimioterapia de primera línea
basada en platino. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4659. Sponsored´s protocol code: B9991001.
Sponsored by: Pfizer S.L.U.
Signed date: 19/04/2017
Pinto Marín A. Estudio en fase II, multicéntrico y abierto de
rucaparib en pacientes con cáncer de próstata metastásico
resistente a la castración asociado con deficiencia de recom-
binación homólogica. Type: Clinical Trial, phase II.
HULP code: 4787. Sponsored´s protocol code: CO-338-052.
Sponsored by: Clovis Oncology Inc.
Signed date: 08/09/2017
Pinto Marín A. Estudio en fase III multinacional, aleatorizado,
con doble enmascaramiento y controlado con placebo sobre
la eficacia y seguridad de ODM-201 en varones con cáncer
de próstata no metastásico de alto riesgo resistente a la cas-
tración. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4463. Sponsored´s protocol code: 17712.
Sponsored by: Bayer AG.
Signed date: 22/11/2017
Pinto Marín A. Estudio exploratorio de fase II, abierto y con
un solo grupo de tratamiento con afatinib oral en monote-
rapia tras el fracaso a platino en pacientes con carcinoma
urotelial avanzado/metastásico con alteraciones genéticas en
los receptores ERBB. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4632. Sponsored´s protocol code: 1200.261.
Sponsored by: Boehringer Ingelheim España S.A.
Signed date: 26/04/2017
Pinto Marín A. Estudio fase II de dos grupos, multicéntrico y
abierto para determinar la eficacia y la seguridad de dos pau-
tas posológicas diferentes de JNJ-42756493, un pan-inhibidor
tirosina quinasa del FGFR, en sujetos con cáncer urotelial
metastásico o no resecable quirúrgicamente con alteraciones
genómicas del FGFR. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4378.
Sponsored´s protocol code: 42756493BLC2001.
Sponsored by: Janssen Cilag International NV.
Signed date: 31/05/2017
Pinto Marín A. Estudio fase II, internacional, multicéntrico,
prospectivo para evaluar la eficacia, la seguridad y la calidad
de vida de pazopanib administrado diariamente por vía oral,
en pacientes con carcinoma de células renales avanzado y/o
metastásico después de terapia previa con tratamiento con
agentes inhibidores del control de la inmunidad (checkpoint
inhibitors). Type: Clinical Trial, phase II.
HULP code: 4877. Sponsored´s protocol code: CPZP034A2410.
Sponsored by: Novartis Farmaceutica S.A.
Signed date: 04/10/2017
Pinto Marín A. Triton 3: un estudio multicéntrico, aleatoriza-
do, abierto de fase III de rucaparib versus elección del médico
para pacientes con cáncer de próstata metastásico resisten-
te a la castración asociado con deficiencia de recombinación
homóloga. Type: Clinical Trial, phase III.
HULP code: 4828. Sponsored´s protocol code: CO-338-063.
Sponsored by: Clovis Oncology Inc.
Signed date: 19/09/2017
Redondo Sánchez A. A randomized, double blinded, phase III
study of atezolizumab versus placebo in patients with late re-
lapse of epithelial ovarian, fallopian tube or peritoneal cancer
treated by platinum-based chemotherapy and bevacizumab
atalante. Type: Clinical Trial, phase III.
HULP code: 4876. Sponsored´s protocol code: GINECO-OV236b.
Sponsored by: Grupo Español de Investigación Cáncer de
Ovario (GEICO).
Signed date: 27/11/2017
Redondo Sánchez A. A randomized, double-blind, placebo-
controlled phase II trial of palbociclib in combination with
letrozole versus letrozole in combination with placebo for
patients with estrogen receptor positive advanced or recu-
rrent endometrial cancer. Type: Clinical Trial, phase II.
HULP code: 4846. Sponsored´s protocol code: ENGOT-EN3-NSGO.
Sponsored by: Grupo Español de Investigación Cáncer de
Ovario (GEICO).
Signed date: 08/08/2017
Redondo Sánchez A. Ensayo clínico ensayo fase II multicén-
trico de palbociclib en segunda línea de sarcomas avanzados
con sobreexpresión de CDK4. Type: Clinical Trial, phase II.
HULP code: 4807. Sponsored´s protocol code: GEIS-51.
Sponsored by: Grupo Español de Investigación en Sarcomas.
Signed date: 29/09/2017
Redondo Sánchez A. Ensayo de fase II aleatorizado, doble
ciego, controlado con placebo, de dicloruro de radio-223 en
combinación con exemestano y everolimus frente a placebo
en combinación con exemestano y everolimus, administrado
a pacientes con cáncer de mama metastásico negativo para
HER2 y positivo para los receptores hormonales, con metas-
tasis óseas. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4263.
Sponsored´s protocol code: BAY 88-8223/17096.
Sponsored by: Bayer Pharma AG.
Signed date: 07/11/2017
Redondo Sánchez A. Ensayo fase II de nab-paclitaxel para
el tratamiento de tumores desmoides y tumores desmo-
plásicos de células pequeñas y redondas y sarcoma de
Ewing en recaída múltiple o refractarios. Type: Clinical Trial,
phase II.
HULP code: 4836. Sponsored´s protocol code: GEIS-39.
Sponsored by: Grupo Español de Investigación en Sarcomas.
Signed date: 11/10/2017
255
 3
Information Groups by Area
3.5 Cancer and Human Molecular Genetics Area
Redondo Sánchez A. Estudio de fase Ib (abierto) / fase II
(aleatorizado, doble ciego) en el que se evalúan gemcitabina
y docetaxel, con o sin olaratumab, en el tratamiento del sar-
coma de tejidos blandos en estadio avanzado. Type: Clinical
Trial, phase II.
HULP code: ANEXO-II 4543.
Sponsored´s protocol code: I5B-MC-JGDL.
Sponsored by: Lilly S.A.
Signed date: 07/06/2017
Redondo Sánchez A. Estudio de fase IB/II para evaluar la efi-
cacia y tolerabilidad de PM01183 en combinación con olapa-
rib en pacientes con tumores sólidos avanzados.Type: Clinical
Trial, phase Ib.
HULP code: 4782.
Sponsored´s protocol code: POLA/ACOG1401.
Sponsored by: Poveda Velasco, Andrés.
Signed date: 13/03/2017
Redondo Sánchez A. Estudio de fase II aleatorizado de
MLN0128 (inhibidor doble de TORC1/2), MLN0128 +
MLN1117 (inhibidor de PI3K), paclitaxel semanal, o la com-
binación de paclitaxel semanal y MLN0128 en mujeres con
cáncer de endometrio avanzado, recurrente o persistente.
Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4614. Sponsored´s protocol code: C31004.
Sponsored by: Millennium Pharmaceuticals Inc.
Signed date: 06/07/2017
Redondo Sánchez A. Estudio de fase III de ADXS11-001
administrado tras la quimiorradioterapia como tratamiento
adyuvante en cáncer de cuello uterino localmente avanzado
de riesgo alto: AIM2CERV. Type: Clinical Trial, phase III.
HULP code: 4649. Sponsored´s protocol code: ADXS001-02.
Sponsored by: Advaxis Inc.
Signed date: 00/01/1900
Redondo Sánchez A. Estudio de fase III para evaluar la efica-
cia y la seguridad de pazopanib en monoterapia frente a pla-
cebo entre mujeres con cáncer epitelial de ovario, de trompa
de falopio o peritoneal primario que no hayan progresado
después de la quimioterapia en primera línea. Type: Clinical
Trial, phase III.
HULP code: ANEXO-V 2880.
Sponsored´s protocol code: VEG110655.
Sponsored by: Novartis Farmaceutica S.A.
Signed date: 22/09/2017
Redondo Sánchez A. Estudio de fase III, aleatorizado y en
doble ciego, del tratamiento de mantenimiento con niraparib
frente a placebo en pacientes con cáncer de ovario sensible
al plantino. Type: Clinical Trial, phase III.
HULP code: ANEXO-II 3996.
Sponsored´s protocol code: PR-30-5011-C.
Sponsored by: Tesaro Inc.
Signed date: 20/01/2017
Redondo Sánchez A. Estudio de fase III, multicéntrico, alea-
torizado, abierto de avelumab (MSB0010718C) en monote-
rapia o en combinación con doxorubicina liposomal pegilada
frente a doxorubicina liposomal pegilada en monoterapia en
pacientes con cáncer de ovario refractario/resistente a plati-
no. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4652. Sponsored´s protocol code: B9991009.
Sponsored by: Pfizer Inc.
256
Signed date: 21/07/2017
Redondo Sánchez A. Estudio de fase IIIB, aleatorizado, en
doble ciego, controlado con placebo y multicéntrico, del re-
tratamiento con olaparib en pacientes con cáncer epitelial de
ovario tratado previamente con un Parpi y con respuesta a
la repetición de la quimioterapia con platino (OREO). Type:
Clinical Trial, phase IIIb.
HULP code: 4844. Sponsored´s protocol code: D0816C00014.
Sponsored by: Astrazeneca AB.
Signed date: 00/01/1900
Redondo Sánchez A. Forward1: un sello abierto, aleatori-
zado fase 3 estudio para evaluar la seguridad y eficacia de
mirvetuximab soravtansine (IMGN853) versus elección del
investigador de la quimioterapia en mujeres con folato del
receptor alfa positivo avanzado cancer epitelial de ovario,
primaria peritoneal cáncer o cáncer primario de trompa de
falopio. Type: Clinical Trial, phase III.
HULP code: 4767. Sponsored´s protocol code: IMGN-0403.
Sponsored by: Immunogen Inc.
Signed date: 27/01/2017
Redondo Sánchez A. Identificación de biomarcadores pronós-
ticos en el osteosarcoma de alto grado. Type: EPA-OD.
HULP code: PI-2797. Sponsored´s protocol code: GEIS 44.
Sponsored by: Grupo Español de Investigación en Sarcomas.
Signed date: 13/07/2017
Redondo Sánchez A. Phase I dose escalation and cohort
expansion study of TSR-042, an anti-PD-1 monoclonal anti-
body, in patients with advanced solid tumors. Type: Clinical
Trial, phase I.
HULP code: 4831. Sponsored´s protocol code: TSR-042.
Sponsored by: Tesaro Inc.
Signed date: 16/03/2017
Redondo Sánchez A. Phase I-II trial of sunitinib plus nivo-
lumab after standard treatment in advanced soft tissue and
bone sarcomas. Type: Clinical Trial, phase I.
HULP code: 4854. Sponsored´s protocol code: GEIS-52.
Sponsored by: Grupo Español de Investigación en Sarcomas.
Signed date: 13/06/2017
Rodríguez Salas N. Estudio de fase III de BBI-608 en combi-
nación con 5-fluorouracilo, ácido folínico e irinotecán (Folfi-
ri) en pacientes adultos con cáncer colorrectal (CCR) metas-
tático previamente tratado. Type: Clinical Trial, phase III.
HULP code: 4725. Sponsored´s protocol code: CANSTEM303C.
Sponsored by: Boston Biomedical Inc.
Signed date: 22/01/2017
Rodríguez Salas N. Estudio de fase III, multicéntrico, aleato-
rizado y abierto, de 3 grupos: encorafenib + cetuximab, con o
sin binimetinib, frente a irinotecan / cetuximab o 5-fluoroura-
cilo (5-fu)/ácido folínico (fa)/irinotecan (folfiri)/cetuximab en
infusión, con una Evaluación previa de la seguridad de enco-
rafenib + binimetinib + cetuximab, en pacientes con cáncer
colorrectal metastásico con la mutante V600E del gen BRAF.
Type: Clinical Trial, phase III.
HULP code: 4748. Sponsored´s protocol code: ARRAY818-302.
Sponsored by: Array Biopharma Inc.
Signed date: 16/02/2017
Rodríguez Salas N. Estudio multicéntrico, fase II de nivolu-
mab en combinación con ipilimumab para pacientes con tu-
mores pediátricos sólidos avanzados del adulto. Type: Clinical
Trial, phase II.
HULP code: 4845. Sponsored´s protocol code: GETHI021.
Sponsored by: Grupo Español de Tumores Huérfanos e
Infrecuentes.
Signed date: 18/07/2017
Rodríguez Salas N. Tratamiento preoperatorio de inducción
con 12 semanas de panitumumab combinado con folfox 6m
en una población enriquecida (quádruple wild-type) de pa-
cientes con cáncer de recto de tercio medio MRT3 y fascia
mesorrectal no invadida. Type: Clinical Trial, phase II.
HULP code: 4835. Sponsored´s protocol code: GEMCAD-1601.
Sponsored by: Grupo GEMCAD.
Signed date: 22/05/2017
Rodríguez Salas N. Tratamiento preoperatorio de inducción
con 12 semanas de panitumumab combinado con folfox 6m
en una población enriquecida (Quádruple Wild-Type) de pa-
cientes con cáncer de recto de tercio medio MRT3 y fascia
mesorrectal no invadida. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4835.
Sponsored´s protocol code: GEMCAD-1601.
Sponsored by: Grupo GEMCAD.
Signed date: 23/06/2017
Rubio Aparicio PM. Ensayo clínico en fase III multicéntri-
co, aleatorizado, doble ciego, controlado por placebo, con
grupos paralelos para investigar la eficacia, seguridad y to-
lerabilidad de naloxona HCL LP comprimidos en pacientes
con estreñimiento inducido por opioides. Type: Clinical Trial,
phase I.
HULP code: 4898. Sponsored´s protocol code: BAY 73-4506/15906.
Sponsored by: Bayer AG.
Signed date: 29/11/2017
Zamora Auñón P. Ensayo de fase III aleatorizado de palboci-
clib con tratamiento endocrino adyuvante estándar frente a
monoterapia con tratamiento endocrino adyuvante estándar
en cáncer de mama precoz con receptores hormonales po-
sitivos (RH+) y HER2-negativo. Type: Clinical Trial, phase III.
HULP code: 4879.
Sponsored´s protocol code: AFT-05-ABCSG 42-BIG 14-03.
Sponsored by: Austrian Breast & Colorectal Cancer Group
(ABCSG).
Signed date: 23/06/2017
Zamora Auñón P. Ensayo de fase III, aleatorizado y abierto
para evaluar la eficacia y la seguridad de palbociclib + tra-
tamiento anti-HER2 + tratamiento endocrino frente a tra-
tamiento anti-HER2 + tratamiento endocrino tras el trata-
miento de inducción para el cáncer de mama metastásico
positivo para receptores hormonales (HR+)/positivo para
HER2. Type: Clinical Trial, phase III.
HULP code: 4945. Sponsored´s protocol code: AFT-38.
Sponsored by: Alliance Foundation Trials Llc.
Signed date: 11/10/2017
Zamora Auñón P. Ensayo en fase II doble ciego y controla-
do con placebo de seribantumab más fulvestrant en mujeres
posmenopáusicas con cáncer de mama metastásico positi-
vo para receptores hormonales, positivo para herregulina
(HRG+) y negativo para HER2 cuya enfermedad ha progresa-
do después de un tratamiento sistémico previo. Type: Clinical
Trial, phase II.
HULP code: 4916. Sponsored´s protocol code: MM-121-02-02-10.
Sponsored by: Merrimack Pharmaceuticals.
Signed date: 12/09/2017
Zamora Auñón P. Estudio de fase IIIB, abierto, multicén-
trico, para evaluar la seguridad y la eficacia de ribociclib
(IEE011) en combinación con letrozol en el tratamiento de
hombres y mujeres postmenopáusicas con cáncer de mama
avanzado (CMA) con receptor hormonal positivo (HR+) y
HER2 negativo (HER2-) que no hayan recibido tratamiento
hormonal para la enfermedad avanzada. Type: Clinical Trial,
phase IIIb.
HULP code: 4817. Sponsored´s protocol code: CLEE011A2404.
Sponsored by: Novartis Farmaceutica S.A.
Signed date: 06/04/2017
Zamora Auñón P. Estudio fase II, aleatorizado, abierto y mul-
ticéntrico, para evaluar el efecto de vinorelbina oral metro-
nómica frente al mejor tratamiento de soporte como terapia
de mantenimiento después de quimioterapia de primera línea
basada en taxanos en pacientes con cáncer de MAAM HER-
2 negativo resistente al tratamiento endocrino. Type: Clinical
Trial, phase II.
HULP code: 4833.
Sponsored´s protocol code: ATRIO-01/16 MAVERICK.
Sponsored by: Fundación para el Fomento de la Investigación
Sanitaria y Biomédica de la Comunidad Valenciana Fisabio.
Signed date: 03/05/2017
Zamora Auñón P. Estudio fase III aleatorizado, multicéntrico,
abierto de lapatinib, trastuzumab, la administración secuencial
de ambos y la adminsitración combinada de ambos como
tratamiento adyuvante en pacientes con cáncer de mama
HER2/ERBB2 positivo. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 2436. Sponsored´s protocol code: EGF 106708.
Sponsored by: Novartis Farmaceutica S.A.
Signed date: 21/07/2017
Zamora Auñón P. Trastuzumab y pertuzumab sin quimiote-
rapia en cáncer de mama HER2 positivo: estrategia adaptada
en función de la respuesta evaluada por FDG-PET. Estudio
Phergain. Type: Clinical Trial, phase II.
HULP code: 4810. Sponsored´s protocol code: PHERGAIN.
Sponsored by: Medica Scientia Innovation Research.
Signed date: 05/04/2017
Patents and Trademarks
Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González
Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez
Hernández JJ, inventors; FIBHULP, UAM, assignees. Geno-
mic fingerprint for the prognosis of the evolution of colo-
rectal adenocarcinoma. P200703229, PCT/ES2008/000756,
EP2236626; 2007 December 04.
Cejas Guerrero P, González Barón M, Casado Sáenz E, Sán-
chez Hernández JJ, Perona Abellón R, inventors; FIBHULP,
UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in
the prognosis of patients diagnosed with colorectal cancer.
P200703230, PCT/ES2008/000757, EP2236625; 2007 Decem-
ber 04.
Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, Sánchez
Navarro I, inventors; FIBHULP, assignee. Method for tumor
subclassification. P200803509, PCT/ES2009/070533; 2008
December 11.
257
 3
Information Groups by Area
3.5 Cancer and Human Molecular Genetics Area
Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo
J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to
obtain useful data for the prediction of a patient’s clinical res-
ponse to an anticancer treatment. P200930400; 2009 July 01.
Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo
J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method
to obtain useful data for the prediction of a patient’s patholo-
gical response to an anticancer treatment. P200930438; 2009
July 10.
Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Cas-
tro Carpeño J, Moreno García V, Burgos Lizalde E, Ca-
sado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP,
UAM, Empresa Pública Hospital del Norte, assignees. Ge-
nomic fingerprint for predicting the clinical response to an
antitumor therapy in colorectal cancer. P201130863, PCT/
ES2012/070379; 2011 May 26.
258
Moreno Rubio J, Cejas Guerrero P, Feliú Batlle J, Ramírez
de Molina AI, Reglero Rada G, Vargas Alonso T, Molina
Arranz S, González-Vallinas Garrachón M, inventors; FI-
BHULP, Fundación Imdea Alimentacion, assignees. Methods
and kits for the prognosis of colorectal cancer. P201231918,
PCT/ES2013/070864; 2012 December 10.
Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, López
Vacas R, Berges Soria J, inventors; FIBHULP, assignee. Method
for tumor subclassification. P201430887, 2014 June 09.
Miranda Utrera N, Castellano D, Villacampa Aubá F, Fres-
no Vara JA, Gámez Pozo A, inventors; FIBH12O, FIBHULP,
assignees. Prognostic method for determining the risk of re-
lapse in renal cancer patients with a clear cell type of renal
carcinoma, stages I and II, and kit for same. P201531360, PCT/
EP2016/072723; 2015 September 23.
Experimental Therapies and
Biomarkers in Cancer Group
21 207.287 11
María Inmaculada Ibáñez de Cáceres. Investigadora Senior
(Contrato Miguel Servet- Tipo 2). Jefe de Laboratorio. HULP
Javier De Castro Carpeño. Jefe de Sección de Oncología. HULP.
Profesor Asociado. UAM
Cristobal Belda Iniesta. Facultativo Especialista de Área en Oncología.
Hospitales de Madrid
Jaime Carrillo García. Investigador Postdoctoral. IIB Alberto Sols
María Isabel Esteban Rodríguez. Facultativo Especialista de Área en
Anatomía Patológica. HULP
María Galardi Castilla. Investigadora Predoctoral. IIB Alberto Sols
Julia Jiménez Hernández. Investigadora Predoctoral. UAM
Cristina Manguán García. Técnico de Laboratorio. IIB Alberto Sols
Olga Pernía Arias. Técnico de Laboratorio. HULP
Rosario Perona Abellón. Profesora de Investigación. IIB Alberto Sols
Verónica Pulido Sanz. Investigadora Predoctoral. HULP
Garcilaso Riesco Eizaguirre. Facultativo Especialista de Área en
Endocrinología y Nutrición. HULP
Carlos Rodríguez Antolín. Investigador Predoctoral. HULP
Rocío Rosas Alonso. Médico Interno Residente en Bioquímica Clínica. HULP
Isabel Sánchez Pérez. Profesora Contratada Doctor. UAM
Leandro Sastre Garzón. Investigador Científico. IIB Alberto Sols
Javier Andrés Soto . Investigador Predoctoral. UAM
Olga Vera Puente. Investigadora Predoctoral. HULP
Strategic Objective
Our research is focused on two distinct areas:
1- Genetic and epigenetic mechanisms involved in the re-
sistance to chemotherapeutic drugs. Drug resistance is a
crucial problem in clinical practice. We have used various
strategies to approach this problem, such as identifying
new targets involved in drug responses and studying their
alterations in human samples. In addition, we have
identified epigenetic changes in tumour suppressor
genes associated with drug resistance and new gene
inducers of chromosome instability associated with
drug responses.
We have identified various targets involved in the
resistance to platinum-derived compounds in non-
small cell lung cancer (NSCLC). One of these tar-
gets, MKP1, is a dual-specific phosphatase expressed
at high levels in biopsies from early-stage NSCLC
and is also associated with tumour progression of
this disease. We have worked towards identifying
the platinum-resistance epigenetic markers (genes
and micro RNAs) for non-invasive cancer diagnosis
in NSCLC. By using genomic and expression reac-
tivation techniques, we have found a gene whose
promoter is methylated in NSCLC biopsies and
predicts resistance to cisplatin with 80% specificity.
We also discovered a combination therapy based
in sequential treatment of gastric cancer cells with
taxol followed by cisplatin, which induces mitotic
catastrophe and increases cell death.
2- Strategies to reactivate telomerase activity in hu-
man cells with defects in telomerase and premature
senescence.
We have identified a genetic suppressor element
(GSE) termed 24-2 that, once expressed in human
cells, is able to recover telomerase activity and pro-
mote survival to cisplatin. This GSE corresponds to
an internal fragment of dyskerin, a protein that is
part of the telomerase complex.
Expression of this GSE reactivates telomerase ac-
tivity in cells with X-linked dyskeratosis congeni-
ta, a disease that is characterised by bone marrow
failure and several other defects associated with a
decrease in telomerase activity.
259
 3
Information Groups by Area
3.5 Cancer and Human Molecular Genetics Area
Research Lines
Translational research:
• Identification of predictive genetic and epigenetic bio-
markers in the emergence of resistance in cancer and
new therapeutic targets in NSCLC and ovarian cancer.
• Identification of novel microRNAs involved in chemo-
radiotherapy response in lung and ovarian cancer as
well as in rare diseases as biomarkers for clinical use.
• Study of the mechanisms of resistance to chemothera-
py in cancer: the role of tumour stem cells in the res-
ponse to chemotherapy in non-small cell lung cancer.
• Development of new strategies for the treatment of
telomerase defective diseases.
Research Activity
Doctoral TheseS
Pintado Berninches L. Uso de los péptidos GSE24.2 y GSE4
como posible tratamiento de células de pacientes con ataxia
telangiectasia. [dissertation]. Madrid: UAM: 2017(11/05/2017).
Director: Perona Abellón R.
Rodríguez Centeno J. Estudio de los telómeros en dict-
yostelium discoideum. Desarrollo de un modelo celular
de disqueratosis congénita[dissertation]. Madrid: UAM:
2017(08/06/2017).
Director: Sastre Garzón L.
Soto J. Identificación de marcadores epigenéticos con sig-
nificado clínico asociado a la respuesta a derivados de
platino en cáncer de ovario[dissertation]. Madrid: UAM:
2017(21/04/2017).
Director: Ibáñez de Cáceres I.
PUBLICATIONS
• Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi
T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin
X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S,
Ostoros G, Kubota K, Gray JE, Paz-Ares L, Carpeño JD, Wadsworth
C, Melillo G, Jiang H, Huang Y, Dennis PA, Ozguroglu M. Durvalumab
after chemoradiotherapy in stage III non-small-cell lung cancer. New
Engl J Med. 2017; 377(20): 1919-29. Article. IF: 79.258; Q1
• Arrizabalaga O, Moreno-Cugnon L, Auzmendi-Iriarte J, Aldaz P, Ibá-
ñez de Cáceres II, Garros-Regúlez L, Moncho-Amor V, Torres-Bayo-
na S, Pernía O, Pintado-Berninches L, Carrasco-Ramírez P, Cortes-
Sempere M, Rosas R, Sánchez-Gómez P, Ruiz I, Caren H, Pollard S,
García I, Sacido AA, Lovell-Badge R, Belda-Iniesta C, Sampron N,
Perona R, Matheu A. High expression of MKP1/DUSP1 counteracts
glioma stem cell activity and mediates HDAC inhibitor response.
Oncogenesis. 2017; 6(12): 401. Article. IF: 4.722; Q1
• Bordas A, Cedillo JL,Arnalich F, Esteban-Rodríguez I, Guerra-Pastrián
L, de Castro J, Martín-Sánchez C, Atienza G, Fernández-Capitán C,
Ríos JJ, Montiel C. Expression patterns for nicotinic acetylcholine
receptor subunit genes in smoking-related lung cancers. Oncotar-
get. 2017; 8(40): 67878-90. Article. Not Indexed
• Carrillo J, Calvete O, Pintado-Berninches L, Manguán-García C, Na-
varro JS, Arias-Salgado EG, Sastre L, Guenechea G, Granados EL, de
Villartay JP, Revy P, Benitez J, Perona R. Mutations in XLF/NHEJ1/
Cernunnos gene results in downregulation of telomerase genes ex-
pression and telomere shortening. Hum Mol Genet. 2017; 26(10):
1900-14. Article. IF: 4.902; Q1
260
• Chabot P, Hsia TC, Ryu JS, Gorbunova V, Belda-Iniesta C, Ball D, Kio
E, Mehta M, Papp K, Qin Q, Qian J, Holen KD, Giranda V, Suh JH.
Veliparib in combination with whole-brain radiation therapy for pa-
tients with brain metastases from non-small cell lung cancer: results
of a randomized, global, placebo-controlled study. J Neuro-Oncol.
2017; 131(1): 105-15. Article. IF: 3.06; Q2
• Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pi-
neda E, Mikkelsen T, Chinot OL, Balana C, Macdonald DR, Westphal
M, Hopkins K, Weller M, Bais C, Sandmann T, Bruey JM, Koeppen
H, Liu B, Verret W, Phan SC, Shames DS. Randomized, double-blind,
placebo-controlled, multicenter phase II study of onartuzumab plus
bevacizumab versus placebo plus bevacizumab in patients with re-
current glioblastoma: Efficacy, safety, and hepatocyte growth factor
and O-6-methylguanine-DNA methyltransferase biomarker analy-
ses. J Clin Oncol. 2017; 35(3): 343-51. Article. IF: 26.303; D1
• Cruz P, de Luján L, de Castro J. Management difficulties in a patient
with EGFR-mutation positive lung adenocarcinoma and cerebral
metastases. Arch Bronconeumol. 2017; 53(1): 37-8. Letter. IF: 2.633;
Q2
• de Castro J, González-Larriba JL, Vázquez S, Massuti B, Sánchez-To-
rres JM, Domine M, Garrido P, Calles A, Artal A, Collado R, García R,
Sereno M, Majem M, Macías J, Juan O, Gómez-Codina J, Hernández
B, Lazaro M, Ortega AL, Cobo M,Trigo JM, Carcereny E, Rolfo C, Ma-
cía S, Muñoz J, Diz P, Méndez M, Rosillo F, Paz-Ares L, Cardona JV, Isla
D. Long-term survival in advanced non-squamous NSCLC patients
treated with first-line bevacizumab-based therapy. Clin Transl Oncol.
2017; 19(2): 219-26. Article. IF: 2.392; Q3
• de Castro J, Tagliaferri P, de Lima VCC, NGS, Thomas M, Arunacha-
lam A, Cao X, Kothari S, Burke T, Myeong H, Grattan A, Lee DH.
Systemic therapy treatment patterns in patients with advanced non-
small cell lung cancer (NSCLC): PIvOTAL study. Eur J Cancer Care.
2017; 26(6): e12734. Article. IF: 2,409; D1
• Ferolla P, Brizzi MP, Meyer T, Mansoor W, Mazieres J, Do Cao C,
Lena H, Berruti A, Damiano V, Buikhuisen W, Gronbaek H, Lombard-
Bohas C, Grohe C, Minotti V, Tiseo M, de Castro J, Reed N, Gislim-
berti G, Singh N, Stankovic M, Oberg K, Baudin E. Efficacy and safety
of long-acting pasireotide or everolimus alone or in combination in
patients with advanced carcinoids of the lung and thymus (LUNA):
an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol.
2017; 18(12): 1652-64. Article. IF: 36.418; D1
• Gandhi L, Ou SHI, Shaw AT, Barlesi F, Dingemans AMC, Kim DW,
Camidge DR, Hughes BGM, Yang JCH, de Castro J, Crino L, Lena H,
Do P, Golding S, Bordogna W, Zeaiter A, Kotb A, Gadgeel S. Effica-
cy of alectinib in central nervous system metastases in crizotinib-
resistant ALK-positive non-small-cell lung cancer: Comparison of
RECIST 1.1 and RANO-HGG criteria. Eur J Cancer. 2017; 82: 27-33.
Article. IF: 7.191; Q1
• García-Romero N, Carrión-Navarro J, Esteban-Rubio S, Lázaro-
Ibáñez E, Peris-Celda M, Alonso MM, Guzmán-de-Villoria J, Fernán-
dez-Carballal C, de Mendivil AO, García-Duque S, Escobedo-Lucea
C, Prat-Acín R, Belda-Iniesta C, Ayuso-Sacido A. DNA sequences
within glioma-derived extracellular vesicles can cross the intact
blood-brain barrier and be detected in peripheral blood of patients.
Oncotarget. 2017; 8(1): 1416-28. Article. Not Indexed
• García-Romero N, Rackov G, Belda-Iniesta C, Ayuso-Sacido A. The
use of peripheral extracellular vesicles for identification of molecu-
lar biomarkers in a solid tumor mouse model. Methods Mol Biol.
2017; 1660: 397-406-. Article. Not Indexed
• Hernández-Jiménez E, Cubillos-Zapata C, Toledano V, de Diego RP,
Fernández-Navarro I, Casitas R, Carpio C, Casas-Martín J, Valentín
J, Varela-Serrano A, Avendaño-Ortiz J, Álvarez E, Aguirre LA, Pérez-
Martínez A, de Miguel MP, Belda-Iniesta C, García-Rio F, López-Co-
llazo E. Monocytes inhibit NK activity via TGF-beta in patients with
obstructive sleep apnoea. Eur Respir J. 2017; 49(6): 1602456. Article.
IF: 12.242; D1
• Hirsch FR, Govindan R, Zvirbule Z, Braiteh F, Rittmeyer A, Belda-
Iniesta C, Isla D, Cosgriff T, Boyer M, Ueda M, Phan S, Gandara DR.
Efficacy and safety results from a phase II, placebo-controlled study
of onartuzumab plus first-line platinum-doublet chemotherapy for
advanced squamous cell non-small-cell lung cancer. Clin Lung Can-
cer. 2017; 18(1): 43-9. Article. IF: 4.204; Q2
• Isla D, de Castro J, Juan O, Grau S, Orofino J, Gordo R, Rubio-Terres
C, Rubio-Rodríguez D. Costs of adverse events associated with er-
lotinib or afatinib in first-line treatment of advanced EGFR-positive
non-small cell lung cancer. Clínicoecon Outcomes Res. 2017; 9: 31-8.
Article. Not Indexed
• Isla D, Majem M, Vinolas N, Artal A, Blasco A, Felip E, Garrido P, Re-
mon J, Baquedano M, Borras JM, Trill MD, García-Campelo R, Juan
O, León C, Lianes P, López-Ríos F, Molins L, Planchuelo MA, Cobo
M, Paz-Ares L, Trigo JM, de Castro J. A consensus statement on the
gender perspective in lung cancer. Clin Transl Oncol. 2017; 19(5):
527-35. Review. IF: 2.392; Q3
• Montejano R, Stella-Ascáriz N, Monge S, Bernardino JI, Pérez-Valero
I, Montes ML, Valencia E, Martín-Carbonero L, Moreno V, González-
García J, Arnalich F, Mingorance J, Berniches LP, Perona R, Arribas JR.
Impact of antiretroviral treatment containing tenofovir difumarate
on the telomere length of Aviremic HIV- infected patients. JAIDS-J
Acq Imm Def. 2017; 76(1): 102-9. Article. IF: 4.116; Q1
• Remón J, Isla D, Garrido P, de Castro J, Majem M, Vinolas N, Artal A,
Carcereny E, García-Campelo MR, Lianes P, Provencio M, Juan O, Diz
P, Blanco R, López-Castro R, Maestu I, Vadell C, Felip E. Efficacy of
tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a
real-world setting: the WORLD07 database. Clin Transl Oncol. 2017;
19(12): 1537-42. Article. IF: 2.392; Q3
• Stella-Ascariz N, Montejano R, Pintado-Berninches L, Monge S,
Bernardino JI, Pérez-Valero I, Montes ML, Mingorance J, Perona R,
Arribas JR. Differential effects of tenofovir, abacavir, emtricitabine,
and darunavir on telomerase activity In vitro. JAIDS-J Acq Imm Def.
2017; 74(1): 91-4. Article. IF: 4.116; Q1
• Vera O, Jiménez J, Pernía O, Rodríguez-Antolín C, Rodríguez C,
Cabo FS, Soto J, Rosas R, López-Magallón S, Rodríguez IE, Dopazo A,
Rojo F, Belda C, Álvarez R, Valentín J, Benítez J, Perona R, de Castro
J, de Cáceres II. DNA methylation of miR-7 is a mechanism involved
in platinum response through MAFG overexpression in cancer cells.
Theranostics. 2017; 7(17): 4118-34. Article. IF: 8.537; D1
Public Projects
de Castro Carpeño J. Deteccion de alteraciones genéticas/
genómicas en DNA tumoral de cáncer de pulmón de célu-
las no pequeñas en estadío I y evaluación de la utilidad del
screening de DNA circulante tumoral en sangre periférica
como estrategia de seguimiento del cáncer (PI12/01463).
ISCIII. 2013-2017.
Managment centre: FIBHULP
de Castro Carpeño J. Plataforma de innovación
(PT13/0006/0012). ISCIII. 2014-2017.
Managment centre: FIBHULP
Ibáñez de Cáceres MI. Contrato Miguel Servet tipo II
(CPII14/00008). ISCIII. 2015-2019.
Managment centre: FIBHULP
Ibáñez de Cáceres MI. Desarrollo y validación de dos proto-
tipos de kit capaces de detectar un biomarcador que sirva a
los oncólogos como herramienta objetiva para personalizar
el tratamiento a pacientes con cáncer de pulmón no micro-
cítico en estadios avanzados. (RTC-2015-4362-1). MINECO.
2015-2017.
Managment centre: FIBHULP
Ibáñez De Cáceres MI. Validación clínica del Epigen Kit: Un
nuevo test para predecir la respuesta al tratamiento del cán-
cer de pulmón no microcítico (CPNM). Epigen-Kit. (RTC-
2016-5314-1). MINECO. 2017-2019.
Managment centre: FIBHULP
Ibáñez de Cáceres MI. Validación preclínica de biomarcado-
res epigenéticos de uso diagnóstico y predictivo en tumores
sólidos tratados con derivados de platino. Nuevos retos clí-
nicos asociados a la biopsia líquida. (PI15/00186). ISCIII. 2016-
2018.
Managment centre: FIBHULP
Perona Abellón R. Estudio molecular integrado en CNMP.
Búsqueda de marcadores moleculares pronósticos, heteroge-
neidad de células circulantes tumorales y sensibilidad extre-
ma a tratamiento (PI14/01495). ISCIII. 2015-2017.
Managment centre: CSIC-UAM
Private Projects
de Castro Carpeño J. Determinación mediante inmunohis-
toquímica de la expresion de PDL-1 en carcinoma de célula
no pequeña de pulmón.Varios. 2016-Ongoing.
Managment centre: FIBHULP
de Castro Carpeño J. ELUXA 2: Estudio de fase III, abierto,
aleatorizado y controlado con producto activo, multicéntrico
e internacional, para evaluar la eficacia de BI1482694 frente a
un doblete de quimioterapia estándar que incluye platino en
pacientes con cáncer de pulmón. Parexel International (Irl)
Limited. 2016-Ongoing.
Managment centre: FIBHULP
de Castro Carpeño J. Estudio de las diferencias de género en
el impacto psicosocial y económico en pacientes con cáncer
no microcítico de pulmón avanzado (IMPULSO). Investiga-
ción en Cáncer de Pulmón en Mujeres. 2015-Ongoing.
Managment centre: ICAPEM
de Castro Carpeño J. Evaluación de la capacidad predictiva
de un perfil proteómica en suero en la predicción de res-
puesta a un regímen de combinación estándar de primera lí-
nea en pacientes con carcinoma no microcítico de pulmón en
estadios IIIB no subsidiarios de radioterapia. Glaxosmithkline
S.A. 2008-Ongoing.
Managment centre: FIBHULP
de Castro Carpeño J. Expresión de colinoquinasa (chock)
y NF-KB en pacientes con carcinoma de colon y su relación
con la respuesta a capecitabina en combinación con oxalipla-
tino. Roche Farma S.A. 2008-Ongoing.
Managment centre: FIBHULP
de Castro Carpeño J. Gestión de la cartera de propiedad
industrial e intelectual.Varios Financiadores. 2017-Ongoing.
Managment centre: FIBHULP
de Castro Carpeño J. Oncología traslacional y la determi-
nación de traslocaciones de ALK en muestras de tumores
sólidos. Pfizer S.L.U.2011-Ongoing.
Managment centre: FIBHULP
de Castro Carpeño J. Programa de e-learning de formación
en cáncer de pulmón en mujeres. Investigación en Cáncer de
Pulmón en Mujeres. 2015-Ongoing.
Managment centre: ICAPEM
261
 3
Information Groups by Area

3.5 Cancer and Human Molecular Genetics Area

Esteban Rodríguez MI. Proyecto para la evaluación retros-
pectiva de muestras pareadas de biopsia y citología para la
detección de reordenamientos de ALK y expresión de PD-L1
en CPNP. Roche Farma S.A.2017-Ongoing.
Managment centre: FIBHULP
Ibáñez de Cáceres MI. Evaluación del proyecto de investi-
gación: contribución del factor de transcripción RUNX2 en
la progresión del cáncer de pulmón. Pontificia Universidad
Javeriana. 2016-Ongoing.
Managment centre: FIBHULP
Ibáñez de Cáceres MI. Estudio comparativo de muestras de
pacientes en parafina para medir el grado de metilacion del
gen IGFBP-3. Igen Biotech S.L. 2015-Ongoing.
Managment centre: FIBHULP
Ibáñez de Cáceres MI. Identificación de marcadores epige-
néticos para diagnóstico no invasivo en resistencia a platinos
y su implicación en el uso de terapias individualizadas. Varios
Financiadores. 2013-Ongoing.
Managment centre: FIBHULP
Ibáñez de Cáceres Mi. Identificación y uso de microRNAs
como marcadores epigenéticos de sensibilidad a cisplatino
en cáncer de pulmón no microcítico: implicación en terapias
individualizadas. Comunidad de Madrid. 2014-Ongoing.
Managment centre: FIBHULP
Ibáñez de Cáceres MI. Papel de los exosomas en la induc-
cion de resistencia a platino en un modelo experimental
de líneas celulares de cáncer de pulmón. Roche Farma S.A.
2017-Ongoing.
Managment centre: FIBHULP
HULP code: 4889. Sponsored´s protocol code: EMR100070-005.
Sponsored by: Merck KGAA.
Signed date: 00/01/1900
de Castro Carpeño J. Ensayo en fase III, aleatorizado, con
el anticuerpo monoclonal anti-PD-1 pembrolizumab (MK-
3475), en comparación con placebo para pacientes con
CPNM en fase temprana después de resección y finalización
del tratamiento complementario de referencia. Type: Clinical
Trial, phase III.
HULP code: ANEXO-I 4558. Sponsored´s protocol code: EORTC
1416-LCG.
Sponsored by: Merck & Co. Inc.
Signed date: 07/04/2017
de Castro Carpeño J. Estudio Cesto, abierto, multicén-
trico, global, en fase II con entrectinib para el tratamiento
de pacientes con tumores sólidos localmente avanzados o
metastásicos que albergan reordenaciones en los genes
NTRK1/2/3, ROS1 o ALK. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4648. Sponsored´s protocol code: RXDX-
101-02.
Sponsored by: Ignyta Inc.
Signed date: 21/07/2017
de Castro Carpeño J. Estudio de biomarcadores no inter-
vencionista en pacientes con cáncer de pulmón no microcí-
tico (NSCLC) del tipo histológico adenocarcinoma elegibles
para el tratamiento con Vargatef® según la ficha técnica au-
torizada. Type: EPA-SP.
HULP code: PI-2388. Sponsored´s protocol code: 1199.223.
Sponsored by: Boehringer Ingelheim España S.A.
Signed date: 24/01/2017
de Castro Carpeño J. Estudio de fase II, de un solo grupo y
abierto, de evaluación de la eficacia, la seguridad y la farmaco-
cinética de hm61713 (bi1482694)) en pacientes con cáncer
de pulmón no microcítico (cpnm) con la mutación t790m
tras el tratamiento con un inhibidor de la tirosina cinasa del
receptor del factor de crecimiento epidérmico (egfr-tki).
Type: Clinical Trial, phase II.
HULP code: ANEXO-II 4461. Sponsored´s protocol code: HM-
EMSI-202.
Sponsored by: Hanmi Pharmaceutical Ltd.
Signed date: 20/10/2017
de Castro Carpeño J. Estudio de fase II, multicéntrico, de
tres cohortes con el inhibidor oral de CMET, INC280, en
pacientes adultos con cáncer de pulmón de células no pe-
queñas (NSCLC) avanzado y EGFR wild type (WT), que han
recibido una o dos líneas previas de terapia sistémica para
enfermedad avanzada/metastásica. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4554. Sponsored´s protocol code: CIN-
C280A2201.
Sponsored by: Novartis Farmacéutica S.A.
Signed date: 16/10/2017
de Castro Carpeño J. Estudio de fase II/III, aleatorizado,
abierto y de dos partes, de dinutuximab e irinotecán versus
irinotecán como tratamiento de segunda línea en sujetos con
cáncer de pulmón microcítico en recidiva o resistente. Type:
Clinical Trial, phase II/III.
HULP code: 4832. Sponsored´s protocol code: DIV-SCLC-301.
Sponsored by: United Therapeutics Corporation.
Signed date: 12/06/2017
de Castro Carpeño J. Estudio de fase III aleatorizado de la
combinación de pembrolizumab (MK 3475) más epacadostat
(INCB024360) solos o con quimioterapia a base de platino
en comparación con pembrolizumab más quimioterapia a base
de platino más placebo como tratamiento de primera línea en
pacientes con cáncer de pulmón no microcítico metastásico.
Type: Clinical Trial, phase III.
HULP code: 4952. Sponsored´s protocol code: MK-3475-715.
Sponsored by: Merck Sharp and Dohme de España S.A.
Signed date: 26/10/2017
de Castro Carpeño J. Estudio de fase III multicéntrico, abier-
to, randomizado de alectinib frente a pemetrexed o doce-
taxel en pacientes con cáncer de pulmón no microcítico
avanzado quinasa del linfoma anaplásico positivo, tratados
previamente con quimioterapia basada en platino y crizotinib.
Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4455. Sponsored´s protocol code: MO29750.
Sponsored by: F. Hoffmann-La Roche Ltd.
Signed date: 16/10/2017

CLINICAL TRIALS de Castro Carpeño J. Estudio de extensión de fase IV, mul-

de Castro Carpeño J. A phase II exploratory study of dur-
valumab (MEDI4736) in HIV-1 patients with advanced solid
tumors. Type: Clinical Trial, phase II.
HULP code: 4762. Sponsored´s protocol code: GECP16/04.
Sponsored by: Grupo Español Cáncer Pulmón.
Signed date: 03/02/2017
de Castro Carpeño J. A randomised phase II trial of osimer-
tinib and bevacizumab versus osimertinib alone as second-li-
ne treatment in stage IIIB-IVB NSLC with confirmed EGFRM
and T790M. Type: Clinical Trial, phase II.
HULP code: 4806.
Sponsored´s protocol code: BOOSTER (ETOP 10/16.
Sponsored by: Grupo Español Cáncer Pulmón.
Signed date: 21/04/2017
de Castro Carpeño J. Ensayo clínico fase II, exploratorio y
multicentrico, de quimioinmunoterapia neo-adyuvante para
el tratamiento del cáncer de pulmón no microcitico estadio
III operable. Type: Clinical Trial, phase II.
HULP code: 4738.
Sponsored´s protocol code: 4738 NADIM (GECP 16/03).
Sponsored by: Grupo Español Cáncer Pulmón.
Signed date: 18/01/2017
de Castro Carpeño J. Ensayo de fase III, abierto, multicéntri-
co de avelumab (MSB0010718C) frente al doblete con base
de platino como tratamiento de primera línea del cáncer de
pulmón no microcítico PD-l1+ recurrente o en estadio IV.
Type: Clinical Trial, phase III.
262
ticéntrico, abierto en pacientes con tumores malignos ALK
positivo que hayan finalizado un estudio previo de ceritinib
(LDK378) patrocinado por Novartis y que vayan a benefi-
ciarse del tratamiento continuado con ceritinib según el cri-
terio del investigador. Type: Clinical Trial, phase IV.
HULP code: 4896. Sponsored´s protocol code: CL-
DK378A2X01B.
Sponsored by: Novartis Farmaceutica S.A.
Signed date: 18/08/2017
de Castro Carpeño J. Estudio de extensión
multicéntrico, internacional de alectinib en
pacientes con tumores positivos para qui-
nasa del linfoma anaplásico (alk) o reorde-
nación durante la transfección (RET). Type:
Clinical Trial, phase IIIb.
HULP code: 4799. Sponsored´s protocol code:
BO39694.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 17/04/2017
de Castro Carpeño J. Estudio de fase
II, de grupos paralelos, sobre MGCD265 en
pacientes con cáncer de pulmón no microcítico localmen-
te avanzado o metastásico con alteraciones genéticas en el
factor de transición epitelio-mesenquimal. Type: Clinical Trial,
phase II.
HULP code: 4531. Sponsored´s protocol code: 265-109.
Sponsored by: Mirati Therapeutics Inc.
Signed date: 17/10/2017
263
 3
Information Groups by Area
3.5 Cancer and Human Molecular Genetics Area
de Castro Carpeño J. Estudio de fase III, abierto y aleato-
rizado para comparar atezolizumab (anticuerpo anti-PD-l1)
con un derivado del platino (cisplatino o carboplatino) en
combinación con pemetrexed o gemcitabina en pacientes
con cáncer de pulmón no microcítico y no epidermoide o
epidermoide en estadio IV seleccionados por PD-l1 que no
han recibido quimioterapia previa.Type: Clinical Trial, phase III.
HULP code: 4837. Sponsored´s protocol code: GO29431.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 24/07/2017
de Castro Carpeño J. Estudio de fase III, aleatorizado y abier-
to de lorlatinib (PF-06463922) en monoterapia en compa-
ración con crizotinib en monoterapia en el tratamiento de
primera línea de pacientes con carcinoma pulmonar no mi-
crocítico avanzado ALK-positivo. Type: Clinical Trial, phase III.
HULP code: 4938. Sponsored´s protocol code: B7461006.
Sponsored by: Pfizer Inc.
Signed date: 18/10/2017
de Castro Carpeño J. Estudio de fase III, aleatorizado, doble
ciego y controlado con placebo de rovalpituzumab tesirina
como tratamiento de mantenimiento después de una prime-
ra línea de tratamiento quimioterápico basado en platino en
pacientes con cáncer de pulmón microcítico en estadio avan-
zado (MERU). Type: Clinical Trial, phase III.
HULP code: 4814. Sponsored´s protocol code: M16-298.
Sponsored by: Abbvie Deutschland GMBH.
Signed date: 20/06/2017
de Castro Carpeño J. Estudio de fase III, multicéntrico, alea-
torizado, en doble ciego y controlado con placebo, para eva-
luar la eficacia y la seguridad de AZD9291 frente a placebo
en pacientes con carcinoma de pulmón no microcítico con
mutación del receptor del factor de crecimiento epidérmico,
en estadio IB-IIIA, tras la resección completa del tumor, con
o sin quimioterapia adyuvante. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4474.
Sponsored´s protocol code: D5164C00001.
Sponsored by: Astrazeneca AB.
Signed date: 10/10/2017
de Castro Carpeño J. Estudio de fase III/IV multicéntrico,
con un solo grupo de tratamiento, para investigar la seguri-
dad a largo plazo y la eficacia de atezolizumab (Tecentriq) en
pacientes con cáncer de pulmón no microcítico localmente
avanzado o metastásico, tratados previamente (Tail). Type:
Clinical Trial, phase III.
HULP code: 4883. Sponsored´s protocol code: MO39171.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 05/09/2017
de Castro Carpeño J. Estudio en fase I, abierto, no aleatori-
zado y multicéntrico para evaluar la farmacocinética, la segu-
ridad y la tolerabilidad de osimertinib tras la administración
de una dosis oral única de 80 mg a pacientes con tumores
sólidos avanzados y función renal normal o disfunción renal
grave. Type: Clinical Trial, phase I.
HULP code: 4774. Sponsored´s protocol code: 4774.
Sponsored by: Astrazeneca AB.
Signed date: 30/01/2017
de Castro Carpeño J. Estudio en fase I, abierto, no aleatori-
zado y multicéntrico para evaluar la farmacocinética, la segu-
ridad y la tolerabilidad de osimertinib tras la administración
de una dosis oral única de 80 mg a pacientes con tumores
264
sólidos avanzados y función renal normal o disfunción renal
grave. Type: Clinical Trial, phase I.
HULP code: 4775. Sponsored´s protocol code: 4775.
Sponsored by: Astrazeneca AB.
Signed date: 30/01/2017
de Castro Carpeño J. Estudio en fase III abierto, multicén-
trico de brigatinib (AP26113) frente a crizotinib en pacientes
con cáncer de pulmón avanzado positivo para ALK. Type: Cli-
nical Trial, phase III.
HULP code: ANEXO-I 4698. Sponsored´s protocol code: AP26113-
13-301.
Sponsored by: Ariad Pharmaceutical Inc.
Signed date: 30/10/2017
de Castro Carpeño J. Estudio en fase III, abierto y aleatori-
zado para investigar la eficacia y seguridad de atezolizumab
(anticuerpo anti-PD-L1) en comparación con el tratamiento
de soporte óptimo. Type: Clinical Trial, phase III.
HULP code: ANEXO-II 4480. Sponsored´s protocol code: GO29527.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 20/02/2017
de Castro Carpeño J. Estudio en fase III, aleatorizado, abierto,
sobre la eficacia y seguridad de dacomitinib (PF-00299804)
frente a gefitinib, en el tratamiento de primera línea del cán-
cer de pulmón no microcitico localmente avanzado o me-
tastásico en pacientes con mutación(es) ectivadora(s) del
receptor del factor de crecimiento epidemico (EGFR). Type:
Clinical Trial, phase III.
HULP code: ANEXO-I 4001. Sponsored´s protocol code: DP312804.
Sponsored by: Sfj Lungcancer Ltd.
Signed date: 30/03/2017
de Castro Carpeño J. Estudio fase III, abierto, aleatorizado de
MPDL3280A (anticuerpo anti-PD-L1) en combinación con
carboplatino + paclitaxel con o sin bevacizumab comparado
con carboplatino  + paclitaxel + bevacizumab en pacientes
con cáncer de pulmón no epidermoide no microcítico  en
estadio IV que no han recibido quimioterapia previa. Type:
Clinical Trial, phase III.
HULP code: ANEXO-I 4405. Sponsored´s protocol code: GO29436.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 05/04/2017
de Castro Carpeño J. Estudio fase III, abierto, multicéntri-
co, aleatorizado que evalúa la eficacia y seguridad de MPD-
L3280A (anticuerpo anti-PD-L1) en combinación con car-
boplatino + paclitaxel o MPDL3280A en combinación con
carboplatino  + NAB-paclitaxel comparado con carboplatino
+ NAB-paclitaxel en pacientes con cáncer de pulmón no mi-
crocítico  escamoso estadio IV que no han recibido quimio-
terapia previa. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4404. Sponsored´s protocol code: GO29437.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 05/04/2017
de Castro Carpeño J. Un estudio multicéntrico, en fase I, abier-
to y no aleatorizado para evaluar el efecto de la rifampicina (un
inductor de CYP3A4) sobre la farmacocinética de AZD9291
en pacientes con cáncer de pulmón no microcítico (CPNM)
positivos para EGFM cuya enfermedad ha progresado con el
tratamiento con TKI del EGFR. Type: Clinical Trial, phase I.
HULP code: ANEXO-I 4360.
Sponsored´s protocol code: D5160C00013.
Sponsored by: Astrazeneca AB.
Signed date: 02/02/2017
de Castro Carpeño J. Un estudio multicéntrico, en fase I,
abierto y no aleatorizado para evaluar el efecto de AZD9291
sobre la farmacocinética de la simvastatina (un sustrato sen-
sible de CYP3a4) en pacientes con cáncer de pulmón no mi-
crocítico (CPNM) positivos para EGFrm cuya enfermedad
ha progresado con el tratamiento con TKI del EGFR. Type:
Clinical Trial, phase I.
HULP code: ANEXO-I 4262.
Sponsored´s protocol code: D5160C00014.
Sponsored by: Astrazeneca AB.
Signed date: 02/02/2017
Esteban Rodríguez I. Estudio no intervencional multinacio-
nal para evaluar la expresión de PD L1 en muestras citológi-
cas frente a histológicas de pacientes con cáncer de pulmón
no microcítico o microcítico. Type: NO-EPA.
HULP code: PI-2583. Sponsored´s protocol code: MO29978.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 10/01/2017
Patents and Trademarks
Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Cas-
tro Carpeño J, Moreno García V, Burgos Lizalde E, Ca-
sado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP,
UAM, Empresa Pública Hospital del Norte, assignees. Ge-
nomic fingerprint for predicting the clinical response to an
antitumor therapy in colorectal cáncer. P201130863, PCT/
ES2012/070379; 2011 May 26.
Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González
Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez
Hernández JJ, inventors; FIBHULP, UAM, assignees. Geno-
mic fingerprint for the prognosis of the evolution of colo-
rectal adenocarcinoma. P200703229, PCT/ES2008/000756,
EP2236626; 2007 December 04.
Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez
Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM,
CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prog-
nosis of patients diagnosed with colorectal cancer. P200703230,
PCT/ES2008/000757, EP2236625; 2007 December 04.
Ibáñez de Cáceres I, Belda Iniesta C, Pernía Arias O, Pe-
rona Abellón R, Cortés Sempere M; inventors. FIBHULP,
CSIC, UAM, Fundación Hospital de Madrid, assignees.
Method for predicting the response to a treatment con-
sisting of radiotherapy combined with cisplatin-based che-
motherapy. P201330783, PCT/ES2014/070433, EP3006572,
US20160122828; 2013 May 29.
Ibáñez de Cáceres I, de Castro Carpeño J, Vera Puente
O, Pernía Arias O, Rodríguez Antolín C, González Muñoz
VM, Martín Palma ME, Salgado Figueroa AM, inventors; FI-
BHULP, FIBIOHRC, assignees. MAFG as a potential therapeu-
tic target to restore chemosensitivity in platinum-resistant
cancer cells. EP17382610.8 (Publication Number pending);
2017 September 15.
Ibáñez de Cáceres I, Pernía Arias O, de Castro Carpeño J,
Vera Puente O, Jiménez Hernández J, Perona Abellón R,
Rojo Todo F, inventors; FIBHULP, CSIC, UAM, Instituto de In-
vestigación Sanitaria FJD, assignees. Determination of methyla-
tion and miRNA levels in response to a platinum-based an-
titumor compound. P201530997, PCT/ES2016/070516; 2015
July 09.
Martínez Máñez R, Murguía Ibáñez JR, Perona Abellón
R, Agostini A, Mondragón Martínez L, Moreno Torres M,
Manguán García C, Marcos Martínez MD, Soto Camino J,
Sancenón Galarza F, inventors; Universidad Politécnica de
Valencia, CSIC, Centro de Investigación Biomédica en Red en
Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN),
Centro de Investigación Biomédica en Red de Enfermedades
Raras (CIBERER), assignees. Release of substances into se-
nescent cells. P201231370, PCT/ES2013/070581, EP2893923,
JP2015529216, US2015306037; 2012 September 04.
Perona Abellón R, Sánchez Pérez I, Machado Pinilla R,
Sastre Garzón L, Murguía Ibáñez JR, inventors; CSIC, UAM,
Universidad Politécnica de Valencia, assignees. Sequence of
nucleotides and peptides GSE 24.2 of dyskerin, which can
induce telomerase activity, method for obtaining same, the-
rapeutic compositions and applications thereof. P200502511,
PCT/ES2006/070152, EP1947175, US20090202503,
US2015337022, AT469212, CA2625981, DK1947175,
JP2009511036, JP5560398, PT1947175; 2005 October 14.
Perona Abellón R, Sastre Garzón L, Machado Pinilla R,
Sánchez Pérez I, inventors; CSIC, UAM, assignees. Use of
inductor agents GSE24.2 for producing pharmaceutical
compositions for treating illnesses relating to cellular se-
nescence. P200703106, PCT/ES2008/070212, EP2216043,
US2011300115, JP2011504483, CA2706467; 2007 Novem-
ber 23.
Perona Abellón R, Sastre Garzón L, Pintado Berninches
L, Carrillo García J, Molina Pachón A, Irradiccio Silva L,
Manguán García C, inventors; CSIC, UAM, Advanced Me-
dical Projects, Centro de Investigación Biomédica en Red
(CIBER), assignees. Peptides derived from GSE 24.2 for trea-
ting diseases caused by oxidative stress and damage to DNA.
P201331573, AU2014338820, CA2931429, EP3061815 PCT/
ES2014/070803; 2013 October 25.
265
 3
Information Groups by Area
3.5 Cancer and Human Molecular Genetics Area
Oto-Neurosurgery
Research Group
13 33.409 4
Luis Lassaletta Atienza. Jefe de Sección de
Otorrinolaringología. HULP
Strategic Objective
Carolina Alfonso Carrillo. Facultativo Especialista de Área en
Otorrinolaringología. HULP
Miryam Calvino Fernández. Investigadora Postdoctoral. UAM
Alejandro Castro Calvo. Facultativo Especialista de Área en
Otorrinolaringología. HULP
Isabel García López. Facultativo Especialista de Área en
Otorrinolaringología. HULP
Javier Gavilán Bouzas. Jefe de Servicio de Otorrinolaringología. HULP
Catedrático. Departamento de Cirugía. Facultad de Medicina. UAM
Teresa González Otero. Facultativo Especialista de Área en Cirugía
Maxilofacial. HULP
Silvia Murillo Cuesta. Investigadora Postdoctoral. IIB Alberto Sols
Carolina Peña Granero. Técnico de Laboratorio (Contrato PTA). HULP
Rosa María Pérez Mora. Facultativo Especialista de Área en
Otorrinolaringología. HULP
Juan Antonio Rey Herranz. Investigador Senior (Contrato MIguel
Servet - I2). Jefe de Laboratorio. HULP
Laura del Río Arroyo. Facultativo Especialista de Área en
Otorrinolaringología. HULP
Lourdes Rodríguez de La Rosa. Técnico de Laboratorio. IIB Alberto
Sols
Isabel Pilar Sánchez Cuadrado. Facultativo Especialista de Área en
Otorrinolaringología. HULP
Miguel Torres Martín. Investigador Postdoctoral. HULP
María Isabel Varela Nieto. Profesor de Investigación. IIB Alberto Sols
Antonio Villalobo Polo. Profesor de Investigación. IIB Alberto Sols
266
The systematic use of magnetic resonance imaging
(MRI) has dramatically increased the diagnosis of
patients with vestibular schwannoma (VS). The ma-
jority of patients with VS complain of hypoacusis
Research Lines
or tinnitus, and very few present more debilitating
symptoms. Therefore, the approach with a patient
with VS is complex because the treatment of the
tumour is directed towards avoiding complications
arising from its growth and not necessarily towards
improving the patient’s quality of life. Currently, there
are no factors that allow us to predict the growth of
vestibular schwannoma.
Recent advances in the field of oncogenetics have
allowed us to better understand the development of
VS.
The study of the correlation between clinical varia-
bles related to the biological behaviour of VS and its
genetic and epigenetic disorders aims to find the fac-
tors that predict the behaviour of VS. This will help
us identify patients who need active treatment of the
tumour and avoid the morbidity associated with the
treatment in those who do not need it.
The cochlear implant (CI) is currently the only so-
lution for relieving the condition in patients with
severe or profound hypoacusis who do not bene-
fit from a prosthetic adaptation with a conventional
hearing aid. It is estimated that there are currently
120,000 adults in Spain with profound sensorineu-
ral hypoacusis. In recent years, new hearing implants
have been developed including osseointegrated implants
and active middle ear implants. It´s excellent and often
spectacular results and its low rate of complications have
transformed CI from an innovative technology in the ex-
perimental phase to a routine, safe and effective proce-
dure, capable of returning deaf individuals to the hearing
world and ending their isolation, increasing their quality
of life. Over the past decade the relationship between
hearing loss and cognitive decline in the older population
has become the subject of research. We also explore the
relationships between the cognitive function and the au-
diometric performances in patients wearing a CI.
Moderate to severe hypoacusis is one of the most preva-
lent medical problems. Ciliated sensory cells and neurons
do not regenerate in mammals, which is the main cause of
sensorineural deafness. Mutations causing deficiencies in
the levels of the Insulin like growth factor type 1 (IGF-1)
also cause sensorineural deafness in humans and mice.
IGF-1 is an essential factor in the postnatal development
of mammals, and its level decreases with ageing. We are
studying the participation of IGF-1 in the development
of the inner ear and in the pathophysiology of hearing
in adults, as well as, the molecular signalling networks
conferring specificity in the otic cellular response to
IGF-1. We are studying the signals that regulate otic de-
velopment and also those involved in otic damage with
the objective of identifying the key factors implicated in
functional repair and regeneration of inner ear cells. Fi-
nally, we are jointly developing an experimental model
of damage associated with the cochlear implant to test
new molecules with otoprotective potential. In short, our
work contributes to the study of auditory pathophysio-
logy, with the ultimate objective of investigating the po-
tential clinical usefulness of IGF-1 in human hypoacusis
originating in the cochlea.
• Tumors of the CNS: vestibular schwannoma, meningio-
mas, gliomas, and other: surgery, oncogenetics, quality
of life, etc.
• Auditory implants: cochlear implants, middle ear im-
plants, bone-conduction implants: surgical aspects, te-
lephone use, quality of life, perception of music, cogni-
tive declive, etc.
• IGF-I deficiency: a rare syndromic human deafness.
• Neurobiology of hearing: molecular and cellular bases
of hearing loss of different aetiology (genetic, noise
exposure, malnutrition, and ototoxic drugs). Identifica-
tion of transcriptional networks.
• Development of experimental models of deafness (ge-
netic, noise exposure, malnutrition, ototoxic drugs and
surgery associated trauma) for pre-clinical studies with
potential therapeutic molecules, thus identifying possi-
ble therapeutic targets, potential markers for diagnosis
and generation of vital guidelines.
• Head and Neck tumors and voice pathology.
• The role of celular senescence in the development of
the inner ear and the audithory pathology.
• Studies on three systems implicated in the develop-
ment of tumor metastasis: the tyrosine kinase recep-
tor ErbB2; the non-receptor tyrosine kinase c-Src; and
the adaptor protein Grb7.
Research Activity
Doctoral TheseS
Lekue Madanabeitia AL. Calidad de vida en pacien-
tes implantados con BAHA[dissertation]. Madrid: UAM:
2017(22/09/2017).
Director: Lassaletta Atienza L.
Pedrero Escalas MF. Ensayo clínico hospitalario: Homeopatía
en las otitis secretoras infantiles. [dissertation]. Madrid: UAM:
2017(17/02/2017).
Directors: Lassaletta Atienza L; Jiménez Antolín JA.
Vallecillo Hernández N. Nuevas estrategias para la preven-
ción de la pérdida auditiva neurosensorial en el ratón: Áci-
dos grasos omega-3 y Dendrogenina B[dissertation]. Madrid:
UAM: 2017(01/09/2017).
Director: Murillo Cuesta S.
BOOKS AND BOOK CHAPTERS
Castro A, Rodrigáñez L, Gavilán J, Ferrero E, Durán M.
Tiroidectomía y vaciamiento ganglionar central del cuello. In:
Durán Poveda M, Ferrero Herrero E. Cirugía Tiroidea con
Imágenes. Madrid: Dykinson S.L., 2017. p.137-41
Castro A, Rodrigáñez L, Gavilán J, Ferrero E, Durán M.
Tiroidectomía y vaciamiento ganglionar lateral del cuello. In:
Durán Poveda M, Ferrero Herrero E. Cirugía Tiroidea con
Imágenes. Madrid: Dykinson S.L., 2017. p.143-8
Durán M, García A, Franco R, González J, Vidal O, Martos
JM, Gavilán J, Castro A, Ferrero E. Aspectos generales de la
monitorización nerviosa intraoperatoria del nervio laríngeo
recurrente en la cirugía tiroidea. In: Durán Poveda M, Ferrero
Herrero E. Cirugía Tiroidea con Imágenes. Madrid: Dykinson
S.L., 2017. p.43-55
García O, Ferrero E, Guadarrama FJ, Yuste P, Castro A, Ro-
drigáñez L, Gavilán J, Durán M. Tratamiento quirúrgico de la
enfermedad de Graves Basedow. In: Durán Poveda M, Ferrero
Herrero E. Cirugía Tiroidea con Imágenes. Madrid: Dykinson
S.L., 2017. p.101-5
Rodrigáñez L, Castro A, Gavilán J, Ferrero E, Durán M.
Vaciamiento ganglionar en el cáncer de tiroides. Anatomía
quirúrgica. In: Durán Poveda M, Ferrero Herrero E. Cirugía
Tiroidea con Imágenes. Madrid: Dykinson S.L., 2017. p.37-42
PUBLICATIONS
• Anguita E,Villalobo A. SRC-family tyrosine kinases and the Ca2+ sig-
nal. BBA-Mol Cell Res. 2017; 1864(6): 915-32. Article. IF: 4.651; Q1
• Banks CA, Jowett N, Azizzadeh B, Beurskens C, Bhama P, Borschel
G, Coombs C, Coulson S, Croxon G, Diels J, Fattah A, Frey M, Ga-
vilán J, Henstrom D, Hohman M, Kim J, Marres H, Redett R, Snyder-
Warwick A, Hadlock T. Worldwide testing of the eFACE facial nerve
clinician-graded scale. Plast Reconstr Surg. 2017; 139(2): 491-8. Arti-
cle. IF: 3.475; Q1
• García-Alcantara F, Murillo-Cuesta S, Pulido S, Bermúdez-Muñoz JM,
Martínez-Vega R, Milo M, Varela-Nieto I, Rivera T. The expression of
oxidative stress response genes is modulated by a combination of
resveratrol and N-acetylcysteine to ameliorate ototoxicity in the
rat cochlea.Hear Res. 2017; 358: 10-21. Article. IF: 2.824; Q1
• García-Palmero I, Pompas-Veganzones N, Villalobo E, Gioria S,
267
 3
Information Groups by Area
3.5 Cancer and Human Molecular Genetics Area
Haiech J, Villalobo A. The adaptors Grb10 and Grb14 are calmo-
dulin-binding proteins. Febs Lett. 2017; 591(8): 1176-86. Article. IF:
2.999; Q2
• Lassaletta L, Polak M, Huesers J, Díaz-Gómez M, Calvino M, Varela-
Nieto I, Gavilán J. Usefulness of electrical auditory brainstem res-
ponses to assess the functionality of the cochlear nerve using an
intracochlear test electrode. Otol Neurotol. 2017; 38(10): e413-20.
Article. IF: 2.182; Q2
• Magarinos M, Pulido S, Aburto MR, de Iriarte Rodríguez R, Varela-
Nieto I. Autophagy in the Vertebrate Inner Ear. Front Cell Dev Biol.
2017; 5: 56. Review. Not Indexed
• Manos M, Giralt J, Rueda A, Cabrera J, Martínez-Trufero J, Marruecos
J, López-Pousa A, Rodrigo JP, Castelo B, Martínez-Galán J, Arias F,
Chaves M, Herranz JJ, Arrazubi V, Baste N, Castro A, Mesia R. Mul-
tidisciplinary management of head and neck cancer: First expert
consensus using Delphi methodology from the Spanish Society for
Head and Neck Cancer (part 1). Oral Oncol. 2017; 70: 58-64. Re-
view. IF: 4.636; D1
• Moraes LS, Santos ACC, Ferreira-Fernandes H, Yoshioka FKN, Tei-
xeira SS, Guimaraes AC, da Rocha CAM, Rey JA, Pinto GR, Burbano
RR. Lack of association between COMT Val158Met and ZDHHC8
rs175174 polymorphisms and susceptibility to schizophrenia in a
Brazilian population. Psychiat Genet. 2017; 27(5): 197-8. Editorial
Material. IF: 1.586; Q4
• Murillo-Cuesta S,Vallecillo N, Cediel R, Celaya AM, Lassaletta L,Vare-
la-Nieto I, Contreras J.A comparative study of drug delivery methods
targeted to the mouse inner ear: Bullostomy versus transtympanic
injection. J Vis Exp. 2017; (121): e54951. Article. IF: 1.184; Q2
• Pardo-Maza A, García-López I, Santiago-Pérez S, Gavilán J. Laryngeal
electromyography for prognosis of vocal fold paralysis. J Voice. 2017;
31(1): 90-3. Article. Not Indexed
• Partearroyo T, Vallecillo N, Pajares MA, Varela-Moreiras G, Varela-
Nieto I. Cochlear homocysteine metabolism at the crossroad of
nutrition and sensorineural hearing loss. Front Mol Neurosci. 2017;
10: 107. Review. IF: 3.902; Q2
• Rodríguez de la Rosa L, Lassaletta L, Calvino M, Murillo-Cuesta S,
Varela-Nieto I. The role of insulin-like growth factor 1 in the pro-
gression of age-related hearing loss. Front Aging Neurosci. 2017; 9:
411. Review. IF: 3.582; Q2
• Santosa KB, Fattah A, Gavilán J, Hadlock TA, Snyder-Warwick AK.
Photographic standards for patients with facial palsy and recom-
mendations by members of the sir Charles Bell Society. JAMA Facial
Plast Su. 2017; 19(4): 275-81. Article. IF: 2.388; Q2
Public Projects
Lassaletta Atienza L. Implantes cocleares y función cogniti-
va. Medidas de resultados auditivos, calidad de vida y calidad
del sonido (PI16/00079). ISCIII. 2017-2019.
Managment centre: FIBHULP
Rey Herranz JA. Contrato de estabilización Miguel Servet
(I2). ISCIII/CAM. 2006-2019.
Managment centre: FIBHULP
Varela Nieto I. Mecanismos de protección y neuropatogéne-
sis en la pérdida auditiva. Factores de protección y reparación
(SAF2014-53979). MINECO. 2015-2017.
Managment centre: IIB Alberto Sols
Varela Nieto I. Nuevos tratamientos para la prevención y
tratamiento de la hipoacusia. Estrategias de prevención.
CDTI. 2015-2017.
268
Managment centre: IIB Alberto Sols
Villalobo Polo A. Dominios de unión de calmodulina del eje
ERBB2/C-SRC/GRB7 como dianas terapéuticas en metástasis
de cáncer de mama (SAF2014-52048). MINECO. 2015-2017.
Managment centre: IIB Albero Sols
Private Projects
Lassaletta Atienza L. Influencia de las estrategias de codifi-
cación y el uso de sistemas de apoyo en la percepción y uso
del teléfono en pacientes adultos con implante coclear. Med-
El Elektromedizinische Geräte Gesellschaft M.B.H. 2011-On-
going.
Managment centre: FIBHULP
Lassaletta Atienza L, Gavilán Bouza J. Medidas de cambios
en la calidad de vida. Hearring Group. 2016-Ongoing.
Managment centre: FIBHULP
Lassaletta Atieza L, Sánchez-Cuadrado IP. Análisis de las
capacidades cognitivas en pacientes mayores con hipoacusia
profunda con y sin implante coclear (IC): un estudio multi-
céntrico prospectivo, longitudinal y comparativo. Med-El Ele-
ktromedizinische Geräte Gesellschaft M.B.H. 2016-Ongoing.
Managment centre: FIBHULP
INTERNATIONAL Projects
Varela Nieto I. Development of a European Network for
preclinical testing of interventions in mouse models of age
and age-related diseases (mouseage) (BM1402). EU: Cost Ac-
tions. 2013-2018.
Managment centre: IIB Alberto Sols
Varela Nieto I. Targear-targeting challenges of active ageing:
innovative integrated strategies for the healing of age-related
hearing loss (FP7-PEOPLE-2013-IAPP). EU: Marie Curie In-
dustry-Academia Partnership and Pathwa. 2013-2018.
Managment centre: IIB Alberto Sols.
Patents and Trademarks
Polak M, Roca-Ribas Serdá F, Gavilán Bouzas J, Lassaletta
Atienza L, Miró Castillo N, Rodrigo Dacosta J, inventors;
MED-EL Elektromedizinische Geraete GmbH, assignee. Hea-
ring treatment in patients with questionable cochlear nerve
functionality. US2011275953, PCT/US2011/035312; 2010
May 05.
Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Navares
Zaera R, Martínez Vega R, Cediel Algovia R, inventors; CSIC,
UCM, assignees. Anechoic acoustic chamber for evaluating
the auditory function in laboratory animals. P201031720;
2010 November 23.
Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Cediel Al-
govia R, inventors; CSIC, UCM, assignees. Method for desig-
ning a reverberating acoustic chamber for hearing test with
animals. Procedimiento para diseñar una cámara acústica re-
verberante para ensayos auditivos con animales. P200802895,
PCT/ES2009/070433; 2008 October 14.
Cancer Molecular Pathology and
Therapeutic Targets Group
17 41.049 6
David Hardisson Hernáez. Jefe de Servicio de Anatomía
Patológica. HULP. Profesor Titular. Facultad de Medicina. UAM
Alberto Berjón García. Médico Adjunto Especialista de Área en
Anatomía Patológica. HULP
Emilio Burgos Lizáldez. Facultativo Especialista de Área en Anatomía
Patológica. HULP
Javier de Santiago García. Jefe de Servicio de Ginecológica
Oncológica. HULP. Profesor Asociado. Facultad de Medicina. UAM
Laura Guerra Pastrián. Médico Adjunto Especialista de Área en
Anatomía Patológica. HULP
Jorge Martín Pérez. Investigador Científico . IIB Alberto Sols
Marta Mendiola Sabio. Investigadora Postdoctoral. HULP
María Miguel Martin. Técnico de Laboratorio. HULP
Alberto Peláez García. Investigador Postdoctoral. HULP
Elia Pérez Fernández. Investigadora Predoctoral. HULP
José Juan Pozo Kreilinger. Facultativo Especialista de Área en
Anatomía Patológica. HULP
Jose Ignacio Sánchez Méndez. Facultativo Especialista de Área en
Ginecología y Obstetricia. HULP. Profesor Asociado. Facultad de Medicina.
UAM
Laura Yébenes Gregorio. Médico Adjunto Especialista de Área en
Anatomía Patológica. HULP
Strategic Objective
The fundamental interest of our research group is
centered in the study of molecular biomarkers that
have a direct implication in the handling of the cancer
patients with the last aim to identify and to validate
therapeutic targets.
• Ovarian cancer Research Line
The ovarian carcinoma is the main cause of gynecolo-
gical cancer mortality in the western societies.
Nevertheless, the classic parameters are imperfect
predictors for patients outcome, partly due to the
complexity of the molecular genetic events that su-
blie these tumors and to the fact that they are not
totally known. Research on this field could identify
more precise markers to correctly stratify the pa-
tients according to their probability to recur and
response to treatments.
Angiogenesis, epithelial to mesenchymal transition
and hypoxia are processes demonstrated to have an
important role in the development of these tumors.
The main objective of this line of investigation,
therefore, is to identify discrete markers or gene
expression profiles related to these events, with
predictive and prognostic value for ovarian cancer
patients.
• Endometrial cancer Research Line
Endometrial carcinoma is the fourth most common
cancer in women in the developed world. Histo-
morphologic criteria are not strongly enouygh
tools to distinguish more aggressive tumors . Based
on molecular characterization, risk stratification
systems could be useful for decision making.
The main objective of this line of investigation, the-
refore, is to identify molecular markers with pre-
dictive and prognostic value for endometrial cancer
patients.
• Breast cancer Research Line
C-Src is sobreexpressed and/or hyperactive in
breast carcinoma biopsies and their implication
in the tumorigenesis has been proved in murine
models.
Our studies on genetically modified human breast
cancer cells and mice can establish the relevance
269
 3
Information Groups by Area
3.5 Cancer and Human Molecular Genetics Area
of the function of scaffolding of SFKs in breast cancer.
In addition, our work can lead to the development of
new prognosis and therapeutic tools to improve the
treatment of the breast cancer.
Angiogenesis and cancer of breast. The angiogenesis is a
key process in tumor development. Our group has been
working for years on the search of biomarkers related to
this process. Specifically on breast cancer, it is important
to identify patients that will benefit of bevacizumab con-
taining regimes.
• Sarcomas Research Line
Bone and Soft tissue sarcomas includes a group of hete-
rogeneous pathologies that were traditionally treated in
the same way. The clinical investigation has allowed the
identification of sub-groups with different response to
treatments. The objective of this line of work is to find
biomarkers for the best stratification of the patients, as
well as to get a better knowledge of the molecular me-
chanisms for the development of these tumors.
• Neuroendocrine tumors Research Line.
The neuroendocrine tumors (NET) include heteroge-
neous neoplasias, regarding morphologic and functiona-
lly features. They constitute a challenge for the medical
management, mainly regarding diagnose and handling.
Although we have improve the knowledge of molecular
events related to their development in the last decade,
we need to better known this tumors, in order to es-
tablish an early detection, that it improves the rates of
survival.
• In vitro 2- and 3D cell culture models for
functional studies.
The identification of potential markers in different patho-
logies might be complemented by functional studies, fo-
cused on the characterization of cancer and estromal
cell features, important for tumor development that it
improves the rates of survival.
Research Lines
• Ovarian and endometrial cancer
• Breast cancer
• Sarcomas
• Neuroendocrine tumors
Research Activity
Doctoral TheseS
Miranda Maldonado IC. Perfil inmunohistoquímico de la res-
puesta inmune celular en la endometritis crónica por Chla-
mydia trachomatis y gérmenes asociados[dissertation]. Ma-
drid: UAM: 2017(20/11/2017).
Directors: Hardisson Hernáez D; Gallegos Ávila MG.
Panal Cusatí M. Relación de los biomarcadores del cán-
cer de mama con la carga tumoral OSNA del ganglio
centinela[dissertation]. Madrid: UAM: 2017(04/09/2017).
Directors: Hardisson Hernáez D; Herrera de la Muela M.
Prieto Pozuelo M. Aplicabilidad de la RT-PCR a tiempo real
a partir de tejido fijado en formol e incluido en parafina a la
270
búsqueda de perfiles de expresión génica con valor pronós-
tico en cáncer de endometrio[dissertation]. Madrid: UAM:
2017(12/09/2017).
Directors: Hardisson Hernáez D; Mendiola Sabio M.
BOOKS AND BOOK CHAPTERS
Mariño Enríquez A, Mendiola Sabio M. Biología Molecular
del GIST. In: Fernández Hernández JA. Tumores del estroma
gastrointestinal: GIST. Manejo multidisciplinar en el siglo XXI.
Murcia: Diego Marín Librero Editor S.L., 2017. p.89-110
PUBLICATIONS
• Álvarez-López C, de Santiago J, Pinera A, Rodríguez R, Herrero B,
Herrera M, Pillado J, Zapardiel I. Utility of three-dimensional ultra-
sonography to assess the position of essure tubal occlusion device
and Its complications. Gynecol Obstet Inves. 2017; 82(2): 170-4. Ar-
ticle. IF: 1.183; Q4
• Barrientos-Ruiz I, Ortiz-Cruz EJ, Serrano-Montilla J, Bernabéu-Ta-
boada D, Pozo-Kreilinger JJ. Are biopsy tracts a concern for see-
ding and local recurrence in sarcomas? Clin Orthop Relat R. 2017;
475(2): 511-8. Article. IF: 4.091; D1
• Bieler BM, Gerber SM, de Nanclares GP, Hardisson D, Lecumberri B.
Intratumoral activating GNAS (R201C) mutation in two unrelated
patients with virilizing ovarian Leydig cell tumors. Endocrinol Dia-
betes Nutr. 2017; 64(6): 335-7. Letter. Not Indexed
• Bordás A, Cedillo JL,Arnalich F, Esteban-Rodríguez I, Guerra-Pastrián
L, de Castro J, Martín-Sánchez C, Atienza G, Fernández-Capitán C,
Rios JJ, Montiel C. Expression patterns for nicotinic acetylcholine
receptor subunit genes in smoking-related lung cancers. Oncotar-
get. 2017; 8(40): 67878-90. Article. Not Indexed
• Carrasco AL, Gutiérrez AH, Gutiérrez PAH, González RR, Martín
JLM, Zapardiel I, García JD. Ileocecal endometriosis: diagnosis and
management. Taiwan J Obstet Gyne. 2017; 56(2): 243-6. Article. IF:
1.029; Q4
• Cejas P, Cavazza A, Yandava CN, Moreno V, Horst D, Moreno-Rubio
J, Burgos E, Mendiola M, Taing L, Goel A, Feliú J, Shivdasani RA. Trans-
criptional regulator CNOT3 defines an aggressive colorectal cancer
subtype. Cancer Res. 2017; 77(3): 766-79. Article. IF: 9.13; Q1
• da Silva IL, Montero-Montero L, Martín-Villar E, Martín-Pérez J, Sainz
B, Renart J, Simoes RT,Veloso ES,Teixeira CS, de Oliveira MC, Ferrei-
ra E, Quintanilla M. Reduced expression of the murine HLA-G ho-
molog Qa-2 is associated with malignancy, epithelial-mesenchymal
transition and stemness in breast cancer cells. SCI Rep-Uk. 2017; 7:
6276. Article. IF: 4.122; Q1
• Espada J, Martín-Pérez J. An update on SRC family of nonreceptor
tyrosine kinases biology. Int Rev Cel Mol Bio. 2017; 331: 83-122.
Review. IF: 3.622; Q2
• Leal MA, Pinera A, de Santiago J, Zapardiel I. Novel technique for
contained power morcellation through umbilicus with insufflated
bag. Gynecol Obstet Inves. 2017; 82(2): 205-7. Article. IF: 1.183; Q4
• López-Ruiz ME,Yébenes L, Berjón A, Hardisson D. Primary leiomyo-
sarcoma of the ovarian vein: Case report and literature review. Int J
Surg Pathol. 2017; 25(4): 339-43. Article. IF: 1.188; Q3
• Machado I, Pozo JJ, Marcilla D, Cruz J, Tardío JC, Astudillo A, Bagué
S. Protocol for the study of bone tumours and standardization of
pathology report. Rev Esp Patol. 2017; 50(1): 34-44. Article. Not
Indexed
• Mayoral-Varo V, Calcabrini A, Sánchez-Bailón MP, Martín-Pérez J.
miR205 inhibits stem cell renewal in SUM159PT breast cancer cells.
Plos One. 2017; 12(11): e0188637. Article. IF: 2.766; Q1
• Orgaz MS, Pessolani TG, Kreilinger JJP, Zamora P, Álvarez CM, Boto-
de-los-Buéis A. Orbital and conjunctival metastasis from lobular
breast carcinoma. Orbit. 2017; 36(4): 197-200. Article. Not Indexed
• Papadia A, Zapardiel I, Bussi B, Ghezzi F, Ceccaroni M, de Ponti E,
Elisei F, Imboden S, de la Noval BD, Gasparri ML, Di Martíno G,
de Santiago J, Mueller M, Vecchione F, Dell’Orto F, Buda A. Sentinel
lymph node mapping in patients with stage I endometrial carcinoma:
a focus on bilateral mapping identification by comparing radiotracer
Tc99(m) with blue dye versus indocyanine green fluorescent dye. J
Cancer Res Clin. 2017; 143(3): 475-80. Article. IF: 3.282; Q2
• Peláez-García A, Yébenes L, Berjón A, Angulo A, Zamora P, Sánchez-
Méndez JI, Espinosa E, Redondo A, Heredia-Soto V, Mendiola M, Feliú
J, Hardisson D. Comparison of risk classification between EndoPre-
dict and MammaPrint in ER-positive/HER2-negative primary invasive
breast cancer. Plos One. 2017; 12(9): e0183452. Article. IF: 2.766; Q1
• Rodríguez-Salas N, Domínguez G, Barderas R, Mendiola M, García-
Albéniz X, Maurel J, Batlle JF. Clinical relevance of colorectal cancer
molecular subtypes. Crit Rev Oncol Hemat. 2017; 109: 9-19. Review.
IF: 4.495; Q1
• Zapardiel I, Blancafort C, Cibula D, Jaunarena I, Gorostidi M, Gil-
Moreno A, de Santiago J. Utility and actual use of European and Spa-
nish guidelines on the management of endometrial cancer among
gynecologic oncologists in Spain. Int J Gynecol Cancer. 2017; 27(6):
1293-7. Article. IF: 2.192; Q2
Private Projects
Hardisson Hernáez D. Actualización y renovación de la ac-
tividad en el Servicio de Anatomía Patológica del Hospital
Universitario La Paz. Dako Diagnosticos S.A. 2011-Ongoing.
Managment centre: FIBHULP
Hardisson Hernáez D. Determinación genómica de mues-
tras del biomarcador del gen KRAS y NRAS. TFS-Amgen-
KRAS-NRAS. 2014-Ongoing.
Managment centre: FIBHULP
Hardisson Hernáez D. Riesgo de recaída en pacientes con
carcinoma de mama primario HER2 negativo y receptores
estrogénicos positivos: estudio comparativo de dos perfiles
de expresión génica (Mammaprint® y Endopredict®). Myriad
Genetic España. 2015-Ongoing.
Managment centre: FIBHULP
Hardisson Hernáez D; Diestro Tejada Md. Ultraestadifi-
cación molecular ganglio centinela carcinoma endometrio:
OSNA (ENDO-OSNA). Sysmex. 2016-Ongoing.
Managment centre: FIBHULP
Mendiola Sabio M. Caracterización molecular del carcinoma
de ovario. Empleo de modelos celulares en tres dimensiones
para el estudio del papel central de HIF1A en los fenóme-
nos de hipoxia y transición epitelio mesénquima y su relación
con la resistencia al tratamiento. Fundación Mutua Madrileña.
2013-Ongoing.
Managment centre: FIBHULP
Mendiola Sabio M. Identificación de perfiles de expresión
génica diferencial relacionados con la angiogénesis entre el
carcinoma de ovario primario y sus metástasis. Varios Finan-
ciadores. 2012-Ongoing.
Managment centre: FIBHULP
Mendiola Sabio M. Papel de Rankl en el sarcoma de Ewing:
un estudio in vitro para la confirmación de una nueva diana
terapéutica. Grupo Español de Investigación en Sarcomas.
2012-Ongoing.
Managment centre: FIBHULP
Mendiola Sabio M. Realización de técnicas de detección
de expresión proteica. Construcción de matrices tisulares
y tinciones con anticuerpos específicos. Fundacio Institut
D´investigació én Ciéncies de la Salut Germans Trias I Pujol.
2015-Ongoing.
Managment centre: FIBHULP
Sánchez Méndez JI. 9º Curso de diagnóstico, tratamiento e
investigación del cáncer de mama. Sánchez Méndez-Patroci-
nio. 2017-Ongoing.
Managment centre: FIBHULP
CLINICAL TRIALS
Hardisson Hernández D. Evaluation of molecular subtype in
the prediction of non-sentinel lymph node affectation, based
on the osna predictive value, total tumor load.Type: NO-EPA.
HULP code: PI-2594. Sponsored´s protocol code: SYS-PAM-2016-01.
Sponsored by: Sysmex Europe GMBH.
Signed date: 04/05/2017
Sánchez Méndez JI. Estudio para la validación del valor pro-
nóstico de la carga tumoral total, determinado por Osna, de
la metástasis en el ganglio centinela del cáncer de mama.Type:
NO-EPA.
HULP code: PI-2872. Sponsored´s protocol code: GES-2017-01.
Sponsored by: Fundación Española de Senología y Patología
Mamaria (SESPM).
Signed date: 11/09/2017
Patents and Trademarks
Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo
J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to
obtain useful data for the prediction of a patient’s clinical res-
ponse to an anticancer treatment. P200930400; 2009 July 01.
Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo
J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method
to obtain useful data for the prediction of a patient’s patholo-
gical response to an anticancer treatment. P200930438; 2009
July 10.
271
 3
Information Groups by Area
3.5 Cancer and Human Molecular Genetics Area
Mechanisms of Tumour
Progression Group
14 91.066 12
Amparo Cano García. Catedrática del Departamento de
Bioquímica. Facultad de Medicina. UAM
Antonio Barbachano Becerril. Investigador Postdoctoral. IIB
Alberto Sols
Patricia Carrasco Ramírez. Investigadora Predoctoral . IIB
Alberto Sols
Alba Costales Carrera. Investigadora Predoctoral. IIB Alberto Sols
Gemma Domínguez Muñoz. Profesora contratada. UAM
Asunción Fernández Barral. Investigadora Postdoctoral. IIB
Alberto Sols
Gemma Ferrer Mayorga. Investigadora Predoctoral. IIB Alberto
Sols
Alfredo Floristán Muruzábal. Investigador Predoctoral. IIB
Alberto Sols
Pablo García Sanz. Investigador Postdoctoral. IIB Alberto Sols
Patricia González Santamaría. Investigadora Postdoctoral. UAM
Marta Hergueta Redondo. Investigadora Predoctoral. UAM
María Jesus Larriba Muñoz. Investigadora Postdoctoral. IIB
Alberto Sols
Celia Jimena López Menéndez. Técnico Superior. IIB Alberto
Sols
Alberto Martín Martín. Investigador Postdoctoral. IIB Alberto Sols
Ester Martín Villar. Investigadora Postdoctoral. IIB Alberto Sols
Saleta Morales Dolores. Técnico de Laboratorio. UAM
Gema Moreno Bueno. Profesora Titular. UAM
Alba Mota Jiménez. Investigadora Predoctoral. IIB Alberto Sols
Alberto Muñoz Terol. Profesor de Investigación. IIB Alberto Sols
Eva Pérez Cuevas. Investigadora Postdoctoral. IIB Alberto Sols
Francisco Portillo Pérez. Catedrático del Departamento de
Bioquímica. Facultad de Medicina. UAM
Miguel Quintanilla Ávila. Profesor de Investigación. IIB Alberto
Sols
272
Vanesa Santos Fernández. Técnico de Laboratorio. IIB Alberto Sols
José David Sarrio López. Investigador Postdoctoral. IIB Alberto Sols
Strategic Objective
Metastasis represents the most life-threatening event
for cancer patients. Invasion of tumour cells from the
primary tumour to adjacent tissues represents the
first step in the metastatic cascade for most solid tu-
mours.
The carcinoma invasion process involves the loss of
Ecadherin mediated cell-cell contacts and cell pola-
rity, degradation of the basement membrane, and
acquisition of migratory properties. These changes
are collectively known as the epithelial-mesenchymal
transition (EMT). Presently, EMT is considered a ma-
nifestation of the epithelial plasticity of carcinomas.
One of the most significant contributions in the last
decade has been the identification of mechanisms res-
ponsible for EMT induction.
Our previous studies, and those of other groups, led
to the identification of several transcription factors
from various families such as E-cadherin repressors
and EMT inducers (EMT-TFs): Snail (Snail1, Snail2),
bHLH (E47, E2-2, Twist) and Zeb (ZEB1/2). The
EMT process is regulated by a plethora of signalling
pathways at the transcriptional and posttranscrip-
tional level, including TGF-b (one of the most potent
EMT inducers), vitamin D (which antagonises Snail1
repression), phosphorylation events and lysyl oxidase-
like 2 (LOXL2). EMT has been recently with stemness,
opening new avenues for tumour initiation and metas-
tatic dissemination.
The group is composed of several principal investiga-
tors leading specific research lines (see below) related
to tumour progression and metastasis. The main objecti-
ves of the group are as follows:
1. Establish the role of various EMT-TFs in tumour pro-
gression and metastasis
2. Determine the role of LOXL2, LOXL3 and the mi-
croenvironment in epithelial plasticity and tumour
progression
3. Determine the role of TGFb/endoglin and podoplanin
in tumour progression
4. Determine the role of vitamin D in the regulation of
EMT and stemness in colorectal tumours
5. Characterise stem cells and their niche in the epider-
mis and their influence on skin carcinogenesis
Research Lines
• Regulation of cell plasticity and tumour metastasis by
EMT factors and lysyl oxidase LOXL2: Studies in mou-
se models of skin and breast tumorigenesis genetically
modified for Loxl2, Snail and E47.
• LOXL3 involvement in melanomagenesis: Studies in
melanoma cell lines and mouse models genetically mo-
dified for Loxl3.
• Genetic and molecular studies in breast and gynaeco-
logical cancers: Identification of novel predictive bio-
markers.
• Characterization of novel resistance mechanisms in
human cancer using high throughput techniques.
• Study of podoplanin role in epidermal homeostasis and
skin cancer.
• Study of vitamin D effect on normal and cancer-as-
sociated fibroblasts and on normal and colon cancer
patient-derived tumour organoids.
• Determine ÄNp73 role in tumour progression.
• Identify molecular alterations responsible for progres-
sion of precancerous colorectal lesions.
Research Activity
Doctoral TheseS
Dayse da Silva IL. Expressão de Qa-2 e sua relação com o
infiltrado linfocítico e a diferenciação celular em dois mo-
delos murinos de adenocarcinoma mamário[dissertation].
Minas Gerais: Universidade Federal de Minas Gerais:
2017(26/06/2017).
Directors: Ferreira E; Quintanilla M.
Molina Crespo A. Análisis de gasdermina b como marcador
de respuesta a tratamiento y nueva diana terapéutica en tu-
mores her2+[dissertation]. Madrid: UAM: 2017(25/09/2017).
Directors: Moreno Bueno G; Sarrio López D.
Mota Jiménez A. Deciphering intratumor molecular hete-
rogeneity in gynecological cancer progression[dissertation].
Madrid: UAM: 2017(12/05/2017).
Director: Moreno Bueno G.
PUBLICATIONS
• Barbachano A, Fernández-Barral A, Ferrer-Mayorga G, Costales-
Carrera A, Larriba MJ, Muñoz A. The endocrine vitamin D system
in the gut. Mol Cell Endocrinol. 2017; 453(C): 79-87. Article. IF:
3.563; Q2
• Cuevas EP, Eraso P, Mazón MJ, Santos V, Moreno-Bueno G, Cano A,
Portillo F. LOXL2 drives epithelial-mesenchymal transition via acti-
vation of IRE1-XBP1 signalling pathway. SCI Rep-Uk. 2017; 7: 44988.
Article. IF: 4.122; Q1
• da Silva IL, Montero-Montero L, Martín-Villar E, Martín-Pérez J, Sainz
B, Renart J, Simoes RT,Veloso ES,Teixeira CS, de Oliveira MC, Ferrei-
ra E, Quintanilla M. Reduced expression of the murine HLA-G ho-
molog Qa-2 is associated with malignancy, epithelial-mesenchymal
transition and stemness in breast cancer cells. SCI Rep-Uk. 2017; 7:
6276. Article. IF: 4.122; Q1
• da Silva IL, Veloso ES, Goncalves INN, Braga AD, Lopes MTP, Cassali
GD, Quintanilla M, Simoes RT, Ferreira E. Qa-2 expression levels
is related with tumor-infiltrating lymphocytes profile during solid
Ehrlich tumor development. Biomed Pharmacother. 2017; 92: 750-6.
Article. IF: 3.457; Q2
• Devis L, Moiola CP, Masia N, Martínez-García E, Santacana M, Stir-
bat TV, Brochard-Wyart F, García A, Alameda F, Cabrera S, Palacios
J, Moreno-Bueno G, Abal M, Thomas W, Dufour S, Matías-Guiu X,
Santamaría A, Reventos J, Gil-Moreno A, Colas E. Activated leuko-
cyte cell adhesion molecule (ALCAM) is a marker of recurrence
and promotes cell migration, invasion, and metastasis in early-stage
endometrioid endometrial cancer. J Pathol. 2017; 241(4): 475-87. Ar-
ticle. IF: 6.253; D1
• Ferrer-Mayorga G, Gómez-López G, Barbachano A, Fernández-Ba-
rral A, Peña C, Pisano DG, Cantero R, Rojo F, Muñoz A, Larriba MJ.
Vitamin D receptor expression and associated gene signature in
tumour stromal fibroblasts predict clinical outcome in colorectal
cancer. Gut. 2017; 66(8): 1449-62. Article. IF: 17.016; D1
• García-Sanz P, Trivino JC, Mota A, Pérez López M, Colas E, Rojo-Se-
bastián A, García A, Gatius S, Ruiz M, Prat J, López-López R, Abal M,
Gil-Moreno A, Reventos J, Matías-Guiu X, Moreno-Bueno G. Chro-
matin remodelling and DNA repair genes are frequently mutated
in endometrioid endometrial carcinoma. Int J Cancer. 2017; 140(7):
1551-63. Article. IF: 7.36; Q1
• Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J,
Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A,
Petit A, Vidal A, Catala I, Soler T, Venturas G, Rojo-Sebastián A, Serra
H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd
V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M,
Gómez-Baldo L, Hernández V, Martínez-Aranda A, Martínez-Iniesta
M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernán-
dez A, Morilla I, Pernas S, Pla MJ, Andréu X, Segui MA, Ballester R,
Castella E, Nellist M, Morales S, Valls J, Velasco A, Matías-Guiu X,
Figueras A, Sánchez-Mut JV, Sánchez-Cespedes M, Cordero A, Gó-
mez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EEW,
Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N,Valdés-Mas
R, Puente XS, Vinals F, Casanovas O, Graupera M, Hernández-Losa
J, Cajal SRY, García-Alonso L, Sáez-Rodríguez J, Esteller M, Sierra A,
Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nan-
jundan M, Cortés J, Lazaro C, Odero MD, Martens JWM, Moreno-
Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA.
Stem cell-like transcriptional reprogramming mediates metastatic
resistance to mTOR inhibition. Oncogene. 2017; 36(19): 2737-49.
Article. IF: 6.854; Q1
• Mota A, Colas E, García-Sanz P, Campoy I, Rojo-Sebastián A, Gatius S,
García A, Chiva L,Alonso S, Gil-Moreno A, González-Tallada X, Díaz-
Feijoo B, Vidal A, Ziober-Malinowska P, Bobinski M, López-López R,
Abal M, Reventos J, Matías-Guiu X, Moreno-Bueno G. Genetic analy-
sis of uterine aspirates improves the diagnostic value and captures
the intra-tumor heterogeneity of endometrial cancers. Modern
Pathol. 2017; 30(1): 134-45. Article. IF: 6.655; D1
273
 3
Information Groups by Area
3.5 Cancer and Human Molecular Genetics Area
• Rodríguez-Salas N Domínguez G Barderas R Mendiola M García-
Albéniz X Maurel J Batlle JF. Clinical relevance of colorectal cancer
molecular subtypes. Crit Rev Oncol Hemat. 2017; 109: 9-19. Review.
IF: 4.495; Q1
• Rodríguez-Ubreva J, Catalá-Moll F, Obermajer N, Álvarez-Errico D,
Ramírez RN, Company C, Vento-Tormo R, Moreno-Bueno G, Ed-
wards RP, Mortazavi A, Kalinski P, Ballestar E. Prostaglandin E2 leads
to the acquisition of DNMT3A-dependent tolerogenic functions in
human myeloid-derived suppressor cells. Cell Rep. 2017; 21(1): 154-
67. Article. IF: 8.032; Q1
• Salvador F, Martín A, López-Menéndez C, Moreno-Bueno G, Santos V,
Vázquez-Naharro A, Santamaría PG, Morales S, Dubus PR, Muinelo-
Romay L, López-López R,Tung JC,Weaver VM, Portillo F, Cano A. Lys-
yl oxidase-like protein LOXL2 promotes lung metastasis of breast
cancer. Cancer Res. 2017; 77(21): 5846-59. Article. IF: 9.13; Q1
• Santamaría PG, Moreno-Bueno G, Portillo F, Cano A. EMT: Present
and future in clinical oncology. Mol Oncol. 2017; 11(7): 718-38. Arti-
cle. IF: 5.264; Q1
• Tamayo M, Manzanares E, Bas M, Martín-Nunes L, Val-Blasco A, La-
rriba MJ, Fernández-Velasco M, Delgado C. Calcitriol (1,25-dihydro-
xyvitamin D3) increases L-type calcium current via protein kinase A
signaling and modulates calcium cycling and contractility in isolated
mouse ventricular myocytes. Heart Rhythm. 2017; 14(3): 432-9. Ar-
ticle. IF: 4.743; Q1
Public Projects
Cano García A. Consorcio CIBER. Área temática cáncer
(CB16-12-00295). ISCIII. 2017-2022.
Managment centre: CIBER
Cano García A. Contribution of loxl2 and loxl3y to tumour
progression and metastasis (SAF2016-76504-R). MINECO.
2016-2019.
Managment centre: UAM
Cano García A. Red Temática de Investigación Cooperativa
en Cáncer (RTICC) (RD12/0036/0007). ISCIII. 2013-2017.
Managment centre: UAM
Dominguez Muñoz G. Implicación de deltanp73 en la disemi-
nación tumoral: valor predictivo de recaida en pacientes con
cáncer colorrectal estadio II (PI15/00246). ISCIII. 2016-2018.
Managment centre: FUBHULP
Moreno Bueno G. Gasdermina b: mediador de respuesta
inflamatoria y terapéutica en cáncer de mama y digestivo
(PI16/00134). ISCIII. 2017-2019.
Managment centre: UAM
Muñoz Terol A. Cáncer de colon: efecto de la vitamina d
sobre organoides normales y tumorales derivados de pacien-
tes y sobre el microambiente tumoral (SAF2016-76377-R).
MINECO. 2016-2019.
Managment centre: IIB Alberto Sols
Muñoz Terol A. Consorcio CIBER. Área temática cáncer
(CB16-12-00273). ISCIII. 2017-2022.
Managment centre: CIBER
Muñoz Terol A. Receptores nucleares en cáncer, metabo-
lismo e inflamación (NURCAMEIN) (red de excelencia)
(SAF2015-71878-REDT). MINECO. 2016-2017.
Managment centre: IIB Alberto Sols
274
Muñoz Terol A. Red Temática de Investigación Cooperativa in endometrial cancer. EP14155510.2, PCT/EP2015/053387; Olmeda Casadomé D, Moreno Bueno G, Portillo Pérez F,
en Cáncer (RTICC) (RD12/0036/0021). ISCIII. 2013-2017. 2014 February 18. Cano García A, inventors; UAM, CSIC, assignees. Method for
Managment centre: IIB Alberto Sols the diagnosis and/or prognosis of breast cancer. P200702342,
García García JF, Martín Moreno AM, Roncador G, Mar-
PCT/ES2008/000563; 2007 August 28.
Quintanilla Ávila M. Función de las glicoproteínas de la su- tínez Torrecuadra JL, Moreno Bueno G, inventors; Funda-
ción MD Anderson International España, Fundación Centro Hergueta Redondo M, Sanz PG, Rojo A, García JF, Moreno-
perficie celular podoplanina y endoglina en la homeostasis
Nacional de Investigaciones Oncológicas (CNIO), assignees; Bueno G, inventors; UAM, CSIC, Fundación MD Anderson
de la piel y la carcinogénesis cutánea (SAF2013-46183-R).
Method for the diagnosis and/or prognosis of lymphomas. International España, assignees; Gasdermin B2 as a new bio-
MINECO. 2014-2017.
P201231304; 2012 August 14. marker of malignance and resistance of Trastuzumab inhibi-
Managment centre: IIB Alberto Sols
tor in Her2+ tumors. P201231560; 2012 October 10. 
Olmeda Casadomé D, Peinado Selgas H, Portillo Pérez F,
Nieto Toledano MA, Cano García A, inventors; UAM, assig-
Private Projects nee. Materials and methods for the derepression of the E-
cadherin promoter. US20060003956; 2004 March 03.
Cano García A. Contribution of LOXL3 to melanomagenesis.
Wordlwide Cancer Research . 2016-Ongoing.
Managment centre: UAM
Cano García A. Understanding the role of lysyl oxidase-like 2
in skin and breast cancer. Association For International Can-
cer Research. 2012-Ongoing.
Managment centre: UAM
Martínez Valverde A. Colaboración para el fomento de
la investigación desarrollada en el grupo idipaz Estrategias
Neuroprotectoras en Enfermedades Neurodegenerati-
vas. Consejo Superior Investigaciones Científicas (CSIC).
2013-Ongoing.
Managment centre: FIBHULP
Moreno Bueno G. Alteraciones moleculares relacionadas
con la progresión tumoral en cáncer de endometrio. AECC.
2011-2016.
Managment centre:MD Anderson International Foundation
Moreno Bueno G. Genomic approach for individualizing en-
dometrial cancer diagnosis, prognosis and treatment. Funda-
ció la Marató de TV3. 2014-2016.
Managment centre: MD Anderson International Foundation
Muñoz Terol A. Estudio de la acción protectora de la com-
binación de la 1,25-dihidroxivitamina d3/vitamina d con la
quimioterápia habitual en cáncer de colon. Farmasierra.
2017-Ongoing.
Managment centre: IIBM-CSIC
INTERNATIONAL Projects
Cano García A. Contribution of LOXL3 to melanomagenesis
(WWCR16-0295). Worldwide Cancer Research (formerly
AICR). 2016-2018.
Managment centre: UAM
Patents and Trademarks
Matías-Guiu Guía FJ, Dolcet Roca FJ, Reventós Puigjaner
J, Colás Ortega E, Prat Díaz de Losada J, Palacios Calvo J,
Abal Posada M, López López R, Moreno Bueno G, Gil More-
no A, inventors; Institut de Recerca Biomèdica de Lleida Fun-
dació Doctor Pifarré, Universitat deLleida, Fundació Hospital
Universitari Vall d’Hebron-Institut de Recerca, Fundació Ins-
titut de Recerca de L’Hospital de la Santa Creu i Sant Pau,
Servicio Andaluz de Salud, Servizo Galego de Saúde, Funda-
ción MD Anderson International España, assignees. Method
to predict risk of recurrence in endometrial carcinoma.
Annexin-A2 as predictor biomarker of recurrent disease
275
 3
Information Groups by Area
3.5 Cancer and Human Molecular Genetics Area
Animal and Cell Models for
Detection and Characterization
of Leukemic Stem Cells Group
11 125.427 9
Carmela Cales Bourdet. Profesora Titular. Departamento
de Bioquímica. Facultad de Medicina. UAM
Mónica Bravo Madrigal. Investigadora Predoctoral. UAM
Miguel Ramón Campanero García. Científico Titular. IIB Alberto
Sols
Miguel Angel Canales Albendea. Jefe de Sección de Hematología.
HULP
Raquel de Paz Arias. Facultativo Especialista de Área en
Hematología. HULP
Bárbara Fernández Morales. Investigadora Predoctoral. UAM
Dolores Hernández Maraver. Facultativo Especialista de Área en
Hematología. HULP
Ana Kerguelen Fuentes. Facultativo Especialista de Área en
Hematología. HULP
Yenny Montenegro Medina. Investigadora Postdoctoral. UAM
Marta Morado Arias. Técnico de Laboratorio. HULP
Gema Pérez Chacón. Investigadora Postdoctoral. IIB Alberto Sols
Juan Manuel Zapata Hernández. Científico Titular. IIB Alberto
Sols
Research Lines
Strategic Objective
Proper homeostasis of stem cells and pluripotent
progenitor is pivotal to the development of haemato-
poietic proliferative disorders such as myelodysplas-
tic or myeloproliferative syndromes, leukaemia and
276
lymphoma. It is well known that alterations in trans-
criptional programs lead to transformed phenotypes,
which are at the basis of the insidious acquisition of
stem-like phenotypes of immature cells. Our group
is interested in the role of transcriptional regulators,
global regulators such as c-myc, c-myb, E2F and epi-
genetic controllers such as PcG factors in limiting the
self-renewal capacity of common myeloid and lym-
phoid progenitors.
Our group has two main activities: basic research
aimed to unravel the molecular mechanisms respon-
sible for the acquisition of malignant haematological
phenotypes (mouse models as well as ex vivo cell
models to approach the questions outlined above);
and research aimed to document clinical parameters
and molecular markers that may be of use to a bet-
ter understanding of the progression and outcome
of haematological diseases, mainly myelodysplasia,
lymphoma and multiple myeloma.
• Role of epigenetic and transcriptional regulators in
myelodysplasia: cellular and animal models
• Molecular and cellular basis of lymphoid neopla-
sias: non Hodgkin lymphomas and chronic lympho-
cytic leukaemia.
• Molecular markers of haematological malignancies.
Research Activity
PUBLICATIONS
• Álvarez-Larran A, Pérez-Encinas M, Ferrer-Marín F, Hernández-Bo-
luda JC, Ramírez MJ, Martínez-López J, Magro E, Cruz Y, Mata MI,
Aragues MP, Fox ML, Cuevas B, Montesdeoca S, Hernández-Rivas JA,
García-Gutiérrez V, Gómez-Casares MT, Steegmann JL, Durán MA,
Gómez M, Kerguelen A, Bárez A, García MC, Boque C, Raya JM, Mar-
tínez C, Albors M, García F, Burgaleta C, Besses C. Risk of thrombo-
sis according to need of phlebotomies in patients with polycythemia
vera treated with hydroxyurea. Haematologica. 2017; 102(1): 103-9.
Article. IF: 9.09; D1
• Álvaro-Blanco J, Urso K, Chiodo Y, Martín-Cortázar C, Kourani O,
Gómez-del Arco P, Rodríguez-Martínez M, Calonge E, Alcamí J, Re-
dondo JM, Iglesias T, Campanero MR. MAZ induces MYB expression
during the exit from quiescence via the E2F site in the MYB promo-
ter. Nucleic Acids Res. 2017; 45(17): 9960-75. Article. IF: 11.561; D1
• Hernández-Boluda JC, Correa JG, García-Delgado R, Martínez-Ló-
pez J, Álvarez-Larran A, Fox ML, García-Gutiérrez V, Pérez-Encinas
M, Ferrer-Marin F, Mata-Vázquez MI, Raya JM, Estrada N, García S,
Kerguelen A, Durán MA, Albors M, Cervantes F. Predictive factors
for anemia response to erythropoiesis-stimulating agents in myelo-
fibrosis. Eur J Haematol. 2017; 98(4): 407-14. Article. IF: 2.595; Q3
• Lahuerta JJ, Paiva B, Vidriales MB, Cordón L, Cedena MT, Puig N,
Martínez-López J, Rosinol L, Gutiérrez NC, Martín-Ramos ML, Oriol
A, Teruel AI, Echeveste MA, de Paz R, de Arriba F, Hernández MT,
Palomera L, Martínez R, Martín A, Alegre A, de la Rubia J, Orfao A,
Mateos MV, Blade J, San-Miguel JF. Depth of response in multiple
myeloma: A pooled analysis of three PETHEMA/GEM clinical trials. J
Clin Oncol. 2017; 35(25): 2900-10. Article. IF: 26.303; D1
• Morado M, Freire Sandes A, Colado E, Subira D, Isusi P, Noya MS,
Vidriales MB, Sempere A, Díaz JA, Minguela A, Álvarez B, Serrano
C, Caballero T, Rey M, Corral AP, Jiménez MCF, Magro E, Lemes A,
Benavente C, Banas H, Merino J, Castejón C, Gutiérrez O, Rabasa
P, Goncalves MV, Pérez-Andrés M, Orfao A. Diagnostic screening
of paroxysmal nocturnal hemoglobinuria: Prospective multicentric
evaluation of the current medical indications. Cytom Part B-Clin Cy.
2017; 92(5): 361-70. Article. IF: 2.757; Q2
• Nomdedeu M, Pereira A, Ramos F, Valcarcel D, Costa D, Arnan M,
Calvo X, Pomares H, Luno E, Díaz-Campelo M, Collado R, de Paz R,
Falantes JF, Pedro C, Marco J, Oirtzabal I, Sánchez-García J,Tormo M,
Cedena MT, Nomdedeu B, Sanz G. Excess mortality in the myelo-
dysplastic syndromes. Am J Hematol. 2017; 92(2): 149-54. Article. IF:
5.303; Q1
• Oller J, Méndez-Barbero N, Ruiz EJ, Villahoz S, Renard M, Canelas
LI, Briones AM, Alberca R, Lozano-Vidal N, Hurle MA, Milewicz D,
Evangelista A, Salaices M, Nistal JF, Jiménez-Borreguero LJ, De Bac-
ker J, Campanero MR, Redondo JM. Nitric oxide mediates aortic
disease in mice deficient in the metalloprotease Adamts1 and in a
mouse model of Marfan syndrome. Nat Med. 2017; 23(2):200-12.
Article. IF: 32.621; Q1
• Pose-Utrilla J, García-Guerra L, del Puerto A, Martín A, Jurado-Ar-
jona J, de León-Reyes NS, Gamir-Morralla A, Serrano AS, García-
Gallo M, Kremer L, Fielitz J, Ireson C, Pérez-Álvarez MJ, Ferrer I,
Hernández F, Ávila J, Lasa M, Campanero MR, Iglesias T. Excitotoxic
inactivation of constitutive oxidative stress detoxification pathway
in neurons can be rescued by PKD1. Nat Commun. 2017; 8: 2275.
Article. IF: 12.353; D1
• Ramos F, Pedro C, Tormo M, de Paz R, Font P, Luno E, Caballero
M, Solano F, Almagro M, Xicoy B, Jiménez M. Impact of anaemia on
health-related quality of life and cardiac remodelling in patients with
lower risk myelodysplastic syndromes. Results of GlobQoL study.
Eur J Cancer Care. 2017; 26(6): e12426. Article. IF: 2.409; D1
• Ramos F, Robledo C, Pereira A, Pedro C, Benito R, de Paz R, del Rey
M, Insunza A,Tormo M, Díez-Campelo M, Xicoy B, Salido E, Sánchez-
del-Real J, Arenillas L, Florensa L, Luno E, del Canizo C, Sanz GF,
Hernández-Rivas JM. Multidimensional assessment of patient condi-
tion and mutational analysis in peripheral blood, as tools to improve
outcome prediction in myelodysplastic syndromes: A prospective
study of the Spanish MDS group. Am J Hematol. 2017; 92(9): E534-
41. Article. IF: 5.303; Q1
• Salar A, Domingo-Domenech E, Panizo C, Nicolas C, Bargay J, Mun-
tanola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Pe-
nalver J, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde
E, García M, García JF, Caballero D, Montalbán C. Long-term results
of a phase 2 study of rituximab and bendamustine for mucosa-as-
sociated lymphoid tissue lymphoma. Blood. 2017; 130(15): 1772-4.
Letter. IF: 15.132; D1
Public Projects
Campanero García MR. Identificación y evaluación de nuevas
dianas terapéuticas en cáncer (SAF2013-45258-P). MINECO.
2014-2018.
Managment centre: UAM
Private Projects
Canales Albendea MA. Programa para la investigación en
neoplasias linfoides. Acero. 2008-Ongoing.
Managment centre: FIBHULP
Canales Albendea MA. Bolsa enfermería. Dr. Canales Bolsa
Enfermería. 2007-Ongoing.
Managment centre: FIBHULP
CLINICAL TRIALS
Canales Albendea MA. Estudio fase II de seguridad y eficacia
de atezolizumab administrado en combinación con terapia
anti-CD20 obinutuzumab o rituximab en pacientes con lin-
foma de células del manto o de la zona marginal y macrog-
lobulinemia de Waldenström refractarios o en recaída. Type:
Clinical Trial, phase II.
HULP code: 4860. Sponsored´s protocol code: MO39107.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 29/06/2017
Canales Albendea MA. Estudio de fase III randomizado, do-
ble ciego y controlado con placebo, de itacitinib o placebo
en combinación con corticosteroides para el tratamiento de
primera línea de la enfermedad de injerto contra huésped en
fase aguda. Type: Clinical Trial, phase III.
HULP code: 4872. Sponsored´s protocol code: INCB 39110-301.
Sponsored by: Incyte Corporation.
Signed date: 13/06/2017
Canales Albendea MA. Estudio de fase 3, aleatorizado, doble
ciego, controlado con placebo y multicéntrico entre benda-
mustina con rituximab (BR) en monoterapia y en combina-
ción con acalabrutinib (ACP-196) en pacientes con linfoma
de células del manto no tratado previamente. Type: Clinical
Trial, phase III.
HULP code: 4824. Sponsored´s protocol code: ACE-LY-308.
Sponsored by: Acerta Pharma B.V.
Signed date: 31/07/2017
Canales Albendea MA. Estudio en fase II de TAK-659 en pa-
cientes con linfoma difuso de células B grandes recidivante o
277
 3
Information Groups by Area
3.5 Cancer and Human Molecular Genetics Area
resistente después de dos o más líneas previas de quimiote-
rapia. Type: Clinical Trial, phase II.
HULP code: 4928. Sponsored´s protocol code: C34004.
Sponsored by: Millennium Pharmaceuticals Inc.
Signed date: 22/09/2017
Canales Albendea MA. Un estudio multicéntrico, aleatori-
zado, doble ciego y controlado con placebo de fase III del
inhibidor de tirosina kinasa de bruton (BTK) ibrutinib, en
combinación con rituximab en comparación con placebo en
combinación con rituximab en sujetos sin tratamiento previo
con linfoma folicular. Type: Clinical Trial, phase III.
HULP code: 4909. Sponsored´s protocol code: PCYC-1141-CA.
Sponsored by: Pharmacyclics Llc.
Signed date: 09/10/2017
Canales Albendea MA. Estudio de fase I, abierto, de deter-
minación de dosis y ampliación de cohortes, para evaluar
la seguridad y la eficacia del tratamiento combinado de
INCB050465 con bendamustina y obinutuzumab en sujetos
con linfoma folicular recidivante o resistente al tratamiento
(Citadel 102). Type: Clinical Trial, phase I.
HULP code: 4881. Sponsored´s protocol code: INCB 50465-102.
Sponsored by: Incyte Corporation.
Signed date: 28/06/2017
Morado Arias M. Subregistro prospectivo, multicéntrico y
observacional de seguridad postautorización para caracteri-
zar el perfil de seguridad a largo plazo del uso comercial de
eliglustat. Type: EPA-LA.
HULP code: PI-3019. Sponsored´s protocol code: PI-3019 OBS14099.
Sponsored by: Sanofi Aventis S.A.
Signed date: 18/12/2017
Canales Albendea MA. Estudio fase III, abierto, de ofatumu-
mab añadido a fludarabina-ciclofosfamida frente a la combi-
nación fludarabina-ciclofosfamida en sujetos con leucemia
linfocitica crónica en recaída. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 2824.
Sponsored´s protocol code: OMB110913.
Sponsored by: Glaxosmithkline S.A.
Signed date: 24/04/2017
Canales Albendea MA. Estudio de fase IB/II, abierto para eva-
luar la seguridad y la farmacocinética de GDC‑0199 (ABT-
199) en combinación con rituximab (R) o obinutuzumab (G)
más ciclofosfamida, doxorrubicina, vincristina y prednisona
(CHOP) en pacientes con linfoma no Hodgkin (LNH) de cé-
lulas B y LDCGB (linfoma difuso de células grandes B). Type:
Clinical Trial, phase Ib.
278
HULP code: ANEXO-I 4354. Sponsored´s protocol code: GO27878.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 06/11/2017
de Paz Arias R. Estudio fase III, multicéntrico, abierto, alea-
torizado de imatinib frente a nilotinib, en pacientes adultos
con leucemia mieloide crónica cromosoma filadelfia positivo
(PH+) en fase cronica (LMC-FC) de nuevo diagnóstico. Type:
Clinical Trial, phase III.
HULP code: ANEXO-II 2412. Sponsored´s protocol code: CAM-
N107A2303.
Sponsored by: Novartis Farmaceutica S.A.
Signed date: 30/05/2017
Canales Albendea MA. Estudio de fase II de brazo único,
abierto, de nivolumab (BMS-936558) en sujetos con linfoma
folicular (LF) recidivante o refractario.Type: Clinical Trial, pha-
se II.
HULP code: ANEXO-II 4085.
Sponsored´s protocol code: CA209-140.
Sponsored by: Bristol Myers Squibb International Corporation.
Signed date: 03/05/2017
Gómez Prieto P. Ensayo aleatorizado y doble ciego para
evaluar la eficacia, la seguridad y la inmunogenicidad de ABP
798 en comparación con rituximab en sujetos con linfoma
no Hodgkin (LNH) de células B CD20+. Type: Clinical Trial,
phase III.
HULP code: ANEXO-II 4216. Sponsored´s protocol code: 20130109.
Sponsored by: Amgen S.A.
Signed date: 31/10/2017
Patents and Trademarks
Campanero García MR, Molina Privado I, inventors; CSIC,
UAM, assignees. Method for identifying patients with sporadic
Burkitt’s lymphoma, identification method and use of com-
pounds for the treatment of sporadic Burkitt’s lymphoma.
P200702595, PCT/ES2008/070182; 2007 October 03.
Molina Privado I, Campanero García MR, Rodríguez Mar-
tínez M, inventors; CSIC, UAM, assignees. Method for the
differential diagnosis between Burkitt lymphoma and diffuse
large B-cell lymphoma. P200900651; 2009 March 09.
Zapata Hernández JM, Pérez Chacón G, inventors; CSIC,
UAM, assignees. Use of an indolic compound with nucleophi-
lic substituents at C3 and the dimeric variants thereof in
the production of a pharmaceutical composition that can be
used in the treatment of B-lymphoid neoplasms. P201331397,
PCT/ES2014/070726; 2013 September 25.
Research and Diagnosis
of Inherited Metabolic
Diseases Group
19 92.058 12
María Belén Pérez González. Profesora Titular. UAM -
CSIC - CBM Severo Ochoa
Patricia Alcaide Alonso. Investigadora Postdoctoral. UAM - CEDEM
Sandra Dolores Arduim Brasil. Investigadora Postdoctoral. UAM
- CSIC - CBM Severo Ochoa
Margarita Castro Reguera. Investigadora Predoctoral. UAM -
CEDEM
Magdalena de Ugarte Pérez. Directora del CEDEM. UAM -
CEDEM
María Jesús Ecay Crespo. Técnico de Laboratorio. CIBERER
Isaac Ferrer López. Técnico de Laboratorio. UAM - CEDEM
María Alejandra Gámez Abascal. Investigadora Senior
(Contrato Ramón y Cajal). UAM - CSIC - CBM Severo Ochoa
Fernando García Muñoz. Técnico de Laboratorio. UAM - CEDEM
Ana Jorge Finnigan. Investigadora Postdoctoral. UAM - CSIC - CBM
Severo Ochoa
Fátima Leal Pérez. Técnico de Laboratorio. CIBERER
Celia Medrano Rodríguez. Investigadora Predoctoral. UAM -
CEDEM
María Begoña Merinero Cortes. Investigadora Senior. UAM -
CEDEM
Rosa María Navarrete López de Soria. Técnico de
Laboratorio. CIBERER
Celia María Lourdes Pérez-Cerdá Silvestre. Investigadora
Senior. UAM - CEDEM
Isabel Reina Alba. Secretaría. UAM - CEDEM
Eva María Richard Rodríguez. Profesora Titular. UAM - CSIC -
CBM Severo Ochoa
María Pilar Rodríguez Pombo. Profesora Titular. UAM - CSIC -
CBM Severo Ochoa
Pedro Ruiz Sala. Investigador Postdoctoral. UAM - CEDEM
María Lourdes Ruiz Desviat. Profesora Titular. UAM - CSIC - CBM
Severo Ochoa
María Paloma Sanz Rebollo. Técnico de Laboratorio. UAM - CEDEM
Ana Isabel Vega Pajares. Investigadora Postdoctoral. UAM - CEDEM
Strategic Objective
• Development of genomic and metabolomic techni-
ques aimed at improving the diagnosis of hereditary
metabolic diseases.
• Study of mitochondrial dysfunction and oxidative
stress as a modifier of the clinical phenotype and as
a potential therapeutic target in organic acidurias.
• Development of novel therapeutic strategies: anti-
sense therapy and pharmacological chaperon.
• Development of animal and cellular models.
• Registry of patients with hereditary metabolic disea-
ses.
Research Lines
• Improved diagnosis of congenital defects of glycos-
ylation and mitochondrial defects through the appli-
cation of genomic techniques (RNAseq and DNA-
seq of exoma and genome) and metabolomics.
• Identification of deep intronic mutations in me-
tabolic disorders gene by transcriptional analysis.
Functional validation in cellular splicing systems.
• Development of antisense therapy and pharmaco-
logical chaperones as therapeutic approaches trans-
verse and applicable to numerous EMH.
• Study of oxidative stress and evaluation of common
signatures of neuropathogenicity and cardiotoxicity
279
 3
Information Groups by Area
3.5 Cancer and Human Molecular Genetics Area
in congenital defects of glycosylation, organic acide-
mias and mitochondrial diseases.
• Evaluation of drugs aimed at the recovery of mito-
chondrial function and biogénesis.
• Search for biomarkers as predictors of severity and as
systems for the evaluation of pharmacological therapies.
• Characterization of pathophysiology in a murine mo-
del of propionic acidemia.
• Identification of dysregulated miRNA in propionic
acidemia and characterization of its association with
pathology and its usefulness as biomarkers.
• Generation of iPS from patient-derived fibroblast with
organic acidemia and congenital defects of glycosyla-
tion. Differentiation to hepatocytes, neural progenitors
or cardiomyocytes.
Research Activity
Doctoral TheseS
Medrano Rodríguez C. Bases Moleculares de los defec-
tos congénitos de glicosilación[dissertation]. Madrid: UAM:
2017(01/03/2017).
Directors: Pérez González B, Pérez Cerdá C.
BOOKS AND BOOK CHAPTERS
Cornejo V , Raimann B, Pérez González B, Ruiz Desviat L,
Arias C. Bases moleculares y cromosómicas de las enferme-
dades genéticas. Hiperfenilalaninemias. In: Colombo M, Cor-
nejo V, Raimann E, (Eds). Errores Innatos en el Metabolismo
del Niño. Chile: Editorial universitaria, 2017. Capitulo 3
Pérez González B, Ruiz Desviat L, Martínez M. Bases mo-
leculares y cromosómicas de las enfermedades genéticas.
Deficiencia de Pterinas. In: Colombo M, Cornejo V, Raimann
E, (Eds). Errores Innatos en el Metabolismo del Niño. Chile:
Editorial universitaria, 2017. Capitulo 3
Pérez González B, Ruiz Desviat L. Bases moleculares y cro-
mosómicas de las enfermedades genéticas. Genética molecu-
lar de enfermedades metabólicas hereditarias y herramientas
diagnósticas más usadas en genética molecular. In: Colombo
M, Cornejo V, Raimann E, (Eds). Errores Innatos en el Metabo-
lismo del Niño. Chile: Editorial universitaria, 2017. Capítulo 1
PUBLICATIONS
• Alonso-Barroso E, Brasil S, Briso-Montiano A, Navarrete R, Pérez-
Cerdá C, Ugarte M, Pérez B, Desviat LR, Richard E. Generation and
characterization of a human iPSC line froma patientwith propionic
acidemia due to defects in the PCCA gene. Stem Cell Res. 2017; 23:
173-7. Editorial Material. IF: 1.829; Q3
• Bellusci M, Quijada-Fraile P, Barrio-Carreras D, Martín-Hernández
E, García-Silva M, Merinero B, Pérez B, Hernández-Lain A. Carnitine
palmitoyltransferase 1A deficiency: abnormal muscle biopsy findings
in a child presenting with Reye’s syndrome. J Inherit Metab Dis.
2017; 40(5): 751-2. Editorial Material. IF: 4.092; Q1
• Bravo-Alonso I, Navarrete R, Arribas-Carreira L, Perona A, Abia D,
Couce ML, García-Cazorla A, Morais A, Domingo R, Ramos MA,
Swanson MA, Van Hove JLK, Ugarte M, Pérez B, Pérez-Cerda C,
Rodríguez-Pombo P. Nonketotic hyperglycinemia: Functional as-
sessment of missense variants in GLDC to understand phenotypes
of the disease. Hum Mutat. 2017; 38(6): 678-91. Article. IF: 5.359; Q1
280
• Cabezas OR, Flanagan SE, Stanescu H, García-Martínez E, Caswell
R, Lango-Allen H, Antán-Gamero M, Argente J, Busse AM, Brandli A,
Cheshire C, Crowne E, Dumitriu S, Drynda R, Hamilton-Shield JP,
Hayes W, Hofherr A, Iancu D, Issler N, Jefferies C, Jones P, Johnson
M, Kesselheim A, Klootwijk E, Koettgen M, Lewis W, Martos JM, Mo-
zere M, Norman J, Patel V, Parrish A, Pérez-Cerdá C, Pozo J, Rahman
SA, Sebire N, Tekman M, Turnpenny PD, van’t Hoff W,Viering DHHM,
Weedon MN,Wilson P, Guay-Woodford L, Kleta R, Hussain K, Ellard
S, Bockenhauer D. Polycystic kidney disease with hyperinsulinemic
hypoglycemia caused by a promoter mutation in phosphomannomu-
tase 2. J Am Soc Nephrol. 2017; 28(8): 2529-39. Article. IF: 8.655; D1
• Casado M, Ferrer-López I, Ruiz-Sala P, Pérez-Cerdá C, Artuch R. Uri-
ne oligosaccharide tests for the diagnosis of oligosaccharidoses. Rev
Anal Chem. 2017; 36(3): 20160019. Article. IF: 2.111; Q2
• Couce ML, Aldámiz-Echevarría L, Bueno MA, Barros P, Belanger-
Quintana A, Blasco J, García-Silva MT, Márquez-Armenteros AM, Vi-
toria I,Vives I, Navarrete R, Fernández-Marmiesse A, Pérez B, Pérez-
Cerda C. Genotype and phenotype characterization in a Spanish
cohort with isovaleric acidemia. J Hum Genet. 2017; 62(3): 355-60.
Article. IF: 2.942; Q2
• Coughlin CR, Swanson MA, Kronquist K, Acquaviva C, Hutchin T,
Rodríguez-Pomba P, Vaisanen ML, Spector E, Creadon-Swindell G,
Bras-Goldberg AM, Rahikkala E, Moilanen JS, Mahieu V, Matthijs G,
Bravo-Alonso I, Pérez-Cerdá C, Ugarte M, Vianey-Saban C, Scharer
GH, Van Hove JLK. The genetic basis of classic nonketotic hyper-
glycinemia due to mutations in GLDC and AMT. Genet Med. 2017;
19(1): 104-11. Article. IF: 9.937; D1
• de Diego V, Martínez-Monseny AF, Muchart J, Cuadras D, Montero
R, Artuch R, Pérez-Cerda C, Pérez B, Pérez-Duenas B, Poretti A, Se-
rrano M. Longitudinal volumetric and 2D assessment of cerebellar
atrophy in a large cohort of children with phosphomannomutase
deficiency (PMM2-CDG). J Inherit Metab Dis. 2017; 40(5): 709-13.
Article. IF: 4.092; Q1
• Godfrey C, Desviat LR, Smedsrod B, Pietri-Rouxel F, Denti MA, Dis-
terer P, Lorain S, Nogales-Gadea G, Sardone V, Anwar R, El Anda-
loussi S, Lehto T, Khoo B, Brolin C, van Roon-Mom WMC, Goyenva-
lle A, Aartsma-Rus A, Arechavala-Gómeza V. Delivery is key: lessons
learnt from developing splice-switching antisense therapies. EMBO
Mol Med. 2017; 9(5): 545-57. Review. IF: 10,293; D1
• Ortigoza-Escobar JD, Alfadhel M, Molero-Luis M, Darin N, Spiegel
R, de Coo IF, Gerards M, Taylor RW, Artuch R, Nashabat M, Ro-
dríguez-Pombo P, Tabarki B, Pérez-Dueñas B. Thiamine deficiency in
childhood with attention to genetic causes: Survival and outcome
predictors. Ann Neurol. 2017; 82(3): 317-30. Article. IF: 10.244; D1
• Peña-Quintana L, Scherer G, Curbelo-Estévez ML, Jiménez-Acosta F,
Hartmann B, La Roche F, Meavilla-Olivas S, Pérez-Cerdá C, García-
Segarra N, Giguere Y, Huppke P, Mitchell GA, Monch E, Trump D, Via-
ney-Saban C, Trimble ER, Vitoria-Miñana I, Reyes-Suárez D, Ramírez-
Lorenzo T, Tugores A. Tyrosinemia type II: Mutation update, 11 novel
mutations and description of 5 independent subjects with a novel
founder mutation. Clin Genet. 2017; 92(3): 306-17.Article. IF: 3.512; Q2
• Pérez-Cerdá C, Girós ML, Serrano M, Ecay MJ, Gort L, Dueñas BP,
Medrano C, García-Alix A, Artuch R, Briones P, Pérez B. A popula-
tion-based study on congenital disorders of protein N- and combi-
ned with o-glycosylation experience in clinical and genetic diagnosis.
J Pediatr-US. 2017; 183: 170-7. Article. IF: 3.667; Q1
• Rice GI, Kitabayashi N, Barth M, Briggs TA, Burton ACE, Carpanelli
ML, Cerisola AM, Colson C, Dale RC, Danti FR, Darin N, de Azua B,
de Giorgis V, de Goede CGL, Desguerre I, de Laet C, Eslahi A, Fahey
MC, Fallon P, Fay A, Fazzi E, Gorman MP, Gowrinathan NR, Hully
M, Kurian MA, Leboucq N, Lin JPSM, Lines MA, Mar SS, Maroofian
R, Martí-Sánchez L, McCullagh G, Mojarrad M, Narayanan V, Orcesi
S, Ortigoza-Escobar JD, Pérez-Dueñas B, Petit F, Ramsey KM, Ras-
mussen M, Rivier F, Rodríguez-Pombo P, Roubertie A, Stodberg TI,
Toosi MB, Toutain A, Uettwiller F, Ulrick N,Vanderver A, Waldman A,
Livingston JH, Crow YJ. Genetic, phenotypic, and interferon biomar-
ker status in ADAR1-related neurological disease. Neuropediatrics. Managment centre: Fundación Severo Ochoa
2017; 48(3): 166-84. Article. IF: 1.605; Q3
Pérez González MB. Bases moleculares del síndrome de
• Rivera-Barahona A, Alonso-Barroso E, Pérez B, Murphy MP, Richard
E, Desviat LR. Treatment with antioxidants ameliorates oxidative deficiencia Glut1 (Glut1ds) e investigación en terapias. CIBE-
damage in a mouse model of propionic acidemia. Mol Genet Metab. RER. 2017-Ongoing.
2017; 122(43132): 43-50. Article. IF: 3.774; Q2 Managment centre: CIBERER
• Rivera-Barahona A, Fulgencio-Covián A, Pérez-Cerdá C, Ramos R, Ba-
Ruiz Desviat L. Análisis genómicos y trasncriptómicos para
rry MA, Ugarte M, Pérez B, Richard E, Desviat LR. Dysregulated miR-
identificar defectos de Splicing y evaluación in vivo de la tera-
NAs and their pathogenic implications for the neurometabolic disease
propionic acidemia. SCI Rep-Uk. 2017; 7: 5727. Article. IF: 4.122; Q1 pia antisentido. Fundación Ramón Areces. 2015-2018.
Managment centre: Fundación Severo Ochoa
• Rivera-Barahona A, Pérez B, Richard E, Desviat LR. Role of miRNAs
in human disease and inborn errors of metabolism. J Inherit Metab
Dis. 2017; 40(4): 471-80. Article. IF: 4.092; Q1
• Serrano NL, de Diego V, Cuadras D, Monseny AFM, Velázquez-Fragua INTERNATIONAL Projects
R, López L, Felipe A, Gutiérrez-Solana LG, Macaya A, Pérez-Dueñas B,
Pérez González MB. European research network directed
Serrano M. A quantitative assessment of the evolution of cerebellar
syndrome in children with phosphomannomutase-deficiency (PMM2-
towards improving diagnosis and treatment of inborn error
CDG). Orphanet J Rare Dis. 2017; 12: 155. Article. IF: 3,607; Q2 of glycosylation (E-rare-3 JTC2015). European Union. 2016-
• Yuste-Checa P, Brasil S, Gámez A, Underhaug J, Desviat LR, Ugarte 2018.
M, Pérez-Cerda C, Martínez A, Pérez B. Pharmacological chape- Managment centre: UAM
roning: A potential treatment for PMM2-CDG. Hum Mutat. 2017;
Pérez González MB. Strengthening the research potential of
38(2): 160-8. Article. IF: 5.359; Q1
image through reinforcement of biomedical science of rare
• Yuste-Checa P, Vega AI, Martín-Higueras C, Medrano C, Gámez A,
diseases in Serbia – en route for innovation (Serbordisinn)
Desviat LR, Ugarte M, Pérez-Cerda C, Pérez B. DPAGT1-CDG:
(FP7-REGPOT). European Union. 2013-2016.
Functional analysis of disease causing pathogenic mutations and role
Managment centre: UAM
of endoplasmic reticulum stress. Plos One. 2017; 12(6): e0179456.
Article. IF: 2.766; Q1
Ruiz Desviat Ml. Networking towards clinical application of
antisense-mediated exon skipping. European cooperation in
Public Projects science and technology (COST BM1207). European Union.
2013-2017.
Pérez González MB. Enfermedades neurometabólicas here- Managment centre: UAM
ditarias: avances en el diagnóstico, la patofisiología y desarro-
llo de terapias dirigidas a estabilizar proteínas. (PI16/00573).
ISCIII. 2017-2019.
Managment centre: UAM
Patents and Trademarks
Pérez González B, Ruiz Desviat L, Jorge Finnigan A, Ugarte
Ruiz Desviat Ml. Propionic acidemia: from models and me-
Pérez M, Martínez Ruiz A, Underhaug J, Barnejee R, inven-
chanisms to biomarkers and therapies. (SAF2016-76004-R).
tors; UAM, Universidad de Bergen, Universidad de Michigan,
MINECO. 2017-2019.
assignees; Compounds useful for the treatment of methylma-
Managment centre: UAM
lonic aciduria. P201330171; 2013 February 11.
Pérez González B, Gámez Abascal A, Yuste Checa P, Ar-
Private Projects duim Brasil S, Ugarte Pérez M, Martínez Ruiz A, Under-
haug J, inventors; UAM, Universidad de Bergen, assignees;
Pérez González MB. Bases moleculares de las enfermedades
neurometabólicas y desarrollo de terapias específicas de mu- Compounds for treating congenital disorders of glycosyla-
tación. Fundación Isabel Gemio. 2016-2020. tion. EP16382373.5; 2016.
281
 3
Information Groups by Area
3.5 Cancer and Human Molecular Genetics Area
Regulation of Ciliary
Structure and Function by
Phosphoinositides Group
1 9.247 1
Francesc García Gonzalo. Investigador Ramón y Cajal. UAM
Pablo Barbeito González. Investigador Postdoctoral. UAM
Raquel Martín Morales. Investigadora Predoctoral. UAM
María Belén Rodero Sierra. Investigadora Predoctoral. UAM
Strategic Objective
Cilia are essential for our health and play important
roles in some of our diseases. Our goal is to better
understand how cilia work and how they can be mani-
pulated to promote human health.
But what are cilia and why are they important for our
health?
Cilia are cell membrane protrusions with an endoskele-
ton consisting of nine microtubule doublets. This basic
architecture, shared by both cilia and flagella, is conser-
ved from unicellular organisms to humans. There are
two kinds of cilia: motile and immotile (a.k.a. primary).
Motile cilia resemble oars, displacingextracellular fluids.
This is how we expel mucus from our bronchi and how
sperm swim. Instead, primary cilia behave like antennae,
detecting optical, mechanical or chemical signals. Our
vision, hearing and smell depend on immotile cilia. Pri-
mary cilia also monitor urine flow in the kidney, act as
sensors forhunger-controlling hormones in the brain,
and control limb and nervous system patterning in the
embryo, among many other functions.
Congenital ciliary defects cause ciliopathies, genetically
and clinically diverse illnesses whose most common
symptoms include mental retardation, retinal degene-
ration, kidney cysts, polydactyly, obesity, sterility, respi-
ratory infections, and skeletal, heart and brain malfor-
mations.Many ciliopathies are rare syndromes (Meckel,
Joubert, Bardet-Biedl, Kartagener, etc.), whereas others
are more common and affect a single organ (polycystic
kidney disease, retinitis pigmentosa).
282
Ciliopathies are not the only diseases cilia are invol-
ved in. Several cancer types, like medulloblastoma and
basal cell carcinoma, arise from abnormal activation of
Hedgehog signaling, a ciliary pathway essential for em-
bryonic development and adult stem cell function. On
the other hand, increasing evidence suggests that cilia
modulate the progression of other diseases, such as
diabetes and Alzheimer’s.
Given that ciliary function is critically dependent on
their composition, our main strategy consists in un-
derstanding the molecular mechanisms underlying: (1)
ciliary accumulation of the receptors and transducers
that sensitize cilia to external stimuli, and (2) the chan-
ges in cilia composition whereby ciliary signals are re-
layed to the rest of the cell.
Research Lines
• Role of phosphoinositides in ciliary signal transduc-
tion
• Regulation of cilia composition by phosphoinositides
• Regulation of cilia composition by transition zone
proteins
• Factors affecting the ciliary localization of Hedgehog
pathway proteins
• Factors affecting the ciliary localization of polycystic
kidney disease proteins
Research Activity
PUBLICATIONS
• García-Gonzalo FR, Reiter JF. Open sesame: How transition fi-
bers and the transition zone control ciliary composition. CSH
Perspect Biol. 2017; 9(2): a028134. Article. IF: 9.247; Q1
Onco-Hematology
Research Group (HUF)
Manuel Hidalgo Medina. Director Grupo. HUF
Carolina Alonso del Pozo. Investigador Clínico Asociado. HUF
Pilar Bravo Barahona. Facultativo Especialista de Área de
Hematología. HUF
Pastora Caballero Guerra. Facultativo Especialista de Área de
Oncología-Radioterapia. HUF
Begoña Caballero Perea. Facultativo Especialista de Área de
Oncología-Radioterapia. HUF
Julia Calzas Rodríguez. Facultativo Especialista de Area de
Oncología Médica. HUF
Beatriz Candel García. Facultativo Especialista de Área de
Farmacia. HUF
María Victoria de Torres Olombrada. Facultativo
Especialista de Área de Oncología-Radioterapia. HUF
María José Expósito Casas. Facultativo Especialista de Área de
Oncología-Radioterapia. HUF
Rafael Flores Cornejo. Facultativo Especilaista de Área de
Hematología. HUF
Ana Carolina Franco Villegas. Facultativo Especilaista de Área
de Hematología. HUF
Tamara García Cañibano. Facultativo Especialista de Área de
Oncología-Radioterapia. HUF
Mario García Gil. Jefe del Servicio de Farmacia. HUF
Juan Antonio Guerra Martínez. Jefe de Servicio de
Oncohematología. HUF
David Gutiérrez Abad. Médico Adjunto. Departamento de
Oncología Médica. HUF
Ignacio Juez Martel. Médico Adjunto. Departamento de Oncología
Médica. HUF
Javier Letéllez Fernández. Facultativo Especialista de Área de
Farmacia. HUF
Ana López Ibáñez. Enfermera de Ensayos Clínicos. Departamento
de Oncología Médica. HUF
José Francisco López Acosta. Técnico Laboratorio. HUF
Amaia López de la Calle Juega. Facultativo Especilaista de
Área de Hematología. HUF
Blanca Ludeña Martínez. Facultativo Especialista de Área de
Oncología-Radioterapia. HUF
Diego Malón Giménez. Facultativo Especialista de Area de Oncología
Médica. HUF
Soraya Marcos Sánchez. Facultativo Especialista de Área de
Oncología-Radioterapia. HUF
Laura María Medina Rodríguez. Investigadora Clínica. HUF
Sara Montemuiño Muñiz. Facultativo Especialista de Área de
Oncología-Radioterapia. HUF
Berta Nasarre López. Farmacéutica. Coordinadora Departamento de
Oncología Médica. HUF
Sofía Perea del Pino. Investigadora Senior. HUF
Laura Rodríguez Lajusticia. Facultativo Especialista de Area de
Oncología Médica. HUF
Francesca Sarno. Investigadora Senior. HUF
Strategic Objective
The main objetive of the group is to translate to the
clinic new strategies to treat cancer patients. In par-
ticular, we envision that an integrated NGS approach
coupled with state-of-the-art molecular and cellular
technologies along with newly developed mouse mo-
dels will help improve the outcome of cancer patients.
The group is actively involved in the design of preci-
sion oncology strategies as well as immuno-oncology
approaches. It is also involved in Clinical Trials to sup-
port these strategic research programs.
Research Lines
• Integrating Genomics and Avatar Mouse Models
to Personalize Pancreatic Cancer Treatment (ERC-
2014-ADG; AVATAR)
• Nanomedicine upscaling for early clinical phases of
multimodal cancer therapy (H2020; NoCanTher)
• EurOPDX Distributed Infrastructure for Research
on patient-derived cancer Xenografts- EdiREX (EU
INFRAIA; EdiREX)
• Regulation of PD1/PDL1 in response to chronic
hypoxia induced by antiangiogenic agents
• Inmunotherapy / Inmunotherapy Toxicity
283
 3
Information Groups by Area

Congenital Malformation
Surgery Group

3.6
Surgery,
Transplant 11 11.327 0

and Health
Technologies Area Leopoldo Martínez Martínez. Facultativo Especialista de
Área en Cirugía Pediátrica. HULP
Rosa María Aras López. Investigadora Postdoctoral. UAM
Research Lines
• Congenital malformations.
Mercedes Díaz González. Facultativo Especialista de Área en • Small bowel transplantation and graft rejection.
Cirugía Pediátrica. HULP • Fetal surgery.
Leopoldo Martínez Martínez José Luis Encinas Hernández. Facultativo Especialista de Área en • Alcohol Fetal Syndrome.
Cirugía Pediátrica. HULP

167 407.477
Sara Lancha Lago. Investigadora Predoctoral. HULP
Ana Lourdes Luis Huertas. Investigadora Postdoctoral. HULP
Research Activity
María Teresa Vallejo Cremades. Investigadora Postdoctoral
136 333.042 (Contrato de Estabilización de Técnicos de Apoyo). Jefe de Laboratorio. Doctoral TheseS
13.77% 30.54% HULP Andrés Moreno AM. Trasplante intestinal y rechazo:
estudio experimental con células troncales mesen-

Strategic Objective quimales derivadas de tejido adiposo para su preven-

Congenital Malformation Surgery Group
Bone Pathophysiology and Biomaterials Group
Cellular Engineering Group
Clinical Pharmacology Group
Osteoarticular Surgery Research – GICOA Group
Reconstructive and Regenerative Research Group
Transplant Group
Rehabilitation - LAMBECOM (HUF)
284
Paediatric surgery is an independent specialty that
deals with all aspects of the surgical diseases of
children. Its scope involves a wide range of clinical
problems such as trauma, tumours and inflammatory
diseases, and, more specifically, malformations. These
conditions almost always have essentially unknown
origins and are caused by unknown mechanisms. Sur-
gery is required at various times in the life of patients
with malformations, ranging from neonatal anatomi-
cal and functional reconstruction to replacement of
dysfunctional organs later in life.
As a consequence, this line of research has an
unusually broad spectrum as it encompasses the stu-
dy of cellular and molecular mechanisms leading to
malformations, the biology of the malformed foetus
and embryo, prenatal chances for intervention on the
malformations, and postnatal treatments including
organ replacement.
ción y perspectivas clínicas futuras en la búsqueda de
la tolerancia inmunológica[dissertation]. Madrid: UAM:
2017(22/06/2017).
Director: Tovar Larrucea JA.
Encinas Hernández JL. El tratamiento quirúrgico pre-
natal del mielingocele[dissertation]. Madrid: UAM:
201716/06/2017).
Directors: López Santamaría M, Tovar Larrucea JA.
PUBLICATIONS
• Domínguez Amillo E, de la Torre Ramos C, Andrés Moreno A,
Encinas Hernández J L, Hernández Oliveros F, López Santa-
maría M. Results of the mesoportal bypass (Rex shunt) in the
treatment of idiopathic extrahepatic portal vein obstruction in
children. Cir Pediatr. 2017; 30(1):22-7. Article. Not Indexed
• Dore Reyes M, de La Torre C, Bret Zurita M, Triana Junco P,
Jiménez Gómez J, Romo Muñoz M, Vilanova Sánchez A, Parrón
285
 3
Information Groups by Area

3.6 Surgery, Transplant and Health Technologies Area

Pajares M, Pérez Vigara A, Encinas Hernández J L, Martínez Martínez • Zozaya C, Triana M, Madero R, Abrams S, Martínez L, Amesty MV,

Bone Pathophysiology
L, Hernández Oliveros F, López-Santamaría M. Benefits of magnetic de Pipaon MS. Predicting full enteral feeding in the postoperative
resonance for the study of pectus excavatum in children: initial ex- period in infants with congenital diaphragmatic hernia. Eur J Pedia-
perience. Cir Pediatr. 2017; 30(2): 71-6. Article. Not Indexed tr Surg. 2017; 27(5): 431-6. Article. IF: 1.494; Q3
• Dore Reyes M, Triana Junco P, Encinas Hernández J L, Alvarado An-
tolín E, Bartha Rasero J L, Núñez Cerezo V, Romo Muñoz M, Gómez and Biomaterials Group
Cervantes M, Sánchez Galán A, Martínez Martínez L, López Santa- Public Projects
maría M. Mesenteric edema as a prenatal ultrasound sign of poor
Encinas Hernández Jl. Estudio del potencial neuroprotector
prognosis in gastroschisis. Cir Pediatr. 2017; 30(3): 131-7. Article.
Not Indexed
e inmunomodulador local de las células madre mesenquima-
les en al cirugía fetal del mielomeningocele de un modelo
• Dore M, Junco PT, Moreno AA, Cerezo VN, Muñoz MR, Galán AS,
teratogénico (PI12/01040). ISCIII. 2013-2017.
Sánchez AV, Prieto G, Ramos E, Hernández F, Martínez LM, Santa-
maría ML. Ultrashort bowel syndrome outcome in children treated Managment centre: FIBHULP
in a multidisciplinary intestinal rehabilitation unit. Eur J Pediatr Surg. Martínez Martínez L. Red de Salud Maternoinfantil y del
2017; 27(1):116-20. Article. IF: 1.494; Q3 Desarrollo (Red SAMID) (RD12/0026/0011). ISCIII. 2013-
• Sánchez-Galán A, Encinas J L, Antolín E, Vilanova A, Dore M, Triana 2017.
P, Bartha J L, López-Santamaría M. Intestinal complications in twin- Managment centre: FIBHULP
to-twin transfusion syndrome (TTTS) treated by laser coagulation
(LC). Cir Pediatr. 2017; 30(1):33-8. Article. Not Indexed Martínez Martínez L. Estudio comparativo del espectro de
• Sánchez-Montenegro C, Vilanova-Sánchez A, Barrena-Delfa S, Te- alcohol fetal según dos patrones de consumo humano y su
norio J, Santos-Simarro F, García-Miñaur S, Lapunzina P, Martínez- prevención con antioxidantes (PI15/01179). ISCIII. 2016-2018.
Martínez L. Costello Syndrome and umbilical ligament rhabdom- Managment centre: FIBHULP
yosarcoma in two pediatric patients: Case reports and review of
the literature. Case Rep Genet. 2017; 2017: 1587610. Article. Not Martínez Martínez L. Red de Salud Maternoinfantil y del
Indexed Desarrollo (Red SAMID) (RD16/0022/0006). ISCIII. 2017-
2021.
• Tovar JA. Leadership in pediatric surgery from a senior’s perspecti-
Managment centre: FIBHULP
11 47.723 8
ve. Eur J Pediatr Surg. 2017; 27(3): 234-9. Review. IF: 1.494; Q3
• Triana P, Dore M, Romo MM, Gómez JJ, Galán AS, Hernández F, Mo- Vallejo Cremades Mt. Contrato de estabilización de técni-
reno AMA, Encinas JL, Martínez L, Santamaría ML. Hepatocellular cos de apoyo. CAM, ISCIII. 2008-2018. the group is to improve the clinical outcome of or-
Nuria Elda Vilaboa Díaz. Investigadora Senior (Contrato
carcinoma: Referral to a transplantation Unit. Eur J Pediatr Surg. Managment centre: FIBHULP Miguel Servet - I2). Jefe de Laboratorio. HULP thopaedic surgery through research on implants and
2017; 27(1): 16-9. Article. IF: 1.494; Q3
Fátima Bensiamar Hadia. Técnico de Laboratorio. HULP - CIBER biomaterials used for manufacturing prosthetic devi-
• Val-Blasco A, Prieto P, González-Ramos S, Benito G, Vallejo Cremades Mt. Técnico en formación Paula Sánchez
Guismera (PEJ16/MED/TL-0746). CAM. 2017-2019. BBN ces. The group is also interested in bone tissue engi-
Vallejo-Cremades MT, Pacheco I, González-Peramato
Alba Boré Medina. Técnico de Laboratorio. HULP - CIBER BBN neering applications, developing surgical procedures
P, Agra N, Terrón V, Delgado C, Managment centre: FIBHULP
that make use of allotransplants, evaluating scaffolds
Martín-Sanz P, Boscá L, Clara Escudero Duch. Investigadora Predoctoral . HULP
Fernández-Velasco M. manufactured by collaborative partners, developing
NOD1 activation in Private Projects Mabel Falguera Uceda. Investigadora Predoctoral. HULP novel gene therapy strategies aimed to heal bone de-
cardiac fibroblasts Eduardo García Cimbrelo. Jefe de Servicio de Cirugía Ortopédica fects and studying the interactions of the immune and
Encinas Hernández JL. El estudio del potencial neuropro- y Traumatológica A. HULP. Profesor Asociado. Departamento de Cirugía. skeletal systems. Specific areas of clinical research on
induces myocardial
fibrosis in a murine
tector e inmunomodulador local del trasplante de células Facultad de Medicina. UAM implants include follow-up studies on various devices
model of type 2 dia- madre mesenquimales y sus implicaciones en la cirugía fetal Enrique Gil Garay. Jefe de Servicio de Cirugía Ortopédica y in use for osteoarticular surgery.
betes. Biochem J. 2017; de los defectos del tubo neural. Fundación Mutua Madrileña. Traumatológica B. HULP. Profesor Titular. Departamento Cirugía. Facultad The main areas of interest in basic research on the
474: 399-410. Article. IF: 2012-Ongoing. de Medicina. UAM biocompatibility of materials include:
3.857; Q2 Managment centre: FIBHULP
Francisco José Mancebo Pascual. Ayudante de Investigación. a) understanding the influence of the surface bioma-
• Zani A, Eaton S, Morini F, Martínez Martínez L. Proyecto de investigación en tecnolo- HULP terial properties on the behaviour of bone-related
Puri P, Rintala R, van gías terapéuticas avanzadas: dinamización del centro de simu- Francisco Manuel Martín Saavedra. Investigador Postdoctoral. cells
Heurn E, Lukac
lación. Curso de suturas.Varios Financiadores. 2015-Ongoing. HULP - CIBER BBN b) the study of cell reactions occurring in the vicinity
M, Bagolan
P, Kuebler
Managment centre: FIBHULP Carmen Martín Hervas. Facultativo Especialista de Área en of implanted materials caused by wear particles
JF, Fried- Vallejo Cremades MT. Formación en investigación de activi- Radiodiagnóstico. HULP. Profesora Asociada. Facultad de Medicina. UAM c) the deliberate manipulation of cell responses after
macher dades organizativas y de gestión de trabajo técnico en labora- Laura Muñoz Moreno. Investigadora Postdoctoral. HULP - CIBER exposure to nanoparticles designed for gene deli-
F, Wijnen torio. Opesa Centro de Formación. 2015-Ongoing. BBN very and optical hyperthermia applications.
R, Tovar Laura Saldaña Quero. Investigadora Senior (Contrato Miguel Servet- The team is also interested in the development of
Managment centre: FIBHULP
JA, Hoellwarth ME, Pierro Tipo I). Jefe de Laboratorio. HULP transcriptional targeting strategies to ensure tight
A. European Paediatric Sur- Vallejo Cremades MT. Formación en investigación en anato- control of the expression of therapeutic proteins
geons’ Association Survey Silvia Sánchez Casanova. Ayudante de Investigación. HULP
mía patológica.Varios Financiadores. 2016-Ongoing. and their potential application in inducing an orches-
on the Management of Managment centre: FIBHULP Gema Vallés Pérez. Investigadora Senior. Responsable de Cultivos
Hirschsprung Disease. Celulares y de los Laboratorios de IdiPAZ. HULP trated expression of growth factors involved in bone
Eur J Pediatr Surg. Vallejo Cremades MT. Servicios de investigación de la plata- healing.
2017; 27(1): 96-101. forma de apoyo de IdiPAZ, laboratorio inmunohistoquímica y
análisis de imagen. IdiPAZ. 2012-Ongoing. Strategic Objective
Research Lines
Article. IF: 1.494;
Q3 Managment centre: FIBHULP The Bone Physiopathology and Biomaterials group
includes basic and clinical researchers from IdiPAZ. • Clinical research in implants for bone repair
The group has broad experience in clinical and basic • Biocompatibility of new materials for potential use
research on biomaterials for orthopaedic implants in implants for bone repair: cell and surface inte-
and bone tissue engineering. The principal goal of ractions, cell and particle interactions
286 287
 3
Information Groups by Area
3.6 Surgery, Transplant and Health Technologies Area
• Study of the interactions between the immune and
skeletal systems
• Control of the expression of therapeutic genes using
gene circuits
Research Activity
Doctoral TheseS
Romanillos Arroyo JO. ¿Mejora la PTH (Teriparatida)
los resultados en fracturas pertrocantéreas inestables
osteoporóticas?[dissertation]. Madrid: UAM: 2017(07/09/2017).
Directors: Gil Garay E; Herruzo Cabrera R.
PUBLICATIONS
• Cruz-Pardos A, García-Rey E, García-Cimbrelo E. Total hip arthro-
plasty with use of the cementless Zweymuller Alloclassic System A
concise follow-up, at a minimum of 25 years, of a previous report.
J Bone Joint Surg Am. 2017; 99(22): 1927-31. Article. IF: 4.583; D1
• Fernández-Calderón MC, Cifuentes SC, Pacha-Olivenza MA, Ga-
llardo-Moreno AM, Saldaña L, González-Carrasco JL, Blanco MT,
Vilaboa N, González-Martín ML, Pérez-Giraldo C. Antibacterial
effect of novel biodegradable and bioresorbable PLDA/Mg com-
posites. Biomed Mater. 2017; 12(1): 15025. Article. IF: 2.897; Q2
• García-Cimbrelo E. CORR Insights (R): femoral morphology in the
dysplastic hip: three-dimensional characterizations with CT. Clin Or-
thop Relat R. 2017; 475(4):1055-7. Editorial Material. IF: 4.091; D1
• García-Rey E, Cruz-Pardos A, García-Cimbrelo E. The evolution of
an uncemented acetabular component in alumina-on-alumina total
hip arthroplasty has improved clinical outcome: a prospective,
comparative five- to 15-year follow-up study. Bone Joint J. 2017;
99B(6): 749-58. Article. IF: 3.581; D1
• Martín-Saavedra F, Crespo L, Escudero-Duch C, Saldaña L, Gómez-
Barrena E,Vilaboa N. Substrate microarchitecture shapes the para-
crine crosstalk of stem cells with endothelial cells and osteoblasts.
SCI Rep-Uk. 2017; 7: 15182. Article. IF: 4.122; Q1
• Martín-Saavedra F, Ruíz-Hernández E, Escudero-Duch C, Prieto M,
Arruebo M, Sadeghi N, Deckers R, Storm G, Hennink WE, Santa-
maría J,Vilaboa N. Lipogels responsive to near-infrared light for the
triggered release of therapeutic agents. Acta Biomater. 2017; 61:
54-65. Article. IF: 6.383; D1
• Palao-Suay R, Martín-Saavedra FM, Aguilar MR, Escudero-Duch C,
Martín-Saldaña S, Parra-Ruíz FJ, Rohner NA,Thomas SN,Vilaboa N,
Roman JS. Photothermal and photodynamic activity of polymeric
nanoparticles based on alpha-tocopheryl succinate-RAFT block
copolymers conjugated to IR-780. Acta Biomater. 2017; 57: 70-84.
Article. IF: 6.383; D1
• Ruíz Ibán MA, Tejedor A, Gil Garay E, Revenga C, Hermosa JC,
Montfort J, Peña M J, López Millán J M, Montero Matamala A, Capa
Grasa A, Navarro MJ, Gobbo M, Loza E. GEDOS-SECOT consen-
sus on the care process of patients with knee osteoarthritis and
arthoplasty. Rev Esp Cir Ortop Traumatol. 2017; 61(5): 296-312.
Article. Not Indexed
• Saldaña L, Vallés G, Bensiamar F, Mancebo FJ, García-Rey E, Vilaboa
N. Paracrine interactions between mesenchymal stem cells and
macrophages are regulated by 1,25-dihydroxyvitamin D3. SCI Rep-
Uk. 2017; 7: 14618. Article. IF: 4.122; Q1
• Vilaboa N, Boré A, Martín-Saavedra F, Bayford M, Winfield N, Fir-
th-Clark S, Kirton SB, Voellmy R. New inhibitor targeting human
transcription factor HSF1: effects on the heat shock response and
tumor cell survival. Nucleic Acids Res. 2017; 45(10): 5797-817. Ar-
ticle. IF: 11.561; D1
288
• Voellmy R, Bloom DC, Vilaboa N, Feller J. Development of recom-
binant HSV-Based Vaccine Vectors. Methods Mol Biol. 2017; 1581:
55-78-. Article. Not Indexed
Public Projects
Escudero Duch C. Contrato predoctoral de formación en
investigación, Instituto de Salud Carlos III (FI14/00447). ISCIII.
2015-2018.
Managment centre: FIBHULP
Saldaña Quero L. Contrato Miguel Servet tipo II
(CPII16/00038). CAM, ISCIII. 2017-2019.
Managment centre: FIBHULP
Saldaña Quero L. Preacondicionamiento inflamatorio de
celulas madre mesenquimales para su aplicacion en terapias
avanzadas de regeneracion osea mediante ingenieria de teji-
dos (PI15/00752). ISCIII. 2016-2018.
Managment centre: FIBHULP
Sánchez Casanova S. Contrato ayuda investigación (PEJ15/
BIO/AI-0250). CAM. 2016-2018.
Managment centre: FIBHULP
Vallés Pérez G. Contrato de graduado superior en for-
mación para programa operativo de empleo juvenil (PEJ-
2014-A-23662). MINECO. 2015-2017.
Managment centre: FIBHULP
Vilaboa Díaz NE. Biofunctionalization of titanium implant
surfaces: protein conformation, osseointegration and anti-
microbial activity (BIOSURFACES2016). CIBER-BBN. 2016-
2017.
Managment centre: CIBER-BBN
Vilaboa Díaz NE. Control espaciotemporal de la expresion
de transgenes mediante irradiación con luz en el infrarrojo
cercano (SAF2013-50364-EXP). MINECO. 2014-2017.
Managment centre: FIBHULP
Vilaboa Díaz NE. Dynamic molecular bio-interfaces for
controlled environments towards vascular morphogenesis
(DYNAMIC-VASC-2). CIBER-BBN. 2016-2017.
Managment centre: CIBER-BBN
Vilaboa Díaz NE. Hacia una terapia avanzada de regenera-
cion osea: intermediarios tisulares activables mediante ener-
gia infrarroja para la expresion controlada de factores osteo-
genicos y angiogenicos (PI15/01118). ISCIII. 2016-2018.
Managment centre: FIBHULP
Vilaboa Díaz NE. Innovative biomedical tools for the early
diagnosis and treatment of osteoporosis and osteoarthritis
(OSTEOMIR). CIBER-BBN. 2016-2017.
Managment centre: CIBER-BBN
Vilaboa Díaz NE. Materiales multifuncionales para los retos
de la sociedad (S2013/MIT-2862). CAM. 2014-2018.
Managment centre: FIBHULP
Vilaboa Díaz NE. Contrato de Estabilización Miguel Servet
(I2). CAM, ISCIII. 2013-2025.
Managment centre: FIBHULP
Vilaboa Díaz NE. NIR-responsive scaffolds for deliberate re-
gulation of transgene expression in bone tissue engineering
(HOT-SCAFF extended). CIBER-BBN. 2016-2017.
Managment centre: CIBER-BBN
Vilaboa Díaz NE. Preparation and application of eardrops
for the inhibition of sensorineuronal hearing loss (NADEAF-
NESS). CIBER-BBN. 2017-Ongoing.
Managment centre: CIBER-BBN
Vilaboa Díaz NE. Red de investigación para el desarrollo
de implantes de titanio funcionalizados (MAT2014-52905-
REDT). MINECO. 2014-2017.
Managment centre: Universidad Politécnica de Valencia
Private Projects
Vilaboa Díaz NE. Animal model of bone regeneration indu-
ced by tissue intermediates responsive to near-infrared light
(AMBIT). Roche Farma S.A. 2016-2017.
Managment centre: FIBHULP
Vilaboa Díaz NE. Caracterización y Evaluación de biomate-
riales de aplicación dental. J Ripoll S.L. 2017-Ongoing.
Managment centre: CIBER-BBN
Vilaboa Díaz NE. Detección de activación de HSF parte II-
parte XI. HSF Pharmaceuticals. 2004-2018.
Managment centre: FIBHULP
Vilaboa Díaz NE. Preparation and application of eardrops
for the inhibition of sensorineuronal hearing loss (NADEAF-
NESS). Alodia Farmaceutica S.L. 2017-Ongoing.
Managment centre: CIBER-BBN
CLINICAL TRIALS
Gil Garay E. Estudio prospectivo, multicéntrico, no aleato-
rizado. Estudio de resultados clínicos del sistema acetabular
R3 en pacientes con enfermedades degenerativas de cadera.
Type: EPA-SP.
HULP code: ANEXO-I 2929.
Sponsored´s protocol code: R3H01/01/05/200.
Sponsored by: Smith Nephew.
Signed date: 18/12/2017
Patents and Trademarks
Vilaboa Díaz NE, González Carrasco JL, Saldaña Quero
L, Frutos Torres E. inventors; FIBHULP, CSIC, CIBER-BBN,
assignees. Method to obtain a metallic-coated biomaterial;
P201030949, PCT/ES2011/070400; 2010 June 21.
Vilaboa Díaz NE, Gónzalez Carrasco JL, Multigner Domín-
guez M, Lieblich Rodríguez M, Muñoz Hernández M, Fru-
tos Torres E, Saldaña Quero L, inventors; FIBHULP, CSIC,
CIBER-BBN, Universidad Alfonso X El Sabio, assignees. Mag-
nesium/polymer composite biomaterial for biomedical appli-
cations; P201030950, PCT/ES2011/070440; 2010 June 21.
Fabiilli M, Wilson C, Padilla F, Martín Saavedra FM, in-
ventors; The regents of the University of Michigan, assignee.
Ultrasound-triggerable agents for tissue engineering; PCT/
US2013/044817, US2013/0330389; 2012 June 08.
Vilaboa Díaz NE, Calzado Martín A, Crespo García L,
Saldaña Quero L, Moreo Calvo P, Alastrué Vera V, inven-
tors; FIBHULP, CIBER-BBN, assignees. Chamber device for
dynamic cell culture on biomaterials; P201330040, PCT/
ES2013/070819; 2013 January 16.
Martín Saavedra FM, Vilaboa Díaz NE, Cebrián Hernando
V, Arruebo Gordo M, Santamaría Ramiro J, Gómez Na-
vascués L, inventors; FIBHULP, CIBER-BBN, Universidad de
Zaragoza, assignees. Fibrin hydrogel with plasmonic nanopar-
ticles; P201330894, PCT/ES2014/070484; 2013 June 14.
González Carrasco JL, Benavente Castro R, Cifuentes Cue-
llar SC, Lieblich Rodríguez M, Olalde Graells B, Atorrasa-
gasti Goyalde G, Argarate Madariaga N, Pacha Olivenza
MA, Fernández Calderón MC, Saldaña Quero L, González
Martín ML, Pérez Giraldo C, Gallardo Moreno AM, inven-
tors; CSIC, Fundación Tecnalia Research & Innovation, FI-
BHULP, Universidad de Extremadura, Centro de Investigación
Biomédica en Red (CIBER). Moldable, biodegradable, biocom-
patible and bioresorbable implant material, method for its
preparation and uses thereof. P201530683; 2015 May 18.
Voellmy R, Vilaboa Díaz NE, inventors; HSF Pharmaceuticals
S.A., assignee. Inhibitors of heat shock factor I and uses the-
reof. US 62/495,501; 2016 September 16.
289
 3
Information Groups by Area
3.6 Surgery, Transplant and Health Technologies Area
Cellular Engineering Group
10 41.795 5
Strategic Objective
María Paz de Miguel González. Investigadora Senior
(Contrato Miguel Servet - I2). Jefe de Laboratorio. HULP
Verónica Aparicio Herranz. Ayudante de Laboratorio. HULP
María Pilar González-Peramato Gutiérrez. Facultativo
Especialista de Área en Anatomía Patológica. HULP
Diana Martín Lorenzo. Técnico de Laboratorio. HULP
Manuel Nistal Martín de Serrano. Catedrático. Departamento de
Histología y Neurociencia. Facultad de Medicina. UAM
Javier Francisco Regadera González. Catedrático. Departamento
de Histología y Neurociencia. Facultad de Medicina. UAM
Diego Sainz de la Maza Redondo. Investigador Predoctoral.
HULP
Directors: de Miguel MP; Arnalich-Montiel F.
290
To ascertain the mechanisms responsible for conver-
ting a differentiated cell into a pluripotent cell and
at the same time how these establish a relations-
hip between cellular reprogramming and oncogenic
transformation, in order to use divergent pathways
governing these processes as clinical early diagnostic
tools and therapeutic targetsfor clinical intervention.
To develop new cell therapy approaches in diverse
organs transplants.
Research Lines
• Molecular mechanisms of cellular re-
programming in normal and neoplastic
environments.
• New techniques and therapies in
transplants.
Research
Activity
Doctoral
TheseS
Sainz de la Maza Redondo D. Iden-
tificación bioquímica, genética y fun-
cional de genes implicados en la poten-
cialidad de células germinales[dissertation].
Madrid: UAM: 2017(13/01/2017).
PUBLICATIONS Managment centre: FIBHULP
• Assaf-Balut C, de la Torre NG, Durán A, Fuentes M, Bordiú E, del
Valle L, Familiar C, Ortola A, Jiménez I, Herraiz MA, Izquierdo N,
de Miguel González MP. Contrato de Estabilización Miguel
Servet (I2) (CP03/0007). CAM, ISCIII. 2010-2025.
Pérez N, Torrejón MJ, Ortega MI, Illana FJ, Runkle I, de Miguel MP, Managment centre: FIBHULP
Montáñez C, Barabash A, Cuesta M, Rubio MA, Calle-Pascual AL.
A mediterranean diet with additional extra virgin olive oil and de Miguel González MP. Fabricación de estroma corneal
pistachios reduces the incidence of gestational diabetes mellitus biomimético. FIPSE-MIT. 2017-Ongoing.
(GDM): A randomized controlled trial: The St. Carlos GDM pre- Managment centre: FIBHULP
vention study. Plos One. 2017; 12(10): 185873. Article. IF: 2.766; Q1
• Carrión Diego M, Álvarez-Maestro M, Gómez Rivas J, González-
Peramato P, Cisneros Ledo J. Extramedullary plasmacytoma of the Private Projects
testicle. Arch Esp Urol. 2017; 70(10): 845-7. Article. IF: 0.465; Q4
de Miguel González MP. Evaluación histopatológica de la
• de la Maza DS, Moratilla A, Aparicio V, Lorca C, Alcaina Y, Martín
biointegración de diversos pigmentos minerales microniza-
D, de Miguel MP. Metabolic reprogramming, autophagy, and reac-
tive oxygen species are necessary for primordial germ cell repro- dos inyectados en el estroma corneal de 56 ojos de cer-
gramming into pluripotency. Oxid Med Cell Longev. 2017; 2017: do. Evaluación histopatológica de 11 córneas irradiadas con
4745252. Article. IF: 4.936; Q2 láser femtosegundo. Vissum Corporación Oftalmologica.
• del Barrio JLA, El Zarif M, de Miguel MP, Azaar A, Makdissy N, Harb 2011-Ongoing.
W, El Achkar I, Arnalich-Montiel F, Alio JL. Cellular therapy with Managment centre: FIBHULP
human autologous adipose-derived adult stem cells for advanced
keratoconus. Cornea. 2017; 36(8): 952-60. Article. IF: 2.464; Q2
de Miguel González MP. La terapia celular en la superficie
ocular: función y aplicaciones biosubstitutivas de las células
• García M, Barrio R, García-Lavandeira M, García-Rendueles AR, Es-
cudero A, Díaz-Rodríguez E, del Blanco DG, Fernández A, de Rijke
madre adultas mesenquimales para la regeneración corneal.
Fundació La Marató TV3. 2012-Ongoing.
YB,Vallespín E, Nevado J, Lapunzina P, Matre V, Hinkle PM, Hokken-
Managment centre: FIBHULP
Koelega ACS, de Miguel MP, Cameselle-Teijeiro JM, Nistal M, Álva-
rez CV, Moreno JC. The syndrome of central hypothyroidism and
de Miguel González MP. Mecanismos moleculares implica-
macroorchidism: IGSF1 controls TRHR and FSHB expression by
differential modulation of pituitary TGF beta and Activin pathways. dos en la reprogramación celular por medio de modificación
metabólica. Anónimo. 2014-Ongoing.
SCI Rep-Uk. 2017; 7: 42937. Article. IF: 4.122; Q1
Managment centre: FIBHULP
• Gilsanz C, Aller MA, Fuentes-Julían S, Prieto I, Blázquez-Martínez
A, Argudo S, Fernández-Delgado J, Belena J, Arias J, de Miguel MP.
de Miguel González MP. Proveer del conocimiento técnico
Adipose-derived mesenchymal stem cells slow disease progres-
necesario para la implantación de láminas corneales descelu-
sion of acute-on-chronic liver failure. Biomed Pharmacother. 2017;
91: 776-87. Article. IF: 3.457; Q2
larizadas y colonizadas o no con células madre mesenquima-
les derivadas de tejido adiposo para su uso en enfermedades
• Hernández-Jiménez E, Cubillos-Zapata C, Toledano V, de Diego RP,
Fernández-Navarro I, Casitas R, Carpio C, Casas-Martín J, Valentín
corneales que involucren el estroma corneal. Optica General
J,Varela-Serrano A, Avendaño-Ortiz J, Álvarez E, Aguirre LA, Pérez- SARRL. 2015-2020.
Martínez A, de Miguel MP, Belda-Iniesta C, García-Rio F, López- Managment centre: FIBHULP
Collazo E. Monocytes inhibit NK activity via TGF-beta in patients
de Miguel González MP. Bioengineered corneal tissue
with obstructive sleep apnoea. Eur Respir J. 2017; 49(6): 1602456.
Article. IF: 12.242; D1
for endothelial transplantation. Roche Farma-FIBHULP.
2015-Ongoing.
• Méndez-López I, Bomfim GHS, Musial DC, Arranz-Tagarro JA, Ve-
lasco-Martín JP, Regadera J, Jurkiewicz NH, Jurkiewicz A, García AG, Managment centre: FIBHULP
Padin JF. Altered mitochondrial function, capacitative calcium entry de Miguel González MP. Bio-ingeniería de tejido corneal
and contractions in the aorta of hypertensive rats. J Hypertens.
para trasplante endotelial: desarrollo de láminas ultrafinas
2017; 35(8): 1594-608. Article. IF: 4.092; Q1
de córnea decelularizada colonizadas por endoletio cor-
• Ruíz-Hurtado G, García-Prieto CF, Pulido-Olmo H,Velasco-Martín
neal humano expandido en cultivo. Roche Farma-FIBHULP.
JP,Villa-Valverde P, Fernández-Valle ME, Boscá L, Fernández-Velasco
2016-Ongoing.
M, Regadera J, Somoza B, Fernández-Alfonso MS. Mild and short-
term caloric restriction prevents obesity-induced cardiomyopathy Managment centre: FIBHULP
in young zucker rats without changing in metabolites and fatty
acids cardiac profile. Front Physiol. 2017; 8: 42. Article. IF: 3.394; Q1
de Miguel González MP. Contribución de la modificación
• Val-Blasco A, Prieto P, González-Ramos S, Benito G,Vallejo-Crema-
metabólica a la reprogramación celular y la transformación
oncogénica. Fundación Domingo Martínez. 2017-Ongoing.
des MT, Pacheco I, González-Peramato P, Agra N,Terrón V, Delgado
C, Martín-Sanz P, Boscá L, Fernández-Velasco M. NOD1 activation Managment centre: FIBHULP
in cardiac fibroblasts induces myocardial fibrosis in a murine mo-
del of type 2 diabetes. Biochem J. 2017; 474: 399-410. Article. IF:
3.857; Q2 Patents and Trademarks
de Miguel González MP, Arnalich Montiel F, Royuela MM,
inventors; FIBHULP, Fundación para la Investigación Biomédi-
Public Projects ca del Hospital Universitario Ramón y Cajal, Universidad de
Aparicio Herranz V. Contrato de garantía juvenil (PEJ15/BIO/ Alcalá, assignees. Corneal endothelium injector; P201131222,
A1-A5). CAM. 2015-2017. PCT/ES2012/070543; 2011 July 18.
291
 3
Information Groups by Area
3.6 Surgery, Transplant and Health Technologies Area
Clinical Pharmacology Group
12 43.697 6
Jesús Frias Iniesta. Jefe de Servicio de Farmacología Clínica.
HULP. Catedrático. Facultad de Medicina. UAM
Strategic Objective
Alberto Borobia Pérez. Facultativo Especialista de Área en
Farmacología Clínica. HULP
Antonio Javier Carcas Sansuán. Facultativo Especialista de Área
en Farmacología Clínica. HULP. Profesor Titular. Facultad de Medicina.
UAM
Alberto García Bartolomé. Investigador Postdoctoral. HULP
José Carlos Martínez Ávila. Investigador Postdoctoral. HULP
Elena Ramírez García. Facultativo Especialista de Área en
Farmacología Clínica. HULP
Hoi Yan Tong . Responsable de Farmacovigilancia. HULP
292
Clinical pharmacology, as a scientific and professional
discipline, has the objective of achieving an effecti-
ve, efficacious and efficient use of drugs, at both the
individual and group level. This means that Clinical
Pharmacology is a cross-sectional discipline that
must establish collaborations with numerous other
disciplines and health professionals.
In this context and in the field of clinical research,
the interests of our group are focused on two fun-
damental aspects:
1. Customisation of drug treatments: research and
development of techniques and methods that in-
dividualise the use of drugs, improve their efficacy
and reduce their risks.
2. The improvement of treatment by obtaining high qua-
lity evidence on the efficacy of clinical trials, strategies
of identification, evaluation and prevention of adverse
reactions to medication (pharmacovigilance program-
mes) and evaluation of the suitability of their use and
effectiveness (studies on the use of medication).
Research Lines
• Therapeutic drug monitoring (TDM) - Development
of individualised therapeutic drug monitoring pro-
grammes and pharmacogenetics.
• Getting quality evidences for the stablishment of drug
efficacy, safety and adecuate use of medicines in humans.
Research Activity
PUBLICATIONS
• Dal-Re R, Carcas AJ. Comparative effectiveness medicines research
cannot assess efficacy. J Clin Epidemiol. 2017; 92: 129. Letter. IF:
4.245; Q1
• Dal-Re R, Carcas AJ, Carne X. Who is willing to participate in low-
risk pragmatic clinical trials without consent? Eur J Clin Pharmacol.
2017; 73(12): 1557-63. Article. IF: 2.679; Q2
• Dal-Re R, Carcas AJ, Carne X, Wendler D. Patients’ beliefs regar-
ding informed consent for low-risk pragmatic trials. BMC Med Res
Methodol. 2017; 17: 145. Article. IF: 2.524; Q2
• Dal-Re R, Carcas AJ, Carne X,Wendler D. Public preferences on writ-
ten informed consent for low-risk pragmatic clinical trials in Spain.
Brit J Clin Pharmaco. 2017; 83(9): 1921-31. Article. IF: 3.838; Q1
• Díaz MQ, Borobia AM, Erce JAG, Maroun-Eid C, Fabra S, Carcas A,
Frías J, Muñoz M. Appropriate use of red blood cell transfusion in
emergency departments: a study in five emergency departments.
Blood Transfus-Italy. 2017; 15(3): 199-206. Article. IF: 2.138; Q3
• González-Herrada C, Rodríguez-Martín S, Cachafeiro L, Lerma
V, González O, Lorente JA, Rodríguez-Miguel A, González-Ramos
J, Roustan G, Ramírez E, Bellón T, de Abajo FJ. Cyclosporine use
in epidermal necrolysis is associated with an important mortality
reduction: Evidence from three different approaches. J Invest Der-
matol. 2017; 137(10): 2092-100. Article. IF: 6.448; D1
• Quintana-Díaz M, Muñoz-Romo R, Gómez-Ramírez S, Pavia J, Bo-
robia AM, García-Erce JA, Muñoz M. A fast-track anaemia clinic in
the Emergency Department: cost-analysis of intravenous iron admi-
nistration for treating iron-deficiency anaemia. Blood Transfus-Italy.
2017; 15(5): 438-46. Article. IF: 2,138; Q3
• Ramírez E, Bellón T, Tong HY, Borobia AM, de Abajo FJ, Lerma V, Hi-
dalgo MAM, Castaner JL, Cabañas R, Fiandor A, González-Ramos J,
Herranz P, Cachafeiro L, González-Herrada C, González O, Aram-
buru JA, Laosa O, Hernández R, Carcas AJ, Frías J. Significant HLA
class I type associations with aromatic antiepileptic drug (AED)-
induced SJS/TEN are different from those found for the same AED-
induced DRESS in the Spanish population. Pharmacol Res. 2017; 115:
168-78. Article. IF: 4.897; D1
• Ramírez E, Medrano-Casique N, Tong HY, Bellón T, Cabañas R, Fian-
dor A, González-Ramos J, Herranz P, Trigo E, Muñoz M, Borobia AM,
Carcas AJ, Frías J. Eosinophilic drug reactions detected by a prospec-
tive pharmacovigilance programme in a tertiary hospital. Brit J Clin
Pharmaco. 2017; 83(2): 400-15. Article. IF: 3.838; Q1
• Rodríguez-Valero N, Borobia AM, Lago M, Sánchez-Seco MP, de Ory
F, Vázquez A, Pérez-Arellano JL, Rodríguez CC, Martínez MJ, Capón
A, Canas E, Salas-Coronas J, Galparsoro AA, Muñoz J. Zika virus
screening among Spanish team members after 2016 Rio de Janeiro,
Brazil, Olympic Games. Emerg Infect Dis. 2017; 23(8): 1426-8. Edito-
rial Material. IF: 7.422; D1
• Tong HY, Borobia AM, Ávila JCM, Lubomirov R, Muñoz M, Banares
MJB, Hernández R, Capitán CF, Ramírez E, Frías J, Carcas AJ. Influen-
ce of two variants of CYP450 oxidoreductase on the stable dose of
acenocoumarol in a Spanish population. Pharmacogenomics. 2017;
18(8): 797-805. Article. IF: 2.302; Q3
• Tong HY, Medrano N, Borobia AM, Ruiz JA, Martínez AM, Martín J,
Quintana M, García S, Carcas AJ, Ramírez E. Hepatotoxicity induced
by acute and chronic paracetamol overdose in children: Where do
we stand? World J Pediatr. 2017; 13(1): 76-83. Article. IF: 1.228; Q3
Public Projects
Carcas Sansuán A. Optimización cinética-dinámica de la do-
sificación de amikacina en pacientes en hemodiálisis conven-
cional: ensayo clínico aleatorizado de dos pautas de adminis-
tración (PI13/01530). ISCIII. 2014-2017.
Managment centre: FIBHULP
Frías Iniesta J. Desarrollo de especialidades farmacéuticas
genéricas antivirales para el tratamiento de hepatitis B y VIH
(RTC-2015-4250-1). MINECO. 2015-2018.
Managment centre: UAM
Frías Iniesta J. Plataforma de unidades de investigación clí-
nica y ensayos clínicos (PT13/0002/0015). ISCIII. 2014-2017.
Managment centre: FIBHULP
García Bartolomé A. Contrato postdoctoral (PEJD-2016/
SAL-3247). CAM. 2017-2019.
Managment centre: FIBHULP
Private Projects
Borobia Pérez AM. Registro de pacientes atendidos en la
unidad de farmacogenética del Hospital La Paz y análisis de
la actividad realizada desde su creación. European Socie-
ty of Pharmacogenomics and Personalised Therapy (ESPT).
2017-Ongoing.
Managment centre: FIBHULP
Frías Iniesta J. Unidad clínica de investigación y control de
ensayos clínicos. Albizu. 2011-Ongoing.
Managment centre: FIBHULP
Ramírez García E. Estudio farmacoepidemiológico para eva-
luar los eventos tromboembólicos de las inmunoglobulinas
inespecíficas. Características diferenciales de los eventos ar-
teriales y venosos. Terumo BCT Europe N.V. 2013-Ongoing.
Managment centre: FIBHULP
293
 3
Information Groups by Area
3.6 Surgery, Transplant and Health Technologies Area
CLINICAL TRIALS
Borobia Pérez A. Ensayo clínico estudio en fase I, en abierto,
de dosis única y no randomizado para evaluar la farmacociné-
tica (FC) y la farmacodinámica (FD) de edoxabán en pacien-
tes pediátricos. Type: Clinical Trial, phase I.
HULP code: ANEXO-I 4634. Sponsored´s protocol code: DU176B-
A-U157.
Sponsored by: Daiichi-Sankyo Development Limited.
Signed date: 28/02/2017
Carcas Sansuán AJ. Riesgo de acidosis láctica asociado al
uso de metformina en pacientes diabéticos tipo 2 con en-
fermedad renal crónica moderada-severa: estudio de casos y
control. Type: , phase EPA-OD.
HULP code: PI-2449. Sponsored´s protocol code: CPC-MET-2016.
Sponsored by: Fundación Idibell.
Signed date: 20/02/2017
Patents and Trademarks
Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee.
Brand name: IBJ IberoAmerican Journals. ESM 3.063.048;
2013 February 12.
Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee
Brand name: IberoAmerican Journals Plus. ESM 3.063.052;
2013 February 12.
Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee
Brand name: IberoAmerican Journals Clinical Pharmacology.
ESM 3.063.053; 2013 February 12.
294
Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Brand
name: IberoAmerican Journals Medicine. ESM 3.063.049;
2013 February 12.
Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ,
Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R,
authors; FIBHULP, UAM, assignees. Brand name: PharmArray.
USM 86.004.412, CM 11.608.403; 2013 July 08, 2013 Fe-
bruary 27.
Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pé-
rez Rodríguez J, Asensio Martín MJ, González Sánchez ML,
Moro Agud M, Lorente Romeo M, López Nieto M, Gómez
Rioja R, authors; FIBHULP, assignee. Brand name: SINOIRES.
CM 13.080.056; 2014 July 14.
Carcas Sansuán AJ, Borobia Pérez AM, authors; FIBHULP,
assignee. Brand name: CRDataX. CM 13.681.614; 2015 May
28.
Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán
AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Da-
pia García I, Muñoz M, authors; FIBHULP, UAM, assignees.
Brand name: ClinPharmarray., CM15489511; 2016 May 31,
2016 September 07.
Osteoarticular Surgery
Research–GICOA Group
29 66.811 7
Enrique Gómez Barrena. Jefe de Sección de Cirugía
Ortopédica y Traumatología. HULP. Catedrático de Cirugía
Ortopédica y Traumatología. Facultad de Medicina. UAM
Samuel Antuña Antuña. Jefe de Sección en Cirugía Ortopédica
y Traumatología. HULP. Profesor Asociado en Cirugía Ortopédica y
Traumatología. Facultad de Medicina. UAM
Raúl Barco Laakso. Facultativo Especialista de Área en Cirugía
Ortopédica y Traumatología. HULP
Ana Cruz Pardos. Facultativo Especialista de Área en Cirugía
Ortopédica y Traumatología. HULP
Marta Domínguez García-Simón. Enfermera Coordinadora de
Ensayos Clínicos. UAM
Eduardo García Rey. Facultativo Especialista de Área en Cirugía
Ortopédica y Traumatología. HULP. Profesor Asociado en Cirugía
Ortopédica y Traumatología. Facultad de Medicina. UAM
Carlos Agustín Hernández Gil. Facultativo Especialista de Área
en Cirugía Ortopédica y Traumatología. HULP
Norma Griset Padilla Eguiluz. Investigadora Predoctoral. UAM
Carlos Emérito Rodríguez Merchan. Jefe de Sección de
Cirugía Ortopédica y Traumatología. HULP
Juan Carlos Rubio Suárez. Jefe de Sección de Cirugía Ortopédica y
Traumatología. HULP
Strategic Objective
Orthopaedic implant studies are required to assess
the results of implants, detect the causes of failure,
and deepen our understanding of the prevention
and solution of these failures. The medical, social, and
economic relevance of orthopaedic implants, and
their influence on quality of life, place this technology
in the centre of translational research in orthopaedic
surgery. Reconstruction based on biological strate-
gies and biomaterials is rapidly evolving, and cutting
edge research on these topics may offer an advantage
in clinical translational research. The group has also
developed studies on sports medicine and ligament
reconstruction, with various outcome approaches
and devices that may enhance surgical results. In this
context, a multidisciplinary clinical and basic research
group on orthopaedic surgery deepens our unders-
tanding of a wide variety of current research topics
in the field and provides further progress towards
clinical translation.
In order to contribute to new advances in the field,
our main clinical and experimental objectives are ad-
dressed by a joint research line that covers issues re-
lated to bone and joint reconstruction. These issues
include the following:
• Failed hip and knee prostheses, including the ma-
terial, biological, and clinical mechanisms of failure.
This research may lead to proposals for mate-
rials and design modifications in orthopaedic im-
plants and reconstructive devices and techniques.
Functional recovery of the patient is the ultimate
goal, considering various scenarios from an experi-
mental and clinical point of view.
• Regenerative medicine approaches to bone and
joint reconstruction, to generate preclinical and
clinical proposals for bone and joint regeneration
and repair, both in traumatic and non-traumatic
bone and soft-tissue injuries.
295
 3
Information Groups by Area

3.6 Surgery, Transplant and Health Technologies Area

Research Lines • Granchi D, Gómez-Barrena E, Rojewski M, Rosset P, Layrolle P, Spa-

zzoli B, Donati DM, Ciapetti G. Changes of bone turnover markers
• Clinical and basic research in Orthopaedics implants, in long bone nonunions treated with a regenerative approach. Stem
and in bone and joint reconstruction Cells Int. 2017: 3674045. Article. IF: 3.989; Q2
• Iorio A, Iserman E, Blanchette V, Dolan G, Ettingshausen CE, Her-
mans C, Negrier C, Oldenburg J, Reininger A, Rodríguez-Merchán
• Saldaña L, Valles G, Bensiamar F, Mancebo FJ, García-Rey E, Vilaboa
N. Paracrine interactions between mesenchymal stem cells and ma-
crophages are regulated by 1,25-dihydroxyvitamin D3. SCI Rep-Uk.
2017; 7: 14618. Article. IF: 4.122; Q1
• Vaquero-Picado A, Rodríguez-Merchán EC. Isolated posterior cru-
ciate ligament tears: an update of management. Efort Open Rev.
CLINICAL TRIALS
Gómez Barrena E. Estudio aleatorizado, doble ciego, doble
simulación, multicéntrico, de diseño adaptativo de escalada
de dosis (parte 1) y dosis-respuesta (parte 2) para evaluar la
seguridad y la eficacia de JNJ-64179375 intravenoso frente a

Research Activity C, Spannagl M,Valentino LA,Young G, Steinitz-Trost KN, Gringeri A.

Doctoral TheseS
Laiglesia Lorenzo MA. Generación de células mesenquima-
les de placenta para uso clínico[dissertation]. Madrid: UAM:
2017(11/09/2017).
Directors: Gómez Barrena E; Gonzalo RM.
Jiménez Diéz V. Estudio anatómico de la región lateral del
codo. Descripción de las estructuras implicadas en la epicon-
dilitis lateral[dissertation]. Madrid: UCM: 2017(01/06/2017).
Directors: Sañudo Tejero JR, Cecilia López D, Barco Laakso, R.
BOOKS AND BOOK CHAPTERS
Rodríguez-Merchan EC, Liddle AD (eds.). Joint Preservation
in the Adult Knee. Bern, Switzerland: Springer International
Publishing, 2017. p.1-180
PUBLICATIONS
• Álvarez-Román MT, Fernández-Bello I, de la Corte-Rodríguez H,
Hernández-Moreno AL, Martín-Salces M, Butta-Coll N, Rivas-Poll-
mar MI, Rivas-Muñoz S, Jiménez-Yuste V. Experience of tailoring
prophylaxis using factor VIII pharmacokinetic parameters estimated
with myPKFiT (R) in patients with severe haemophilia A without
inhibitors. Haemophilia. 2017; 23(1): E50-4. Letter. IF: 2.768; Q2
• Barco R, Antuna SA. Medial elbow pain. Efort Open Rev. 2017; 2(8):
362-71. Review. Not Indexed
• Barco R, Streubel PN, Morrey BF, Sánchez-Sotelo J. Total elbow ar-
throplasty for distal humeral fractures A ten-year-minimum follow-
up Study. J Bone Joint Surg Am. 2017; 99(18): 1524-31. Article. IF:
4.583; D1
• Carbonell-Escobar R, Rubio-Suárez JC, Ibarzabal-Gil A, Rodríguez-
Merchán EC. Analysis of the variables affecting outcome in fractures
of the tibial pilon treated by open reduction and internal fixation. J
Clin Orthop Trauma. 2017; 8(4): 332-8. Article. Not Indexed
• Cruz-Pardos A, García-Rey E, García-Cimbrelo E. Total hip arthro-
plasty with use of the cementless zweymuller alloclassic system a
concise follow-up, at a minimum of 25 years, of a previous report. J
Bone Joint Surg Am. 2017; 99(22): 1927-31. Article. IF: 4.583; D1
• de la Corte-Rodríguez H, Rodríguez-Merchán EC. The health as-
sessment questionnaire disability index (HAQ-DI) as a valid alter-
native for measuring the functional capacity of people with haemo-
philia. Thromb Res. 2017; 153: 51-6. Article. IF: 2.779; Q2
• García-Rey E, Cruz-Pardos A, García-Cimbrelo E. The evolution of
an uncemented acetabular component in alumina-on-alumina total
hip arthroplasty has improved clinical outcome: A prospective, com-
parative five to 15 year follow-up study. Bone Joint J. 2017; 99B(6):
749-58. Article. IF: 3.581; D1
• García-Rey E. Screws are not needed when secure interference fit
of uncemented acetabular components is adequate: a 5-to 15-year
follow-up with clinical and radiological analysis. Hip Int. 2017; 27(3):
267-72. Article. IF: 1.276; Q3
• Gómez-Barrena E. CORR Insights(A (R)): Periprosthetic occult frac-
tures of the acetabulum occur frequently during primary THA. Clin
Orthop Relat R. 2017; 475(2): 495-7. Editorial Material. IF: 4.091; D1
296
Target plasma factor levels for personalized treatment in haemophi-
2017; 2(4): 89-96. Review. Not Indexed apixaban oral en sujetos sometidos a un reemplazo total de
rodilla. Type: Clinical Trial, phase II.
lia: A Delphi consensus statement. Haemophilia. 2017; 23(3): E170-9. HULP code: 4890. Sponsored´s protocol code: 64179375THR2001.
Article. IF: 2.768; Q2 Private Projects Sponsored by: Janssen Cilag International NV.
• Keller L, Schwinte P, Gómez-Barrena E, Arruebo M, Benkirane-Jessel Signed date: 18/10/2017
Antuña Antuña S. Convenio para un proyecto de investiga-
N. Smart implants as a novel strategy to regenerate well-founded
ción. Sociedad Española de Cirugía Ortopédica y Traumato- Gómez Barrena E. A multi-centre, open-label, randomized,
cartilage. Trends Biotechnol. 2017; 35(1): 8-11. Editorial Material. IF:
logía. 2008-Ongoing.
13.578; D1 comparative clinical trial of two different doses of bone ma-
Managment centre: FIBHULP rrow autologous human mesenchymal stem cells plus bio-
• Liddle AD, Rodríguez-Merchán EC. Evidence-based management of
the knee in hemophilia. JBJS Rev. 2017; 5(8): e12. Review. Not In- Antuña Antuña S. Terapia celular con células troncales del material versus iliac crest autologous graft, for bone healing
dexed tejido adiposo en roturas del manguito rotador. Iaces Mee- in non-union after long bone fractures. Type: Clinical Trial,
• Martínez-Pérez M, Pérez-Jorge C, Lozano D, Portal-Núñez S, Pérez- tings. 2015-Ongoing. phase III.
Tanoira R, Conde A, Arenas MA, Hernández-López JM, de Dambo- Managment centre: FIBHULP HULP code: 4773. Sponsored´s protocol code: ORTHOUNION.
renea JJ, Gómez-Barrena E, Esbrit P, Esteban J. Evaluation of bacterial Sponsored by: Universidad Autónoma de Madrid.
Barco Laakso R. Terapia celular con células troncales deri-
adherence of clinical isolates of Staphylococcus sp. using a competi- Signed date: 12/05/2017
tive model. Bone Joint Res. 2017; 6(5): 315-22. Article. IF: 2.362; Q2 vadas del tejido adiposo (ASC) para mejorar el proceso de
reparación en suturas tendinosas. Unión tendón-hueso (ro-
• Martín-Saavedra F, Crespo L, Escudero-Duch C, Saldaña L, Gómez-
Barrena E, Vilaboa N. Substrate microarchitecture shapes the para-
turas del manguito rotador); unión tendón-músculo (roturas Patents and Trademarks
del tendón de aquiles). Sociedad Española de Cirugía Orto-
crine crosstalk of stem cells with endothelial cells and osteoblasts. Arenas Vara MA, Conde del Campo A, De Damborenea
pédica y Traumatología. 2009-Ongoing.
SCI Rep-Uk. 2017; 7: 15182. Article. IF: 4.122; Q1
Managment centre: FIBHULP González JJ, Matykina E, Esteban Moreno J, Gómez Barre-
• Rodríguez-Merchán E. Knee Bracing after anterior cruciate ligament na E, Pérez-Jorge Peremarch C, Pérez Tanoira R, inventors;
reconstruction reply. Orthopedics. 2017; 40(2): 70. Letter. IF: 1.463; Q3 Gómez Barrena E. Actualización y renovación de la actividad CSIC, Instituto de Investigación Sanitaria Fundación Jiménez
• Rodríguez-Merchán EC, de la Corte-Rodríguez H. Acute hemophilic en el servicio de C.O.T. “a” del Hospital Universitario La Paz. Díaz, assignees. Titanium materials anodised with fluorine.
hemarthrosis: is local cryotherapy recommended? Expert Rev He- Servicios Hospitalarios S.L. 2012-Ongoing. P201030720, PCT/ES2011/070342; 2010 May 14.
matol. 2017; 10(12): 1029-32. Review. IF: 1.937; Q3 Managment centre: FIBHULP
• Rodríguez-Merchán EC, de la Corte-Rodríguez H. Side effects and
potential risk factors of botulinum toxin type A intramuscular in-
jections in knee flexion contractures of hemophiliacs. Expert Rev INTERNATIONAL Projects
Hematol. 2017; 10(7): 587-94. Review. IF: 1.937; Q3
Gómez Barrena E. ORTHOpedic randomized clinical trial
• Rodríguez-Merchán EC, Liddle AD. Pathogenesis and treatment op- with expanded bone marrow MSC and bioceramics versus
tions for hemophilic synovitis. Expert Opin Orphan Drugs. 2017; autograft in long bone nonUNIONs (ORTHOUNION). UE.
5(2): 173-9. Review. IF: 0.684; Q4
2017-2021.
• Rodríguez-Merchán EC. Fibrin glue for local haemostasis in haemo- Managment centre: FIBHULP
philia surgery. Hosp Pract (1995). 2017; 45(5):187-91. Review. Not
Indexed
• Rodríguez-Merchán EC. Intra-articular corticosteroid injections
in haemophilic arthropathy: are they recommended? Hosp Pract
(1995). 2017: 43191. Article. Not Indexed
• Rodríguez-Merchán EC. Joint distraction in advanced osteoarthritis
of the ankle. Arch Bone Jt Surg. 2017; 5(4): 208-12. Review. Not
Indexed
• Rodríguez-Merchán EC. Management of hemophilic arthropathy of
the ankle. Cardiovasc Hematol Disord Drug Targets. 2017; 17(2):
111-8. Article. Not Indexed
• Rodríguez-Merchán EC. Platelet-rich plasma intra-articular injec-
tions for haemophilic synovitis: Scientific knowledge does not sup-
port its use. Haemophilia. 2017; 23(5): e486-7. Letter. IF: 2.768; Q2
• Rodríguez-Merchán EC. Should arterial embolization in recurrent
spontaneous hemophilic hemarthroses refractory to intensive pro-
phylaxis be the first invasive resort? Cardiovasc Hematol Disord
Drug Targets. 2017; 17(1): 33-7. Article. Not Indexed
• Rodríguez-Merchán EC. Simultaneous bilateral total knee arthro-
plasty in hemophilia: is it recommended? Expert Rev Hematol. 2017;
10(10): 847-51. Review. IF: 1.937; Q3
• Román-Belmonte JM, de la Corte-Rodríguez H, Rodríguez-Merchán
EC. Comparative analysis of two methods of data entry into elec-
tronic medical records: A randomized clinical trial (research letter).
J Eval Clin Pract. 2017; 23(6): 1478-81. Letter. IF: 1.483; Q3
297
 3
Information Groups by Area
3.6 Surgery, Transplant and Health Technologies Area
Reconstructive and
Regenerative Research Group
4 8.977 0
Luis Landín Jarillo. Facultativo Especialista de Área en
Cirugía Plástica. HULP
Sergio Álvarez García-Peñuela. Médico Interno Residente
en Cirugía Plástica y Reparadora. HULP
Jorge Bonastre Juliá. Facultativo Especialista de Área en Cirugía
Plástica. HULP
Elena Bravo Brañas. Facultativo Especialista de Área en Cirugía
Plástica. HULP
César Casado Sánchez. Facultativo Especialista de Área en
Cirugía Plástica. HULP
Marta García Redondo. Investigadora Posdoctoral. HULP
Álvaro González Miranda. Facultativo Especialista de Área
en Cirugía Plástica. HULP
Carmen Iglesias Urraca. Facultativo Especialista de Área en
Cirugía Plástica. HULP
José Ramón Martínez Méndez. Facultativo Especialista de
Área en Cirugía Plástica. HULP
Strategic
Objective
The objective of the Reconstructive and Rege-
nerative Traslational Research Group is to apply
knowledge in basic science to improve health in
a clinical context through research techniques,
focusing on the treatment and functional im-
provement of patients presenting oncological,
traumatic and burns that limit autonomy of the
patients.
Research Lines
• Research in Regenerative Medicine.
• Research in alterations of the healing proces-
ses.
• Research on burned.
• Research in post-oncological reconstruction.
• Research on posttraumatic reconstruction.
• Research in transplants.
298
Research Activity
PUBLICATIONS
• Domínguez A, Alsina E, Landín L, García-Miguel JF, Casado C, Gil-
sanz F. Transfusion requirements in burn patients undergoing pri-
mary wound excision: effect of tranexamic acid. Minerva Aneste-
siol. 2017; 83(4): 353-60. Article. IF: 2.693; Q2
• Hirche C, Citterio A, Hoeksema H, Koller J, Lehner M, Martínez
JR, Monstrey S, Murray A, Plock JA, Sander F, Schulz A, Ziegler B,
Kneser U. Eschar removal by bromelain based enzymatic debri-
dement (Nexobrid (R)) in burns: An European consensus. Burns.
2017; 43(8): 1640-53. Article. IF: 2.134; Q2
• Rojas S, del Caz MDP, Vico JRE, Villaverde E, Llinas A, Martínez JR,
Brage C,Valero J, Rodríguez AG, Barreiro JG, López-Suso E, Fernán-
dez-Canamaque JL, López R, Murat J. EHTIC study: Evaluation of a
new hemostatic agent based on tissue factor in skin grafting proce-
dures. Burns. 2017; 43(4): 780-8. Article. IF: 2.134; Q2
• Tang JB, Landín L, Cavadas PC, Thione A, Chen J, Pons G, Masia
J. Unique techniques or approaches in microvascular and micro-
lymphatic surgery. Clin Plast Surg. 2017; 44(2): 403-414. Article. IF:
2.016; Q2
Private Projects
Bonastre Juliá J. Inducción de tolerancia con galactomana-
no en un modelo de trasplante de extremedidad posterior
en ratas. FIBHULP. 2016-Ongoing.
Managment centre: FIBHULP
Casado Sánchez C. Formación en investigación en cirugía
plástica. Mediwound Germany GMBH. 2016-Ongoing.
Managment centre: FIBHULP
Landín Jarillo L. Efecto de la preservación en frío sobre el
rechazo crónico en el modelo de trasplante de extremidad
posterior en ratas.Varios Financiadores. 2011-Ongoing.
Managment centre: FIBHULP
Landín Jarillo L. Protocolo de inmunosupresión reducida
tras condicionamiento con precursores hematopoyéticos
en trasplante de tejidos compuesto. Cortes. 2015-Ongoing.
Managment centre: FIBHULP
Transplant Group
16 32.432 2
Francisco Hernández Oliveros. Facultativo Especialista de
Área en Cirugía Pediátrica. HULP
Virginia Amesty Morello. Facultativo Especialista de Área en Cirugía
Pediátrica. HULP
Ane Miren Andrés Moreno. Facultativo Especialista de Área en
Cirugía Pediátrica Pediátrica. HULP. Profesor Asociado. UAM
Carlos Andrés de la Torre Ramos. Facultativo Especialista de
Área en Cirugía Pediátrica. HULP
Jesús Carlos de Vicente Sánchez. Facultativo Especialista de Área
en Anestesiología. HULP
María Isabel del Barrio Gómez de Agüero. Jefe de Sección de
Neumología Pediátrica. HULP
Álvaro González Rocafort. Facultativo Especialista de Área del
Servicio de Cirugía Cardiovascular Infantil. HULP
Manuel Molina Arias. Médico Adjunto en Gastroenterología y
Nutrición Infantil. HULP
María Jesús Pascau González Garzón. Supervisora de la Unidad
de Trasplante Pediátrico. HULP
Antonio Pérez Ferrer. Facultativo Especialista de Área en el
servicio de Anestesiología y Reanimación. HULP. Profesor Colaborador.
UAM
Esther Ramos Boluda. Facultativo Especialista de Área en Servicio
de Gastroenterología y Nutrición Pediátrica. HULP
Fernando Reinoso Barbero. Jefe de Servicio de Anestesia-
Reanimación y Dolor Infantil. HULP
Strategic Objective
a. To establish a reliable model of multivisceral trans-
plantation in rodents.
b. To establish the intestinal transplant model in mice,
this objective is meant to take advantage of the im-
munological reactive panel available in mice, wider
than this in rats.
c. To establish an experimental model of organ per-
fusion aiming to perform studies in CCD donor
organs and ischemia reperfusion phenomena.
d. To develop safe and effective techniques of
blood-saving in our practice.
e. To establish guidelines for the transition from
child to adult life in transplanted children.
Research Lines
• Experimental models in solid organ transplanta-
tion including cellular therapy.
• Clinical research in paediatric solid organ trans-
plantation.
• Health related quality of life of transplanted pa-
tients.
• Graft optimization strategies.
• Blood-saving techniques in solid organ transplan-
tation.
• Intestinal barrier failure in children undergoing
transplantation (SOT/HSCP).
• Prothrombotic states in transplanted patients.
• Antibiotics optimization program in transplanted
children.
Research Activity
Doctoral TheseS
Andrés Moreno AM. Trasplante intestinal y rechazo:
estudio experimental con células troncales mesen-
quimales derivadas de tejido adiposo para su preven-
ción y perspectivas clínicas futuras en la búsqueda de
la tolerancia inmunológica[dissertation]. Madrid: UAM:
2017(22/06/2017).
Directors: Tovar Larrucea JA, López Santamaría M.
299
 3
Information Groups by Area
3.6 Surgery, Transplant and Health Technologies Area
PUBLICATIONS
• Alonso M, Builes L, Morán P, Ortega A, Fernández E, Reinoso-Barbe-
ro F. Clinical experience with desflurane for paediatric anaesthesia
outside the operating room. Rev Esp Anestesiol Reanim. 2017; 64(1):
6-12. Article. Not Indexed
• Aroca A, Polo L, Pérez-Farinós N, González-Rocafort A, Rey J, Sán-
chez R, Bret M, Uceda A, Labrandero C, Sanz E, García-Guereta L.
Porcine pulmonary prosthesis versus bovine jugular vein to repair
the right ventricular outflow tract in children with congenital heart
disease. Cir Cardiov. 2017; 24(3): 129-34. Article. Not indexed
• Aroca A, Polo L, Pérez-Farinós N, González-Rocafort A, Sánchez R,
Bret M, Rey J, Ruiz J, González A, Arreo V, Pérez N, Peña N, Jofre C,
Leyra F, Sánchez-Recalde A. Do porcine pulmonary bioprosthesis
perform the same job in children as in adults? A word of caution.
Cir Cardiov. 2017; 24(3): 135-41. Article. Not Indexed
• Díez Rodríguez-Labajo A, Castarlenas E, Miro J, Reinoso-Barbero F.
Agreement between child self-reported and parent-reported sco-
res for chronic pain secondary to specific pediatric diseases. Rev
Esp Anestesiol Reanim. 2017; 64(3):131-6. Article. Not Indexed
• Domínguez Amillo E, de la Torre Ramos C, Andrés Moreno A, En-
cinas Hernández JL, Hernández Oliveros F, López Santamaría M.
Results of the mesoportal bypass (Rex shunt) in the treatment of
idiopathic extrahepatic portal vein obstruction in children. Cir Pe-
diatr. 2017; 30(1):22-7. Article. Not Indexed
• Dore M, Junco PT, Moreno AA, Cerezo VN, Muñoz MR, Galán AS,
Sánchez AV, Prieto G, Ramos E, Hernández F, Martínez LM, Santa-
maría ML. Ultrashort bowel syndrome outcome in children treated
in a multidisciplinary intestinal rehabilitation unit. Eur J Pediatr Surg.
2017; 27(1): 116-20. Article. IF: 1.494; Q3
• Dore Reyes M, de la Torre C, Bret Zurita M, Triana Junco P, Jiménez
Gómez J, Romo Muñoz M,Vilanova Sánchez A, Parrón Pajares M, Pé-
rez Vigara A, Encinas Hernández JL, Martínez Martínez L, Hernández
Oliveros F, López-Santamaría M. Benefits of magnetic resonance for
the study of pectus excavatum in children: initial experience. Cir
Pediatr. 2017; 30(2): 71-6. Article. Not Indexed
• González-Jiménez D, Muñoz-Codoceo R, Garriga-García M, Molina-
Arias M, Álvarez-Beltrán M, García-Romero R, Martínez-Costa C,
Meavilla-Olivas SM, Pena-Quintana L, Gallego-Gutiérrez S, Marugán-
de-Miguélsanz JM, Suárez-Cortina L, Castejón-Ponce EN, Leis-Tra-
bazo R, Martín-Cruz F, Díaz-Martín JJ, Bousono-García C. Excess
weight in patients with cystic fibrosis: is it always beneficial? Nutr
Hosp. 2017; 34(3): 578-83. Article. Not Indexed
• Habre W, Disma N, Virag K, Becke K, Hansen TG, Joehr M, Leva B,
Morton NS,Vermeulen PM, Zielinska M, Boda K,Veyckemans F, Klim-
scha W, Konecny R, Luntzer R, Morawk-Wintersperger U, Neiger F,
Rustemeyer L, Breschan C, Frey D, Platzer M, Germann R, Oeding
J, Stoegermuller B, Ziegler B, Brotatsch P, Gutmann A, Mausser G,
Messerer B, Toller W, Vittinghoff M, Zangl G, Seidel-Ahyai N, Ho-
chhold C, Kroess R, Paal P, Cnudde S, Coucke P, Loveniers B, Mitchell
J, Kahn D, Pirotte T, Pregardien C, Veyckemans F, Coppens M, De
Baerdemaeker L, De Hert S, Heyse B, Neckebroek M, Parashchanka
A, Van Limmen J, Van Den Eynde N, Vanpeteghem C, Wyffels P, Lalot
M, Lechat JP, Stevens F, Casaer S, De Groote F, De Pooter F, De
Ville A, Gerin M, Magasich N, Torres CS, Van Deenen D, Berghmans
J, Himpe D, Roofthooft E, Joukes E, Smitz C, Van Reeth V, Huygens
C, Lauweryns J, De Smet K, Najafi N, Poelaert J, Van de Velde A, Van
Mossevelde V, Bekavac I, Butkovic D, Litvic DH, Soric IK, Maretic H,
Moscatello D, Popovic L, Micic S, Tus IS, Fabris LK, Simurina T, Sulen
N, Kesi-Valpotic G, Djapic D, Zurek J, Jureckova L, Mackova I, Skacel
M, Weinlichova S, Divak J, Frelich M, Urbanec R, Biskupova V, Mixa V,
Pavlickova J, Afshari A, Bottger M, Ellekvist MB, Johansen M, Madsen
BI, Nilsson JC, Schousboe BMB, Clausen NG, Hansen TG, Steen NP,
Ilmoja ML, Tonise V, Karjagin J, Kikas R, Isohanni M, Lyly A, Takala A,
Happo J, Kiviluoma K, Martikainen K, Aantaa R, Manner T, Vilo S,
Amory C, Ludot H, Lambotte P, Busche R, Jacqmarcq O, Lejus C,
300
Corouge J, Erb C, Garrigue D, Gillet P, Laffargue A, Lambelin V, Le
Freche H, Peresbota D, Richart P, Berton J, Chapotte C, Colbus L,
• Rocafort AG, Aroca A, Abelleira C, Carnicer H, Labrandero C, Vi-
llagrá S. Stented bovine jugular vein graft (Melody Valve) in mitral
Private Projects
Lehousse T, Monrigal J, Baujard C, Roulleau P, Staiti G, Batoz H, Bor- position. Could be an alternative for mechanical valve replacement Hernández Oliveros F. Inducción de tolerancia mediante el
des M, Didier A, Hamonic Y, Lagarde S, Nouette-Gaulain K, Semjen F, in the pediatric population? Rev Esp Cardiol. 2017; 70(8): 675-7. uso de progenitores hematopoyéticos en un modelo expe-
Zaghet B, Dekens J, Delcuze A, Dupont H, Legrand A, Raffoflandreur Letter. IF: 5.166; Q1 rimental de trasplante intestinal alogénico. Fundación Mutua
C, Audren N, Camus B, Cartal M, Chazelet C, Davin I, Guillier M, • Triana P, Dore M, Romo MM, Gómez JJ, Galán AS, Hernández F, Mo- Madrileña. 2017-Ongoing.
Desjeux L, Larcher C, Grein E, Leclercq M, Levitchi R, Rosu L, Simon reno AMA, Encinas JL, Martínez L, Santamaría ML. Hepatocellular Managment centre: FIBHULP
D, Zang A, Migeon A, Gagey AC, Bourdaud N, Carre AC, Duflo F, Ri- carcinoma: Referral to a transplantation unit. Eur J Pediatr Surg.
che JC, Robert P, Druot E, Maupain O, Orliaguet G, Sabau L, Taright 2017; 27(1): 16-9. Article. IF: 1.494; Q3 Pérez Ferrer A. Evaluación in vitro mediante tromboelasto-
H, Uhrig L, Verchere-Montmayeur J, Debrabant L, Pilla C, Podvin A, • Wanden-Berghe Lozano C,Virgili Casas N, Ramos Boluda E, Cuerda
grafia de la eficacia de la transfusión de plaquetas congeladas.
Roth B, Dahmani S, Julien-Marsollier F, Sabourdin N, Alexandri B, Compes C, Moreno Villares JM, Pereira Cunill JL, Gómez Candela C, Abbvie. 2013-Ongoing.
Brezac G, de la Briere F, Hayem C, Lhubat E, Mission JP, Remond C, Burgos Pelaez R, Penacho Lázaro MA, Pérez de la Cruz A, Álvarez Managment centre: FIBHULP
Dadure C, Maniora M, Marie A, Pirat P, Saour AC, Sola C, Ecoffey C, Hernández J, Gonzalo Marín M, Matia Martin P, Martínez Faedo C,
Reinoso Barbero F. Estudio observcional de la influencia de
Wodey E, Adam C, Standl T, Schindler E, Yamamoto T, Brackhahn M, Sánchez Martos EA, Sanz Paris A, Campos Martin C, Martín Folgue-
la distracción por videojuegos electrónicos en los niños in-
Eich CB, Guericke H, Kindermann P, Laschat M, Schink C, Wappler F, ras T, Martín Palmero MA, Martín Fontalba MA, Luengo Pérez LM,
Hoehne C, Skordou N, Ulrici J, Jetzek-Zader M, Kienbaum P, Meyer- gresados por enfermedades oncológicas. Fundación Juegate-
Zugasti Murillo A, Martínez Ramírez MJ, Carabana Pérez F, Martí-
Treschan T, Picker O, Schaefer MS, Mielke G, Baethge S, Ramminger nez Costa C, Díaz Guardiola P, Tejera Pérez C, Pares Marimón RM,
rapia. 2015-Ongoing.
A, Bauer M, Bollinger M, Hinz J, Quintel M, Russo SG, Bauer M, Geil Irles Rocamora JA, Garde Orbaiz C, Ponce González MA, García Managment centre: FIBHULP
D, Kortgen A, Preussler NP, Hofmann U, Raber M, Reindl D, Becke K,
Zafra MV, Sánchez Sánchez R, Urgeles Planella JR, Apezetxea Ce- Reinoso Barbero F. Successful ultrasound guidance for tap
Oppenrieder K, Schierlinger B, Roth J, Funk W, Fischer T, Gernoth C, laya A, Sánchez-Vilar Burdiel O, Joaquín Ortiz C, Suárez Llanos JP,
Wiefelsputz C, Volger H, Zederer N, Diers A, Huber M, Schorer C, bloks decreases the need for rescue analgesia alter open ap-
Pintor de la Maza B, Leyes García P, Gil Martínez MC, Mauri Roca
Weyland A, Schwarzkopf K, Grau C, Roth W, Holy R, Mader T, Peter pendectomy in children.Varios Financiadores. 2011-Ongoing.
S, Carrera Santaliestra MJ. Home and ambulatory artificial nutrition
L, Supthut H, Kuehhirt T, Milde A, Fiedler F, Isselhorst C, Grundmann (NADYA) group report - Home parenteral nutrition in Spain, 2016. Managment centre: FIBHULP
U, Pattar A, Reinert J, Ehm B, Fritzsche K, Gaebler R, Meybohm P, Nutr Hosp. 2017; 34(5): 1497-501-. Article. Not indexed
Hein M, Guzmán I, Jokinen J, Kranke P, Goebel U, Harris S, Eisner
• Zozaya C, Triana M, Madero R, Abrams S, Martínez L, Amesty MV,
C, Ochsenreiter M, Schoeler M, Thil E, Ellerkmann R, Hoeft A, Neu-
de Pipaón MS. Predicting full enteral feeding in the postoperative
mann C, Weber S, Keilhauer J, Kloessing J, Schramm M, Trieschmann
period in infants with congenital diaphragmatic hernia. Eur J Pediatr
U, Knauss K, Sinner B, Steinmann J, Koessler H, Kalliardou E, Mali-
Surg. 2017 ;27(5): 431-6. Article. IF: 1.494; Q3
siova A, Tsiotou A, Chloropoulou P, Chrysi M, Iordanidou D, Ntavlis
M, Rarosi F, Boda KB, Guerin C, Irwin J, Magner C, Nakhjavani S,
O’Hare B, Galvin D, Jamil Y, Lesmes C, Barak Y, Fisher H, Kachko L,
Katz J, Kirilov D, Levinzon M, Manevich Y, Nekrasov K, Peled E, Sanko
E, Schmain D, Sheinkin O, Simhi E, Tarabikin A, Trabkin E, Yagudaev I,
Zeitlin Y, Zunser I, (Reinoso Valverde F). Incidence of severe critical
events in paediatric anaesthesia (APRICOT): a prospective multi-
centre observational study in 261 hospitals in Europe. Lancet Respir
Med. 2017; 5(5): 412-25. Article. IF: 21.466; D1
• Hernández Oliveros F. Pediatric surgery in the European reference
networks: look after, share, treat. Cir Pediatr. 2017; 30(1): 43132.
Editorial Material. Not indexed
• Lázaro de Lucas C, Tesouro Rodríguez L, Magallares García LN,
Martínez-Ojinaga Nodal E, Ramos Boluda E. Severe diarrhoea due
to autoimmune enteropathy: Treatment and outcomes. An Pediatr.
2017; 17(30275): 30278. Article. IF: 1.318; Q3
• Pérez RS, Rey-Lois J, Polo-López L, González-Rocafort A, Builes-
Cardona LM, Uceda-Galiano A, Labrandero-de Lera C, Marín-Huar-
te N, Sanabria-Carretero P, Verdu-Sánchez C, Menéndez-Suso JJ,
Villar-Sánchez-Real MA, Segura-Escobar J, Peinado AA. Is an ECMO
necessary to repair highly complex congenital heart disease? Our
experience over the last 6 years. Cir Cardiov . 2017; 24(1): 8-13.
Article. Not Indexed
301
 3
Information Groups by Area

3.6 Surgery, Transplant and Health Technologies Area

Rehabilitation - Laboratory
of Analysis of the Movement,
Biomechanics, Ergonamics and
Motor Control. LAMBECOM

Juan Carlos Miangolarra Page. Responsable del Servicio

Clínico de Rehabilitación. Director del LAMBECOM. HUF
Paula Peña Moneva. Médico Especialista en Medicina Física y
Rehabilitación. HUF
Marta Conejo Fraile. Médico Especialista en Medicina Física y
Rehabilitación. HUF
Mónica Martínez Maside. Médico Especialista en Medicina Física y
Rehabilitación. HUF
Isabel O´Mullony Muñoz. Médico Especialista en Medicina Física y
Rehabilitación. HUF
Montserrat Molina Guerrero. Médico Especialista en Medicina
Física y Rehabilitación. HUF
María Pilar Valverde Mateos. Médico Especialista en Medicina
Física y Rehabilitación. HUF
María Carratalá Tejada. Profesor Contratado Doctor.
Fisioterapeuta. Universidad Rey Juan Carlos
Francisco Molina Rueda. Profesor Visitante. Fisioterapeuta.
Universidad Rey Juan Carlos
Roberto Cano Cuerda. Profesor Contratado Doctor. Fisioterapeuta.
Universidad Rey Juan Carlos
Isabel Alguacil Diego. Profesor Contratado Doctor. Médico
especialista en Medicina Física y Rehabilitación. Universidad Rey Juan
Carlos
Marta Pérez de Heredia Torres. Profesor Titular. Terapeuta
Ocupacional. Universidad Rey Juan Carlos
Susana Collado Vázquez. Profesor Contratado Doctor. Universidad
Strategic Objective post-surgical): coxarthrosis, gonarthrosis,
pathology of the ankle and foot. Vascular and
muscular response. Isokinetic response. Detection of
simulators / psychogenic disorders
Rey Juan Carlos Clinical rehabilitation - neurorehabilitation diabetic-origin peripheral neuropathy, including • Detection of fall risks
Alicia Cuesta Gómez. Profesor Visitante. Fisioterapeuta. Universidad Clinical biomechanics lower limb amputation/dysgenesis, fibromyalgia
• Electromyographic records. Evaluation and study of
Rey Juan Carlos Neurosciences syndrome.
muscle strength.
Esther Monge Pereira. Profesor Visitante. Fisioterapeuta. Universidad • Applicability and study of the functionality of orthotic
devices, prosthetics and support products. • Evaluation of the effectiveness of training programs,
Rey Juan Carlos
Patricia Sánchez-Herrera Baeza. Profesor Visitante Lector. Research Lines • Diagnosis of balance disorders. rehabilitation and any medical or surgical therapeutic
intervention. Pre- and post-botulinum toxin, neuromo-
Terapeuta Ocupacional. Universidad Rey Juan Carlos • Motion analysis in subjects with neurological patho- • Balance analysis.
tor, reconstructive, functional and functional orthopedic
Aikaterini Koutsou. Investigadora. Ingeniera Industrial. Universidad logy: unexpected brain damage (acute stroke/Ictus, • Assessment of body damage and disability (expert re-
ports on occupational accidents, traffic accidents, as- surgery and arthroplasties.
Rey Juan Carlos cranioencephalic trauma, etc.), Cerebral Palsy, de-
generative movement disorder (Parkinson’s disease, saults in criminal acts, civil liability, disabilities, social ser- • Rehabilitation robotics
Pilar Fernández González. Ayudante de investigación.
Fisioterapeuta. Universidad Rey Juan Carlos Multiple Sclerosis). vices, professional negligence). • Brain-computer interface (BCI) in Neurological Rehabi-
María Dolores Vialás González. Técnico de Laboratorio. • Motion analysis in musculoskeletal pathology: upper • Occupational and ergonomic evaluation. litation.
Universidad Rey Juan Carlos and lower limbs. Degenerative pathology (pre and • Evaluation of work performance, collaboration, neuro- • Functional electrical stimulation (FES).
302 303
 4
Associated
Clinicians
6.1 Anesthesiology

6.2 Angiology and Vascular Surgery

6.3 Biostatistics

“Si no invertimos 6.4 Molecular Hepatology

ahora en investigación,
dentro de cinco
o diez años
no tendremos nada.” 6.5 Nutrition and Functional
Margarita Salas
(1938)
Foods Research (NUTRINVEST)

6.6 Orthopedic Surgery and

Traumatology

6.7 Pediatric Nephrology

6.8 Pediatric Surgery

6.9 Pharmacy

6.10 Radiotherapy Oncology

304 305
 4 Associated Clinicians
Anesthesiology
28 39.637 2
Group Leader
Fernando Gilsanz Rodríguez
Research Areas
• Surgery, Transplantation and Health Technology
Research Activity
Doctoral TheseS
Anta Redondo D. Anestesia intradural con mepivacaina hi-
perbárica a dosis bajas en la cirugía ambulatoria de la her-
nia inguinal[dissertation]. Madrid: UAM: 2017(05/07/2017).
Directors: Gilsanz Rodríguez F, Gredilla Díaz E.
Burgos Frías N. Estudio predictivo de las necesida-
des transfusionales del paciente quemado quirúrgico
y validación del método[dissertation]. Madrid: UAM:
2017(20/09/2017).
Directors: Gilsanz Rodríguez F, Domínguez Ruiz Huerta A.
Fernández Mulero S. Relación entre los niveles de
creatinquinasa plasmática postoperatoria y el dete-
rioro de la función renal tras cirugía de la fractura de
cadera[dissertation]. Madrid: UAM: 2017(27/07/2017).
Directors: Gilsanz Rodríguez F, Aguilar Sánchez JL.
López-Tofiño Alcázar A. Supervivencia y calidad de
vida al año tras un episodio de shock séptico en pa-
cientes postquirúrgicos[dissertation]. Madrid: UAM:
2017(05/05/2017).
Directors: Gilsanz Rodríguez F
Mirón Rodríguez MF. Anestesia general en cirugía mayor
ambulatoria odontológica con discapacitados intelectua-
306
les. Estudio prospectivo observacional[dissertation].
Madrid: UAM: 2017(29/06/2017).
Directors: Gilsanz Rodríguez F, García Miguel MF.
Salgado Aranda P. Factores de riesgo de colonización
intestinal por enterobacterias productoras de car-
bapenemasas al ingreso en una unidad de cuidados
críticos[dissertation]. Madrid: UAM: 2017(16/09/2017).
Directors: Gilsanz Rodríguez F, Maseda Garrido E.
BOOKS AND BOOK CHAPTERS
Miro Rodríguez MF, Gilsanz Rodríguez F, García-Mi-
guel FJ. Anestesia general en cirugía mayor ambulatoria
odontológica con discapacitados intelectuales. Estudio
prospectivo observacional. Cáceres: Mirón, 2017
Díaz Díez-Picazo L, Gilsanz Rodríguez F. Cirugía en
defectos de la oxidación de los ácidos grasos. In: Couce
Pico ML, Aldámiz-Echevarría Azuara L, González-Lamu-
ño Leguina D, García Jiménez MC. Enfermedades raras
metabólicas. Procedimientos de urgencias y de situacio-
nes de riesgo. Madrid: Ergón Creaciones, 2017. p. 389-97
Guasch E, Gilsanz F. Hemorragia masiva obstétrica;
enfoque terapéutico actual. In: Álvarez C, Núñez M,
Illescas L. Perioperatorio y analgesia regional obstétrica.
Uruguay: BiblioMédica ediciones, 2017. p. 277-98
Borges Sá M, Maseda E, Vidal Cortés P, Zaragoza
Crespo R. Código Sepsis Nacional. In: Ramasco Rueda F,
González de Castro R. Manual de infecciones periope-
ratorias. Madrid: Ergón Craciones, 2017. p. 267-90
Montero Feijoo A, Salgado Aranda P, Gilsanz Rodrí-
guez F, Maseda E. Candidiasis intraabdominal. In: Ra-
masco Rueda F, González de Castro R. Manual de infec-
ciones perioperatorias. Madrid: Ergón Craciones, 2017.
p. 223-32
Salgado Aranda P, Montero Feijóo AM, Gilsanz Rodríguez F,
Maseda E. Actitud ante infecciones multirresistentes. In: Ra-
masco Rueda F, González de Castro R. Manual de infecciones
perioperatorias. Madrid: Ergón Creaciones, 2017. p. 399-406
Salgado Aranda P, Montero Feijóo AM, Gilsanz Rodríguez F,
Palacios Lázaro E, Maseda E. Fascitis necrotizante grave por
mucor asociada a neutropenia. In: Ramasco Rueda F, González
de Castro R. Manual de infecciones perioperatorias. Madrid:
Ergón Creaciones, 2017. p. 461-4
Castillo Máfia MP, Maseda E. Infección grave por Clostri-
dium difficile que precisa colectomia. In: Ramasco Rueda F,
González de Castro R. Manual de infecciones perioperato-
rias. Madrid: Ergón Creaciones, 2017. p. 545-8
PUBLICATIONS
• Almirante B, Garnacho-Montero J, Maseda E, Candel FJ, Grau S, Gui-
nea J, Moreno I, Muñoz P, Ruiz-Santana S. Candidemia and invasive
candidiasis approach in critically ill patients: role of the echinocan-
dins. Rev Esp Quim. 2017; 30(5):355-67. Article. IF: 0.605; Q4
• Bluth T, Teichmann R, Kiss T, Bobek I, Canet J, Cinnella G, de Baerde-
maeker L, Gregoretti C, Hedenstierna G, Hemmes SN, Hiesmayr M,
Hollmann MW, Jaber S, Laffey JG, Licker MJ, Markstaller K, Matot I,
Muller G, Mills GH, Mulier JP, Putensen C, Rossaint R, Schmitt J, Sen-
turk M, Neto AS, Severgnini P, Sprung J, Melo MFV, Wrigge H, Schultz
MJ, Pelosi P, de Abreu MG, (Maseda E). Protective intraoperative ven-
tilation with higher versus lower levels of positive end-expiratory
pressure in obese patients (PROBESE): study protocol for a rando-
mized controlled trial. Trials. 2017; 18: 202. Article. IF: 2.067; Q3
• Bouza E, Martínez-Alarcón J, Maseda E, Palomar M, Zaragoza R, Pé-
rez-Granda MJ, Muñoz P, Burillo A. Quality of the aetiological diag-
nosis of ventilator-associated pneumonia in Spain in the opinion of
intensive care specialists and microbiologists. Enferm Infec Micr Cl.
2017; 35(3):153-64. Article. IF: 1.707; Q3
• Brogly N, Guasch Arévalo E, Kollmann Camaiora A, Alsina Marcos E,
García García C, Gilsanz Rodríguez F. Modern approach to an old
technique: Narrative revision of techniques used to locate the epi-
dural space. Rev Esp Anestesiol Reanim. 2017; 64(8): 460-6. Article.
Not Indexed
• Candel FJ, Pacheco CP, Ruiz-Camps I, Maseda E, Sánchez-Benito MD,
Montero A, Puig M, Gilsanz F, Aguilar J, Matesanz M. Update on ma-
nagement of invasive candidiasis. Rev Esp Quim. 2017; 30(6): 397-
406. Review. IF: 0.605; Q4
• Collis R, Guasch E. Managing major obstetric haemorrhage: Pharma-
cotherapy and transfusion. Best Pract Res Clin Anaesthesiol. 2017;
31(1):107-24. Review. Not Indexed
• Domínguez A, Alsina E, Landín L, García-Miguel JF, Casado C, Gilsanz
F. Transfusion requirements in burn patients undergoing primary
wound excision: effect of tranexamic acid. Minerva Anestesiol. 2017;
83(4): 353-60. Article. IF: 2.693; Q2
• Errando-Oyonarte CL, Moreno-Sanz C,Vila-Caral P, Ruiz de Adana-
Belbel JC, Vázquez-Alonso E, Ramírez-Rodríguez JM, Veiga-Ruiz G,
Guasch-Arévalo E, Lora-Tamayo D’Ocon JI. Recommendations on
the use of deep neuromuscular blockade by anaesthesiologists and
surgeons. AQUILES (Anestesia QUIrurgica para Lograr Eficiencia y
Seguridad) Consensus. Rev Esp Anestesiol Reanim. 2017; 64(2): 95-
104. Article. Not Indexed
• Ferrer R, Zaragoza R, Llinares P, Maseda E, Rodríguez A, Quindós G.
Impact of a multifaceted educational intervention including serious
games to improve the management of invasive candidiasis in critica-
lly ill patients. Med Intensiva. 2017; 41(1): 3-11. Article. IF: 1.755; Q4
• Guasch E, Iannuccelli F, Brogly N, Gilsanz F. Failed epidural for labor:
what now? Minerva Anestesiol. 2017; 83(11): 1207-13. Article. IF:
2.693; Q2
• Hinojosa FQ, Revelo M, Salazar A, Maggi G, Schiraldi R, Brogly N,
Gilsanz F. Levosimendan as a treatment for acute renal failure asso-
ciated with cardiogenic shock after hip fracture. Rev Bras Aneste-
siol. 2017; 67(1): 89-91. Article. IF: 0.85; Q4
• Kahan BC, Koulenti D, Arvaniti K, Beavis V, Campbell D, Chan M,
Moreno R, Pearse RM. Critical care admission following elective
surgery was not associated with survival benefit: prospective analy-
sis of data from 27 countries. Intens Care Med. 2017; 43(7): 971-9.
Article. IF: 15.008; D1
• Kollmann-Camaiora A, Brogly N, Alsina E, Gilsanz F. Use of the cu-
mulative sum method (CUSUM) to assess the learning curves of
ultrasound-guided continuous femoral nerve block. Rev Esp Anes-
tesiol Reanim. 2017; 64(8): 453-9. Article. Not Indexed
• López M, Calvo M, Sancho A, Brogly N, Guasch E, Gilsanz F. Effective
volumes of 1.5% mepivacaine with different sodium concentration
for ultrasound guided popliteal block. J Clin Anesth. 2017; 37:139-
44. Article. IF: 1.818; Q3
• Maseda E, Salgado P, Anillo V, Ruiz-Carrascoso G, Gómez-Gil R, Mar-
tín-Funke C, Giménez MJ, Granizo JJ,Aguilar L, Gilsanz F. Risk factors
for colonization by carbapenemase-producing enterobacteria at ad-
mission to a Surgical ICU: A retrospective study. Enferm Infec Micr
Cl. 2017; 35(6): 333-7. Article. IF: 1.707; Q3
• Montero A, Aranda PS, Gilsanz F, Maseda E. Antimicrobial manage-
ment in nosocomial peritonitis: microbiota, drug and time. Rev Esp
Quim. 2017; 30: 34-8. Article. IF: 0.605; Q4
• Orejón RU, Martínez IH,Torres EM, Escudero CJ, Rivas JG, Sebastián
JD,Tolsada MDU. Impact of a goal directed therapy in the implemen-
tation of an ERAS (Enhanced recovery after surgery) protocol in
laparoscopic radical cystectomy. Arch Esp Urol. 2017; 70(8): 707-14.
Article. IF: 0.465; Q4
• Pérez-Ferrer A, Gredilla-Díaz E, de Vicente-Sánchez J, Navarro-Suay
R, Gilsanz-Rodríguez F. Vancomycin added to the wash solution of
the cell-saver. Effect on bacterial contamination. Rev Esp Anestesiol
Reanim. 2017; 64(4): 185-91. Article. Not Indexed
• Ripolles-Melchor J, Chappell D, Aya HD, Espinosa A, Mhyten MG,
Abad-Gurumeta A, Bergese SD, Casans-Francés R, Calvo-Vecino JM.
Fluid therapy recommendations for major abdominal surgery. Via
RICA recommendations revisited. Part II: Goal directed hemodyna-
mic therapy. Rationale for optimising intravascular volume. Rev Esp
Anestesiol Reanim. 2017; 64(6): 339-47. Article. Not Indexed
• Ripolles-Melchor J, Chappell D, Aya HD, Espinosa A, Mhyten MG,
Abad-Gurumeta A, Bergese SD, Casans-Francés R, Calvo-Vecino JM.
Fluid therapy recommendations for major abdominal surgery. Via
RICA recommendations revisited. Part III: Goal directed hemody-
namic therapy. Rationale for maintaining vascular tone and contrac-
tility. Rev Esp Anestesiol Reanim. 2017; 64(6): 348-59. Article. Not
Indexed
• Ripolles-Melchor J, Chappell D, Espinosa A, Mhyten MG, Abad-
Gurumeta A, Bergese SD, Casans-Frances R, Calvo-Vecino JM. Pe-
rioperative fluid therapy recommendations for major abdominal
surgery. Via RICA recommendations revisited. Part I: Physiological
background. Rev Esp Anestesiol Reanim. 2017; 64(6):328-38. Article.
Not Indexed
• Salinas BT, Camaiora AK, Marcos EA, Gilsanz F. Chest pain during
cesarean delivery in relation to anomalous right coronary artery: A
case report. A A Case Rep. 2017; 9(4): 119-22. Article. Not Indexed
• Sartelli M, Labricciosa FM, Barbadoro P, Pagani L, Ansaloni L, Brink
AJ, Carlet J, Khanna A, Chichom-Mefire A, Coccolini F, Di Saverio
S, May AK, Viale P, Watkins RR, Scudeller L, Abbo LM, Abu-Zidan F,
Adesunkanmi AK, Al-Dahir S, Al-Hasan MN, Alis H, Alves C, da Silva
ARA, Augustin G, Bala M, Barie PS, Beltrán MA, Bhangu A, Bouchra
B, Brecher SM, Cainzos MA, Camacho-Ortiz A, Catani M, Chandy SJ,
Jusoh AC, Cherry-Bukowiec JR, Chiara O, Colak E, Cornely OA, Cui
YF, Demetrashvili Z, de Simone B, de Waele JJ, Dhingra S, Di Mar-
zo F, Dogjani A, Dorj G, Dortet L, Duane T, Elmangory MM, Enani
307
 4 Associated Clinicians

Angiology and
MA, Ferrada P, Foianini JE, Gachabayov M, Gandhi C, Ghnnam WM, Managment centre: FIBHULP
Giamarellou H, Gkiokas G, Gomi H, Goranovic T, Griffiths EA, Gro-
nerth RIG, Monteiro JCH, Hardcastle TC, Hecker A, Hodonou AM, Maseda Garrido E. Jornada científica de actualización en in-

Vascular Surgery
Ioannidis O, Isik A, Iskandar KA, Kafil HS, Kanj SS, Kaplan LJ, Kapoor vestigación anestésica. Pfizer S.L.U. 2016-Ongoing.
G, Karamarkovic AR, Kenig J, Kerschaever I, Khamis F, Khokha V, Ki- Managment centre: FIBHULP
guba R, Kim HB, Ko WC, Koike K, Kozlovska I, Kumar A, Lagunes
Maseda Garrido E. Eficacia y seguridad de micafungina en
L, Latifi R, Lee JG, Lee YR, Leppaniemi A, Li YS, Liang SY, Lowman
pacientes post-quirúrgicos. Estudio MYCREA. Astellas Phar-
W, Machain GM, Maegele M, Major P, Malama S, Manzano-Núñez R,
Marinis A, Casas IM, Marwah S, Maseda E, McFarlane ME, Memish
ma S.A. 2013-Ongoing.
Z, Mertz D, Mesina C, Mishra S, Moore EE, Munyika A, Mylonakis E, Managment centre: FIBHULP
Napolitano L, Negoi I, Nestorovic MD, Nicolau DP, Omari AH, Or-
Brogly N. Curso de simulación alto realismo: eventos críti-
dóñez CA, Paiva JA, Pant ND, Parreira JG, Pedziwiatr M, Pereira B,
cos en anestesia: de la simulación a la realidad. Formación y
Ponce-de-León A, Poulakou G, Preller J, Pulcini C, Pupelis G, Quio-
preparación de los anestesiólogos de mañana. Varios Finan-
dettis M, Rawson TM, Reis T, Rems M, Rizoli S, Roberts J, Pereira
ciadores. 2017-Ongoing.
NR, Rodríguez-Baño J, Sakakushev B, Sanders J, Santos N, Sato N,
Sawyer RG, Scarpelini S, Scoccia L, Shafiq N, Shelat V, Sifri CD, Siri- Managment centre: FIBHULP
bumrungwong B, Soreide K, Soto R, de Souza HP,Talving P,Trung NT,
Tessier JM,Tumbarello M, Ulrych J, Uranues S,Van Goor H,Vereczkei
A, Wagenlehner F, Xiao YH, Yuan KC, Wechsler-Fordos A, Zahar JR,
Zakrison TL, Zuckerbraun B, Zuidema WP, Catena F. The Global
Alliance for Infections in Surgery: defining a model for
antimicrobial stewardship-results from an internatio-
nal cross-sectional survey. World J Emerg Surg. 2017;
12: 34. Article. IF: 3.198; Q1
• Shander A, Gilsanz F. Monitoring, safety and efficiency
in the use of blood components. Rev Esp Anestesiol
Reanim. 2017; 64(1): 43221. Article. Not Indexed
• Suárez-de-la-Rica A, Anillo V, Montero A, Hernández- 2 2.118 0
Gancedo C, López-Tofino A, Gilsanz F, Maseda E. Risk
factors for acute kidney injury in critically ill patients
with complicated intra-abdominal infection. J Crit
Care. 2017; 38: 104-8. Article. IF: 2.872; Q2
• Uña Orejón R, del Huercio Martínez I, Ureta Tol- Concepción Rodríguez NA. Estudio de validación diagnósti-
sada MP. Is albumin a real alternative to starches in
Group Leader ca: relación entre espectroscopía óptica e índice tobillo bra-
septic patients? Rev Esp Anestesiol Reanim. 2017; Álvaro Fernández Heredero zo en la enfermedad arterial periférica[dissertation]. Madrid:
64(8): 483-4. Article. Not Indexed UAM: 2017(22/09/2017).
• Uña Orejón R, Gisbert de la Cuadra L, Garríguez Pérez Directors: Riera del Moral L, Rodríguez Montes JA.
D, Diéz Sebastián J, Ureta Tolsada MP. Maintenance fluid
therapy in a tertiary hospital: A prevalence study. Rev Esp Research Areas Álvarez García J. Tratamiento mediante implante de células
Anestesiol Reanim. 2017; 64(6):306-12. Article. Not In- troncales mesenquimales de la isquemia crítica de las extre-
• Cardiovascular
dexed midades en un modelo murino experimental[dissertation].
• Zaragoza R, Ferrer R, Llinares P, Maseda E, Rodríguez A,
Madrid: UAM: 2017(24/01/2017).
Directors: Riera del Moral L, García Arranz M.
Grau S, Quindós G. EPICO 4.0. ‘Total quality’ in the management
of invasive candidiasis in critically ill patients by analysing the inte- Research Activity
grated process. Rev Iberoam Micol. 2017; 34(3): 143-57. Article. IF:
0.989; Q4 Doctoral TheseS PUBLICATIONS
• García JA, Gómez-Heras SG, del Moral LR, Largo C, García-Olmo
Fernández Heredero A. Incidencia y factores asocia- D, García-Arranz M. The effects of allogenic stem cells in a murine
PRIVATE Projects dos a nefropatía inducida por contrastes en pacien- model of hind limb diabetic ischemic tissue. PEERJ. 2017; 5: e3664.
tes sometidos a reparación endovascular de aneuris- Article. IF: 2.118; Q2
Gilsanz Rodríguez F. Actividades de formación en investi-
mas de aorta abdominal[dissertation]. Madrid: UAM: • Rodríguez NC, Manzano EM, Esquivel DR, Gutiérrez JL, de Cubas
gación en anestesia inhalatoria: jornadas científicas sobre el
2017(10/05/2017). LR. Laser diode treatment of a giant lateral-neck venous malforma-
manejo de la vía aérea en anestesia inhalatoria pediátrica con
desflurano. Baxter S.L. 2011-Ongoing. Directors: Riera del Moral L, Rodríguez Montes JA. tion. Angiologia. 2017; 69(3): 190-2. Letter. Not Indexed

Managment centre: FIBHULP

Gilsanz Rodríguez F. Jornada temática con simula-
ción de alto realismo sobre hipertermia maligna
de la teoría de la práctica. Draft Grupo de Co-
municación Healthcare S.A. 2016-Ongoing.
Managment centre: FIBHULP
Gilsanz Rodríguez F. The elderly brain during
general anesthesia and emregence -from neuro-
biology to electroencephalography. Masimo Eu-
rope Limited. 2016-Ongoing.

308 309
 4 Associated Clinicians
Biostatistics
12 32.74 8
Group Leader lopathy correlates with multiple organ dysfunction in the
hypothermia era. Pediatr Crit Care Me. 2017; 18(3): 234-40.
Rosario Madero Jarabo Article. IF: 3.092; Q1
• Carrión DM, Gregorio SAY, Rivas JG, Bazán AA, Sebastián JD,
Martínez-Piñeiro L. The role of hemostatic agents in preventing
Research Areas complications in laparoscopic partial nephrectomy. Cent Euro-
pean J Urol. 2017; 70(4): 362-7. Article. Not Indexed
• Surgery, Transplantation and Health Technology
• Custodio A, Carmona-Bayonas A, Jiménez-Fonseca P, Sánchez
ML, Viúdez A, Hernández R, Cano JM, Echavarría I, Pericay C,
Mangas M, Visa L, Buxo E, García T, Palomo AR, Mancenido FA,
Research Activity Lacalle A, Macías I, Azkarate A, Ramchandani A, Montes AF, Ló-
pez C, Longo F, Bayona RS, Limón ML, Díaz-Serrano A, Hurtado
A, Madero R, Gómez C, Gallego J. Nomogram-based prediction
Doctoral TheseS of survival in patients with advanced oesophagogastric ade-
Díaz Almirón M. Desarrollo del Algoritmo CAPRI para nocarcinoma receiving first-line chemotherapy: a multicenter
la estimación de la abundancia de complejos enzimáti- prospective study in the era of trastuzumab. Brit J Cancer. 2017;
116(12): 1526-35. Article. IF: 5.922; Q1
cos y su aplicación en la modelización del metabolis-
mo en cáncer de mama[dissertation]. Madrid: UAM: • de Pipaón MS, Dorronsoro I, Álvarez-Cuervo L, Butte NF, Ma-
dero R, Barrios V, Coya J, Martínez-Biarge M, Martos-Moreno
2017(15/09/2017).
GA, Fewtrell MS, Argente J, Quero J. The impact of intrauteri-
Directors: Gámez-Pozo A, Fresno Vara JA. ne and extrauterine weight gain in premature infants on later
body composition. Pediatr Res. 2017; 82(4): 658-64. Article. IF:
PUBLICATIONS 3.123; Q1
• Fuentes B, Sanz-Cuesta BE, Gutiérrez-Fernández M, Martínez-
• Alsina M, Martín-Ancel A, Alarcón-Allen A, Arca G, Gayá F, Sánchez P, Lisbona A, Madero-Jarabo R, Delgado-Mederos R,
García-Alix A. The Severity of hypoxic-ischemic encepha- Gallego-Cullere J, Rodríguez-Yánez M, Martínez-Zabaleta M,
310
Freijo M, de Lecinana MA, Portilla JC, Gil-Núñez A, Díez-Tejedor • Tagarro A, Otheo E, Baquero-Artigao F, Navarro ML,Velasco R, Ruiz
E. Glycemia in Acute Stroke II study: a call to improve post-stroke M, Penin M, Moreno D, Rojo P, Madero R. Dexamethasone for pa-
hyperglycemia management in clinical practice. Eur J Neurol. 2017; rapneumonic pleural effusion: A randomized, double-blind, clinical
24(9): 1091-8. Article. IF: 4.621; Q1 trial. J Pediatr-Us. 2017; 185: 117. Article. IF: 3.667; Q1
• Gámez-Pozo A, Trilla-Fuertes L, Berges-Soria J, Selevsek N, Ló- • Uña Orejón R, Gisbert de la Cuadra L, Garríguez Pérez D, Díez Se-
pez-Vacas R, Díaz-Almirón M, Nanni P, Arevalillo JM, Navarro H, bastián J, Ureta Tolsada M P. Maintenance fluid therapy in a tertiary
hospital:A prevalence study. Rev Esp Anestesiol Reanim. 2017; 64(6):
Grossmann J, Moreno FG, Rioja RG, Prado-Vázquez G, Zapater-Mo-
306-12. Article. Not Indexed
ros A, Main P, Feliú J, del Prado PM, Zamora P, Ciruelos E, Espinosa
E,Vara JAF. Functional proteomics outlines the complexity of breast • Zozaya C, Triana M, Madero R, Abrams S, Martínez L, Amesty MV,
cancer molecular subtypes. SCI Rep-Uk. 2017; 7: 10100. Article. IF: de Pipaón MS. Predicting full enteral feeding in the postoperative
4.122; Q1 period in infants with congenital diaphragmatic hernia. Eur J Pediatr
Surg. 2017; 27(5): 431-6. Article. IF: 1.494; Q3
• Gámez-Pozo A, Trilla-Fuertes L, Prado-Vázquez G, Chiva C, López-
Vacas R, Nanni P, Berges-Soria J, Grossmann J, Díaz-Almirón M, Ci-
ruelos E, Sabido E, Espinosa E, Vara JAF. Prediction of adjuvant che-
motherapy response in triple negative breast cancer with discovery Private Projects
and targeted proteomics. Plos One. 2017; 12(6): e0178296. Article. Madero Jarabo R. Plataforma bioestadística. Fundación de
IF: 2.766; Q1
la Sociedad Española de Alergología e Inmunología Clínica.
• López-Oliva MO, Flores J, Madero R, Escuín F, Santana MJ, Bellón T, 2017-Ongoing.
Selgas R, Jiménez C. Cytomegalovirus infection after kidney trans-
Managment centre: FIBHULP
plantation and long-term graft loss. Nefrología. 2017; 37(5): 515-25.
Article. IF: 1.167; Q4
• Ossorio M, Bajo MA, del Peso G, Martínez V, Fernández M, Castro
MJ, Rodríguez-Sanz A, Madero R, Bellón T, Selgas R. Sustained low
peritoneal effluent CCL18 levels are associated with preservation
of peritoneal membrane function in peritoneal dialysis. Plos One.
2017; 12(4): e0175835. Article. IF: 2.766; Q1
311
 4 Associated Clinicians
Molecular Hepatology
20 96.609 12
Group Leader
• Benito JM, García-Samaniego J, García M, Madejón A, Martín-
Javier García-Samaniego Rey
Research Areas
• Large System Pathology
• Blach S, Zeuzem S, Manns M, Altraif I, Duberg AS, Muljono DH,
Research Activity
Doctoral TheseS
Hernández Martín A. Interacciones entre los virus de la
Hepatitis B y Delta en diferentes situaciones clínicas. Iden-
tificación de marcadores de replicación de virus delta en
pacientes con evidencia de infección pasada por el virus
de la hepatitis B[dissertation]. Madrid: Universidad Euro-
pea: (28/09/2017).
Directors: García-Samaniego Rey J, Madejón Seiz A.
Jaquotot Herranz M. Utilidad de la monitorización de los
niveles de infliximab y anticuerpos anti-infliximab en el
manejo de los pacientes con enfermedad inflamatoria
intestinal[dissertation]. Madrid: UAM: (28/09/2017).
Director: Martín Arranz MD.
PUBLICATIONS
• Alonso S, Riveiro-Barciela M, Fernández I, Rincón D, Real Y, Llere-
na S, Gea F, Olveira A, Fernández-Carrillo C, Polo B, Carrión JA,
Gómez A, Devesa MJ, Baliellas C, Castro A, Ampuero J, Granados
R, Pascasio JM, Rubín A, Salmerón J, Badía E, Planas JMM, Lens S,
Turnes J, Montero JL, Buti M, Esteban R, Fernández-Rodríguez
CM. Effectiveness and safety of sofosbuvir-based regimens plus
an NS5A inhibitor for patients with HCV genotype 3 infection
312
and cirrhosis. Results of a multicenter real-life cohort. J Viral
Hepatitis. 2017; 24(4): 304-11. Article. IF: 4.237; Q1
Carbonero L, Cabello A, Álvarez B, Górgolas M, Rallón N.
Both hepatitis C virus-specific T cell responses and IL28B
rs12979860 single-nucleotide polymorphism genotype in-
fluence antihepatitis C virus treatment outcome in patients
with chronic hepatitis C. J Interf Cytok Res. 2017; 37(6): 278-
86. Article. IF: 2.419; Q3
Waked I, Alavian SM, Lee MH, Negro F, Abaalkhail F, Abdou A,
Abdulla M, Abou Rached A, Aho I, Akarca U, Al Ghazzawi I, Al
Kaabi S, Al Lawati F, Al Namaani K, Al Serkal Y, Al-Busafi SA,
Al-Dabal L, Aleman S, Alghamdi AS, Aljumah AA, Al-Romaihi
HE, Andersson MI, Arendt V, Arkkila P, Assiri AM, Baatarkhuu
O, Bane A, Ben-Ari Z, Bergin C, Bessone F, Bihl F, Bizri AR, Bla-
chier M, Blasco AJ, Mello CEB, Bruggmann P, Brunton CR, Ca-
linas F, Chan HLY, Chaudhry A, Cheinquer H, Chen CJ, Chien
RN, Choi MS, Christensen PB, Chuang WL, Chulanov V, Cis-
neros L, Clausen MR, Cramp ME, Craxi A, Croes EA, Dalgard
O, Daruich JR, de Ledinghen V, Dore GJ, El-Sayed MH, Ergor
G, Esmat G, Estes C, Falconer K, Farag E, Ferraz MLG, Ferrei-
ra PR, Flisiak R, Frankova S, Gamkrelidze I, Gane E, García-
Samaniego J, Khan AG, Gountas I, Goldis A, Gottfredsson M,
Grebely J, Gschwantler M, Pessoa MG, Gunter J, Hajarizadeh
B, Hajelssedig O, Hamid S, Hamoudi W, Hatzakis A, Himatt
SM, Hofer H, Hrstic I, Hui YT, Hunyady B, Idilman R, Jafri W,
Jahis R, Janjua NZ, Jarcuska P, Jeruma A, Jonasson JG, Kamel
Y, Kao JH, Kaymakoglu S, Kershenobich D, Khamis J, Kim YS,
Kondili L, Koutoubi Z, Krajden M, Krarup H, Lai MS, Laleman
W, Lao WC, Lavanchy D, Lazaro P, Leleu H, Lesi O, Lesmana
LA, Li M, Liakina V, Lim YS, Luksic B, Mahomed A, Maimets M,
Makara M, Malu AO, Marinho RT, Marotta P, Mauss S, Memon
MS, Correa MCM, Méndez-Sánchez N, Merat S, Metwally AM,
Mohamed R, Moreno C, Mourad FH, Mullhaupt B, Murphy K,
Nde H, Njouom R, Nonkovic D, Norris S, Obekpa S, Oguche
S, Olafsson S, Oltman M, Omede O, Omuemu C, Opare-Sem
O, Ovrehus ALH, Owusu-Ofori S, Oyunsuren TS, Papatheo-
doridis G, Pasini K, Peltekian KM, Phillips RO, Pimenov N, Poustchi
H, Prabdial-Sing N, Qureshi H, Ramji A, Razavi-Shearer D, Razavi-
Shearer K, Redae B, Reesink HW, Ridruejo E, Robbins S, Roberts LR,
Roberts SK, Rosenberg WM, Roudot-Thoraval F, Ryder SD, Safadi R,
Sagalova O, Salupere R, Sanai FM, Ávila JFS, Saraswat V, Sarmento-
Castro R, Sarrazin C, Schmelzer JD, Schreter I, Seguin-Devaux C,
Shah SR, Sharara AI, Sharma M, Shevaldin A, Shiha GE, Sievert W,
Sonderup M, Souliotis K, Speiciene D, Sperl J, Starkel P, Stauber RE,
Stedman C, Struck D, Su TH, Sypsa V, Tan SS, Tanaka J, Thompson AJ,
Tolmane I, Tomasiewicz K, Valantinas J, Van Damme P, van der Meer
AJ, van Thiel I, Van Vlierberghe H, Vince A, Vogel W, Wedemeyer H,
Weis N, Wong VWS,Yaghi C,Yosry A,Yuen MF,Yunihastuti E,Yusuf A,
Zuckerman E, Razavi H. Global prevalence and genotype distribu-
tion of hepatitis C virus infection in 2015: a modelling study. Lancet
Gastroenterol Hepatol. 2017; 2(3): 161-76. Article. Not Indexed
• Bonanad C, González-Parra E, Rivera R, Carrascosa JM, Daudén E,
Olveira A, Botella-Estrada R. Clinical, diagnostic, and therapeutic im-
plications in psoriasis associated with cardiovascular disease. Actas
Dermosifiliogr. 2017; 108(9): 800-8. Review. Not Indexed
• Buti M, Calleja JL, García-Samaniego J, Serra MA, Crespo J, Romero
M, Simón MA,Turnes J, Blasco AJ, Lázaro P, Robbins S, Razavi H. Elimi-
nation of hepatitis C in Spain: Adaptation of a mathematical model
based on the public health strategic plan for addressing hepatitis C
in the National Health System. Med Clin-Barcelona. 2017; 148(6):
277-82. Article. IF: 1.168; Q3
• Calleja JL, Crespo J, Rincón D, Ruiz-Antorán B, Fernández I, Pere-
lló C, Gea F, Lens S, García-Samaniego J, Sacristán B, García-Eliz M,
Llerena S, Pascasio JM, Turnes J, Torrás X, Morillas RM, Llaneras J,
Serra MA, Diago M, Rodríguez CF, Ampuero J, Jorquera F, Simón MA,
Arenas J, Navascúes CA, Banares R, Muñoz R, Albillos A, Mariño Z.
Effectiveness, safety and clinical outcomes of direct-acting antiviral
therapy in HCV genotype 1 infection: Results from a Spanish real-
world cohort. J Hepatol. 2017; 66(6): 1138-48. Article. IF: 14.911; D1
• Carrillo CF, Lens S, Llop E, Pascasio JM, Crespo J, Arenas J, Fernández
I, Baliellas C, Carrión JA, de la Mata M, Buti M, Castells L, Albillos A,
Romero M, Turnes J, Pons C, Moreno-Planas JM, Moreno-Palomares
JJ, Fernández-Rodríguez C, García-Samaniego J, Prieto M, Bermejo
MF, Salmerón J, Badía E, Salcedo M, Herrero JI, Granados R, Ble M,
Mariño Z, Calleja JL. Treatment of hepatitis C virus infection in pa-
tients with cirrhosis and predictive value of model for end-stage
liver disease: Analysis of data from the Hepa-C Registry. Hepatology.
2017; 65(6): 1810-22. Article. IF: 14.079; D1
• Casanova MJ, Chaparro M, García-Sánchez V, Nantes O, Leo E, Ro-
jas-Feria M, Jauregui-Amezaga A, García-López S, Huguet JM, Argüe-
lles-Arias F, Aicart M, Marín-Jiménez I, Gómez-García M, Muñoz F,
Esteve M, Bujanda L, Cortés X, Tosca J, Pineda JR, Manosa M, Llao
J, Guardiola J, Pérez-Martínez I, Muñoz C, González-Lama Y, Hino-
josa J, Vázquez JM, Martínez-Montiel MP, Rodríguez GE, Pajares R,
García-Sepulcre MF, Hernández-Martínez A, Pérez-Calle JL, Beltrán
B, Busquets D, Ramos L, Bermejo F, Barrio J, Barreiro-de Acosta M,
Roncedo O, Calvet X, Hervias D, Gomollón F, Domínguez-Antonaya
M, Alcain G, Sicilia B, Dueñas C, Gutiérrez A, Lorente-Poyatos R,
Domínguez M, Khorrami S, Muñoz C, Taxonera C, Rodríguez-Pérez
A, Ponferrada A,Van Domselaar M, Arias-Rivera ML, Merino O, Cas-
tro E, Marrero JM, Martín-Arranz M, Botella B, Fernández-Salazar
L, Monfort D, Opio V, García-Herola A, Menacho M, Ramírez-de la
Piscina P, Ceballos D, Almela P, Navarro-Llavat M, Robles-Alonso V,
Vega-López AB, Moraleja I, Novella MT, Castaño-Milla C, Sánchez-
Torres A, Benítez JM, Rodríguez C, Castro L, Garrido E, Domenech
E, García-Planella E, Gisbert JP. Evolution after anti-TNF disconti-
nuation in patients with inflammatory bowel disease: A multicenter
long-term follow-up study. Am J Gastroenterol. 2017; 112(1): 120-
31. Article. IF: 10.231; D1
• Crespo J, Calleja JL, Fernández I, Sacristán B, Ruiz-Antorán B, Am-
puero J, Hernández-Conde M, García-Samaniego J, Gea F, Buti M,
Cabezas J, Lens S, Morillas RM, Salcines JR, Pascasio JM, Turnes J,
Sáez-Royuela F, Arenas J, Rincón D, Prieto M, Jorquera F, Ruano JJS,
Navascúes CA, Molina E, Moya AG, Moreno-Planas JM. Real-world
effectiveness and safety of oral combination antiviral therapy for
hepatitis C virus genotype 4 infection. Clin Gastroenterol H. 2017;
15(6): 945-9. Article. IF: 7.683; Q1
• Detrez I,Van Stappen T,Arranz MDM, Papamichael K, Gils A. Current
practice for therapeutic drug monitoring of biopharmaceuticals in
inflammatory bowel disease. Ther Drug Monit. 2017;39(4):344-349.
Article. IF: 2,092; Q2
• Domenech E, García V, Iborra M, Gutiérrez A, García-López S,
Arranz MD, García-Planella E, Calvo M, Castro L, Mínguez M, Taxo-
nera C, Julia B, Cea-Calvo L, Romero C, Barreiro-de Acosta A. In-
cidence and management of recurrence in patients with Crohn’s
disease who have undergone intestinal resection: The Practicrohn
Study. Inflamm Bowel Dis. 2017; 23(10): 1840-6. Article. IF: 4.347; Q1
• López-Sanromán A,Vera-Mendoza I, Domenech E, Taxonera C, Ruiz
VV, Marín-Jiménez I, Guardiola J, Castro L, Esteve M, Iglesias E, Ceba-
llos D, Martínez-Montiel P, Gisbert JP, Mínguez M, Echarri A, Calvet
X, Barrio J, Hinojosa J, Martín-Arranz MD, Márquez-Mosquera L,
Bermejo F, Rimola J, Pons V, Nos P. Adalimumab vs azathioprine in
the prevention of postoperative Crohn’s disease recurrence. A GE-
TECCU Randomised Trial. J Crohns Colitis. 2017; 11(11): 1293-301.
Article. IF: 6.637; Q1
• Mariño Z, Pascasio-Acevedo JM, Gallego A, Diago M, Baliellas C, Mo-
rillas R, Prieto M, Moreno JM, Sánchez-Antolín G, Vergara M, Forne
M, Fernández I, Castro MA, Pascual S, Gómez A, Castells L, Montero
JL, Crespo J, Calleja JL, García-Samaniego J, Carrión JA, Arencibia
AC, Blasco A, López-Núñez C, Sánchez-Ruano JJ, Gea-Rodríguez F,
Giráldez A, Cabezas J, Hontangas V, Torras X, Castellote J, Romero-
Gómez M, Turnes J, de Artaza T, Narváez I, Cuervas-Mons V, Forns
X. High efficacy of Sofosbuvir plus Simeprevir in a large cohort of
Spanish cirrhotic patients infected with genotypes 1 and 4. Liver Int.
2017; 37(12): 1823-32. Article. IF: 4.5; Q1
• Montes ML, Olveira A, Ahumada A, Aldamiz T, García-Samaniego J,
Clemente A, Berenguer J, González-García J, Martín-Carbonero L.
Similar effectiveness of direct-acting antiviral against hepatitis C vi-
rus in patients with and without HIV infection. AIDS. 2017; 31(9):
1253-60. Article. IF: 4.914; Q1
• Perelló C, Carrión JA, Ruiz-Antorán B, Crespo J, Turnes J, Llaneras
J, Lens S, Delgado M, García-Samaniego J, García-Paredes F, Fernán-
dez I, Morillas RM, Rincón D, Porres JC, Prieto M, Lázaro Ríos M,
Fernández-Rodríguez C, Hermo JA, Rodríguez M, Herrero JI, Ruiz P,
Fernández JR, Macías M, Pascasio JM, Moreno JM, Serra MA, Arenas
J, Real Y, Jorquera F, Calleja JL. Effectiveness and safety of ombitasvir,
paritaprevir, ritonavir +/- dasabuvir +/- ribavirin: An early access pro-
gramme for Spanish patients with genotype 1/4 chronic hepatitis C
virus infection. J Viral Hepatitis. 2017; 24(3): 226-37. Article. IF: 4.237;
Q1
• Rallón N, García M, García-Samaniego J, Rodríguez N, Cabello A,
Restrepo C, Álvarez B, García R, Górgolas M, Benito JM. HCV coin-
fection contributes to HIV pathogenesis by increasing immune ex-
haustion in CD8 T-cells. Plos One. 2017; 12(3): e0173943. Article. IF:
2.766; Q1
• Rallón N, Restrepo C,Vicario JL, del Romero J, Rodríguez C, García-
Samaniego J, García M, Cabello A, Górgolas M, Benito JM. Human
leucocyte antigen (HLA)-DQB1*03:02 and HLA-A*02:01 have op-
posite patterns in their effects on susceptibility to HIV infection.
HIV Med. 2017; 18(8): 587-94. Article. IF: 2.932; Q2
• Razavi H, Robbins S, Zeuzem S, Negro F, Buti M, Duberg AS, Roudot-
Thoraval F, Craxi A, Manns M, Marinho RT, Hunyady B, Colombo M,
Aleman S, Antonov K, Arkkila P, Athanasakis K, Blach S, Blachier M,
Blasco AJ, Calinas F, Calleja JL, Christensen PB, Cramp ME, Croes E,
de Knegt RJ, de Ledinghen V, Delile JM, Estes C, Falconer K, Farkkila
M, Flisiak R, Frankova S, Gamkrelidze I, García-Samaniego J, Genov
J, Gerstoft J, Gheorghe L, Goldis A, Gountas I, Gregorcic S, Gs-
chwantler M, Gunter J, Halota W, Harcouet L, Hezode C, Hoffmann
P, Horvath G, Hrstic I, Jarcuska P, Jelev D, Jeruma A, Kaberg M, Kie-
313
 4 Associated Clinicians
ran J, Kondili LA, Kotzev I, Krarup H, Kristian P, Lagging M, Laleman
W, Lazaro P, Liakina V, Luksic B, Maimets M, Makara M, Mateva L,
Maticic M, Mennini FS, Mitova R, Moreno C, Mossong J, Murphy K,
Nde H, Nemecek V, Nonkovic D, Norris S, Oltman M, Ovrehus ALH,
Papatheodoridis G, Pasini K, Razavi-Shearer D, Razavi-Shearer K,
Reesink HW, Reic T, Rozentale B, Ryder SD, Salupere R, Sarmento-
Castro R, Sarrazín C, Schmelzer JD, Schreter I, Seguín-Devaux C,
Simojoki K, Simonova M, Smit PJ, Souliotis K, Speiciene D, Sperl J,
Starkel P, Struck D, Sypsa V, Thornton L, Tolmane I, Tomasiewicz K,
Valantinas J,Van Damme P, de Vijver DV, van der Meer AJ, van Santen
D,Van Vlierberghe H,Vandijck D,Vella S,Videcnik-Zorman J,Vogel W,
Weis N, Hatzakis A. Hepatitis C virus prevalence and level of inter-
vention required to achieve the WHO targets for elimination in the
European Union by 2030: a modelling study. Lancet Gastroenterol
Hepatol. 2017; 2(5): 325-36. Article. Not Indexed
• Riveiro-Barciela M, Tabernero D, Calleja JL, Lens S, Manzano ML,
Rodríguez FG, Crespo J, Piqueras B, Pascasio JM, Comas C, Gutié-
rrez ML, Aguirre A, Suárez E, García-Samaniego J, Rivero M, Acero
D, Fernández-Bermejo M, Moreno D, Sánchez-Pobre P, de Cuenca
B, Moreno-Palomares JJ, Esteban R, Buti M. Effectiveness and safety
of entecavir or tenofovir in a Spanish cohort of chronic hepatitis
B patients: Validation of the page-B score to predict hepatocellular
carcinoma. Digest Dis Sci. 2017; 62(3): 784-93. Article. IF: 2.819; Q3
• Taxonera C, Ponferrada A, Bermejo F, Riestra S, Saro C, Martín-
Arranz MD, Cabriada JL, Barreiro-de Acosta M, de Castro ML, Ló-
pez-Serrano P, Barrio J, Suárez C, Iglesias E, Argüelles-Arias F, Ferrer
I, Marín-Jiménez I, Hernández-Camba A, Bastida G, Van Domselaar
M, Martínez-Montiel P, Olivares D, Alba C, Gisbert JP. Early tuber-
culin skin test for the diagnosis of latent tuberculosis infection in
patients with inflammatory bowel disease. J Crohns Colitis. 2017;
11(7): 792-800. Article. IF: 6.637; Q1
Public Projects
García-Samaniego Rey J. Networked Biomedical Research
Center for Hepatic and Digestive Diseases (CIBERehd).
ISCIII. 2009-2017.
Managment Centre: FIBHULP
Private Projects
García-Samaniego Rey J. Identificación, en plasma y PBMCS,
de variantes de resistencia a tratamiento con telaprevir o
boceprevir frente al VHC mediante Cold-PCR. Uso en mo-
nitorización de respuesta a tratamiento. Roche Pharma S.A.
2013-Ongoing.
Managment Centre: FIBHULP
García-Samaniego Rey J. Estudios inmunológicos. Proyecto
hepatitis C: Impacto del tratamiento con nuevos antivirales.
CIBERehd. 2017-2018.
Managment Centre: CIBERehd
Madejón Seiz A. Análisis genético y epigenético del VHB en
pacientes portado. Gilead Sciencies Inc. 2013-Ongoing.
Managment Centre: FIBHULP
Madejón Seiz A. Development of a detection system of ge-
netic polymorphisms with clinical implication in the develop-
ment of human oral cancers. Arcis Ltd. 2015-2018.
Managment Centre: CIBERehd
Martín Arranz MD. Efecto terapéutico de la administración
colonoscópica de células madre mesenquimales derivadas de
tejido adiposo humano de diferentes donantes (HASC) en un
314
modelo de colitis de rata por enema de TNBS. Varios Finan-
ciadores. 2010-Ongoing.
Managment Centre: FIBHULP
Martín Arranz MD. Estudio nacional en enfermedad inflama-
toria intestinal sobre determinantes genéticos y ambientales.
ENEIDA. Abbott Laboratories S.A. 2012-Ongoing.
Managment Centre: FIBHULP
CLINICAL TRIALS
García-Samaniego Rey J. Estudio clínico de fase III, aleato-
rizado, doble ciego, controlado con placebo para evaluar la
seguridad y eficacia de selonsertib en pacientes con estea-
tohepatitis no alcohólica (EHNA) y fibrosis en puentes (F3).
Type: Clinical Trial, phase III.
HULP code: 4785. Sponsored´s protocol code: GS-US-384-1943.
Sponsored by: Gilead Sciences Inc.
Signed date: 30/03/2017
García-Samaniego Rey J. Estudio clínico de fase III, aleato-
rizado, doble ciego, controlado con placebo para evaluar la
seguridad y eficacia de selonsertib en pacientes con estea-
tohepatitis no alcohólica (EHNA) y fibrosis en puentes (F3).
Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4785. Sponsored´s protocol code: GS-
US-384-1943.
Sponsored by: Gilead Sciences Inc.
Signed date: 30/03/2017
García-Samaniego Rey J. Ensayo fase II, multicéntrico, do-
ble ciego, aleatorizado, de grupos paralelos y controlado con
placebo para investigar la seguridad, tolerabilidad, farmaco-
dinámica y farmacocinética de distintas dosis orales de BI
1467335 durante 12 semanas de tratamiento, en compa-
ración con placebo en pacientes con evidencia clínica de
EHNA. Type: Clinical Trial, phase II.
HULP code: 4893. Sponsored´s protocol code: 1386.4.
Sponsored by: Boehringer Ingelheim España S.A.
Signed date: 05/07/2017
García-Samaniego Rey J. Estudio en fase IIB, abierto, multi-
céntrico y aleatorizado para investigar la eficacia, seguridad
y farmacocinética de pautas de tratamiento diferentes con
al-335, odalasvir y simeprevir en sujetos con hepatitis C cró-
nica sin cirrosis, infectados por los genotipos 1, 2, 4, 5 y 6
del virus, que hayan, o no, recibido tratamiento previamente.
Type: Clinical Trial, phase II.
HULP code: 4617. Sponsored´s protocol code: 64294178HPC2001.
Sponsored by: Janssen Cilag International NV.
Signed date: 10/01/2017
García-Samaniego Rey J. Estudio en fase III, aleatorizado,
doble ciego y controlado con placebo para evaluar la segu-
ridad y la eficacia de selonsertib en pacientes con cirrosis
compensada debida a esteatohepatitis no alcohólica (EHNA).
Type: Clinical Trial, phase III.
HULP code: 4786. Sponsored´s protocol code: GS-US-384-1944.
Sponsored by: Gilead Sciences Inc.
Signed date: 30/03/2017
García-Samaniego Rey J. Estudio en fase III, aleatorizado,
doble ciego y controlado con placebo para evaluar la segu-
ridad y la eficacia de selonsertib en pacientes con cirrosis
compensada debida a esteatohepatitis no alcohólica (EHNA).
Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4786. Sponsored´s protocol code: GS-
US-384-1944.
Sponsored by: Gilead Sciences Inc.
Signed date: 21/08/2017
García-Samaniego Rey J. Estudio prospectivo de seguimien-
to de 3 años de duración en pacientes tratados en un estudio
anterior en fase II o III con una pauta posológica que conten-
ga odalasvir y AL-335 con o sin simeprevir para el tratamien-
to de la infección por el virus de la hepatitis c (VHC). Type:
Clinical Trial, phase II.
HULP code: 4790. Sponsored´s protocol code: 64294178HPC3001.
Sponsored by: Janssen Cilag International NV.
Signed date: 21/03/2017
García-Samaniego Rey J. Evidencia en vida real de la efec-
tividad de paritaprevir/r/ombitasvir ± dasabuvir (régimen
Abbvie) ± ribavirina en pacientes con hepatitis C crónica –
estudio observacional retrospectivo en España. (Estudio VIE-
REAL). Type: EPA-OD.
HULP code: PI-2508B. Sponsored´s protocol code: ABB-
OMB-2016-01.
Sponsored by: Abbvie Spain S.L.U.
Signed date: 03/02/2017
Martín Arranz MD. Estudio abierto de extensión y super-
visión de la seguridad de pacientes con colitis ulcerosa de
moderada a grave previamente inscritos en estudios de fase
III con etrolizumab. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4274. Sponsored´s protocol code: GA28951.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 16/02/2017
Martín Arranz MD. Estudio aleatorizado de optimización de
dosis para evaluar la eficacia y la seguridad de cobitolimod en
pacientes con colitis ulcerosa activa de carácter moderado o
severo. Type: Clinical Trial, phase II.
HULP code: 4797. Sponsored´s protocol code: CSUC-01/16.
Sponsored by: Index Pharmaceuticals AB.
Signed date: 20/04/2017
Martín Arranz MD. Estudio de extensión del estudio
APD334-003 en pacientes con colitis ulcerosa activa mode-
rada o grave. Type: Clinical Trial, phase II.
HULP code: ANEXO-I 4541. Sponsored´s protocol code: APD334-
005.
Sponsored by: Arena Pharmaceuticals Inc.
Signed date: 16/01/2017
Martín Arranz MD. Estudio de extensión del estudio
APD334-003 en pacientes con colitis ulcerosa activa mode-
rada o grave. Type: Clinical Trial, phase II.
HULP code: ANEXO-II 4541. Sponsored´s protocol code: APD334-
005.
Sponsored by: Arena Pharmaceuticals Inc.
Signed date: 13/06/2017
Martín Arranz MD. Estudio de fase III, aleatorizado, doble
ciego, controlado con placebo y de grupos paralelos para
evaluar la eficacia y la seguridad de SHP647 como tratamien-
to de inducción en sujetos con colitis ulcerosa de moderada
a grave (Fígaro UC 302). Type: Clinical Trial, phase III.
HULP code: 4971. Sponsored´s protocol code: SHP647-302.
Sponsored by: Shire Human Genetic Therapies Inc.
Signed date: 28/12/2017
Martín Arranz MD. Estudio de fase III, aleatorizado, doble
ciego, controlado con placebo y de grupos paralelos sobre
la eficacia y la seguridad de SHP647 como tratamiento de
mantenimiento en sujetos con colitis ulcerosa de moderada
a grave (Fígaro UC 303). Type: Clinical Trial, phase III.
HULP code: 4972. Sponsored´s protocol code: SHP647-303.
Sponsored by: Shire Human Genetic Therapies Inc.
Signed date: 28/12/2017
Martín Arranz MD. Estudio de fase III, aleatorizado, multi-
céntrico, doble ciego, con doble simulación, para evaluar la
eficacia y seguridad de etrolizumab comparado con inflixi-
mab en pacientes con colitis ulcerosa activa entre moderada
e intensa que no han recibido tratamiento previo con inhibi-
dores del FNT. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4273. Sponsored´s protocol code: GA29103.
Sponsored by: F.Hoffmann-La Roche Ltd.
Signed date: 09/01/2017
Martín Arranz MD. Estudio de fase III, de extensión de segu-
ridad a largo plazo de SHP647 en sujetos con colitis ulcerosa
de moderada a grave (AIDA). Type: Clinical Trial, phase III.
HULP code: 4965. Sponsored´s protocol code: SHP647-304.
Sponsored by: Shire Human Genetic Therapies Inc.
Signed date: 28/12/2017
Martín Arranz MD. Estudio de fase III, multicéntrico, aleato-
rizado, doble ciego y controlado con placebo para investigar
la eficacia y la seguridad de mongersen (GED-0301) en el tra-
tamiento de sujetos adultos y adolescentes con enfermedad
de Crohn activa. Type: Clinical Trial, phase III.
HULP code: 4816. Sponsored´s protocol code: GED-0301-CD-003.
Sponsored by: Celgene International Sarl.
Signed date: 06/04/2017
Martín Arranz MD. Estudio de fase III multicentrico, doble
ciego y controlado con placebo de la eficacia y seguridad
de etrolizumab durante la inducción y el mantenimiento en
pacientes con colitis ulcerosa activa de moderada a grave
resistentes o intolerantes a los inhibidores del FNT.Type: Cli-
nical Trial, phase III.
HULP code: ANEXO-I 4188. Sponsored´s protocol code: GA28950.
Sponsored by: F. Hoffmann-La Roche Ltd.
Signed date: 09/01/2017
Martín Arranz MD. Estudio de inducción multicéntrico, alea-
torizado, doble ciego y controlado con placebo para evaluar
la eficacia y la seguridad de risankizumab en sujetos con en-
fermedad de Crohn activa moderada o grave sin respuesta
al tratamiento biológico previo. Type: Clinical Trial, phase III.
HULP code: 4935. Sponsored´s protocol code: M15-991.
Sponsored by: Abbvie Deutschland GMBH.
Signed date: 18/12/2017
Martín Arranz MD. Estudio de inducción multicéntrico, alea-
torizado, doble ciego y controlado con placebo para evaluar
la eficacia y la seguridad de risankizumab en sujetos con en-
fermedad de Crohn activa moderada o grave. Type: Clinical
Trial, phase III.
HULP code: 4937. Sponsored´s protocol code: M16-006.
Sponsored by: Abbvie Deutschland GMBH.
315
 4 Associated Clinicians
Signed date: 18/12/2017
Martín Arranz MD. Estudio de seguridad posautorización de
golimumab para la colitis ulcerosa (CU) usando el registro
español Eneida. Type: EPA-SP.
HULP code: PI-2631. Sponsored´s protocol code: MK825-042-00.
Sponsored by: Merck Sharp & Dhome Corp.
Signed date: 28/06/2017
Martín Arranz MD. Estudio en fase I abierto, aleatorizado, de
grupos paralelos para evaluar la farmacocinética, la eficacia y
la seguridad de CT-P13 subcutáneo y CT-P13 intravenoso en
pacientes con enfermedad activa de Crohn y pacientes con
colitis ulcerosa activa. Type: Clinical Trial, phase I.
HULP code: 4901. Sponsored´s protocol code: CT-P13 1.6.
Sponsored by: Celltrion Inc.
Signed date: 06/09/2017
Martín Arranz MD. Estudio en fase II, multicéntrico, de ex-
tension en ensayo abierto para observar la eficacia a largo
plazo, seguridad y tolerabilidad a repetidas administraciones
de ABT 494 en sujetos con enfermedad de Crohn. Type: Cli-
nical Trial, phase II.
HULP code: 4671. Sponsored´s protocol code: M14-327.
Sponsored by: Abbvie Spain S.L.U.
Signed date: 28/02/2017
Martín Arranz MD. Estudio fase III, multicéntrico, aleatori-
zado, doble ciego, de grupos paralelos y controlado con pla-
cebo para evaluar la eficacia y seguridad de células madre
alogénicas expandidas derivadas del tejido adiposo (EASC)
para el tratamiento de la enfermedad de Crohn fistulizante
perianal tras un periodo de 24 semanas. Estudio Admire-CD.
Type: Clinical Trial, phase III.
HULP code: ANEXO-II 3581. Sponsored´s protocol code: CX601-
0302.
Sponsored by: Tigenix S.A.U.
Signed date: 23/01/2017
Martín Arranz MD. Estudio fase III, multicéntrico, interna-
cional, aleatorizado, doble ciego, de grupos paralelos y con-
trolado con placebo para evaluar la eficacia y la seguridad de
células madre. Type: Clinical Trial, phase III.
HULP code: 4848. Sponsored´s protocol code: Cx601-0303.
Sponsored by: Tigenix S.A.U.
Signed date: 02/06/2017
Martín Arranz MD. Estudio multicéntrico aleatorizado, doble
ciego y controlado con placebo, con tratamiento de mante-
nimiento durante 52 semanas y una extensión abierta para
evaluar la eficacia y la seguridad de risankizumab en sujetos
con enfermedad de Crohn que respondan al tratamiento de
inducción en los estudios M16-006 o M15-991. Type: Clinical
Trial, phase III.
HULP code: 4936. Sponsored´s protocol code: M16-000.
Sponsored by: Abbvie Deutschland GMBH.
Signed date: 21/12/2017
Martín Arranz MD. Estudio multicéntrico de fase II, aleatori-
zado, doble ciego y controlado con placebo de grupos para-
lelos para investigar la seguridad y la eficacia de APD334 en
pacientes con colitis ulcerativa activa de moderada a grave.
Type: Clinical Trial, phase II.
HULP code: ANEXO-II 4498. Sponsored´s protocol code: APD334-
003.
316
Sponsored by: Arena Pharmaceuticals Inc. HULP code: ANEXO-I PI-1629. Sponsored´s protocol code: ABB-
Signed date: 30/03/2017 ADA-2013-01.
Sponsored by: Abbvie Spain S.L.U.
Martín Arranz MD. Estudio multicéntrico de fase II, aleatori-
Signed date: 04/10/2017
zado, doble ciego y controlado con placebo de grupos para-
lelos para investigar la seguridad y la eficacia de APD334 en Olveira Martín A. Estudio multicéntrico de fase III, doble
pacientes con colitis ulcerativa activa de moderada a grave. ciego, aleatorizado, a largo plazo y controlado con placebo
Type: Clinical Trial, phase II. para evaluar la seguridad y la eficacia del ácido obeticólico
HULP code: ANEXO-III 4498. Sponsored´s protocol code: APD334- en sujetos con esteatohepatitis no alcohólica. Type: Clinical
Trial, phase III.
003.
Sponsored by: Arena Pharmaceuticals Inc. HULP code: 4759. Sponsored´s protocol code: 747-303.
Signed date: 13/06/2017 Sponsored by: Intercept Pharmaceuticals Inc.
Signed date: 07/02/2017
Martín Arranz MD. Estudio multicéntrico de fase II, alea-
torizado, doble ciego y controlado con placebo de grupos
paralelos para investigar la seguridad y la efica- cia de
APD334 en pacientes con colitis ulcera-
tiva activa de moderada a grave. Type:
Clinical Trial, phase II.
HULP code: ANEXO-I 4498. Sponsored´s
protocol code: APD334-003.
Sponsored by: Arena Pharmaceuticals
Inc.
Signed date: 16/01/2017
Martín Arranz MD. Estudio multicéntri-
co, aleatorizado, doble ciego, controlado
con placebo, prueba de concepto de
ustekinumab en pacientes con lupus
eritematoso sistémico activo. Type: Cli-
nical Trial, phase III.
HULP code: 4765. Sponsored´s protocol code:
CNTO1275CRD3005.
Sponsored by: Janssen Cilag International
NV.
Signed date: 25/01/2017
Martín Arranz MD. Etudio multicéntrico, alea-
torizado, doble ciego, controlado con place-
bo, prueba de concepto de ustekinumab en
pacientes con lupus eritematoso sistémico
activo. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4765. Sponsored´s protocol
code: CNTO1275CRD3005.
Sponsored by: Janssen Cilag International NV.
Signed date: 19/10/2017
Martín Arranz MD. Groupe d´etude thérapeutique des
affections inflammatoires digestives; (co-sponsor) GETEC-
CU (Grupo Español de Trabajo en Enfermedad de Crohn
y Colitis Ulcerosa) para la realizacion del estudio observa-
cional titulado: IBD cancer and serious infections in Europe:
I-CARE. Type: EPA-SP.
HULP code: ANEXO-I PI-2115. Sponsored´s protocol code: GET-
EII-2015-01.
Sponsored by: Grupo Español de Trabajo en Enfermedad de
Crohn y Colitis Ulcerosa (GETECCU).
Signed date: 30/06/2017
Martín Arranz MD. Registro no intervencionista de larga
duración para evaluar la seguridad y la efectividad de humira
(Adalimumab) en pacientes con colitis ulcerosa (CU) de ac-
tividad moderada a grave (Legacy). Type: EPA-LA.
317
 4 Associated Clinicians
Nutrinvest
4 1.161 0
Group Leader
Carmen Gómez Candela
Research Areas
• Surgery, Transplantation and Health Technology
Research Activity
Doctoral TheseS
de Arriba Sánchez A. Ensayo piloto sobre una nueva fór-
mula inmunomoduladora preoperatoria en cáncer de
cabeza y cuello[dissertation]. Madrid: 2017(23/06/2017).
Directors: Gómez Candela C, López Plaza B
Iglesias Rosado C. Efecto del consumo de productos
cárnicos con antioxidantes naturales y omega-3 sobre
factores de riesgo cardiovascular en una población con
dislipemia[dissertation]. Madrid: UAX: 2017(14/07/2017).
Directors: Gómez Candela C, Bermejo López LM
Quirós Fernández R. Estudio de intervención nutri-
cional para evaluar el efecto de la suplementación oral
con hidroxitirosol y punicalagina sobre diferentes mar-
cadores tempranos de la aterosclerosis en sujetos de
mediana edad, aparentemente sanos sin enfermedad
cardiovascular establecida[dissertation]. Madrid: UAM:
2017(13/07/2017).
Directors: Gómez Candela C, López Plaza B
Santurino Fontecha C. Desarrollo de un queso de ca-
bra enriquecido de manera natural en omega-3 y áci-
do linoleico conjugado. Ensayo clínico en voluntarios
318
con sobrepeso y obesidad[dissertation]. Madrid: UAM:
2017(28/07/2017).
Directors: Fontecha Alonso FJ, Gómez Candela C
BOOKS AND BOOK CHAPTERS
Gómez Candela C, Pelegrina B, Palma Milla S. Nu-
trición en los trastornos de la conducta alimentaria. In:
Gil Hernández A. Tratado de nutrición. Nutrición y en-
fermedad. Madrid: Editorial Médica Panamericana, 2017.
p. 567-586.
Gómez Candela C, Pelegrina B, Palma Milla S. ¿Cuánto
cuesta el tratamiento con nutrición parenteral domici-
liaria? In: Burgos Peláez R, Calvo Pulido J, Cantón Blanco
A, Cigarrán Guldris S, Cuerda Compñes MC, Gómez
Candela C. Jornadas síndrome intestino corto. Madrid:
Comunicaciones y Ediciones Sanitarias S. L. p. 127-36
López Plaza B, Bermejo López L. Nutrición y trastor-
nos del sistema inmune. In: Ortega Anta RM. Experto
universitario en nutrición clínica y salud nutricional. Nu-
trición en la prevención y control de diversos problemas
y enfermedades I. Madrid: Editorial Médica Panamerica-
na, 2017. P. 1-30
Bermejo López L, López Plaza B. Alimentación en las per-
sonas de edad avanzada. Diferencias en función de la edad
y situación sanitaria. In: Ortega Anta RM. Experto universi-
tario en nutrición clínica y salud nutricional. Salud nutricio-
nal. Madrid: Editorial Médica Panamericana, 2017. P. 1-35
Pelegrina Cortés B, Gómez Candela C, López Plaza
B, Bermejo López L, Palma Milla S. Nutrición y enfer-
medades cardiovasculares. In: Ortega Anta RM. Experto
universitario en nutrición clínica y salud nutricional. Nu-
trición en la prevención y control de diversos problemas
y enfermedades II. Madrid: Editorial Médica Panameri-
cana, 2017. P. 1-40
PUBLICATIONS
• González E, Díez JJ, Torres AP, Bajo MA, del Peso G, Sánchez-Vi-
llanueva R, Grande C, Rodríguez O, Coronado M, Candela CG,
Díaz-Almirón M, Iglesias P, Selgas R. Body composition analysis and
adipocytokine concentrations in haemodialysis patients: abdominal
fat gain as an additional cardiovascular risk factor. Nefrología. 2017;
37(2):138-48. Article. IF: 1.167; Q4
• Plaza BL, López LMB. Nutrition and immune system disorders. Nutr
Hosp. 2017; 34(Supl 4): 68-71. Article. Not Indexed
• Wanden-Berghe C, Luengo LM, Álvarez J, Burgos R, Cuerda C, Ma-
tía P, Candela CG, Olmos MAM, Gonzalo M, Calleja A, Campos C,
de la Cruz AP, Irles JA, Leyes P, Sánchez R, Román DD, Cardona
D, Santacruz N, Suárez JP, Ballesta C, Sales J, Penacho MA, Gárdez
C, Martínez MJ, Canovas B, Moreno JM, del Olmo D, Carabana F,
Virgili N, Higuera I, Mauri S, Sánchez-Vilar O, Miserachs N, Ponce
MA, García Y, Morán JM, Apezetxea A, Tejera C, Calanas A, Cantón A,
Díaz P. Spanish home enteral nutrition registry of the year 2014 and
2015 from the NADYA-SENPE Group. Nutr Hosp. 2017; 34(1): 15-8.
Article. Not Indexed
• Wanden-Berghe Lozano C,Virgili Casas N, Ramos Boluda E, Cuerda
Compes C, Moreno Villares JM, Pereira Cunill JL, Gómez Candela C,
Burgos Peláez R, Penacho Lázaro MA, Pérez de la Cruz A, Álvarez
Hernández J, Gonzalo Marín M, Matía Martín P, Martínez Faedo C,
Sánchez Martos EA, Sanz París A, Campos Martín C, Martín Folgue-
ras T, Martín Palmero MA, Martín Fontalba MA, Luengo Pérez LM,
Zugasti Murillo A, Martínez Ramírez MJ, Carabana Pérez F, Martínez
Costa C, Díaz Guardiola P, Tejera Pérez C, Pares Marimón RM, Irles
Rocamora JA, Garde Orbáiz C, Ponce González MA, García Zafra
MV, Sánchez Sánchez R, Urgeles Planella JR, Apezetxea Celaya A,
Sánchez-Vilar Burdiel O, Joaquín Ortiz C, Suárez Llanos JP, Pintor de
la Maza B, Leyes García P, Gil Martínez MC, Mauri Roca S, Carrera
Santaliestra MJ. Home and ambulatory artificial nutrition (NADYA)
Group Report - Home parenteral nutrition in Spain, 2016. Nutr
Hosp. 2017; 34(5): 1497-501. Article. Not Indexed
Public Projects
Gómez Candela C. Investigación y desarrollo clínico de una
nueva molécula para el control de peso y prevención de la
obesidad (FAT-BINDER DAMM) (RTC-2016-5317-1). MINE-
CO. 2016-2018.
Management centre: FIBHULP
Gómez Candela C. Alimentos funcionales y estrategias nu-
tricionales eficaces para la prevención y tratamiento de en-
fermedades crónicas (S2013/ABI-2728-ALIBIRD). MINECO.
2014-2018.
Management centre: FIBHULP
Private Projects
Coronado Poggio M. Pruebas de investigación PET del estu-
dio multicéntrico abierto de fase 2 del anticuerpo monoclo-
nal anti-CCR4 KW-0761 (mogamulizumab) en pacientes con
linfoma de célula T periférico (LCTP) previamente tratado.
Kyowa Hakko Kirin Pharma Inc. 2012-Ongoing.
Management centre: FIBHULP
Gómez Candela C. Plan de sustentación científica de la efi-
cacia de probióticos en homeostasis inmune.Varios Financia-
dores. 2010-Ongoing.
Management centre: FIBHULP
Gómez Candela C. Perspectivas de la actividad investigadora
de la Unidad de Nutrición Clínica y Dietética. Varios Finan-
ciadores. 2008-Ongoing.
Management centre: FIBHULP
Gómez Candela C. SATISFOOD: desarrollo y validación de
alimentos saciantes mediante la integración de las señales
pre y postingestivas. Creaciones Aromáticas Industriales S.A.
2017-Ongoing.
Management centre: FIBHULP
Gómez Candela C. Estudio observacional para el cono-
cimiento de los factores de riesgo asociados al cáncer de
mama en mujeres de reciente diagnóstico de la enfermedad
en la Comunidad de Madrid. Linical Spain S.L.U. 2017-On-
going.
Management centre: FIBHULP
Gómez Candela C. Desarrollo de nuevos alimentos nutricio-
nal y sensorialmente adecuados para pacientes oncológicos
(ALISENOC17). Adventia Pharma S.L. 2017-Ongoing.
Management centre: FIBHULP
Gómez Candela C. Formación orientada a la investigación en
el área de la nutrición y dietética. Paxvax Spain S.L. 2017-On-
going.
Management centre: FIBHULP
CLINICAL TRIALS
Gómez Candela C. A phase 3, randomized, open-label, asses-
sor-blind, non-inferiority, active-comparator study evaluating
the efficacy and safety of liprotamase in subjects with cystic
fibrosis-related exocrine pancreatic insufficiency. Type: Clini-
cal Trial, phase III.
HULP code: 4834. Sponsored´s protocol code: AN-EPI3333.
Sponsored by: Linical France Sarl.
Signed date: 12/04/2017
Gómez Candela C. Estudio retrospectivo de costes en pa-
cientes con nutrición parenteral domiciliaria y síndrome de
intestino corto, en la práctica clínica real en España. Estudio
Cosincor. Type: EPA-OD.
HULP code: PI-2726. Sponsored´s protocol code: CHI-NPD-2016-01.
Sponsored by: Shire Pharmaceuticals Ibérica S.L.
Signed date: 23/06/2017
319
 4 Associated Clinicians

Sánchez Márquez JM, Pérez Martín-Buitrago M. Inmovili- A rare vascular complication. Rev Esp Cir Ortop Traumatol. 2017;

Orthopedic Surgery
zación de extremidades. In: Cartón Sánchez AJ, Barreda Bonis 61(6): 436-40. Article. Not Indexed
AC, Menéndez Suso JJ, Ruiz Domínguez JA, Guerrero-Fer- • Barrientos-Ruiz I, Ortiz-Cruz EJ, Serrano-Montilla J, Bernabéu-Ta-
nández J. Manual de diagnóstico y terapéutica en pediatría. boada D, Pozo-Kreilinger JJ. Are biopsy tracts a concern for see-

and Traumatology Madrid: Editorial Médica Panamericana S.A., 2017. p. 2167-8

Sánchez Márquez JM, Pérez Martín-Buitrago M. Vendajes.
In: Cartón Sánchez AJ, Barreda Bonis AC, Menéndez Suso JJ,
Ruiz Domínguez JA, Guerrero-Fernández J. Manual de diag-
nóstico y terapéutica en pediatría. Madrid: Editorial Médica
Panamericana S.A., 2017. p. 2245-6
González Morán G, Salcedo Montejo M, Sánchez Márquez
JM. Alteraciones de la marcha. In: Cartón Sánchez AJ, Barreda
Bonis AC, Menéndez Suso JJ, Ruiz Domínguez JA, Guerrero-
Fernández J. Manual de diagnóstico y terapéutica en pediatría.
Madrid: Editorial Médica Panamericana S.A., 2017. p. 599-601
Sánchez Márquez JM, Fernández-Baíllo N, Pizones Arce J.
Alteraciones de la columna. In: Cartón Sánchez AJ, Barreda
Bonis AC, Menéndez Suso JJ, Ruiz Domínguez JA, Guerrero-
Fernández J. Manual de diagnóstico y terapéutica en pediatría.
Madrid: Editorial Médica Panamericana S.A., 2017. p. 603-5
Salcedo Montejo M, González Morán G, Sánchez Márquez
JM. Patología de las caderas. In: Cartón Sánchez AJ, Barreda
Bonis AC, Menéndez Suso JJ, Ruiz Domínguez JA, Guerrero-
Fernández J. Manual de diagnóstico y terapéutica en pediatría.
Madrid: Editorial Médica Panamericana S.A., 2017. p. 607-9
Moraleda Novo L, Cabello Blanco J, Sánchez Márquez JM.
Patología de las rodillas. In: Cartón Sánchez AJ, Barreda Bonis
AC, Menéndez Suso JJ, Ruiz Domínguez JA, Guerrero-Fer-
nández J. Manual de diagnóstico y terapéutica en pediatría.
Madrid: Editorial Médica Panamericana S.A., 2017. p. 611-2
ding and local recurrence in sarcomas? Clin Orthop Relat R. 2017;
475(2): 511-8. Article. IF: 4.091; D1
• Carbonell-Escobar R, Rubio-Suárez JC, Ibarzábal-Gil A, Rodríguez-
Merchán EC. Analysis of the variables affecting outcome in fractures
of the tibial pilon treated by open reduction and internal fixation. J
Clin Orthop Trauma. 2017; 8(4): 332-8. Article. Not Indexed
• Colomina MJ, Koo M, Basora M, Pizones J, Mora L, Bago J. Intraope-
rative tranexamic acid use in major spine surgery in adults: a mul-
ticentre, randomized, placebo-controlled trial. Brit J Anaesth. 2017;
118(3): 380-90. Article. IF: 6.499; D1
• Delfino R, Pizones J, Ruiz-Juretschke C, Sánchez-Mariscal F, Zúñiga L,
Izquierdo E. Selective anterior thoracolumbar fusion in adolescent
idiopathic scoliosis long-term results after 17-year follow-up. Spine.
2017; 42(13): E788-94. Article. IF: 2.792; Q1
• Moro-Lago I, Talavera G, Moraleda L, González-Morán G. Clinical
presentation and treatment of septic arthritis in children. Rev Esp
Cir Ortop Traumatol. 2017; 61(3): 170-5. Article. Not Indexed
• Pizones J, Martín-Buitrago MP, Pérez-Grueso FJS, Vila-Casademunt
A, Alanay A, Obeid I, Kleinstuck F, Acaroglu ER, Pellise F. Function
and clinical symptoms are the main factors that motivate thoraco-
lumbar adult scoliosis patients to pursue surgery. Spine. 2017; 42(1):
E31-6. Article. IF: 2.792; Q1
• Redondo A, Bague S, Bernabéu D, Ortiz-Cruz E,Valverde C, Álvarez
R, Martínez-Trufero J, López-Martín JA, Correa R, Cruz J, López-
Pousa A, Santos A, del Muro XG, Martín-Broto J. Malignant bone tu-
mors (other than Ewing’s): clinical practice guidelines for diagnosis,
treatment and follow-up by Spanish Group for Research on Sarco-
mas (GEIS). Cancer Chemoth Pharm. 2017; 80(6): 1113. Article. IF:
2.808; Q2

11 24.893 6
Group Leader
Francisco Javier Sánchez Pérez-Grueso
Research Areas
• Surgery, Transplantation and Health Technology
Research Activity
Doctoral TheseS
Laiglesia Lorenzo MA. Generación de células mesen-
quimales de placenta para uso clínico[dissertation].
Madrid: UAM: 2017(11/09/2017).
Directors: Gómez Barrena E; Gonzalo RM.
Jiménez Diéz V. Estudio anatómico de la región lateral
del codo. Descripción de las estructuras implicadas
en la epicondilitis lateral[dissertation]. Madrid: UCM:
2017(01/06/2017).
320
Directors: Sañudo Tejero JR, Cecilia López D, Barco
Laakso, R.
Romanillos Arroyo JO. ¿Mejora la PTH (Teriparati-
da) los resultados en fracturas pertrocantéreas ines-
tables osteoporóticas?[dissertation]. Madrid: UAM:
2017(07/09/2017).
Directors: Gil Garay E; Herruzo Cabrera R.
BOOKS AND BOOK CHAPTERS
Vaquero Picado A, Rodríguez-Merchán EC. Cartilage
injuries of the knee. In: Rodríguez-Merchán EC, Liddle AD
(Eds.). Joint preservation in the adult knee. Switzerland:
Springer International Publishing, 2017. p. 127-141
Peleteiro-Pensado M, Barrientos-Ruiz I, Ortiz-Cruz EJ.
Bone tumors around the knee. In: Rodríguez-Merchán
EC, Liddle AD (Eds.). Joint preservation in the adult knee.
Switzerland: Springer International Publishing, 2017. p.
153-173
Cabello Blanco J, Moraleda Novo L, Sánchez Márquez JM.
Patología de los pies. In: Cartón Sánchez AJ, Barreda Bonis
AC, Menéndez Suso JJ, Ruiz Domínguez JA, Guerrero-Fer-
nández J. Manual de diagnóstico y terapéutica en pediatría.
Madrid: Editorial Médica Panamericana S.A., 2017. p. 613-6
Vázquez Estévez J, Salcedo Montejo M. Traumatismos mús-
culo-esqueléticos. In: Cartón Sánchez AJ, Barreda Bonis AC,
Menéndez Suso JJ, Ruiz Domínguez JA, Guerrero-Fernández
J. Manual de diagnóstico y terapéutica en pediatría. Madrid:
Editorial Médica Panamericana S.A., 2017. p. 513-6
Salcedo M. Traumatismos musculoesqueléticos. In: Lluna
González J, Delgado Muñoz MD, Fernández Gallego V, García
Sala Viguer C, Vázquez Estévez JJ. Asistencia inicial al trauma
pediátrico (AITP). Madrid: Arán Ediciones, 2017
González Morán G. Traumatismo raquimedular. In: Lluna
González J, Delgado Muñoz MD, Fernández Gallego V, García
Sala Viguer C, Vázquez Estévez JJ. Asistencia inicial al trauma
pediátrico (AITP). Madrid: Arán Ediciones, 2017
PUBLICATIONS
• Álvarez Postigo M, Pizones Arce J, Izquierdo Núñez E. Lumbar seg-
mental artery pseudoaneurysm after L5 pedicle screw placement.
• Ruiz-Juretschke C, Pizones J, Delfino R, Sánchez-Mariscal F, Zúñiga
L, Izquierdo E. Long-term pulmonary function after open anterior
thoracolumbar surgery in thoracolumbar/lumbar idiopathic adoles-
cent scoliosis. Spine. 2017; 42(16): 1241-7. Article. IF: 2.792; Q1
• Sánchez-Mariscal F, Gómez-Rice A, Rodríguez-López T, Zúñiga L,
Pizones J, Núñez-García A, Izquierdo E. Preoperative and postope-
rative sagittal plane analysis in adult idiopathic scoliosis in patients
older than 40 years of age. Spine J. 2017; 17(1): 56-61. Article. IF:
3.119; Q1
• Vaquero-Picado A, Rodríguez-Merchán EC. Isolated posterior cru-
ciate ligament tears: an update of management. Efort Open Rev.
2017; 2(4): 89-96. Article. Not Indexed
Private Projects
Sánchez Pérez-Grueso FJ. Clínical outcomes following con-
servatives and surgical treatment of adult spine deformity.
Fundacio Hospital Vall D’Hebron. 2012-Ongoing.
Managment Centre: FIBHULP
Sánchez Márquez JM. Corrección gradual de escoliosis ex-
perimental en minicerdos mediante la utilización de metales
con memoria de forma. Sociedad para el Estudio de las En-
fermedades del Raquis. 2014-Ongoing.
Managment Centre: FIBHULP
321
 4 Associated Clinicians
Pediatric Surgery
17 26. 58
Group Leader
Manuel López Santamaría
Research Areas
• Surgery, Transplantation and Health Technology
Research Activity
Doctoral TheseS
Andrés Moreno AM. Trasplante intestinal y rechazo:
estudio experimental con células troncales mesen-
quimales derivadas de tejido adiposo para su preven-
ción y perspectivas clínicas futuras en la búsqueda de
la tolerancia inmunológica[dissertation]. Madrid: UAM:
2017(22/06/2017).
Director: Tovar Larrucea JA.
Encinas Hernández JL. El tratamiento quirúrgico pre-
natal del mielingocele [dissertation]. Madrid: UAM:
2017(16/06/2017).
Directors: López Santamaría M, Tovar Larrucea JA.
Novo Torres JR. Tratamiento percutáneo de las estenosis
biliares en el trasplante hepático infantil[dissertation]. Ma-
drid: UAM: 2017(25/09/2017).
Directors: Garzón Moll G, López Santamaría M.
BOOKS AND BOOK CHAPTERS
Vázquez Estévez J, Salcedo Montejo M. Traumatismos
músculo-esqueléticos. In: Cartón Sánchez AJ, Barreda Bonis
AC, Menéndez Suso JJ, Ruiz Domínguez JA, Guerrero-Fer-
nández J. Manual de diagnóstico y terapéutica en pediatría.
Madrid: Editorial Médica Panamericana S.A., 2017. p. 513-6
Carceller Benito F. Complicaciones en cirugía de la epilep-
sia refractaria en niños. In: Villarejo Ortega F, Pérez Jiménez
MA, Fournier del Castillo MC, Budke Neukamp M. Cirugía
de la epilepsia en niños. Madrid: Ergón, 2017. p.271-82
322
2 hensive review of current management. Berlín: Springer, 2017
Márquez Pérez T, Villarejo Ortega F, Saceda Gutiérrez
JM. Síndrome de Rasmussen: Cirugía de la epilepsia en
el síndrome de Rasmussen. In: Villarejo Ortega F, Pérez
Jiménez MA, Fournier del Castillo MC, Budke Neukamp
M. Cirugía de la epilepsia en niños. Madrid: Ergón, 2017.
p.195-8
Saceda Gutiérrez JM, Márquez Pérez T, Villarejo Or-
tega F. Síndrome de Rasmussen: Tratamiento quirúrgi-
co de la encefalitis de Rasmussen. In: Villarejo Ortega
F, Pérez Jiménez MA, Fournier del Castillo MC, Budke
Neukamp M. Cirugía de la epilepsia en niños. Madrid:
Ergón, 2017. p.195-8
Saceda Gutiérrez JM, Carceller Benito F. Traumatis-
mo craneoencefálico y traumatismo espinal. In: Cartón
Sánchez AJ, Barreda Bonis AC, Menéndez Suso JJ, Ruiz
Domínguez JA, Guerrero-Fernández J. Manual de diag-
nóstico y terapéutica en pediatría. Madrid: Editorial Mé-
dica Panamericana S.A., 2017. p. 483-8
Saceda Gutiérrez JM, Carceller Benito F. Malformacio-
nes craneales. Evaluación diagnóstica. In: Cartón Sánchez
AJ, Barreda Bonis AC, Menéndez Suso JJ, Ruiz Domín-
guez JA, Guerrero-Fernández J. Manual de diagnóstico y
terapéutica en pediatría. Madrid: Editorial Médica Pana-
mericana S.A., 2017. p. 559-562
Saceda Gutiérrez JM, Carceller Benito F. Hidrocefa-
lia. In: Cartón Sánchez AJ, Barreda Bonis AC, Menéndez
Suso JJ, Ruiz Domínguez JA, Guerrero-Fernández J. Ma-
nual de diagnóstico y terapéutica en pediatría. Madrid:
Editorial Médica Panamericana S.A., 2017. p.563-565
Saceda Gutiérrez JM, Carceller Benito F. Complicacio-
nes de las válvulas de derivación. In: Cartón Sánchez AJ,
Barreda Bonis AC, Menéndez Suso JJ, Ruiz Domínguez
JA, Guerrero-Fernández J. Manual de diagnóstico y tera-
péutica en pediatría. Madrid: Editorial Médica Panameri-
cana S.A., 2017. p.567-569
Saceda Gutiérrez JM, Carceller Benito F. Malforma-
ciones de fosa posterior. Malformación de Chiari, Dandy
Walker y siringomielia. In: Orduña López J, López Pisón J
(eds). Neurocirugía Pediátrica para Pediatras. Madrid: Er-
gón, 2017. p. 87-94
Noval Martínez S, Álvarez Muelas A, Carceller Benito F, Sa-
ceda Gutiérrez JM. Tumores del nervio óptico en la infancia:
Gliomas. In: Arbizu Duralde A, Sánchez Orgaz M (Eds). Diag-
nóstico por la imagen en patología ocular y orbitaria. Madrid:
Sociedad Española de Oftamología, 2017. p.431-42
Álvarez Muelas A, Gómez García E, Muñoz Caro JM, Martín
Pérez M, Rato Ordiales Millán A, Carceller Benito F, Saceda
Gutiérrez JM, Granados Fernández M. Malformaciones orbi-
tarias y craneofaciales. In: Arbizu Duralde A, Sánchez Orgaz M
(Eds). Diagnóstico por la imagen en patología ocular y orbita-
ria. Madrid: Sociedad Española de Oftamología, 2017. p.465-87
Granados Fernández M, Utrilla Contreras C, Zafra Agraz B,
Carceller Benito F. Tumores orbitarios en la edad pediátrica.
In: Arbizu Duralde A, Sánchez Orgaz M (Eds). Diagnóstico por
la imagen en patología ocular y orbitaria. Madrid: Sociedad
Española de Oftamología, 2017. p.489-98
López Gutiérrez JC. Strategy in pediatric patients. In: Kim Y, Lee
B,Yakes W, Do Y. Congenital vascular malformations: A compre-
Vázquez J. Prólogo a la tercera edición del curso de Asisten-
cia Inicial al Trauma Pediátrico. In: Lluna González J, Delgado
Muñoz MD, Fernández Gallego V, García Sala Viguer C, Váz-
quez Estévez JJ. Asistencia inicial al trauma pediátrico (AITP).
Madrid: Arán Ediciones, 2017
Vázquez J, Pérez R, Ibáñez V. Traumatismo torácico. In:
Lluna González J, Delgado Muñoz MD, Fernández Gallego V,
García Sala Viguer C, Vázquez Estévez JJ. Asistencia inicial al
trauma pediátrico (AITP). Madrid: Arán Ediciones, 2017
Vázquez J. Politraumatismo. In: Cartón Sánchez AJ, Barreda
Bonis AC, Menéndez Suso JJ, Ruiz Domínguez JA, Guerrero-
Fernández J. Manual de diagnóstico y terapéutica en pediatría.
Madrid: Editorial Médica Panamericana S.A., 2017
Gómez M, Jiménez J, Váquez J. Traumatismo Abdominal. In:
Cartón Sánchez AJ, Barreda Bonis AC, Menéndez Suso JJ, Ruiz
Domínguez JA, Guerrero-Fernández J. Manual de diagnóstico
y terapéutica en pediatría. Madrid: Editorial Médica Paname-
ricana S.A., 2017
Vázquez J, Rey C, García-Moreno F. Traumatismo en situa-
ciones especiales (pediátrico, embarazada y anciano). Ceba-
llos Esparragón J, Pérez Díaz MD. Cirugía del paciente poli-
traumatizado. Madrid: Editorial Arán, 2017
PUBLICATIONS
• Arroyo VA, López-Gutiérrez JC, Martínez R, Fernández-Pineda I.
Identical presentation of scapular osteolysis in two patients with
thoracic kaposiform hemangioendothelioma. Pediatr Dermatol.
2017; 34(3): E146-9. Article. IF: 1.041; Q4
• Domínguez Amillo E, de la Torre Ramos C, Andrés Moreno A, En-
cinas Hernández JL, Hernández Oliveros F, López Santamaría M.
Results of the mesoportal bypass (Rex shunt) in the treatment of
idiopathic extrahepatic portal vein obstruction in children. Cir Pe-
diatr. 2017; 30(1): 22-7. Article. Not Indexed
• Fernández-Pineda I, López-Gutiérrez JC. Hepatic hemangioma and
Kasabach-Merritt phenomenon. Pediatr Neonatol. 2017; 58(2):200-
1. Letter. IF: 1.232; Q3
• Giner J, Esteban I, Carceller F, Saceda J, Regojo RM. Spinal adrenal
cortical adenoma associated with Beckwith-Wiedemann syndrome:
case report and review of the literature. Child Nerv Syst. 2017;
33(6): 1009-13. Review. IF: 1.235; Q3
• Gutiérrez JCL. Dermal matrices. An option in the management of
circumferential nevi of extremities. J Plast Reconstr Aes. 2017; 70(4):
544-5. Letter. IF: 2.158; Q2
• Ivars M, López-Gutiérrez JC, Redondo P. A warning sign of other
vascular/skeletal abnormalities. J Am Acad Dermatol. 2017; 76(5):
E155-6. Editorial Material. IF: 6.898; D1
• Junco PT, Dore M, Cerezo VN, Gómez JJ, Ferrero MM, González MD,
López-Pereira P, López-Gutiérrez JC. Penile reconstruction with
skin grafts and dermal matrices: Indications and management. Euro-
pean J Pediatr Surg Rep. 2017; 5(1): E47-50. Article. Not Indexed
• López-Gutiérrez JC, Redondo P, Ivars M. Fingertip capillary malfor-
mation and associated disorders: Report of 9 cases. Pediatrics. 2017;
140(1): e20162967. Article. IF: 5.515; D1
• Martínez-López A, Blasco-Morente G, Pérez-López I, Herrera-Gar-
cía JD, Luque-Valenzuela M, Sánchez-Cano D, López-Gutiérrez JC,
Ruiz-Villaverde R,Tercedor-Sánchez J. CLOVES syndrome: review of
a PIK3CA-related overgrowth spectrum (PROS). Clin Genet. 2017;
91(1): 14-21. Review. IF: 3.512; Q2
• Moro-Lago I, Talavera G, Moraleda L, González-Moran G. Clinical
presentation and treatment of septic arthritis in children. Rev Esp
Cir Ortop Traumatol. 2017; 61(3): 170-5. Article. Not Indexed
• Ruiz YG, Gutiérrez JCL. Multiple tissue expansion for giant congeni-
tal melanocytic nevus. Ann Plas Surg. 2017; 79(6): E37-40. Article. IF:
1.536; Q3
• Tardaguila AR, Madero JMA, Parente A, Romero RM, Rivas S. Geni-
tal reconstruction with Integra (TM) artificial dermis after radical
resection in a boy with diffuse lymphangiomatosis. Arch Esp Urol.
2017; 70(10): 847-51. Article. IF: 0.465; Q4
• Triana P, Dore M, Cerezo VN, Cervantes M, Sánchez AV, Ferrero
MM, González MD, López-Gutiérrez JC. Sirolimus in the treatment
of vascular anomalies. Eur J Pediatr Surg. 2017; 27(1): 86-90. Article.
IF: 1.494; Q3
• Triana PJ, Dore M, Núñez VC, Jiménez JG, Miguel MF, Díaz MG, Ri-
cardo JN, Andrés A, Santamaría ML, López-Gutiérrez JC. Pancreatic
Kaposiform hemangioendothelioma not responding to sirolimus.
European J Pediatr Surg Rep. 2017; 5(1): E32-5. Article. Not Indexed
• Vaquero-Picado A, Rodríguez-Merchán EC. Isolated posterior cru-
ciate ligament tears: an update of management. Efort Open Rev.
2017; 2(4): 89-96. Article. Not Indexed
• Vega Mata N, López Gutiérrez JC,Vivanco Allende B, Fernández Gar-
cía M S. Different clinical features of acral abortive hemangiomas.
Case Rep Dermatol Med. 2017; 2017: 2897617. Article. Not Indexed
• Zani A, Eaton S, Morini F, Puri P, Rintala R, van Heurn E, Lukac M,
Bagolan P, Kuebler JF, Friedmacher F, Wijnen R, Tovar JA, Hoellwarth
ME, Pierro A. European Paediatric Surgeons’ Association Survey on
the management of Hirschsprung disease. Eur J Pediatr Surg. 2017;
27(1): 96-101. Article. IF: 1.494; Q3
Private Projects
Vázquez Estévez JJ. Curso de investigación sobre la asisten-
cia inicial al trauma pediátrico dirigido a instructores. Varios
Financiadores. 2016-Ongoing.
Managment Centre: FIBHULP
Vázquez Estévez JJ. Tratamientos de depuración extracor-
porea en pacientes criticos. de la investigación a la práctica
clínica. Nikkiso America Inc. 2016-Ongoing.
Managment Centre: FIBHULP
Vázquez Estévez JJ. Jornada científica: manejo de heridos en
atentados terroristas con múltiples víctimas. 2017-Ongoing.
Varios Financiadores.
Managment Centre: FIBHULP
Vázquez Estévez JJ. Jornada científica: cirugia de control de
daños en pediatría.Varios Financiadores. 2016-Ongoing.
Managment Centre: FIBHULP
323
 4 Associated Clinicians

Pediatric Nephrology
Inglés Torres E, Zarauza Santoveña A. Otras entidades
polisintomáticas en nefrología. Reflujo vesicoureteral. In:
Guerrero Fernández J, Cartón Sánchez A, Barreda Bonis A,
Menéndez Suso J, Ruiz Domínguez J. Manual de diagnóstico
y terapéutica en pediatría. Madrid: Editorial Médica Paname-
ricana, 2017
Rodríguez López S, Espinosa Román L. Otras entidades
polisintomáticas en nefrología.Tubulopatías. In: Guerrero Fer-
nández J, Cartón Sánchez A, Barreda Bonis A, Menéndez Suso
J, Ruiz Domínguez J. Manual de diagnóstico y terapéutica en
pediatría. Madrid: Editorial Médica Panamericana, 2017
PUBLICATIONS
(Alonso Melgar A). Infants requiring maintenance dialysis: Outco-
mes of hemodialysis and peritoneal dialysis. Am J Kidney Dis. 2017;
69(5): 617-25. Article. IF: 7.129; D1
CLINICAL TRIALS
Alonso Melgar A. Estudio de grupo único de ALXN1210 en
pacientes adultos y adolescentes con síndrome hemolítico
urémico atípico (SHUA) sin tratamiento previo con inhibido-
res del complemento. Type: Clinical Trial, phase III.
HULP code: ANEXO-I 4739. Sponsored´s protocol code:
ALXN1210-aHUS-311.
Sponsored by: Alexion Pharmaceutical Inc.
Signed date: 05/05/201

• Chesnaye NC, Schaefer F, Bonthuis M, Holman R, Baiko S, Baskin E,
Bjerre A, Cloarec S, Cornelissen EAM, Espinosa L, Heaf J, Stone R,
Shtiza D, Zagozdzon I, Harambat J, Jager KJ, Groothoff JW, van Stra-
len KJ. Mortality risk disparities in children receiving chronic renal
replacement therapy for the treatment of end-stage renal disease
across Europe: an ESPN-ERA/EDTA registry analysis. Lancet. 2017;
389(10084): 2128-37. Article. IF: 53.254; D1
• Deschenes G, Vivarelli M, Peruzzi L, (Espinosa-Román L). Variability
3 62.625 2 of diagnostic criteria and treatment of idiopathic nephrotic syndro-
me across European countries. Eur J Pediatr. 2017; 176(5): 647-54.
Article. IF: 2.242; Q2
• Vidal E, van Stralen KJ, Chesnaye NC, Bonthuis M, Holmberg C,
Zurowska A, Trivelli A, da Silva JEE, Herthelius M, Adams B, Bjerre A,
Group Leader guez J. Manual de diagnóstico y terapéutica en pediatría.
Jankauskiene A, Miteva P, Emirova K, Bayazit AK, Mache CJ, Sánchez-
Madrid: Editorial Médica Panamericana, 2017
Laura Espinosa Román Moreno A, Harambat J, Groothoff JW, Jager KJ, Schaefer F, Verrina E,
Arango Sancho P, Fernández Camblor C. Hematuria.
In: Guerrero Fernández J, Cartón Sánchez A, Barreda
Alonso Melgar A. Estudio de grupo único de ALXN1210 en
pacientes adultos y adolescentes con síndrome hemolítico
urémico atípico (SHUA) sin tratamiento previo con inhibido-
res del complemento. Type: Clinical Trial, phase III.
HULP code: 4739. Sponsored´s protocol code: ALXN1210-
aHUS-311.
Sponsored by: Alexion Pharmaceutical Inc.
Signed date: 31/01/2017
Alonso Melgar A. Estudio en fase III multicéntrico y abierto
de ALXN1210 en niños y adolescentes con síndrome hemo-
lítico urinémico atípico (SHUA). Type: Clinical Trial, phase III.
HULP code: 4796. Sponsored´s protocol code: ALXN1210-Ahus-312.
Sponsored by: Alexion Pharmaceutical Inc.
Signed date: 10/07/2017

Research Areas Bonis A, Menéndez Suso J, Ruiz Domínguez J. Manual de

diagnóstico y terapéutica en pediatría. Madrid: Editorial
• Large System Pathology Médica Panamericana, 2017
García Pose A, Peña Carrión A. Proteinuria. Sospecha
de síndrome nefrótico. In: Guerrero Fernández J, Car-
Research Activity tón Sánchez A, Barreda Bonis A, Menéndez Suso J, Ruiz
Domínguez J. Manual de diagnóstico y terapéutica en
pediatría. Madrid: Editorial Médica Panamericana, 2017
Doctoral TheseS
Martínez Sáenz de Jubera J, Alonso Melgar A. Insu-
Cara Fuentes G. Rol of CD80 in the pathegenesis of pro-
ficiencia renal. Insuficiencia renal aguda. In: Guerrero
teinuria in minimal change disease[dissertation]. Madrid:
Fernández J, Cartón Sánchez A, Barreda Bonis A, Me-
UAX: (01/06/2017). néndez Suso J, Ruiz Domínguez J. Manual de diagnóstico
Director: Espinosa Román L. y terapéutica en pediatría. Madrid: Editorial Médica Pa-
namericana, 2017

BOOKS AND BOOK CHAPTERS Ballesteros Moya E, Fiorita F, Fernández Camblor C.

Ruiz Hernández F, Melgosa Hijosa M. Hipertensión arte-
rial. In: Guerrero Fernández J, Cartón Sánchez A, Barreda
Bonis A, Menéndez Suso J, Ruiz Domínguez J. Manual de
diagnóstico y terapéutica en pediatría. Madrid: Editorial
Médica Panamericana, 2017
Carrasco Hidalgo-Barquero M, Zarauza Santoveña A.
Sospecha de nefropatía. Historia clínica y Exploraciones
complementarias. In: Guerrero Fernández J, Cartón Sán-
chez A, Barreda Bonis A, Menéndez Suso J, Ruiz Domín-
324
Enfermedad renal crónica.Trasplante renal. In: Guerrero
Fernández J, Cartón Sánchez A, Barreda Bonis A, Me-
néndez Suso J, Ruiz Domínguez J. Manual de diagnóstico
y terapéutica en pediatría. Madrid: Editorial Médica Pa-
namericana, 2017
Hernández Zúñiga LC, Bravo Feito J. Poliuria. In: Gue-
rrero Fernández J, Cartón Sánchez A, Barreda Bonis A,
Menéndez Suso J, Ruiz Domínguez J. Manual de diagnós-
tico y terapéutica en pediatría. Madrid: Editorial Médica
Panamericana, 2017
325
 4 Associated Clinicians
Pharmacy
7 10.346 0
Group Leader
Alicia Herrero Ambrosio
Research Areas
• Large System Pathology
Research Activity
Doctoral TheseS
Pérez Robles T. Evaluación de la adherencia al tratamiento
profiláctico en pacientes con hemofilia y su relación con
los episodios de sangrado[dissertation]. Madrid: UCM:
(16/06/207).
Directors: Romero Garrido JA, Benedí González B, Igle-
sias Peinado I.
Moro Agud M. Análisis de la mejora continua de la calidad
de un Servicio de Farmacia certificado por la Norma ISO
9001. Evolución de 8 años[dissertation]. Madrid: UCM:
(26/06/2017).
Directors: Romero Garrido JA, Herrero Ambrosio A;
Benedí González J.
Casado Abad MG. Evaluación de la implantación de un
sistema de trazabilidad mediante lectura de código de
barras en el proceso farmacoterapéutico del paciente
oncológico[dissertation]. Madrid: UAM: 2017(01/05/2018).
Directors: Zamora Auñon P, Romero JA, Benedi J.
PUBLICATIONS
• Castellar FR, Jiménez CS, Zarzuelo AD, Ambrosio AH, de los
Bueis AB. Intraocular minocycline for the treatment of ocular
pythiosis. Am J Health-Syst Ph. 2017; 74(11): 821-5. Article. IF:
1.872; Q3
• García-Martín A, Maroun-Eid C, Campino-Villegas A, Oliva-
Manuel B, Herrero-Ambrosio A, Quintana-Díaz M. Perception
survey on the value of the hospital pharmacist at the emer-
gency department. Farm Hosp. 2017; 41(3): 357-70. Article. Not
Indexed
• Goycochea-Valdivia WA, Moreno-Ramos F, Paño-Pardo JR, Ara-
cil-Santos FJ, Baquero-Artigao F, del Rosal-Rabes T, Mellado-Peña
MJ, Escosa-García L. Identifying priorities to improve paediatric
in-hospital antimicrobial use by cross-sectional evaluation of
prevalence and appropriateness of prescription. Enferm Infec
Micr Cl. 2017; 35(9): 556-62. Article. IF: 1.707; Q3
• López-Oliva MO, Álvarez L, Testillano ML, Pérez T, Nieto MF,
Santana MJ, González E, Herrero A, Selgas R, Jiménez C. Switch
to belatacept in kidney graft recipients. Nefrología. 2017; 37(5):
326
550-2. Letter. IF: 1.167;
Q4
• Roldán T, Ríos JJ, Villamañán
E,Waxman AB. Complications
associated with the use of oral
anticoagulation in patients with
pulmonary arterial hypertension from
two referral centers. Pulm Circ. 2017; 7(3):
692-701. Article. IF: 2.283; Q2
• Roldán T, Villamañán E, Ríos JJ, Waxman AB. As-
sessment of the quality of anticoagulation management in
patients with pulmonary arterial hypertension. Thromb Res.
2017; 160: 83-90. Article. IF: 2.779; Q2
• Sobrino-Jiménez C, Jiménez-Nacher I, Moreno-Ramos F,
González-Fernández MA, Freire-González M, González-Gar-
cía J, Herrero-Ambrosio A. Analysis of antiretroviral therapy
modification in routine clinical practice in the management
of HIV infection. Eur J Hosp Pharm-SP. 2017; 24(2): 96-100.
Article. IF: 0.538; Q4
Private Projects
Herrero Ambrosio A. XI Jornadas farmacéuticas sobre
el tratamiento de las coagulopatías congénitas. Amgen
S.A. 2016-Ongoing.
Managment Centre: FIBHULP
Herrero Ambrosio A. Actualización y promoción de la
actividad investigadora en el Servicio de Farmacia del
Hospital Universitario la Paz. Vifor Pharma España S.L.
2016-Ongoing.
Managment Centre: FIBHULP
Herrero Ambrosio A. Implantación del módulo ePA-
SE en la elaboración de antineoplásicos. Amgen S.A.
2013-Ongoing.
Managment Centre: FIBHULP
Herrero Ambrosio A. Desarrollo de un sistema de gestión de
medicamentos en investigación. Sanofi Aventis S.A. 2008-On-
going.
Managment Centre: FIBHULP
Herrero Ambrosio A. Informatización y optimización de pro-
cesos en la unidad de ensayos clínicos del servicio de farma-
cia.Vifor Pharma España S.L. 2015-Ongoing.
Managment Centre: FIBHULP
Herrero Ambrosio A. XI Jornadas farmacéuticas sobre el tra-
tamiento de las coagulopatias congénitas. Janssen-Cilag Espa-
ña S.A. 2016-Ongoing.
Managment Centre: FIBHULP
Herrero Ambrosio A. Evaluación de la notificación de alergias
a fármacos en pacientes hospitalizados. Utilidad de la pres-
cripción electrónica en la prevención de errores de medica-
ción. Amgen S.A. 2012-Ongoing.
Managment Centre: FIBHULP
Romero Garrido JA. Estudio de adherencia al tratamiento de
los pacientes en profilaxis con factores de la coagulación y su
relación con los episodios de sangrado. CAM. 2014-Ongoing.
Managment Centre: FIBHULP
Romero Garrido JA. Estudio de adherencia al tratamien-
to sustitutivo con factores de la coagulación en pacientes
diagnosticados de hemofilia grave en regimen de demanda
y profilaxis y su relación con episodios de sangrado. Pfizer
S.L.U. 2016-Ongoing.
Managment Centre: FIBHULP
Villamañán Bueno E. Análisis de errores de medicación en
pacientes Hospitalizados derivados de la discontuniación en-
tre niveles asistenciales. Amgen S.A. 2013-Ongoing.
Managment Centre: FIBHULP
Villamañán Bueno E. Iatrogenia asociada a nuevas tecno-
logías: errores de medicación inducidos o potenciados por
la prescripción electrónica asistida. Varios Financiadores.
2012-Ongoing.
Managment Centre: FIBHULP
Villamañán Bueno E. Evaluación de las objeciones alegadas
por un comite ético de investigación clínica a los consen-
timientos informados de los estudios clínicos. Amgen S.A.
2016-Ongoing.
Managment Centre: FIBHULP
327
 4 Associated Clinicians
Radiotherapy Oncology
Group Leader
Rosa María Morera López
Research Areas
• Cancer and Human Molecular Genetics
Research Activity
BOOKS AND BOOK CHAPTERS
Sánchez Méndez JI (cord), Belinchón Olmeda B, Berjón
García A, Cánser Cuenca E, Escabias del Pozo C, López
Rodríguez MJ, Martí Álvarez C, Martínez Serrano B,
Marinaccio L, Meléndez Gispert M, Quintes Viqueira
A, Rodríguez Patón MA, Sánchez Martínez C, Sánchez-
Pastor M, Yébenes Gregorio L, York Pineda E. Lo que
siempre quisiste saber sobre cirugía de mama…y nunca te
atreviste a preguntar. Madrid: Sociedad Española de Seno-
logía y Patología Mamaria, 2017
PRIVATE Projects
Morera López RM. Actualización y renovación de la acti-
vidad investigadora en el Servicio de Oncología Radiote-
rápica del Hospital Universitario La Paz. Abbott Labora-
tories S.A. 2010-Ongoing.
Managment Centre: FIBHULP
328
CLINICAL TRIALS
Manso de Lema A. Optimizing irradiation through mo-
lecular assessment of lymph node after primary siste-
mic treatment (Optimal IIA). Type: NO-EPA.
HULP code: CONTRATO PI-2856.
Sponsored´s protocol code: GIC-RAD-2016-01.
Sponsored by: Grupo de Investigación Clínica en Onco-
logía Radioterápica.
Signed date: 25/07/2017
Morera López RM. Estudio multicéntrico para el tra-
tamiento de metástasis pulmonares con radioterapia
estereotaxica corporal (SBRT) en pacientes Oligomert.
Type: NO-EPA.
HULP code: CONTRATO PI-2634.
Sponsored´s protocol code: GICOR-SEOR 2-16.
Sponsored by: Grupo de Investigación Clínica en Onco-
logía Radioterápica.
Signed date: 09/05/2017
Morera López RM. Caracterización y epidemiología en
España del dolor irruptivo oncológico. Type: NO-EPA.
HULP code: CONTRATO PI-2596.
Sponsored´s protocol code: CARPE-DIO.
Sponsored by: Takeda Farmacéutica España S.A.U.
Signed date: 16/01/2017
 Hospital Universitario La Paz
w w w. i d i ppara
Fundación a zla .Investigación
es Biomédica